All	O
live	O
births	O
greater	O
than	O
or	O
=	O
23	O
weeks	O
at	O
the	O
University	O
of	O
Vermont	O
in	O
1995	O
(	O
n	O
=	O
2395	O
)	O
were	O
retrospectively	O
analyzed	O
for	O
delivery	O
route	O
,	O
indication	O
for	O
cesarean	O
,	O
gestational	O
age	O
,	O
parity	O
,	O
and	O
practice	O
group	O
(	O
to	O
reflect	O
risk	O
status	O
)	O
.	O
The	O
total	O
cesarean	O
rate	O
was	O
14.4	O
%	O
(	O
344	O
of	O
2395	O
)	O
,	O
and	O
the	O
primary	O
rate	O
was	O
11.4	O
%	O
(	O
244	O
of	O
2144	O
)	O
.	O
Abnormal	O
presentation	O
was	O
the	O
most	O
common	O
indication	O
(	O
25.6	O
%	O
,	O
88	O
of	O
344	O
)	O
.	O
The	O
``	O
corrected	O
''	O
cesarean	O
rate	O
(	O
maternal-fetal	O
medicine	O
and	O
transported	O
patients	O
excluded	O
)	O
was	O
12.4	O
%	O
(	O
273	O
of	O
2194	O
)	O
,	O
and	O
the	O
``	O
corrected	O
''	O
primary	O
rate	O
was	O
9.6	O
%	O
(	O
190	O
of	O
1975	O
)	O
.	O
Furthermore	O
,	O
when	O
all	O
deliveries	O
were	O
analyzed	O
,	O
regardless	O
of	O
risk	O
status	O
but	O
limited	O
to	O
gestational	O
age	O
greater	O
than	O
or	O
=	O
36	O
weeks	O
,	O
the	O
rates	O
did	O
not	O
change	O
(	O
12.6	O
%	O
,	O
280	O
of	O
2214	O
;	O
primary	O
9.2	O
%	O
,	O
183	O
of	O
1994	O
)	O
.	O
Arrest	O
of	O
dilation	O
was	O
the	O
most	O
common	O
indication	O
in	O
both	O
``	O
corrected	O
''	O
subgroups	O
(	O
23.4	O
and	O
24.6	O
%	O
,	O
respectively	O
)	O
.	O
Cesarean	O
rates	O
at	O
tertiary	O
care	O
hospitals	O
should	O
be	O
compared	O
with	O
rates	O
at	O
community	O
hospitals	O
only	O
after	O
correcting	O
for	O
dissimilar	O
patient	O
groups	O
or	O
gestational	O
age	O
.	O
In	O
the	O
third	O
trimester	O
,	O
the	O
amniotic	O
fluid	O
index	O
(	O
AFI	O
)	O
may	O
be	O
affected	O
by	O
maternal	O
fluid	O
status	O
.	O
As	O
the	O
ambient	O
temperature	O
increases	O
,	O
there	O
is	O
an	O
increase	O
in	O
insensible	O
fluid	O
loss	O
and	O
the	O
potential	O
for	O
dehydration	O
.	O
We	O
hypothesize	O
that	O
as	O
temperature	O
increases	O
there	O
would	O
be	O
a	O
concomitant	O
decrease	O
in	O
AFI	O
.	O
From	O
June	O
11	O
to	O
August	O
16	O
,	O
1993	O
,	O
during	O
a	O
period	O
of	O
unusual	O
high	O
heat	O
,	O
42	O
women	O
with	O
singleton	O
pregnancies	O
between	O
27	O
and	O
40	O
weeks	O
'	O
gestation	O
undergoing	O
serial	O
antenatal	O
testing	O
had	O
AFI	O
determinations	O
recorded	O
at	O
least	O
weekly	O
.	O
The	O
daily	O
high	O
ambient	O
temperature	O
in	O
our	O
urban	O
area	O
was	O
subsequently	O
obtained	O
.	O
A	O
2-	O
,	O
3-	O
,	O
and	O
4-day	O
mean	O
temperature	O
prior	O
to	O
the	O
test	O
date	O
was	O
compared	O
to	O
AFI	O
using	O
a	O
Spearman-rank	O
Correlation	O
.	O
The	O
daily	O
high	O
temperature	O
ranged	O
from	O
71	O
to	O
104	O
degrees	O
F	O
and	O
AFI	O
values	O
ranged	O
from	O
1.7	O
to	O
24.7	O
cm	O
during	O
the	O
study	O
period	O
.	O
There	O
was	O
a	O
significant	O
correlation	O
between	O
the	O
2-	O
,	O
3-	O
,	O
and	O
4-day	O
mean	O
temperature	O
and	O
AFI	O
,	O
with	O
the	O
4-day	O
mean	O
being	O
the	O
most	O
significant	O
(	O
r	O
=	O
0.31	O
,	O
p	O
&	O
#	O
60	O
;	O
0.001	O
)	O
.	O
Fluctuations	O
in	O
ambient	O
temperature	O
are	O
inversely	O
correlated	O
to	O
changes	O
in	O
AFI	O
.	O
This	O
relationship	O
should	O
be	O
taken	O
into	O
account	O
when	O
interpreting	O
the	O
AFI	O
as	O
a	O
measure	O
of	O
fetal	O
well-being	O
.	O
This	O
study	O
tested	O
the	O
hypothesis	O
that	O
to	O
reduce	O
the	O
rate	O
of	O
macrosomic	O
infants	O
in	O
gestational	O
diabetes	O
cases	O
,	O
good	O
glycemic	O
control	O
should	O
be	O
initiated	O
before	O
34	O
completed	O
gestational	O
weeks	O
.	O
The	O
study	O
population	O
included	O
84	O
women	O
with	O
gestational	SYMP
diabetes	SYMP
,	O
ascertained	O
by	O
universal	O
screening	O
of	O
all	O
women	O
attending	O
the	O
antenatal	O
clinic	O
of	O
the	O
Hadassah	O
Medical	O
Center	O
,	O
over	O
a	O
2-year	O
period	O
.	O
The	O
60	O
women	O
(	O
71	O
%	O
)	O
,	O
who	O
initiated	O
treatment	O
before	O
34	O
completed	O
weeks	O
,	O
composed	O
the	O
``	O
early	O
''	O
group	O
.	O
The	O
24	O
women	O
(	O
29	O
%	O
)	O
,	O
who	O
initiated	O
treatment	O
after	O
the	O
34th	O
week	O
,	O
composed	O
the	O
``	O
late	O
''	O
group	O
.	O
All	O
patients	O
were	O
managed	O
by	O
an	O
intensified	O
protocol	O
,	O
including	O
stringent	O
glycemic	SYMP
control	SYMP
.	O
In	O
the	O
``	O
early	O
''	O
and	O
``	O
late	O
''	O
groups	O
,	O
mean	O
gestational	O
age	O
at	O
the	O
beginning	O
of	O
treatment	O
was	O
30.0	O
+/-	O
3.8	O
and	O
36.2	O
+/-	O
1.2	O
weeks	O
,	O
and	O
duration	O
of	O
treatment	O
was	O
9.6	O
+/-	O
4.1	O
and	O
3.7	O
+/-	O
1.8	O
weeks	O
,	O
respectively	O
.	O
Maternal	O
characteristics	O
were	O
similar	O
in	O
the	O
two	O
groups	O
.	O
The	O
rate	O
of	O
macrosomic	O
and	O
large-for-gestational-age	O
infants	O
were	O
5	O
and	O
11	O
%	O
,	O
respectively	O
,	O
in	O
the	O
early	O
group	O
as	O
compared	O
to	O
25	O
and	O
29	O
%	O
in	O
the	O
``	O
late	O
''	O
group	O
(	O
p	O
&	O
#	O
60	O
;	O
0.05	O
)	O
.	O
No	O
significant	O
differences	O
were	O
found	O
between	O
the	O
two	O
groups	O
in	O
the	O
mode	O
of	O
delivery	O
or	O
Apgar	O
scores	O
.	O
We	O
conclude	O
that	O
to	O
reduce	O
the	O
rate	O
of	O
macrosomic	SYMP
infants	SYMP
in	SYMP
gestational	SYMP
diabetes	SYMP
cases	SYMP
,	O
good	SYMP
glycemic	SYMP
control	SYMP
should	O
be	O
initiated	O
before	O
34	O
completed	O
gestational	O
weeks	O
.	O
Our	O
aim	O
was	O
to	O
investigate	O
the	O
contribution	O
of	O
certain	O
antenatally	O
detectable	O
markers	O
leading	O
to	O
the	O
diagnosis	O
of	O
trisomic	O
fetuses	O
we	O
observed	O
over	O
a	O
period	O
of	O
6	O
years	O
.	O
In	O
our	O
study	O
,	O
we	O
specifically	O
analyzed	O
the	O
role	O
played	O
by	O
advanced	O
maternal	O
age	O
and	O
sonographically	O
discovered	O
abnormalities	O
in	O
the	O
detection	O
of	O
autosomal	SYMP
trisomies	SYMP
.	O
All	O
together	O
,	O
27	O
fetuses	O
had	O
this	O
disorder	O
,	O
representing	O
28.7	O
%	O
(	O
27	O
of	O
94	O
)	O
of	O
all	O
cytogenetic	SYMP
aberrations	SYMP
detected	O
at	O
our	O
center	O
over	O
the	O
same	O
period	O
.	O
Down	SYMP
syndrome	SYMP
(	O
12	O
cases	O
)	O
and	O
Edward	SYMP
syndrome	SYMP
(	O
11	O
cases	O
)	O
were	O
the	O
most	O
common	O
trisomies	SYMP
,	O
while	O
4	O
cases	O
of	O
Patau	SYMP
syndrome	SYMP
were	O
also	O
diagnosed	O
.	O
The	O
most	O
common	O
indication	O
leading	O
to	O
diagnosis	O
was	O
abnormal	O
ultrasound	O
finding	O
(	O
48.2	O
%	O
)	O
,	O
followed	O
by	O
advanced	O
maternal	O
age	O
(	O
44.4	O
%	O
)	O
.	O
However	O
,	O
63	O
%	O
of	O
the	O
trisomic	O
fetuses	O
belonged	O
to	O
mothers	O
aged	O
35	O
years	O
and	O
above	O
.	O
Down	SYMP
syndrome	SYMP
fetuses	O
(	O
41.7	O
%	O
)	O
had	O
prenatally	O
detected	O
sonographic	O
anomalies	O
,	O
63.6	O
%	O
for	O
Edward	SYMP
syndrome	SYMP
,	O
and	O
all	O
fetuses	O
with	O
Patau	SYMP
syndrome	SYMP
(	O
4	O
of	O
4	O
)	O
showed	O
abnormal	O
sonographic	O
signs	O
.	O
Trisomy	SYMP
21	SYMP
presented	O
with	O
the	O
following	O
features	O
:	O
hydramnios	O
,	O
complex	O
malformations	O
,	O
pyelectasis	SYMP
,	O
and	O
duodenal	SYMP
atresia	SYMP
.	O
Trisomy	SYMP
18	SYMP
fetuses	O
showed	O
hydramnios	O
,	O
intrauterine	O
growth	O
retardation	O
,	O
microcephaly	SYMP
,	O
spina	SYMP
bifida	SYMP
,	O
and	O
nonimmune	SYMP
hydrops	SYMP
fetalis	SYMP
.	O
Signs	O
observed	O
in	O
fetuses	O
with	O
trisomy	SYMP
13	SYMP
were	O
:	O
hydrocephalus	O
,	O
intrauterine	O
growth	O
retardation	O
,	O
oligoanhydramnios	O
,	O
complex	O
malformations	O
,	O
severe	O
fetal	O
bradycardia	SYMP
and	O
hydronephrosis	SYMP
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
the	O
rate	O
of	O
preeclampsia	SYMP
is	O
increased	O
in	O
triplet	O
as	O
compared	O
to	O
twin	O
gestations	O
.	O
Fifty-three	O
triplet	O
pregnancies	O
between	O
1986	O
and	O
1993	O
at	O
The	O
New	O
York	O
Hospital-Cornell	O
Medical	O
Center	O
were	O
reviewed	O
.	O
These	O
were	O
matched	O
for	O
maternal	O
age	O
,	O
parity	O
,	O
and	O
race	O
to	O
twin	O
gestations	O
(	O
N	O
=	O
53	O
)	O
from	O
the	O
same	O
population	O
.	O
Severe	O
preeclampsia	SYMP
was	O
defined	O
by	O
standard	O
criteria	O
.	O
Student	O
's	O
t-test	O
,	O
Fisher	O
exact	O
test	O
,	O
and	O
Chi-square	O
were	O
used	O
for	O
statistical	O
analysis	O
.	O
The	O
rate	O
of	O
severe	O
preeclampsia	SYMP
was	O
increased	O
significantly	O
in	O
the	O
triplet	O
group	O
12	O
of	O
53	O
(	O
22.6	O
%	O
)	O
as	O
compared	O
with	O
the	O
twin	O
group	O
3	O
of	O
53	O
(	O
5.7	O
%	O
)	O
(	O
OR	O
=	O
4.9	O
,	O
95	O
%	O
CI	O
1.2-23.5	O
,	O
p	O
=	O
0.02	O
)	O
.	O
The	O
rate	O
of	O
overall	O
preeclampsia	SYMP
was	O
not	O
significantly	O
different	O
in	O
the	O
triplet	O
18	O
of	O
53	O
(	O
33.96	O
%	O
)	O
or	O
twin	O
12	O
of	O
53	O
(	O
22.6	O
%	O
)	O
groups	O
.	O
In	O
this	O
retrospective	O
,	O
case-controlled	O
study	O
,	O
the	O
rate	O
of	O
severe	O
pre-eclampsia	SYMP
was	O
significantly	O
increased	O
in	O
triplet	O
gestations	O
as	O
compared	O
to	O
twins	O
although	O
the	O
overall	O
rate	O
of	O
preeclampsia	SYMP
was	O
not	O
.	O
This	O
information	O
may	O
be	O
useful	O
in	O
counseling	O
patients	O
with	O
high	O
order	O
multifetal	O
gestations	O
.	O
We	O
conducted	O
a	O
survey	O
and	O
audit	O
of	O
thermal	O
equipment	O
use	O
in	O
very	O
low-birth-weight	O
infants	O
in	O
five	O
Ohio	O
neonatal	O
intensive	O
care	O
units	O
(	O
NICUs	O
)	O
to	O
document	O
regional	O
practice	O
.	O
The	O
survey	O
indicated	O
a	O
variety	O
of	O
thermal	O
care	O
styles	O
.	O
Two	O
NICUs	O
preferred	O
to	O
admit	O
infants	O
to	O
incubators	O
,	O
the	O
other	O
three	O
favoring	O
radiant	O
warmers	O
.	O
These	O
three	O
NICUs	O
moved	O
infants	O
from	O
radiant	O
warmers	O
into	O
incubators	O
at	O
significantly	O
different	O
mean	O
ages	O
.	O
The	O
audit	O
demonstrated	O
inconsistent	O
use	O
of	O
plastic	O
covers	O
,	O
warming	O
mattresses	O
,	O
and	O
added	O
humidity	O
under	O
radiant	O
warmers	O
,	O
and	O
discrepancies	O
between	O
survey	O
responses	O
and	O
actual	O
use	O
within	O
NICUs	O
.	O
Inter-NICU	O
variability	O
of	O
thermal	O
equipment	O
use	O
may	O
complicate	O
fluid	O
management	O
.	O
This	O
report	O
describes	O
a	O
full-term	O
newborn	O
with	O
massive	SYMP
fetomaternal	SYMP
hemorrhage	SYMP
.	O
Fetal	O
movements	O
were	O
decreased	O
48	O
hr	O
prior	O
to	O
delivery	O
.	O
On	O
the	O
day	O
of	O
delivery	O
,	O
they	O
were	O
absent	O
.	O
The	O
nonstress	O
test	O
was	O
abnormal	O
with	O
low	O
biophysical	O
profile	O
and	O
decreased	O
beat-to-beat	O
variability	O
.	O
The	O
infant	O
presented	O
with	O
extreme	O
pallor	O
,	O
hypotonia	SYMP
,	O
hepatosplenomegaly	SYMP
,	O
and	O
ascites	SYMP
.	O
The	O
initial	O
hemoglobin	O
was	O
2.2	O
g/dL	O
,	O
the	O
Kleihauer-Betke	O
stain	O
was	O
27.6	O
%	O
(	O
highest	O
level	O
ever	O
reported	O
)	O
.	O
Right	O
temporal	O
and	O
cerebellar	O
hemorrhages	O
were	O
present	O
.	O
Sequelae	O
include	O
severe	O
developmental	O
delay	O
and	O
asymmetric	O
double	O
hemiplegia	SYMP
.	O
Omphalocele-Exstrophy-Imperforate	SYMP
anus-Spinal	SYMP
defects	SYMP
(	SYMP
OEIS	SYMP
complex	SYMP
)	SYMP
,	O
a	O
combination	O
of	O
omphalocele	SYMP
,	O
exstrophy	SYMP
of	SYMP
the	SYMP
bladder	SYMP
,	O
an	O
imperforate	O
anus	O
and	O
spinal	SYMP
defects	SYMP
,	O
arises	O
from	O
a	O
single	O
localized	O
defect	O
in	O
the	O
early	O
development	O
of	O
the	O
mesoderm	O
that	O
will	O
later	O
contribute	O
to	O
infraumbilical	O
mesenchyme	O
,	O
cloacal	O
septum	O
,	O
and	O
caudal	O
vertebrae	O
.	O
In	O
this	O
report	O
,	O
we	O
document	O
the	O
perinatal	O
features	O
of	O
two	O
cases	O
of	O
OEIS	SYMP
complex	SYMP
associated	O
with	O
meningomyeloceles	SYMP
and	O
severe	O
lower	O
limb	O
defects	O
,	O
and	O
discuss	O
the	O
prenatal	O
diagnosis	O
,	O
inheritance	O
,	O
and	O
differential	O
diagnosis	O
of	O
this	O
association	O
of	O
malformations	O
.	O
Although	O
long-term	O
survival	O
can	O
be	O
achieved	O
by	O
successful	O
corrective	SYMP
surgery	SYMP
,	O
the	O
associated	O
structural	O
defects	O
such	O
as	O
large	SYMP
meningomyelocele	SYMP
and	O
severe	O
limb	SYMP
aplasia	SYMP
or	O
hypoplasia	SYMP
,	O
as	O
seen	O
in	O
our	O
patient	O
,	O
can	O
influence	O
the	O
patient	O
's	O
quality	O
of	O
life	O
.	O
We	O
would	O
like	O
to	O
emphasize	O
that	O
an	O
accurate	O
prenatal	O
diagnosis	O
of	O
OEIS	SYMP
complex	SYMP
and	O
associated	O
malformations	O
is	O
important	O
for	O
the	O
detailed	O
counseling	O
of	O
the	O
family	O
as	O
well	O
as	O
appropriate	O
perinatal	O
management	O
by	O
the	O
obstetricians	O
,	O
pediatric	O
surgeons	O
,	O
urologists	O
,	O
neurosurgeons	O
,	O
and	O
neonatologists	O
.	O
Nonimmune	SYMP
hydrops	SYMP
fetails	SYMP
diagnosed	O
at	O
21	O
weeks	O
'	O
gestation	O
with	O
profound	O
ascites	SYMP
,	O
hydrothorax	SYMP
,	O
and	O
pericardial	SYMP
effusion	SYMP
receded	O
gradually	O
with	O
regression	O
of	O
a	O
subchorial	O
placental	O
lucencies	O
immediately	O
below	O
the	O
umbilical	O
cord	O
insertion	O
.	O
Careful	O
inspection	O
of	O
the	O
delivered	O
placenta	O
revealed	O
that	O
there	O
was	O
a	O
yellowish	O
lesion	O
of	O
fibrin	O
deposits	O
below	O
the	O
cord	O
insertion	O
site	O
,	O
which	O
resulted	O
from	O
the	O
absorption	O
of	O
hematoma	O
.	O
A	O
subchorial	O
placental	O
hematoma	SYMP
,	O
which	O
detected	O
as	O
a	O
subchorial	O
placental	O
lucencies	SYMP
by	O
ultrasonography	O
,	O
can	O
be	O
a	O
cause	O
of	O
reversible	O
nonimmune	SYMP
hydrops	SYMP
fetalis	SYMP
.	O
The	O
mitochondrial	SYMP
diseases	SYMP
are	O
uncommon	O
multisystem	O
disorders	O
characterized	O
by	O
the	O
presence	O
of	O
functionally	O
and/or	O
structurally	O
abnormal	O
mitochondria	O
.	O
As	O
there	O
have	O
been	O
few	O
reports	O
of	O
the	O
obstetrical	O
care	O
of	O
affected	O
patients	O
,	O
we	O
wish	O
to	O
document	O
two	O
pregnancies	O
in	O
a	O
woman	O
with	O
a	O
Chronic	SYMP
Progressive	SYMP
External	SYMP
Ophthalmoplegia	SYMP
(	SYMP
Kearns-Sayre-like	SYMP
syndrome	SYMP
)	SYMP
.	O
Both	O
pregnancies	O
were	O
complicated	O
by	O
preterm	O
labor	O
and	O
hypertension	SYMP
.	O
CONTEXT	O
:	O
Four	O
genetic	O
loci	O
have	O
been	O
identified	O
as	O
contributing	O
to	O
Alzheimer	SYMP
disease	SYMP
(	SYMP
AD	SYMP
)	SYMP
,	O
including	O
the	O
amyloid	O
precursor	O
protein	O
gene	O
,	O
the	O
presenilin	O
1	O
gene	O
,	O
the	O
presenilin	O
2	O
gene	O
,	O
and	O
the	O
apolipoprotein	O
E	O
gene	O
,	O
but	O
do	O
not	O
account	O
for	O
all	O
the	O
genetic	O
risk	O
for	O
AD	O
.	O
OBJECTIVE	O
:	O
To	O
identify	O
additional	O
genetic	O
risk	O
factors	O
for	O
late-onset	O
AD	O
.	O
DESIGN	O
:	O
A	O
complete	O
genomic	O
screen	O
was	O
performed	O
(	O
N=280	O
markers	O
)	O
.	O
Critical	O
values	O
for	O
chromosomal	O
regional	O
follow-up	O
were	O
a	O
P	O
value	O
of	O
.05	O
or	O
less	O
for	O
affected	O
relative	O
pair	O
analysis	O
or	O
sibpair	O
analysis	O
,	O
a	O
parametric	O
lod	O
score	O
of	O
1.0	O
or	O
greater	O
,	O
or	O
both	O
.	O
Regional	O
follow-up	O
included	O
analysis	O
of	O
additional	O
markers	O
and	O
a	O
second	O
data	O
set	O
.	O
SETTING	O
:	O
Clinic	O
populations	O
in	O
the	O
continental	O
United	O
States	O
.	O
PATIENTS	O
:	O
greater	O
than	O
From	O
a	O
series	O
of	O
multiplex	O
families	O
affected	O
with	O
late-onset	O
(	O
greater	O
than	O
or	O
=60	O
years	O
)	O
AD	O
ascertained	O
during	O
the	O
last	O
14	O
years	O
(	O
National	O
Insititute	O
of	O
Neurological	O
Disorders	O
and	O
Stroke-Alzheimer	O
's	O
Disease	O
and	O
Related	O
Disorders	O
Association	O
diagnostic	O
criteria	O
)	O
and	O
for	O
which	O
DNA	O
has	O
been	O
obtained	O
,	O
a	O
subset	O
of	O
16	O
families	O
(	O
135	O
total	O
family	O
members	O
,	O
52	O
of	O
whom	O
were	O
patients	O
with	O
AD	O
)	O
was	O
used	O
for	O
the	O
genomic	O
screen	O
.	O
A	O
second	O
subset	O
of	O
38	O
families	O
(	O
216	O
total	O
family	O
members	O
,	O
89	O
of	O
whom	O
were	O
patients	O
with	O
AD	O
)	O
was	O
used	O
for	O
the	O
follow-up	O
analysis	O
.	O
MAIN	O
OUTCOME	O
MEASURES	O
:	O
Linkage	O
analysis	O
results	O
generated	O
using	O
both	O
genetic	O
model-dependent	O
(	O
lod	O
score	O
)	O
and	O
model-independent	O
methods	O
.	O
RESULTS	O
:	O
Fifteen	O
chromosomal	O
regions	O
warranted	O
initial	O
follow-up	O
.	O
Follow-up	O
analyses	O
revealed	O
4	O
regions	O
of	O
continued	O
interest	O
on	O
chromosomes	O
4	O
,	O
6	O
,	O
12	O
,	O
and	O
20	O
,	O
with	O
the	O
strongest	O
results	O
observed	O
forchromosome	O
12	O
.	O
Peak	O
2-point	O
affecteds-only	O
lod	O
scores	O
(	O
n=54	O
)	O
were	O
1.3	O
,	O
1.6	O
,	O
2.7	O
,	O
and	O
2.2	O
and	O
affected	O
relative	O
pairs	O
P	O
values	O
(	O
n=54	O
)	O
were	O
.04	O
,	O
.03	O
,	O
.14	O
,	O
and	O
.04	O
for	O
D12S373	O
,	O
D12S1057	O
,	O
D12S1042	O
,	O
and	O
D12S390	O
,	O
respectively	O
.	O
Sibpair	O
analysis	O
(	O
n=54	O
)	O
resulted	O
in	O
maximum	O
lod	O
scores	O
(	O
MLSs	O
)	O
of	O
1.5	O
,	O
2.6	O
,	O
3.2	O
,	O
and	O
2.3	O
for	O
these	O
markers	O
,	O
with	O
a	O
peak	O
multipoint	O
MLS	O
of	O
3.5	O
.	O
A	O
priori	O
stratification	O
by	O
APOE	O
genotype	O
identified	O
27	O
families	O
that	O
had	O
at	O
least	O
1	O
member	O
with	O
AD	O
whose	O
genotype	O
did	O
not	O
contain	O
an	O
APOE*4	O
allele	O
.	O
Analysis	O
of	O
these	O
27	O
families	O
resulted	O
in	O
MLSs	O
of	O
1.0	O
,	O
2.4	O
,	O
3.7	O
,	O
and	O
3.3	O
and	O
a	O
peak	O
multipoint	O
MLS	O
of	O
3.9	O
.	O
CONCLUSIONS	O
:	O
A	O
complete	O
genomic	O
screen	O
in	O
families	O
affected	O
with	O
late-onset	O
AD	O
identified	O
4	O
regions	O
of	O
interest	O
after	O
follow-up	O
.	O
Chromosome	O
12	O
gave	O
the	O
strongest	O
and	O
most	O
consistent	O
results	O
with	O
a	O
peak	O
multipoint	O
MLS	O
of	O
3.5	O
,	O
suggesting	O
that	O
this	O
region	O
contains	O
a	O
new	O
susceptibility	O
gene	O
for	O
AD	O
.	O
Additional	O
analyses	O
are	O
necessary	O
to	O
identify	O
the	O
chromosome	O
12	O
susceptibility	O
gene	O
for	O
AD	O
and	O
to	O
follow	O
up	O
the	O
regions	O
of	O
interest	O
on	O
chromosomes	O
4	O
,	O
6	O
,	O
and	O
20	O
.	O
CONTEXT	O
:	O
A	O
mutation	O
in	O
the	O
BRCA1	O
gene	O
may	O
confer	O
substantial	O
risk	O
for	O
breast	O
and/or	O
ovarian	O
cancer	SYMP
.	O
However	O
,	O
knowledge	O
regarding	O
all	O
possible	O
mutations	O
and	O
the	O
relationship	O
between	O
risk	O
factors	O
and	O
mutations	O
is	O
incomplete	O
.	O
OBJECTIVES	O
:	O
To	O
identify	O
BRCA1	O
mutations	O
and	O
to	O
determine	O
factors	O
that	O
best	O
predict	O
presence	O
of	O
a	O
deleterious	O
BRCA1	O
mutation	O
in	O
patients	O
with	O
breast	O
and/or	O
ovarian	O
cancer	SYMP
.	O
DESIGN	O
:	O
A	O
complete	O
sequence	O
analysis	O
of	O
the	O
BRCA1	O
coding	O
sequence	O
and	O
flanking	O
intronic	O
regions	O
was	O
performed	O
in	O
798	O
women	O
in	O
a	O
collaborative	O
effort	O
involving	O
institutions	O
from	O
the	O
United	O
States	O
,	O
Italy	O
,	O
Germany	O
,	O
Finland	O
,	O
and	O
Switzerland	O
.	O
PARTICIPANTS	O
:	O
Institutions	O
selected	O
798	O
persons	O
representing	O
families	O
(	O
1	O
person	O
for	O
each	O
family	O
)	O
thought	O
to	O
be	O
at	O
elevated	O
a	O
priori	O
risk	O
of	O
BRCA1	O
mutation	O
due	O
to	O
potential	O
risk	O
factors	O
,	O
such	O
as	O
multiple	O
cases	O
of	O
breast	SYMP
cancer	SYMP
,	O
early	O
age	O
of	O
breast	SYMP
cancer	SYMP
diagnosis	O
,	O
and	O
cases	O
of	O
ovarian	SYMP
cancer	SYMP
.	O
No	O
participant	O
was	O
from	O
a	O
family	O
in	O
which	O
genetic	O
markers	O
showed	O
linkage	O
to	O
the	O
BRCA1	O
locus	O
.	O
MAJOR	O
OUTCOME	O
MEASURES	O
:	O
Sequence	O
variants	O
detected	O
in	O
this	O
sample	O
are	O
presented	O
along	O
with	O
analyses	O
designed	O
to	O
determine	O
predictive	O
characteristics	O
of	O
those	O
testing	O
positive	O
for	O
BRCA1	O
mutations	O
.	O
RESULTS	O
:	O
In	O
102	O
women	O
(	O
12.8	O
%	O
)	O
,	O
clearly	O
deleterious	O
mutations	O
were	O
detected	O
.	O
Fifty	O
new	O
genetic	O
alterations	O
were	O
found	O
including	O
24	O
deleterious	O
mutations	O
,	O
24	O
variants	O
of	O
unknown	O
significance	O
,	O
and	O
2	O
rare	O
polymorphisms	O
.	O
In	O
a	O
subset	O
of	O
71	O
Ashkenazi	O
Jewish	O
women	O
,	O
only	O
2	O
distinct	O
deleterious	O
mutations	O
were	O
found	O
:	O
185delAG	O
in	O
17	O
cases	O
and	O
5382insC	O
in	O
7	O
cases	O
.	O
A	O
bias	O
in	O
prior	O
reports	O
for	O
mutations	O
in	O
exon	O
11	O
was	O
revealed	O
.	O
Characteristics	O
of	O
a	O
patient	O
's	O
specific	O
diagnosis	O
(	O
unilateral	O
or	O
bilateral	O
breast	SYMP
cancer	SYMP
,	O
with	O
or	O
without	O
ovarian	SYMP
cancer	SYMP
)	O
,	O
early	O
age	O
at	O
diagnosis	O
,	O
Ashkenazi	O
Jewish	O
ethnicity	O
,	O
and	O
family	O
history	O
of	O
cancer	O
were	O
positively	O
associated	O
with	O
the	O
probability	O
of	O
her	O
carrying	O
a	O
deleterious	O
BRCA1	O
mutation	O
.	O
CONCLUSIONS	O
:	O
Using	O
logistic	O
regression	O
analysis	O
,	O
we	O
provide	O
a	O
method	O
for	O
evaluating	O
the	O
probability	O
of	O
a	O
woman	O
's	O
carrying	O
a	O
deleterious	O
BRCA1	O
mutation	O
for	O
a	O
wide	O
range	O
of	O
cases	O
,	O
which	O
can	O
be	O
an	O
important	O
tool	O
for	O
clinicians	O
as	O
they	O
incorporate	O
genetic	O
susceptibility	O
testing	O
into	O
their	O
medical	O
practice	O
.	O
CONTEXT	O
:	O
Approximately	O
9	O
%	O
of	O
prostate	SYMP
cancer	SYMP
cases	O
have	O
been	O
estimated	O
to	O
result	O
from	O
inheritance	O
of	O
mutated	O
prostate	O
cancer	O
susceptibility	O
genes	O
.	O
Few	O
data	O
exist	O
as	O
to	O
whether	O
there	O
are	O
clinical	O
differences	O
between	O
prostate	SYMP
cancers	SYMP
that	O
are	O
inherited	O
and	O
those	O
that	O
occur	O
in	O
the	O
general	O
population	O
.	O
OBJECTIVE	O
:	O
To	O
investigate	O
phenotypic	O
characteristics	O
of	O
families	O
potentially	O
linked	O
to	O
the	O
hereditary	O
prostate	O
cancer	O
1	O
(	O
HPC1	O
)	O
locus	O
on	O
chromosome	O
1q24-25	O
.	O
DESIGN	O
:	O
Retrospective	O
case	O
study	O
in	O
which	O
clinical	O
data	O
were	O
extracted	O
from	O
medical	O
and	O
pathological	O
records	O
.	O
FAMILIES	O
:	O
A	O
total	O
of	O
74	O
North	O
American	O
families	O
with	O
hereditary	O
prostate	SYMP
cancer	SYMP
.	O
Prostate	O
cancer	O
cases	O
from	O
the	O
National	O
Cancer	O
Data	O
Base	O
were	O
used	O
as	O
a	O
reference	O
population	O
for	O
comparison	O
.	O
MAIN	O
OUTCOME	O
MEASURES	O
:	O
The	O
families	O
were	O
divided	O
into	O
2	O
groups	O
:	O
either	O
potentially	O
linked	O
(	O
33	O
families	O
with	O
133	O
men	O
with	O
prostate	SYMP
cancer	SYMP
)	O
,	O
and	O
thus	O
likely	O
to	O
be	O
carrying	O
an	O
altered	O
HPC1	O
gene	O
,	O
or	O
potentially	O
unlinked	O
(	O
41	O
families	O
with	O
172	O
men	O
with	O
prostate	SYMP
cancer	SYMP
)	O
,	O
on	O
the	O
basis	O
of	O
haplotype	O
analysis	O
in	O
the	O
region	O
of	O
HPC1	O
.	O
The	O
age	O
at	O
diagnosis	O
of	O
prostate	SYMP
cancer	SYMP
,	O
serum	O
prostate-specific	O
antigen	O
levels	O
,	O
digital	O
rectal	O
examination	O
status	O
,	O
stage	O
,	O
grade	O
,	O
primary	O
treatment	O
of	O
prostate	SYMP
cancers	SYMP
,	O
and	O
occurrence	O
of	O
other	O
cancers	SYMP
were	O
compared	O
between	O
the	O
groups	O
.	O
RESULTS	O
:	O
The	O
mean	O
age	O
at	O
diagnosis	O
of	O
prostate	SYMP
cancer	SYMP
for	O
men	O
in	O
potentially	O
linked	O
families	O
was	O
significantly	O
lower	O
than	O
for	O
men	O
in	O
potentially	O
unlinked	O
families	O
(	O
63.7	O
vs	O
65.9	O
years	O
,	O
respectively	O
,	O
P=.01	O
;	O
mean	O
age	O
at	O
diagnosis	O
in	O
the	O
reference	O
population	O
was	O
71.6	O
years	O
)	O
.	O
Higher-grade	O
cancers	SYMP
(	O
grade	O
3	O
)	O
were	O
more	O
common	O
in	O
potentially	O
linked	O
families	O
,	O
and	O
advanced-stage	O
disease	O
was	O
found	O
in	O
41	O
%	O
of	O
the	O
case	O
patients	O
in	O
potentially	O
linked	O
families	O
compared	O
with	O
31	O
%	O
in	O
both	O
the	O
potentially	O
unlinked	O
families	O
and	O
the	O
reference	O
groups	O
(	O
P=.03	O
for	O
the	O
latter	O
comparison	O
)	O
.	O
In	O
the	O
other	O
clinical	O
parameters	O
,	O
we	O
found	O
no	O
significant	O
differences	O
between	O
the	O
groups	O
.	O
A	O
modest	O
excess	O
of	O
breast	SYMP
cancer	SYMP
and	O
colon	SYMP
cancer	SYMP
was	O
found	O
in	O
potentially	O
linked	O
families	O
in	O
comparison	O
with	O
potentially	O
unlinked	O
families	O
,	O
but	O
this	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O
CONCLUSIONS	O
:	O
Families	O
that	O
provide	O
evidence	O
for	O
segregation	O
of	O
an	O
altered	O
HPC1	O
gene	O
are	O
characterized	O
by	O
multiple	O
cases	O
of	O
prostate	SYMP
cancer	SYMP
that	O
,	O
in	O
most	O
respects	O
,	O
are	O
indistinguishable	O
from	O
nonhereditary	O
cases	O
.	O
However	O
,	O
3	O
characteristics	O
were	O
observed	O
:	O
younger	O
age	O
at	O
diagnosis	O
,	O
higher-grade	O
tumors	SYMP
,	O
and	O
more	O
advanced-stage	O
disease	O
.	O
Our	O
study	O
shows	O
that	O
a	O
significant	O
fraction	O
of	O
hereditary	O
prostate	SYMP
cancers	SYMP
are	O
diagnosed	O
in	O
advanced	O
stages	O
,	O
emphasizing	O
the	O
clinical	O
importance	O
of	O
early	O
detection	O
in	O
men	O
potentially	O
carrying	O
prostate	O
cancer	O
susceptibility	O
genes	O
.	O
These	O
findings	O
support	O
the	O
current	O
recommendations	O
to	O
screen	O
men	O
with	O
a	O
positive	O
family	O
history	O
of	O
prostate	SYMP
cancer	SYMP
beginning	O
at	O
age	O
40	O
years	O
.	O
CONTEXT	O
:	O
Susceptibility	O
to	O
multiple	SYMP
sclerosis	SYMP
(	SYMP
MS	SYMP
)	SYMP
involves	O
a	O
genetically	O
complex	O
autoimmune	O
component	O
.	O
However	O
,	O
except	O
for	O
genes	O
in	O
the	O
HLA	O
system	O
,	O
specific	O
susceptibility	O
loci	O
are	O
unknown	O
or	O
unconfirmed	O
.	O
OBJECTIVE	O
:	O
To	O
investigate	O
several	O
loci	O
spanning	O
3	O
candidate	O
regions	O
for	O
a	O
role	O
in	O
multiple	SYMP
sclerosis	SYMP
(	SYMP
MS	SYMP
)	SYMP
susceptibility	O
in	O
2	O
ethnic	O
groups	O
using	O
both	O
single-locus	O
and	O
haplotype	O
analyses	O
.	O
The	O
3	O
regions	O
include	O
HLA	O
on	O
chromosome	O
6p21.3	O
,	O
APOE	O
on	O
chromosome	O
19ql	O
3.2	O
,	O
and	O
MBP	O
(	O
myelin	O
basic	O
protein	O
)	O
on	O
chromosome	O
18q23	O
.	O
DESIGN	O
:	O
Case-control	O
association	O
testing	O
.	O
SUBJECTS	O
:	O
A	O
total	O
of	O
120	O
Caucasian	O
patients	O
with	O
MS	O
and	O
107	O
unrelated	O
control	O
individuals	O
from	O
California	O
,	O
and	O
32	O
patients	O
and	O
32	O
unrelated	O
control	O
individuals	O
from	O
Beijing	O
,	O
China	O
.	O
All	O
patients	O
with	O
MS	O
were	O
diagnosed	O
as	O
having	O
clinically	O
definite	O
disease	O
according	O
to	O
published	O
criteria	O
.	O
MAIN	O
OUTCOME	O
MEASURES	O
:	O
Chi2	O
Testing	O
of	O
loci	O
and	O
individual	O
alleles	O
and	O
haplotypes	O
.	O
Haplotype	O
frequencies	O
were	O
estimated	O
with	O
standard	O
maximum	O
likelihood	O
methods	O
.	O
RESULTS	O
:	O
The	O
HLA	O
effect	O
is	O
due	O
to	O
the	O
class	O
II	O
DR2	O
haplotype	O
,	O
DRB1*1501-DQA1*0102-DRB1*0602	O
;	O
contributions	O
to	O
MS	O
susceptibility	O
from	O
additional	O
DRB1-DQB1	O
alleles	O
or	O
other	O
HLA	O
region	O
loci	O
were	O
not	O
observed	O
.	O
Variation	O
within	O
the	O
MBP	O
locus	O
on	O
chromosome	O
18q23	O
showed	O
no	O
effect	O
in	O
MS	O
.	O
The	O
distribution	O
of	O
haplotypes	O
from	O
5	O
loci	O
within	O
the	O
chromosome	O
19q13.2	O
region	O
,	O
including	O
D19S178	O
,	O
D19S574	O
,	O
APOE	O
,	O
APOC2	O
,	O
and	O
D19S219	O
,	O
differed	O
between	O
patient	O
and	O
control	O
samples	O
.	O
D19S574	O
showed	O
a	O
significant	O
effect	O
(	O
P=.015	O
)	O
in	O
Caucasian	O
patients	O
with	O
MS	O
due	O
to	O
the	O
increased	O
frequency	O
of	O
a	O
single	O
allele	O
(	O
P=.002	O
)	O
.	O
The	O
APOE	O
variation	O
,	O
prominent	O
in	O
other	O
neurological	O
diseases	O
,	O
showed	O
no	O
influence	O
on	O
MS	O
susceptibility	O
,	O
despite	O
its	O
location	O
within	O
the	O
chromosome	O
19q13.2	O
region	O
.	O
Interaction	O
effects	O
between	O
DR2	O
and	O
chromosome	O
19q13.2	O
or	O
MBP	O
in	O
MS	O
susceptibility	O
were	O
not	O
apparent	O
.	O
CONCLUSIONS	O
:	O
The	O
significant	O
chromosome	O
19q13.2	O
single-locus	O
and	O
multilocus	O
haplotype	O
associations	O
with	O
MS	O
in	O
Caucasian	O
and	O
Chinese	O
patient	O
samples	O
indicate	O
an	O
effect	O
from	O
a	O
nearby	O
disease	O
susceptibility	O
locus	O
.	O
These	O
initial	O
observations	O
are	O
an	O
encouraging	O
step	O
toward	O
the	O
description	O
of	O
non-HLA	O
genetic	O
susceptibility	O
to	O
MS	O
.	O
CONTEXT	O
:	O
There	O
is	O
a	O
substantial	O
risk	O
of	O
a	O
second	O
cancer	O
for	O
persons	O
with	O
hereditary	O
retinoblastoma	O
,	O
which	O
is	O
enhanced	O
by	O
radiotherapy	O
.	O
OBJECTIVE	O
:	O
To	O
examine	O
long-term	O
risk	O
of	O
new	O
primary	O
cancers	O
in	O
survivors	O
of	O
childhood	O
retinoblastoma	O
and	O
quantify	O
the	O
role	O
of	O
radiotherapy	O
in	O
sarcoma	O
development	O
.	O
DESIGN	O
:	O
Cohort	O
incidence	O
study	O
of	O
patients	O
with	O
retinoblastoma	O
followed	O
for	O
a	O
median	O
of	O
20	O
years	O
,	O
and	O
nested	O
case-control	O
study	O
of	O
a	O
radiation	O
dose-response	O
relationship	O
for	O
bone	O
and	O
soft	O
tissue	O
sarcomas	O
.	O
SETTING/PARTICIPANTS	O
:	O
A	O
total	O
of	O
1604	O
patients	O
with	O
retinoblastoma	SYMP
who	O
survived	O
at	O
least	O
1	O
year	O
after	O
diagnosis	O
,	O
identified	O
from	O
hospital	O
records	O
in	O
Massachusetts	O
and	O
New	O
York	O
during	O
1914	O
to	O
1984	O
.	O
RESULTS	O
:	O
Incidence	O
of	O
subsequent	O
cancers	SYMP
was	O
statistically	O
significantly	O
elevated	O
only	O
in	O
the	O
961	O
patients	O
with	O
hereditary	O
retinoblastoma	SYMP
,	O
in	O
whom	O
190	O
cancers	SYMP
were	O
diagnosed	O
,	O
vs	O
6.3	O
expected	O
in	O
the	O
general	O
population	O
(	O
relative	O
risk	O
(	O
RR	O
)	O
,	O
30	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
26-47	O
)	O
)	O
.	O
Cumulative	O
incidence	O
(	O
+/-SE	O
)	O
of	O
a	O
second	O
cancer	SYMP
at	O
50	O
years	O
after	O
diagnosis	O
was	O
51.0	O
%	O
(	O
+/-6.2	O
%	O
)	O
for	O
hereditary	O
retinoblastoma	SYMP
,	O
and	O
5.0	O
%	O
(	O
+/-3.0	O
%	O
)	O
for	O
nonhereditary	O
retinoblastoma	SYMP
.	O
All	O
114	O
sarcomas	SYMP
of	O
diverse	O
histologic	O
types	O
occurred	O
in	O
patients	O
with	O
hereditary	O
retinoblastoma	SYMP
.	O
For	O
soft	O
tissue	O
sarcomas	SYMP
,	O
the	O
RRs	O
showed	O
a	O
stepwise	O
increase	O
at	O
all	O
dose	O
categories	O
,	O
and	O
were	O
statistically	O
significant	O
at	O
10	O
to	O
29.9	O
Gy	O
and	O
30	O
to	O
59.9	O
Gy	O
.	O
A	O
radiation	O
risk	O
for	O
all	O
sarcomas	O
combined	O
was	O
evident	O
at	O
doses	O
above	O
5	O
Gy	O
,	O
rising	O
to	O
10.7-fold	O
at	O
doses	O
of	O
60	O
Gy	O
or	O
greater	O
(	O
P	O
&	O
#	O
60	O
;	O
.05	O
)	O
.	O
CONCLUSIONS	O
:	O
Genetic	O
predisposition	O
has	O
a	O
substantial	O
impact	O
on	O
risk	O
of	O
subsequent	SYMP
cancers	SYMP
in	O
retinoblastoma	SYMP
patients	O
,	O
which	O
is	O
further	O
increased	O
by	O
radiation	SYMP
treatment	SYMP
.	O
A	O
radiation	O
dose-response	O
relationship	O
is	O
demonstrated	O
for	O
all	O
sarcomas	O
and	O
,	O
for	O
the	O
first	O
time	O
in	O
humans	O
,	O
for	O
soft	O
tissue	O
sarcomas	O
.	O
Retinoblastoma	SYMP
patients	O
should	O
be	O
examined	O
for	O
new	O
cancers	SYMP
and	O
followed	O
into	O
later	O
life	O
to	O
determine	O
whether	O
their	O
extraordinary	O
cancer	O
risk	O
extends	O
to	O
common	O
cancers	SYMP
of	O
adulthood	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
rate	O
of	O
recent	O
cocaine	O
use	O
among	O
a	O
metropolitan	O
population	O
of	O
predominantly	O
Hispanic	O
and	O
African-American	O
women	O
with	O
preterm	O
premature	SYMP
rupture	SYMP
of	SYMP
the	SYMP
membranes	SYMP
(	SYMP
PROM	SYMP
)	SYMP
and	O
to	O
ascertain	O
the	O
impact	O
of	O
cocaine	O
on	O
the	O
latency	O
period	O
between	O
rupture	O
of	O
membranes	O
and	O
delivery	O
.	O
Urine	O
toxicology	O
screens	O
were	O
prospectively	O
obtained	O
on	O
147	O
women	O
with	O
preterm	SYMP
PROM	SYMP
.	O
The	O
urine	O
screen	O
did	O
not	O
influence	O
management	O
decisions	O
.	O
All	O
women	O
were	O
expectantly	O
managed	O
without	O
tocolytics	O
until	O
37	O
weeks	O
'	O
gestation	O
unless	O
they	O
developed	O
clinical	O
chorioamnionitis	O
,	O
or	O
nonreassuring	O
fetal	O
heart	O
rate	O
tracing	O
or	O
biophysical	O
profile	O
.	O
Demographic	O
information	O
,	O
hours	O
from	O
rupture	O
of	O
membranes	O
to	O
delivery	O
,	O
gestational	O
age	O
,	O
and	O
birth	O
weight	O
at	O
delivery	O
were	O
compared	O
using	O
Fisher	O
's	O
exact	O
,	O
Mann-Whitney	O
U	O
,	O
and	O
randomization	O
tests	O
where	O
appropriate	O
.	O
The	O
rate	O
of	O
positive	O
urine	O
drug	O
screens	O
for	O
cocaine	O
was	O
8.2	O
%	O
.	O
Women	O
in	O
the	O
cocaine	O
positive	O
group	O
were	O
of	O
higher	O
parity	O
(	O
3	O
,	O
(	O
0-7	O
)	O
vs.	O
1	O
,	O
(	O
0-6	O
)	O
,	O
p	O
=	O
0.001	O
)	O
and	O
tended	O
to	O
be	O
older	O
(	O
27	O
,	O
(	O
23-42	O
)	O
vs.	O
25	O
,	O
(	O
14-40	O
)	O
)	O
.	O
There	O
was	O
a	O
higher	O
rate	O
of	O
recent	O
cocaine	O
use	O
among	O
African-American	O
women	O
(	O
20.4	O
%	O
)	O
as	O
compared	O
to	O
non-African-Americans	O
(	O
1.2	O
%	O
,	O
p	O
=	O
0.0001	O
)	O
.	O
Cocaine-positive	O
women	O
presented	O
at	O
an	O
earlier	O
gestational	O
age	O
(	O
32	O
weeks	O
'	O
,	O
(	O
24-34	O
)	O
vs.	O
33	O
weeks	O
'	O
,	O
(	O
23-36	O
)	O
,	O
p	O
=	O
0.02	O
)	O
and	O
had	O
a	O
significantly	O
longer	O
membrane	O
rupture	O
to	O
delivery	O
interval	O
than	O
women	O
with	O
a	O
negative	O
urine	O
drug	O
screen	O
(	O
174	O
hr	O
,	O
(	O
6-475	O
)	O
vs.	O
33	O
hours	O
(	O
1-833	O
)	O
,	O
p	O
=	O
0.01	O
)	O
.	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
reason	O
for	O
delivery	O
between	O
the	O
two	O
groups	O
of	O
patients	O
.	O
Recent	O
cocaine	O
use	O
among	O
women	O
with	O
preterm	SYMP
PROM	SYMP
is	O
common	O
in	O
only	O
some	O
segments	O
of	O
an	O
urban	O
population	O
.	O
Women	O
with	O
recent	O
cocaine	O
use	O
present	O
with	O
ruptured	O
membranes	O
at	O
an	O
earlier	O
gestational	O
age	O
and	O
may	O
actually	O
have	O
a	O
longer	O
latency	O
period	O
than	O
women	O
who	O
do	O
not	O
use	O
cocaine	O
.	O
The	O
objective	O
of	O
this	O
article	O
is	O
to	O
explore	O
attitudes	O
of	O
an	O
inner-city	O
,	O
pregnant	O
cohort	O
about	O
general	O
and	O
HIV-related	O
prenatal	O
care	O
.	O
Responses	O
to	O
an	O
interview	O
at	O
initial	O
prenatal	O
care	O
enrollment	O
were	O
compared	O
using	O
Chi-square	O
and	O
Fisher	O
's	O
exact	O
tests	O
.	O
Of	O
75	O
women	O
,	O
drug	O
users	O
(	O
51	O
%	O
)	O
were	O
more	O
likely	O
to	O
say	O
that	O
they	O
would	O
defer	O
initiating	O
prenatal	O
care	O
(	O
P	O
=	O
0.03	O
)	O
and	O
to	O
minimize	O
the	O
risk	O
of	O
drug	O
or	O
alcohol	O
use	O
to	O
the	O
fetus	O
(	O
P	O
=	O
0.04	O
)	O
.	O
Most	O
(	O
85	O
%	O
)	O
viewed	O
pregnancy	O
as	O
inappropriate	O
for	O
HIV	SYMP
infected	O
women	O
and	O
primarily	O
drug	O
users	O
(	O
P	O
=	O
0.06	O
)	O
would	O
abort	O
if	O
HIV	SYMP
infected	O
.	O
Over	O
half	O
thought	O
HIV	SYMP
transmission	O
occurred	O
most	O
times	O
or	O
always	O
.	O
Only	O
20	O
%	O
had	O
heard	O
of	O
a	O
drug	O
to	O
reduce	O
this	O
risk	O
,	O
but	O
95	O
%	O
would	O
take	O
such	O
a	O
therapy	O
.	O
These	O
inner-city	O
,	O
pregnant	O
women	O
disapproved	O
of	O
pregnancy	O
if	O
HIV	SYMP
infected	O
and	O
thought	O
the	O
risk	O
of	O
transmission	O
was	O
high	O
.	O
They	O
knew	O
little	O
of	O
how	O
to	O
reduce	O
this	O
risk	O
but	O
nearly	O
all	O
would	O
accept	O
a	O
drug	O
to	O
prevent	O
transmission	O
.	O
The	O
association	O
of	O
parvovirus	SYMP
B19	SYMP
infection	SYMP
and	O
hydrops	SYMP
fetalis	SYMP
is	O
well	O
known	O
.	O
However	O
,	O
the	O
association	O
of	O
parvovirus	SYMP
and	O
fetal	O
pleural	O
or	O
pericardial	SYMP
effusions	SYMP
has	O
not	O
been	O
reported	O
.	O
We	O
present	O
five	O
cases	O
of	O
isolated	O
pleural	O
or	O
pericardial	SYMP
effusion	SYMP
with	O
documented	O
maternal	O
parvovirus	SYMP
infection	SYMP
in	O
four	O
of	O
these	O
pregnancies	O
.	O
In	O
the	O
absence	O
of	O
structural	O
or	O
karyotypic	O
abnormalities	O
,	O
spontaneous	O
resolution	O
of	O
the	O
effusion	O
portends	O
for	O
a	O
successful	O
pregnancy	O
outcome	O
.	O
BACKGROUND	O
:	O
Cochlear	SYMP
implantation	SYMP
is	O
nowadays	O
a	O
reliable	O
and	O
well-accepted	O
method	O
of	O
auditory	O
rehabilitation	O
in	O
selected	O
adults	O
and	O
children	O
.	O
METHODS	O
:	O
We	O
present	O
rehabilitation	O
data	O
on	O
21	O
adult	O
patients	O
provided	O
with	O
the	O
Nucleus	O
CI22	O
M	O
cochlear	O
implant	O
using	O
the	O
SPEAK	O
strategy	O
.	O
RESULTS	O
:	O
Results	O
of	O
first	O
tune-up	O
show	O
an	O
open	O
set	O
speech	O
understanding	O
in	O
approximately	O
50	O
%	O
of	O
patients	O
.	O
Long-term	O
results	O
also	O
reveal	O
further	O
improvement	O
in	O
patients	O
who	O
had	O
no	O
open	O
set	O
speech	O
understanding	O
.	O
Our	O
data	O
seem	O
to	O
indicate	O
similar	O
results	O
in	O
comparison	O
to	O
other	O
groups	O
using	O
the	O
CIS	O
strategy	O
.	O
CONCLUSIONS	O
:	O
In	O
adults	O
,	O
open	O
set	O
speech	O
understanding	O
can	O
be	O
achieved	O
even	O
at	O
the	O
first	O
tune-up	O
.	O
Results	O
of	O
early	O
rehabilitation	O
seem	O
to	O
be	O
influenced	O
by	O
duration	O
and	O
etiology	O
of	O
deafness	SYMP
,	O
experience	O
with	O
hearing	O
aids	O
,	O
and	O
other	O
factors	O
.	O
Adverse	O
drug	O
effects	O
are	O
manifold	O
and	O
heterogenous	O
.	O
Many	O
situations	O
may	O
hamper	O
the	O
signalling	O
(	O
i.e	O
.	O
the	O
detection	O
of	O
early	O
warning	O
signs	O
)	O
of	O
adverse	O
effects	O
and	O
new	O
signals	O
often	O
differ	O
from	O
previous	O
experiences	O
.	O
Signals	O
have	O
qualitative	O
and	O
quantitative	O
aspects	O
.	O
Different	O
categories	O
of	O
adverse	O
effects	O
need	O
different	O
methods	O
for	O
detection	O
.	O
Current	O
pharmacovigilance	O
is	O
predominantly	O
based	O
on	O
spontaneous	O
reporting	O
and	O
is	O
mainly	O
helpful	O
in	O
detecting	O
type	O
B	O
effects	O
(	O
those	O
effects	O
that	O
are	O
often	O
allergic	O
or	O
idiosyncratic	O
reactions	O
,	O
characteristically	O
occurring	O
in	O
only	O
a	O
minority	O
of	O
patients	O
and	O
usually	O
unrelated	O
to	O
dosage	O
and	O
that	O
are	O
serious	O
,	O
unexpected	O
and	O
unpredictable	O
)	O
and	O
unusual	O
type	O
A	O
effects	O
(	O
those	O
effects	O
that	O
are	O
related	O
to	O
the	O
pharmacological	O
effects	O
of	O
the	O
drug	O
and	O
are	O
dosage-related	O
)	O
.	O
Examples	O
of	O
other	O
sources	O
of	O
signals	O
are	O
prescription	O
event	O
monitoring	O
,	O
large	O
automated	O
data	O
resources	O
on	O
morbidity	O
and	O
drug	O
use	O
(	O
including	O
record	O
linkage	O
)	O
,	O
case-control	O
surveillance	O
and	O
follow-up	O
studies	O
.	O
Type	O
C	O
effects	O
(	O
those	O
effects	O
related	O
to	O
an	O
increased	O
frequency	O
of	O
'spontaneous	O
'	O
disease	O
)	O
are	O
difficult	O
to	O
study	O
,	O
however	O
,	O
and	O
continue	O
to	O
pose	O
a	O
pharmacoepidemiological	O
challenge	O
.	O
Seven	O
basic	O
considerations	O
can	O
be	O
identified	O
that	O
determine	O
the	O
evidence	O
contained	O
in	O
a	O
signal	O
:	O
quantitative	O
strength	O
of	O
the	O
association	O
,	O
consistency	O
of	O
the	O
data	O
,	O
exposure	O
response	O
relationship	O
,	O
biological	O
plausibility	O
,	O
experimental	O
findings	O
,	O
possible	O
analogies	O
and	O
the	O
nature	O
and	O
quality	O
of	O
the	O
data	O
.	O
A	O
proposal	O
is	O
made	O
for	O
a	O
standard	O
signal	O
management	O
procedure	O
at	O
pharmacovigilance	O
centres	O
,	O
including	O
the	O
following	O
steps	O
:	O
signal	O
delineation	O
,	O
literature	O
search	O
,	O
preliminary	O
inventory	O
of	O
data	O
,	O
collection	O
of	O
additional	O
information	O
,	O
consultation	O
with	O
the	O
World	O
Health	O
Organization	O
Centre	O
for	O
International	O
Drug	O
Monitoring	O
and	O
the	O
relevant	O
drug	O
companies	O
,	O
aggregated	O
data	O
assessment	O
and	O
a	O
report	O
in	O
writing	O
.	O
A	O
better	O
understanding	O
of	O
the	O
conditions	O
and	O
mechanisms	O
involved	O
in	O
the	O
detection	O
of	O
adverse	O
drug	O
effects	O
may	O
further	O
improve	O
strategies	O
for	O
pharmacovigilance	O
.	O
OBJECTIVE	O
:	O
To	O
study	O
the	O
safety	O
and	O
efficacy	O
of	O
methylphenidate	SYMP
in	O
children	O
with	O
the	O
dual	O
diagnosis	O
of	O
epilepsy	SYMP
and	O
attention	SYMP
deficit	SYMP
hyperactivity	SYMP
disorder	SYMP
(	SYMP
ADHD	SYMP
)	SYMP
.	O
STUDY	O
DESIGN	O
:	O
Thirty	O
children	O
,	O
aged	O
6.4	O
to	O
16.4	O
years	O
,	O
with	O
epilepsy	SYMP
and	O
ADHD	SYMP
were	O
studied	O
during	O
a	O
4-month	O
period	O
.	O
During	O
the	O
initial	O
2	O
months	O
of	O
the	O
study	O
,	O
the	O
children	O
were	O
treated	O
with	O
antiepileptic	SYMP
drugs	SYMP
(	SYMP
AEDs	SYMP
)	SYMP
only	O
,	O
and	O
for	O
the	O
remaining	O
2	O
months	O
,	O
methylphenidate	SYMP
was	O
added	O
at	O
a	O
morning	O
dose	O
of	O
0.3	O
mg/kg	O
.	O
They	O
underwent	O
neurologic	O
assessment	O
,	O
brain	O
computed	O
tomography	O
,	O
IQ	O
testing	O
,	O
and	O
assessment	O
with	O
the	O
Childhood	O
Behavior	O
Checklist	O
at	O
baseline	O
before	O
methylphenidate	SYMP
therapy	SYMP
.	O
Electroencephalography	O
,	O
AED	O
determinations	O
,	O
and	O
the	O
continuous-performance	O
task	O
(	O
CPT	O
)	O
test	O
were	O
done	O
at	O
baseline	O
and	O
after	O
2	O
months	O
of	O
methylphenidate	O
therapy	O
.	O
A	O
double-blind	O
,	O
crossover	O
design	O
was	O
used	O
to	O
compare	O
the	O
effects	O
of	O
methylphenidate	SYMP
versus	O
placebo	O
on	O
an	O
electroencephalogram	O
,	O
AED	O
levels	O
,	O
and	O
the	O
CPT	O
.	O
On	O
the	O
2	O
days	O
of	O
testing	O
,	O
the	O
child	O
received	O
AEDs	SYMP
and	O
a	O
capsule	O
containing	O
either	O
placebo	O
or	O
methylphenidate	SYMP
.	O
RESULTS	O
:	O
None	O
of	O
the	O
25	O
children	O
of	O
this	O
sample	O
who	O
were	O
seizure	O
free	O
had	O
attacks	O
while	O
taking	O
methylphenidate	O
.	O
Of	O
the	O
5	O
children	O
with	O
seizures	SYMP
,	O
3	O
had	O
an	O
increase	O
in	O
attacks	O
,	O
whereas	O
the	O
other	O
2	O
showed	O
no	O
change	O
or	O
a	O
reduction	O
.	O
There	O
were	O
no	O
significant	O
changes	O
in	O
AED	O
levels	O
or	O
electroencephalographic	O
findings	O
.	O
Methylphenidate	SYMP
benefited	O
70	O
%	O
of	O
children	O
according	O
to	O
parental	O
report	O
;	O
methylphenidate	SYMP
also	O
enhanced	O
performance	O
on	O
the	O
CPT	O
.	O
Side	O
effects	O
of	O
methylphenidate	SYMP
were	O
mild	O
and	O
transient	O
.	O
CONCLUSION	O
:	O
Methylphenidate	SYMP
is	O
effective	O
in	O
treating	O
children	O
with	O
epilepsy	SYMP
and	O
ADHD	SYMP
and	O
safe	O
in	O
children	O
who	O
are	O
seizure	O
free	O
.	O
Caution	O
is	O
warranted	O
for	O
those	O
still	O
having	O
seizures	O
while	O
receiving	O
AED	O
therapy	O
.	O
The	O
temporal	O
properties	O
of	O
semantic	O
and	O
phonological	O
processes	O
in	O
speech	O
production	O
were	O
investigated	O
in	O
a	O
new	O
experimental	O
paradigm	O
using	O
movement-related	O
brain	O
potentials	O
.	O
The	O
main	O
experimental	O
task	O
was	O
picture	O
naming	O
.	O
In	O
addition	O
,	O
a	O
2-choice	O
reaction	O
go/no-go	O
procedure	O
was	O
included	O
,	O
involving	O
a	O
semantic	O
and	O
a	O
phonological	O
categorization	O
of	O
the	O
picture	O
name	O
.	O
Lateralized	O
readiness	O
potentials	O
(	O
LRPs	O
)	O
were	O
derived	O
to	O
test	O
whether	O
semantic	O
and	O
phonological	O
information	O
activated	O
motor	O
processes	O
at	O
separate	O
moments	O
in	O
time	O
.	O
An	O
LRP	O
was	O
only	O
observed	O
on	O
no-go	O
trials	O
when	O
the	O
semantic	O
(	O
not	O
the	O
phonological	O
)	O
decision	O
determined	O
the	O
response	O
hand	O
.	O
Varying	O
the	O
position	O
of	O
the	O
critical	O
phoneme	O
in	O
the	O
picture	O
name	O
did	O
not	O
affect	O
the	O
onset	O
of	O
the	O
LRP	O
but	O
rather	O
influenced	O
when	O
the	O
LRP	O
began	O
to	O
differ	O
on	O
go	O
and	O
no-go	O
trials	O
and	O
allowed	O
the	O
duration	O
of	O
phonological	O
encoding	O
of	O
a	O
word	O
to	O
be	O
estimated	O
.	O
These	O
results	O
provide	O
electrophysiological	O
evidence	O
for	O
early	O
semantic	O
activation	O
and	O
later	O
phonological	O
encoding	O
.	O
The	O
effects	O
of	O
alanine	O
and	O
glycine	O
substitution	O
for	O
tryptophan	O
upon	O
the	O
species	O
heterogeneity	O
of	O
gramicidin	O
A	O
analogs	O
incorporated	O
into	O
SDS	O
micelles	O
have	O
been	O
investigated	O
.	O
The	O
sequential	O
replacement	O
of	O
the	O
four	O
tryptophan	O
residues	O
in	O
gramicidin	O
A	O
at	O
positions	O
15	O
,	O
13	O
,	O
11	O
,	O
and	O
9	O
with	O
glycine	O
showed	O
that	O
there	O
was	O
no	O
detectable	O
effect	O
at	O
position	O
15	O
but	O
increasing	O
heterogeneity	O
of	O
species	O
in	O
the	O
micelles	O
proceeding	O
toward	O
the	O
interior	O
of	O
the	O
micelle	O
at	O
position	O
9	O
.	O
The	O
replacement	O
of	O
tryptophan	O
at	O
positions	O
15	O
and	O
9	O
with	O
alanine	O
was	O
found	O
to	O
produce	O
more	O
species	O
heterogeneity	O
than	O
found	O
with	O
glycine	O
substitution	O
at	O
the	O
same	O
positions	O
.	O
An	O
increase	O
in	O
the	O
SDS	O
concentration	O
reduces	O
the	O
number	O
of	O
different	O
species	O
present	O
in	O
micelles	O
.	O
With	O
the	O
Gly-11	O
,	O
Gly-13	O
,	O
and	O
Gly-15	O
analogs	O
,	O
the	O
increase	O
in	O
SDS	O
concentration	O
results	O
in	O
the	O
formation	O
of	O
a	O
single	O
species	O
;	O
however	O
,	O
for	O
the	O
Gly-9	O
,	O
Ala-9	O
,	O
and	O
Ala-15	O
analogs	O
,	O
heterogeneity	O
remains	O
.	O
Molecular	O
dynamics	O
in	O
torsion-angle	O
space	O
was	O
applied	O
to	O
nuclear	O
magnetic	O
resonance	O
structure	O
calculation	O
using	O
nuclear	O
Overhauser	O
effect-derived	O
distances	O
and	O
J-coupling-constant-derived	O
dihedral	O
angle	O
restraints	O
.	O
Compared	O
to	O
two	O
other	O
commonly	O
used	O
algorithms	O
,	O
molecular	O
dynamics	O
in	O
Cartesian	O
space	O
and	O
metric-matrix	O
geometry	O
combined	O
with	O
Cartesian	O
molecular	O
dynamics	O
,	O
the	O
method	O
shows	O
increased	O
computational	O
efficiency	O
and	O
success	O
rate	O
for	O
large	O
proteins	O
,	O
and	O
it	O
shows	O
a	O
dramatically	O
increased	O
radius	O
of	O
convergence	O
for	O
DNA	O
.	O
The	O
torsion-angle	O
molecular	O
dynamics	O
algorithm	O
starts	O
from	O
an	O
extended	O
strand	O
conformation	O
and	O
proceeds	O
in	O
four	O
stages	O
:	O
high-temperature	O
torsion-angle	O
molecular	O
dynamics	O
,	O
slow-cooling	O
torsion-angle	O
molecular	O
dynamics	O
,	O
Cartesian	O
molecular	O
dynamics	O
,	O
and	O
minimization	O
.	O
Tests	O
were	O
carried	O
out	O
using	O
experimental	O
NMR	O
data	O
for	O
protein	O
G	O
,	O
interleukin-8	O
,	O
villin	O
14T	O
,	O
and	O
a	O
12	O
base-pair	O
duplex	O
of	O
DNA	O
,	O
and	O
simulated	O
NMR	O
data	O
for	O
bovine	O
pancreatic	O
trypsin	O
inhibitor	O
.	O
For	O
villin	O
14T	O
,	O
a	O
monomer	O
consisting	O
of	O
126	O
residues	O
,	O
structure	O
determination	O
by	O
torsion-angle	O
molecular	O
dynamics	O
has	O
a	O
success	O
rate	O
of	O
85	O
%	O
,	O
a	O
more	O
than	O
twofold	O
improvement	O
over	O
other	O
methods	O
.	O
In	O
the	O
case	O
of	O
the	O
12	O
base-pair	O
DNA	O
duplex	O
,	O
torsion-angle	O
molecular	O
dynamics	O
had	O
a	O
success	O
rate	O
of	O
52	O
%	O
while	O
Cartesian	O
molecular	O
dynamics	O
and	O
metric-matrix	O
distance	O
geometry	O
always	O
failed	O
.	O
The	O
wavelet-transform	O
method	O
is	O
used	O
to	O
quantify	O
the	O
magnetic	O
resonance	O
spectroscopy	O
(	O
MRS	O
)	O
parameters	O
:	O
chemical	O
shift	O
,	O
apparent	O
relaxation	O
time	O
T2	O
,	O
resonance	O
amplitude	O
,	O
and	O
phase	O
.	O
Wavelet	O
transformation	O
is	O
a	O
time-frequency	O
representation	O
which	O
separates	O
each	O
component	O
from	O
the	O
FID	O
,	O
then	O
successively	O
quantifies	O
it	O
and	O
subtracts	O
it	O
from	O
the	O
raw	O
signal	O
.	O
Two	O
iterative	O
procedures	O
have	O
been	O
developed	O
.	O
They	O
have	O
been	O
combined	O
with	O
a	O
nonlinear	O
regression	O
analysis	O
method	O
and	O
tested	O
on	O
both	O
simulated	O
and	O
real	O
sets	O
of	O
biomedical	O
MRS	O
data	O
selected	O
with	O
respect	O
to	O
the	O
main	O
problems	O
usually	O
encountered	O
in	O
quantifying	O
biomedical	O
MRS	O
,	O
specifically	O
``	O
chemical	O
noise	O
,	O
''	O
resulting	O
from	O
overlapping	O
resonances	O
,	O
and	O
baseline	O
distortion	O
.	O
The	O
results	O
indicate	O
that	O
the	O
wavelet-transform	O
method	O
can	O
provide	O
efficient	O
and	O
accurate	O
quantification	O
of	O
MRS	O
data	O
.	O
BACKGROUND	O
:	O
Antiplatelet	SYMP
therapy	SYMP
with	SYMP
aspirin	SYMP
and	SYMP
systematic	SYMP
anticoagulation	SYMP
with	SYMP
warfarin	SYMP
reduce	O
cardiovascular	SYMP
morbidity	SYMP
and	SYMP
mortality	SYMP
after	SYMP
myocardial	SYMP
infarction	SYMP
when	O
given	O
alone	O
.	O
In	O
the	O
Coumadin	O
Aspirin	O
Reinfarction	O
Study	O
(	O
CARS	O
)	O
,	O
we	O
aimed	O
to	O
find	O
out	O
whether	O
a	O
combination	O
of	O
low-dose	O
warfarin	SYMP
and	O
low-dose	SYMP
aspirin	SYMP
would	O
give	O
superior	O
results	O
to	O
standard	O
aspirin	SYMP
monotherapy	SYMP
without	O
excessive	O
bleeding	O
risk	O
.	O
METHODS	O
:	O
We	O
used	O
a	O
randomised	O
double-blind	O
study	O
design	O
.	O
At	O
293	O
sites	O
,	O
we	O
randomly	O
assigned	O
8803	O
patients	O
who	O
had	O
had	O
myocardial	SYMP
infarction	SYMP
,	O
treatment	O
with	O
160	SYMP
mg	SYMP
aspirin	SYMP
,	O
3	SYMP
mg	SYMP
warfarin	SYMP
with	SYMP
80	SYMP
mg	SYMP
aspirin	SYMP
,	O
or	O
1	SYMP
mg	SYMP
warfarin	SYMP
with	SYMP
80	SYMP
mg	SYMP
aspirin	SYMP
.	O
Patients	O
took	O
a	O
single	O
tablet	O
daily	O
,	O
and	O
attended	O
for	O
prothrombin	O
time	O
(	O
PT	O
)	O
measurements	O
at	O
weeks	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
6	O
,	O
and	O
12	O
,	O
and	O
then	O
every	O
3	O
months	O
.	O
Patients	O
were	O
followed	O
up	O
for	O
a	O
maximum	O
of	O
33	O
months	O
(	O
median	O
14	O
months	O
)	O
.	O
FINDINGS	O
:	O
The	O
primary	O
event	O
was	O
first	O
occurrence	O
of	O
reinfarction	O
,	O
non-fatal	O
ischaemic	SYMP
stroke	SYMP
,	O
or	O
cardiovascular	O
death	O
.	O
1-year	O
life-table	O
estimates	O
for	O
the	O
primary	O
event	O
were	O
8.6	O
%	O
(	O
95	O
%	O
CI	O
7.6-9.6	O
)	O
for	O
160	O
mg	O
aspirin	SYMP
,	O
8.4	O
%	O
(	O
7.4-9.4	O
)	O
for	O
3	O
mg	O
warfarin	SYMP
with	O
80	O
mg	O
aspirin	SYMP
,	O
and	O
8.8	O
%	O
(	O
7.6-10	O
)	O
for	O
1	O
mg	O
warfarin	SYMP
with	O
80	O
mg	O
aspirin	SYMP
.	O
Primary	O
comparisons	O
were	O
done	O
with	O
all	O
follow-up	O
data	O
.	O
The	O
relative	O
risk	O
of	O
the	O
primary	O
event	O
for	O
the	O
160	O
mg	O
aspirin	O
group	O
compared	O
with	O
the	O
3	O
mg	O
warfarin	O
with	O
80	O
mg	O
aspirin	O
group	O
was	O
0.95	O
(	O
0.81-1.12	O
,	O
p	O
=	O
0.57	O
)	O
.	O
For	O
spontaneous	O
major	O
haemorrhage	O
(	O
not	O
procedure	O
related	O
)	O
,	O
1-year	O
life-table	O
estimates	O
were	O
0.74	O
%	O
(	O
0.43-1.1	O
)	O
in	O
the	O
160	O
mg	O
aspirin	O
group	O
and	O
1.4	O
%	O
(	O
0.94-1.8	O
)	O
in	O
the	O
3	O
mg	O
warfarin	O
with	O
80	O
mg	O
aspirin	O
group	O
(	O
p	O
=	O
0.014	O
log	O
rank	O
on	O
follow-up	O
)	O
.	O
For	O
the	O
3382	O
patients	O
assigned	O
3	O
mg	O
warfarin	SYMP
with	O
80	O
mg	O
aspirin	SYMP
,	O
the	O
INR	O
results	O
were	O
:	O
at	O
week	O
1	O
(	O
n	O
=	O
2985	O
)	O
median	O
1.51	O
(	O
IQR	O
1.23-2.13	O
)	O
;	O
at	O
week	O
4	O
(	O
n	O
=	O
2701	O
)	O
1.27	O
(	O
1.13-1.64	O
)	O
;	O
at	O
month	O
6	O
(	O
n	O
=	O
2145	O
)	O
1.19	O
(	O
1.08-1.44	O
)	O
.	O
INTERPRETATION	O
:	O
Low	O
,	O
fixed-dose	O
warfarin	SYMP
(	SYMP
1	SYMP
mg	SYMP
or	SYMP
3	SYMP
mg	SYMP
)	SYMP
combined	SYMP
with	SYMP
low-dose	SYMP
aspirin	SYMP
(	SYMP
80	SYMP
mg	SYMP
)	SYMP
in	O
patients	O
who	O
have	O
had	O
myocardial	SYMP
infarction	SYMP
does	O
not	O
provide	O
clinical	O
benefit	O
beyond	O
that	O
achievable	O
with	O
160	O
mg	O
aspirin	SYMP
monotherapy	SYMP
.	O
BACKGROUND	O
:	O
There	O
is	O
serological	O
evidence	O
for	O
an	O
association	O
between	O
Chlamydia	SYMP
pneumoniae	SYMP
and	O
coronary	SYMP
heart	SYMP
disease	SYMP
.	O
We	O
investigated	O
the	O
hypothesis	O
that	O
an	SYMP
antichlamydial	SYMP
macrolide	SYMP
antibiotic	SYMP
,	SYMP
roxithromycin	SYMP
,	O
can	O
prevent	O
or	O
reduce	O
recurrent	O
major	O
ischaemic	O
events	O
in	O
patients	O
with	O
unstable	SYMP
angina	SYMP
.	O
METHODS	O
:	O
The	O
effect	O
of	O
roxithromycin	SYMP
was	O
assessed	O
in	O
a	O
double-blind	O
,	O
randomised	O
,	O
prospective	O
,	O
multicentre	O
,	O
parallel-group	O
,	O
placebo-controlled	O
pilot	O
study	O
of	O
202	O
patients	O
with	O
unstable	SYMP
angina	SYMP
or	O
non-Q-wave	SYMP
myocardial	SYMP
infarction	SYMP
.	O
Patients	O
were	O
randomly	O
assigned	O
either	O
roxithromycin	SYMP
150	O
mg	O
orally	O
twice	O
a	O
day	O
(	O
n	O
=	O
102	O
)	O
or	O
placebo	O
orally	O
twice	O
a	O
day	O
(	O
n	O
=	O
100	O
)	O
.	O
The	O
treatment	O
was	O
for	O
30	O
days	O
.	O
Patients	O
were	O
followed	O
up	O
for	O
6	O
months	O
.	O
We	O
report	O
the	O
primary	O
clinical	O
endpoints	O
(	O
cardiac	SYMP
ischaemic	SYMP
death	SYMP
,	O
myocardial	SYMP
infarction	SYMP
,	O
and	O
severe	O
recurrent	O
ischaemia	SYMP
)	O
,	O
assessed	O
at	O
day	O
31	O
,	O
in	O
202	O
patients	O
on	O
an	O
intention-to-treat	O
basis	O
.	O
FINDINGS	O
:	O
A	O
statistically	O
significant	O
reduction	O
in	O
the	O
primary	O
composite	O
triple	O
endpoint	O
rates	O
was	O
observed	O
in	O
the	O
roxithromycin	O
group	O
:	O
p	O
=	O
0.032	O
.	O
The	O
rate	O
of	O
severe	O
recurrent	O
ischaemia	O
,	O
myocardial	O
infarction	O
,	O
and	O
ischaemic	O
death	O
was	O
5.4	O
%	O
,	O
2.2	O
%	O
,	O
and	O
2.2	O
%	O
in	O
the	O
placebo	O
group	O
and	O
1.1	O
%	O
,	O
0	O
%	O
,	O
and	O
0	O
%	O
,	O
in	O
the	O
roxithromycin	O
group	O
,	O
respectively	O
.	O
No	O
major	O
drug-related	O
adverse	O
effects	O
were	O
observed	O
.	O
INTERPRETATION	O
:	O
Antichlamydial	SYMP
antibiotics	SYMP
may	O
be	O
useful	O
in	O
therapeutic	O
intervention	O
in	O
addition	O
to	O
standard	O
medication	O
in	O
patients	O
with	O
coronary-artery	SYMP
disease	SYMP
.	O
Large-scale	O
trials	O
are	O
needed	O
to	O
confirm	O
these	O
preliminary	O
observations	O
.	O
BACKGROUND	O
:	O
Stage	SYMP
Ib	SYMP
and	SYMP
IIa	SYMP
cervical	SYMP
carcinoma	SYMP
can	O
be	O
cured	O
by	O
radical	SYMP
surgery	SYMP
or	O
radiotherapy	SYMP
.	O
These	O
two	O
procedures	O
are	O
equally	O
effective	O
,	O
but	O
differ	O
in	O
associated	O
morbidity	O
and	O
type	O
of	O
complications	O
.	O
In	O
this	O
prospective	O
randomised	O
trial	O
of	O
radiotherapy	SYMP
versus	O
surgery	SYMP
,	O
our	O
aim	O
was	O
to	O
assess	O
the	O
5-year	O
survival	O
and	O
the	O
rate	O
and	O
pattern	O
of	O
complications	O
and	O
recurrences	O
associated	O
with	O
each	O
treatment	O
.	O
METHODS	O
:	O
Between	O
September	O
,	O
1986	O
,	O
and	O
December	O
,	O
1991	O
,	O
469	O
women	O
with	O
newly	O
diagnosed	O
stage	O
Ib	O
and	O
IIa	O
cervical	SYMP
carcinoma	SYMP
were	O
referred	O
to	O
our	O
institute	O
.	O
343	O
eligible	O
patients	O
were	O
randomised	O
:	O
172	O
to	O
surgery	SYMP
and	O
171	O
to	O
radical	O
radiotherapy	SYMP
.	O
Adjuvant	O
radiotherapy	O
was	O
delivered	O
after	O
surgery	O
for	O
women	O
with	O
surgical	O
stage	O
pT2b	O
or	O
greater	O
,	O
less	O
than	O
3	O
mm	O
of	O
safe	O
cervical	O
stroma	O
,	O
cut-through	O
,	O
or	O
positive	O
nodes	O
.	O
The	O
primary	O
outcome	O
measures	O
were	O
5-year	O
survival	O
and	O
the	O
rate	O
of	O
complications	O
.	O
The	O
analysis	O
of	O
survival	O
and	O
recurrence	O
was	O
by	O
intention	O
to	O
treat	O
and	O
analysis	O
of	O
complications	O
was	O
by	O
treatment	O
delivered	O
.	O
FINDINGS	O
:	O
170	O
patients	O
in	O
the	O
surgery	O
group	O
and	O
167	O
in	O
the	O
radiotherapy	O
group	O
were	O
included	O
in	O
the	O
intention-to-treat	O
analysis	O
;	O
scheduled	O
treatment	O
was	O
delivered	O
to	O
169	O
and	O
158	O
women	O
,	O
respectively	O
,	O
62	O
of	O
114	O
women	O
with	O
cervical	O
diameters	O
of	O
4	O
cm	O
or	O
smaller	O
and	O
46	O
of	O
55	O
with	O
diameters	O
larger	O
than	O
4	O
cm	O
received	O
adjuvant	O
therapy	O
.	O
After	O
a	O
median	O
follow-up	O
of	O
87	O
(	O
range	O
57-120	O
)	O
months	O
,	O
5-year	O
overall	O
and	O
disease-free	O
survival	O
were	O
identical	O
in	O
the	O
surgery	O
and	O
radiotherapy	O
groups	O
(	O
83	O
%	O
and	O
74	O
%	O
,	O
respectively	O
,	O
for	O
both	O
groups	O
)	O
,	O
86	O
women	O
developed	O
recurrent	O
disease	O
:	O
42	O
(	O
25	O
%	O
)	O
in	O
the	O
surgery	O
group	O
and	O
44	O
(	O
26	O
%	O
)	O
in	O
the	O
radiotherapy	O
group	O
.	O
Significant	O
factors	O
for	O
survival	O
in	O
univariate	O
and	O
multivariate	O
analyses	O
were	O
:	O
cervical	O
diameter	O
,	O
positive	O
lymphangiography	O
,	O
and	O
adeno-carcinomatous	O
histotype	O
.	O
48	O
(	O
28	O
%	O
)	O
surgery-group	O
patients	O
had	O
severe	O
morbidity	O
compared	O
with	O
19	O
(	O
12	O
%	O
)	O
radiotherapy-group	O
patients	O
(	O
p	O
=	O
0.0004	O
)	O
.	O
INTERPRETATION	O
:	O
There	O
is	O
no	O
treatment	O
of	O
choice	O
for	O
early-stage	O
cervical	SYMP
carcinoma	SYMP
in	O
terms	O
of	O
overall	O
or	O
disease-free	O
survival	O
.	O
The	O
combination	O
of	O
surgery	SYMP
and	O
radiotherapy	SYMP
has	O
the	O
worst	O
morbidity	O
,	O
especially	O
urological	O
complications	O
.	O
The	O
optimum	O
therapy	O
for	O
each	O
patient	O
should	O
take	O
account	O
of	O
clinical	O
factors	O
such	O
as	O
menopausal	O
status	O
,	O
age	O
,	O
medical	O
illness	O
,	O
histological	O
type	O
,	O
and	O
cervical	O
diameter	O
to	O
yield	O
the	O
best	O
cure	O
with	O
minimum	O
complications	O
.	O
Today	O
's	O
technology	O
links	O
health	O
care	O
providers	O
and	O
patients	O
across	O
town	O
,	O
in	O
the	O
next	O
state	O
or	O
even	O
another	O
country	O
.	O
Nursing	O
across	O
state	O
lines	O
poses	O
complications	O
:	O
state-bound	O
regulatory	O
and	O
licensure	O
issues	O
.	O
This	O
article	O
discusses	O
many	O
of	O
the	O
nutritional	O
topics	O
important	O
to	O
the	O
intensivist	O
.	O
Nutritional	O
assessment	O
,	O
substrate	O
immunonutrition	O
,	O
and	O
disease	O
specific	O
issues	O
are	O
presented	O
.	O
Early	O
introduction	O
of	O
enteral	O
feeds	O
and	O
the	O
use	O
of	O
nutritional	O
modulation	O
are	O
emphasized	O
.	O
PROBLEM	O
:	O
To	O
compare	O
the	O
expression	O
by	O
T-lymphocytes	O
of	O
an	O
immunomodulatory	O
protein	O
known	O
as	O
progesterone-induced	O
blocking	O
factor	O
(	O
PIBF	O
)	O
in	O
conception	O
versus	O
non-conception	O
cycles	O
even	O
when	O
there	O
has	O
been	O
definite	O
fertilization	O
and	O
embryo	O
formation	O
.	O
METHOD	O
:	O
PIBF	O
expression	O
on	O
T	O
lymphocytes	O
was	O
measured	O
using	O
an	O
immunohistochemical	O
method	O
with	O
a	O
PIBF-specific	O
polyclonal	O
antibody	O
.	O
These	O
levels	O
were	O
determined	O
in	O
patients	O
undergoing	O
three	O
types	O
of	O
therapy	O
:	O
non-in	O
vitro	O
fertilization	O
(	O
IVF	O
)	O
,	O
IVF-embryo	O
transfer	O
(	O
ET	O
)	O
,	O
and	O
frozen	O
ET	O
.	O
Sera	O
were	O
drawn	O
12	O
days	O
from	O
ovulation	O
in	O
non-IVF	O
cycles	O
or	O
9	O
days	O
after	O
ET	O
and	O
were	O
assayed	O
for	O
PIBF	O
and	O
beta	O
human	O
chorionic	O
gondotropin	O
.	O
Comparison	O
of	O
the	O
frequency	O
of	O
lymphocyte	O
expression	O
of	O
PIBF	O
in	O
pregnant	O
versus	O
non-pregnant	O
women	O
were	O
made	O
.	O
RESULTS	O
:	O
PIBF	O
was	O
detected	O
in	O
29.5	O
%	O
of	O
non-pregnant	O
women	O
and	O
52.5	O
%	O
of	O
pregnant	O
women	O
.	O
There	O
were	O
no	O
differences	O
in	O
PIBF	O
levels	O
by	O
therapy	O
used	O
in	O
non-pregnant	O
cases	O
or	O
in	O
the	O
pregnant	O
group	O
.	O
CONCLUSION	O
:	O
These	O
data	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
maternal	O
expression	O
of	O
PIBF	O
in	O
T-lymphocytes	O
soon	O
after	O
trophoblast	O
invasion	O
may	O
depend	O
on	O
successful	O
implantation	O
.	O
Many	O
amino	O
acids	O
contain	O
an	O
asymmetric	O
centre	O
,	O
occurring	O
as	O
laevorotatory	O
,	O
L	O
,	O
or	O
dextrorotatory	O
,	O
D	O
,	O
compounds	O
.	O
It	O
is	O
generally	O
assumed	O
that	O
abiotic	O
synthesis	O
of	O
amino	O
acids	O
on	O
the	O
early	O
Earth	O
resulted	O
in	O
racemic	O
mixtures	O
(	O
L-	O
and	O
D-enantiomers	O
in	O
equal	O
abundance	O
)	O
.	O
But	O
the	O
origin	O
of	O
life	O
required	O
,	O
owing	O
to	O
conformational	O
constraints	O
,	O
the	O
almost	O
exclusive	O
selection	O
of	O
either	O
L-	O
or	O
D-enantiomers	O
,	O
and	O
the	O
question	O
of	O
why	O
living	O
systems	O
on	O
the	O
Earth	O
consist	O
of	O
L-enantiomers	O
rather	O
than	O
D-enantiomers	O
is	O
unresolved	O
.	O
A	O
substantial	O
fraction	O
of	O
the	O
organic	O
compounds	O
on	O
the	O
early	O
Earth	O
may	O
have	O
been	O
derived	O
from	O
comet	O
and	O
meteorite	O
impacts	O
.	O
It	O
has	O
been	O
reported	O
previously	O
that	O
amino	O
acids	O
in	O
the	O
Murchison	O
meteorite	O
exhibit	O
an	O
excess	O
of	O
L-enantiomers	O
,	O
raising	O
the	O
possibility	O
that	O
a	O
similar	O
excess	O
was	O
present	O
in	O
the	O
initial	O
inventory	O
of	O
organic	O
compounds	O
on	O
the	O
Earth	O
.	O
The	O
stable	O
carbon	O
isotope	O
compositions	O
of	O
individual	O
amino	O
acids	O
in	O
Murchison	O
support	O
an	O
extraterrestrial	O
origin	O
--	O
rather	O
than	O
a	O
terrestrial	O
overprint	O
of	O
biological	O
amino	O
acids-although	O
reservations	O
have	O
persisted	O
.	O
Here	O
we	O
show	O
that	O
individual	O
amino-acid	O
enantiomers	O
from	O
Murchison	O
are	O
enriched	O
in	O
15N	O
relative	O
to	O
their	O
terrestrial	O
counterparts	O
,	O
so	O
confirming	O
an	O
extraterrestrial	O
source	O
for	O
an	O
L-enantiomer	O
excess	O
in	O
the	O
Solar	O
System	O
that	O
may	O
predate	O
the	O
origin	O
of	O
life	O
on	O
the	O
Earth	O
.	O
Home	O
care	O
workers	O
face	O
an	O
increasing	O
risk	O
for	O
workplace	O
violence	O
.	O
A	O
proactive	O
preventive	O
approach	O
is	O
presented	O
that	O
suggests	O
strategies	O
to	O
use	O
during	O
the	O
previsit	O
phase	O
,	O
the	O
visit	O
experience	O
,	O
and	O
on	O
an	O
ongoing	O
basis	O
.	O
The	O
miracidia	O
of	O
Fasciola	O
hepatica	O
and	O
Trichobilharzia	O
ocellata	O
approach	O
their	O
host	O
snails	O
Lymnaea	O
truncatula	O
and	O
L.	O
stagnalis	O
by	O
increasing	O
their	O
rate	O
of	O
change	O
of	O
direction	O
(	O
RCD	O
)	O
in	O
increasing	O
gradients	O
of	O
snail-conditioned	O
water	O
(	O
SCW	O
)	O
,	O
and	O
they	O
perform	O
a	O
turnback	O
swimming	O
in	O
decreasing	O
gradients	O
.	O
Both	O
hostfinding	O
responses	O
in	O
both	O
species	O
were	O
induced	O
by	O
glycoconjugates	O
with	O
a	O
molecular	O
weight	O
of	O
greater	O
than	O
30	O
kDa	O
that	O
were	O
sensitive	O
to	O
hydrolysis	O
with	O
pronase	O
E	O
and	O
oxidation	O
with	O
NaIO4	O
.	O
Alkaline	O
cleavage	O
revealed	O
that	O
they	O
contained	O
carbohydrates	O
linked	O
O-glycosidically	O
via	O
serine	O
and	O
N-acetylgalactosamine	O
.	O
Miracidia	O
clearly	O
preferred	O
SCW	O
from	O
their	O
specific	O
host	O
snail	O
versus	O
other	O
sympatric	O
snail	O
species	O
and	O
did	O
not	O
respond	O
to	O
water	O
conditioned	O
with	O
fish	O
,	O
tadpoles	O
,	O
or	O
leeches	O
.	O
Differences	O
in	O
the	O
chemical	O
characteristics	O
of	O
SCW	O
from	O
the	O
intermediate	O
hosts	O
L.	O
truncatula	O
and	O
L.	O
stagnalis	O
could	O
be	O
shown	O
by	O
sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
electrophoresis	O
,	O
blotting	O
,	O
and	O
subsequent	O
carbohydrate	O
detection	O
.	O
The	O
first	O
step	O
of	O
purification	O
of	O
the	O
effective	O
signaling	O
SCW	O
components	O
from	O
both	O
snail	O
species	O
was	O
achieved	O
by	O
ion-exchange	O
chromatography	O
.	O
Black	O
patients	O
with	O
colon	SYMP
cancer	SYMP
in	O
the	O
Black/White	O
Cancer	O
Survival	O
Study	O
were	O
found	O
to	O
have	O
a	O
poorer	O
survival	O
than	O
white	O
patients	O
.	O
More	O
advanced-stage	O
disease	O
at	O
diagnosis	O
was	O
the	O
primary	O
determinant	O
,	O
accounting	O
for	O
60	O
%	O
of	O
the	O
excess	O
mortality	O
.	O
After	O
adjusting	O
for	O
stage	O
,	O
factors	O
such	O
as	O
poverty	O
,	O
other	O
socioeconomic	O
conditions	O
,	O
and	O
treatment	O
did	O
not	O
further	O
explain	O
the	O
remaining	O
survival	O
deficit	O
.	O
This	O
study	O
examined	O
the	O
aggressiveness	O
of	O
colon	SYMP
tumors	SYMP
in	O
blacks	O
and	O
whites	O
to	O
explore	O
its	O
role	O
in	O
the	O
racial	O
survival	O
differences	O
.	O
Tumor	O
characteristics	O
of	O
703	O
cases	O
of	O
newly	O
diagnosed	O
invasive	O
colon	O
adenocarcinoma	SYMP
were	O
centrally	O
evaluated	O
by	O
a	O
gastrointestinal	O
pathologist	O
,	O
blinded	O
in	O
regard	O
to	O
the	O
age	O
,	O
race	O
,	O
and	O
sex	O
of	O
the	O
patients	O
.	O
Blacks	O
were	O
less	O
likely	O
to	O
have	O
poorly	O
differentiated	O
(	O
grade	O
3	O
)	O
tumors	SYMP
(	O
odds	O
ratio	O
(	O
OR	O
)	O
,	O
0.44	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.22-0.88	O
)	O
and	O
lymphoid	O
reaction	O
(	O
OR	O
,	O
0.49	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.26-0.90	O
)	O
when	O
compared	O
with	O
whites	O
.	O
These	O
black/white	O
(	O
B/W	O
)	O
differences	O
remained	O
statistically	O
significant	O
after	O
adjusting	O
for	O
age	O
,	O
sex	O
,	O
metropolitan	O
area	O
,	O
summary	O
stage	O
,	O
socioeconomic	O
status	O
,	O
body	O
mass	O
index	O
,	O
and	O
health	O
care	O
access	O
and	O
utilization	O
.	O
In	O
addition	O
,	O
blacks	O
were	O
less	O
likely	O
to	O
have	O
high-grade	O
(	O
grade	O
3	O
)	O
nuclear	SYMP
atypia	SYMP
,	O
mitotic	O
activity	O
,	O
and	O
tubule	O
formation	O
,	O
although	O
these	O
ORs	O
did	O
not	O
reach	O
a	O
statistical	O
significance	O
level	O
of	O
0.05	O
.	O
Similar	O
B/W	O
differences	O
were	O
observed	O
for	O
patients	O
with	O
advanced	O
disease	O
but	O
not	O
with	O
early	O
stage	O
.	O
Comparison	O
by	O
anatomical	O
subsite	O
showed	O
that	O
blacks	O
had	O
statistically	O
significantly	O
better	O
differentiated	O
tumors	SYMP
for	O
cancers	SYMP
of	O
the	O
proximal	O
and	O
transverse	O
colon	O
but	O
not	O
for	O
the	O
distal	O
.	O
No	O
racial	O
differences	O
were	O
found	O
for	O
blood	O
vessel	O
and	O
lymphatic	SYMP
invasion	SYMP
,	O
necrosis	SYMP
,	O
fibrosis	SYMP
,	O
and	O
mucinous	O
type	O
of	O
histology	O
.	O
The	O
findings	O
,	O
therefore	O
,	O
are	O
the	O
opposite	O
of	O
those	O
hypothesized	O
.	O
After	O
adjusting	O
for	O
stage	O
,	O
more	O
aggressive	O
tumor	O
characteristics	O
do	O
not	O
explain	O
the	O
adverse	O
survival	O
differential	O
in	O
blacks	O
.	O
This	O
suggests	O
that	O
there	O
may	O
be	O
racial	O
differences	O
in	O
environmental	O
exposure	O
,	O
and	O
that	O
the	O
intensity	O
and	O
mode	O
of	O
delivery	O
of	O
carcinogen	O
insult	O
as	O
well	O
as	O
host	O
susceptibility	O
may	O
differ	O
by	O
race	O
and	O
anatomical	O
subsite	O
.	O
Future	O
studies	O
should	O
explore	O
the	O
B/W	O
differences	O
in	O
tumor	O
biology	O
using	O
molecular	O
markers	O
that	O
precede	O
the	O
conventional	O
histological	O
parameters	O
evaluated	O
here	O
.	O
A	O
new	O
method	O
is	O
described	O
for	O
detection	O
of	O
mutations	O
in	O
the	O
lysosomal	O
alpha-glucosidase	O
gene	O
(	O
GAA	O
)	O
leading	O
to	O
Glycogen	SYMP
Storage	SYMP
Disease	SYMP
type	SYMP
II	SYMP
(	SYMP
GSDII	SYMP
)	SYMP
.	O
A	O
key	O
feature	O
of	O
the	O
method	O
is	O
isolation	O
and	O
reverse	O
transcription	O
of	O
mRNA	O
followed	O
by	O
PCR	O
amplification	O
of	O
lysosomal	O
alpha-glucosidase	O
cDNA	O
with	O
M13-extended	O
primers	O
.	O
Dye	O
labeled	O
primers	O
are	O
used	O
for	O
cycle	O
sequencing	O
and	O
an	O
ABI	O
PRISM	O
377	O
DNA	O
sequencing	O
system	O
for	O
analysis	O
.	O
The	O
method	O
is	O
rapid	O
and	O
complementary	O
to	O
the	O
automated	O
sequencing	O
of	O
all	O
the	O
19	O
,	O
PCR	O
amplified	O
,	O
coding	O
exons	O
of	O
the	O
GAA	O
gene	O
.	O
The	O
advantages	O
and	O
pitfalls	O
of	O
this	O
new	O
method	O
are	O
discussed	O
in	O
the	O
light	O
of	O
the	O
results	O
obtained	O
with	O
an	O
infantile	O
GSDII	O
patient	O
.	O
A	O
new	O
splice	O
site	O
mutation	O
in	O
the	O
GAA	O
gene	O
of	O
this	O
patient	O
was	O
identified	O
,	O
IVS16	O
(	O
+2T	O
--	O
greater	O
than	O
C	O
)	O
,	O
resulting	O
in	O
the	O
deletion	O
of	O
16	O
base	O
pairs	O
of	O
exon	O
16	O
.	O
The	O
presence	O
of	O
clinical	O
autonomic	SYMP
dysfunction	SYMP
in	O
patients	O
with	O
neurologic	SYMP
diseases	SYMP
,	O
such	O
as	O
multiple	SYMP
sclerosis	SYMP
,	O
Parkinson	SYMP
's	SYMP
disease	SYMP
,	O
and	O
cerebrovascular	O
accident	O
,	O
has	O
become	O
increasingly	O
recognized	O
in	O
the	O
past	O
decade	O
.	O
Very	O
few	O
autonomic	O
tests	O
have	O
been	O
done	O
on	O
pediatric	O
patients	O
thus	O
far	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
autonomic	O
function	O
in	O
patients	O
with	O
cerebral	SYMP
palsy	SYMP
using	O
two	O
noninvasive	O
tests	O
:	O
sympathetic	O
skin	O
response	O
(	O
SSR	O
)	O
and	O
R-R	O
interval	O
variation	O
(	O
RRIV	O
)	O
.	O
Twenty-four	O
patients	O
with	O
cerebral	SYMP
palsy	SYMP
and	O
24	O
control	O
subjects	O
between	O
the	O
ages	O
of	O
4	O
and	O
12	O
yr	O
were	O
enrolled	O
in	O
this	O
study	O
.	O
There	O
was	O
no	O
significant	O
difference	O
of	O
mean	O
latency	O
,	O
amplitude	O
,	O
or	O
amplitude	O
ratio	O
of	O
SSR	O
between	O
the	O
two	O
groups	O
under	O
electric	O
stimulus	O
,	O
startling	O
stimulus	O
,	O
and	O
deep	O
breathing	O
conditions	O
.	O
No	O
significant	O
difference	O
in	O
frequency	O
of	O
absent	O
response	O
and	O
asymmetric	O
response	O
was	O
also	O
noted	O
.	O
Mean	O
heart	O
rate	O
under	O
relaxed	O
sitting	O
condition	O
was	O
significantly	O
higher	O
in	O
the	O
study	O
group	O
.	O
Significant	O
negative	O
correlation	O
between	O
heart	O
rate	O
and	O
age	O
was	O
noted	O
in	O
the	O
control	O
group	O
but	O
was	O
not	O
present	O
in	O
the	O
study	O
group	O
.	O
Also	O
,	O
there	O
was	O
no	O
statistical	O
difference	O
of	O
mean	O
RRIV	O
between	O
the	O
two	O
groups	O
.	O
No	O
objective	O
evidence	O
of	O
autonomic	O
disturbance	O
in	O
patients	O
with	O
cerebral	SYMP
palsy	SYMP
was	O
found	O
in	O
this	O
study	O
.	O
A	O
two-credits	O
per	O
semester	O
clinical	O
medicine	O
course	O
was	O
established	O
in	O
the	O
Department	O
of	O
Physical	O
Medicine	O
and	O
Rehabilitation	O
(	O
PM	O
&	O
#	O
38	O
;	O
R	O
)	O
in	O
cooperation	O
with	O
the	O
Johns	O
Hopkins	O
University	O
undergraduate	O
Human	O
Biology	O
faculty	O
to	O
present	O
the	O
variety	O
of	O
inpatient	O
consultation	O
personnel	O
,	O
units	O
,	O
patient	O
diagnostic	O
groups	O
,	O
and	O
functional	O
problems	O
.	O
College	O
students	O
spend	O
4	O
hr	O
weekly	O
on	O
the	O
PM	O
&	O
#	O
38	O
;	O
R	O
consultation	O
service	O
as	O
team	O
members	O
under	O
resident	O
supervision	O
.	O
The	O
curriculum	O
emphasizes	O
student	O
understanding	O
of	O
the	O
roles	O
of	O
rehabilitation	O
team	O
members	O
.	O
Objectives	O
include	O
demonstration	O
of	O
working	O
knowledge	O
of	O
the	O
Biopsychosocial	O
Model	O
,	O
the	O
World	O
Health	O
Organization	O
Model	O
of	O
disablement	O
and	O
interdisciplinary	O
rehabilitation	O
intervention	O
.	O
The	O
course	O
includes	O
simulations	O
of	O
physical	O
impairments	O
,	O
demonstrations	O
of	O
adaptive	O
equipment	O
,	O
interactive	O
chart	O
reviews	O
,	O
readings	O
,	O
and	O
audio	O
lectures	O
.	O
A	O
retrospective	O
sequential	O
review	O
was	O
made	O
of	O
the	O
last	O
100	O
physical	O
medicine	O
and	O
rehabilitation	O
consultations	O
with	O
student	O
attendance	O
.	O
The	O
results	O
confirm	O
student	O
exposure	O
to	O
many	O
ward	O
settings	O
(	O
surgery	O
,	O
30	O
%	O
;	O
neurology/neurosurgery	O
,	O
28	O
%	O
;	O
medicine	O
,	O
24	O
%	O
;	O
intensive	O
care	O
,	O
15	O
%	O
;	O
oncology	O
,	O
2	O
%	O
;	O
and	O
psychiatry	O
,	O
1	O
%	O
)	O
,	O
patient	O
complexity	O
(	O
averaging	O
10	O
problems	O
)	O
,	O
and	O
multiple	O
ICD-9	O
diagnosis	O
categories	O
(	O
circulatory	O
,	O
36	O
%	O
;	O
neurologic	O
,	O
22	O
%	O
;	O
musculoskeletal	O
,	O
17	O
%	O
;	O
neoplasms	O
,	O
10	O
%	O
;	O
injury	O
,	O
5	O
%	O
;	O
endocrine	O
,	O
4	O
%	O
;	O
infections	O
,	O
3	O
%	O
;	O
and	O
others	O
,	O
3	O
%	O
)	O
.	O
The	O
rehabilitation	O
consultation	O
service	O
is	O
particularly	O
effective	O
as	O
an	O
introduction	O
to	O
hospital-based	O
medical	O
practice	O
due	O
to	O
the	O
diagnostic	O
variety	O
of	O
the	O
patients	O
,	O
the	O
functional	O
approach	O
of	O
rehabilitation	O
,	O
and	O
student	O
exposure	O
to	O
multiple	O
hospital	O
settings	O
.	O
The	O
Biopsychosocial	O
Model	O
of	O
medical	O
practice	O
is	O
demonstrated	O
through	O
multiple	O
interdisciplinary	O
perspectives	O
of	O
needs	O
and	O
interventions	O
for	O
patients	O
with	O
obvious	O
functional	O
deficits	O
.	O
This	O
process	O
develops	O
a	O
rudimentary	O
understanding	O
of	O
the	O
effect	O
of	O
illness	O
on	O
the	O
person	O
and	O
the	O
variety	O
of	O
medically	O
effective	O
therapeutic	O
modalities	O
.	O
This	O
study	O
is	O
designed	O
to	O
investigate	O
the	O
immediate	O
effectiveness	O
of	O
electrotherapy	SYMP
on	O
myofascial	SYMP
trigger	SYMP
points	SYMP
of	SYMP
upper	SYMP
trapezius	SYMP
muscle	SYMP
.	O
Sixty	O
patients	O
(	O
25	O
males	O
and	O
35	O
females	O
)	O
who	O
had	O
myofascial	SYMP
trigger	SYMP
points	SYMP
in	O
one	O
side	O
of	O
the	O
upper	O
trapezius	O
muscles	O
were	O
studied	O
.	O
The	O
involved	O
upper	O
trapezius	O
muscles	O
were	O
treated	O
with	O
three	O
different	O
methods	O
according	O
to	O
a	O
random	O
assignment	O
:	O
group	O
A	O
muscles	O
(	O
n	O
=	O
18	O
)	O
were	O
given	O
placebo	O
treatment	O
(	O
control	O
group	O
)	O
;	O
group	O
B	O
muscles	O
(	O
n	O
=	O
20	O
)	O
were	O
treated	O
with	O
electrical	SYMP
nerve	SYMP
stimulation	SYMP
(	SYMP
ENS	SYMP
)	SYMP
therapy	SYMP
;	O
and	O
group	O
C	O
muscles	O
(	O
n	O
=	O
22	O
)	O
were	O
given	O
electrical	SYMP
muscle	SYMP
stimulation	SYMP
(	SYMP
EMS	SYMP
)	SYMP
therapy	SYMP
.	O
The	O
effectiveness	O
of	O
treatment	O
was	O
assessed	O
by	O
conducting	O
three	O
measurements	O
on	O
each	O
muscle	O
before	O
and	O
immediately	O
after	O
treatment	O
:	O
subjective	O
pain	O
intensity	O
(	O
(	O
PI	O
)	O
with	O
a	O
visual	O
analog	O
scale	O
)	O
,	O
pressure	O
pain	O
threshold	O
(	O
(	O
PT	O
)	O
with	O
algometry	O
)	O
,	O
and	O
range	O
of	O
motion	O
(	O
(	O
ROM	O
)	O
with	O
a	O
goniometer	O
)	O
of	O
upper	O
trapezius	O
muscle	O
(	O
lateral	O
bending	O
of	O
cervical	O
spine	O
to	O
the	O
opposite	O
side	O
)	O
.	O
When	O
the	O
effectiveness	O
of	O
treatment	O
was	O
compared	O
with	O
that	O
of	O
the	O
placebo	O
group	O
(	O
group	O
A	O
)	O
,	O
there	O
was	O
significant	O
improvement	O
in	O
PI	O
and	O
PT	O
in	O
group	O
B	O
(	O
P	O
&	O
#	O
60	O
;	O
0.01	O
)	O
but	O
not	O
in	O
group	O
C	O
(	O
P	O
greater	O
than	O
0.05	O
)	O
.	O
The	O
improvement	O
of	O
ROM	O
was	O
significantly	O
more	O
in	O
group	O
C	O
(	O
P	O
&	O
#	O
60	O
;	O
0.01	O
)	O
as	O
compared	O
with	O
that	O
in	O
group	O
A	O
or	O
group	O
B	O
.	O
When	O
each	O
group	O
was	O
divided	O
into	O
two	O
additional	O
subgroups	O
based	O
on	O
the	O
initial	O
PI	O
,	O
it	O
was	O
found	O
that	O
ENS	O
could	O
reduce	O
PI	O
and	O
increase	O
PT	O
significantly	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
,	O
but	O
did	O
not	O
significantly	O
(	O
P	O
greater	O
than	O
0.05	O
)	O
improve	O
ROM	O
,	O
as	O
compared	O
with	O
the	O
placebo	O
group	O
for	O
both	O
subgroups	O
.	O
EMS	O
could	O
significantly	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
improve	O
ROM	O
,	O
but	O
not	O
PT	O
,	O
better	O
than	O
the	O
placebo	O
groups	O
,	O
for	O
either	O
subgroup	O
.	O
It	O
could	O
reduce	O
PI	O
significantly	O
more	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
than	O
placebo	O
controls	O
only	O
for	O
the	O
subgroup	O
with	O
mild	O
to	O
moderate	O
pain	O
,	O
but	O
not	O
with	O
severe	O
pain	O
.	O
For	O
pain	O
relief	O
,	O
ENS	O
was	O
significantly	O
better	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
than	O
EMS	O
;	O
but	O
for	O
the	O
improvement	O
of	O
ROM	O
,	O
EMS	O
was	O
significantly	O
better	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
than	O
ENS	O
.	O
It	O
is	O
concluded	O
that	O
ENS	SYMP
is	O
more	O
effective	O
for	O
immediate	O
relief	O
of	O
myofascial	SYMP
trigger	SYMP
point	SYMP
pain	SYMP
than	O
EMS	SYMP
,	O
and	O
EMS	SYMP
has	O
a	O
better	O
effect	O
on	O
immediate	O
release	O
of	O
muscle	SYMP
tightness	SYMP
than	O
ENS	SYMP
.	O
Because	O
activity	O
and	O
regular	O
exercise	O
are	O
important	O
factors	O
to	O
maintain	O
general	O
good	O
health	O
in	O
senior	O
citizens	O
,	O
we	O
investigated	O
whether	O
senior	O
dancing	O
has	O
any	O
effect	O
on	O
peripheral	O
or	O
lumbar	O
bone	O
density	O
.	O
We	O
performed	O
a	O
prospective	O
study	O
over	O
a12-mo	O
period	O
on	O
bone	O
density	O
at	O
a	O
spinal	O
and	O
peripheral	O
measuring	O
site	O
in	O
28	O
female	O
senior	O
members	O
(	O
mean	O
age	O
:	O
67	O
+/-	O
2	O
yr	O
)	O
of	O
a	O
dancing	O
group	O
in	O
Vienna	O
.	O
Lumbar	O
bone	O
mineral	O
density	O
was	O
assessed	O
by	O
quantitative	O
computed	O
tomography	O
(	O
qCT	O
)	O
and	O
radial	O
bone	O
density	O
by	O
single	O
photon	O
absorptiometry	O
of	O
the	O
distal	O
forearm	O
.	O
The	O
mean	O
training	O
time	O
per	O
week	O
was	O
3.2	O
+/-	O
0.8	O
h.	O
In	O
the	O
entire	O
group	O
of	O
female	O
dancers	O
,	O
no	O
significant	O
effects	O
of	O
dancing	O
on	O
radial	O
or	O
lumbar	O
bone	O
density	O
could	O
be	O
observed	O
.	O
Linear	O
regression	O
analysis	O
showed	O
that	O
the	O
lower	O
the	O
qCT	O
at	O
the	O
beginning	O
of	O
the	O
observation	O
period	O
,	O
the	O
higher	O
was	O
the	O
percentage	O
increase	O
of	O
spinal	O
qCT	O
in	O
the	O
entire	O
group	O
during	O
12	O
mo	O
of	O
dancing	O
(	O
r	O
=	O
0.52	O
,	O
P	O
&	O
#	O
60	O
;	O
0.0001	O
)	O
.	O
For	O
additional	O
evaluation	O
,	O
females	O
were	O
divided	O
into	O
two	O
subgroups	O
,	O
osteoporotic	O
or	O
nonosteoporotic	O
,	O
based	O
on	O
x-rays	O
and	O
lumbar	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
as	O
measured	O
by	O
qCT	O
.	O
The	O
group	O
classified	O
as	O
dancers	O
with	O
osteoporosis	O
(	O
group	O
I	O
)	O
showed	O
a	O
significant	O
increase	O
in	O
lumbar	O
bone	O
density	O
,	O
whereas	O
in	O
the	O
group	O
of	O
dancers	O
without	O
signs	O
of	O
osteoporosis	SYMP
(	O
group	O
II	O
)	O
,	O
BMD	O
remained	O
unchanged	O
.	O
Additionally	O
,	O
radial	O
bone	O
density	O
did	O
not	O
show	O
any	O
changes	O
in	O
either	O
group	O
.	O
Group	O
I	O
showed	O
a	O
significant	O
correlation	O
between	O
basal	O
spinal	O
BMD	O
and	O
the	O
percentage	O
change	O
of	O
BMD	O
during	O
the	O
observation	O
period	O
(	O
r	O
=	O
0.7	O
,	O
P	O
&	O
#	O
60	O
;	O
0.001	O
)	O
.	O
Changes	O
of	O
the	O
biochemical	O
parameters	O
were	O
observed	O
in	O
the	O
bone-specific	O
isoenzyme	O
of	O
alkaline	O
phosphatase	O
,	O
a	O
marker	O
of	O
osteoblastic	O
activity	O
,	O
in	O
group	O
I	O
giving	O
additional	O
evidence	O
of	O
increased	O
bone	O
formation	O
.	O
OBJECTIVES	O
:	O
To	O
estimate	O
the	O
prevalence	O
of	O
Chlamydia	SYMP
trachomatis	SYMP
in	O
asymptomatic	O
women	O
attending	O
general	O
practice	O
:	O
to	O
assess	O
the	O
potential	O
of	O
the	O
ligase	O
chain	O
reaction	O
as	O
a	O
screening	O
tool	O
;	O
and	O
to	O
evaluate	O
selective	O
screening	O
criteria	O
.	O
DESIGN	O
:	O
Cross	O
sectional	O
survey	O
.	O
SETTING	O
:	O
Four	O
general	O
practices	O
in	O
northeast	O
London	O
.	O
SUBJECTS	O
:	O
890	O
women	O
aged	O
18-35	O
years	O
attending	O
general	O
practice	O
for	O
a	O
cervical	O
smear	O
or	O
a	O
``	O
young	O
well	O
woman	O
''	O
check	O
between	O
October	O
1994	O
and	O
January	O
1996	O
.	O
The	O
women	O
were	O
tested	O
for	O
C	SYMP
trachomatis	SYMP
with	O
confirmed	O
enzyme	O
immunoassay	O
(	O
endocervical	O
specimens	O
)	O
and	O
ligase	O
chain	O
reaction	O
assay	O
on	O
urine	O
specimens	O
.	O
MAIN	O
OUTCOME	O
MEASURES	O
:	O
Prevalence	O
of	O
C	SYMP
trachomatis	SYMP
infection	SYMP
in	O
women	O
aged	O
18-35	O
on	O
the	O
basis	O
of	O
each	O
test	O
;	O
sensitivity	O
and	O
specificity	O
of	O
both	O
tests	O
in	O
this	O
population	O
.	O
RESULTS	O
:	O
Prevalence	O
of	O
confirmed	O
infection	O
was	O
2.6	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
1.6	O
%	O
to	O
3.6	O
%	O
)	O
in	O
all	O
women	O
.	O
Prevalence	O
on	O
the	O
basis	O
of	O
enzyme	O
immunoassay	O
was	O
1.6	O
%	O
(	O
0.8	O
%	O
to	O
2.7	O
%	O
)	O
,	O
with	O
a	O
sensitivity	O
of	O
60	O
%	O
and	O
a	O
specificity	O
of	O
100	O
%	O
.	O
Prevalence	O
on	O
the	O
basis	O
of	O
ligase	O
chain	O
reaction	O
was	O
2.5	O
%	O
(	O
1.5	O
%	O
to	O
3.9	O
%	O
)	O
,	O
with	O
90	O
%	O
sensitivity	O
and	O
99.8	O
%	O
specificity	O
.	O
Screening	O
all	O
women	O
aged	O
&	O
#	O
60	O
;	O
or	O
=	O
25	O
and	O
all	O
women	O
who	O
had	O
had	O
two	O
or	O
more	O
partners	O
in	O
the	O
past	O
year	O
would	O
have	O
detected	O
87	O
%	O
(	O
20/23	O
)	O
of	O
infections	O
.	O
CONCLUSION	O
:	O
Ligase	O
chain	O
reaction	O
on	O
urine	O
samples	O
performs	O
at	O
least	O
as	O
well	O
as	O
enzyme	O
immunoassay	O
on	O
cervical	O
specimens	O
in	O
this	O
low	O
prevalence	O
population	O
.	O
It	O
offers	O
potential	O
as	O
a	O
non-invasive	O
screening	O
tool	O
.	O
A	O
simple	O
selective	O
screening	O
strategy	O
might	O
be	O
appropriate	O
and	O
would	O
be	O
able	O
to	O
detect	O
most	O
cases	O
of	O
infection	SYMP
.	O
However	O
,	O
a	O
rigorous	O
economic	O
evaluation	O
of	O
possible	O
screening	O
strategies	O
is	O
needed	O
first	O
.	O
Recently	O
,	O
many	O
advances	O
have	O
been	O
made	O
in	O
the	O
study	O
of	O
sexual	O
differentiation	O
,	O
including	O
the	O
discoveries	O
of	O
the	O
gene	O
for	O
antim1/4llerian	O
hormone	O
as	O
well	O
as	O
the	O
gene	O
for	O
its	O
receptor	O
.	O
However	O
,	O
the	O
etiology	O
of	O
the	O
clinical	O
syndrome	O
of	O
m1/4llerian	O
agenesis	O
remains	O
elusive	O
.	O
We	O
hypothesize	O
that	O
activating	O
mutations	O
of	O
either	O
the	O
antim1/4llerian	O
hormone	O
gene	O
or	O
its	O
receptor	O
gene	O
may	O
cause	O
m1/4llerian	O
duct	O
regression	O
in	O
a	O
genetic	O
female	O
during	O
embryogenesis	O
.	O
This	O
clinical	O
commentary	O
discusses	O
the	O
current	O
management	O
of	O
the	O
syndrome	O
including	O
the	O
Abbe-McIndoe	SYMP
procedure	SYMP
,	O
the	O
most	O
commonly	O
used	O
method	O
of	O
surgical	SYMP
correction	SYMP
,	O
and	O
the	O
Frank	SYMP
vaginal	SYMP
dilation	SYMP
method	SYMP
,	O
the	O
most	O
common	O
nonsurgical	O
method	O
of	O
correction	O
.	O
OBJECTIVES	O
:	O
Obesity	SYMP
is	O
an	O
important	O
clinical	O
problem	O
,	O
and	O
the	O
use	O
of	O
dexfenfluramine	SYMP
hydrochloride	SYMP
for	O
weight	O
reduction	O
has	O
been	O
widely	O
publicized	O
since	O
its	O
approval	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
.	O
However	O
,	O
animal	O
and	O
human	O
studies	O
have	O
demonstrated	O
toxic	O
effects	O
of	O
fenfluramines	SYMP
that	O
clinicians	O
should	O
be	O
aware	O
of	O
when	O
considering	O
prescribing	O
the	O
drugs	O
.	O
Our	O
purpose	O
was	O
to	O
systematically	O
review	O
data	O
on	O
brain	O
serotonin	O
neurotoxicity	O
in	O
animals	O
treated	O
with	O
fenfluramines	SYMP
and	O
the	O
evidence	O
linking	O
fenfluramines	SYMP
to	O
primary	SYMP
pulmonary	SYMP
hypertension	SYMP
(	SYMP
PPH	SYMP
)	SYMP
.	O
DATA	O
SOURCES	O
:	O
Archival	O
articles	O
and	O
reviews	O
identified	O
through	O
a	O
computerized	O
search	O
of	O
MEDLINE	O
from	O
1966	O
to	O
April	O
1997	O
using	O
``	O
fenfluramine	O
(	O
s	O
)	O
,	O
''	O
``	O
serotonin	O
,	O
''	O
``	O
neurotoxicity	O
,	O
''	O
``	O
behavior	O
,	O
''	O
``	O
anorexigens	O
,	O
''	O
``	O
weight	O
loss	O
,	O
''	O
and	O
``	O
primary	O
pulmonary	O
hypertension	O
''	O
as	O
index	O
terms	O
.	O
STUDY	O
SELECTION	O
:	O
Reports	O
dealing	O
with	O
long-term	O
effects	O
of	O
fenfluramines	SYMP
on	O
brain	O
serotonin	O
neurons	O
,	O
body	O
weight	O
,	O
and	O
pulmonary	O
function	O
in	O
animals	O
and	O
humans	O
.	O
DATA	O
EXTRACTION	O
:	O
Reports	O
were	O
reviewed	O
by	O
individuals	O
with	O
expertise	O
in	O
serotonin	O
neurobiology	O
,	O
neurotoxicity	O
,	O
neuropsychiatry	O
,	O
and	O
pulmonary	O
medicine	O
and	O
evaluated	O
for	O
appropriateness	O
for	O
inclusion	O
in	O
this	O
review	O
.	O
DATA	O
SYNTHESIS	O
:	O
Fenfluramines	SYMP
cause	O
dose-related	O
,	O
long-lasting	O
reductions	O
in	O
serotonin	O
axonal	O
markers	O
in	O
all	O
the	O
animal	O
species	O
tested	O
and	O
with	O
all	O
the	O
routes	O
of	O
drug	O
administration	O
used	O
.	O
Doses	O
of	O
fenfluramines	O
that	O
produce	O
signs	O
of	O
brain	O
serotonin	O
neurotoxicity	O
in	O
animals	O
are	O
on	O
the	O
same	O
order	O
as	O
those	O
used	O
to	O
treat	O
humans	O
for	O
weight	O
loss	O
when	O
one	O
takes	O
into	O
account	O
known	O
relations	O
between	O
body	O
mass	O
and	O
drug	O
clearance	O
.	O
However	O
,	O
no	O
human	O
studies	O
have	O
been	O
conducted	O
,	O
and	O
the	O
pathological	O
and	O
clinical	O
potential	O
for	O
neurotoxicity	O
in	O
humans	O
is	O
unknown	O
.	O
Appetite	O
suppressants-most	O
commonly	O
fenfluramines	SYMP
-increase	O
the	O
risk	O
of	O
developing	O
PPH	SYMP
(	O
odds	O
ratio	O
,	O
6.3	O
)	O
,	O
particularly	O
when	O
used	O
for	O
more	O
than	O
3	O
months	O
(	O
odds	O
ratio	O
,	O
greater	O
than	O
20	O
)	O
.	O
CONCLUSIONS	O
:	O
Fenfluramine	SYMP
and	O
dexfenfluramine	SYMP
have	O
been	O
demonstrated	O
to	O
damage	O
brain	O
serotonin	O
neurons	O
in	O
animal	O
studies	O
.	O
It	O
is	O
not	O
known	O
if	O
such	O
damage	O
occurs	O
in	O
humans	O
or	O
if	O
there	O
are	O
clinical	O
consequences	O
.	O
Use	O
of	O
fenfluramines	SYMP
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
PPH	SYMP
.	O
Future	O
studies	O
should	O
address	O
the	O
long-term	O
consequences	O
of	O
prolonged	O
use	O
of	O
fenfluramines	SYMP
.	O
Moxonidine	SYMP
(	SYMP
Physiotens-Solvay	SYMP
)	SYMP
was	O
introduced	O
last	O
year	O
as	O
the	O
first	O
of	O
a	O
new	O
class	O
of	O
centrally-acting	O
antihypertensive	SYMP
agents	SYMP
,	O
the	O
selective	O
imidazoline	O
receptor	O
agonists	O
.	O
The	O
manufacturer	O
claims	O
that	O
moxonidine	SYMP
``	O
accurately	O
targets	O
imidazoline	O
receptors	O
at	O
the	O
cardiovascular	O
control	O
centre	O
in	O
the	O
brainstem	O
''	O
and	O
is	O
``	O
as	O
effective	O
as	O
current	O
first-line	O
therapies	O
for	O
essential	SYMP
hypertension	SYMP
``	O
.	O
Other	O
claims	O
suggest	O
that	O
it	O
causes	O
fewer	O
unwanted	O
effects	O
than	O
older	O
centrally-acting	O
antihypertensive	SYMP
drugs	SYMP
such	O
as	O
clonidine	SYMP
and	O
methyldopa	SYMP
.	O
Is	O
moxonidine	SYMP
a	O
useful	O
addition	O
to	O
the	O
growing	O
number	O
of	O
antihypertensives	O
on	O
the	O
market	O
?	O
This	O
article	O
discusses	O
dental	O
anxiety	O
and	O
phobia	O
.	O
The	O
author	O
presents	O
background	O
information	O
,	O
including	O
incidence	O
and	O
etiology	O
.	O
A	O
discussion	O
of	O
evaluative	O
techniques	O
for	O
assessing	O
anxiety	O
levels	O
follows	O
.	O
Examination	O
and	O
treatment	O
planning	O
are	O
considered	O
in	O
relation	O
to	O
this	O
patient	O
's	O
special	O
needs	O
.	O
The	O
article	O
stresses	O
behavioral	O
treatment	O
modalities	O
that	O
eliminate	O
the	O
debilitating	O
phobia	O
.	O
In	O
closing	O
,	O
the	O
author	O
presents	O
practical	O
information	O
regarding	O
prevention	O
of	O
dental	O
phobia	O
and	O
the	O
merits	O
of	O
incorporating	O
this	O
type	O
of	O
patient	O
into	O
a	O
dental	O
practice	O
.	O
In	O
order	O
to	O
evaluate	O
the	O
applicability	O
of	O
anthelminthic	SYMP
treatment	SYMP
of	O
wild	O
foxes	O
(	O
Vulpes	O
vulpes	O
)	O
to	O
limit	O
their	O
infection	SYMP
with	SYMP
Echinococcus	SYMP
multilocularis	SYMP
,	O
bait	O
pellets	O
,	O
each	O
containing	O
50	O
mg	O
praziquantel	SYMP
,	O
were	O
repeatedly	O
distributed	O
in	O
an	O
area	O
of	O
566	O
km2	O
where	O
many	O
foxes	O
are	O
infected	O
,	O
in	O
southern	O
Germany	O
.	O
After	O
six	O
baiting	O
campaigns	O
(	O
15-20	O
baits/km2	O
)	O
over	O
a	O
period	O
of	O
14	O
months	O
,	O
the	O
prevalence	O
of	O
the	O
cestode	O
in	O
foxes	O
,	O
initially	O
32	O
%	O
,	O
had	O
fallen	O
to	O
4	O
%	O
.	O
The	O
effect	O
was	O
most	O
pronounced	O
in	O
the	O
central	O
part	O
of	O
the	O
treated	O
area	O
,	O
where	O
no	O
positive	O
fox	O
was	O
found	O
in	O
the	O
2	O
months	O
before	O
the	O
end	O
of	O
the	O
trial	O
.	O
The	O
study	O
was	O
controlled	O
for	O
other	O
factors	O
that	O
could	O
influence	O
the	O
parasite	O
's	O
prevalence	O
,	O
such	O
as	O
the	O
availability	O
of	O
intermediate	O
hosts	O
.	O
While	O
the	O
potential	O
of	O
this	O
baiting	O
method	O
to	O
remove	O
E	O
.	O
multilocularis	O
from	O
wild	O
hosts	O
has	O
been	O
demonstrated	O
,	O
the	O
question	O
of	O
its	O
long-term	O
efficacy	O
and	O
other	O
unresolved	O
problems	O
have	O
to	O
be	O
addressed	O
by	O
consecutive	O
studies	O
before	O
routine	O
application	O
can	O
be	O
recommended	O
.	O
In	O
patients	O
with	O
chronic	SYMP
myeloid	SYMP
leukemia	SYMP
(	SYMP
CML	SYMP
)	SYMP
,	O
the	O
neoplastic	O
(	O
BCR-ABL+	O
)	O
progenitor	O
cells	O
are	O
characterized	O
by	O
an	O
increased	O
proliferative	O
activity	O
.	O
Whether	O
these	O
cells	O
are	O
also	O
resistant	O
to	O
apoptosis	O
and	O
if	O
so	O
,	O
under	O
what	O
conditions	O
remains	O
controversial	O
.	O
We	O
now	O
show	O
that	O
highly	O
purified	O
populations	O
of	O
very	O
primitive	O
neoplastic	O
progenitor	O
cells	O
obtained	O
directly	O
from	O
CML	O
patients	O
survive	O
and	O
proliferate	O
in	O
vitro	O
for	O
several	O
weeks	O
in	O
the	O
absence	O
of	O
any	O
added	O
growth	O
factors	O
(	O
except	O
insulin	O
)	O
.	O
In	O
contrast	O
,	O
purified	O
primary	O
normal	O
progenitors	O
maintained	O
under	O
the	O
same	O
conditions	O
die	O
rapidly	O
.	O
Nevertheless	O
,	O
both	O
primary	O
CML	O
cells	O
and	O
BCR-ABL+	O
BAF3	O
cells	O
show	O
the	O
same	O
dose-dependent	O
sensitivity	O
to	O
TNF-alpha	O
or	O
ceramide-induced	O
apoptosis	O
as	O
their	O
respective	O
normal	O
counterparts	O
.	O
In	O
fact	O
,	O
time	O
course	O
studies	O
demonstrated	O
an	O
even	O
faster	O
onset	O
of	O
apoptosis	O
in	O
ceramide-treated	O
BCR-ABL+	O
BAF3	O
cells	O
as	O
compared	O
to	O
normal	O
controls	O
.	O
BCR-ABL+	O
cells	O
treated	O
with	O
ceramide	O
also	O
showed	O
a	O
rapid	O
and	O
sequential	O
increase	O
in	O
the	O
tyrosine	O
phosphorylation	O
of	O
p210	O
(	O
BCR-ABL	O
)	O
,	O
p46-56SHC	O
and	O
p120Cbl	O
.	O
These	O
findings	O
suggest	O
growth	O
factor	O
deprivation	O
and	O
treatment	O
with	O
TNF-alpha	O
or	O
ceramide	O
trigger	O
different	O
initial	O
events	O
both	O
of	O
which	O
can	O
lead	O
to	O
apoptosis	O
in	O
factor-dependent	O
hematopoietic	O
cells	O
.	O
However	O
,	O
in	O
the	O
first	O
case	O
,	O
activation	O
of	O
apoptosis	O
is	O
blocked	O
by	O
the	O
basal	O
activity	O
of	O
p210	O
(	O
BCR-ABL	O
)	O
,	O
whereas	O
in	O
the	O
second	O
,	O
the	O
presence	O
of	O
p210	O
(	O
BCR-ABL	O
)	O
appears	O
to	O
accelerate	O
the	O
onset	O
of	O
apoptosis	O
by	O
a	O
mechanism	O
that	O
may	O
involve	O
an	O
activation	O
of	O
its	O
kinase	O
function	O
.	O
Clinically	O
,	O
the	O
hallmark	O
of	O
the	O
human	SYMP
amnesic	SYMP
syndrome	SYMP
is	O
an	O
impaired	O
ability	O
to	O
consciously	O
recollect	O
or	O
remember	O
daily	O
events	O
.	O
If	O
the	O
medial	O
region	O
of	O
the	O
temporal	O
lobes	O
,	O
including	O
the	O
hippocampus	O
and	O
related	O
structures	O
,	O
is	O
critical	O
for	O
establishing	O
these	O
new	O
memories	O
,	O
then	O
this	O
brain	O
region	O
should	O
be	O
active	O
whenever	O
events	O
are	O
experienced	O
,	O
regardless	O
of	O
whether	O
subjects	O
are	O
asked	O
explicitly	O
to	O
learn	O
and	O
remember	O
.	O
Here	O
we	O
show	O
that	O
the	O
medial	O
temporal	O
region	O
is	O
active	O
during	O
encoding	O
and	O
that	O
the	O
hemisphere	O
activated	O
and	O
the	O
amount	O
of	O
activation	O
depend	O
on	O
the	O
type	O
of	O
stimulus	O
presented	O
(	O
objects	O
or	O
words	O
)	O
,	O
whether	O
the	O
stimulus	O
can	O
be	O
encoded	O
for	O
meaning	O
(	O
real	O
objects	O
and	O
words	O
versus	O
nonsense	O
objects	O
and	O
words	O
)	O
,	O
and	O
task	O
experience	O
(	O
first	O
versus	O
the	O
second	O
time	O
a	O
task	O
is	O
performed	O
)	O
.	O
These	O
findings	O
demonstrate	O
that	O
the	O
medial	O
temporal	O
lobe	O
memory	O
system	O
is	O
engaged	O
automatically	O
when	O
we	O
attend	O
to	O
a	O
perceptual	O
event	O
and	O
that	O
the	O
location	O
and	O
amount	O
of	O
activation	O
depend	O
on	O
stimulus	O
characteristics	O
(	O
physical	O
form	O
,	O
meaning	O
)	O
and	O
experience	O
.	O
The	O
involvement	O
of	O
structures	O
in	O
the	O
medial	O
temporal	O
lobe	O
during	O
the	O
encoding	O
of	O
visual	O
associations	O
was	O
studied	O
with	O
functional	O
magnetic	O
resonance	O
imaging	O
.	O
In	O
11	O
out	O
of	O
12	O
normal	O
healthy	O
volunteers	O
this	O
task	O
resulted	O
in	O
activation	O
in	O
posterior	O
portions	O
of	O
the	O
parahippocampal	O
region	O
,	O
close	O
to	O
the	O
collateral	O
sulcus	O
.	O
In	O
seven	O
subjects	O
activation	O
was	O
encountered	O
in	O
the	O
hippocampal	O
formation	O
.	O
The	O
visual	O
association	O
task	O
as	O
adapted	O
for	O
this	O
study	O
may	O
provide	O
a	O
sensitive	O
measure	O
to	O
study	O
anterograde	O
amnesia	O
prevalent	O
in	O
Alzheimer	O
's	O
disease	O
.	O
Therefore	O
,	O
the	O
present	O
paradigm	O
enables	O
the	O
study	O
of	O
individual	O
changes	O
in	O
learning	O
and	O
memory	O
capacities	O
over	O
time	O
.	O
Altered	O
calcium	O
(	O
Ca2+	O
)	O
homeostasis	O
is	O
thought	O
to	O
play	O
a	O
key	O
role	O
in	O
aging	O
and	O
neuropathology	O
resulting	O
in	O
memory	O
deficits	O
.	O
Several	O
forms	O
of	O
hippocampal	O
synaptic	O
plasticity	O
are	O
dependent	O
on	O
Ca2+	O
,	O
providing	O
a	O
potential	O
link	O
between	O
altered	O
Ca2+	O
homeostasis	O
and	O
memory	O
deficits	O
associated	O
with	O
aging	O
.	O
The	O
current	O
study	O
reviews	O
evidence	O
for	O
Ca2+	O
dysregulation	O
during	O
aging	O
which	O
could	O
interact	O
with	O
Ca	O
(	O
2+	O
)	O
-dependent	O
synaptic	O
plasticity	O
.	O
The	O
authors	O
suggest	O
that	O
changes	O
in	O
Ca2+	O
regulation	O
could	O
adjust	O
the	O
thresholds	O
for	O
synaptic	O
modification	O
,	O
favoring	O
processes	O
for	O
depression	O
of	O
synaptic	O
strength	O
during	O
aging	O
.	O
Transiently	O
evolked	O
otoacoustic	O
emissions	O
(	O
TEOAE	O
)	O
have	O
been	O
reported	O
in	O
several	O
studies	O
as	O
absent	O
in	O
a	O
small	O
minority	O
of	O
normal	O
ears	O
.	O
Other	O
studies	O
have	O
reported	O
TEOAEs	O
in	O
all	O
normal	O
ears	O
.	O
Differences	O
between	O
studies	O
may	O
arise	O
directly	O
from	O
criteria	O
for	O
TEOAE	O
identification	O
,	O
criteria	O
for	O
selection	O
of	O
normals	O
,	O
or	O
statistically	O
due	O
to	O
limited	O
sample	O
sizes	O
.	O
In	O
order	O
to	O
understand	O
and	O
model	O
cochlear	O
processes	O
involved	O
in	O
TEOAE	O
generation	O
,	O
it	O
needs	O
to	O
be	O
known	O
whether	O
the	O
presence	O
of	O
normal	O
hearing	O
leads	O
automatically	O
to	O
generation	O
of	O
TEOAEs	O
.	O
The	O
present	O
study	O
set	O
out	O
to	O
establish	O
in	O
a	O
large	O
sample	O
if	O
any	O
ears	O
could	O
be	O
found	O
that	O
lacked	O
TEOAEs	O
despite	O
normal	O
hearing	O
threshold	O
levels	O
(	O
HTL	O
)	O
.	O
A	O
total	O
of	O
397	O
ears	O
from	O
highly	O
cooperative	O
adult	O
subjects	O
were	O
examined	O
under	O
laboratory	O
conditions	O
.	O
Using	O
cross	O
correlation	O
between	O
replicate	O
nonlinear	O
waveforms	O
as	O
the	O
criterion	O
,	O
TEOAEs	O
were	O
present	O
in	O
99.2	O
%	O
of	O
the	O
sample	O
(	O
lower	O
CI	O
98.1	O
%	O
)	O
.	O
However	O
,	O
careful	O
visual	O
assessment	O
of	O
the	O
recorded	O
waveforms	O
for	O
the	O
remaining	O
ears	O
did	O
not	O
unequivocally	O
show	O
absence	O
of	O
TEOAE	O
characteristics	O
in	O
any	O
ear	O
with	O
normal	O
HTLs	O
.	O
While	O
TEOAE	O
strength	O
varies	O
widely	O
among	O
ears	O
,	O
no	O
clear	O
evidence	O
was	O
found	O
to	O
show	O
that	O
TEOAEs	O
can	O
be	O
absent	O
when	O
HTLs	O
are	O
normal	O
.	O
In	O
addition	O
to	O
a	O
long	O
form	O
of	O
591	O
amino	O
acids	O
(	O
aa	O
)	O
,	O
two	O
other	O
forms	O
of	O
PRL	O
receptor	O
(	O
PRLR	O
)	O
,	O
differing	O
in	O
the	O
length	O
of	O
their	O
cytoplasmic	O
domains	O
,	O
have	O
been	O
identified	O
in	O
the	O
rat	O
.	O
The	O
Nb2	O
form	O
,	O
lacking	O
198	O
aa	O
in	O
the	O
cytoplasmic	O
domain	O
,	O
is	O
able	O
to	O
transmit	O
a	O
lactogenic	O
signal	O
similar	O
to	O
the	O
long	O
form	O
,	O
whereas	O
the	O
short	O
form	O
of	O
291	O
aa	O
is	O
inactive	O
.	O
The	O
ability	O
of	O
PRL	O
to	O
activate	O
the	O
promoter	O
of	O
the	O
beta-casein	O
gene	O
or	O
the	O
lactogenic	O
hormone	O
responsive	O
element	O
fused	O
to	O
the	O
luciferase	O
reporter	O
was	O
assessed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
or	O
293	O
fibroblasts	O
transiently	O
transfected	O
with	O
PRLR	O
cDNAs	O
.	O
The	O
function	O
of	O
the	O
short	O
form	O
was	O
examined	O
after	O
cotransfection	O
of	O
both	O
the	O
long	O
and	O
short	O
forms	O
.	O
These	O
results	O
clearly	O
show	O
that	O
the	O
short	O
form	O
acts	O
as	O
a	O
dominant	O
negative	O
inhibitor	O
through	O
the	O
formation	O
of	O
inactive	O
heterodimers	O
,	O
resulting	O
in	O
an	O
inhibition	O
of	O
Janus	O
kinase	O
2	O
(	O
JAK2	O
)	O
activation	O
.	O
The	O
present	O
study	O
also	O
investigates	O
the	O
possible	O
participation	O
of	O
cytoplasmic	O
receptors	O
in	O
the	O
signal	O
transduction	O
pathway	O
,	O
using	O
cotransfection	O
experiments	O
and	O
a	O
new	O
approach	O
that	O
selectively	O
determines	O
the	O
contribution	O
of	O
cytoplasmic	O
receptors	O
in	O
the	O
process	O
of	O
signal	O
transduction	O
.	O
We	O
cotransfected	O
Chinese	O
hamster	O
ovary	O
cells	O
with	O
two	O
cDNA	O
constructs	O
:	O
a	O
cytoplasmic	O
(	O
soluble	O
)	O
form	O
of	O
the	O
receptor	O
with	O
a	O
deleted	O
signal	O
peptide	O
(	O
delta-19	O
)	O
,	O
which	O
is	O
unable	O
to	O
bind	O
PRL	O
,	O
and	O
a	O
functionally	O
inactive	O
receptor	O
mutant	O
(	O
lacking	O
box	O
1	O
)	O
,	O
which	O
is	O
anchored	O
in	O
the	O
plasma	O
membrane	O
and	O
able	O
to	O
bind	O
PRL	O
.	O
This	O
approach	O
has	O
allowed	O
us	O
to	O
show	O
that	O
delta-19	O
,	O
lacking	O
expression	O
at	O
the	O
plasma	O
membrane	O
,	O
can	O
transduce	O
the	O
hormonal	O
message	O
,	O
at	O
least	O
to	O
a	O
limited	O
extent	O
(	O
up	O
to	O
30	O
%	O
of	O
wild	O
type	O
efficiency	O
)	O
,	O
providing	O
that	O
association/activation	O
occurs	O
with	O
a	O
PRL-PRLR	O
complex	O
initiated	O
at	O
the	O
cell	O
surface	O
level	O
;	O
box	O
1	O
of	O
the	O
cytoplasmic	O
form	O
is	O
necessary	O
to	O
rescue	O
this	O
partial	O
transcriptional	O
activity	O
of	O
the	O
inactive	O
mutant	O
.	O
This	O
partial	O
recovery	O
is	O
also	O
parallel	O
to	O
the	O
partial	O
activation	O
of	O
JAK2	O
,	O
indicating	O
that	O
the	O
signal	O
transduction	O
pathway	O
implicated	O
JAK2	O
.	O
Our	O
results	O
provide	O
evidence	O
that	O
heterodimerization	O
of	O
receptors	O
can	O
be	O
implicated	O
either	O
in	O
the	O
positive	O
or	O
in	O
negative	O
activation	O
of	O
gene	O
transcription	O
.	O
BACKGROUND	O
:	O
Inadequate	O
dietary	O
intake	O
of	O
calcium	O
and	O
vitamin	O
D	O
may	O
contribute	O
to	O
the	O
high	O
prevalence	O
of	O
osteoporosis	SYMP
among	O
older	O
persons	O
.	O
METHODS	O
:	O
We	O
studied	O
the	O
effects	O
of	O
three	O
years	O
of	O
dietary	O
supplementation	O
with	O
calcium	O
and	O
vitamin	O
D	O
on	O
bone	O
mineral	O
density	O
,	O
biochemical	O
measures	O
of	O
bone	O
metabolism	O
,	O
and	O
the	O
incidence	O
of	O
nonvertebral	O
fractures	O
in	O
176	O
men	O
and	O
213	O
women	O
65	O
years	O
of	O
age	O
or	O
older	O
who	O
were	O
living	O
at	O
home	O
.	O
They	O
received	O
either	O
500	O
mg	O
of	O
calcium	O
plus	O
700	O
IU	O
of	O
vitamin	O
D3	O
(	O
cholecalciferol	O
)	O
per	O
day	O
or	O
placebo	O
.	O
Bone	O
mineral	O
density	O
was	O
measured	O
by	O
dual-energy	O
x-ray	O
absorptiometry	O
,	O
blood	O
and	O
urine	O
were	O
analyzed	O
every	O
six	O
months	O
,	O
and	O
cases	O
of	O
nonvertebral	O
fracture	O
were	O
ascertained	O
by	O
means	O
of	O
interviews	O
and	O
verified	O
with	O
use	O
of	O
hospital	O
records	O
.	O
RESULTS	O
:	O
The	O
mean	O
(	O
+/-SD	O
)	O
changes	O
in	O
bone	O
mineral	O
density	O
in	O
the	O
calcium-vitamin	O
D	O
and	O
placebo	O
groups	O
were	O
as	O
follows	O
:	O
femoral	O
neck	O
,	O
+0.50+/-4.80	O
and	O
-0.70+/-5.03	O
percent	O
,	O
respectively	O
(	O
P=0.02	O
)	O
;	O
spine	O
,	O
+2.12+/-4.06	O
and	O
+1.22+/-4.25	O
percent	O
(	O
P=0.04	O
)	O
;	O
and	O
total	O
body	O
,	O
+0.06+/-1.83	O
and	O
-1.09+/-1.71	O
percent	O
(	O
P	O
&	O
#	O
60	O
;	O
0.001	O
)	O
.	O
The	O
difference	O
between	O
the	O
calcium-vitamin	O
D	O
and	O
placebo	O
groups	O
was	O
significant	O
at	O
all	O
skeletal	O
sites	O
after	O
one	O
year	O
,	O
but	O
it	O
was	O
significant	O
only	O
for	O
total-body	O
bone	O
mineral	O
density	O
in	O
the	O
second	O
and	O
third	O
years	O
.	O
Of	O
37	O
subjects	O
who	O
had	O
nonvertebral	O
fractures	O
,	O
26	O
were	O
in	O
the	O
placebo	O
group	O
and	O
11	O
were	O
in	O
the	O
calcium-vitamin	O
D	O
group	O
(	O
P=0.02	O
)	O
.	O
CONCLUSIONS	O
:	O
In	O
men	O
and	O
women	O
65	O
years	O
of	O
age	O
or	O
older	O
who	O
are	O
living	O
in	O
the	O
community	O
,	O
dietary	SYMP
supplementation	SYMP
with	SYMP
calcium	SYMP
and	SYMP
vitamin	SYMP
D	SYMP
moderately	O
reduced	O
bone	SYMP
loss	SYMP
measured	O
in	O
the	O
femoral	O
neck	O
,	O
spine	O
,	O
and	O
total	O
body	O
over	O
the	O
three-year	O
study	O
period	O
and	O
reduced	O
the	O
incidence	O
of	O
nonvertebral	SYMP
fractures	SYMP
.	O
The	O
sterilization	O
and	O
contaminated	O
waste	O
disposal	O
practices	O
in	O
all	O
14	O
dental	O
clinics	O
operated	O
by	O
the	O
Southern	O
Sydney	O
Area	O
Health	O
Service	O
were	O
surveyed	O
.	O
All	O
of	O
the	O
clinics	O
used	O
autoclaves	O
for	O
sterilization	O
.	O
All	O
hand	O
instruments	O
,	O
handpieces	O
and	O
triplex	O
syringes	O
were	O
autoclaved	O
between	O
patients	O
.	O
Chemical	O
disinfection	O
solutions	O
were	O
used	O
in	O
12	O
of	O
the	O
14	O
dental	O
clinics	O
,	O
mainly	O
for	O
surface	O
decontamination	O
.	O
Five	O
dental	O
clinics	O
had	O
separate	O
storage	O
areas	O
for	O
contaminated	O
waste	O
which	O
compiled	O
with	O
contaminated	O
waste	O
separation	O
and	O
disposal	O
guidelines	O
.	O
The	O
practice	O
of	O
recapping	O
needles	O
with	O
fingers	O
and	O
some	O
inadequate	O
washing	O
facilities	O
are	O
areas	O
that	O
require	O
particular	O
attention	O
.	O
Safety	O
and	O
efficacy	O
are	O
crucial	O
but	O
separate	O
issues	O
for	O
vitamin	O
and	O
mineral	O
supplements	O
.	O
Misinterpretation	O
of	O
``	O
safe	O
and	O
adequate	O
''	O
to	O
mean	O
``	O
safety	O
limit	O
''	O
would	O
impose	O
restrictions	O
on	O
vitamin	O
and	O
mineral	O
intakes	O
that	O
are	O
not	O
needed	O
to	O
ensure	O
safety	O
.	O
Substantial	O
evidence	O
indicates	O
that	O
intakes	O
greater	O
than	O
the	O
recommended	O
dietary	O
allowances	O
(	O
RDAs	O
)	O
of	O
certain	O
vitamins	O
and	O
minerals	O
such	O
as	O
calcium	O
,	O
folic	O
acid	O
,	O
vitamin	O
E	O
,	O
selenium	O
,	O
and	O
chromium	O
reduce	O
the	O
risk	O
of	O
certain	O
diseases	O
for	O
some	O
people	O
.	O
Limitation	O
of	O
intakes	O
to	O
the	O
RDAs	O
would	O
preclude	O
reductions	O
in	O
disease	O
risk	O
from	O
these	O
nutrients	O
.	O
The	O
margin	O
of	O
safety	O
between	O
the	O
usual	O
dietary	O
intake	O
and	O
the	O
intake	O
that	O
would	O
produce	O
adverse	O
effects	O
varies	O
greatly	O
among	O
the	O
different	O
nutrients	O
.	O
Very	O
high	O
intakes	O
of	O
vitamins	O
A	O
and	O
D	O
,	O
niacin	O
,	O
pyridoxine	O
,	O
and	O
selenium	O
have	O
produced	O
adverse	O
effects	O
.	O
Many	O
widely	O
discussed	O
putative	O
adverse	O
effects	O
of	O
vitamin	O
C	O
,	O
vitamin	O
E	O
,	O
and	O
trivalent	O
chromium	O
have	O
little	O
factual	O
basis	O
.	O
There	O
is	O
no	O
evidence	O
of	O
adverse	O
effects	O
from	O
beta-carotene	O
supplements	O
except	O
in	O
current	O
heavy	O
smokers	O
.	O
The	O
mutator	O
hypothesis	O
of	O
tumorigenesis	O
suggests	O
that	O
loss	O
of	O
chromosomal	O
stability	O
or	O
maintenance	O
functions	O
results	O
in	O
elevated	O
mutation	O
rates	O
,	O
leading	O
to	O
the	O
accumulation	O
of	O
the	O
numerous	O
mutations	O
required	O
for	O
multistep	O
carcinogenesis	O
.	O
The	O
human	O
DNA	O
mismatch	O
repair	O
(	O
MMR	O
)	O
genes	O
are	O
highly	O
conserved	O
homologues	O
of	O
the	O
Escherichia	O
coli	O
MutHLS	O
system	O
,	O
which	O
contribute	O
to	O
genomic	O
stability	O
by	O
surveillance	O
and	O
repair	O
of	O
replication	O
misincorporation	O
errors	O
and	O
exogenous	O
DNA	O
damage	O
.	O
Mutations	O
in	O
one	O
of	O
these	O
MMR	O
genes	O
,	O
hMSH2	O
,	O
account	O
for	O
about	O
half	O
of	O
all	O
cases	O
of	O
genetically	O
linked	O
hereditary	O
non-polyposis	O
colorectal	O
cancer	O
.	O
Loss	O
of	O
function	O
of	O
p53	O
has	O
also	O
been	O
proposed	O
to	O
increase	O
cellular	O
hypermutability	O
,	O
thereby	O
accelerating	O
carcinogenesis	O
,	O
although	O
a	O
clear	O
role	O
for	O
p53	O
in	O
genomic	O
instability	O
remains	O
controversial	O
.	O
p53	O
is	O
mutated	O
frequently	O
in	O
a	O
wide	O
range	O
of	O
human	O
cancers	SYMP
,	O
including	O
colonic	SYMP
tumours	SYMP
.	O
Both	O
Msh2-	O
and	O
p53-targeted	O
knockout	O
mice	O
are	O
viable	O
and	O
susceptible	O
to	O
cancer	SYMP
.	O
Here	O
we	O
demonstrate	O
that	O
combined	O
Msh2	O
and	O
p53	O
ablation	O
(	O
Msh2-/-p53-/-	O
)	O
results	O
in	O
developmental	O
arrest	O
of	O
all	O
female	O
embryos	O
at	O
9.5	O
days	O
.	O
In	O
contrast	O
,	O
male	O
Msh2-/-p53-/-	O
mice	O
are	O
viable	O
,	O
but	O
succumb	O
to	O
tumours	SYMP
significantly	O
earlier	O
(	O
t1-2	O
is	O
73	O
days	O
)	O
than	O
either	O
Msh2-/-	O
or	O
p53-/-	O
littermates	O
.	O
Furthermore	O
,	O
the	O
frequency	O
of	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
in	O
tumours	O
from	O
Msh2-/-p53-/-	O
mice	O
is	O
not	O
significantly	O
different	O
than	O
in	O
Msh2-/-	O
mice	O
.	O
Synergism	O
in	O
tumorigenesis	O
and	O
independent	O
segregation	O
of	O
the	O
MSI	O
phenotype	O
suggest	O
that	O
Msh2	O
and	O
p53	O
are	O
not	O
genetically	O
epistatic	O
.	O
Our	O
data	O
(	O
Reddy	O
et	O
al	O
.	O
,	O
Radiat	O
.	O
Res	O
.	O
141	O
,	O
252-258	O
,	O
1995	O
)	O
on	O
the	O
kinetics	O
of	O
the	O
repair	O
of	O
potentially	O
lethal	O
damage	O
in	O
log-phase	O
Chinese	O
hamster	O
V79	O
cells	O
are	O
used	O
to	O
test	O
some	O
predictions	O
which	O
arise	O
from	O
the	O
different	O
assumptions	O
of	O
the	O
repair-misrepair	O
(	O
RMR	O
)	O
(	O
C	O
.	O
A	O
.	O
Tobias	O
,	O
Radiat	O
.	O
Res	O
.	O
104	O
,	O
S77-S95	O
,	O
1985	O
)	O
,	O
lethal-potentially	O
lethal	O
(	O
LPL	O
)	O
(	O
S.	O
B	O
.	O
Curtis	O
,	O
Radiat	O
.	O
Res	O
.	O
106	O
,	O
252-270	O
,	O
1986	O
)	O
and	O
double-strand	O
break	O
(	O
DSB	O
)	O
(	O
J	O
.	O
Y	O
.	O
Ostashevsky	O
,	O
Radiat	O
.	O
Res	O
.	O
118	O
,	O
437-466	O
,	O
1989	O
)	O
models	O
.	O
The	O
LPL	O
model	O
defines	O
the	O
time	O
available	O
for	O
repair	O
of	O
PLD	O
(	O
t	O
(	O
rep	O
)	O
)	O
as	O
the	O
time	O
taken	O
to	O
reach	O
maximal	O
survival	O
in	O
a	O
delayed-plating	O
recovery	O
experiment	O
.	O
Those	O
data	O
show	O
that	O
after	O
this	O
time	O
has	O
elapsed	O
,	O
contrary	O
to	O
the	O
expectation	O
of	O
the	O
LPL	O
model	O
,	O
survival	O
can	O
be	O
increased	O
by	O
changing	O
the	O
medium	O
used	O
for	O
delayed	O
plating	O
from	O
fresh	O
growth	O
medium	O
to	O
conditioned	O
medium	O
.	O
According	O
to	O
the	O
RMR	O
model	O
,	O
all	O
potentially	O
lethal	O
lesions	O
should	O
also	O
be	O
committed	O
by	O
that	O
time	O
and	O
be	O
unavailable	O
for	O
repair	O
in	O
the	O
new	O
medium	O
.	O
Only	O
the	O
DSB	O
model	O
correctly	O
predicted	O
that	O
PLD	O
(	O
=	O
DSBs	O
)	O
would	O
still	O
be	O
available	O
for	O
repair	O
after	O
that	O
time	O
.	O
Second	O
,	O
data	O
for	O
split-dose	O
recovery	O
are	O
used	O
to	O
predict	O
the	O
first-order	O
kinetics	O
time	O
constant	O
for	O
DSB	O
repair	O
(	O
tau	O
(	O
DSBR	O
)	O
)	O
using	O
the	O
DSB	O
model	O
(	O
24	O
+/-	O
1.5	O
min	O
)	O
.	O
This	O
value	O
is	O
nearly	O
identical	O
to	O
the	O
value	O
of	O
27	O
+/-	O
1	O
min	O
determined	O
from	O
the	O
data	O
obtained	O
by	O
Cheong	O
et	O
al	O
.	O
using	O
pulsed-field	O
gel	O
electrophoresis	O
(	O
PFGE	O
)	O
(	O
Mutat	O
.	O
Res	O
.	O
274	O
,	O
111-122	O
,	O
1992	O
)	O
.	O
The	O
value	O
based	O
on	O
PFGE	O
is	O
used	O
to	O
calculate	O
the	O
value	O
of	O
t	O
(	O
rep	O
)	O
predicted	O
by	O
the	O
DSB	O
model	O
(	O
2.6	O
+/-	O
0.1	O
h	O
)	O
,	O
which	O
agrees	O
with	O
the	O
value	O
determined	O
experimentally	O
as	O
the	O
time	O
when	O
changing	O
the	O
delayed-plating	O
medium	O
from	O
growth	O
medium	O
to	O
conditioned	O
medium	O
no	O
longer	O
gives	O
the	O
full	O
recovery	O
seen	O
with	O
delayed	O
plating	O
in	O
conditioned	O
medium	O
(	O
2.5	O
h	O
)	O
.	O
However	O
,	O
some	O
recovery	O
was	O
seen	O
for	O
a	O
change	O
in	O
the	O
medium	O
(	O
growth	O
medium	O
to	O
conditioned	O
medium	O
)	O
up	O
to	O
5-6	O
h	O
postirradiation	O
.	O
Reanalysis	O
of	O
the	O
original	O
data	O
on	O
DSB	O
repair	O
shows	O
that	O
they	O
are	O
consistent	O
with	O
two	O
first-order	O
repair	O
rates	O
(	O
18	O
+/-	O
7	O
min	O
and	O
about	O
52	O
min	O
)	O
.	O
These	O
results	O
are	O
consistent	O
with	O
two	O
pools	O
of	O
DSBs	O
(	O
or	O
cells	O
)	O
,	O
each	O
with	O
their	O
own	O
t	O
(	O
rep	O
)	O
.	O
The	O
early	O
t	O
(	O
rep	O
)	O
,	O
associated	O
with	O
tau	O
(	O
fast	O
)	O
,	O
is	O
predicted	O
to	O
be	O
1.7	O
+/-	O
0.7	O
h	O
,	O
and	O
the	O
late	O
t	O
(	O
rep	O
)	O
,	O
associated	O
with	O
tau	O
(	O
slow	O
)	O
,	O
is	O
predicted	O
to	O
be	O
about	O
5	O
h.	O
Both	O
values	O
are	O
in	O
excellent	O
agreement	O
with	O
the	O
times	O
at	O
which	O
changing	O
from	O
growth	O
medium	O
to	O
conditioned	O
medium	O
no	O
longer	O
gives	O
the	O
full	O
recovery	O
seen	O
in	O
conditioned	O
medium	O
only	O
(	O
the	O
early	O
t	O
(	O
rep	O
)	O
)	O
,	O
and	O
the	O
time	O
when	O
changing	O
from	O
growth	O
medium	O
to	O
conditioned	O
medium	O
produces	O
no	O
further	O
increase	O
in	O
survival	O
(	O
the	O
late	O
t	O
(	O
rep	O
)	O
)	O
,	O
respectively	O
.	O
It	O
is	O
noted	O
that	O
attempts	O
to	O
correlate	O
radiosensitivity	O
with	O
the	O
rates	O
of	O
DSB	O
repair	O
,	O
rather	O
than	O
using	O
an	O
explicit	O
model	O
such	O
as	O
the	O
DSB	O
model	O
,	O
are	O
unlikely	O
to	O
be	O
productive	O
since	O
survival	O
depends	O
on	O
both	O
tau	O
(	O
DSBR	O
)	O
and	O
t	O
(	O
rep	O
)	O
(	O
as	O
defined	O
in	O
the	O
DSB	O
model	O
)	O
and	O
the	O
latter	O
may	O
be	O
the	O
more	O
important	O
determinant	O
of	O
radiosensitivity	O
(	O
as	O
it	O
appears	O
to	O
be	O
for	O
ataxia	O
telangiectasia	O
cells	O
compared	O
to	O
normal	O
fibroblasts	O
and	O
for	O
irs	O
compared	O
to	O
V79	O
cells	O
)	O
.	O
CONTEXT	O
:	O
Adolescents	O
'	O
concerns	O
about	O
privacy	O
in	O
clinical	O
settings	O
decrease	O
their	O
willingness	O
to	O
seek	O
health	O
care	O
for	O
sensitive	O
problems	O
and	O
may	O
inhibit	O
their	O
communication	O
with	O
physicians	O
.	O
OBJECTIVE	O
:	O
To	O
investigate	O
the	O
influence	O
of	O
physicians	O
'	O
assurances	O
of	O
confidentiality	O
on	O
adolescents	O
'	O
willingness	O
to	O
disclose	O
information	O
and	O
seek	O
future	O
health	O
care	O
.	O
DESIGN	O
:	O
Randomized	O
controlled	O
trial	O
.	O
SETTING	O
:	O
Three	O
suburban	O
public	O
high	O
schools	O
in	O
California	O
.	O
PARTICIPANTS	O
:	O
The	O
562	O
participating	O
adolescents	O
represented	O
92	O
%	O
of	O
students	O
in	O
mandatory	O
classes	O
.	O
INTERVENTION	O
:	O
After	O
random	O
assignment	O
to	O
1	O
of	O
3	O
groups	O
,	O
the	O
adolescents	O
listened	O
to	O
a	O
standardized	O
audiotape	O
depiction	O
of	O
an	O
office	O
visit	O
during	O
which	O
they	O
heard	O
a	O
physician	O
who	O
assured	O
unconditional	O
confidentiality	O
,	O
a	O
physician	O
who	O
assured	O
conditional	O
confidentiality	O
,	O
or	O
a	O
physician	O
who	O
did	O
not	O
mention	O
confidentiality	O
.	O
MAIN	O
OUTCOME	O
MEASURES	O
:	O
Adolescents	O
'	O
willingness	O
to	O
disclose	O
general	O
information	O
,	O
willingness	O
to	O
disclose	O
information	O
about	O
sensitive	O
topics	O
,	O
intended	O
honesty	O
,	O
and	O
likelihood	O
of	O
return	O
visits	O
to	O
the	O
physician	O
depicted	O
in	O
the	O
scenario	O
were	O
assessed	O
by	O
anonymous	O
written	O
questionnaire	O
.	O
RESULTS	O
:	O
Assurances	O
of	O
confidentiality	O
increased	O
the	O
number	O
of	O
adolescents	O
willing	O
to	O
disclose	O
sensitive	O
information	O
about	O
sexuality	O
,	O
substance	O
use	O
,	O
and	O
mental	O
health	O
from	O
39	O
%	O
(	O
68/175	O
)	O
to	O
46.5	O
%	O
(	O
178/383	O
)	O
(	O
beta=.10	O
,	O
P=.02	O
)	O
and	O
increased	O
the	O
number	O
willing	O
to	O
seek	O
future	O
health	O
care	O
from	O
53	O
%	O
(	O
93/175	O
)	O
to	O
67	O
%	O
(	O
259/386	O
)	O
(	O
beta=.17	O
,	O
P	O
&	O
#	O
60	O
;	O
.001	O
)	O
.	O
When	O
comparing	O
the	O
unconditional	O
with	O
the	O
conditional	O
groups	O
,	O
assurances	O
of	O
unconditional	O
confidentiality	O
increased	O
the	O
number	O
of	O
adolescents	O
willing	O
to	O
return	O
for	O
a	O
future	O
visit	O
by	O
10	O
percentage	O
points	O
,	O
from	O
62	O
%	O
(	O
122/196	O
)	O
to	O
72	O
%	O
(	O
137/190	O
)	O
(	O
beta=.14	O
,	O
P=.001	O
)	O
.	O
CONCLUSIONS	O
:	O
Adolescents	O
are	O
more	O
willing	O
to	O
communicate	O
with	O
and	O
seek	O
health	O
care	O
from	O
physicians	O
who	O
assure	O
confidentiality	O
.	O
Further	O
investigation	O
is	O
needed	O
to	O
identify	O
a	O
confidentiality	O
assurance	O
statement	O
that	O
explains	O
the	O
legal	O
and	O
ethical	O
limitations	O
of	O
confidentiality	O
without	O
decreasing	O
adolescents	O
'	O
likelihood	O
of	O
seeking	O
future	O
health	O
care	O
for	O
routine	O
and	O
nonreportable	O
sensitive	O
health	O
concerns	O
.	O
BACKGROUND	O
:	O
Diabetic	O
foot	SYMP
infections	SYMP
cause	O
substantial	O
morbidity	O
and	O
mortality	O
.	O
Neutrophil	O
superoxide	O
generation	O
,	O
a	O
crucial	O
part	O
of	O
neutrophil	O
bactericidal	O
activity	O
,	O
is	O
impaired	O
in	O
diabetes	SYMP
.	O
Granulocyte-colony	O
stimulating	O
factor	O
(	O
G-CSF	O
)	O
increases	O
the	O
release	O
of	O
neutrophils	O
from	O
the	O
bone	O
marrow	O
and	O
improves	O
neutrophil	O
function	O
.	O
We	O
assessed	O
G-CSF	SYMP
as	O
adjuvant	O
therapy	O
for	O
the	O
treatment	O
of	O
severe	SYMP
foot	SYMP
infections	SYMP
in	SYMP
diabetic	SYMP
patients	SYMP
.	O
METHODS	O
:	O
40	O
diabetic	O
patients	O
with	O
foot	SYMP
infections	SYMP
were	O
enrolled	O
in	O
a	O
double-blind	O
placebo-controlled	O
study	O
.	O
On	O
admission	O
,	O
patients	O
were	O
randomly	O
assigned	O
G-CSF	SYMP
(	SYMP
filgrastim	SYMP
)	SYMP
therapy	SYMP
(	O
n	O
=	O
20	O
)	O
or	O
placebo	O
(	O
n	O
=	O
20	O
)	O
for	O
7	O
days	O
.	O
Both	O
groups	O
received	O
similar	O
antibiotic	SYMP
and	SYMP
insulin	SYMP
treatment	SYMP
.	O
Neutrophils	O
from	O
the	O
peripheral	O
blood	O
of	O
these	O
participants	O
and	O
from	O
healthy	O
controls	O
were	O
stimulated	O
with	O
opsonised	O
zymosan	O
,	O
and	O
superoxide	O
production	O
was	O
measured	O
by	O
a	O
spectrophotometric	O
assay	O
(	O
reduction	O
of	O
ferricytochrome	O
C	O
)	O
.	O
FINDINGS	O
:	O
G-CSF	O
therapy	O
was	O
associated	O
with	O
earlier	O
eradication	O
of	O
pathogens	O
from	O
the	O
infected	O
ulcer	O
(	O
median	O
4	O
(	O
range	O
2-10	O
)	O
vs	O
8	O
(	O
2-79	O
)	O
days	O
in	O
the	O
placebo	O
group	O
;	O
p	O
=	O
0.02	O
)	O
,	O
quicker	O
resolution	O
of	O
cellulitis	O
less	O
than	O
(	O
7	O
(	O
5-20	O
)	O
vs	O
12	O
(	O
5-93	O
)	O
days	O
;	O
p	O
=	O
0.03	O
)	O
,	O
shorter	O
hospital	O
stay	O
(	O
10	O
(	O
7-31	O
)	O
vs	O
17.5	O
(	O
9-100	O
)	O
days	O
;	O
p	O
=	O
0.02	O
)	O
,	O
and	O
a	O
shorter	O
duration	O
of	O
intravenous	O
antibiotic	O
treatment	O
(	O
8.5	O
(	O
5-30	O
)	O
vs	O
14.5	O
(	O
8-63	O
)	O
days	O
;	O
p	O
=	O
0.02	O
)	O
.	O
No	O
G-CSF-treated	O
patient	O
needed	O
surgery	SYMP
,	O
whereas	O
two	O
placebo	O
recipients	O
underwent	O
to	O
amputation	SYMP
and	O
two	O
had	O
extensive	O
debridement	SYMP
under	O
anaesthesia	O
.	O
After	O
7	O
days	O
'	O
treatment	O
,	O
neutrophil	O
superoxide	O
production	O
was	O
significantly	O
higher	O
in	O
the	O
G-CSF	O
group	O
than	O
in	O
the	O
placebo	O
group	O
(	O
16.1	O
(	O
4.2-24.2	O
)	O
vs	O
7.3	O
(	O
2.1-11.5	O
)	O
nmol	O
per	O
10	O
(	O
6	O
)	O
neutrophils	O
in	O
30	O
min	O
;	O
p	O
&	O
#	O
60	O
;	O
0.0001	O
)	O
.	O
G-CSF	SYMP
therapy	SYMP
was	O
generally	O
well	O
tolerated	O
.	O
INTERPRETATION	O
:	O
G-CSF	SYMP
treatment	SYMP
was	O
associated	O
with	O
improved	O
clinical	O
outcome	O
of	O
foot	SYMP
infection	SYMP
in	SYMP
diabetic	SYMP
patients	SYMP
.	O
This	O
improvement	O
may	O
be	O
related	O
to	O
an	O
increase	O
in	O
neutrophil	O
superoxide	O
production	O
.	O
BACKGROUND	O
:	O
Accelerated	SYMP
infusion	SYMP
of	SYMP
alteplase	SYMP
(	SYMP
tissue	SYMP
plasminogen	SYMP
activator	SYMP
)	SYMP
over	O
a	O
period	O
of	O
90	O
minutes	O
induces	O
more	O
rapid	O
lysis	O
of	O
coronary-artery	SYMP
thrombi	SYMP
than	O
a	O
3-hour	O
infusion	O
.	O
With	O
two	O
bolus	O
doses	O
of	O
alteplase	SYMP
,	O
further	O
shortening	O
the	O
duration	O
of	O
administration	O
,	O
complete	O
reperfusion	O
was	O
achieved	O
in	O
more	O
than	O
85	O
percent	O
of	O
the	O
patients	O
in	O
initial	O
angiographic	O
studies	O
.	O
We	O
tested	O
the	O
hypothesis	O
that	O
double-bolus	SYMP
alteplase	SYMP
is	O
at	O
least	O
as	O
effective	O
as	O
accelerated	O
infusion	O
.	O
METHODS	O
:	O
In	O
398	O
hospitals	O
,	O
7169	O
patients	O
with	O
acute	SYMP
myocardial	SYMP
infarction	SYMP
were	O
randomly	O
assigned	O
to	O
weight-adjusted	O
,	O
accelerated	O
infusion	O
of	O
100	O
mg	O
of	O
alteplase	SYMP
or	O
to	O
a	O
bolus	O
of	O
50	O
mg	O
of	O
alteplase	SYMP
over	O
a	O
period	O
of	O
1	O
to	O
3	O
minutes	O
followed	O
30	O
minutes	O
later	O
by	O
a	O
second	O
bolus	O
of	O
50	O
mg	O
(	O
or	O
40	O
mg	O
for	O
patients	O
who	O
weighed	O
less	O
than	O
60	O
kg	O
)	O
.	O
The	O
primary	O
end	O
point	O
was	O
death	O
from	O
any	O
cause	O
at	O
30	O
days	O
.	O
The	O
trial	O
was	O
stopped	O
prematurely	O
because	O
of	O
concern	O
about	O
the	O
safety	O
of	O
the	O
double-bolus	SYMP
injection	SYMP
.	O
RESULTS	O
:	O
Thirty-day	O
mortality	O
was	O
higher	O
in	O
the	O
double-bolus	O
group	O
than	O
in	O
the	O
accelerated-infusion	O
group	O
:	O
7.98	O
percent	O
as	O
compared	O
with	O
7.53	O
percent	O
.	O
The	O
absolute	O
difference	O
was	O
0.44	O
percent	O
,	O
with	O
a	O
one-sided	O
95	O
percent	O
upper	O
boundary	O
of	O
1.49	O
percent	O
,	O
which	O
exceeded	O
the	O
prespecified	O
upper	O
limit	O
of	O
0.40	O
percent	O
to	O
indicate	O
equivalence	O
in	O
30-day	O
mortality	O
between	O
the	O
two	O
regimens	O
.	O
The	O
respective	O
rates	O
of	O
any	O
stroke	SYMP
and	O
of	O
hemorrhagic	SYMP
stroke	SYMP
were	O
1.92	O
and	O
1.12	O
percent	O
after	O
double-bolus	O
alteplase	SYMP
,	O
as	O
compared	O
with	O
1.53	O
and	O
0.81	O
percent	O
after	O
an	O
accelerated	O
infusion	O
of	O
alteplase	SYMP
(	O
P=0.24	O
and	O
P=0.23	O
,	O
respectively	O
)	O
.	O
CONCLUSIONS	O
:	O
Double-bolus	O
alteplase	SYMP
was	O
not	O
shown	O
to	O
be	O
equivalent	O
,	O
according	O
to	O
the	O
prespecified	O
criteria	O
,	O
to	O
accelerated	O
infusion	O
with	O
regard	O
to	O
30-day	O
mortality	O
.	O
There	O
was	O
also	O
a	O
slightly	O
higher	O
rate	O
of	O
intracranial	SYMP
hemorrhage	SYMP
with	O
the	O
double-bolus	SYMP
method	SYMP
.	O
Therefore	O
,	O
accelerated	SYMP
infusion	SYMP
of	SYMP
alteplase	SYMP
over	O
a	O
period	O
of	O
90	O
minutes	O
remains	O
the	O
preferred	O
regimen	O
.	O
BACKGROUND	O
:	O
Fenfluramine	SYMP
and	O
phentermine	SYMP
have	O
been	O
individually	O
approved	O
as	O
anorectic	SYMP
agents	SYMP
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
.	O
When	O
used	O
in	O
combination	O
the	O
drugs	O
may	O
be	O
just	O
as	O
effective	O
as	O
either	O
drug	O
alone	O
,	O
with	O
the	O
added	O
advantages	O
of	O
the	O
need	O
for	O
lower	O
doses	O
of	O
each	O
agent	O
and	O
perhaps	O
fewer	O
side	O
effects	O
.	O
Although	O
the	O
combination	O
has	O
not	O
been	O
approved	O
by	O
the	O
FDA	O
,	O
in	O
1996	O
the	O
total	O
number	O
of	O
prescriptions	O
in	O
the	O
United	O
States	O
for	O
fenfluramine	SYMP
and	O
phentermine	SYMP
exceeded	O
18	O
million	O
.	O
METHODS	O
:	O
We	O
identified	O
valvular	O
heart	O
diseasein	O
24	O
women	O
treated	O
with	O
fenfluramine-phentermine	O
who	O
had	O
no	O
history	O
of	O
cardiac	O
disease	O
.	O
The	O
women	O
presented	O
with	O
cardiovascular	SYMP
symptoms	SYMP
or	O
a	O
heart	SYMP
murmur	SYMP
.	O
As	O
increasing	O
numbers	O
of	O
these	O
patients	O
with	O
similar	O
clinical	O
features	O
were	O
identified	O
,	O
there	O
appeared	O
to	O
be	O
an	O
association	O
between	O
these	O
features	O
and	O
fenfluramine-phentermine	SYMP
therapy	SYMP
.	O
RESULTS	O
:	O
Twenty-four	O
women	O
(	O
mean	O
(	O
+/-SD	O
)	O
age	O
,	O
44+/-8	O
years	O
)	O
were	O
evaluated	O
12.3+/-7.1	O
months	O
after	O
the	O
initiation	O
of	O
fenfluramine-phentermine	SYMP
therapy	SYMP
.	O
Echocardiography	O
demonstrated	O
unusual	O
valvular	O
morphology	O
and	O
regurgitation	O
in	O
all	O
patients	O
.	O
Both	O
right-sided	O
and	O
left-sided	O
heart	O
valves	O
were	O
involved	O
.	O
Eight	O
women	O
also	O
had	O
newly	O
documented	O
pulmonary	SYMP
hypertension	SYMP
.	O
To	O
date	O
,	O
cardiac	SYMP
surgical	SYMP
intervention	SYMP
has	O
been	O
required	O
in	O
five	O
patients	O
.	O
The	O
heart	O
valves	O
had	O
a	O
glistening	O
white	O
appearance	O
.	O
Histopathological	O
findings	O
included	O
plaque-like	O
encasement	O
of	O
the	O
leaflets	O
and	O
chordal	O
structures	O
with	O
intact	O
valve	O
architecture	O
.	O
The	O
histopathological	O
features	O
were	O
identical	O
to	O
those	O
seen	O
in	O
carcinoid	O
or	O
ergotamine-induced	O
valve	SYMP
disease	SYMP
.	O
CONCLUSIONS	O
:	O
These	O
cases	O
arouse	O
concern	O
that	O
fenfluramine-phentermine	SYMP
therapy	SYMP
may	O
be	O
associated	O
with	O
valvular	SYMP
heart	SYMP
disease	SYMP
.	O
Candidates	O
for	O
fenfluramine-phentermine	SYMP
therapy	SYMP
should	O
be	O
informed	O
about	O
serious	O
potential	O
adverse	O
effects	O
,	O
including	O
pulmonary	SYMP
hypertension	SYMP
and	O
valvular	SYMP
heart	SYMP
disease	SYMP
.	O
Between	O
1987	O
and	O
1992	O
,	O
all	O
patients	O
presenting	O
to	O
the	O
senior	O
author	O
with	O
a	O
symptomatic	O
failed	O
silicone	O
implant	O
arthroplasty	O
refractory	O
to	O
conservative	O
treatment	O
were	O
converted	O
to	O
a	O
metatarsophalangeal	O
joint	O
arthrodesis	O
.	O
Internal	O
fixation	O
was	O
achieved	O
with	O
either	O
dual	O
intrameduilary	O
threaded	O
Steinmann	O
pins	O
or	O
an	O
obliquely	O
placed	O
AO	O
compression	O
screw	O
and	O
a	O
three-	O
or	O
four-hole	O
one-third	O
tubular	O
dorsal	O
neutralization	O
plate	O
.	O
Bone	SYMP
grafting	SYMP
was	O
used	O
to	O
maintain	O
hallux	O
length	O
.	O
Successful	O
arthrodesis	SYMP
was	O
achieved	O
in	O
all	O
five	O
feet	O
in	O
patients	O
with	O
rheumatoid	SYMP
arthritis	SYMP
.	O
Subjectively	O
,	O
patients	O
improved	O
from	O
an	O
average	O
of	O
0.69	O
before	O
arthrodesis	SYMP
to	O
4.89	O
after	O
arthrodesis	SYMP
.	O
The	O
average	O
walking	O
tolerance	O
improved	O
from	O
1.11	O
to	O
4.80	O
,	O
and	O
the	O
overall	O
level	O
of	O
satisfaction	O
improved	O
from	O
0.0	O
to	O
4.79	O
.	O
The	O
patient	O
's	O
ability	O
to	O
wear	O
shoes	O
improved	O
from	O
0.87	O
to	O
3.1	O
.	O
Successful	O
arthrodesis	SYMP
produces	O
a	O
foot	O
that	O
is	O
more	O
functional	O
and	O
durable	O
than	O
excisional	SYMP
arthroplasty	SYMP
.	O
Subjectively	O
,	O
these	O
patients	O
stated	O
that	O
their	O
level	O
of	O
pain	O
,	O
walking	O
tolerance	O
,	O
and	O
overall	O
satisfaction	O
improved	O
significantly	O
after	O
the	O
arthrodesis	SYMP
.	O
Clinically	O
,	O
there	O
was	O
no	O
evidence	O
of	O
transfer	SYMP
lesions	SYMP
,	O
tenderness	O
,	O
or	O
hallux	SYMP
subluxation	SYMP
.	O
Hallux	O
length	O
was	O
well	O
maintained	O
after	O
surgery	SYMP
with	O
bone	SYMP
grafting	SYMP
,	O
but	O
it	O
was	O
more	O
difficult	O
to	O
obtain	O
the	O
alignment	O
goals	O
.	O
The	O
average	O
postoperative	O
metatarsophalangeal	O
dorsiflexion	O
angle	O
was	O
15.6	O
degrees	O
and	O
the	O
first	O
metatarsophalangeal	O
angle	O
was	O
3.1	O
degrees	O
.	O
Despite	O
this	O
,	O
patient	O
satisfaction	O
was	O
high	O
.	O
Arthrodesis	SYMP
of	O
the	O
first	O
metatarsophalangeal	O
joint	O
using	O
a	O
bone	SYMP
graft	SYMP
to	O
salvage	O
failed	O
silicone	SYMP
implant	SYMP
arthroplasty	SYMP
produces	O
acceptable	O
subjective	O
and	O
radiographic	O
results	O
.	O
Although	O
technically	O
demanding	O
,	O
it	O
provides	O
long-term	O
stability	O
to	O
the	O
hallux	O
,	O
restores	O
weightbearing	O
,	O
and	O
allows	O
for	O
maintenance	O
of	O
a	O
propulsive	O
gait	O
.	O
We	O
recommend	O
this	O
procedure	O
instead	O
of	O
an	O
excisional	SYMP
arthroplasty	SYMP
to	O
maintain	O
high	O
level	O
of	O
function	O
and	O
overall	O
patient	O
satisfaction	O
.	O
OBJECTIVE	O
:	O
To	O
estimate	O
the	O
crude	O
incidence	O
rates	O
of	O
cerebrovascular	SYMP
accidents	SYMP
among	O
the	O
black	O
residents	O
of	O
Harare	O
.	O
DESIGN	O
:	O
Prospective	O
community-based	O
study	O
.	O
SETTING	O
:	O
Black	O
residents	O
of	O
Harare	O
,	O
Zimbabwe	O
.	O
PARTICIPANTS	O
:	O
Two	O
hundred	O
and	O
seventy-three	O
'first-ever	O
'	O
strokes	SYMP
prospectively	O
identified	O
over	O
a	O
12-month	O
period	O
.	O
MAIN	O
OUTCOME	O
STUDY	O
FACTORS	O
:	O
Cerebrovascular	SYMP
accident	SYMP
first-week	O
fatality	O
rate	O
;	O
age-	O
and	O
sex-related	O
incidence	O
.	O
RESULTS	O
:	O
The	O
crude	O
incidence	O
rate	O
was	O
estimated	O
to	O
be	O
30.7	O
per	O
100000	O
(	O
95	O
%	O
confidence	O
interval	O
27.1-34.4	O
)	O
and	O
the	O
standardised	O
rate	O
was	O
68	O
per	O
100000	O
.	O
Fifty-one	O
per	O
cent	O
of	O
stroke	SYMP
victims	O
were	O
below	O
the	O
age	O
of	O
54	O
years	O
.	O
Thirty-five	O
per	O
cent	O
of	O
patients	O
died	O
within	O
1	O
week	O
of	O
the	O
stroke	O
.	O
Overall	O
,	O
the	O
age-specific	O
rates	O
for	O
both	O
sexes	O
rose	O
with	O
age	O
,	O
with	O
the	O
rates	O
for	O
women	O
being	O
higher	O
at	O
all	O
age	O
strata	O
except	O
for	O
the	O
group	O
45-54	O
years	O
.	O
CONCLUSION	O
:	O
With	O
a	O
standardised	O
rate	O
of	O
68	O
per	O
100000	O
and	O
a	O
first-week	O
mortality	O
rate	O
of	O
35	O
%	O
,	O
stroke	SYMP
must	O
now	O
be	O
considered	O
an	O
important	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
the	O
population	O
.	O
OBJECTIVE	O
:	O
To	O
explore	O
the	O
long-term	O
effect	O
of	O
calcium	SYMP
supplementation	SYMP
during	O
pregnancy	O
on	O
the	O
offspring	O
's	O
blood	O
pressure	O
during	O
childhood	O
.	O
DESIGN	O
:	O
Follow	O
up	O
of	O
a	O
population	O
enrolled	O
in	O
a	O
double	O
blind	O
,	O
randomised	O
,	O
placebo	O
controlled	O
trial	O
.	O
SETTING	O
:	O
Perinatal	O
research	O
unit	O
,	O
World	O
Health	O
Organisation	O
's	O
collaborative	O
research	O
centre	O
.	O
SUBJECTS	O
:	O
591	O
children	O
at	O
a	O
mean	O
age	O
of	O
7	O
years	O
whose	O
mothers	O
were	O
randomly	O
assigned	O
during	O
pregnancy	O
to	O
receive	O
2	O
g/day	O
of	O
elemental	O
calcium	O
(	O
n	O
=	O
298	O
)	O
or	O
placebo	O
(	O
n	O
=	O
293	O
)	O
.	O
MAIN	O
OUTCOME	O
MEASURES	O
:	O
Mean	O
blood	O
pressure	O
and	O
rate	O
of	O
high	SYMP
blood	SYMP
pressure	SYMP
of	O
children	O
.	O
RESULTS	O
:	O
Overall	O
,	O
systolic	O
blood	O
pressure	O
was	O
lower	O
in	O
the	O
calcium	O
group	O
(	O
mean	O
difference	O
-1.4	O
mm	O
Hg	O
;	O
95	O
%	O
confidence	O
interval	O
-3.2	O
to	O
0.5	O
)	O
than	O
in	O
the	O
placebo	O
group	O
.	O
The	O
effect	O
was	O
found	O
predominantly	O
among	O
children	O
whose	O
body	O
mass	O
index	O
at	O
assessment	O
was	O
above	O
the	O
median	O
for	O
this	O
population	O
(	O
mean	O
difference	O
in	O
systolic	O
blood	O
pressure	O
-5.8	O
mm	O
Hg	O
(	O
-9.8	O
mm	O
Hg	O
to	O
-1.7	O
mm	O
Hg	O
)	O
for	O
children	O
with	O
an	O
index	O
greater	O
than	O
17.5	O
and	O
-3.2	O
mm	O
Hg	O
(	O
-6.3	O
mm	O
Hg	O
to	O
-0.1	O
mm	O
Hg	O
)	O
for	O
those	O
with	O
an	O
index	O
of	O
greater	O
than	O
15.7	O
to	O
17.5	O
)	O
.	O
The	O
risk	O
of	O
high	O
systolic	O
blood	O
pressure	O
was	O
also	O
lower	O
in	O
the	O
calcium	O
group	O
than	O
in	O
the	O
placebo	O
group	O
(	O
relative	O
risk	O
0.59	O
;	O
0.39	O
to	O
0.90	O
)	O
and	O
particularly	O
among	O
children	O
in	O
the	O
highest	O
fourth	O
of	O
body	O
mass	O
index	O
(	O
0.43	O
;	O
0.26	O
to	O
0.71	O
)	O
.	O
CONCLUSION	O
:	O
Calcium	SYMP
supplementation	SYMP
during	O
pregnancy	O
is	O
associated	O
with	O
lower	O
systolic	O
blood	O
pressure	O
in	O
the	O
offspring	O
,	O
particularly	O
among	O
overweight	O
children	O
.	O
The	O
fast	O
reaction	O
of	O
peroxynitrite	O
with	O
CO2	O
and	O
the	O
high	O
concentration	O
of	O
dissolved	O
CO2	O
in	O
vivo	O
(	O
ca	O
.	O
1	O
mM	O
)	O
suggest	O
that	O
CO2	O
modulates	O
most	O
of	O
the	O
reactions	O
of	O
peroxynitrite	O
in	O
biological	O
systems	O
.	O
The	O
addition	O
of	O
peroxynitrite	O
to	O
CO2	O
produces	O
of	O
the	O
adduct	O
ONOO-CO2-	O
(	O
1	O
)	O
.	O
The	O
production	O
of	O
1	O
greatly	O
accelerates	O
the	O
decomposition	O
of	O
peroxynitrite	O
to	O
give	O
nitrate	O
.	O
We	O
now	O
show	O
that	O
the	O
formation	O
of	O
1	O
is	O
followed	O
by	O
reformation	O
of	O
CO2	O
(	O
rather	O
than	O
another	O
carbonate	O
species	O
such	O
as	O
CO3	O
=	O
or	O
HCO3-	O
)	O
.	O
To	O
show	O
this	O
,	O
it	O
is	O
necessary	O
to	O
study	O
systems	O
with	O
limiting	O
concentrations	O
of	O
CO2	O
.	O
(	O
When	O
CO2	O
is	O
present	O
in	O
excess	O
,	O
its	O
concentration	O
remains	O
nearly	O
constant	O
during	O
the	O
decomposition	O
of	O
peroxynitrite	O
,	O
and	O
the	O
recycling	O
of	O
CO2	O
,	O
although	O
it	O
occurs	O
,	O
can	O
not	O
be	O
detected	O
kinetically	O
)	O
.	O
We	O
find	O
that	O
CO2	O
is	O
a	O
true	O
catalyst	O
of	O
the	O
decomposition	O
of	O
peroxynitrite	O
,	O
and	O
this	O
fundamental	O
insight	O
into	O
its	O
action	O
must	O
be	O
rationalized	O
by	O
any	O
in	O
vivo	O
or	O
in	O
vitro	O
reaction	O
mechanism	O
that	O
is	O
proposed	O
.	O
When	O
the	O
concentration	O
of	O
CO2	O
is	O
lower	O
than	O
that	O
of	O
peroxynitrite	O
,	O
the	O
reformation	O
of	O
CO2	O
amplifies	O
the	O
fraction	O
of	O
peroxynitrite	O
that	O
reacts	O
with	O
CO2	O
.	O
Even	O
low	O
concentrations	O
of	O
CO2	O
that	O
result	O
from	O
the	O
dissolution	O
of	O
ambient	O
CO2	O
can	O
have	O
pronounced	O
catalytic	O
effects	O
.	O
These	O
effects	O
can	O
cause	O
deviations	O
from	O
predicted	O
kinetic	O
behavior	O
in	O
studies	O
of	O
peroxynitrite	O
in	O
noncarbonate	O
buffers	O
in	O
vitro	O
,	O
and	O
since	O
1	O
and	O
other	O
intermediates	O
derived	O
from	O
it	O
are	O
oxidants	O
and/or	O
nitrating	O
agents	O
,	O
some	O
of	O
the	O
reactions	O
attributed	O
to	O
peroxynitrite	O
may	O
depend	O
on	O
the	O
availability	O
of	O
CO2	O
.	O
A	O
prospective	O
,	O
randomized	O
,	O
placebo-controlled	O
,	O
double-blind	O
,	O
parallel-group	O
,	O
6-month	O
study	O
assessed	O
the	O
efficacy	O
and	O
safety	O
of	O
ropinirole	SYMP
,	SYMP
a	SYMP
nonergoline	SYMP
D2-dopamine	SYMP
agonist	SYMP
,	O
in	O
patients	O
with	O
early	SYMP
Parkinson	SYMP
's	SYMP
disease	SYMP
(	O
n	O
=	O
241	O
;	O
Hoehn	O
&	O
#	O
38	O
;	O
Yahr	O
stages	O
I	O
to	O
III	O
)	O
with	O
limited	O
or	O
no	O
prior	O
dopaminergic	SYMP
therapy	SYMP
.	O
Patients	O
(	O
mean	O
age	O
,	O
62.8	O
years	O
)	O
,	O
stratified	O
by	O
concomitant	O
use	O
of	O
selegiline	SYMP
,	O
were	O
randomized	O
to	O
ropinirole	SYMP
(	O
n	O
=	O
116	O
)	O
or	O
placebo	O
(	O
n	O
=	O
125	O
)	O
.	O
The	O
starting	O
dose	O
of	O
ropinirole	SYMP
was	O
0.25	O
mg	O
tid	O
with	O
titration	O
to	O
at	O
least	O
1.5	O
mg	O
tid	O
(	O
maximum	O
dose	O
,	O
8	O
mg	O
tid	O
)	O
.	O
Primary	O
efficacy	O
endpoint	O
was	O
the	O
percentage	O
improvement	O
in	O
Unified	O
Parkinson	SYMP
's	SYMP
Disease	SYMP
Rating	O
Scale	O
(	O
UPDRS	O
)	O
motor	O
score	O
.	O
Ropinirole-treated	O
patients	O
had	O
a	O
significantly	O
greater	O
percentage	O
improvement	O
in	O
UPDRS	O
motor	O
score	O
than	O
patients	O
who	O
received	O
placebo	O
(	O
+24	O
%	O
vs	O
-3	O
%	O
;	O
p	O
&	O
#	O
60	O
;	O
0.001	O
)	O
.	O
Ropinirole	SYMP
was	O
well	O
tolerated	O
and	O
patient	O
withdrawals	O
were	O
infrequent	O
.	O
Most	O
adverse	O
experiences	O
were	O
related	O
to	O
peripheral	O
dopaminergic	O
activity	O
.	O
Ropinirole	SYMP
monotherapy	SYMP
is	O
an	O
effective	O
and	O
well-tolerated	O
therapeutic	O
option	O
for	O
treatment	O
of	O
early	SYMP
Parkinson	SYMP
's	SYMP
disease	SYMP
.	O
Starfish	O
oocytes	O
can	O
be	O
fertilized	O
after	O
germinal	O
vesicle	O
breakdown	O
(	O
GVBD	O
)	O
and	O
artificial	O
parthenogenesis	O
can	O
be	O
induced	O
by	O
activating	O
the	O
oocytes	O
after	O
GVBD	O
(	O
post-GVBD	O
activation	O
)	O
.	O
In	O
the	O
present	O
study	O
,	O
parthenogenotes	O
were	O
obtained	O
by	O
the	O
activation	O
of	O
immature	O
oocytes	O
with	O
caffeine	O
before	O
treatment	O
with	O
1-methyladenine	SYMP
(	SYMP
1-MeAde	SYMP
)	SYMP
to	O
induce	O
oocyte	O
maturation	O
.	O
Most	O
of	O
the	O
caffeine-treated	O
eggs	O
developed	O
as	O
tetraploids	O
,	O
as	O
parthenogenotes	O
produced	O
by	O
the	O
post-GVBD	O
activation	O
.	O
The	O
parthengenotes	O
were	O
derived	O
only	O
from	O
eggs	O
that	O
failed	O
to	O
extrude	O
polar	O
bodies	O
,	O
mostly	O
from	O
eggs	O
failing	O
to	O
extrude	O
a	O
second	O
polar	O
body	O
.	O
Eggs	O
derived	O
from	O
immature	O
oocytes	O
activated	O
by	O
A23187	O
,	O
treated	O
with	O
1-MeAde	SYMP
and	O
post-treated	O
with	O
cytochalasin	SYMP
B	SYMP
failed	O
to	O
extrude	O
polar	O
bodies	O
,	O
and	O
eventually	O
developed	O
into	O
parthenogenetic	O
embryos	O
.	O
These	O
results	O
indicate	O
that	O
the	O
present	O
parthenogenesis	O
mechanism	O
shares	O
the	O
same	O
characteristics	O
as	O
that	O
achieved	O
by	O
post-GVBD	O
activation	O
in	O
the	O
suppression	O
of	O
polar	O
body	O
formation	O
as	O
a	O
key	O
means	O
for	O
successful	O
starfish	O
parthenogenesis	O
.	O
We	O
hypothesized	O
that	O
fluoride	SYMP
partly	O
acts	O
by	O
changing	O
the	O
levels	O
of	O
circulating	O
calcium-regulating	O
hormones	O
and	O
skeletal	O
growth	O
factors	O
.	O
The	O
effects	O
of	O
oral	SYMP
fluoride	SYMP
on	O
24	O
female	O
,	O
Dutch-Belted	O
,	O
young	O
adult	O
rabbits	O
were	O
studied	O
.	O
The	O
rabbits	O
were	O
divided	O
into	O
two	O
study	O
groups	O
,	O
one	O
control	O
and	O
the	O
other	O
receiving	O
about	O
16	O
mg	O
fluoride/rabbit/day	O
in	O
their	O
drinking	O
water	O
.	O
After	O
6	O
months	O
of	O
fluoride	SYMP
dosing	SYMP
,	O
all	O
rabbits	O
were	O
euthanized	O
and	O
bone	O
and	O
blood	O
samples	O
were	O
taken	O
for	O
analyses	O
.	O
Fluoride	SYMP
treatment	SYMP
increased	O
serum	O
and	O
bone	O
fluoride	O
levels	O
by	O
over	O
an	O
order	O
of	O
magnitude	O
(	O
P	O
&	O
#	O
60	O
;	O
0.001	O
)	O
,	O
but	O
did	O
not	O
affect	O
body	O
weight	O
or	O
the	O
following	O
serum	O
biochemical	O
variables	O
:	O
urea	O
,	O
creatinine	O
,	O
phosphorus	O
,	O
total	O
protein	O
,	O
albumin	O
,	O
bilirubin	O
,	O
SGOT	O
,	O
or	O
total	O
alkaline	O
phosphatase	O
.	O
No	O
skeletal	SYMP
fluorosis	SYMP
or	O
osteomalacia	SYMP
was	O
observed	O
histologically	O
,	O
nor	O
did	O
fluoride	SYMP
affect	O
serum	O
PTH	O
or	O
Vitamin	O
D	O
metabolites	O
(	O
P	O
greater	O
than	O
0.4	O
)	O
.	O
BAP	O
was	O
increased	O
37	O
%	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
by	O
fluoride	O
;	O
serum	O
TRAP	O
was	O
increased	O
42	O
%	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
;	O
serum	O
IGF-1	O
was	O
increased	O
40	O
%	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
.	O
Fluoride	SYMP
increased	O
the	O
vertebral	O
BV/TV	O
by	O
35	O
%	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
and	O
tibial	O
ash	O
weight	O
by	O
10	O
%	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
.	O
However	O
,	O
the	O
increases	O
in	O
bone	O
mass	O
and	O
bone	O
formation	O
were	O
not	O
reflected	O
in	O
improved	O
bone	O
strength	O
.	O
Fluoride	O
decreased	O
bone	O
strength	O
by	O
about	O
19	O
%	O
in	O
the	O
L5	O
vertebra	O
(	O
P	O
&	O
#	O
60	O
;	O
0.01	O
)	O
and	O
25	O
%	O
in	O
the	O
femoral	O
neck	O
(	O
P	O
&	O
#	O
60	O
;	O
0	O
.	O
05	O
)	O
.	O
X-ray	O
diffraction	O
showed	O
altered	O
mineral	O
crystal	O
thickness	O
in	O
fluoride-treated	O
bones	O
(	O
P	O
&	O
#	O
60	O
;	O
0.001	O
)	O
,	O
and	O
there	O
was	O
a	O
negative	O
association	O
between	O
crystal	O
width	O
and	O
fracture	O
stress	O
of	O
the	O
femur	O
(	O
P	O
&	O
#	O
60	O
;	O
0.02	O
)	O
.	O
In	O
conclusion	O
,	O
fluoride	O
's	O
effects	O
on	O
bone	O
mass	O
and	O
bone	O
turnover	O
were	O
not	O
mediated	O
by	O
PTH	O
.	O
IGF-1	O
was	O
increased	O
by	O
fluoride	O
and	O
was	O
associated	O
with	O
increased	O
bone	O
turnover	O
,	O
but	O
was	O
not	O
correlated	O
with	O
bone	O
formation	O
markers	O
.	O
High-dose	O
fluoride	SYMP
treatment	SYMP
did	O
not	O
improve	O
,	O
but	O
decreased	O
,	O
bone	O
strength	O
in	O
rabbits	O
,	O
even	O
in	O
the	O
absence	O
of	O
impaired	O
mineralization	O
.	O
PURPOSE	O
:	O
To	O
determine	O
the	O
effect	O
of	O
various	O
methods	O
of	O
managing	O
the	O
posterior	O
capsule	O
and	O
anterior	O
vitreous	O
on	O
the	O
rate	O
of	O
posterior	SYMP
capsule	SYMP
opacification	SYMP
in	O
pediatric	O
eyes	O
implanted	O
with	O
posterior	SYMP
chamber	SYMP
intraocular	SYMP
lenses	SYMP
(	SYMP
PC	SYMP
IOLs	SYMP
)	SYMP
.	O
SETTING	O
:	O
Cullen	O
Eye	O
Institute	O
,	O
Baylor	O
College	O
of	O
Medicine	O
,	O
Houston	O
,	O
Texas	O
,	O
USA	O
.	O
METHODS	O
:	O
We	O
reviewed	O
the	O
charts	O
of	O
20	O
eyes	O
of	O
15	O
children	O
(	O
aged	O
1.5	O
to	O
2	O
years	O
)	O
who	O
had	O
primary	O
cataract	SYMP
surgery	SYMP
with	SYMP
PC	SYMP
IOL	SYMP
implantation	SYMP
during	O
the	O
past	O
5	O
years	O
.	O
The	O
posterior	O
capsule	O
and	O
anterior	O
vitreous	O
were	O
managed	O
in	O
a	O
variety	O
of	O
ways	O
:	O
In	O
5	O
eyes	O
,	O
the	O
posterior	O
capsule	O
was	O
left	O
intact	O
;	O
in	O
15	O
eyes	O
,	O
a	O
posterior	SYMP
continuous	SYMP
curvilinear	SYMP
capsulorhexis	SYMP
(	SYMP
PCCC	SYMP
)	SYMP
was	O
performed	O
-	O
6	O
with	O
and	O
9	O
without	O
anterior	SYMP
vitrectomy	SYMP
;	O
in	O
8	O
eyes	O
,	O
posterior	SYMP
optic	SYMP
capture	SYMP
was	O
performed	O
-	O
3	O
with	O
and	O
5	O
without	O
vitrectomy	SYMP
.	O
The	O
follow-up	O
ranged	O
from	O
1	O
to	O
4.5	O
years	O
(	O
mean	O
2	O
years	O
)	O
.	O
RESULTS	O
:	O
Visually	O
significant	O
secondary	O
cataract	SYMP
developed	O
in	O
the	O
five	O
eyes	O
with	O
intact	O
posterior	O
capsules	O
and	O
in	O
the	O
four	O
eyes	O
that	O
had	O
PCCC	SYMP
without	O
vitrectomy	SYMP
and	O
without	O
posterior	SYMP
optic	SYMP
capture	SYMP
(	O
i.e	O
.	O
,	O
the	O
optic	O
was	O
left	O
in	O
the	O
capsular	O
bag	O
)	O
.	O
The	O
optical	O
axis	O
remained	O
clear	O
in	O
the	O
six	O
eyes	O
that	O
had	O
PC	SYMP
IOL	SYMP
implantation	SYMP
with	O
vitrectomy	SYMP
(	O
with	O
or	O
without	O
posterior	SYMP
optic	SYMP
capture	SYMP
)	O
.	O
Initially	O
,	O
all	O
eyes	O
that	O
had	O
optic	SYMP
capture	SYMP
without	O
vitrectomy	SYMP
also	O
remained	O
clear	O
,	O
but	O
after	O
6	O
months	O
,	O
four	O
of	O
five	O
developed	O
opacification	SYMP
.	O
CONCLUSION	O
:	O
In	O
this	O
series	O
,	O
PCCC	SYMP
with	SYMP
anterior	SYMP
vitrectomy	SYMP
was	O
the	O
only	O
effective	O
method	O
of	O
preventing	O
or	O
delaying	O
secondary	SYMP
cataract	SYMP
formation	SYMP
in	O
infants	O
and	O
children	O
.	O
Evidence	O
for	O
the	O
presence	O
of	O
a	O
serotonin1A	O
(	O
5-HT1A	O
)	O
receptor	O
subtype	O
in	O
the	O
salmonid	O
fish	O
brain	O
has	O
recently	O
been	O
presented	O
.	O
In	O
the	O
present	O
study	O
the	O
potent	O
5-HT1A	O
receptor	O
agonist	O
,	O
8-hydroxy-2-	O
(	O
di-n-propylamino	O
)	O
-tetralin	O
(	O
8-OH-DPAT	O
)	O
was	O
tested	O
for	O
its	O
effect	O
on	O
plasma	O
cortisol	O
concentrations	O
in	O
rainbow	O
trout	O
(	O
Oncorhynchus	O
mykiss	O
)	O
.	O
Blood	O
was	O
sampled	O
and	O
8-OH-DPAT	O
administered	O
through	O
a	O
catheter	O
in	O
the	O
dorsal	O
aorta	O
.	O
Thirty	O
minutes	O
after	O
the	O
injection	O
of	O
40	O
microg	O
of	O
8-OH-DPAT/kg	O
,	O
plasma	O
cortisol	O
levels	O
had	O
increased	O
from	O
12	O
to	O
149	O
ng/ml	O
,	O
whereupon	O
they	O
fell	O
,	O
reaching	O
baseline	O
levels	O
after	O
4	O
h.	O
The	O
effect	O
of	O
1-40	O
microg	O
8-OH-DPAT/kg	O
on	O
plasma	O
cortisol	O
concentrations	O
was	O
dose-dependent	O
.	O
The	O
results	O
lends	O
further	O
support	O
to	O
the	O
hypothesis	O
that	O
the	O
brain	O
serotonergic	O
system	O
plays	O
a	O
key	O
role	O
in	O
integrating	O
autonomic	O
,	O
behavioral	O
and	O
neuroendocrine	O
stress-responses	O
in	O
fish	O
as	O
well	O
as	O
mammals	O
,	O
suggesting	O
that	O
not	O
only	O
the	O
structural	O
and	O
biochemical	O
organization	O
,	O
but	O
also	O
the	O
function	O
of	O
the	O
serotonergic	O
system	O
has	O
been	O
conserved	O
during	O
vertebrate	O
evolution	O
.	O
OBJECTIVE	O
:	O
To	O
assess	O
the	O
medicalising	O
effect	O
of	O
prescribing	O
antibiotics	SYMP
for	O
sore	SYMP
throat	SYMP
.	O
SETTING	O
:	O
11	O
general	O
practices	O
in	O
England	O
.	O
DESIGN	O
:	O
Randomised	O
trial	O
of	O
three	O
approaches	O
to	O
sore	SYMP
throat	SYMP
:	O
a	O
10	O
day	O
prescription	O
of	O
antibiotics	SYMP
,	O
no	O
antibiotics	O
,	O
or	O
a	O
delayed	O
prescription	O
if	O
the	O
sore	SYMP
throat	SYMP
had	O
not	O
started	O
to	O
settle	O
after	O
three	O
days	O
.	O
PATIENTS	O
:	O
716	O
patients	O
aged	O
4	O
and	O
over	O
with	O
sore	SYMP
throat	SYMP
and	O
an	O
abnormal	O
physical	O
sign	O
:	O
84	O
%	O
had	O
tonsillitis	SYMP
or	O
pharyngitis	SYMP
.	O
OUTCOME	O
MEASURES	O
:	O
Number	O
and	O
rate	O
of	O
patients	O
making	O
a	O
first	O
return	O
with	O
sore	SYMP
throat	SYMP
,	O
pharyngitis	SYMP
,	O
or	O
tonsillitis	SYMP
.	O
Early	O
returns	O
(	O
within	O
two	O
weeks	O
)	O
and	O
complications	O
(	O
otitis	SYMP
media	SYMP
,	O
sinusitis	SYMP
,	O
quinsy	SYMP
)	O
.	O
Outcomes	O
were	O
documented	O
in	O
675	O
subjects	O
(	O
94	O
%	O
)	O
.	O
RESULTS	O
:	O
Mean	O
follow	O
up	O
time	O
was	O
similar	O
(	O
antibiotic	O
group	O
1.07	O
years	O
,	O
other	O
two	O
groups	O
1.03	O
years	O
)	O
.	O
More	O
of	O
those	O
initially	O
prescribed	O
antibiotics	SYMP
initially	O
returned	O
to	O
the	O
surgery	O
with	O
sore	SYMP
throat	SYMP
(	O
38	O
%	O
v	O
27	O
%	O
,	O
adjusted	O
hazard	O
ratio	O
for	O
return	O
1.39	O
%	O
,	O
95	O
%	O
confidence	O
interval	O
1.03	O
to	O
1.89	O
)	O
.	O
Antibiotics	SYMP
prescribed	O
for	O
sore	SYMP
throat	SYMP
during	O
the	O
previous	O
year	O
had	O
an	O
additional	O
effect	O
(	O
hazard	O
ratio	O
1.69	O
,	O
1.20	O
to	O
2.37	O
)	O
.	O
Longer	O
duration	O
of	O
illness	O
(	O
greater	O
than	O
5	O
days	O
)	O
was	O
associated	O
with	O
increased	O
return	O
within	O
six	O
weeks	O
(	O
hazard	O
ratio	O
2.90	O
,	O
1.70	O
to	O
4.92	O
)	O
.	O
Prior	O
attendance	O
with	O
upper	SYMP
respiratory	SYMP
conditions	SYMP
was	O
also	O
associated	O
with	O
increased	O
reattendance	O
.	O
There	O
was	O
no	O
difference	O
between	O
groups	O
in	O
early	O
return	O
(	O
13/238	O
(	O
5.5	O
%	O
)	O
v	O
27/437	O
(	O
6	O
%	O
)	O
)	O
,	O
or	O
complications	O
(	O
2/236	O
(	O
0.8	O
%	O
)	O
v	O
3/434	O
(	O
0.7	O
%	O
)	O
)	O
.	O
CONCLUSIONS	O
:	O
Complications	O
and	O
early	O
return	O
resulting	O
from	O
no	O
or	O
delayed	O
prescribing	O
of	O
antibiotics	SYMP
for	O
sore	SYMP
throat	SYMP
are	O
rare	O
.	O
Both	O
current	O
and	O
previous	O
prescribing	O
for	O
sore	SYMP
throat	SYMP
increase	O
reattendance	O
.	O
To	O
avoid	O
medicalising	O
a	O
self	O
limiting	O
illness	O
doctors	O
should	O
avoid	O
antibiotics	SYMP
or	O
offer	O
a	O
delayed	O
prescription	O
for	O
most	O
patients	O
with	O
sore	SYMP
throat	SYMP
.	O
This	O
study	O
was	O
designed	O
to	O
determine	O
and	O
compare	O
the	O
dose-response	O
characteristics	O
,	O
speed	O
of	O
onset	O
,	O
and	O
relative	O
potency	O
of	O
single-dose	O
epidural	SYMP
fentanyl	SYMP
(	SYMP
F	SYMP
)	SYMP
and	O
sufentanil	SYMP
(	SYMP
S	SYMP
)	SYMP
for	O
postoperative	SYMP
pain	SYMP
relief	SYMP
.	O
Eighty	O
women	O
undergoing	O
cesarean	O
section	O
(	O
C/S	O
)	O
with	O
epidural	O
2	O
%	O
lidocaine	O
with	O
epinephrine	O
(	O
1	O
:	O
200	O
,	O
000	O
)	O
were	O
randomly	O
assigned	O
to	O
receive	O
double-blind	O
epidural	O
administration	O
of	O
F	O
(	O
25	O
,	O
50	O
,	O
100	O
,	O
or	O
200	O
microg	O
)	O
or	O
S	O
(	O
5	O
,	O
10	O
,	O
20	O
,	O
or	O
30	O
microg	O
)	O
(	O
n	O
=	O
10	O
per	O
group	O
)	O
upon	O
complaint	O
of	O
pain	O
postoperatively	O
.	O
Visual	O
analog	O
scales	O
(	O
VAS	O
,	O
0-100	O
mm	O
)	O
were	O
used	O
to	O
assess	O
pain	O
and	O
sedation	O
at	O
baseline	O
;	O
at	O
3	O
,	O
6	O
,	O
9	O
,	O
12	O
,	O
15	O
,	O
20	O
,	O
25	O
,	O
30	O
,	O
45	O
,	O
and	O
60	O
min	O
;	O
and	O
every	O
30	O
min	O
until	O
further	O
analgesia	O
was	O
requested	O
.	O
The	O
study	O
was	O
terminated	O
at	O
30	O
min	O
if	O
satisfactory	O
analgesia	O
was	O
not	O
achieved	O
.	O
Side	O
effects	O
were	O
recorded	O
.	O
A	O
dose-response	O
was	O
demonstrated	O
for	O
both	O
opioids	O
.	O
F	O
25	O
microg	O
and	O
S	O
5	O
microg	O
were	O
ineffective	O
,	O
with	O
significantly	O
fewer	O
women	O
achieving	O
VAS	O
scores	O
&	O
#	O
60	O
;	O
10	O
mm	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
compared	O
with	O
F	O
100	O
or	O
200	O
microg	O
and	O
S	O
20	O
or	O
30	O
microg	O
)	O
.	O
F	O
100	O
and	O
200	O
microg	O
and	O
S	O
20	O
and	O
30	O
microg	O
all	O
achieved	O
VAS	O
scores	O
&	O
#	O
60	O
;	O
10	O
mm	O
in	O
all	O
women	O
with	O
no	O
differences	O
in	O
time	O
to	O
50	O
%	O
reduction	O
in	O
VAS	O
(	O
mean	O
11-16	O
min	O
)	O
and	O
no	O
differences	O
in	O
duration	O
of	O
analgesia	O
(	O
mean	O
117-138	O
min	O
)	O
.	O
The	O
50	O
%	O
and	O
95	O
%	O
effective	O
dose	O
values	O
for	O
each	O
opioid	O
to	O
achieve	O
a	O
VAS	O
score	O
&	O
#	O
60	O
;	O
10	O
mm	O
were	O
F	O
33	O
microg	O
and	O
92	O
microg	O
and	O
S	O
6.7	O
microg	O
and	O
17.5	O
microg	O
.	O
There	O
were	O
no	O
differences	O
among	O
groups	O
in	O
sedation	O
scores	O
or	O
side	O
effects	O
.	O
Our	O
data	O
suggest	O
that	O
the	O
relative	O
analgesic	O
potency	O
of	O
epidural	O
S	O
:	O
F	O
is	O
approximately	O
5	O
and	O
that	O
there	O
are	O
no	O
differences	O
between	O
the	O
opioids	O
in	O
the	O
onset	O
,	O
duration	O
,	O
and	O
effectiveness	O
of	O
analgesia	O
when	O
equianalgesic	O
doses	O
are	O
administered	O
postoperatively	O
after	O
lidocaine	O
anesthesia	O
for	O
C/S	O
.	O
We	O
describe	O
2	O
cases	O
in	O
which	O
intraoperative	O
transesophageal	O
echocardiography	O
detected	O
complications	O
related	O
to	O
the	O
proximal	O
coronary	O
arteries	O
during	O
homograft	SYMP
aortic	SYMP
valve	SYMP
and	SYMP
root	SYMP
replacement	SYMP
.	O
In	O
both	O
cases	O
,	O
cardiopulmonary	SYMP
bypass	SYMP
could	O
not	O
be	O
discontinued	O
despite	O
the	O
use	O
of	O
large	O
doses	O
of	O
inotropic	SYMP
drugs	SYMP
.	O
Transesophageal	O
echocardiography	O
demonstrated	O
aliasing	O
on	O
color	O
flow	O
mapping	O
in	O
the	O
left	O
main	O
coronary	O
artery	O
in	O
1	O
case	O
and	O
proximal	O
right	O
coronary	O
artery	O
in	O
the	O
other	O
,	O
along	O
with	O
severely	O
depressed	O
left	O
ventricular	O
anterior	O
wall	O
and	O
right	O
ventricular	O
function	O
,	O
respectively	O
.	O
Coronary	SYMP
artery	SYMP
bypass	SYMP
grafting	SYMP
was	O
performed	O
in	O
both	O
cases	O
,	O
and	O
the	O
outcome	O
was	O
successful	O
.	O
Granulocyte	O
colony-stimulating	O
factor	O
(	O
G-CSF	O
)	O
has	O
been	O
used	O
to	O
improve	O
granulocyte	O
count	O
in	O
chronic	O
neutropenia	O
and	O
myelodysplasia	O
,	O
to	O
minimize	O
the	O
incidence	O
and	O
duration	O
of	O
neutropenia	O
during	O
conventional	O
chemotherapy	O
,	O
and	O
to	O
mobilize	O
peripheral	O
blood	O
stem	O
cells	O
prior	O
to	O
leukapheresis	O
for	O
use	O
in	O
autologous	O
and	O
allogeneic	O
marrow	O
transplantation	O
.	O
The	O
most	O
common	O
toxicity	O
is	O
bone	SYMP
pain	SYMP
,	O
and	O
other	O
reactions	O
such	O
as	O
inflammation	SYMP
at	O
the	O
site	O
of	O
injection	SYMP
have	O
also	O
occurred	O
.	O
In	O
patients	O
with	O
chronic	SYMP
neutropenia	SYMP
,	O
splenomegaly	SYMP
has	O
been	O
described	O
with	O
long-term	O
use	O
,	O
and	O
extramedullary	SYMP
hematopoiesis	SYMP
has	O
also	O
been	O
reported	O
.	O
However	O
,	O
thus	O
far	O
,	O
no	O
life-threatening	O
sequelae	O
of	O
these	O
effects	O
are	O
found	O
in	O
the	O
literature	O
.	O
We	O
now	O
describe	O
a	O
case	O
of	O
spontaneous	O
splenic	SYMP
rupture	SYMP
four	O
days	O
following	O
a	O
six-day	O
course	O
of	O
G-CSF	SYMP
therapy	SYMP
in	O
an	O
allogeneic	O
donor	O
of	O
peripheral	O
blood	O
stem	O
cells	O
.	O
Evidence-based	O
medicine	O
(	O
EBM	O
)	O
aids	O
clinical	O
decision	O
making	O
in	O
all	O
fields	O
of	O
medicine	O
,	O
including	O
primary	O
care	O
.	O
General	O
practice	O
is	O
characterized	O
by	O
particular	O
emphasis	O
on	O
the	O
doctor-patient	O
relationship	O
and	O
on	O
biomedical	O
,	O
personal	O
and	O
contextual	O
perspectives	O
in	O
diagnosis	O
.	O
Most	O
evidence	O
available	O
to	O
general	O
practitioners	O
(	O
GPs	O
)	O
addresses	O
only	O
the	O
bio-medical	O
perspective	O
and	O
is	O
often	O
not	O
directly	O
applicable	O
to	O
primary	O
care	O
,	O
as	O
it	O
derives	O
from	O
secondary	O
or	O
tertiary	O
care	O
.	O
Emphasis	O
on	O
the	O
biomedical	O
domain	O
and	O
the	O
randomized	O
controlled	O
trial	O
(	O
RCT	O
)	O
alone	O
reflects	O
a	O
reductionist	O
approach	O
that	O
fails	O
to	O
do	O
justice	O
to	O
the	O
philosophy	O
of	O
general	O
practice	O
.	O
The	O
art	O
of	O
medicine	O
is	O
founded	O
on	O
context	O
,	O
anecdote	O
,	O
patient	O
stories	O
of	O
illness	O
and	O
personal	O
experience	O
,	O
and	O
we	O
should	O
continue	O
to	O
blend	O
this	O
with	O
good	O
quality	O
and	O
appropriate	O
research	O
findings	O
in	O
patient	O
care	O
.	O
Abdominal	SYMP
tuberculosis	SYMP
is	O
not	O
uncommon	O
in	O
the	O
UK	O
,	O
especially	O
in	O
Asian	O
immigrants	O
.	O
It	O
resembles	O
Crohn	SYMP
's	SYMP
disease	SYMP
clinically	O
and	O
radiologically	O
,	O
and	O
it	O
may	O
be	O
difficult	O
to	O
differentiate	O
between	O
them	O
,	O
even	O
at	O
laparotomy	O
or	O
histology	O
.	O
The	O
distinction	O
is	O
important	O
,	O
however	O
,	O
for	O
proper	O
management	O
of	O
the	O
two	O
conditions	O
.	O
Every	O
effort	O
must	O
be	O
made	O
to	O
exclude	O
abdominal	SYMP
tuberculosis	SYMP
before	O
the	O
patient	O
is	O
diagnosed	O
as	O
having	O
Crohn	SYMP
's	SYMP
disease	SYMP
and	O
is	O
treated	O
with	O
steroids	SYMP
.	O
PURPOSE	O
:	O
The	O
American	O
Urological	O
Association	O
convened	O
the	O
Female	SYMP
Stress	SYMP
Urinary	SYMP
Incontinence	SYMP
Clinical	O
Guidelines	O
Panel	O
to	O
analyze	O
the	O
literature	O
regarding	O
surgical	SYMP
procedures	SYMP
for	O
treating	O
stress	SYMP
urinary	SYMP
incontinence	SYMP
in	O
the	O
otherwise	O
healthy	O
female	O
subject	O
and	O
to	O
make	O
practice	O
recommendations	O
based	O
on	O
the	O
treatment	O
outcomes	O
data	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
The	O
panel	O
searched	O
the	O
MEDLINE	O
data	O
base	O
for	O
all	O
articles	O
through	O
1993	O
on	O
surgical	SYMP
treatment	SYMP
of	O
female	SYMP
stress	SYMP
urinary	SYMP
incontinence	SYMP
.	O
Outcomes	O
data	O
were	O
extracted	O
from	O
articles	O
accepted	O
after	O
panel	O
review	O
.	O
The	O
data	O
were	O
then	O
meta-analyzed	O
to	O
produce	O
outcome	O
estimates	O
for	O
alternative	O
surgical	SYMP
procedures	SYMP
.	O
RESULTS	O
:	O
The	O
data	O
indicate	O
that	O
after	O
48	O
months	O
retropubic	SYMP
suspensions	SYMP
and	O
slings	SYMP
appear	O
to	O
be	O
more	O
efficacious	O
than	O
transvaginal	SYMP
suspensions	SYMP
,	O
and	O
also	O
more	O
efficacious	O
than	O
anterior	SYMP
repairs	SYMP
.	O
The	O
literature	O
suggests	O
higher	O
complication	O
rates	O
when	O
synthetic	O
materials	O
are	O
used	O
for	O
slings	SYMP
.	O
CONCLUSIONS	O
:	O
The	O
panel	O
found	O
sufficient	O
acceptable	O
long-term	O
outcomes	O
data	O
(	O
longer	O
than	O
48	O
months	O
)	O
to	O
conclude	O
that	O
surgical	SYMP
treatment	SYMP
of	O
female	SYMP
stress	SYMP
urinary	SYMP
incontinence	SYMP
is	O
effective	O
,	O
offering	O
a	O
long-term	O
cure	O
in	O
a	O
significant	O
percentage	O
of	O
women	O
.	O
The	O
evidence	O
supports	O
surgery	SYMP
as	O
initial	O
therapy	O
and	O
as	O
a	O
secondary	O
form	O
of	O
therapy	O
after	O
failure	O
of	O
other	O
treatments	O
for	O
stress	SYMP
urinary	SYMP
incontinence	SYMP
.	O
Retropubic	SYMP
suspensions	SYMP
and	O
slings	SYMP
are	O
the	O
most	O
efficacious	O
procedures	O
for	O
long-term	O
success	O
(	O
based	O
on	O
cure/dry	O
rates	O
)	O
.	O
However	O
,	O
in	O
the	O
panel	O
's	O
opinion	O
retropubic	SYMP
suspensions	SYMP
and	O
sling	SYMP
procedures	SYMP
are	O
associated	O
with	O
slightly	O
higher	O
complication	O
rates	O
,	O
including	O
longer	O
convalescence	O
and	O
postoperative	SYMP
voiding	SYMP
dysfunction	SYMP
.	O
A	O
55-year-old	O
lady	O
underwent	O
repeat	O
aortic	SYMP
valve	SYMP
replacement	SYMP
using	O
a	O
16-mm	O
Carbomedics	O
prosthesis	O
.	O
She	O
made	O
an	O
uneventful	O
postoperative	O
recovery	O
and	O
now	O
leads	O
an	O
unrestricted	O
life	O
.	O
Doppler	O
echocardiography	O
reveals	O
a	O
21-mm	O
Hg	O
gradient	O
across	O
the	O
valve	O
at	O
rest	O
.	O
This	O
did	O
not	O
increase	O
with	O
an	O
infusion	O
of	O
30	O
mcg/kg	O
per	O
min	O
of	O
dobutamine	O
,	O
which	O
resulted	O
in	O
an	O
increase	O
in	O
the	O
cardiac	O
output	O
from	O
1.96	O
to	O
5.46	O
l/min	O
.	O
BACKGROUND	O
:	O
For	O
more	O
than	O
30	O
years	O
it	O
has	O
been	O
known	O
that	O
gastric	O
acid	O
secretion	O
is	O
inversely	O
related	O
to	O
the	O
extent	O
and	O
severity	O
of	O
corpal	SYMP
gastritis	SYMP
.	O
We	O
therefore	O
evaluated	O
the	O
effect	O
of	O
cure	O
of	O
Helicobacter	SYMP
pylori	SYMP
infection	SYMP
on	O
basal	O
and	O
pentagastrin-stimulated	O
acid	O
secretion	O
.	O
METHODS	O
:	O
Basal	O
acid	O
output	O
(	O
BAO	O
)	O
and	O
maximal	O
acid	O
output	O
(	O
MAO	O
)	O
were	O
assessed	O
in	O
11	O
H.	O
pylori-infected	O
dyspeptic	O
patients	O
(	O
8	O
women	O
and	O
3	O
men	O
;	O
mean	O
age	O
,	O
28	O
years	O
)	O
before	O
and	O
after	O
successful	O
anti-H	O
.	O
pylori	O
therapy	O
.	O
RESULTS	O
:	O
The	O
gastritis	O
index	O
was	O
significantly	O
lower	O
after	O
therapy	O
and	O
was	O
associated	O
with	O
an	O
increase	O
in	O
both	O
BAO	O
and	O
MAO	O
after	O
cure	O
of	O
the	O
H.	SYMP
pylori	SYMP
infection	SYMP
(	O
BAO	O
from	O
0.3	O
mmol/h	O
and	O
MAO	O
from	O
4.8	O
mmol/h	O
to	O
19	O
mmol/	O
h	O
)	O
.	O
Basal	O
and	O
stimulated	O
acid	O
concentrations	O
also	O
increased	O
(	O
29.1	O
+/-	O
36.6	O
to	O
54	O
+/-	O
31	O
mmol/l	O
and	O
72.5	O
+/-	O
46	O
to	O
120.1	O
+/-	O
30	O
mmol/l	O
,	O
respectively	O
,	O
for	O
basal	O
and	O
stimulated	O
acid	O
concentrations	O
;	O
P	O
&	O
#	O
60	O
;	O
0.05	O
for	O
peak	O
and	O
MAO	O
,	O
P	O
=	O
0.07	O
for	O
BAO	O
)	O
.	O
CONCLUSION	O
:	O
Gastric	O
acid	O
secretion	O
increased	O
into	O
the	O
normal	O
range	O
after	O
successful	O
treatment	O
of	O
H.	SYMP
pylori	SYMP
infection	SYMP
,	O
suggesting	O
that	O
gastric	O
function	O
can	O
recover	O
to	O
normal	O
or	O
almost	O
normal	O
after	O
cure	O
of	O
H.	SYMP
pylori	SYMP
infection	SYMP
.	O
OBJECTIVE	O
:	O
Reports	O
suggest	O
that	O
there	O
is	O
an	O
increased	O
incidence	O
of	O
preeclampsia	SYMP
after	O
a	O
previously	O
normal	O
pregnancy	O
if	O
there	O
is	O
a	O
change	O
in	O
paternity	O
.	O
We	O
hypothesize	O
that	O
there	O
is	O
a	O
higher	O
incidence	O
of	O
preeclampsia	SYMP
(	SYMP
proteinuric	SYMP
hypertension	SYMP
)	SYMP
in	O
women	O
conceiving	O
by	O
intrauterine	O
insemination	O
with	O
donor	O
sperm	O
versus	O
intrauterine	O
insemination	O
with	O
partner	O
sperm	O
.	O
STUDY	O
DESIGN	O
:	O
This	O
was	O
a	O
retrospective	O
cohort	O
study	O
.	O
In	O
women	O
with	O
primary	O
infertility	SYMP
all	O
pregnancies	O
achieved	O
by	O
either	O
partner	O
or	O
donor	O
intrauterine	SYMP
insemination	SYMP
carried	O
to	O
birth	O
of	O
a	O
fetus	O
(	O
greater	O
than	O
20	O
weeks	O
)	O
were	O
identified	O
.	O
The	O
medical	O
records	O
were	O
examined	O
for	O
the	O
maternal	O
and	O
pregnancy	O
outcome	O
data	O
.	O
The	O
relative	O
risk	O
and	O
95	O
%	O
confidence	O
interval	O
were	O
calculated	O
for	O
the	O
risk	O
of	O
preeclampsia	SYMP
.	O
The	O
baseline	O
data	O
were	O
compared	O
with	O
t	O
tests	O
,	O
chi	O
2	O
analysis	O
and	O
Fisher	O
's	O
exact	O
test	O
where	O
appropriate	O
.	O
RESULTS	O
:	O
Forty-four	O
patients	O
in	O
the	O
partner	O
intrauterine	SYMP
insemination	SYMP
group	O
and	O
37	O
in	O
the	O
donor	SYMP
insemination	SYMP
group	O
were	O
identified	O
as	O
having	O
primary	O
infertility	SYMP
.	O
Three	O
cases	O
of	O
mild	O
preeclampsia	SYMP
were	O
found	O
in	O
the	O
partner	SYMP
insemination	SYMP
program	O
and	O
nine	O
cases	O
of	O
preeclampsia	SYMP
(	O
five	O
severe	O
,	O
four	O
mild	O
)	O
in	O
the	O
donor	SYMP
insemination	SYMP
program	O
(	O
relative	O
risk	O
1.85	O
,	O
95	O
%	O
confidence	O
interval	O
1.20	O
to	O
2.85	O
)	O
.	O
CONCLUSIONS	O
:	O
There	O
is	O
a	O
higher	O
incidence	O
of	O
preeclampsia	SYMP
in	O
women	O
conceiving	O
by	O
intrauterine	SYMP
insemination	SYMP
with	O
washed	O
donor	O
sperm	O
compared	O
with	O
intrauterine	SYMP
insemination	SYMP
with	O
washed	O
partner	O
sperm	O
.	O
CONCLUSIONS	O
:	O
There	O
is	O
a	O
higher	O
incidence	O
of	O
preeclampsia	SYMP
in	O
women	O
conceiving	O
by	O
intrauterine	SYMP
insemination	SYMP
with	O
washed	O
donor	O
sperm	O
compared	O
with	O
intrauterine	SYMP
insemination	SYMP
with	O
washed	O
partner	O
sperm	O
.	O
This	O
supports	O
,	O
indirectly	O
,	O
an	O
immunologic	O
basis	O
for	O
preeclampsia	SYMP
.	O
The	O
antigenic	O
factor	O
would	O
appear	O
to	O
be	O
located	O
on	O
the	O
sperm	O
as	O
opposed	O
to	O
the	O
seminal	O
fluid	O
itself	O
.	O
After	O
a	O
rapid	O
examination	O
of	O
a	O
few	O
basic	O
concepts	O
concerning	O
cellular	O
aging	O
and	O
programmed	O
cell	O
death	O
,	O
the	O
aging	O
of	O
the	O
tissues	O
and	O
organs	O
,	O
the	O
authors	O
discuss	O
the	O
principal	O
theories	O
on	O
senescence	O
.	O
They	O
underline	O
that	O
it	O
is	O
necessary	O
to	O
agree	O
in	O
considering	O
the	O
various	O
genetic	O
and	O
epigenetic	O
,	O
endogenous	O
and	O
exogenous	O
mechanisms	O
that	O
lead	O
to	O
the	O
complex	O
aging	O
phenomenon	O
multiple	O
and	O
interrelated	O
.	O
In	O
particular	O
they	O
stress	O
the	O
hypothesis	O
that	O
senescence	O
can	O
be	O
due	O
to	O
a	O
sum	O
of	O
molecular	O
damages	O
caused	O
by	O
free	O
radicals	O
,	O
and	O
to	O
the	O
loss	O
of	O
telomeric	O
DNA	O
.	O
Radical	O
reactions	O
can	O
cause	O
mutations	O
,	O
inactivation	O
or	O
a	O
decrease	O
in	O
the	O
turnover	O
of	O
mitochondrial	O
DNA	O
which	O
is	O
more	O
vulnerable	O
than	O
the	O
nuclear	O
genoma	O
to	O
the	O
attack	O
of	O
mutagenic	O
agents	O
,	O
acting	O
also	O
as	O
a	O
continuous	O
source	O
of	O
initial	O
and/or	O
promoting	O
factors	O
of	O
the	O
carcinogenetic	O
process	O
.	O
The	O
somatic	O
cells	O
become	O
senescent	O
because	O
during	O
cell	O
division	O
,	O
they	O
lose	O
the	O
mechanisms	O
for	O
the	O
lengthening	O
of	O
the	O
telomere	O
.	O
The	O
telomerase	O
prevents	O
the	O
shortening	O
of	O
telomeres	O
in	O
neoplastic	O
cells	O
and	O
therefore	O
renders	O
them	O
immortal	O
.	O
Paradoxically	O
the	O
protection	O
of	O
the	O
telomere	O
is	O
exactly	O
what	O
must	O
be	O
avoided	O
in	O
the	O
case	O
of	O
tumor	O
cells	O
.	O
Recently	O
the	O
demonstration	O
that	O
telomerase	O
is	O
not	O
always	O
involved	O
in	O
the	O
restoration	O
of	O
telomere	O
length	O
shows	O
the	O
complexity	O
of	O
the	O
problems	O
connected	O
to	O
the	O
cause	O
of	O
senescence	O
.	O
Chromosomally	O
integrated	O
retroviral	O
switch	O
(	O
S	O
)	O
substrates	O
have	O
been	O
developed	O
to	O
reveal	O
switch	O
recombinase-like	O
activities	O
(	O
SRLA	O
)	O
in	O
pre-B	O
and	O
mature	O
B	O
cell	O
lines	O
.	O
Switch	O
substrate	O
retrovectors	O
(	O
SSR	O
)	O
contain	O
a	O
long-terminal	O
repeat-driven	O
neomycin	O
(	O
Neo	O
)	O
gene	O
for	O
proviral	O
chromosomal	O
maintenance	O
(	O
pre-	O
and	O
post-S	O
recombination	O
)	O
and	O
a	O
CMV	O
promoter-driven	O
,	O
chimeric	O
hygromycin-thymidine	O
kinase	O
(	O
Hytk	O
)	O
gene	O
(	O
flanked	O
by	O
S	O
mu	O
and	O
S	O
gamma	O
2b	O
recombination	O
targets	O
)	O
to	O
select	O
for	O
(	O
ganciclovir	O
)	O
and	O
against	O
(	O
hygromycin	O
B	O
)	O
S	O
region	O
recombination	O
.	O
The	O
retro-substrates	O
'	O
strong	O
,	O
constitutive	O
promoters	O
ensure	O
that	O
variations	O
in	O
cellular	O
switch	O
recombinase	O
activities	O
are	O
independent	O
of	O
S	O
region	O
accessibility	O
control	O
.	O
By	O
initially	O
selecting	O
for	O
proviral	O
integrants	O
in	O
hygromycin	O
followed	O
by	O
shifting	O
into	O
neomycin	O
+	O
ganciclovir	O
to	O
select	O
for	O
S	O
sequence-mediated	O
deletions	O
,	O
switch	O
recombinations	O
can	O
be	O
specifically	O
forestalled	O
in	O
B	O
cell	O
lines	O
whilst	O
most	O
switch-incompetent	O
cells	O
do	O
not	O
survive	O
secondary	O
selection	O
.	O
A	O
qualitative	O
,	O
direct	O
PCR	O
assay	O
reveals	O
that	O
SSR	O
recombinations	O
are	O
stochastic	O
in	O
B	O
cell	O
lines	O
generating	O
a	O
product	O
array	O
akin	O
to	O
natural	O
GH	O
class	O
switching	O
.	O
A	O
semi-quantitative	O
DC-PCR	O
assay	O
detects	O
a	O
significant	O
recombinase	O
activity	O
only	O
in	O
a	O
restricted	O
set	O
of	O
late	O
stage	O
pre-B	O
and	O
mature	O
B	O
cell	O
lines	O
.	O
BCL1B1	O
mature	O
B	O
cells	O
have	O
the	O
highest	O
level	O
of	O
recombinase	O
activity	O
with	O
25	O
%	O
or	O
more	O
of	O
proviral	O
integrants	O
accumulating	O
S	O
mu/S	O
gamma	O
2b	O
substrate	O
recombinations	O
within	O
10-14	O
cell	O
generations	O
.	O
The	O
SSR	O
recombinase	O
assay	O
can	O
be	O
performed	O
in	O
a	O
transient	O
fashion	O
wherein	O
extensive	O
,	O
B	O
cell-specific	O
recombination	O
can	O
be	O
visualized	O
within	O
only	O
a	O
few	O
cell	O
divisions	O
post	O
proviral	O
integration	O
.	O
We	O
propose	O
that	O
switch	O
recombinase	O
activity	O
becomes	O
activated	O
during	O
B	O
cell	O
ontogeny	O
independent	O
of	O
or	O
prior	O
to	O
the	O
acquisition	O
of	O
CH	O
locus	O
accessibility	O
and	O
that	O
endogenous	O
S	O
segment	O
targeting	O
to	O
pre-existing	O
recombinase	O
requires	O
a	O
level	O
of	O
accessibility	O
beyond	O
transcriptional	O
activation	O
.	O
OBJECTIVE	O
:	O
To	O
determine	O
the	O
prevalence	O
of	O
illicit	O
drug	O
abuse	O
and	O
alcohol	O
use	O
in	O
an	O
obstetric	O
population	O
based	O
in	O
an	O
urban	O
maternity	O
hospital	O
.	O
SETTING	O
:	O
A	O
collaborative	O
study	O
between	O
the	O
Rotunda	O
Hospital	O
,	O
Dublin	O
and	O
the	O
Irish	O
National	O
Drug	O
Advisory	O
&	O
#	O
38	O
;	O
Treatment	O
Centre	O
.	O
DESIGN	O
:	O
A	O
prospective	O
study	O
consisting	O
of	O
anonymous	O
,	O
unlinked	O
urine	O
testing	O
of	O
504	O
'first	O
visit	O
'	O
antenatal	O
patients	O
and	O
a	O
separate	O
group	O
of	O
515	O
patients	O
six	O
weeks	O
after	O
delivery	O
.	O
METHODS	O
&	O
#	O
38	O
;	O
OUTCOME	O
MEASURES	O
:	O
Toxicological	O
screening	O
using	O
enzyme-linked	O
immunoassay	O
techniques	O
,	O
with	O
all	O
positive	O
samples	O
being	O
reanalysed	O
.	O
Drug	O
histories	O
were	O
taken	O
and	O
samples	O
were	O
tested	O
for	O
alcohol	O
and	O
six	O
of	O
the	O
most	O
commonly	O
abused	O
drugs	O
.	O
The	O
pre-	O
and	O
postnatal	O
prevalence	O
of	O
abuse	O
was	O
matched	O
with	O
demographic	O
data	O
.	O
RESULTS	O
:	O
The	O
prevalence	O
of	O
chemical	O
substance	O
misuse	O
in	O
the	O
antenatal	O
population	O
was	O
2.8	O
%	O
and	O
5.6	O
%	O
in	O
the	O
postnatal	O
population	O
.	O
Substances	O
identified	O
included	O
benzodiazepines	O
,	O
cannabis	O
,	O
amphetamines	O
,	O
opiates	O
and	O
cocaine	O
.	O
Less	O
than	O
2	O
%	O
of	O
samples	O
tested	O
positive	O
for	O
alcohol	O
.	O
None	O
of	O
the	O
women	O
yielding	O
positive	O
samples	O
had	O
been	O
pre-identified	O
on	O
the	O
basis	O
of	O
history	O
.	O
A	O
significant	O
proportion	O
of	O
the	O
women	O
were	O
in	O
the	O
high	O
risk	O
categories	O
with	O
regard	O
to	O
age	O
and	O
socio-economic	O
status	O
.	O
CONCLUSION	O
:	O
The	O
prevalence	O
of	O
drug	O
misuse	O
antenatally	O
was	O
nearly	O
3	O
%	O
and	O
postnatally	O
almost	O
6	O
%	O
.	O
Substance	O
abusers	O
in	O
pregnancy	O
are	O
more	O
likely	O
to	O
be	O
single	O
,	O
unemployed	O
,	O
and	O
to	O
have	O
had	O
a	O
previous	O
pregnancy	O
.	O
Schizophrenic	SYMP
illnesses	SYMP
occur	O
with	O
approximately	O
the	O
same	O
incidence	O
in	O
all	O
human	O
populations	O
with	O
a	O
characteristic	O
distribution	O
(	O
slightly	O
earlier	O
in	O
males	O
)	O
of	O
ages	O
of	O
onset	O
.	O
Given	O
that	O
the	O
predisposition	O
(	O
which	O
presumably	O
is	O
genetic	O
)	O
is	O
associated	O
with	O
a	O
procreative	O
disadvantage	O
why	O
do	O
such	O
illnesses	O
persist	O
?	O
Here	O
it	O
is	O
suggested	O
that	O
these	O
conditions	O
are	O
a	O
manifestation	O
of	O
genetic	O
diversity	O
in	O
the	O
evolution	O
of	O
the	O
specifically	O
human	O
characteristic	O
of	O
language	O
,	O
an	O
innovation	O
that	O
has	O
occurred	O
by	O
a	O
process	O
of	O
progressive	O
hemispheric	O
specialization-the	O
establishment	O
of	O
dominance	O
for	O
some	O
critical	O
component	O
of	O
language	O
in	O
one	O
or	O
the	O
other	O
hemisphere	O
.	O
Individuals	O
who	O
develop	O
schizophrenic	SYMP
symptoms	SYMP
show	O
lesser	O
anatomical	O
and	O
functional	O
asymmetries	O
than	O
the	O
population	O
as	O
a	O
whole	O
;	O
such	O
symptoms	O
may	O
reflect	O
'dominance	O
failure	O
'	O
for	O
language	O
.	O
Cloacal	SYMP
anomalies	SYMP
are	O
extremely	O
rare	O
and	O
have	O
variable	O
presentations	O
.	O
Prenatal	O
diagnosis	O
can	O
be	O
difficult	O
especially	O
if	O
they	O
present	O
in	O
late	O
gestation	O
.	O
Here	O
we	O
present	O
two	O
cases	O
diagnosed	O
in	O
the	O
late	O
third	O
trimester	O
and	O
review	O
the	O
literature	O
regarding	O
prenatal	O
diagnosis	O
of	O
cloacal	SYMP
anomalies	SYMP
.	O
OBJECTIVE	O
:	O
To	O
determine	O
whether	O
patients	O
with	O
myocardial	SYMP
amyloidosis	SYMP
due	O
either	O
to	O
AL	O
(	O
primary	O
)	O
amyloid	O
or	O
familial	O
amyloid	O
have	O
distinguishing	O
echocardiographic	O
or	O
electrocardiographic	O
features	O
;	O
and	O
to	O
compare	O
the	O
prevalence	O
of	O
heart	SYMP
failure	SYMP
and	O
survival	O
in	O
the	O
two	O
types	O
of	O
amyloidosis	SYMP
in	O
relation	O
to	O
echocardiographic	O
findings	O
.	O
DESIGN	O
:	O
Blinded	O
group	O
comparison	O
of	O
randomly	O
selected	O
cases	O
of	O
cardiac	SYMP
amyloidosis	SYMP
.	O
SETTING	O
:	O
International	O
referral	O
centre	O
for	O
amyloid	O
research	O
and	O
treatment	O
.	O
PATIENTS	O
:	O
36	O
patients	O
with	O
cardiac	SYMP
amyloid	SYMP
heart	SYMP
disease	SYMP
,	O
of	O
whom	O
12	O
had	O
familial	O
and	O
24	O
had	O
primary	O
AL	O
amyloidosis	SYMP
.	O
RESULTS	O
:	O
Familial	O
and	O
AL	O
echocardiograms	O
were	O
morphologically	O
indistinguishable	O
,	O
with	O
similar	O
left	O
ventricular	O
wall	O
thickness	O
,	O
mean	O
(	O
SD	O
)	O
15.4	O
(	O
2.3	O
)	O
nu	O
15.8	O
(	O
2.5	O
)	O
mm	O
,	O
respectively	O
;	O
right	O
ventricular	O
wall	O
thickness	O
was	O
also	O
similar	O
between	O
amyloid	O
types	O
:	O
9.6	O
(	O
2.8	O
)	O
nu	O
9.7	O
(	O
6.5	O
)	O
mm	O
,	O
respectively	O
.	O
Doppler	O
indices	O
of	O
left	O
and	O
right	O
ventricular	O
function	O
,	O
left	O
ventricular	O
volume	O
,	O
and	O
ejection	O
fraction	O
were	O
also	O
similar	O
.	O
Low	O
voltage	O
electrocardiograms	O
(	O
&	O
#	O
60	O
;	O
0.5	O
mV	O
)	O
were	O
more	O
common	O
in	O
the	O
AL	O
(	O
16/24	O
,	O
67	O
%	O
)	O
than	O
in	O
the	O
familial	O
group	O
(	O
4/12	O
,	O
25	O
%	O
)	O
,	O
P	O
&	O
#	O
60	O
;	O
0.05	O
.	O
The	O
one	O
year	O
survival	O
for	O
familial	O
and	O
AL	O
forms	O
was	O
92	O
%	O
(	O
11/12	O
)	O
nu	O
38	O
%	O
(	O
6/24	O
)	O
,	O
respectively	O
,	O
with	O
virtually	O
all	O
deaths	O
due	O
to	O
cardiac	O
causes	O
.	O
CONCLUSIONS	O
:	O
Although	O
cardiac	O
involvement	O
is	O
echocardiographically	O
indistinguishable	O
,	O
cardiac	O
mortality	O
is	O
very	O
different	O
between	O
the	O
two	O
forms	O
of	O
amyloidosis	SYMP
.	O
Preservation	O
of	O
electrocardiographic	O
voltage	O
in	O
familial	O
amyloidosis	SYMP
suggests	O
that	O
the	O
particular	O
biochemical	O
characteristics	O
of	O
distinct	O
types	O
of	O
amyloid	O
fibril	O
have	O
different	O
pathological	O
effects	O
on	O
the	O
myocardium	O
.	O
This	O
distinction	O
becomes	O
critical	O
in	O
the	O
evaluation	O
,	O
treatment	O
,	O
and	O
management	O
of	O
patients	O
who	O
have	O
a	O
diagnosis	O
within	O
the	O
spectrum	O
of	O
the	O
protein	SYMP
deposition	SYMP
diseases	SYMP
.	O
OBJECTIVE	O
:	O
To	O
examine	O
the	O
relationship	O
between	O
plasma	O
plasminogen	O
activator	O
inhibitor	O
1	O
(	O
PAI-1	O
)	O
activity	O
and	O
PAI-1	O
gene	O
(	O
4G/5G	O
)	O
polymorphism	O
and	O
diabetic	SYMP
retinopathy	SYMP
in	O
Pima	O
Indians	O
with	O
type	O
2	O
diabetes	SYMP
.	O
RESEARCH	O
DESIGN	O
AND	O
METHODS	O
:	O
We	O
studied	O
171	O
Pima	O
Indians	O
with	O
type	O
2	O
diabetes	SYMP
between	O
the	O
ages	O
of	O
30-70	O
years	O
in	O
a	O
population-based	O
epidemiological	O
survey	O
.	O
Plasma	O
PAI-1	O
activity	O
was	O
measured	O
by	O
a	O
spectrophotometric	O
assay	O
and	O
PAI-1	O
4G/5G	O
promoter	O
genotype	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
using	O
allele-specific	O
primers	O
.	O
Retinopathy	SYMP
was	O
assessed	O
by	O
ophthalmoscopy	O
after	O
pupillary	O
dilation	O
and	O
classified	O
as	O
any	O
retinopathy	SYMP
or	O
as	O
nonproliferative	O
and	O
proliferative	O
.	O
RESULTS	O
:	O
Retinopathy	SYMP
was	O
present	O
in	O
70	O
(	O
41	O
%	O
)	O
subjects	O
,	O
and	O
4	O
(	O
2.3	O
%	O
)	O
subjects	O
had	O
proliferative	O
retinopathy	SYMP
.	O
Plasma	O
PAI-1	O
activity	O
was	O
not	O
significantly	O
different	O
among	O
subjects	O
with	O
and	O
without	O
retinopathy	SYMP
(	O
17.1	O
+/-	O
vs.	O
19.7	O
+/-	O
9.1	O
arbitrary	O
units	O
(	O
AU	O
)	O
/ml	O
,	O
P	O
=	O
0.09	O
)	O
.	O
PAI-1	O
activity	O
was	O
negatively	O
correlated	O
with	O
duration	O
of	O
diabetes	SYMP
(	O
rs	O
=	O
-0.18	O
,	O
P	O
=	O
0.02	O
)	O
.	O
In	O
a	O
logistic	O
regression	O
analysis	O
controlled	O
for	O
age	O
,	O
sex	O
,	O
BMI	O
,	O
and	O
duration	O
of	O
diabetes	SYMP
,	O
any	O
retinopathy	SYMP
was	O
significantly	O
associated	O
with	O
fasting	O
plasma	O
glucose	O
concentrations	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
,	O
2-h	O
postload	O
glucose	O
(	O
P	O
=	O
0.02	O
)	O
,	O
and	O
HbA1c	O
(	O
P	O
=	O
0.008	O
)	O
,	O
but	O
not	O
with	O
PAI-1	O
activity	O
(	O
P	O
=	O
0.48	O
)	O
.	O
The	O
prevalence	O
of	O
retinopathy	SYMP
in	O
the	O
three	O
genotype	O
groups	O
differed	O
significantly	O
(	O
4G/4G	O
,	O
4G/5G	O
,	O
and	O
5G/5G	O
were	O
44	O
,	O
49	O
,	O
and	O
24	O
%	O
,	O
respectively	O
;	O
chi	O
2	O
=	O
8.22	O
,	O
df	O
=	O
2	O
,	O
P	O
=	O
0.016	O
)	O
and	O
remained	O
significant	O
after	O
controlling	O
for	O
age	O
,	O
sex	O
,	O
BMI	O
,	O
duration	O
of	O
diabetes	SYMP
,	O
glycated	O
hemoglobin	O
,	O
and	O
urine	O
albumin-to-creatine	O
ratio	O
in	O
a	O
logistic	O
regression	O
analysis	O
.	O
The	O
odds	O
ratios	O
for	O
retinopathy	SYMP
in	O
subjects	O
with	O
4G/4G	O
and	O
4G/5G	O
,	O
compared	O
with	O
the	O
5G/5G	O
genotype	O
,	O
were	O
2.0	O
and	O
3.1	O
,	O
respectively	O
.	O
CONCLUSIONS	O
:	O
Although	O
diabetic	SYMP
retinopathy	SYMP
in	O
Pima	O
Indians	O
with	O
type	O
2	O
diabetes	SYMP
is	O
not	O
associated	O
with	O
PAI-1	O
activity	O
,	O
subjects	O
with	O
the	O
4G/4G	O
and	O
4G/5G	O
genotype	O
had	O
a	O
higher	O
prevalence	O
of	O
retinopathy	SYMP
compared	O
with	O
5G/5G	O
PAI-1genotype	O
.	O
These	O
preliminary	O
findings	O
indicate	O
that	O
in	O
Pima	O
Indians	O
with	O
type	O
2	O
diabetes	SYMP
,	O
presence	O
of	O
the	O
4G	O
allele	O
of	O
the	O
PAI-1	O
gene	O
was	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
diabetic	SYMP
retinopathy	SYMP
.	O
BACKGROUND	O
:	O
Diagnostic	O
peritoneal	O
lavage	O
(	O
DPL	O
)	O
is	O
used	O
to	O
diagnose	O
intra-abdominal	SYMP
injury	SYMP
in	O
patients	O
with	O
stab	SYMP
wounds	SYMP
and	O
blunt	SYMP
trauma	SYMP
.	O
Because	O
exploratory	SYMP
celiotomy	SYMP
is	O
routinely	O
performed	O
on	O
patients	O
with	O
gunshot	SYMP
wounds	SYMP
to	SYMP
the	SYMP
abdomen	SYMP
,	O
DPL	O
is	O
rarely	O
employed	O
.	O
However	O
,	O
several	O
studies	O
have	O
questioned	O
routine	O
exploration	O
and	O
have	O
drawn	O
attention	O
to	O
the	O
associated	O
morbidity	O
of	O
negative	O
celiotomy	O
.	O
Diagnostic	O
peritoneal	O
lavage	O
is	O
an	O
easily	O
performed	O
and	O
inexpensive	O
test	O
that	O
may	O
be	O
useful	O
in	O
this	O
situation	O
.	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
performance	O
of	O
DPL	O
in	O
the	O
diagnosis	O
of	O
intra-abdominal	SYMP
injury	SYMP
in	O
hemodynamically	O
stable	O
patients	O
with	O
gunshot	SYMP
wounds	SYMP
to	O
the	O
abdomen	O
.	O
DESIGN	O
:	O
A	O
prospective	O
clinical	O
trial	O
.	O
SETTING	O
:	O
Two	O
urban	O
trauma	O
centers	O
.	O
PATIENTS	O
:	O
Patients	O
with	O
gunshot	SYMP
wounds	SYMP
to	O
the	O
abdomen	O
and	O
a	O
systolic	O
blood	O
pressure	O
of	O
at	O
least	O
90	O
mm	O
Hg	O
.	O
INTERVENTIONS	O
:	O
Clinical	O
predication	O
of	O
intra-abdominal	SYMP
injury	SYMP
in	O
the	O
emergency	O
department	O
and	O
DPL	O
performed	O
in	O
the	O
operating	O
room	O
before	O
the	O
initiation	O
of	O
celiotomy	O
.	O
Injuries	O
found	O
during	O
the	O
celiotomy	O
were	O
recorded	O
.	O
MAIN	O
OUTCOME	O
MEASURES	O
:	O
The	O
results	O
of	O
the	O
clinical	O
evaluation	O
and	O
DPL	O
were	O
compared	O
with	O
the	O
findings	O
of	O
the	O
celiotomy	O
.	O
RESULTS	O
:	O
Forty-four	O
patients	O
were	O
enrolled	O
into	O
the	O
study	O
.	O
Intra-abdominal	SYMP
injury	SYMP
was	O
present	O
in	O
32	O
(	O
73	O
%	O
)	O
of	O
these	O
patients	O
.	O
The	O
senior	O
surgery	O
resident	O
correctly	O
predicted	O
the	O
presence	O
of	O
intra-abdominal	SYMP
injury	SYMP
in	O
36	O
(	O
82	O
%	O
)	O
of	O
the	O
patients	O
(	O
sensitivity	O
=	O
90.0	O
%	O
,	O
specificity	O
=	O
58.3	O
%	O
,	O
positive	O
predictive	O
value	O
=	O
85.3	O
%	O
,	O
negative	O
predictive	O
value	O
=	O
63.6	O
%	O
,	O
phi	O
=	O
0.52	O
,	O
P	O
&	O
#	O
60	O
;	O
.01	O
)	O
in	O
the	O
emergency	O
department	O
before	O
DPL	O
and	O
celiotomy	O
were	O
performed	O
.	O
Diagnostic	O
peritoneal	O
lavage	O
correctly	O
identified	O
the	O
presence	O
or	O
absence	O
of	O
intra-abdominal	SYMP
injury	SYMP
in	O
40	O
(	O
91	O
%	O
)	O
of	O
the	O
patients	O
(	O
positive	O
predictive	O
value	O
=	O
96.7	O
%	O
,	O
negative	O
predictive	O
value	O
=	O
78.6	O
%	O
,	O
phi	O
=	O
0.79	O
,	O
P	O
&	O
#	O
60	O
;	O
.01	O
)	O
.	O
CONCLUSIONS	O
:	O
Clinical	O
judgment	O
is	O
highly	O
accurate	O
in	O
separating	O
patients	O
with	O
tangential	O
gunshot	SYMP
wounds	SYMP
to	O
the	O
abdomen	O
from	O
those	O
with	O
intra-abdominal	SYMP
injury	SYMP
but	O
may	O
miss	O
patients	O
with	O
intra-abdominal	SYMP
hemorrhage	SYMP
.	O
Diagnostic	O
peritoneal	O
lavage	O
is	O
highly	O
predictive	O
of	O
the	O
presence	O
of	O
intra-abdominal	SYMP
injury	SYMP
.	O
The	O
return	O
of	O
gross	O
blood	O
on	O
aspiration	O
or	O
a	O
lavage	O
red	O
blood	O
cell	O
count	O
greater	O
than	O
10	O
x	O
10	O
(	O
9	O
)	O
/L	O
should	O
prompt	O
an	O
urgent	O
celiotomy	O
.	O
Missed	O
injuries	O
are	O
rare	O
and	O
most	O
likely	O
to	O
be	O
bowel	SYMP
perforations	SYMP
.	O
Diagnostic	O
peritoneal	O
lavage	O
is	O
an	O
objective	O
test	O
that	O
may	O
augment	O
clinical	O
judgment	O
in	O
selecting	O
hemodynamically	O
stable	O
patients	O
with	O
potential	O
tangential	O
gunshot	SYMP
wounds	SYMP
for	O
observation	O
and	O
is	O
especially	O
useful	O
in	O
identifying	O
intra-abdominal	SYMP
hemorrhage	SYMP
.	O
BACKGROUND	O
:	O
To	O
evaluate	O
the	O
frequency	O
of	O
Blastocystis	SYMP
hominis	SYMP
parasitation	SYMP
and	O
to	O
ascertain	O
its	O
role	O
as	O
an	O
intestinal	O
a	O
prospective	O
study	O
during	O
18	O
months	O
pathogen	O
has	O
been	O
carried	O
out	O
.	O
SUBJECTS	O
AND	O
METHODS	O
:	O
The	O
study	O
included	O
2	O
,	O
039	O
patients	O
,	O
which	O
were	O
classified	O
in	O
three	O
groups	O
(	O
asymptomatic	O
(	O
group	O
A	O
)	O
,	O
with	O
suspicion	O
of	O
parasitosis	SYMP
(	O
group	O
B	O
)	O
,	O
with	O
diarrhoea	SYMP
(	O
group	O
C	O
)	O
)	O
.	O
In	O
all	O
cases	O
a	O
coproparasitological	O
study	O
was	O
performed	O
.	O
In	O
the	O
group	O
C	O
the	O
presence	O
of	O
non-parasitic	O
enteropathogens	O
was	O
also	O
investigated	O
.	O
In	O
patients	O
with	O
B	O
.	O
hominis	O
in	O
the	O
absence	O
of	O
other	O
pathogens	O
clinical	O
and	O
epidemiological	O
characteristics	O
were	O
evaluated	O
.	O
Also	O
,	O
its	O
was	O
determined	O
the	O
morphology	O
and	O
quantification	O
of	O
parasites	O
.	O
RESULTS	O
:	O
Parasites	O
were	O
identified	O
in	O
26.2	O
%	O
of	O
population	O
.	O
B	O
.	O
hominis	O
was	O
identified	O
in	O
336	O
patients	O
(	O
16.5	O
%	O
)	O
.	O
The	O
frequency	O
of	O
parasitation	SYMP
was	O
superior	O
in	O
adults	O
(	O
p	O
&	O
#	O
60	O
;	O
0.0001	O
)	O
,	O
with	O
a	O
slight	O
predominance	O
in	O
the	O
female	O
sex	O
.	O
The	O
rate	O
of	O
asymptomatic	O
carriers	O
was	O
3.3	O
%	O
.	O
In	O
21	O
patients	O
B	O
.	O
hominis	O
(	O
group	O
C	O
)	O
was	O
observed	O
in	O
absence	O
of	O
other	O
enteropathogens	O
.	O
Statistical	O
significant	O
association	O
was	O
found	O
between	O
B	O
.	O
hominis	O
,	O
in	O
absence	O
of	O
other	O
pathogens	O
and	O
the	O
presence	O
of	O
clinical	O
manifestations	O
(	O
p	O
&	O
#	O
60	O
;	O
0.0001	O
)	O
,	O
the	O
most	O
common	O
of	O
which	O
were	O
diarrhoea	SYMP
and	O
abdominal	SYMP
pain	SYMP
.	O
We	O
did	O
not	O
find	O
a	O
statistically	O
significant	O
association	O
between	O
the	O
number	O
of	O
B	O
.	O
hominis	O
present	O
and	O
stool	O
characteristics	O
.	O
The	O
vacuolar	O
form	O
was	O
the	O
predominant	O
morphological	O
type	O
.	O
The	O
ameboid	O
form	O
was	O
observed	O
only	O
in	O
diarrhoeal	O
stools	O
.	O
CONCLUSIONS	O
:	O
B	O
.	O
hominis	O
is	O
the	O
most	O
frequent	O
parasite	O
found	O
in	O
faecal	O
parasitological	O
investigation	O
.	O
In	O
absence	O
of	O
other	O
causes	O
,	O
B	O
.	O
hominis	O
must	O
be	O
considered	O
as	O
a	O
pathogen	O
.	O
BACKGROUND	O
:	O
The	O
cause	O
of	O
severe	O
acquired	O
hyperammonemia	O
,	O
an	O
uncommon	O
but	O
often	O
fatal	O
complication	O
of	O
organ	O
transplantation	O
and	O
chemotherapy	O
for	O
cancer	O
,	O
is	O
obscure	O
.	O
OBJECTIVE	O
:	O
To	O
test	O
the	O
hypothesis	O
that	O
liver	O
glutamine	O
synthetase	O
deficiency	O
may	O
explain	O
hyperammonemia	SYMP
in	O
patients	O
who	O
have	O
had	O
organ	SYMP
transplantation	SYMP
or	O
are	O
receiving	O
chemotherapy	SYMP
.	O
DESIGN	O
:	O
Case	O
report	O
.	O
PATIENTS	O
:	O
Two	O
patients	O
who	O
had	O
fatal	O
hyperammonemia	SYMP
after	O
orthotopic	O
lung	SYMP
transplantation	SYMP
.	O
MEASUREMENTS	O
:	O
Liver	O
tissue	O
was	O
analyzed	O
to	O
determine	O
the	O
activities	O
of	O
two	O
urea	O
cycle	O
enzymes	O
and	O
glutamine	O
synthetase	O
.	O
Western	O
blot	O
assays	O
for	O
hepatic	O
glutamine	O
synthetase	O
were	O
performed	O
to	O
determine	O
whether	O
glutamine	O
synthetase	O
deficiency	O
resulted	O
from	O
reduced	O
enzyme	O
levels	O
.	O
RESULTS	O
:	O
Activities	O
of	O
carbamoyl	O
phosphate	O
synthetase	O
I	O
and	O
ornithine	O
carbamoyltransferase	O
in	O
the	O
liver	O
were	O
normal	O
.	O
The	O
activity	O
of	O
hepatic	O
glutamine	O
synthetase	O
was	O
markedly	O
reduced	O
(	O
in	O
patient	O
1	O
,	O
12	O
%	O
of	O
the	O
mean	O
value	O
in	O
controls	O
;	O
in	O
patient	O
2	O
,	O
28	O
%	O
of	O
the	O
mean	O
value	O
in	O
controls	O
)	O
,	O
and	O
a	O
concomitant	O
reduction	O
in	O
the	O
amount	O
of	O
glutamine	O
synthetase	O
protein	O
was	O
observed	O
.	O
CONCLUSION	O
:	O
Hyperammonemia	O
after	O
transplantation	O
was	O
associated	O
with	O
hepatic	O
glutamine	O
synthetase	O
deficiency	O
in	O
two	O
patients	O
,	O
but	O
the	O
causal	O
relation	O
between	O
these	O
two	O
conditions	O
must	O
be	O
further	O
studied	O
.	O
Postnatal	O
growth	O
was	O
prospectively	O
measured	O
from	O
birth	O
to	O
1	O
y	O
in	O
54	O
term	O
infants	O
born	O
small	O
for	O
gestational	O
age	O
(	O
SGA	O
)	O
,	O
fed	O
either	O
breast	O
milk	O
or	O
a	O
standard	O
term	O
infant	O
formula	O
.	O
Breastfeeding	O
was	O
associated	O
with	O
a	O
0.36	O
and	O
0.64	O
standard	O
deviation	O
(	O
SD	O
)	O
increase	O
in	O
weight	O
at	O
2	O
weeks	O
and	O
3	O
months	O
of	O
age	O
,	O
respectively	O
,	O
which	O
persisted	O
beyond	O
the	O
breastfeeding	O
period	O
(	O
0.64	O
SD	O
at	O
1	O
y	O
)	O
.	O
Breastfed	O
infants	O
also	O
showed	O
greater	O
catch-up	O
growth	O
in	O
head	O
circumference	O
(	O
SD	O
score	O
(	O
SDS	O
)	O
0.53	O
higher	O
at	O
3	O
months	O
)	O
,	O
and	O
greater	O
body	O
length	O
gain	O
(	O
SDS	O
0.68	O
higher	O
at	O
6	O
months	O
)	O
.	O
This	O
increased	O
growth	O
was	O
independent	O
of	O
potentially	O
confounding	O
obstetric	O
,	O
social	O
and	O
demographic	O
factors	O
.	O
Our	O
findings	O
suggest	O
that	O
breastfeeding	O
may	O
promote	O
faster	O
growth	O
in	O
infants	O
compromised	O
by	O
poor	O
growth	O
in	O
utero	O
.	O
SGA	O
infants	O
may	O
be	O
programmed	O
for	O
a	O
number	O
of	O
adverse	O
outcomes	O
;	O
the	O
possibility	O
that	O
such	O
events	O
are	O
altered	O
by	O
choice	O
of	O
postnatal	O
diet	O
is	O
a	O
key	O
issue	O
for	O
future	O
research	O
.	O
BACKGROUND	O
:	O
Few	O
studies	O
have	O
explored	O
the	O
health	O
practices	O
of	O
critical	O
care	O
nurses	O
.	O
Critical	O
care	O
nurses	O
routinely	O
teach	O
patients	O
about	O
using	O
healthy	O
practices	O
such	O
as	O
low-fat	O
diets	O
,	O
exercise	O
,	O
and	O
routine	O
screening	O
examinations	O
.	O
However	O
,	O
it	O
may	O
be	O
even	O
more	O
important	O
that	O
the	O
nurses	O
themselves	O
have	O
a	O
healthy	O
lifestyle	O
,	O
thus	O
serving	O
as	O
role	O
models	O
for	O
patients	O
.	O
Nurses	O
are	O
selling	O
a	O
product	O
,	O
and	O
that	O
product	O
is	O
health	O
.	O
The	O
best	O
salespersons	O
are	O
those	O
who	O
are	O
genuinely	O
committed	O
to	O
their	O
product	O
and	O
model	O
its	O
benefits	O
.	O
Therefore	O
,	O
critical	O
care	O
nurses	O
'	O
healthful	O
practices	O
can	O
have	O
a	O
profound	O
effect	O
on	O
their	O
patients	O
.	O
OBJECTIVES	O
:	O
The	O
purpose	O
of	O
this	O
descriptive	O
exploratory	O
study	O
was	O
to	O
examine	O
critical	O
care	O
nurses	O
'	O
responses	O
to	O
three	O
questions	O
about	O
health	O
practices	O
in	O
their	O
daily	O
lives	O
:	O
(	O
1	O
)	O
What	O
are	O
critical	O
care	O
nurses	O
doing	O
currently	O
to	O
stay	O
healthy	O
?	O
(	O
2	O
)	O
Do	O
they	O
anticipate	O
making	O
any	O
changes	O
in	O
their	O
lifestyle	O
in	O
the	O
future	O
?	O
(	O
3	O
)	O
Would	O
they	O
recommend	O
their	O
lifestyle	O
to	O
their	O
patients	O
?	O
METHODS	O
:	O
One	O
hundred	O
twenty-seven	O
critical	O
care	O
nurses	O
attending	O
a	O
midwestern	O
critical	O
care	O
conference	O
completed	O
a	O
two-part	O
questionnaire	O
designed	O
to	O
produce	O
a	O
health	O
profile	O
.	O
In	O
a	O
man-on-the-street	O
approach	O
,	O
23	O
nurses	O
participated	O
in	O
an	O
interview	O
via	O
video	O
camera	O
.	O
Descriptive	O
statistics	O
were	O
used	O
to	O
analyze	O
the	O
data	O
retrieved	O
from	O
the	O
questionnaires	O
.	O
Interviews	O
were	O
transcribed	O
verbatim	O
and	O
analyzed	O
for	O
themes	O
with	O
a	O
constant	O
comparative	O
method	O
.	O
RESULTS	O
:	O
More	O
than	O
70	O
%	O
of	O
the	O
critical	O
care	O
nurses	O
who	O
responded	O
engage	O
in	O
exercise	O
and	O
follow	O
a	O
healthy	O
,	O
low-fat	O
diet	O
.	O
Seventy-one	O
percent	O
said	O
that	O
they	O
anticipate	O
making	O
a	O
change	O
in	O
their	O
lifestyle	O
in	O
the	O
future	O
,	O
and	O
70	O
%	O
said	O
that	O
they	O
would	O
recommend	O
their	O
lifestyle	O
to	O
their	O
patients	O
.	O
Five	O
themes	O
emerged	O
from	O
the	O
videotaped	O
interviews	O
:	O
(	O
1	O
)	O
Heart-healthy	O
practices	O
predominated	O
the	O
responses	O
.	O
(	O
2	O
)	O
Incorporating	O
a	O
healthy	O
lifestyle	O
was	O
easy	O
for	O
some	O
and	O
a	O
struggle	O
for	O
others	O
.	O
(	O
3	O
)	O
Critical	O
care	O
nurses	O
readily	O
listed	O
barriers	O
to	O
healthy	O
living	O
.	O
(	O
4	O
)	O
The	O
nurses	O
had	O
a	O
positive	O
attitude	O
about	O
their	O
healthy	O
lifestyles	O
and	O
felt	O
optimistic	O
about	O
being	O
role	O
models	O
for	O
their	O
patients	O
.	O
(	O
5	O
)	O
Future	O
plans	O
were	O
either	O
singular	O
in	O
focus	O
or	O
limited	O
to	O
maintenance	O
of	O
current	O
health	O
habits	O
.	O
CONCLUSIONS	O
:	O
The	O
majority	O
of	O
the	O
nurses	O
reported	O
practicing	O
a	O
healthy	O
lifestyle	O
and	O
thought	O
that	O
they	O
were	O
good	O
role	O
models	O
for	O
patients	O
.	O
Cytochrome	O
P450	O
1A1	O
(	O
CYP1A1	O
)	O
and	O
glutathione	O
S-transferase	O
M1	O
(	O
GSTM1	O
)	O
genetic	O
polymorphisms	O
are	O
involved	O
in	O
the	O
activation	O
and	O
detoxification	O
of	O
chemical	O
carcinogens	O
found	O
in	O
tobacco	O
smoke	O
;	O
thus	O
they	O
may	O
influence	O
host	O
susceptibility	O
to	O
lung	SYMP
cancer	SYMP
.	O
In	O
this	O
study	O
at	O
Massachusetts	O
General	O
Hospital	O
(	O
Boston	O
,	O
MA	O
,	O
USA	O
)	O
of	O
416	O
cases	O
and	O
446	O
controls	O
(	O
mostly	O
White	O
)	O
we	O
evaluated	O
the	O
association	O
between	O
the	O
CYP1A1	O
MspI	O
and	O
GSTM1	O
polymorphisms	O
and	O
lung	SYMP
cancer	SYMP
risk	O
,	O
and	O
their	O
interaction	O
with	O
cigarette	O
smoke	O
.	O
The	O
CYP1A1	O
MspI	O
heterozygous	O
genotype	O
was	O
present	O
in	O
18	O
percent	O
of	O
cases	O
and	O
16	O
percent	O
of	O
controls	O
,	O
and	O
one	O
percent	O
of	O
cases	O
and	O
controls	O
were	O
CYP1A1	O
MspI	O
homozygous	O
variant	O
.	O
The	O
GSTM1	O
null	O
genotype	O
was	O
detected	O
in	O
54	O
percent	O
of	O
cases	O
and	O
52	O
percent	O
of	O
controls	O
.	O
After	O
adjusting	O
for	O
age	O
,	O
gender	O
,	O
pack-years	O
of	O
smoking	O
,	O
and	O
years	O
since	O
quitting	O
smoking	O
,	O
while	O
neither	O
the	O
CYP1A1	O
MspI	O
heterozygous	O
genotype	O
alone	O
nor	O
the	O
GSTM1	O
null	O
genotype	O
alone	O
were	O
associated	O
with	O
a	O
significant	O
increase	O
in	O
lung	SYMP
cancer	SYMP
risk	O
,	O
having	O
both	O
genetic	O
traits	O
was	O
associated	O
with	O
a	O
twofold	O
increase	O
in	O
risk	O
(	O
95	O
percent	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1.0-3.4	O
)	O
.	O
Our	O
data	O
did	O
not	O
provide	O
enough	O
evidence	O
for	O
a	O
substantial	O
modification	O
of	O
the	O
effect	O
of	O
pack-years	O
on	O
lung	SYMP
cancer	SYMP
risk	O
by	O
the	O
CYP1A1	O
MspI	O
and	O
GSTM1	O
genotypes	O
.	O
However	O
,	O
limitations	O
of	O
our	O
study	O
preclude	O
a	O
conclusion	O
about	O
this	O
potential	O
interaction	O
.	O
BACKGROUND	O
:	O
Thrombolytic	SYMP
treatment	SYMP
has	O
been	O
shown	O
to	O
accelerate	O
resolution	O
of	O
major	SYMP
pulmonary	SYMP
embolism	SYMP
and	O
lead	O
to	O
a	O
rapid	O
improvement	O
of	O
right-side	O
hemodynamics	O
.	O
However	O
,	O
the	O
association	O
between	O
these	O
favorable	O
effects	O
and	O
the	O
clinical	O
outcome	O
of	O
patients	O
who	O
have	O
no	O
severe	O
hemodynamic	SYMP
compromise	SYMP
at	O
presentation	O
remains	O
unknown	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
The	O
present	O
multicenter	O
registry	O
included	O
719	O
consecutive	O
patients	O
with	O
major	SYMP
pulmonary	SYMP
embolism	SYMP
according	O
to	O
clinical	O
,	O
echocardiographic	O
,	O
scintigraphic	O
,	O
and	O
cardiac	O
catheterization	O
criteria	O
.	O
Symptom	O
onset	O
was	O
acute	O
(	O
&	O
#	O
60	O
;	O
48	O
hours	O
)	O
in	O
63	O
%	O
of	O
patients	O
.	O
All	O
patients	O
were	O
hemodynamically	O
stable	O
(	O
ie	O
,	O
without	O
evidence	O
of	O
cardiogenic	SYMP
shock	SYMP
)	O
at	O
presentation	O
.	O
less	O
than	O
TREATONLYPrimary	O
thrombolytic	O
treatment	O
(	O
within	O
24	O
hours	O
of	O
diagnosis	O
)	O
was	O
given	O
to	O
169	O
patients	O
(	O
23.5	O
%	O
)	O
,	O
whereas	O
the	O
remaining	O
550	O
patients	O
were	O
initially	O
treated	O
with	O
heparin	SYMP
alone	O
.	O
Overall	O
30-day	O
mortality	O
was	O
significantly	O
lower	O
in	O
the	O
patients	O
who	O
received	O
thrombolytic	SYMP
agents	SYMP
(	O
4.7	O
versus	O
11.1	O
%	O
,	O
P=.016	O
)	O
.	O
Clinical	O
factors	O
associated	O
with	O
a	O
higher	O
death	O
rate	O
were	O
syncope	SYMP
(	O
P=.012	O
)	O
,	O
arterial	SYMP
hypotension	SYMP
(	O
P=.021	O
)	O
,	O
history	O
of	O
congestive	SYMP
heart	SYMP
failure	SYMP
(	O
P=.013	O
)	O
,	O
and	O
chronic	SYMP
pulmonary	SYMP
disease	SYMP
(	O
P=.032	O
)	O
.	O
However	O
,	O
only	O
primary	SYMP
thrombolysis	SYMP
was	O
found	O
by	O
multivariate	O
analysis	O
to	O
be	O
an	O
independent	O
predictor	O
of	O
survival	O
(	O
odds	O
ratio	O
for	O
in-hospital	O
death	O
,	O
0.46	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.21	O
to	O
1.00	O
)	O
.	O
Patients	O
who	O
underwent	O
early	O
thrombolytic	O
treatment	O
had	O
a	O
reduced	O
rate	O
of	O
recurrent	O
pulmonary	O
embolism	O
(	O
7.7	O
versus	O
18.7	O
%	O
,	O
P	O
&	O
#	O
60	O
;	O
.001	O
)	O
but	O
also	O
a	O
higher	O
frequency	O
of	O
major	O
bleeding	O
episodes	O
(	O
21.9	O
%	O
versus	O
7.8	O
%	O
,	O
P	O
&	O
#	O
60	O
;	O
.001	O
)	O
.	O
Cerebral	SYMP
bleeding	SYMP
occurred	O
in	O
2	O
patients	O
in	O
each	O
treatment	O
group	O
,	O
and	O
1	O
patient	O
in	O
each	O
group	O
died	O
of	O
a	O
bleeding	SYMP
complication	O
.	O
CONCLUSIONS	O
:	O
The	O
results	O
of	O
our	O
study	O
suggest	O
that	O
thrombolysis	SYMP
may	O
favorably	O
affect	O
the	O
clinical	O
outcome	O
of	O
hemodynamically	O
stable	O
patients	O
with	O
major	SYMP
pulmonary	SYMP
embolism	SYMP
.	O
A	O
66-year-old	O
male	O
engineer	O
diagnosed	O
with	O
malignant	SYMP
pleural	SYMP
mesothelioma	SYMP
4	O
years	O
previously	O
had	O
thoracotomy	SYMP
,	SYMP
radiotherapy	SYMP
,	SYMP
and	SYMP
chemotherapy	SYMP
.	O
He	O
was	O
followed	O
regularly	O
with	O
chest	O
computed	O
tomography	O
(	O
CT	O
)	O
scan	O
and	O
had	O
been	O
asymptomatic	O
.	O
During	O
one	O
of	O
his	O
physical	O
examinations	O
,	O
routine	O
sigmoidoscopy	O
showed	O
incidental	O
colonic	SYMP
polyps	SYMP
which	O
were	O
biopsied	O
.	O
Subsequently	O
,	O
recurrence	O
of	O
pleural	SYMP
mesothelioma	SYMP
and	O
peritoneal	O
involvement	O
by	O
mesothelioma	SYMP
was	O
documented	O
.	O
Two	O
of	O
the	O
polyps	O
showed	O
metastatic	SYMP
malignant	SYMP
mesothelioma	SYMP
in	O
the	O
lamina	O
propia	O
which	O
strongly	O
resembled	O
adenocarcinoma	SYMP
histologically	O
causing	O
difficulty	O
in	O
making	O
definitive	O
diagnosis	O
.	O
Review	O
of	O
the	O
literature	O
disclosed	O
no	O
previously	O
documented	O
similar	O
occurrence	O
.	O
This	O
case	O
shows	O
the	O
importance	O
of	O
clinical	O
history	O
and	O
ancillary	O
laboratory	O
procedures	O
such	O
as	O
immunohistochemistry	O
and	O
electron	O
microscopy	O
to	O
avoid	O
diagnostic	O
pitfalls	O
.	O
The	O
authors	O
report	O
the	O
postoperative	O
magnetic	O
resonance	O
(	O
MR	O
)	O
imaging	O
findings	O
in	O
36	O
patients	O
with	O
advanced	SYMP
Parkinson	SYMP
's	SYMP
disease	SYMP
who	O
underwent	O
unilateral	SYMP
microelectrode-guided	SYMP
posteroventral	SYMP
pallidotomy	SYMP
.	O
The	O
lesions	O
were	O
placed	O
within	O
1	O
mm	O
of	O
the	O
ventral	O
border	O
of	O
the	O
globus	O
pallidus	O
internus	O
(	O
GPi	O
)	O
to	O
include	O
pallidothalamic	O
outflow	O
pathways	O
.	O
Sequential	O
MR	O
studies	O
were	O
obtained	O
within	O
1	O
to	O
3	O
days	O
postoperatively	O
and	O
at	O
6-month	O
follow-up	O
examination	O
.	O
Thirty-four	O
(	O
94	O
%	O
)	O
of	O
the	O
36	O
patients	O
enjoyed	O
sustained	O
moderate	O
or	O
marked	O
improvement	O
of	O
their	O
parkinsonian	SYMP
symptoms	SYMP
6	O
months	O
postoperatively	O
.	O
Transient	O
side	O
effects	O
occurred	O
in	O
five	O
patients	O
(	O
14	O
%	O
)	O
,	O
but	O
there	O
were	O
no	O
persistent	O
complications	O
.	O
The	O
pallidal	O
radiofrequency	O
lesions	O
were	O
prolate	O
spheroid	O
shaped	O
and	O
were	O
composed	O
of	O
three	O
concentric	O
zones	O
in	O
the	O
early	O
postoperative	O
studies	O
.	O
The	O
mean	O
volume	O
of	O
the	O
middle	O
zone	O
,	O
corresponding	O
to	O
the	O
area	O
of	O
hemorrhagic	SYMP
coagulation	SYMP
necrosis	SYMP
,	O
was	O
44.4	O
+/-	O
17.6	O
mm3	O
;	O
the	O
mean	O
lesion	O
volume	O
as	O
defined	O
by	O
the	O
outer	O
zone	O
,	O
corresponding	O
to	O
perilesional	SYMP
edema	SYMP
,	O
was	O
262.2	O
+/-	O
111.6	O
mm3	O
.	O
Additional	O
edema	SYMP
spreading	O
to	O
the	O
internal	O
capsule	O
was	O
noted	O
in	O
32	O
of	O
34	O
cases	O
and	O
to	O
the	O
optic	O
tract	O
in	O
11	O
of	O
34	O
cases	O
.	O
In	O
two	O
patients	O
small	O
ischemic	SYMP
infarctions	SYMP
involving	O
the	O
corona	O
radiata	O
were	O
found	O
,	O
and	O
in	O
one	O
a	O
venous	SYMP
infarction	SYMP
was	O
detected	O
.	O
Ischemic	SYMP
infarction	SYMP
resulted	O
in	O
mild	O
transient	O
Broca	SYMP
's	SYMP
aphasia	SYMP
in	O
one	O
patient	O
,	O
but	O
there	O
was	O
no	O
detectable	O
neurological	O
deficit	O
in	O
the	O
other	O
two	O
.	O
The	O
mean	O
volume	O
of	O
late-phase	O
(	O
6	O
months	O
)	O
lesions	O
was	O
22	O
+/-	O
28.8	O
mm3	O
.	O
In	O
three	O
patients	O
no	O
lesion	O
was	O
identified	O
despite	O
sustained	O
clinical	O
improvement	O
.	O
The	O
lesion	O
was	O
located	O
in	O
the	O
posteroventral	O
GPi	O
in	O
all	O
cases	O
except	O
in	O
one	O
patient	O
in	O
whom	O
it	O
was	O
confined	O
to	O
the	O
GP	O
externus	O
(	O
GPe	O
)	O
.	O
This	O
49-year-old	O
woman	O
did	O
not	O
experience	O
sustained	O
benefit	O
.	O
The	O
authors	O
found	O
no	O
consistent	O
correlations	O
between	O
lesion	O
size	O
and	O
location	O
and	O
clinical	O
outcome	O
as	O
measured	O
by	O
a	O
global	O
outcome	O
score	O
,	O
the	O
Unified	O
Parkinson	O
's	O
Disease	O
Rating	O
Scale	O
motor	O
,	O
activities	O
of	O
daily	O
living	O
,	O
and	O
bradykinesia	O
``	O
off	O
''	O
scores	O
or	O
rating	O
of	O
dyskinesias	O
.	O
Lesioning	O
of	O
pallidal	O
and	O
subpallidal	O
pathways	O
may	O
contribute	O
to	O
the	O
sustained	O
clinical	O
benefit	O
in	O
this	O
series	O
.	O
Magnetic	O
resonance	O
imaging	O
analysis	O
showed	O
that	O
intraoperative	O
microelectrode	O
recording	O
facilitated	O
accurate	O
placement	O
of	O
the	O
lesion	O
in	O
this	O
critical	O
area	O
.	O
A	O
commercially	O
available	O
health	O
food	O
product	O
of	O
cold-pressed	O
hemp	O
seed	O
oil	O
ingested	O
by	O
one	O
volunteer	O
twice	O
a	O
day	O
for	O
4	O
1/2	O
days	O
(	O
135	O
mL	O
total	O
)	O
.	O
Urine	O
specimens	O
collected	O
from	O
the	O
volunteer	O
were	O
subjected	O
to	O
standard	O
workplace	O
urine	O
drug	O
testing	O
procedures	O
,	O
and	O
the	O
following	O
concentrations	O
of	O
11-nor-delta9-	O
tetrahydrocannabinol	O
carboxylic	O
acid	O
(	O
9-THCA	O
)	O
were	O
detected	O
:	O
41	O
ng/mL	O
9-THCA	O
at	O
45	O
h	O
,	O
49	O
ng/mL	O
at	O
69	O
h	O
,	O
and	O
55	O
ng/mL	O
at	O
93	O
h.	O
Ingestion	O
was	O
discontinued	O
after	O
93	O
h	O
,	O
and	O
the	O
following	O
concentrations	O
were	O
detected	O
:	O
68	O
ng/mL	O
at	O
108	O
h	O
,	O
57	O
ng/mL	O
at	O
117	O
h	O
,	O
31	O
ng/mL	O
at	O
126	O
h	O
,	O
and	O
20	O
ng/mL	O
at	O
142	O
h.	O
The	O
first	O
specimen	O
that	O
tested	O
negative	O
(	O
50	O
ng/mL	O
initial	O
immunoassay	O
test	O
,	O
15	O
ng/mL	O
confirmatory	O
gas	O
chromatographic-mass	O
spectrometric	O
test	O
)	O
was	O
at	O
146	O
h	O
,	O
which	O
was	O
53	O
h	O
after	O
the	O
last	O
hemp	O
seed	O
oil	O
ingestion	O
.	O
Four	O
subsequent	O
specimens	O
taken	O
to	O
177	O
h	O
were	O
also	O
negative	O
.	O
This	O
study	O
indicates	O
that	O
a	O
workplace	O
urine	O
drug	O
test	O
positive	O
for	O
cannabinoids	O
may	O
arise	O
from	O
the	O
consumption	O
of	O
commercially	O
available	O
cold-pressed	O
hemp	O
seed	O
oil	O
.	O
OBJECTIVE	O
:	O
We	O
determined	O
the	O
sensitivity	O
and	O
specificity	O
of	O
neonatal	O
brain-stem	O
auditory	O
evoked	O
potentials	O
(	O
BAEP	O
)	O
as	O
markers	O
for	O
subsequent	O
hearing	SYMP
impairment	SYMP
and	O
for	O
developmental	SYMP
problems	SYMP
found	O
later	O
in	O
infancy	O
and	O
childhood	O
.	O
METHODS	O
:	O
BAEP	O
studies	O
were	O
performed	O
before	O
discharge	O
in	O
infants	O
treated	O
with	O
extracorporeal	SYMP
membrane	SYMP
oxygenation	SYMP
(	SYMP
ECMO	SYMP
)	SYMP
,	O
and	O
two	O
specific	O
abnormalities	O
were	O
analyzed	O
:	O
elevated	O
threshold	O
and	O
delayed	O
central	O
auditory	O
conduction	O
.	O
Behavioral	O
audiometry	O
was	O
repeated	O
during	O
periodic	O
follow-up	O
until	O
reliable	O
responses	O
were	O
obtained	O
for	O
all	O
frequencies	O
,	O
and	O
standardized	O
developmental	O
testing	O
was	O
also	O
conducted	O
.	O
The	O
sensitivity	O
and	O
specificity	O
of	O
an	O
elevated	O
threshold	O
on	O
the	O
neonatal	O
BAEP	O
for	O
detecting	O
subsequent	O
hearing	O
loss	O
,	O
and	O
the	O
relationship	O
of	O
any	O
neonatal	O
BAEP	O
abnormality	O
to	O
language	O
or	O
developmental	O
disorders	O
in	O
infancy	O
,	O
were	O
calculated	O
.	O
RESULTS	O
:	O
Test	O
results	O
for	O
46	O
ECMO-treated	O
infants	O
(	O
57.5	O
%	O
)	O
were	O
normal	O
,	O
and	O
those	O
for	O
34	O
infants	O
(	O
42.5	O
%	O
)	O
were	O
abnormal	O
,	O
with	O
either	O
elevated	O
wave	O
V	O
threshold	O
,	O
prolonged	O
wave	O
I-V	O
interval	O
,	O
or	O
both	O
on	O
neonatal	O
BAEP	O
recordings	O
.	O
Most	O
significantly	O
,	O
7	O
(	O
58	O
%	O
)	O
of	O
the	O
12	O
children	O
with	O
subsequent	O
sensorineural	SYMP
hearing	SYMP
loss	SYMP
had	O
left	O
the	O
hospital	O
after	O
showing	O
normal	O
results	O
on	O
threshold	O
tests	O
.	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
frequency	O
of	O
hearing	SYMP
loss	SYMP
between	O
subjects	O
with	O
abnormal	O
(	O
5/21	O
,	O
or	O
24	O
%	O
)	O
and	O
those	O
with	O
normal	O
BAEP	O
thresholds	O
(	O
7/59	O
,	O
or	O
12	O
%	O
;	O
Fisher	O
Exact	O
Test	O
,	O
p	O
=	O
0.28	O
)	O
.	O
Therefore	O
the	O
sensitivity	O
of	O
neonatal	O
BAEP	O
testing	O
for	O
predicting	O
subsequent	O
hearing	SYMP
loss	SYMP
was	O
only	O
42	O
%	O
.	O
Neonatal	O
BAEP	O
specificity	O
for	O
excluding	O
subsequent	O
hearing	SYMP
loss	SYMP
was	O
76	O
%	O
.	O
In	O
contrast	O
,	O
on	O
language	O
development	O
testing	O
,	O
19	O
children	O
demonstrated	O
receptive	O
language	O
delay	O
.	O
Of	O
these	O
children	O
,	O
12	O
(	O
63	O
%	O
)	O
had	O
abnormal	O
neonatal	O
BAEP	O
recordings	O
and	O
7	O
(	O
37	O
%	O
)	O
had	O
a	O
normal	O
BAEP	O
threshold	O
,	O
normal	O
central	O
auditory	O
conduction	O
test	O
results	O
,	O
or	O
both	O
(	O
p	O
=	O
0.04	O
)	O
.	O
CONCLUSIONS	O
:	O
Neonatal	O
BAEP	O
threshold	O
recordings	O
were	O
of	O
limited	O
value	O
for	O
predicting	O
subsequent	O
hearing	SYMP
loss	SYMP
common	O
in	O
ECMO	SYMP
-treated	O
survivors	O
.	O
However	O
,	O
an	O
abnormal	O
neonatal	O
BAEP	O
significantly	O
increased	O
the	O
probability	O
of	O
finding	O
a	O
receptive	O
language	O
delay	O
during	O
early	O
childhood	O
,	O
even	O
in	O
those	O
with	O
subsequently	O
normal	O
audiometry	O
findings	O
.	O
Because	O
neonatal	O
ECMO	SYMP
is	O
associated	O
with	O
a	O
high	O
risk	O
of	O
hearing	SYMP
and	SYMP
receptive	SYMP
language	SYMP
disorders	SYMP
,	O
parents	O
should	O
be	O
counseled	O
that	O
audiologic	O
and	O
developmental	O
follow-up	O
evaluations	O
in	O
surviving	O
children	O
are	O
essential	O
regardless	O
of	O
the	O
results	O
of	O
neonatal	O
BAEP	O
testing	O
.	O
The	O
Federated	O
Council	O
of	O
Internal	O
Medicine	O
has	O
developed	O
a	O
resource	O
guide	O
to	O
help	O
internal	O
medicine	O
residency	O
programs	O
produce	O
internists	O
who	O
are	O
prepared	O
for	O
today	O
's	O
practice	O
of	O
internal	O
medicine	O
and	O
the	O
challenges	O
of	O
practice	O
in	O
the	O
future	O
.	O
The	O
guide	O
situates	O
general	O
internal	O
medicine	O
as	O
the	O
primary	O
care	O
profession	O
that	O
focuses	O
on	O
preventive	O
,	O
short-term	O
,	O
and	O
long-term	O
care	O
of	O
adult	O
patients	O
.	O
It	O
assumes	O
that	O
a	O
single	O
pathway	O
is	O
sufficient	O
for	O
educating	O
general	O
internists	O
and	O
subspecialty-bound	O
trainees	O
.	O
It	O
identifies	O
the	O
learning	O
experiences	O
that	O
should	O
be	O
part	O
of	O
general	O
internal	O
medicine	O
residency	O
training	O
,	O
lists	O
the	O
clinical	O
competencies	O
that	O
are	O
important	O
for	O
primary	O
care	O
practice	O
,	O
and	O
describes	O
the	O
role	O
of	O
the	O
integrative	O
disciplines	O
that	O
should	O
inform	O
the	O
care	O
of	O
every	O
patient	O
.	O
It	O
also	O
describes	O
a	O
process	O
that	O
program	O
directors	O
and	O
local	O
program	O
committees	O
can	O
use	O
to	O
develop	O
competency-based	O
curricula	O
.	O
BACKGROUND	O
:	O
Darier	SYMP
disease	SYMP
is	O
an	O
uncommon	O
genodermatosis	SYMP
characterized	O
by	O
the	O
symmetrical	O
eruption	O
of	O
keratotic	O
reddish-brown	O
papules	O
occurring	O
in	O
the	O
seborrheic	O
areas	O
of	O
the	O
body	O
.	O
A	O
unilateral	O
,	O
or	O
localized	O
,	O
variant	O
has	O
been	O
identified	O
.	O
We	O
report	O
4	O
new	O
cases	O
of	O
localized	O
Darier	SYMP
disease	SYMP
and	O
review	O
the	O
English-language	O
literature	O
.	O
The	O
implications	O
of	O
these	O
cases	O
on	O
future	O
genetic	O
studies	O
are	O
also	O
discussed	O
.	O
OBSERVATIONS	O
:	O
Localized	O
Darier	SYMP
disease	SYMP
occurred	O
with	O
equal	O
frequency	O
in	O
males	O
and	O
females	O
.	O
The	O
average	O
age	O
at	O
onset	O
was	O
27	O
years	O
.	O
The	O
most	O
frequent	O
site	O
of	O
involvement	O
was	O
the	O
trunk	O
(	O
40	O
%	O
(	O
16/40	O
)	O
)	O
.	O
This	O
condition	O
was	O
aggravated	O
by	O
sunlight	O
,	O
heat	O
,	O
or	O
sweating	O
in	O
42	O
%	O
(	O
19/40	O
)	O
of	O
reported	O
cases	O
,	O
and	O
38	O
%	O
(	O
15/40	O
)	O
of	O
the	O
patients	O
responded	O
to	O
treatment	O
with	O
topical	O
tretinoin	SYMP
.	O
CONCLUSIONS	O
:	O
Many	O
of	O
the	O
clinical	O
features	O
of	O
localized	O
Darier	SYMP
disease	SYMP
suggest	O
that	O
it	O
is	O
a	O
genetic	O
mosaic	O
of	O
generalized	O
Darier	SYMP
disease	SYMP
.	O
Further	O
studies	O
of	O
localized	O
Darier	SYMP
disease	SYMP
may	O
therefore	O
prove	O
to	O
be	O
instrumental	O
in	O
the	O
search	O
for	O
the	O
Darier	SYMP
disease	SYMP
gene	O
.	O
UV	O
radiation	O
induces	O
two	O
major	O
DNA	O
damage	O
products	O
,	O
the	O
cyclobutane	O
pyrimidine	O
dimer	O
(	O
CPD	O
)	O
and	O
,	O
at	O
a	O
lower	O
frequency	O
,	O
the	O
pyrimidine	O
(	O
6-4	O
)	O
pyrimidinone	O
dimer	O
(	O
6-4	O
product	O
)	O
.	O
Although	O
Escherichia	O
coli	O
and	O
Saccharomyes	O
cerevisiae	O
produce	O
a	O
CPD-specific	O
photolyase	O
that	O
eliminates	O
only	O
this	O
class	O
of	O
dimer	O
,	O
Arabidopsis	O
thaliana	O
,	O
Drosphila	O
melanogaster	O
,	O
Crotalus	O
atrox	O
,	O
and	O
Xenopus	O
laevis	O
have	O
recently	O
been	O
shown	O
to	O
photoreactivate	O
both	O
CPDs	O
and	O
6-4	O
products	O
.	O
We	O
describe	O
the	O
isolation	O
and	O
characterization	O
of	O
two	O
new	O
classes	O
of	O
mutants	O
of	O
Arabidopsis	O
,	O
termed	O
uvr2	O
and	O
uvr3	O
,	O
that	O
are	O
defective	O
in	O
the	O
photoreactivation	O
of	O
CPDs	O
and	O
6-4	O
products	O
,	O
respectively	O
.	O
We	O
demonstrate	O
that	O
the	O
CPD	O
photolyase	O
mutation	O
is	O
genetically	O
linked	O
to	O
a	O
DNA	O
sequence	O
encoding	O
a	O
type	O
II	O
(	O
metazoan	O
)	O
CPD	O
photolyase	O
.	O
In	O
addition	O
,	O
we	O
are	O
able	O
to	O
generate	O
plants	O
in	O
which	O
only	O
CPDs	O
or	O
6-4	O
products	O
are	O
photoreactivated	O
in	O
the	O
nuclear	O
genome	O
by	O
exposing	O
these	O
mutants	O
to	O
UV	O
light	O
and	O
then	O
allowing	O
them	O
to	O
repair	O
one	O
or	O
the	O
other	O
class	O
of	O
dimers	O
.	O
This	O
provides	O
us	O
with	O
a	O
unique	O
opportunity	O
to	O
study	O
the	O
biological	O
consequences	O
of	O
each	O
of	O
these	O
two	O
major	O
UV-induced	O
photoproducts	O
in	O
an	O
intact	O
living	O
system	O
.	O
A	O
diffuse	O
macular	SYMP
erythroderma	SYMP
and	O
subsequent	O
desquamation	SYMP
after	O
1	O
to	O
2	O
weeks	O
are	O
two	O
of	O
the	O
five	O
major	O
diagnostic	O
criteria	O
of	O
toxic	SYMP
shock	SYMP
syndrome	SYMP
(	SYMP
TSS	SYMP
)	SYMP
.	O
We	O
present	O
the	O
case	O
of	O
a	O
15-month-old	O
girl	O
with	O
TSS	SYMP
,	O
but	O
without	O
erythroderma	SYMP
or	O
desquamation	SYMP
.	O
She	O
was	O
admitted	O
with	O
high	SYMP
fever	SYMP
,	O
shock	SYMP
,	O
and	O
multiorgan	O
involvement	O
.	O
Minimal	O
or	O
no	O
cutaneous	O
signs	O
were	O
present	O
.	O
Initially	O
the	O
diagnosis	O
of	O
the	O
syndrome	O
of	O
hemorrhagic	SYMP
shock	SYMP
and	O
encephalopathy	SYMP
was	O
made	O
.	O
After	O
7	O
days	O
,	O
a	O
TSS	SYMP
toxin	O
1-producing	O
strain	O
of	O
Staphylococcus	O
aureus	O
was	O
cultured	O
from	O
an	O
inguinal	O
lymph	O
node	O
,	O
where	O
inflammation	SYMP
had	O
already	O
been	O
noticed	O
on	O
admission	O
.	O
Moreover	O
,	O
the	O
girl	O
had	O
no	O
antibodies	O
against	O
this	O
toxin	O
.	O
The	O
serum	O
cytokine	O
profile	O
during	O
the	O
acute	O
phase	O
of	O
her	O
illness	O
showed	O
high	O
levels	O
of	O
tumor	O
necrosis	O
factor-alpha	O
,	O
interleukin-6	O
and	O
interferon-gamma	O
,	O
as	O
is	O
seen	O
during	O
activation	O
of	O
the	O
immune	O
system	O
by	O
TSS	SYMP
toxin	O
1	O
.	O
Other	O
possible	O
causes	O
for	O
the	O
patient	O
's	O
illness	O
were	O
excluded	O
.	O
We	O
conclude	O
that	O
the	O
patient	O
had	O
TSS	SYMP
without	O
rash	SYMP
.	O
Without	O
the	O
evidence	O
implicating	O
a	O
TSS	SYMP
toxin	O
1-producing	O
strain	O
of	O
S.	O
aureus	O
as	O
the	O
cause	O
of	O
her	O
disease	O
,	O
a	O
diagnosis	O
of	O
syndrome	O
of	O
hemorrhagic	SYMP
shock	SYMP
and	O
encephalopathy	SYMP
would	O
have	O
been	O
made	O
.	O
It	O
is	O
possible	O
that	O
some	O
cases	O
of	O
syndrome	O
of	O
hemorrhagic	SYMP
shock	SYMP
and	O
encephalopathy	SYMP
represent	O
a	O
variant	O
of	O
TSS	SYMP
in	O
small	O
children	O
.	O
BACKGROUND	O
:	O
The	O
growing	O
teratoma	O
syndrome	O
refers	O
to	O
the	O
phenomenon	O
whereby	O
germ	O
cell	O
tumors	O
enlarge	O
after	O
chemotherapy	O
despite	O
complete	O
eradication	O
of	O
malignant	O
cells	O
and	O
normalization	O
of	O
serum	O
tumor	O
markers	O
.	O
This	O
clinical	O
scenario	O
must	O
be	O
differentiated	O
from	O
that	O
in	O
which	O
germ	SYMP
cell	SYMP
tumors	SYMP
maintain	O
their	O
malignant	O
characteristics	O
with	O
elevated	O
levels	O
of	O
serum	O
tumor	O
markers	O
.	O
METHODS	O
:	O
Hospital	O
record	O
review	O
was	O
conducted	O
of	O
2	O
cases	O
.	O
RESULTS	O
:	O
Two	O
male	O
patients	O
are	O
presented	O
,	O
1	O
with	O
a	O
metastatic	SYMP
germ	SYMP
cell	SYMP
tumor	SYMP
of	O
both	O
the	O
retroperitoneum	O
and	O
mediastinum	O
(	O
with	O
elevated	O
alpha-fetoprotein	O
level	O
)	O
and	O
1	O
with	O
a	O
primary	SYMP
germ	SYMP
cell	SYMP
tumor	SYMP
of	O
the	O
mediastinum	O
(	O
with	O
elevated	O
alpha-fetoprotein	O
and	O
beta-human	O
chorionic	O
gonadotropin	O
levels	O
)	O
.	O
After	O
completion	O
of	O
chemotherapy	SYMP
and	O
normalization	O
of	O
tumor	O
markers	O
,	O
both	O
patients	O
presented	O
with	O
pulmonary	SYMP
symptoms	SYMP
attributable	O
to	O
their	O
massively	O
enlarging	O
mediastinal	SYMP
teratomas	SYMP
.	O
The	O
clinical	O
and	O
roentgenographic	O
features	O
of	O
patients	O
with	O
thoracic	O
manifestations	O
of	O
the	O
growing	O
teratoma	SYMP
syndrome	SYMP
,	O
as	O
well	O
as	O
its	O
management	O
,	O
are	O
reviewed	O
.	O
CONCLUSIONS	O
:	O
After	O
chemotherapy	SYMP
in	O
patients	O
with	O
primary	SYMP
or	SYMP
metastatic	SYMP
mediastinal	SYMP
germ	SYMP
cell	SYMP
tumors	SYMP
whose	O
tumor	O
markers	O
normalize	O
,	O
a	O
growing	O
mass	O
in	O
the	O
mediastinum	O
may	O
represent	O
the	O
growing	O
teratoma	SYMP
syndrome	SYMP
.	O
The	O
chicken	O
calmodulin	O
I	O
(	O
CaMI	O
)	O
gene	O
has	O
been	O
isolated	O
and	O
characterized	O
on	O
the	O
level	O
of	O
cDNA	O
and	O
genomic	O
DNA	O
.	O
The	O
deduced	O
amino	O
acid	O
(	O
aa	O
)	O
sequence	O
is	O
identical	O
to	O
the	O
one	O
of	O
chicken	O
CaMII	O
which	O
consists	O
of	O
148	O
aa	O
.	O
The	O
CaMI	O
gene	O
contains	O
six	O
exons	O
.	O
Its	O
intron/exon	O
organization	O
is	O
identical	O
to	O
that	O
of	O
the	O
chicken	O
CaMII	O
and	O
the	O
CaMI	O
and	O
CaMIII	O
genes	O
of	O
rat	O
and	O
human	O
.	O
Expression	O
of	O
the	O
CaMI	O
gene	O
was	O
detected	O
in	O
all	O
chicken	O
tissues	O
examined	O
,	O
although	O
at	O
varying	O
levels	O
.	O
The	O
gene	O
is	O
transcribed	O
into	O
four	O
mRNAs	O
of	O
0.8	O
,	O
1.4	O
,	O
1.7	O
and	O
4.4	O
kb	O
as	O
determined	O
by	O
Northern	O
blot	O
analysis	O
.	O
Our	O
results	O
demonstrate	O
that	O
the	O
``	O
multigene-one-protein	O
''	O
principle	O
of	O
CaM	O
synthesis	O
is	O
not	O
only	O
applicable	O
to	O
mammals	O
whose	O
CaM	O
is	O
encoded	O
by	O
three	O
different	O
genes	O
,	O
but	O
also	O
to	O
chickens	O
.	O
BACKGROUND	O
:	O
We	O
assessed	O
the	O
accuracy	O
of	O
two	O
electron	O
beam	O
computed	O
tomography	O
(	O
EBCT	O
)	O
protocols	O
for	O
predicting	O
coronary	SYMP
events	SYMP
.	O
METHODS	O
AND	O
RESULTS	O
:	O
In	O
1994	O
,	O
24	O
months	O
after	O
enrollment	O
in	O
a	O
longitudinal	O
study	O
,	O
326	O
high-risk	O
adults	O
underwent	O
both	O
3-	O
and	O
6-mm	O
image-slice	O
thickness	O
EBCT	O
scanning	O
and	O
were	O
followed	O
up	O
for	O
32.0+/-4.0	O
additional	O
months	O
.	O
Events	O
were	O
defined	O
as	O
either	O
coronary	O
death	O
,	O
myocardial	SYMP
infarction	SYMP
,	O
or	O
revascularization	SYMP
.	O
We	O
monitored	O
these	O
subjects	O
for	O
the	O
32-month	O
postscanning	O
period	O
with	O
yearly	O
phone	O
calls	O
and	O
acquisition	O
of	O
records	O
for	O
all	O
hospital	O
admissions	O
.	O
At	O
the	O
time	O
of	O
scanning	O
,	O
11	O
subjects	O
(	O
3	O
%	O
)	O
had	O
already	O
suffered	O
12	O
events	O
(	O
5	O
infarctions	SYMP
and	O
7	O
revascularizations	SYMP
)	O
during	O
the	O
24-month	O
prescanning	O
period	O
.	O
During	O
the	O
postscanning	O
period	O
,	O
18	O
subjects	O
(	O
6	O
%	O
)	O
suffered	O
23	O
events	O
(	O
5	O
coronary	O
deaths	O
,	O
6	O
infarctions	SYMP
,	O
and	O
12	O
revascularizations	SYMP
)	O
.	O
Thus	O
,	O
28	O
subjects	O
(	O
9	O
%	O
)	O
suffered	O
35	O
events	O
.	O
Calcium	O
quantities	O
calculated	O
for	O
both	O
protocols	O
,	O
performed	O
on	O
the	O
same	O
subjects	O
,	O
were	O
sorted	O
in	O
ascending	O
order	O
and	O
divided	O
into	O
equal	O
quartiles	O
.	O
When	O
revascularizations	SYMP
were	O
included	O
,	O
there	O
was	O
a	O
significant	O
trend	O
toward	O
higher	O
frequencies	O
of	O
events	O
with	O
increasing	O
calcium	O
quantity	O
(	O
P	O
&	O
#	O
60	O
;	O
.01	O
)	O
.	O
However	O
,	O
coronary	O
death	O
and	O
infarction	SYMP
were	O
not	O
significantly	O
more	O
frequent	O
in	O
higher	O
quartiles	O
.	O
These	O
relationships	O
were	O
preserved	O
in	O
the	O
subjects	O
without	O
prior	O
events	O
at	O
the	O
time	O
of	O
scanning	O
.	O
CONCLUSIONS	O
:	O
Calcium	O
quantities	O
from	O
the	O
3-mm	O
and	O
the	O
more	O
reproducible	O
6-mm	O
scanning	O
are	O
equally	O
accurate	O
for	O
predicting	O
events	O
.	O
Coronary	O
calcium	O
amount	O
appears	O
to	O
be	O
a	O
weak	O
predictor	O
of	O
coronary	O
death	O
and	O
infarction	SYMP
.	O
Its	O
predictive	O
accuracy	O
is	O
superior	O
for	O
predicting	O
revascularization	SYMP
.	O
Research	O
into	O
the	O
genetic	O
component	O
of	O
some	O
complex	O
behaviors	O
often	O
causes	O
controversy	O
,	O
depending	O
on	O
the	O
social	O
meaning	O
and	O
significance	O
of	O
the	O
behavior	O
under	O
study	O
.	O
Research	O
into	O
sexual	O
orientation-simplistically	O
referred	O
to	O
as	O
``	O
gay	O
gene	O
''	O
research-is	O
an	O
example	O
of	O
research	O
that	O
provokes	O
intense	O
controversy	O
.	O
This	O
research	O
is	O
worrisome	O
for	O
many	O
reasons	O
,	O
including	O
the	O
fact	O
that	O
it	O
has	O
been	O
used	O
to	O
harm	O
lesbians	O
and	O
gay	O
men	O
.	O
Many	O
homosexual	O
people	O
have	O
been	O
forced	O
to	O
undergo	O
``	O
treatments	O
''	O
to	O
change	O
their	O
sexual	O
orientation	O
.	O
Other	O
chose	O
to	O
undergo	O
them	O
to	O
escape	O
discrimination	O
and	O
social	O
disapprobation	O
.	O
But	O
there	O
are	O
other	O
reasons	O
to	O
worry	O
about	O
such	O
research	O
.	O
The	O
very	O
motivation	O
for	O
seeking	O
an	O
``	O
origin	O
''	O
of	O
homosexuality	O
reveals	O
homophobia	O
.	O
Moreover	O
,	O
such	O
research	O
may	O
lead	O
to	O
prenatal	O
tests	O
that	O
claim	O
to	O
predict	O
for	O
homosexuality	O
.	O
For	O
homosexual	O
people	O
who	O
live	O
in	O
countries	O
with	O
no	O
legal	O
protections	O
these	O
dangers	O
are	O
particularly	O
serious	O
.	O
The	O
efficiency	O
of	O
testicular	SYMP
sperm	SYMP
retrieval	SYMP
by	SYMP
testicular	SYMP
fine	SYMP
needle	SYMP
aspiration	SYMP
(	SYMP
TEFNA	SYMP
)	SYMP
was	O
compared	O
with	O
open	SYMP
biopsy	SYMP
and	SYMP
testicular	SYMP
sperm	SYMP
extraction	SYMP
(	SYMP
TESE	SYMP
)	SYMP
,	O
in	O
37	O
rigorously	O
selected	O
patients	O
with	O
non-obstructive	SYMP
azoospermia	SYMP
.	O
All	O
patients	O
underwent	O
TEFNA	SYMP
and	O
TESE	SYMP
consecutively	O
.	O
Thus	O
,	O
each	O
patient	O
served	O
as	O
his	O
own	O
control	O
.	O
The	O
case	O
was	O
regarded	O
as	O
successful	O
if	O
at	O
least	O
one	O
testicular	O
spermatozoon	O
was	O
found	O
allowing	O
intracytoplasmic	O
sperm	O
injection	O
(	O
ICSI	O
)	O
of	O
at	O
least	O
one	O
oocyte	O
.	O
The	O
mean	O
age	O
of	O
the	O
male	O
patients	O
was	O
32.7	O
years	O
(	O
range	O
24-47	O
)	O
.	O
Whereas	O
by	O
TEFNA	SYMP
spermatozoa	O
enabling	O
performance	O
of	O
ICSI	O
were	O
found	O
in	O
only	O
four	O
patients	O
out	O
of	O
37	O
(	O
11	O
%	O
)	O
,	O
open	SYMP
biopsy	SYMP
and	SYMP
TESE	SYMP
yielded	O
spermatozoa	O
in	O
16	O
cases	O
(	O
43	O
%	O
)	O
.	O
The	O
negative	O
predictive	O
value	O
of	O
high	O
serum	O
follicle	O
stimulating	O
hormone	O
(	O
FSH	O
)	O
concentrations	O
(	O
greater	O
than	O
or	O
=10	O
IU/l	O
)	O
(	O
predicting	O
failure	O
to	O
find	O
spermatozoa	O
for	O
ICSI	O
)	O
was	O
low	O
(	O
38.4	O
%	O
)	O
.	O
The	O
positive	O
predictive	O
value	O
(	O
predicting	O
the	O
chance	O
to	O
find	O
spermatozoa	O
for	O
ICSI	O
)	O
of	O
normal-sized	O
testicle	O
was	O
not	O
different	O
from	O
that	O
of	O
small-sized	O
(	O
&	O
#	O
60	O
;	O
15	O
ml	O
)	O
testicle	O
(	O
50	O
%	O
)	O
.	O
Complications	O
included	O
one	O
case	O
of	O
testicular	SYMP
bleeding	SYMP
following	O
fine	SYMP
needle	SYMP
aspiration	SYMP
,	O
treated	O
locally	O
,	O
and	O
two	O
cases	O
of	O
extratunical	SYMP
haematomata	SYMP
following	O
TESE	O
requiring	O
no	O
intervention	O
.	O
In	O
patients	O
with	O
non-obstructive	O
azoospermia	O
,	O
TEFNA	O
has	O
a	O
significantly	O
lower	O
yield	O
compared	O
to	O
TESE	O
.	O
Performance	O
of	O
ICSI	O
with	O
testicular	O
sperm	O
in	O
these	O
cases	O
resulted	O
in	O
satisfactory	O
fertilization	O
and	O
high	O
embryo	O
transfer	O
rates	O
.	O
The	O
implantation	O
and	O
pregnancy	O
rates	O
per	O
embryo	O
transfer	O
were	O
13	O
and	O
29	O
%	O
respectively	O
.	O
Neither	O
serum	O
FSH	O
values	O
nor	O
testicular	O
size	O
were	O
predictive	O
of	O
the	O
chances	O
to	O
find	O
spermatozoa	O
for	O
ICSI	O
.	O
Some	O
complications	O
may	O
occur	O
even	O
following	O
TEFNA	SYMP
.	O
Cyclin	O
D1	O
,	O
the	O
regulatory	O
subunit	O
of	O
certain	O
protein	O
kinases	O
thought	O
to	O
advance	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
is	O
now	O
established	O
as	O
a	O
proto-oncogene	O
,	O
with	O
evidence	O
indicating	O
that	O
its	O
derangement	O
may	O
contribute	O
to	O
the	O
uncontrolled	O
cell	O
growth	O
characteristic	O
of	O
tumors	SYMP
.	O
The	O
chromosomal	O
translocation	O
t	O
(	O
11	O
;	O
14	O
)	O
(	O
q13	O
:	O
q32	O
)	O
,	O
involving	O
rearrangement	O
of	O
the	O
BCL-1	O
locus	O
,	O
is	O
closely	O
associated	O
with	O
human	SYMP
lymphoid	SYMP
neoplasia	SYMP
affecting	O
mantle	SYMP
cell	SYMP
lymphomas	SYMP
(	SYMP
MCL	SYMP
)	SYMP
.	O
Recently	O
,	O
the	O
putative	O
BCL-1	O
proto-oncogene	O
turned	O
out	O
to	O
be	O
none	O
other	O
than	O
the	O
cyclin	O
D1	O
gene	O
.	O
Although	O
the	O
observed	O
break	O
points	O
in	O
the	O
BCL-1	O
locus	O
are	O
not	O
tightly	O
clustered	O
,	O
its	O
rearrangement	O
has	O
been	O
documented	O
in	O
40-70	O
%	O
of	O
cases	O
of	O
mantle	SYMP
cell	SYMP
lymphoma	SYMP
,	O
whereas	O
it	O
only	O
rarely	O
occurs	O
in	O
other	O
B	SYMP
cell	SYMP
lymphomas	SYMP
.	O
Of	O
note	O
,	O
all	O
of	O
the	O
known	O
break	O
points	O
leave	O
the	O
cyclin	O
D1	O
coding	O
region	O
structurally	O
intact	O
and	O
result	O
in	O
increased	O
protein	O
expression	O
,	O
implying	O
that	O
this	O
may	O
provide	O
a	O
highly	O
sensitive	O
and	O
specific	O
marker	O
for	O
MCL	SYMP
.	O
Recent	O
studies	O
demonstrated	O
that	O
immunohistochemical	O
detection	O
in	O
paraffin-embedded	O
material	O
,	O
using	O
a	O
monoclonal	O
antibody	O
,	O
is	O
very	O
useful	O
for	O
routine	O
diagnosis	O
.	O
Current	O
knowledge	O
of	O
cyclin	O
D1	O
overexpression	O
in	O
malignant	SYMP
lymphomas	SYMP
,	O
with	O
emphasis	O
on	O
its	O
clinicopathologic	O
significance	O
,	O
is	O
reviewed	O
.	O
In	O
the	O
mammalian	O
central	O
nervous	O
system	O
,	O
a	O
diverse	O
group	O
of	O
basic	O
helix-loop-helix	O
(	O
bHLH	O
)	O
proteins	O
is	O
involved	O
in	O
the	O
determination	O
of	O
progenitor	O
cells	O
and	O
,	O
subsequently	O
,	O
in	O
regulating	O
neuronal	O
differentiation	O
.	O
Here	O
we	O
report	O
the	O
identification	O
of	O
a	O
novel	O
subfamily	O
of	O
bHLH	O
proteins	O
,	O
defined	O
by	O
two	O
mammalian	O
enhancer-of-split-	O
and	O
hairy-related	O
proteins	O
,	O
termed	O
SHARP-1	O
and	O
SHARP-2	O
.	O
In	O
contrast	O
to	O
known	O
bHLH	O
genes	O
,	O
detectable	O
transcription	O
of	O
SHARP	O
genes	O
begins	O
at	O
the	O
end	O
of	O
embryonic	O
development	O
marking	O
differentiated	O
neurons	O
that	O
have	O
reached	O
a	O
final	O
position	O
,	O
and	O
increases	O
as	O
postnatal	O
development	O
proceeds	O
.	O
In	O
the	O
adult	O
,	O
SHARP	O
genes	O
are	O
expressed	O
in	O
subregions	O
of	O
the	O
CNS	O
that	O
have	O
been	O
associated	O
with	O
adult	O
plasticity	O
.	O
In	O
PC12	O
cells	O
,	O
a	O
model	O
system	O
to	O
study	O
neurite	O
outgrowth	O
,	O
SHARP	O
genes	O
can	O
be	O
induced	O
by	O
NGF	O
with	O
the	O
kinetics	O
of	O
an	O
immediate-early	O
gene	O
.	O
Similarly	O
,	O
within	O
1	O
h	O
after	O
the	O
administration	O
of	O
kainic	O
acid	O
in	O
vivo	O
,	O
SHARP-2	O
is	O
induced	O
in	O
neurons	O
throughout	O
the	O
rat	O
cerebral	O
cortex	O
.	O
This	O
suggests	O
that	O
neuronal	O
bHLH	O
proteins	O
are	O
also	O
involved	O
in	O
the	O
``	O
adaptive	O
''	O
changes	O
of	O
mature	O
CNS	O
neurons	O
which	O
are	O
coupled	O
to	O
glutamatergic	O
stimulation	O
.	O
The	O
embryonic	O
development	O
of	O
the	O
face	O
has	O
been	O
studied	O
in	O
many	O
reviews	O
,	O
this	O
work	O
purposes	O
only	O
to	O
clear	O
up	O
some	O
points	O
which	O
remain	O
obscure	O
concerning	O
cervico-facial	O
morphogenesis	O
.	O
In	O
the	O
first	O
part	O
of	O
this	O
study	O
only	O
the	O
facial	O
development	O
,	O
properly	O
speaking	O
,	O
is	O
considered	O
,	O
although	O
it	O
can	O
not	O
be	O
separate	O
of	O
cervical	O
development	O
to	O
which	O
a	O
second	O
study	O
will	O
be	O
reserved	O
.	O
In	O
the	O
present	O
study	O
we	O
recall	O
the	O
particular	O
aspects	O
of	O
the	O
neurulation	O
in	O
the	O
cephalic	O
area	O
,	O
then	O
the	O
establishment	O
of	O
the	O
facial	O
processes	O
.	O
Then	O
we	O
approach	O
among	O
other	O
things	O
the	O
way	O
to	O
consider	O
the	O
maxillary	O
process	O
with	O
regard	O
to	O
the	O
other	O
facial	O
processes	O
.	O
After	O
is	O
considered	O
constitution	O
and	O
natured	O
of	O
the	O
prechordal	O
plate	O
which	O
has	O
been	O
diversely	O
explained	O
.	O
Finally	O
,	O
the	O
modelling	O
of	O
the	O
face	O
is	O
evocated	O
,	O
in	O
which	O
the	O
dissociation	O
between	O
the	O
olfactive	O
and	O
buccal	O
spheres	O
is	O
pointed	O
out	O
,	O
with	O
the	O
disparition	O
of	O
the	O
muzzle	O
,	O
as	O
it	O
is	O
established	O
in	O
the	O
haplorhinae	O
,	O
a	O
class	O
of	O
primates	O
in	O
which	O
the	O
human	O
being	O
is	O
involved	O
.	O
This	O
phenomenon	O
raises	O
different	O
questions	O
,	O
in	O
particular	O
about	O
the	O
relation	O
of	O
this	O
disposition	O
with	O
the	O
nasoseptal	O
center	O
,	O
the	O
medial	O
part	O
of	O
the	O
nasodorsal	O
center	O
.	O
A	O
case-control	O
study	O
was	O
performed	O
in	O
eight	O
pairs	O
of	O
women	O
to	O
determine	O
whether	O
preeclamptic	O
women	O
developed	O
abnormalities	O
in	O
minor	O
hemoglobins	O
,	O
glycolytic	O
enzymes	O
,	O
or	O
other	O
blood	O
components	O
that	O
might	O
provide	O
insight	O
into	O
the	O
pathophysiology	O
of	O
preeclampsia	SYMP
,	O
or	O
that	O
in	O
combination	O
might	O
be	O
used	O
as	O
a	O
marker	O
for	O
the	O
condition	O
.	O
These	O
variables	O
and	O
standard	O
clinical	O
tests	O
were	O
analyzed	O
as	O
discriminators	O
between	O
preeclamptic	O
and	O
control	O
women	O
.	O
The	O
subjects	O
were	O
matched	O
for	O
age	O
,	O
ethnicity	O
,	O
parity	O
,	O
and	O
gestational	O
age	O
.	O
Blood	O
samples	O
were	O
taken	O
at	O
the	O
time	O
of	O
diagnosis	O
of	O
preeclampsia	SYMP
and	O
at	O
comparable	O
gestational	O
ages	O
for	O
matched	O
normal	O
controls	O
.	O
Variables	O
differing	O
significantly	O
between	O
groups	O
included	O
increases	O
in	O
uric	O
acid	O
(	O
UA	O
)	O
,	O
low-density	O
lipoproteins	O
(	O
LDL	O
)	O
,	O
phosphoglycerate	O
kinase	O
(	O
PGK	O
)	O
,	O
and	O
mean	O
platelet	O
volume	O
(	O
MPV	O
)	O
,	O
and	O
decreases	O
in	O
glyceraldehyde	O
phosphate	O
dehydrogenase	O
(	O
G3PD	O
)	O
in	O
preeclamptic	O
women	O
compared	O
to	O
normal	O
controls	O
.	O
Discriminant	O
analysis	O
revealed	O
the	O
following	O
function	O
to	O
separate	O
the	O
groups	O
:	O
0.7764	O
(	O
UA	O
)	O
+	O
0.8086	O
(	O
PGK	O
)	O
-0.7032	O
(	O
G3PD	O
)	O
+	O
0.1399	O
(	O
LDL	O
)	O
-0.2386	O
(	O
MPV	O
)	O
.	O
A	O
discriminant	O
score	O
of	O
greater	O
than	O
or	O
=	O
275	O
indicated	O
a	O
greater	O
than	O
or	O
=	O
90	O
%	O
probability	O
of	O
preeclampsia	SYMP
.	O
The	O
results	O
are	O
consistent	O
with	O
perturbations	O
in	O
red	O
cell	O
glycolysis	O
in	O
preeclampsia	SYMP
.	O
Further	O
prospective	O
studies	O
are	O
warranted	O
to	O
test	O
the	O
efficacy	O
of	O
this	O
discriminant	O
function	O
in	O
predicting	O
preeclampsia	SYMP
.	O
A	O
novel	O
technique	O
for	O
patterning	O
immobilized	O
antibody	O
layers	O
based	O
upon	O
photolithography	O
and	O
oxygen	O
plasma	O
exposure	O
has	O
been	O
developed	O
.	O
Mouse	O
monoclonal	O
antibodies	O
specific	O
for	O
thiabendazole	SYMP
(	O
a	O
post-harvest	O
fungicide	O
and	O
veterinary	O
anthelmintic	O
)	O
were	O
covalently	O
linked	O
through	O
free	O
amine	O
groups	O
to	O
aminosilanized	O
silicon	O
dioxide	O
films	O
using	O
glutaraldehyde	O
.	O
Immobilized	O
antibody	O
layers	O
were	O
stabilized	O
with	O
sucrose	O
,	O
dehydrated	O
,	O
and	O
stored	O
refrigerated	O
with	O
desiccant	O
.	O
Photolithographic	O
patterning	O
was	O
performed	O
with	O
a	O
positive	O
photoresist	O
with	O
modified	O
bake	O
temperatures	O
and	O
times	O
,	O
selective	O
UV	O
exposure	O
with	O
a	O
contact	O
mask	O
,	O
and	O
aqueous	O
alkaline	O
solubilization	O
of	O
exposed	O
resist	O
.	O
Exposed	O
regions	O
of	O
immobilized	O
antibody	O
were	O
then	O
removed	O
by	O
exposure	O
to	O
a	O
low	O
power	O
,	O
radio	O
frequency	O
oxygen	O
discharge	O
.	O
Residual	O
resist	O
was	O
stripped	O
with	O
acetone	O
.	O
Successful	O
patterning	O
was	O
demonstrated	O
by	O
challenging	O
surfaces	O
with	O
goat	O
anti-mouse	O
antibody	O
conjugated	O
to	O
tetramethylrhodamine	O
isothiocyanate	O
.	O
Sucrose	O
stabilization	O
was	O
necessary	O
for	O
antibody	O
to	O
undergo	O
photoresist	O
processing	O
without	O
loss	O
of	O
binding	O
activity	O
.	O
Challenge	O
with	O
enzyme	O
linked	O
antigen	O
of	O
oxygen	O
plasma	O
exposed	O
antibody	O
layers	O
demonstrated	O
that	O
plasma	O
treatment	O
completely	O
neutralized	O
antibody	O
capture	O
ability	O
.	O
Ellipsometry	O
measurements	O
of	O
oxygen	O
plasma	O
exposed	O
antibody	O
layers	O
indicated	O
complete	O
removal	O
of	O
immobilized	O
antibodies	O
.	O
Fluorescent	O
imaging	O
demonstrated	O
smallest	O
line	O
widths	O
of	O
2-3	O
microns	O
.	O
Immune	O
cells	O
in	O
vivo	O
routinely	O
perform	O
highly	O
selective	O
immunosensing	O
in	O
blood	O
and	O
tissues	O
as	O
part	O
of	O
their	O
normal	O
immune	O
surveillance	O
functions	O
.	O
We	O
have	O
been	O
investigating	O
the	O
potential	O
of	O
exploiting	O
the	O
immunosensing	O
detection	O
abilities	O
of	O
excitable	O
immune	O
cells	O
(	O
i.e	O
.	O
the	O
mast	O
cell	O
)	O
for	O
the	O
development	O
of	O
whole	O
cell	O
immunobiosensors	O
.	O
A	O
key	O
feature	O
is	O
that	O
these	O
immune	O
cells	O
can	O
be	O
selectively	O
engineered	O
to	O
recognize	O
specific	O
antigens	O
in	O
vitro	O
.	O
In	O
the	O
presence	O
of	O
antigen	O
,	O
these	O
cells	O
undergo	O
excitable	O
activation	O
responses	O
which	O
result	O
in	O
increased	O
metabolism	O
and	O
the	O
exocytosis	O
of	O
stored	O
intracellular	O
mediators	O
.	O
We	O
have	O
previously	O
determined	O
that	O
mast	O
cell	O
metabolic	O
responses	O
can	O
be	O
thermally	O
transduced	O
in	O
real	O
time	O
,	O
thus	O
indicating	O
the	O
possibility	O
of	O
whole	O
cell	O
thermoelectric	O
immunobiosensing	O
.	O
In	O
this	O
work	O
we	O
investigated	O
the	O
use	O
of	O
enzyme	O
amplification	O
systems	O
to	O
enhance	O
the	O
direct	O
transduction	O
of	O
immune	O
cell	O
responses	O
to	O
analyte	O
.	O
It	O
was	O
found	O
that	O
with	O
appropriate	O
enzymes	O
,	O
peak	O
outputs	O
occurred	O
within	O
approximately	O
5	O
min	O
(	O
4-20	O
times	O
faster	O
than	O
without	O
enzymes	O
)	O
and	O
peak	O
response	O
magnitudes	O
were	O
up	O
to	O
nine-fold	O
greater	O
than	O
without	O
enzymes	O
.	O
An	O
easy-to-use	O
technique	O
for	O
detection	O
of	O
antibodies	O
specific	O
for	O
the	O
parasite	O
L.	O
donovani	O
in	O
human	O
serum	O
sample	O
has	O
been	O
developed	O
.	O
The	O
method	O
is	O
based	O
on	O
an	O
evanescent	O
wave	O
generated	O
from	O
a	O
tapered	O
configuration	O
of	O
decladded	O
optical	O
fibre	O
and	O
does	O
not	O
require	O
any	O
volumetric	O
measurement	O
.	O
Tapered	O
fibres	O
are	O
immobilized	O
with	O
the	O
purified	O
cell	O
surface	O
protein	O
of	O
L.	O
donovani	O
by	O
covalent	O
bonding	O
.	O
Treated	O
fibres	O
are	O
incubated	O
with	O
the	O
patient	O
serum	O
for	O
10	O
min	O
followed	O
by	O
incubation	O
with	O
goat	O
anti	O
human	O
IgG	O
tagged	O
FITC	O
.	O
Fluorescent	O
intensity	O
from	O
the	O
fibre	O
has	O
been	O
shown	O
to	O
be	O
proportional	O
to	O
L.	O
donovani	O
specific	O
antibodies	O
present	O
in	O
the	O
test	O
sera	O
.	O
Direct	O
readings	O
can	O
be	O
obtained	O
after	O
signal	O
enhancement	O
through	O
a	O
photomultiplier	O
tube	O
within	O
5	O
min	O
.	O
The	O
system	O
,	O
when	O
tested	O
on	O
12	O
positive	O
sera	O
,	O
did	O
not	O
show	O
any	O
false	O
negative	O
result	O
.	O
Also	O
,	O
no	O
false	O
positive	O
result	O
was	O
obtained	O
with	O
serum	O
samples	O
of	O
patients	O
infected	O
with	O
leprosy	SYMP
,	O
tuberculosis	SYMP
,	O
typhoid	SYMP
and	O
malaria	SYMP
,	O
showing	O
the	O
specificity	O
of	O
the	O
sensor	O
and	O
efficacy	O
of	O
the	O
technique	O
.	O
We	O
present	O
an	O
optical	O
biosensor	O
design	O
that	O
expands	O
the	O
utility	O
of	O
enzyme	O
biosensors	O
.	O
These	O
biosensors	O
are	O
fabricated	O
by	O
site-selective	O
photodeposition	O
of	O
analyte-sensitive	O
polymer	O
matrices	O
on	O
optical	O
imaging	O
fibres	O
.	O
These	O
dual-analyte	O
arrays	O
allow	O
for	O
the	O
simultaneous	O
,	O
independent	O
measurement	O
of	O
the	O
analyte	O
of	O
interest	O
and	O
the	O
transducing	O
analyte	O
.	O
The	O
first	O
integrated	O
optical-biosensors	O
using	O
this	O
design	O
have	O
been	O
prepared	O
that	O
allow	O
both	O
the	O
dependent	O
and	O
independent	O
analytes	O
to	O
be	O
measured	O
simultaneously	O
,	O
for	O
example	O
penicillin	O
and	O
pH	O
(	O
Healey	O
&	O
#	O
38	O
;	O
Walt	O
,	O
1995	O
)	O
or	O
glucose	O
and	O
O2	O
(	O
Li	O
&	O
#	O
38	O
;	O
Walt	O
,	O
1995	O
)	O
.	O
Independent	O
measurement	O
of	O
the	O
transducing	O
analyte	O
allows	O
penicillin	SYMP
or	O
glucose	O
to	O
be	O
quantitated	O
in	O
the	O
presence	O
of	O
a	O
concurrent	O
pH	O
or	O
O2	O
change	O
,	O
respectively	O
.	O
Penicillin	SYMP
can	O
be	O
measured	O
in	O
the	O
range	O
0.25-10.0	O
mM	O
in	O
the	O
pH	O
range	O
6.2-7.5	O
.	O
Glucose	O
can	O
be	O
measured	O
in	O
the	O
range	O
0.6-20.0	O
mM	O
in	O
the	O
O2	O
range	O
20-100	O
%	O
.	O
The	O
utility	O
of	O
the	O
sensor	O
design	O
was	O
demonstrated	O
by	O
using	O
the	O
penicillin-dual-analyte	O
biosensor	O
to	O
quantitate	O
penicillin	SYMP
produced	O
during	O
a	O
Penicillium	O
chrysogenum	O
fermentation	O
.	O
The	O
characterization	O
of	O
low	O
molecular	O
weight	O
ligand	O
interaction	O
with	O
receptor	O
molecules	O
is	O
of	O
importance	O
for	O
the	O
investigation	O
of	O
biological	O
processes	O
and	O
for	O
drug	O
research	O
.	O
We	O
report	O
on	O
the	O
investigation	O
of	O
the	O
binding	O
of	O
low	O
molecular	O
weight	O
ligands	O
to	O
immobilized	O
receptors	O
by	O
label-free	O
detection	O
.	O
Reflectometric	O
interference	O
spectroscopy	O
,	O
an	O
optical	O
transducer	O
which	O
allows	O
the	O
monitoring	O
of	O
a	O
few	O
picograms	O
per	O
square	O
millimetre	O
changes	O
in	O
surface	O
coverage	O
,	O
was	O
used	O
to	O
study	O
two	O
model	O
systems	O
.	O
In	O
both	O
cases	O
detection	O
of	O
the	O
binding	O
event	O
was	O
successful	O
.	O
High	O
affinity	O
binding	O
of	O
biotin	O
to	O
immobilized	O
streptavidin	O
was	O
clearly	O
detectable	O
at	O
receptor	O
surface	O
concentrations	O
as	O
low	O
as	O
1-2	O
x	O
10	O
(	O
10	O
)	O
binding	O
sites/mm2	O
.	O
Linear	O
correlation	O
between	O
the	O
receptor	O
surface	O
concentration	O
and	O
the	O
response	O
to	O
biotin	O
binding	O
was	O
observed	O
.	O
Using	O
immobilized	O
DNA	O
,	O
we	O
investigated	O
the	O
binding	O
of	O
common	O
intercalators	O
with	O
respect	O
to	O
kinetics	O
and	O
thermodynamics	O
by	O
evaluation	O
of	O
the	O
association	O
and	O
the	O
dissociation	O
part	O
of	O
the	O
binding	O
curve	O
.	O
Bi-exponential	O
increase	O
and	O
decrease	O
of	O
intercalator	O
loading	O
was	O
observed	O
,	O
indicating	O
complex	O
interaction	O
kinetics	O
.	O
The	O
four	O
structurally	O
different	O
intercalators	O
showed	O
significant	O
distinction	O
in	O
binding	O
kinetics	O
and	O
equilibrium	O
signals	O
.	O
Improvement	O
of	O
experimental	O
parameters	O
is	O
required	O
to	O
obtain	O
more	O
reliable	O
kinetic	O
data	O
.	O
An	O
amperometric	O
lactate	O
oxidase	O
catheter	O
has	O
been	O
developed	O
for	O
in	O
vivo	O
application	O
to	O
real-time	O
lactate	O
monitoring	O
.	O
The	O
electrochemical	O
behaviour	O
of	O
the	O
1	O
x	O
3	O
mm	O
Pt-Ag/AgCl	O
thin	O
film	O
electrode	O
is	O
not	O
significantly	O
influenced	O
by	O
lactate	O
oxidase-polyurethane	O
covering	O
.	O
Gamma-irradiation	O
(	O
25	O
kGy	O
)	O
is	O
suitable	O
for	O
the	O
sterilization	O
procedure	O
.	O
The	O
final	O
lactate	O
catheter	O
is	O
characterized	O
by	O
a	O
linear	O
concentration	O
range	O
between	O
0.5	O
and	O
20	O
mmol/l	O
lactate	O
with	O
a	O
sensitivity	O
around	O
2	O
nA	O
mmol-1	O
l-1	O
lactate	O
.	O
The	O
accuracy	O
is	O
demonstrated	O
by	O
the	O
measurement	O
of	O
control	O
sera	O
.	O
Both	O
physiological	O
and	O
pathological	O
materials	O
correlate	O
well	O
with	O
the	O
declared	O
values	O
.	O
The	O
dry	O
stored	O
lactate	O
catheter	O
needs	O
about	O
10	O
min	O
for	O
hydration	O
and	O
is	O
characterized	O
by	O
response	O
times	O
t98	O
%	O
of	O
less	O
than	O
2	O
min	O
.	O
Ex	O
vivo	O
whole	O
blood	O
measurements	O
using	O
the	O
lactate	O
catheter	O
(	O
y	O
)	O
give	O
a	O
correlation	O
with	O
the	O
BIOSEN	O
Med	O
L	O
(	O
x	O
)	O
of	O
y	O
=	O
(	O
1.010x	O
+	O
0.513	O
)	O
mmol/l	O
(	O
r	O
=	O
0.9748	O
)	O
.	O
Lactate	O
values	O
obtained	O
by	O
continuous	O
catheter	O
operation	O
ex	O
vivo	O
correlate	O
well	O
with	O
those	O
obtained	O
by	O
BIOSEN	O
Med	O
L.	O
First	O
subcutaneous	O
implantation	O
(	O
dog	O
)	O
underlines	O
the	O
characteristics	O
obtained	O
ex	O
vivo	O
:	O
after	O
30	O
min	O
hydration	O
the	O
lactate	O
catheter	O
follows	O
the	O
lactate	O
concentration	O
measured	O
ex	O
vivo	O
with	O
samples	O
from	O
the	O
leg	O
vein	O
by	O
BIOSEN	O
Med	O
L	O
.	O
The	O
diffusion-limited	O
binding	O
kinetics	O
of	O
antigen	O
(	O
or	O
antibody	O
)	O
in	O
solution	O
to	O
antibody	O
(	O
or	O
antigen	O
)	O
immobilized	O
on	O
a	O
biosensor	O
and	O
other	O
surfaces	O
is	O
analyzed	O
within	O
a	O
fractal	O
framework	O
.	O
Often	O
,	O
the	O
binding	O
kinetics	O
may	O
be	O
described	O
by	O
a	O
single-fractal	O
analysis	O
.	O
In	O
some	O
cases	O
,	O
the	O
binding	O
curve	O
exhibits	O
complexities	O
.	O
Then	O
,	O
for	O
these	O
cases	O
,	O
the	O
dual-fractal	O
analysis	O
provides	O
an	O
improved	O
fit	O
when	O
compared	O
with	O
a	O
single-fractal	O
analysis	O
.	O
This	O
indicates	O
a	O
change	O
in	O
the	O
reaction	O
mechanism	O
on	O
the	O
surface	O
.	O
It	O
is	O
of	O
interest	O
to	O
note	O
that	O
the	O
state	O
of	O
disorder	O
(	O
or	O
the	O
fractal	O
dimension	O
)	O
and	O
the	O
binding	O
rate	O
coefficient	O
both	O
increase	O
as	O
the	O
reaction	O
progresses	O
on	O
the	O
biosensor	O
surface	O
.	O
For	O
example	O
,	O
for	O
the	O
binding	O
of	O
10	O
nM	O
insulin	O
growth	O
factor-1	O
in	O
solution	O
to	O
insulin	O
growth	O
factor	O
binding	O
protein-1	O
immobilized	O
on	O
a	O
biosensor	O
surface	O
,	O
a	O
64	O
%	O
increase	O
in	O
the	O
fractal	O
dimension	O
from	O
1.73	O
(	O
Df1	O
)	O
to	O
2.85	O
(	O
Df2	O
)	O
leads	O
to	O
an	O
increase	O
in	O
the	O
binding	O
rate	O
coefficient	O
by	O
a	O
factor	O
of	O
31.8	O
from	O
3.92	O
(	O
k1	O
)	O
to	O
125	O
(	O
k2	O
)	O
.	O
Furthermore	O
,	O
as	O
the	O
IGF-1	O
concentration	O
in	O
solution	O
increases	O
from	O
10	O
to	O
80	O
nM	O
in	O
solution	O
,	O
k2	O
and	O
Df2	O
exhibit	O
a	O
linear	O
increase	O
.	O
k1	O
and	O
Df1	O
exhibit	O
a	O
linear	O
increase	O
with	O
the	O
reciprocal	O
of	O
the	O
IGF-1	O
concentration	O
in	O
solution	O
.	O
The	O
different	O
examples	O
analyzed	O
and	O
presented	O
together	O
provide	O
a	O
means	O
by	O
which	O
the	O
antigen-antibody	O
reactions	O
may	O
be	O
better	O
controlled	O
by	O
noting	O
the	O
magnitude	O
of	O
the	O
changes	O
in	O
the	O
fractal	O
dimension	O
and	O
in	O
the	O
binding	O
rate	O
coefficient	O
as	O
the	O
reaction	O
progresses	O
on	O
the	O
biosensor	O
surface	O
.	O
Also	O
,	O
the	O
magnitude	O
of	O
the	O
changes	O
in	O
the	O
binding	O
rate	O
coefficients	O
(	O
k1	O
and	O
k2	O
)	O
and	O
in	O
the	O
fractal	O
dimensions	O
(	O
Df1	O
and	O
Df2	O
)	O
as	O
different	O
parameters	O
are	O
changed	O
for	O
the	O
different	O
biosensor	O
applications	O
are	O
of	O
particular	O
value	O
,	O
since	O
they	O
provide	O
us	O
with	O
a	O
measure	O
or	O
extent	O
of	O
changes	O
in	O
the	O
binding	O
rate	O
coefficient	O
on	O
changing	O
different	O
experimental	O
parameter	O
values	O
.	O
It	O
is	O
of	O
interest	O
to	O
note	O
the	O
effect	O
of	O
different	O
parameters	O
on	O
the	O
extent	O
or	O
heterogeneity	O
that	O
exists	O
on	O
the	O
surface	O
and	O
how	O
this	O
influences	O
the	O
binding	O
rate	O
coefficients	O
.	O
This	O
may	O
be	O
one	O
method	O
to	O
help	O
manipulate	O
or	O
control	O
the	O
binding	O
rate	O
coefficients	O
on	O
the	O
reaction	O
surface	O
.	O
To	O
determine	O
if	O
microscopic	O
urinalysis	O
is	O
needed	O
in	O
all	O
pediatric	O
emergency	O
room	O
patients	O
screened	O
for	O
urinary	SYMP
tract	SYMP
infections	SYMP
(	SYMP
UTI	SYMP
)	SYMP
,	O
we	O
compared	O
the	O
dipstick	O
urinalysis	O
and	O
complete	O
urinalysis	O
(	O
dipstick	O
and	O
microscopy	O
)	O
with	O
urine	O
cultures	O
in	O
236	O
children	O
,	O
aged	O
3	O
weeks	O
to	O
21	O
years	O
.	O
The	O
ability	O
to	O
detect	O
UTI	SYMP
by	O
dipstick	O
only	O
and	O
by	O
complete	O
urinalysis	O
was	O
the	O
same	O
,	O
however	O
microscopic	O
evaluation	O
added	O
many	O
false-positive	O
results	O
without	O
detecting	O
additional	O
UTIs	SYMP
.	O
Because	O
the	O
ability	O
to	O
detect	O
UTI	SYMP
(	O
sensitivity	O
)	O
is	O
maintained	O
,	O
we	O
now	O
offer	O
a	O
dipstick	O
only	O
urinalysis	O
to	O
our	O
emergency	O
room	O
for	O
children	O
2	O
years	O
of	O
age	O
or	O
older	O
,	O
with	O
a	O
microscopic	O
analysis	O
performed	O
automatically	O
if	O
dipstick	O
results	O
are	O
positive	O
.	O
If	O
no	O
microscopic	O
urinalysis	O
is	O
required	O
,	O
testing	O
turn-around	O
time	O
is	O
reduced	O
by	O
12.3	O
min/test	O
and	O
the	O
hospital	O
charge	O
is	O
reduced	O
from	O
U.S	O
.	O
$	O
32	O
to	O
U.S	O
.	O
$	O
12	O
.	O
Using	O
video-intensified	O
fluorescence	O
microscopy	O
and	O
a	O
pseudocolor	O
display	O
of	O
fluorescence	O
intensity	O
,	O
we	O
analyzed	O
the	O
distribution	O
of	O
microinjected	O
molecules	O
within	O
the	O
nurse-cell/oocyte	O
syncytium	O
of	O
Drosophila	O
ovarian	O
follicles	O
.	O
We	O
varied	O
the	O
composition	O
and	O
the	O
osmolarity	O
of	O
the	O
culture	O
solution	O
as	O
well	O
as	O
the	O
electrical	O
charge	O
and	O
the	O
molecular	O
mass	O
of	O
the	O
microinjected	O
fluorescent	O
probe	O
.	O
As	O
culture	O
solutions	O
,	O
we	O
used	O
four	O
simple	O
salines	O
(	O
IMADS	O
)	O
and	O
a	O
complex	O
tissue-culture	O
medium	O
(	O
R-14	O
)	O
that	O
matched	O
the	O
osmolarity	O
of	O
adult	O
hemolymph	O
.	O
Small	O
amounts	O
of	O
two	O
anionic	O
dyes	O
(	O
Lucifer	O
Yellow	O
CH	O
and	O
Lucifer	O
Yellow	O
dextran	O
)	O
as	O
well	O
as	O
of	O
two	O
cationic	O
dyes	O
(	O
rhodamine	O
6G	O
and	O
tetramethylrhodamine	O
dextran-lysine	O
)	O
were	O
iontophoretically	O
microinjected	O
either	O
into	O
a	O
nurse	O
cell	O
or	O
into	O
the	O
oocyte	O
of	O
stage-10	O
follicles	O
.	O
In	O
the	O
tissue-culture	O
medium	O
,	O
within	O
a	O
few	O
seconds	O
following	O
microinjection	O
,	O
all	O
tested	O
dyes	O
passed	O
through	O
the	O
intercellular	O
bridges	O
in	O
both	O
the	O
anterior	O
direction	O
(	O
to	O
the	O
nurse	O
cells	O
)	O
and	O
the	O
posterior	O
direction	O
(	O
to	O
the	O
oocyte	O
)	O
,	O
independent	O
of	O
their	O
electrical	O
charge	O
or	O
molecular	O
mass	O
.	O
In	O
all	O
simple	O
salines	O
,	O
irrespective	O
of	O
their	O
osmolarity	O
,	O
Lucifer	O
Yellow	O
CH	O
was	O
found	O
to	O
preferentially	O
migrate	O
in	O
the	O
posterior	O
direction	O
and	O
to	O
accumulate	O
in	O
the	O
oocyte	O
due	O
to	O
progressive	O
binding	O
to	O
yolk	O
spheres	O
.	O
Thus	O
,	O
with	O
this	O
sensitive	O
method	O
,	O
no	O
correlation	O
was	O
detectable	O
between	O
the	O
external	O
osmolarity	O
,	O
the	O
electrical	O
charge	O
and	O
the	O
preferential	O
direction	O
of	O
migration	O
of	O
a	O
microinjected	O
probe	O
.	O
Our	O
results	O
indicate	O
that	O
the	O
electrical	O
gradient	O
described	O
by	O
other	O
authors	O
does	O
not	O
exert	O
significant	O
influence	O
on	O
the	O
migration	O
of	O
charged	O
molecules	O
through	O
intercellular	O
bridges	O
in	O
situ	O
.	O
The	O
AF-4	O
gene	O
on	O
human	O
chromosome	O
4q21	O
is	O
involved	O
in	O
reciprocal	O
translocations	O
to	O
the	O
ALL-1	O
gene	O
on	O
chromosome	O
11q23	O
,	O
which	O
are	O
associated	O
with	O
acute	SYMP
lymphoblastic	SYMP
leukaemias	SYMP
.	O
A	O
set	O
of	O
recombinant	O
phage	O
carrying	O
genomic	O
fragments	O
for	O
the	O
coding	O
region	O
and	O
flanking	O
sequences	O
of	O
the	O
AF-4	O
gene	O
were	O
isolated	O
.	O
Phage	O
inserts	O
were	O
assembled	O
into	O
four	O
contigs	O
with	O
21	O
exons	O
,	O
and	O
an	O
intron	O
phase	O
map	O
was	O
produced	O
enabling	O
the	O
interpretation	O
of	O
translocation-generated	O
fusion	O
proteins	O
.	O
The	O
gene	O
contains	O
two	O
alternative	O
first	O
exons	O
,	O
1a	O
and	O
1b	O
,	O
both	O
including	O
a	O
translation	O
initiation	O
codon	O
.	O
The	O
translocation	O
breakpoint	O
cluster	O
region	O
is	O
flanked	O
by	O
exons	O
3	O
and	O
6	O
and	O
two	O
different	O
polyadenylation	O
signals	O
were	O
identified	O
.	O
Polyclonal	O
antisera	O
directed	O
against	O
three	O
different	O
portions	O
of	O
the	O
AF-4	O
protein	O
were	O
produced	O
and	O
used	O
to	O
detect	O
a	O
116	O
kD	O
protein	O
in	O
cellular	O
extracts	O
of	O
human	O
B-lymphoblastoid	O
and	O
proB	O
cell	O
lines	O
.	O
In	O
mitogen-stimulated	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
the	O
AF-4	O
antigen	O
was	O
predominantly	O
located	O
in	O
the	O
nucleus	O
.	O
The	O
AF-4	O
gene	O
is	O
a	O
member	O
of	O
the	O
AF-4	O
,	O
LAF-4	O
and	O
FMR-2	O
gene	O
family	O
.	O
The	O
members	O
of	O
this	O
family	O
encode	O
serine-proline-rich	O
proteins	O
with	O
properties	O
of	O
nuclear	O
transcription	O
factors	O
.	O
Comparison	O
of	O
AF-4	O
protein	O
coding	O
sequences	O
with	O
the	O
LAF-4	O
and	O
FMR-2	O
sequences	O
revealed	O
five	O
highly	O
conserved	O
domains	O
of	O
potential	O
functional	O
relevance	O
.	O
Immunoglobulin	O
superfamily	O
molecules	O
in	O
the	O
brain	O
are	O
involved	O
in	O
distinct	O
aspects	O
of	O
nervous	O
system	O
histogenesis	O
,	O
for	O
example	O
neuronal	O
migration	O
and	O
axonal	O
growth	O
.	O
To	O
identify	O
novel	O
members	O
of	O
this	O
superfamily	O
in	O
the	O
chick	O
nervous	O
system	O
,	O
we	O
developed	O
a	O
polymerase	O
chain	O
reaction-based	O
approach	O
making	O
use	O
of	O
sequence	O
motifs	O
of	O
immunoglobulin-like	O
domains	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
report	O
the	O
molecular	O
cloning	O
of	O
three	O
isoforms	O
,	O
the	O
biochemical	O
analysis	O
and	O
the	O
immunohistochemical	O
characterization	O
of	O
one	O
of	O
the	O
proteins	O
identified	O
in	O
this	O
screen	O
.	O
This	O
molecule	O
has	O
91	O
%	O
sequence	O
identity	O
with	O
the	O
limbic	O
system-associated	O
membrane	O
protein	O
(	O
LAMP	O
)	O
characterized	O
in	O
the	O
rat	O
and	O
is	O
therefore	O
referred	O
to	O
as	O
the	O
chicken	O
homologue	O
of	O
the	O
latter	O
(	O
chLAMP	O
)	O
.	O
The	O
molecule	O
is	O
a	O
glycosylphosphatidyl-inositol-anchored	O
60	O
kDa	O
protein	O
with	O
three	O
immunoglobulin-like	O
domains	O
and	O
contains	O
40	O
%	O
N-linked	O
carbohydrate	O
.	O
We	O
identify	O
three	O
different	O
mRNA	O
forms	O
of	O
chLAMP	O
and	O
show	O
that	O
two	O
forms	O
with	O
distinct	O
5'-termini	O
are	O
differentially	O
transcribed	O
in	O
neural	O
development	O
.	O
In	O
addition	O
,	O
we	O
demonstrate	O
using	O
a	O
fusion	O
protein	O
expressed	O
in	O
eukaryotic	O
cells	O
that	O
chLAMP	O
has	O
homophilic	O
binding	O
activity	O
.	O
The	O
protein	O
was	O
found	O
on	O
a	O
subset	O
of	O
axons	O
in	O
the	O
central	O
and	O
peripheral	O
nervous	O
system	O
and	O
is	O
likely	O
to	O
be	O
involved	O
in	O
specific	O
cell-cell	O
interactions	O
in	O
neurohistogenesis	O
.	O
Two	O
novel	O
cDNAs	O
,	O
DNAS1L2	O
and	O
DNAS1L3	O
,	O
are	O
predicted	O
to	O
encode	O
proteins	O
of	O
299	O
and	O
305	O
amino	O
acids	O
with	O
56	O
and	O
46	O
%	O
residue	O
identity	O
(	O
71	O
and	O
63	O
%	O
similarity	O
)	O
,	O
respectively	O
,	O
to	O
deoxyribonuclease	O
I	O
(	O
DNase	O
I	O
)	O
.	O
DNAS1L2	O
is	O
located	O
on	O
a	O
16p13.3	O
cosmid	O
,	O
while	O
DNAS1L3	O
maps	O
to	O
3p14.3-p21.1	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
and	O
by	O
PCR	O
analysis	O
of	O
a	O
radiation	O
hybrid	O
panel	O
.	O
Northern	O
analysis	O
revealed	O
DNAS1L3	O
expression	O
nearly	O
exclusively	O
in	O
liver	O
,	O
while	O
DNAS1L2	O
expression	O
was	O
detected	O
in	O
brain	O
by	O
RT-PCR	O
.	O
The	O
previously	O
defined	O
DNL1L	O
or	O
DNAS1L1	O
is	O
expressed	O
highest	O
in	O
heart	O
and	O
skeletal	O
muscle	O
,	O
while	O
DNase	O
I	O
is	O
expressed	O
in	O
the	O
pancreas	O
,	O
parotid	O
gland	O
,	O
and	O
kidney	O
.	O
Thus	O
,	O
to	O
date	O
,	O
four	O
DNase	O
I-like	O
genes	O
that	O
show	O
different	O
tissue	O
expression	O
patterns	O
are	O
known	O
.	O
A	O
comparison	O
of	O
DNAS1L1	O
,	O
DNAS1L2	O
,	O
and	O
DNAS1L3	O
with	O
the	O
well-characterized	O
DNase	O
I	O
suggests	O
that	O
the	O
DNAS1L	O
proteins	O
are	O
unlikely	O
to	O
be	O
glycosylated	O
or	O
bind	O
actin	O
;	O
however	O
,	O
catalytic	O
and	O
calcium-	O
and	O
DNA-binding	O
residues	O
are	O
conserved	O
,	O
and	O
potentially	O
cleavable	O
signal	O
peptides	O
are	O
present	O
among	O
all	O
these	O
proteins	O
.	O
This	O
analysis	O
also	O
identifies	O
regions	O
of	O
high	O
conservation	O
among	O
these	O
proteins	O
with	O
no	O
currently	O
assigned	O
function	O
.	O
Two	O
different	O
responses	O
to	O
the	O
therapy	O
were	O
observed	O
in	O
a	O
group	O
of	O
patients	O
receiving	O
the	O
protease	SYMP
inhibitor	SYMP
indinavir	SYMP
.	O
In	O
one	O
,	O
suppression	O
of	O
virus	O
replication	O
occurred	O
and	O
has	O
persisted	O
for	O
90	O
weeks	O
(	O
bDNA	O
,	O
&	O
#	O
60	O
;	O
500	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
RNA	O
copies/ml	O
)	O
.	O
In	O
the	O
second	O
group	O
,	O
a	O
rebound	O
in	O
virus	O
levels	O
in	O
plasma	O
followed	O
the	O
initial	O
sharp	O
decline	O
observed	O
at	O
the	O
start	O
of	O
therapy	O
.	O
This	O
was	O
associated	O
with	O
the	O
emergence	O
of	O
drug-resistant	O
variants	O
.	O
Sequence	O
analysis	O
of	O
the	O
protease	O
gene	O
during	O
the	O
course	O
of	O
therapy	O
revealed	O
that	O
in	O
this	O
second	O
group	O
there	O
was	O
a	O
sequential	O
acquisition	O
of	O
protease	O
mutations	O
at	O
amino	O
acids	O
46	O
,	O
82	O
,	O
54	O
,	O
71	O
,	O
89	O
,	O
and	O
90	O
.	O
In	O
the	O
six	O
patients	O
in	O
this	O
group	O
,	O
there	O
was	O
also	O
an	O
identical	O
mutation	O
in	O
the	O
gag	O
p7/p1	O
gag	O
protease	O
cleavage	O
site	O
.	O
In	O
three	O
of	O
the	O
patients	O
,	O
this	O
change	O
was	O
seen	O
as	O
early	O
as	O
6	O
to	O
10	O
weeks	O
after	O
the	O
start	O
of	O
therapy	O
.	O
In	O
one	O
patient	O
,	O
a	O
second	O
mutation	O
occurred	O
at	O
the	O
gag	O
p1/p6	O
cleavage	O
site	O
,	O
but	O
it	O
appeared	O
18	O
weeks	O
after	O
the	O
time	O
of	O
appearance	O
of	O
the	O
p7/p1	O
mutation	O
.	O
Recombinant	O
HIV-1	O
variants	O
containing	O
two	O
or	O
three	O
mutations	O
in	O
the	O
protease	O
gene	O
were	O
constructed	O
either	O
with	O
mutations	O
at	O
the	O
p7/p1	O
cleavage	O
site	O
or	O
with	O
wild-type	O
(	O
WT	O
)	O
gag	O
sequences	O
.	O
When	O
recombinant	O
HIV-1-containing	O
protease	O
mutations	O
at	O
46	O
and	O
82	O
was	O
grown	O
in	O
MT2	O
cells	O
,	O
there	O
was	O
a	O
68	O
%	O
reduction	O
in	O
its	O
rate	O
of	O
replication	O
compared	O
to	O
the	O
WT	O
virus	O
.	O
Introduction	O
of	O
an	O
additional	O
mutation	O
at	O
the	O
gag	O
p7/p1	O
protease	O
cleavage	O
site	O
compensated	O
for	O
the	O
partially	O
defective	O
protease	O
gene	O
.	O
Similarly	O
,	O
rates	O
of	O
replication	O
of	O
viruses	O
with	O
mutations	O
M46L/I	O
,	O
I54V	O
,	O
and	O
V82A	O
in	O
protease	O
were	O
enhanced	O
both	O
in	O
the	O
presence	O
and	O
in	O
the	O
absence	O
of	O
Indinavir	O
when	O
combined	O
with	O
mutations	O
in	O
the	O
gag	O
p7/p1	O
and	O
the	O
gag	O
p1/p6	O
cleavage	O
sites	O
.	O
Optimal	O
rates	O
of	O
virus	O
replication	O
require	O
protease	O
cleavage	O
of	O
precursor	O
polyproteins	O
.	O
A	O
mutation	O
in	O
the	O
cleavage	O
site	O
that	O
enhanced	O
the	O
availability	O
of	O
a	O
protein	O
that	O
was	O
rate	O
limiting	O
for	O
virus	O
maturation	O
would	O
confer	O
on	O
that	O
virus	O
a	O
significant	O
growth	O
advantage	O
and	O
may	O
explain	O
the	O
uniform	O
emergence	O
of	O
viruses	O
with	O
alterations	O
at	O
the	O
p7/p1	O
cleavage	O
site	O
.	O
This	O
is	O
the	O
first	O
report	O
of	O
the	O
emergence	O
of	O
mutations	O
in	O
the	O
gag	O
p7/p1	O
protease	O
cleavage	O
sites	O
in	O
patients	O
receiving	O
protease	SYMP
therapy	SYMP
and	O
identifies	O
this	O
change	O
as	O
an	O
important	O
determinant	O
of	O
HIV-1	O
resistance	O
to	O
protease	O
inhibitors	O
in	O
patient	O
populations	O
.	O
A	O
novel	O
intracellular	O
calcium-binding	O
protein	O
from	O
Echinococcus	O
granulosus	O
is	O
described	O
in	O
this	O
work	O
.	O
A	O
cDNA	O
was	O
isolated	O
from	O
a	O
lambdagt11	O
protoscolex	O
expression	O
library	O
and	O
the	O
deduced	O
amino	O
acid	O
sequence	O
has	O
at	O
least	O
fifteen	O
sequentially	O
repeated	O
twelve-residue	O
repeats	O
that	O
resemble	O
the	O
calcium-binding	O
loop	O
of	O
EF-hands	O
;	O
however	O
,	O
the	O
dodecamer	O
motif	O
has	O
no	O
flanking	O
helices	O
.	O
The	O
cDNA	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
using	O
the	O
pGEX	O
vector	O
,	O
and	O
a	O
recombinant	O
fusion	O
protein	O
(	O
EgCaBP1-GST	O
)	O
was	O
obtained	O
.	O
The	O
recombinant	O
fusion	O
protein	O
binds	O
calcium	O
when	O
assayed	O
with	O
45Ca	O
.	O
It	O
is	O
possible	O
that	O
the	O
calcium-binding	O
motifs	O
present	O
a	O
secondary	O
structure	O
similar	O
to	O
the	O
parallel	O
beta	O
roll	O
structure	O
described	O
for	O
an	O
alkaline	O
protease	O
from	O
Pseudomonas	O
aeruginosa	O
.	O
A	O
native	O
protein	O
of	O
more	O
than	O
300	O
kDa	O
was	O
recognized	O
by	O
an	O
anti-EgCaBP1	O
monoclonal	O
antibody	O
by	O
Western-blot	O
analysis	O
.	O
Immunohistochemistry	O
using	O
a	O
pool	O
of	O
anti-EgCaBP1-GST	O
mouse	O
sera	O
demonstrated	O
a	O
strong	O
association	O
of	O
the	O
protein	O
with	O
calcareous	O
corpuscles	O
.	O
The	O
possible	O
role	O
of	O
this	O
protein	O
and	O
that	O
of	O
the	O
calcareous	O
corpuscles	O
in	O
the	O
protoscolex	O
are	O
discussed	O
.	O
The	O
enzyme	O
activity	O
of	O
mitogen-activated	O
protein	O
kinase	O
(	O
MAP	O
kinase	O
)	O
increases	O
in	O
response	O
to	O
agents	O
acting	O
on	O
a	O
variety	O
of	O
cell	O
surface	O
receptors	O
,	O
including	O
receptors	O
linked	O
to	O
heterotrimeric	O
G	O
proteins	O
.	O
In	O
this	O
report	O
,	O
we	O
demonstrated	O
that	O
Raf-1	O
protein	O
kinase	O
activity	O
in	O
the	O
mouse	O
parotid	O
glands	O
was	O
induced	O
by	O
chronic	O
isoproterenol	O
administration	O
in	O
whole	O
animals	O
.	O
To	O
investigate	O
the	O
molecular	O
nature	O
underlying	O
cellular	O
responses	O
to	O
Raf-1	O
activation	O
,	O
we	O
have	O
stably	O
transfected	O
rat	O
salivary	O
epithelial	O
Pa-4	O
cells	O
with	O
human	O
Raf-1-estrogen	O
receptor	O
fusion	O
gene	O
(	O
DeltaRaf-1	O
:	O
ER	O
)	O
and	O
used	O
mRNA	O
differential	O
display	O
in	O
search	O
of	O
messages	O
induced	O
by	O
DeltaRaf-1	O
:	O
ER	O
activation	O
.	O
Through	O
this	O
approach	O
,	O
the	O
gene	O
encoding	O
non-histone	O
chromosomal	O
protein	O
HMGI-C	O
was	O
identified	O
as	O
one	O
of	O
the	O
target	O
genes	O
activated	O
by	O
oncogenic	O
Raf-1	O
kinase	O
.	O
Activation	O
of	O
Raf-1	O
kinase	O
resulted	O
in	O
a	O
delayed	O
and	O
sustained	O
increase	O
of	O
HMGI-C	O
expression	O
in	O
the	O
Pa-4	O
cells	O
.	O
The	O
induction	O
of	O
HMGI-C	O
mRNA	O
level	O
is	O
sensitive	O
to	O
both	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
and	O
transcription	O
inhibitor	O
actinomycin	O
D	O
.	O
The	O
role	O
of	O
the	O
extracellular	O
signal-related	O
kinase	O
(	O
ERK	O
)	O
signaling	O
pathway	O
in	O
the	O
HMGI-C	O
induction	O
was	O
highlighted	O
by	O
the	O
result	O
that	O
the	O
MAP	O
kinase	O
kinase	O
(	O
MEK	O
)	O
inhibitor	O
,	O
PD	O
98059	O
,	O
blocked	O
DeltaRaf-1	O
:	O
ER-	O
and	O
12-O-tetradecanoylphorbol-13-acetate-stimulated	O
HMGI-C	O
induction	O
.	O
Altogether	O
,	O
these	O
findings	O
support	O
the	O
notion	O
that	O
the	O
Raf/MEK/ERK	O
signaling	O
module	O
,	O
at	O
least	O
in	O
part	O
,	O
regulates	O
transcriptional	O
activation	O
of	O
the	O
chromosomal	O
architectural	O
protein	O
HMGI-C	O
.	O
Pendred	SYMP
syndrome	SYMP
is	O
a	O
recessively	O
inherited	O
disorder	O
with	O
the	O
hallmark	O
features	O
of	O
congenital	SYMP
deafness	SYMP
and	O
thyroid	SYMP
goitre	SYMP
.	O
By	O
some	O
estimates	O
,	O
the	O
disorder	O
may	O
account	O
for	O
upwards	O
of	O
10	O
%	O
of	O
hereditary	SYMP
deafness	SYMP
.	O
Previous	O
genetic	O
linkage	O
studies	O
localized	O
the	O
gene	O
to	O
a	O
broad	O
interval	O
on	O
human	O
chromosome	O
7q22-31.1	O
.	O
Using	O
a	O
positional	O
cloning	O
strategy	O
,	O
we	O
have	O
identified	O
the	O
gene	O
(	O
PDS	O
)	O
mutated	O
in	O
Pendred	SYMP
syndrome	SYMP
and	O
found	O
three	O
apparently	O
deleterious	O
mutations	O
,	O
each	O
segregating	O
with	O
the	O
disease	O
in	O
the	O
respective	O
families	O
in	O
which	O
they	O
occur	O
.	O
PDS	O
produces	O
a	O
transcript	O
of	O
approximately	O
5	O
kb	O
that	O
was	O
found	O
to	O
be	O
expressed	O
at	O
significant	O
levels	O
only	O
in	O
the	O
thyroid	O
.	O
The	O
predicted	O
protein	O
,	O
pendrin	O
,	O
is	O
closely	O
related	O
to	O
a	O
number	O
of	O
known	O
sulphate	O
transporters	O
.	O
These	O
studies	O
provide	O
compelling	O
evidence	O
that	O
defects	O
in	O
pendrin	O
cause	O
Pendred	SYMP
syndrome	SYMP
thereby	O
launching	O
a	O
new	O
area	O
of	O
investigation	O
into	O
thyroid	O
physiology	O
,	O
the	O
pathogenesis	O
of	O
congenital	SYMP
deafness	SYMP
and	O
the	O
role	O
of	O
altered	O
sulphate	O
transport	O
in	O
human	O
disease	O
.	O
We	O
report	O
the	O
cDNA	O
cloning	O
,	O
partial	O
genomic	O
organization	O
,	O
and	O
expression	O
pattern	O
of	O
Stra10	O
,	O
a	O
novel	O
retinoic	O
acid-inducible	O
gene	O
in	O
P19	O
embryonal	SYMP
carcinoma	SYMP
cells	O
.	O
Four	O
murine	O
cDNA	O
isoforms	O
have	O
been	O
isolated	O
,	O
which	O
are	O
likely	O
to	O
result	O
from	O
alternative	O
splicing	O
.	O
The	O
predicted	O
protein	O
sequences	O
exhibit	O
approximately	O
85	O
%	O
identity	O
with	O
the	O
Pbx-related	O
Meis1	O
homeobox	O
gene	O
products	O
,	O
which	O
are	O
involved	O
in	O
myeloid	SYMP
leukemia	SYMP
in	O
BXH-2	O
mice	O
,	O
and	O
one	O
of	O
the	O
Stra10	O
isoforms	O
corresponds	O
to	O
the	O
recently	O
published	O
Meis2	O
sequence	O
(	O
Nakamura	O
et	O
al	O
.	O
(	O
1996	O
)	O
Oncogene	O
13	O
:	O
2235-2242	O
)	O
.	O
The	O
Meis2	O
homeodomain	O
is	O
identical	O
to	O
that	O
of	O
Meis1	O
,	O
and	O
is	O
most	O
closely	O
related	O
to	O
those	O
of	O
the	O
Pbx/TGIF	O
homeobox	O
gene	O
products	O
.	O
By	O
in	O
situ	O
hybridization	O
analysis	O
,	O
we	O
show	O
that	O
the	O
Meis2	O
gene	O
displays	O
spatially	O
restricted	O
expression	O
patterns	O
in	O
the	O
developing	O
nervous	O
system	O
,	O
limbs	O
,	O
face	O
,	O
and	O
in	O
various	O
viscera	O
.	O
In	O
adult	O
mice	O
,	O
Meis2	O
is	O
mainly	O
expressed	O
in	O
the	O
brain	O
and	O
female	O
genital	O
tract	O
,	O
with	O
a	O
different	O
distribution	O
of	O
the	O
alternative	O
splice	O
forms	O
in	O
these	O
organs	O
.	O
A	O
methodical	O
strategy	O
for	O
the	O
isolation	O
of	O
microsatellite	O
markers	O
specific	O
for	O
targeted	O
regions	O
of	O
bovine	O
chromosomes	O
is	O
presented	O
.	O
The	O
procedure	O
involves	O
directed	O
microdissection	O
of	O
one	O
defined	O
subchromosomal	O
area	O
,	O
its	O
DOP-PCR-amplification	O
and	O
cloning	O
.	O
With	O
this	O
approach	O
,	O
a	O
library	O
specific	O
to	O
the	O
BTA	O
6q21-31	O
chromosomal	O
region	O
was	O
constructed	O
.	O
Eleven	O
unique	O
microsatellite-containing	O
sequences	O
were	O
isolated	O
,	O
converted	O
into	O
sequence-tagged	O
microsatellite	O
sites	O
,	O
and	O
characterized	O
concerning	O
their	O
species-specific	O
origin	O
.	O
Seven	O
primer	O
pairs	O
generated	O
bovine-specific	O
PCR	O
products	O
and	O
provided	O
a	O
set	O
of	O
microsatellite	O
markers	O
that	O
generally	O
revealed	O
high	O
informativity	O
in	O
the	O
HF	O
breed	O
.	O
Linkage	O
analysis	O
assigned	O
six	O
of	O
them	O
to	O
their	O
predefined	O
subchromosomal	O
origin	O
on	O
BTA	O
6	O
corresponding	O
to	O
the	O
specific	O
rehybridization	O
signal	O
of	O
the	O
DOP-PCR	O
product	O
generated	O
from	O
the	O
microdissected	O
chromosome	O
area	O
6q21-31	O
.	O
The	O
results	O
underline	O
the	O
usefulness	O
of	O
the	O
BTA	O
6q21-31	O
library	O
for	O
targeted	O
isolation	O
of	O
unique	O
sequences	O
that	O
are	O
specific	O
for	O
the	O
dissected	O
chromosomal	O
region	O
as	O
demonstrated	O
here	O
by	O
the	O
isolation	O
of	O
microsatellite	O
markers	O
.	O
Phylogeographic	O
structure	O
was	O
determined	O
for	O
the	O
yellow	O
mongoose	O
,	O
Cynictis	O
penicillata	O
,	O
using	O
mtDNA	O
RFLPs	O
and	O
control	O
region	O
sequences	O
.	O
The	O
RFLP	O
analysis	O
revealed	O
13	O
haplotypes	O
which	O
showed	O
weak	O
geographical	O
patterning	O
consistent	O
with	O
a	O
recent	O
range	O
expansion	O
from	O
a	O
refugial	O
population	O
(	O
s	O
)	O
.	O
An	O
analysis	O
of	O
molecular	O
variance	O
(	O
AMOVA	O
)	O
revealed	O
no	O
correspondence	O
between	O
mtDNA	O
phylogeography	O
and	O
subspecies	O
delimitation	O
,	O
nor	O
between	O
matrilines	O
and	O
areas	O
characterized	O
by	O
a	O
high	O
incidence	O
of	O
the	O
viverrid-type	SYMP
rabies	SYMP
,	O
of	O
which	O
the	O
yellow	O
mongoose	O
is	O
the	O
principal	O
vector	O
.	O
The	O
lack	O
of	O
structure	O
was	O
also	O
shown	O
by	O
control	O
region	O
sequences	O
although	O
four	O
of	O
the	O
maternal	O
lineages	O
shared	O
a	O
near-perfect	O
81	O
bp	O
repeat	O
.	O
We	O
speculate	O
that	O
regional	O
hot	O
spots	O
of	O
the	O
viverrid	SYMP
rabies	SYMP
biotype	O
reflect	O
population	O
density	O
differences	O
in	O
the	O
yellow	O
mongoose	O
that	O
are	O
not	O
underscored	O
by	O
genetic	O
partitioning	O
,	O
at	O
least	O
at	O
the	O
level	O
of	O
resolution	O
provided	O
by	O
our	O
analyses	O
.	O
The	O
indoor	O
pollution	O
,	O
where	O
the	O
patients	O
pass	O
in	O
general	O
close	O
to	O
90	O
%	O
of	O
their	O
time	O
,	O
is	O
an	O
important	O
factor	O
to	O
take	O
in	O
consideration	O
if	O
one	O
wants	O
to	O
evaluate	O
suitably	O
the	O
effects	O
of	O
the	O
air	O
pollution	O
on	O
the	O
health	O
.	O
Causes	O
of	O
this	O
kind	O
of	O
pollution	O
are	O
partially	O
linked	O
to	O
the	O
external	O
pollution	O
and	O
the	O
outdoor	O
environment	O
and	O
also	O
are	O
function	O
of	O
human	O
activities	O
and	O
introduced	O
products	O
in	O
the	O
habitat	O
(	O
heating	O
,	O
tabagisme	O
,	O
handywork	O
,	O
products	O
of	O
maintenance	O
,	O
coatings	O
,	O
materials	O
of	O
construction	O
,	O
etc	O
.	O
)	O
.	O
The	O
effects	O
on	O
health	O
are	O
as	O
various	O
as	O
the	O
pollutants	O
,	O
going	O
from	O
sharp	O
intoxication	O
to	O
irritations	O
or	O
simply	O
desagreements	O
.	O
In	O
this	O
problem	O
of	O
public	O
health	O
we	O
may	O
not	O
underestimated	O
sensitive	O
persons	O
and	O
risky	O
group	O
as	O
well	O
as	O
long	O
terme	O
effects	O
,	O
and	O
chronic	O
exposition	O
effects	O
.	O
The	O
search	O
of	O
solutions	O
needs	O
multiple	O
competences	O
from	O
the	O
physician	O
,	O
who	O
has	O
to	O
play	O
an	O
essential	O
role	O
.	O
Dioxins	O
are	O
a	O
family	O
of	O
chlorinated	O
aromatic	O
hydrocarbons	O
that	O
are	O
produced	O
during	O
combustion	O
processes	O
in	O
the	O
presence	O
of	O
a	O
chlorine	O
donor	O
and	O
as	O
by-products	O
of	O
the	O
chlorine-processing	O
chemical	O
industries	O
.	O
Several	O
dioxins	O
are	O
extremely	O
stable	O
compounds	O
and	O
persist	O
for	O
years	O
in	O
the	O
environment	O
.	O
Exposure	O
to	O
dioxins	O
occurs	O
mainly	O
via	O
the	O
ingestion	O
of	O
contaminated	O
food	O
.	O
The	O
lipophilic	O
character	O
of	O
dioxins	O
prevents	O
their	O
excretion	O
in	O
the	O
urine	O
and	O
causes	O
their	O
accumulation	O
in	O
body	O
fat	O
.	O
The	O
mechanisms	O
of	O
dioxin	O
action	O
are	O
similar	O
to	O
those	O
of	O
a	O
hormone	O
.	O
Dioxins	O
bind	O
to	O
a	O
specific	O
intracellular	O
receptor	O
and	O
the	O
complex	O
acts	O
as	O
a	O
transcription	O
factor	O
that	O
induces	O
the	O
production	O
of	O
a	O
great	O
number	O
of	O
proteins	O
.	O
Certain	O
dioxins	O
,	O
particularly	O
2	O
,	O
3	O
,	O
7	O
,	O
8-tetrachlorodibenzo-p-dioxin	O
,	O
are	O
very	O
toxic	O
and	O
able	O
to	O
induce	O
numerous	O
clinical	O
conditions	O
.	O
The	O
carcinogenicity	O
of	O
dioxins	O
is	O
well	O
documented	O
in	O
animal	O
models	O
and	O
has	O
been	O
described	O
in	O
humans	O
after	O
professional	O
and	O
accidental	O
exposures	O
.	O
Recent	O
experimental	O
data	O
also	O
indicate	O
that	O
dioxins	O
can	O
cause	O
dysfunction	SYMP
of	SYMP
the	SYMP
sexual	SYMP
and	SYMP
thyroid	SYMP
hormone	SYMP
systems	SYMP
and	O
that	O
the	O
administration	O
of	O
dioxins	O
induces	O
several	O
conditions	O
related	O
to	O
hormonal	SYMP
dysfunction	SYMP
.	O
Chronic	O
exposure	O
of	O
female	O
Rhesus	O
monkeys	O
increases	O
the	O
incidence	O
and	O
severity	O
of	O
endometriosis	SYMP
.	O
The	O
administration	O
of	O
dioxins	O
during	O
pregnancy	O
and	O
nursing	O
causes	O
altered	O
development	O
of	O
the	O
reproductive	O
system	O
,	O
decreased	O
spermatogenesis	O
,	O
hypothyroidism	SYMP
and	O
disturbed	O
psychomotor	O
development	O
in	O
the	O
offspring	O
.	O
The	O
particular	O
sensibility	O
of	O
the	O
fetus	O
and	O
newborn	O
is	O
of	O
concern	O
because	O
the	O
exposition	O
to	O
dioxins	O
is	O
particularly	O
important	O
during	O
those	O
periods	O
of	O
life	O
.	O
In	O
humans	O
a	O
series	O
of	O
conditions	O
related	O
to	O
hormonal	SYMP
dysfunction	SYMP
as	O
undescended	O
testis	O
,	O
decreased	O
spermatogenesis	O
,	O
testicular	SYMP
cancer	SYMP
and	O
endometriosis	SYMP
have	O
increased	O
in	O
incidence	O
during	O
the	O
last	O
decades	O
.	O
The	O
chronological	O
parallelism	O
with	O
the	O
appearance	O
of	O
dioxins	O
in	O
the	O
environment	O
suggests	O
that	O
these	O
might	O
exert	O
biological	O
effects	O
at	O
the	O
prevailing	O
level	O
of	O
exposure	O
.	O
Nevertheless	O
this	O
hypothesis	O
is	O
currently	O
unconfirmed	O
by	O
epidemiological	O
studies	O
.	O
The	O
implications	O
of	O
this	O
scientific	O
incertitude	O
for	O
the	O
implementation	O
of	O
preventive	O
measures	O
are	O
briefly	O
discussed	O
.	O
This	O
presentation	O
summarizes	O
the	O
debate	O
on	O
the	O
suggested	O
progressive	O
impairment	O
of	O
semen	O
quality	O
(	O
the	O
``	O
sperm	O
fall	O
''	O
)	O
in	O
the	O
last	O
forty	O
years	O
in	O
the	O
developed	O
countries	O
.	O
The	O
various	O
available	O
data	O
strongly	O
suggesting	O
an	O
environmental	O
toxic	O
origin	O
for	O
the	O
``	O
sperm	O
fall	O
''	O
will	O
be	O
presented	O
as	O
well	O
as	O
the	O
most	O
frequently	O
suspected	O
class	O
of	O
substances	O
,	O
the	O
xenoestrogens	O
.	O
Diabetes	SYMP
mellitus	SYMP
is	O
a	O
still	O
growing	O
disease	O
.	O
New	O
diagnostic	O
criteria	O
lowered	O
the	O
cut	O
off	O
value	O
to	O
126	O
mg/dl	O
,	O
in	O
order	O
to	O
detect	O
more	O
rapidly	O
diabetes	SYMP
and	O
its	O
complications	O
.	O
The	O
treatment	O
of	O
diabetes	SYMP
2	SYMP
by	O
the	O
classic	SYMP
oral	SYMP
antidiabetic	SYMP
drugs	SYMP
(	SYMP
sulfamides	SYMP
and	SYMP
biguanides	SYMP
)	SYMP
is	O
completed	O
by	O
intestinal	SYMP
glycosidases	SYMP
inhibitors	SYMP
and	O
thiazolidendiones	SYMP
.	O
These	O
last	O
drugs	O
seem	O
very	O
attractive	O
because	O
they	O
decrease	O
insulin	O
resistance	O
in	O
obese	O
,	O
diabetics	O
.	O
Their	O
hepatic	O
side	O
effects	O
must	O
be	O
however	O
under	O
control	O
.	O
Better	O
knowledge	O
of	O
non	O
lipidic	O
effects	O
of	O
statins	O
on	O
the	O
arterial	O
wall	O
and	O
the	O
discovery	O
of	O
the	O
action	O
of	O
fibrates	O
on	O
PPAR	O
(	O
Peroxisome	O
Proliferator	O
Activated	O
Receptors	O
)	O
improved	O
strongly	O
the	O
therapeutic	O
management	O
of	O
hyperlipidemias	SYMP
.	O
Recent	O
intervention	O
studies	O
have	O
demonstrated	O
the	O
necessity	O
to	O
treat	O
vigorously	O
dysipidemias	SYMP
.	O
Despite	O
Beta-blockade	SYMP
therapy	SYMP
has	O
been	O
considered	O
as	O
an	O
absolute	O
contraindication	O
in	O
the	O
treatment	O
of	O
heart	SYMP
failure	SYMP
,	O
it	O
has	O
been	O
shown	O
that	O
they	O
could	O
have	O
a	O
beneficial	O
effect	O
,	O
provided	O
that	O
they	O
were	O
introduced	O
at	O
very	O
low	O
dose	O
,	O
and	O
very	O
progressively	O
in	O
addition	O
of	O
the	O
traditional	O
treatment	O
.	O
The	O
advances	O
in	O
the	O
understanding	O
of	O
the	O
neuro-hormonal	O
mechanisms	O
of	O
heart	O
failure	O
have	O
modified	O
the	O
therapeutic	O
strategy	O
:	O
the	O
deleterious	O
effect	O
of	O
the	O
activation	O
of	O
the	O
sympathetic	O
nervous	O
system	O
on	O
the	O
myocardium	O
has	O
served	O
as	O
the	O
rationale	O
for	O
randomized	O
clinical	O
trials	O
comparing	O
beta-blockade	O
to	O
placebo	O
:	O
the	O
current	O
data	O
are	O
promising	O
,	O
suggesting	O
a	O
beneficial	O
effect	O
on	O
survival	O
as	O
well	O
as	O
on	O
quality	O
of	O
life	O
.	O
However	O
,	O
these	O
results	O
have	O
to	O
be	O
confirmed	O
by	O
larger	O
trials	O
,	O
currently	O
underway	O
,	O
before	O
to	O
consider	O
that	O
beta-blockade	O
should	O
definitely	O
be	O
incorporated	O
in	O
the	O
treatment	O
of	O
heart	O
failure	O
.	O
Calcium	SYMP
antagonists	SYMP
have	O
been	O
used	O
for	O
treatment	O
of	O
cardiovascular	SYMP
diseases	SYMP
for	O
more	O
than	O
25	O
years	O
.	O
Several	O
recent	O
retrospective	O
studies	O
have	O
suggested	O
that	O
chronic	O
treatment	O
with	O
short-acting	SYMP
dihydropyridines	SYMP
increased	O
the	O
incidence	O
of	O
cardiac	SYMP
events	SYMP
,	O
cancer	SYMP
and	O
gastrointestinal	SYMP
bleedings	SYMP
.	O
Randomized	O
prospective	O
studies	O
have	O
,	O
however	O
,	O
never	O
been	O
able	O
to	O
confirm	O
these	O
observations	O
.	O
In	O
addition	O
,	O
well-conducted	O
studies	O
using	O
verapamil	SYMP
and	O
diltiazem	SYMP
have	O
suggested	O
that	O
these	O
calcium	SYMP
antagonists	SYMP
may	O
even	O
improve	O
cardiovascular	SYMP
mortality	SYMP
and	SYMP
morbidity	SYMP
of	O
the	O
hypertensive	O
patient	O
.	O
There	O
is	O
therefore	O
no	O
reason	O
to	O
believe	O
that	O
the	O
questionable	O
results	O
derived	O
from	O
retrospective	O
studies	O
of	O
the	O
effects	O
of	O
short-acting	O
calcium	O
antagonists	O
on	O
cardiac	O
and	O
noncardiac	O
events	O
may	O
apply	O
to	O
the	O
newer	O
generation	O
of	O
long-acting	O
calcium	O
antagonists	O
.	O
Sumatriptan	SYMP
and	O
other	O
selective	O
serotonin	SYMP
agonists	SYMP
represent	O
a	O
major	O
breakthrough	O
in	O
acute	SYMP
migraine	SYMP
treatment	O
.	O
These	O
drugs	O
are	O
very	O
efficacious	O
and	O
generally	O
devoided	O
of	O
important	O
side	O
effects	O
,	O
but	O
they	O
are	O
expensive	O
and	O
therefore	O
have	O
to	O
be	O
compared	O
with	O
other	O
,	O
more	O
conventional	O
drugs	O
with	O
established	O
or	O
assumed	O
efficacy	O
.	O
We	O
summarize	O
the	O
pharmacologic	O
characteristics	O
of	O
Sumatriptan	SYMP
and	O
give	O
recommendations	O
about	O
its	O
use	O
in	O
clinical	O
practice	O
.	O
Fiercer	O
competition	O
between	O
athletes	O
and	O
a	O
wider	O
knowledge	O
of	O
optimal	O
training	O
regimens	O
dramatically	O
influence	O
current	O
training	O
methods	O
.	O
A	O
single	O
training	O
bout	O
per	O
day	O
was	O
previously	O
considered	O
sufficient	O
,	O
whereas	O
today	O
athletes	O
regularly	O
train	O
twice	O
a	O
day	O
or	O
more	O
.	O
Consequently	O
,	O
the	O
number	O
of	O
athletes	O
who	O
are	O
overtraining	O
and	O
have	O
insufficient	O
rest	O
is	O
increasing	O
.	O
Positive	O
overtraining	O
can	O
be	O
regarded	O
as	O
a	O
natural	O
process	O
when	O
the	O
end	O
result	O
is	O
adaptation	O
and	O
improved	O
performance	O
:	O
the	O
supercompensation	O
principle	O
--	O
which	O
includes	O
the	O
breakdown	O
process	O
(	O
training	O
)	O
followed	O
by	O
the	O
recovery	O
process	O
(	O
rest	O
)	O
--	O
is	O
well	O
known	O
in	O
sports	O
.	O
However	O
,	O
negative	O
overtraining	O
,	O
causing	O
maladaptation	O
and	O
other	O
negative	O
consequences	O
such	O
as	O
staleness	O
,	O
can	O
occur	O
.	O
Physiological	O
,	O
psychological	O
,	O
biochemical	O
and	O
immunological	O
symptoms	O
must	O
be	O
considered	O
,	O
both	O
independently	O
and	O
together	O
,	O
to	O
fully	O
understand	O
the	O
'staleness	O
'	O
syndrome	O
.	O
However	O
,	O
psychological	O
testing	O
may	O
reveal	O
early-warning	O
signs	O
more	O
readily	O
than	O
the	O
various	O
physiological	O
or	O
immunological	O
markers	O
.	O
The	O
time	O
frame	O
of	O
training	O
and	O
recovery	O
is	O
also	O
important	O
since	O
the	O
consequences	O
of	O
negative	O
overtraining	O
comprise	O
an	O
overtraining-response	O
continuum	O
from	O
short	O
to	O
long	O
term	O
effects	O
.	O
An	O
athlete	O
failing	O
to	O
recover	O
within	O
72	O
hours	O
has	O
presumably	O
negatively	O
overtrained	O
and	O
is	O
in	O
an	O
overreached	O
state	O
.	O
For	O
an	O
elite	O
athlete	O
to	O
refrain	O
from	O
training	O
for	O
greater	O
than	O
72	O
hours	O
is	O
extremely	O
undesirable	O
,	O
highlighting	O
the	O
importance	O
of	O
a	O
carefully	O
monitored	O
recovery	O
process	O
.	O
There	O
are	O
many	O
methods	O
used	O
to	O
measure	O
the	O
training	O
process	O
but	O
few	O
with	O
which	O
to	O
match	O
the	O
recovery	O
process	O
against	O
it	O
.	O
One	O
such	O
framework	O
for	O
this	O
is	O
referred	O
to	O
as	O
the	O
total	O
quality	O
recovery	O
(	O
TQR	O
)	O
process	O
.	O
By	O
using	O
a	O
TQR	O
scale	O
,	O
structured	O
around	O
the	O
scale	O
developed	O
for	O
ratings	O
of	O
perceived	O
exertion	O
(	O
RPE	O
)	O
,	O
the	O
recovery	O
process	O
can	O
be	O
monitored	O
and	O
matched	O
against	O
the	O
breakdown	O
(	O
training	O
)	O
process	O
(	O
TQR	O
versus	O
RPE	O
)	O
.	O
The	O
TQR	O
scale	O
emphasises	O
both	O
the	O
athlete	O
's	O
perception	O
of	O
recovery	O
and	O
the	O
importance	O
of	O
active	O
measures	O
to	O
improve	O
the	O
recovery	O
process	O
.	O
Furthermore	O
,	O
directing	O
attention	O
to	O
psychophysiological	O
cues	O
serves	O
the	O
same	O
purpose	O
as	O
in	O
RPE	O
,	O
i.e	O
.	O
increasing	O
self-awareness	O
.	O
This	O
article	O
reviews	O
and	O
conceptualises	O
the	O
whole	O
overtraining	O
process	O
.	O
In	O
doing	O
so	O
,	O
it	O
(	O
i	O
)	O
aims	O
to	O
differentiate	O
between	O
the	O
types	O
of	O
stress	O
affecting	O
an	O
athlete	O
's	O
performance	O
:	O
(	O
ii	O
)	O
identifies	O
factors	O
influencing	O
an	O
athlete	O
's	O
ability	O
to	O
adapt	O
to	O
physical	O
training	O
:	O
(	O
iii	O
)	O
structures	O
the	O
recovery	O
process	O
.	O
The	O
TQR	O
method	O
to	O
facilitate	O
monitoring	O
of	O
the	O
recovery	O
process	O
is	O
then	O
suggested	O
and	O
a	O
conceptual	O
model	O
that	O
incorporates	O
all	O
of	O
the	O
important	O
parameters	O
for	O
performance	O
gain	O
(	O
adaptation	O
)	O
and	O
loss	O
(	O
maladaptation	O
)	O
.	O
Little	O
attention	O
has	O
been	O
directed	O
toward	O
identifying	O
the	O
changes	O
which	O
occur	O
in	O
salivary	O
composition	O
in	O
response	O
to	O
exercise	O
.	O
To	O
address	O
this	O
,	O
our	O
article	O
first	O
refers	O
to	O
the	O
main	O
aspects	O
of	O
salivary	O
gland	O
physiology	O
.	O
A	O
knowledge	O
of	O
the	O
neural	O
control	O
of	O
salivary	O
secretion	O
is	O
especially	O
important	O
for	O
the	O
understanding	O
of	O
the	O
effects	O
of	O
exertion	O
on	O
salivary	O
secretion	O
.	O
Both	O
salivary	O
output	O
and	O
composition	O
depend	O
on	O
the	O
activity	O
of	O
the	O
autonomic	O
nervous	O
system	O
and	O
any	O
modification	O
of	O
this	O
activity	O
can	O
be	O
observed	O
indirectly	O
by	O
alternations	O
in	O
the	O
salivary	O
excretion	O
.	O
The	O
effects	O
of	O
physical	O
activity	O
(	O
with	O
reference	O
to	O
factors	O
such	O
as	O
exercise	O
intensity	O
and	O
duration	O
,	O
or	O
type	O
of	O
exercise	O
protocol	O
)	O
on	O
salivary	O
composition	O
are	O
then	O
considered	O
.	O
Exercise	O
might	O
indeed	O
induce	O
changes	O
in	O
several	O
salivary	O
components	O
such	O
as	O
immunoglobulins	O
,	O
hormones	O
,	O
lactate	O
,	O
proteins	O
and	O
electrolytes	O
.	O
Saliva	O
composition	O
might	O
therefore	O
be	O
used	O
as	O
an	O
alternative	O
noninvasive	O
indicator	O
of	O
the	O
response	O
of	O
the	O
different	O
body	O
tissues	O
and	O
systems	O
to	O
physical	O
exertion	O
.	O
In	O
this	O
respect	O
,	O
the	O
response	O
of	O
salivary	O
amylase	O
and	O
salivary	O
electrolytes	O
to	O
incremental	O
levels	O
of	O
exercise	O
is	O
of	O
particular	O
interest	O
.	O
Beyond	O
a	O
certain	O
intensity	O
of	O
exercise	O
,	O
and	O
coinciding	O
with	O
the	O
accumulation	O
of	O
blood	O
lactate	O
(	O
anaerobic	O
threshold	O
or	O
AT	O
)	O
,	O
a	O
'saliva	O
threshold	O
'	O
(	O
Tsa	O
)	O
does	O
indeed	O
exist	O
.	O
Tsa	O
is	O
the	O
point	O
during	O
exercise	O
at	O
which	O
the	O
levels	O
of	O
salivary	O
alpha-amylase	O
and	O
electrolytes	O
(	O
especially	O
Na+	O
)	O
also	O
begin	O
to	O
rise	O
above	O
baseline	O
levels	O
.	O
The	O
occurrence	O
of	O
the	O
2	O
thresholds	O
(	O
AT	O
and	O
Tsa	O
)	O
might	O
,	O
in	O
turn	O
,	O
be	O
attributable	O
to	O
the	O
same	O
underlying	O
mechanism	O
,	O
that	O
of	O
increased	O
adrenal	O
sympathetic	O
activity	O
at	O
high	O
exercise	O
intensities	O
.	O
Fat	O
is	O
an	O
extremely	O
important	O
substrate	O
for	O
muscle	O
contraction	O
,	O
both	O
at	O
rest	O
and	O
during	O
exercise	O
.	O
Triglycerides	O
(	O
TGs	O
)	O
,	O
stored	O
in	O
adipose	O
tissue	O
and	O
within	O
muscle	O
fibres	O
,	O
are	O
considered	O
to	O
be	O
the	O
main	O
source	O
of	O
the	O
free	O
fatty	O
acids	O
(	O
FFAs	O
)	O
oxidised	O
during	O
exercise	O
.	O
It	O
is	O
still	O
unclear	O
,	O
however	O
,	O
how	O
the	O
use	O
of	O
these	O
substrates	O
is	O
regulated	O
during	O
exercise	O
.	O
The	O
regulation	O
seems	O
to	O
be	O
multifactorial	O
and	O
includes	O
:	O
(	O
i	O
)	O
dietary	O
and	O
nutritional	O
status	O
;	O
(	O
ii	O
)	O
hormonal	O
milieu	O
;	O
(	O
iii	O
)	O
exercise	O
mode	O
,	O
intensity	O
and	O
duration	O
;	O
and	O
(	O
iv	O
)	O
training	O
status	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
mechanism	O
for	O
FFA	O
transport	O
from	O
its	O
storage	O
as	O
triglycerides	O
in	O
adipose	O
tissue	O
and	O
muscle	O
to	O
its	O
place	O
of	O
utilisation	O
in	O
heart	O
,	O
skeletal	O
muscle	O
,	O
kidney	O
and	O
liver	O
is	O
more	O
clearly	O
understood	O
.	O
It	O
has	O
been	O
determined	O
that	O
the	O
plasma	O
FFA	O
turnover	O
rate	O
is	O
sufficiently	O
rapid	O
to	O
account	O
for	O
most	O
of	O
the	O
fat	O
metabolised	O
during	O
low	O
intensity	O
exercise	O
(	O
25	O
to	O
40	O
%	O
VO2max	O
)	O
.	O
However	O
,	O
an	O
exercise	O
intensity	O
of	O
65	O
%	O
VO2max	O
results	O
in	O
a	O
slight	O
decrease	O
in	O
the	O
amount	O
of	O
plasma	O
FFA	O
uptake	O
by	O
muscle	O
tissue	O
.	O
Other	O
studies	O
have	O
found	O
that	O
during	O
prolonged	O
exercise	O
,	O
muscle	O
TGs	O
become	O
the	O
predominant	O
source	O
of	O
energy	O
obtained	O
from	O
fat	O
.	O
Furthermore	O
,	O
it	O
is	O
widely	O
documented	O
that	O
endurance	O
activities	O
increase	O
the	O
energy	O
utilisation	O
from	O
fat	O
while	O
sparing	O
carbohydrate	O
sources	O
.	O
For	O
example	O
,	O
during	O
exercise	O
on	O
a	O
cycle	O
ergometer	O
,	O
nonplasma	O
FFAs	O
and	O
plasma	O
FFAs	O
contribute	O
40	O
%	O
,	O
and	O
carbohydrates	O
60	O
%	O
,	O
of	O
the	O
total	O
calculated	O
amount	O
of	O
energy	O
expenditure	O
before	O
exercise	O
and	O
vice	O
versa	O
after	O
exercise	O
(	O
60	O
%	O
nonplasma	O
and	O
plasma	O
FFAs	O
and	O
40	O
%	O
carbohydrates	O
)	O
.	O
Although	O
it	O
was	O
many	O
years	O
before	O
it	O
was	O
fully	O
demonstrated	O
,	O
fat	O
is	O
now	O
known	O
to	O
be	O
transported	O
in	O
the	O
blood	O
as	O
FFA	O
bound	O
to	O
the	O
protein	O
carrier	O
albumin	O
.	O
The	O
mobilisation	O
of	O
FFA	O
is	O
primarily	O
a	O
function	O
of	O
sympathetic	O
nervous	O
activity	O
directed	O
towards	O
the	O
adipocytes	O
,	O
or	O
the	O
'fat	O
pad	O
'	O
.	O
This	O
nervous	O
activity	O
can	O
be	O
direct	O
or	O
may	O
be	O
an	O
effect	O
of	O
circulating	O
catecholamines	O
such	O
as	O
adrenaline	O
(	O
epinephrine	O
)	O
.	O
This	O
article	O
summarises	O
the	O
role	O
of	O
fat	O
metabolism	O
during	O
exercise	O
.	O
As	O
the	O
clinical	O
availability	O
of	O
glycohaemoglobin/GHb	O
measurement	O
increases	O
,	O
so	O
does	O
the	O
need	O
for	O
comparable	O
and	O
accurate	O
values	O
among	O
different	O
laboratories	O
and	O
different	O
methods	O
.	O
At	O
least	O
there	O
should	O
be	O
comparability	O
,	O
i.e	O
.	O
,	O
commutability	O
or	O
feasibility	O
of	O
providing	O
comparable	O
results	O
from	O
different	O
assays	O
in	O
different	O
laboratories	O
.	O
A	O
clinical	O
joint	O
study	O
on	O
insulin	SYMP
therapy	SYMP
,	O
a	O
survey	O
of	O
the	O
actual	O
inter-laboratory	O
differences	O
in	O
GHb	O
measurement	O
among	O
41	O
institutions	O
and	O
an	O
assessment	O
of	O
11	O
assay	O
methods	O
for	O
the	O
determination	O
of	O
GHb	O
were	O
performed	O
using	O
commercial	O
calibrators	O
and	O
fresh	O
blood	O
samples	O
.	O
Data	O
on	O
the	O
actual	O
state	O
of	O
inter-laboratory	O
and	O
inter-assay	O
differences	O
of	O
observed	O
values	O
were	O
useful	O
for	O
comparing	O
results	O
among	O
facilities	O
.	O
The	O
recommendation	O
of	O
the	O
Japan	O
Diabetes	O
Society	O
to	O
measure	O
only	O
the	O
stable	O
GHb	O
component	O
and	O
to	O
correct	O
the	O
GHb	O
percentage	O
by	O
two-point	O
calibration	O
with	O
assigned	O
values	O
,	O
was	O
effective	O
but	O
not	O
sufficient	O
.	O
Even	O
after	O
correction	O
,	O
8	O
out	O
of	O
11	O
methods	O
still	O
remained	O
of	O
little	O
practical	O
use	O
because	O
of	O
their	O
large	O
relative	O
errors	O
.	O
Inter-method	O
differences	O
among	O
11	O
available	O
assay	O
methods	O
were	O
great	O
even	O
after	O
correction	O
and	O
depended	O
on	O
not	O
only	O
the	O
methods	O
but	O
the	O
samples	O
used	O
for	O
the	O
determination	O
.	O
The	O
performance	O
of	O
some	O
methods	O
or	O
instruments	O
used	O
are	O
only	O
poor	O
at	O
distinguishing	O
the	O
stable	O
glycated	O
haemoglobin	O
itself	O
.	O
Some	O
alternative	O
measurement	O
system	O
with	O
comparability	O
,	O
commutability	O
and	O
precision	O
should	O
be	O
established	O
.	O
An	O
urgent	O
and	O
worldwide	O
problem	O
to	O
remove	O
inter-laboratory	O
differences	O
in	O
the	O
measurement	O
of	O
GHb	O
needs	O
to	O
be	O
solved	O
.	O
Users	O
in	O
clinical	O
practice	O
must	O
recognize	O
these	O
problems	O
,	O
and	O
,	O
before	O
supply	O
,	O
the	O
providers	O
should	O
check	O
their	O
method	O
and	O
keep	O
records	O
that	O
are	O
readily	O
traceable	O
.	O
A	O
postal	O
survey	O
was	O
performed	O
to	O
determine	O
the	O
current	O
practices	O
and	O
attitudes	O
of	O
radiologists	O
towards	O
the	O
imaging	O
of	O
suspected	O
lower	O
limb	O
deep	SYMP
vein	SYMP
thrombosis	SYMP
(	SYMP
DVT	SYMP
)	SYMP
.	O
One	O
hundred	O
and	O
twenty-seven	O
departments	O
responded	O
to	O
a	O
questionnaire	O
sent	O
in	O
March	O
1996	O
.	O
The	O
results	O
show	O
that	O
87	O
%	O
of	O
hospitals	O
possess	O
colour	O
Doppler	O
ultrasound	O
(	O
CDUS	O
)	O
machines	O
and	O
that	O
46	O
%	O
of	O
departments	O
perform	O
ultrasound	O
as	O
the	O
first	O
line	O
investigation	O
in	O
over	O
90	O
%	O
of	O
cases	O
.	O
Thirty	O
per	O
cent	O
of	O
departments	O
considered	O
calf	O
vein	O
visualization	O
to	O
be	O
generally	O
adequate	O
and	O
34	O
%	O
thought	O
that	O
clinicians	O
in	O
their	O
hospitals	O
invariably	O
anticoagulated	O
patients	O
with	O
isolated	SYMP
calf	SYMP
thrombus	SYMP
.	O
In	O
hospitals	O
where	O
venography	O
was	O
routinely	O
used	O
as	O
the	O
first	O
line	O
investigation	O
,	O
the	O
most	O
common	O
reasons	O
were	O
:	O
the	O
perceived	O
inferiority	O
of	O
ultrasound	O
(	O
US	O
)	O
in	O
demonstrating	O
below-knee	O
clot	SYMP
,	O
its	O
time-consuming	O
nature	O
and	O
the	O
limited	O
access	O
to	O
suitable	O
ultrasound	O
machines	O
.	O
The	O
widespread	O
use	O
of	O
ultrasound	O
is	O
encouraging	O
,	O
however	O
,	O
there	O
are	O
clearly	O
diverse	O
views	O
.	O
A	O
significant	O
minority	O
of	O
departments	O
depend	O
principally	O
upon	O
venography	O
in	O
the	O
diagnosis	O
of	O
DVT	SYMP
.	O
Existential	O
phenomenology	O
and	O
the	O
sociological	O
tradition	O
.	O
Dual	O
leadership	O
in	O
complex	O
organizations	O
.	O
Scientists	O
at	O
major	O
and	O
minor	O
universities	O
:	O
a	O
study	O
of	O
productivity	O
and	O
recognition	O
.	O
Demotion	O
in	O
industrial	O
management	O
.	O
Career	O
anchorage	O
:	O
managerial	O
mobility	O
motivations	O
.	O
Social	O
class	O
and	O
premarital	O
sexual	O
permissiveness	O
:	O
a	O
re-examination	O
.	O
A	O
comment	O
on	O
``	O
anomy	O
''	O
.	O
A	O
factor	O
analytic	O
exploration	O
of	O
the	O
alienation	O
,	O
anomia	O
and	O
authoritarianism	O
domain	O
.	O
Technical	O
note	O
on	O
two	O
rates	O
of	O
mixed	O
marriage	O
.	O
Some	O
comments	O
on	O
awareness	O
.	O
On	O
experimental	O
design	O
.	O
Observations	O
on	O
the	O
incidence	O
of	O
following	O
of	O
visual	O
and	O
auditory	O
stimuli	O
in	O
naive	O
mallard	O
ducklings	O
(	O
Anas	O
platyrhynchos	O
)	O
.	O
The	O
comfort	O
movements	O
of	O
Anatidae	O
.	O
Potential	O
ethological	O
isolating	O
mechanisms	O
and	O
assortative	O
mating	O
in	O
the	O
domestic	O
fowl	O
.	O
An	O
experimental	O
study	O
of	O
conflict	O
and	O
fear	O
:	O
an	O
analysis	O
of	O
behavior	O
of	O
young	O
chicks	O
toward	O
a	O
mealworm	O
.	O
I	O
.	O
The	O
behavior	O
of	O
chicks	O
which	O
do	O
not	O
eat	O
the	O
mealworm	O
.	O
The	O
measuring	O
function	O
of	O
the	O
first	O
legs	O
of	O
Araneus	O
diadematus	O
Cl	O
.	O
The	O
transport	O
of	O
prey	O
by	O
ants	O
.	O
Courtship	O
behaviour	O
in	O
the	O
Drosophila	O
obscura	O
group	O
.	O
II	O
.	O
Comparative	O
studies	O
.	O
Vision	O
versus	O
touch	O
in	O
form	O
discrimination	O
.	O
Short-term	O
retention	O
as	O
a	O
function	O
of	O
method	O
of	O
measurement	O
,	O
recording	O
time	O
,	O
and	O
meaningfulness	O
of	O
the	O
material	O
.	O
The	O
conservation	O
of	O
a	O
shape	O
property	O
and	O
a	O
proposal	O
about	O
the	O
origin	O
of	O
the	O
conservations	O
.	O
Persisting	O
odours	O
as	O
a	O
biasing	O
factor	O
in	O
open-field	O
research	O
with	O
mice	O
.	O
The	O
display	O
of	O
information	O
and	O
the	O
judgment	O
of	O
contingency	O
.	O
Vividness	O
of	O
words	O
and	O
learning	O
to	O
learn	O
in	O
free-recall	O
learning	O
.	O
Genetic	O
study	O
of	O
the	O
memorization	O
of	O
words	O
and	O
pictures	O
Amylase	O
production	O
by	O
Streptomyces	O
species	O
.	O
Physico-chemical	O
studies	O
on	O
the	O
stability	O
of	O
penicillin	SYMP
salts	SYMP
.	O
IV	O
.	O
A	O
statistical	O
evaluation	O
.	O
Studies	O
on	O
nitrogen	O
metabolism	O
of	O
Penicillium	O
chrysogenum	O
Thom	O
.	O
I	O
.	O
Effects	O
of	O
lactose	O
and	O
sucrose	O
additions	O
on	O
nitrogen	O
metabolism	O
.	O
Studies	O
on	O
nitrogen	O
metabolism	O
of	O
Penicillium	O
chrysogenum	O
Thom	O
.	O
II	O
.	O
Amino	O
acid	O
metabolism	O
and	O
its	O
relation	O
to	O
the	O
biosynthesis	O
of	O
penicillin	SYMP
.	O
The	O
contribution	O
of	O
thoracic	SYMP
surgery	SYMP
to	O
our	O
discipline	O
.	O
Research	O
past	O
and	O
present	O
,	O
with	O
particular	O
reference	O
to	O
the	O
application	O
of	O
the	O
techniques	O
of	O
basic	O
science	O
to	O
the	O
problems	O
of	O
adrenal	O
pathology	O
.	O
Some	O
inflammatory	SYMP
disorders	SYMP
of	O
the	O
large	O
intestine	O
.	O
Coexistence	O
of	O
subdural	O
and	O
archnoidal	O
collections	O
of	O
fluid	O
:	O
an	O
unusual	O
case	O
.	O
The	O
scope	O
of	O
sphincterotomy	SYMP
in	O
biliary	SYMP
and	SYMP
pancreatic	SYMP
surgery	SYMP
.	O
Sarcoidosis	SYMP
involving	O
the	O
veriform	O
appendix	O
.	O
``	O
Chronic	SYMP
pancreatitis	SYMP
``	O
and	O
carcinoma	SYMP
of	SYMP
the	SYMP
pancreas	SYMP
.	O
A	O
method	O
to	O
aid	O
correct	O
diagnosis	O
.	O
Control	O
of	O
post-haemorrhoidectomy	SYMP
bleeding	SYMP
with	O
a	SYMP
Foley	SYMP
catheter	SYMP
and	SYMP
a	SYMP
pack	SYMP
.	O
Diagnosis	O
and	O
therapy	O
of	O
chronic	SYMP
aspecific	SYMP
pancreatitis	SYMP
Behavior	O
of	O
the	O
tetanus	SYMP
patient	O
subjected	O
to	O
resuscitation	SYMP
treatment	SYMP
Further	O
data	O
on	O
mediastinal	SYMP
and	SYMP
pulmonary	SYMP
tumors	SYMP
of	O
the	O
child	O
.	O
Review	O
and	O
personal	O
cases	O
Dextran	O
of	O
low	O
molecular	O
weight	O
in	O
peripheral	SYMP
arterial	SYMP
insufficiency	SYMP
Clinico-statistical	O
considerations	O
on	O
vescicular	SYMP
mole	SYMP
On	O
the	O
significance	O
of	O
histologic	O
findings	O
in	O
neoplasms	SYMP
of	O
the	O
trophoblast	O
(	O
case	O
contributions	O
)	O
Diagnostic	O
evaluation	O
of	O
the	O
patient	O
with	O
high	SYMP
blood	SYMP
pressure	SYMP
.	O
Epidemiology	O
of	O
hypertension	SYMP
.	O
Renal	SYMP
vascular	SYMP
hypertension	SYMP
;	O
diagnosis	O
and	O
treatment	O
.	O
The	O
use	O
of	O
radioactive	O
isotopes	O
in	O
the	O
diagnosis	O
of	O
hypertension	SYMP
.	O
The	O
angiogram	O
in	O
the	O
study	O
of	O
hypertension	SYMP
.	O
Guanethidine	O
.	O
Hepatocerebral	SYMP
degeneration	SYMP
(	SYMP
portal	SYMP
systemic	SYMP
encephalopathy	SYMP
)	SYMP
.	O
The	O
relationship	O
to	O
fatty	O
acids	O
.	O
Oviposition	O
and	O
its	O
regulation	O
in	O
the	O
polygynous	O
society	O
of	O
Polistes	O
gallicus	O
L	O
.	O
Interaction	O
of	O
aggressive	O
and	O
sexual	O
behavior	O
in	O
male	O
mice	O
.	O
Conflict	O
and	O
conditioned	O
aversive	O
stimuli	O
in	O
the	O
development	O
of	O
experimental	O
neuroses	O
.	O
Study	O
of	O
the	O
effect	O
of	O
newer	O
analeptic	O
(	O
Micoren	O
)	O
in	O
hypoventilation	O
syndrome	O
.	O
Treatment	O
of	O
a	SYMP
disorder	SYMP
of	SYMP
perception	SYMP
and	SYMP
concept	SYMP
formation	SYMP
in	O
a	O
case	O
of	O
school	O
failure	O
.	O
Rorschach	O
correlates	O
of	O
time	O
estimation	O
.	O
Use	O
of	O
food	O
in	O
child	SYMP
psychotherapy	SYMP
.	O
About	O
genital	O
discharge	O
with	O
special	O
consideration	O
of	O
its	O
cervical	O
manifestation	O
Auto-uro	SYMP
therapy	SYMP
:	O
status	O
and	O
future	O
prospects	O
Clinical	O
experience	O
with	O
the	O
surface	SYMP
anesthetic	SYMP
xylocaine	SYMP
in	O
obstetrics	O
The	O
problem	O
of	O
medicinal	O
management	O
of	O
labor	O
Conglutination	O
of	O
the	O
labia	O
minora	O
The	O
fight	O
against	O
hemolytic	SYMP
disease	SYMP
of	O
the	O
newborn	O
in	O
general	O
practice	O
Long	O
term	O
results	O
in	O
the	O
300	O
most	O
grave	O
cases	O
out	O
of	O
4000	O
hyperthyroid	SYMP
patients	SYMP
treated	O
with	O
iodine	SYMP
I-131	SYMP
at	O
the	O
center	O
of	O
Ancona	O
On	O
socalled	O
nervous	O
exhaustion	O
Examination	O
of	O
neonatal	O
archaic	O
(	O
primitive	O
)	O
reflexes	O
in	O
icterus	SYMP
gravis	SYMP
Urologic	O
complications	O
in	O
non-recurrent	SYMP
cancer	SYMP
of	O
the	O
cervix	O
Prolonged	SYMP
cortisone	SYMP
therapy	SYMP
in	O
treatment	O
of	O
allergic	SYMP
diseases	SYMP
The	O
complexing	O
of	O
calcium	O
by	O
citrate	O
,	O
ortho-	O
and	O
polyphosphates	O
.	O
A	O
method	O
of	O
determining	O
the	O
patency	O
of	O
the	O
nasolacrimal	O
apparatus	O
.	O
Intra-arterial	O
infusion	O
of	O
the	O
head	O
and	O
neck	O
.	O
Anatomic	O
and	O
distributional	O
problems	O
.	O
Lymphatics	O
of	O
the	O
mouth	O
and	O
neck	O
.	O
Effect	O
of	O
sodium	O
ions	O
on	O
the	O
behavior	O
of	O
rest	O
and	O
action	O
potentials	O
of	O
the	O
cell	O
membrane	O
of	O
the	O
rat	O
myometrium	O
Studies	O
on	O
contractile	O
properties	O
of	O
the	O
blood	O
serum	O
Twin	O
pregnancy	O
and	O
fetal	O
and	O
infantile	O
perinatal	SYMP
mortality	SYMP
Fate	O
of	O
the	O
2d	O
twin	O
Differential	O
diagnosis	O
of	O
infectious	SYMP
hepatitis	SYMP
in	O
pregnancy	O
Epithelial	O
metaplasia	SYMP
of	O
the	O
endometrium	O
Leukoplakia	SYMP
of	O
the	O
vaginal	O
portion	O
of	O
the	O
uterus	O
and	O
its	O
clinical	O
evaluation	O
Blood	O
loss	O
in	O
artificial	O
interruption	O
of	O
pregnancy	O
Modified	SYMP
bra	SYMP
in	O
the	O
prevention	O
of	O
mastitis	SYMP
in	O
nursing	O
mothers	O
Hormonal	O
phenomenon	O
after	O
the	O
excision	O
of	O
hydatiform	O
mole	O
Fetal	O
chondrodystrophy	O
Malignant	SYMP
mesodermal	SYMP
mixed	SYMP
tumor	SYMP
of	O
the	O
uterus	O
following	O
irradiation	SYMP
Supportive	O
role	O
of	O
nurse	O
in	O
first	O
stage	O
of	O
labor	O
``	O
can	O
not	O
be	O
emphasized	O
enough	O
''	O
,	O
according	O
to	O
patient	O
.	O
Toxemia	SYMP
of	O
pregnancy	O
.	O
Outpatient	O
care	O
--	O
the	O
role	O
of	O
the	O
nurse	O
.	O
Abandonment	O
:	O
deepest	O
fear	O
of	O
hospitalized	O
children	O
.	O
Support	O
in	O
first	O
stage	O
of	O
labor	O
.	O
The	O
family	O
physician	O
and	O
cervical	SYMP
carcinoma	SYMP
--	O
challenge	O
and	O
opportunity	O
.	O
Purposeful	O
``	O
heroic	O
''	O
heart	O
treatment	O
Skilled	O
workers	O
are	O
vital	O
to	O
maintenance	O
cost	O
cuts	O
.	O
Karen	O
:	O
the	O
other	O
side	O
of	O
the	O
picture	O
.	O
Rhesus	SYMP
haemolytic	SYMP
disease	SYMP
;	O
an	O
approach	O
to	O
prevention	O
.	O
Tumours	SYMP
of	O
the	O
uterus	O
.	O
2	O
.	O
Malignancy	O
.	O
Cancer	SYMP
of	O
the	O
vulva	O
.	O
Effects	O
of	O
smoking	O
on	O
selected	O
clinical	O
obstetric	O
factors	O
.	O
Amniotic	SYMP
fluid	SYMP
embolism	SYMP
.	O
A	O
review	O
of	O
the	O
syndrome	O
with	O
a	O
report	O
of	O
4	O
cases	O
.	O
Chronic	SYMP
histiocytosis	SYMP
X	SYMP
associated	O
with	O
pregnancy	O
.	O
Disseminated	SYMP
lupus	SYMP
erythematosus	SYMP
in	O
pregnancy	O
.	O
Intralesional	SYMP
therapy	SYMP
with	SYMP
betamethasone	SYMP
.	O
Strucutre	O
of	O
the	O
influenza	SYMP
virus	SYMP
2	O
students	O
at	O
Quo	O
Vadis	O
.	O
Double	O
aortic	O
arch	O
associated	O
with	O
tetralogy	O
of	O
Fallot	O
in	O
infants	O
;	O
report	O
of	O
two	O
cases	O
.	O
Tested	O
questionnaires	O
help	O
administration	O
learn	O
if	O
programs	O
are	O
a	O
success	O
,	O
and	O
why	O
.	O
Dumping	SYMP
syndrome	SYMP
following	O
pyloroplasty	SYMP
.	O
Measured	O
subtotal	O
gastrectomy	O
for	O
duodenal	O
ulcer	O
.	O
The	O
lesions	O
in	O
bovine	O
udders	O
shedding	O
nonhemolytic	O
coagulase-negative	O
staphylococci	O
.	O
Repository	O
vitamin	O
B	O
12	O
preparations	O
.	O
Mass	O
spectrometry	O
in	O
structural	O
and	O
stereochemical	O
problems	O
.	O
93	O
.	O
Further	O
observations	O
on	O
the	O
importance	O
of	O
interatomic	O
distance	O
in	O
the	O
McLafferty	O
rearrangement	O
.	O
Synthesis	O
and	O
fragmentation	O
behavior	O
of	O
deuterium-labeled	O
12-keto	O
steroids	O
.	O
Treatment	O
of	O
childhood	SYMP
schizophrenia	SYMP
.	O
A	O
three-year	O
comparison	O
of	O
day	O
and	O
residental	O
treatment	O
.	O
Polycystic	O
ovaries	O
associated	O
with	O
congenital	SYMP
adrenal	SYMP
hyperplasia	SYMP
.	O
Beta-propiolactone	SYMP
as	O
used	O
in	O
sterilization	O
of	O
homografts	O
not	O
carcinogenic	O
for	O
mice	O
.	O
New	O
operations	O
in	O
children	O
's	O
cardiac	O
disease	O
.	O
Effect	O
of	O
diabetes	SYMP
and	O
starvation	O
on	O
myocardial	O
triglyceride	O
and	O
free	O
fatty	O
acid	O
utilization	O
.	O
Effect	O
of	O
epinephrine	O
on	O
myocardial	O
triglyceride	O
and	O
free	O
fatty	O
acid	O
utilization	O
.	O
Diurnal	O
periodicity	O
in	O
the	O
metabolic	O
activity	O
of	O
bone	O
tissue	O
.	O
Fine	O
structure	O
of	O
desmosomes	O
.	O
,	O
hemidesmosomes	O
,	O
and	O
an	O
adepidermal	O
globular	O
layer	O
in	O
developing	O
newt	O
epidermis	O
.	O
Redundant	O
myelin	O
sheaths	O
and	O
other	O
ultrastructural	O
features	O
of	O
the	O
toad	O
cerebellum	O
.	O
A	O
radioautographic	O
study	O
with	O
H3-thymidine	O
on	O
adrenal	O
medulla	O
nuclei	O
of	O
rats	O
intermittently	O
exposed	O
to	O
cold	O
.	O
A	O
fine	O
structural	O
analysis	O
of	O
the	O
epidermis	O
of	O
the	O
earthworm	O
,	O
Lumbricus	O
terrestris	O
L	O
.	O
Effect	O
of	O
thoracic	O
cava	O
obstruction	O
on	O
response	O
of	O
proximal	O
tubule	O
sodium	O
reabsorption	O
to	O
saline	O
infusion	O
.	O
The	O
metabolism	O
of	O
intravenously	O
injected	O
isotopic	O
cholic	O
acid	O
in	O
Laennec	SYMP
's	SYMP
cirrhosis	SYMP
.	O
The	O
origin	O
and	O
glyceride	O
distribution	O
of	O
fatty	O
acids	O
in	O
rat	O
adipose	O
tissue	O
.	O
Absorption	O
of	O
medium	O
and	O
long	O
chain	O
triglycerides	O
:	O
factors	O
influencing	O
their	O
hydrolysis	O
and	O
transport	O
.	O
The	O
effect	O
of	O
epinephrine	O
on	O
immunoreactive	O
insulin	O
levels	O
in	O
man	O
.	O
The	O
role	O
of	O
the	O
liver	O
in	O
serum-induced	O
hypercoagulability	SYMP
.	O
Comparative	O
fates	O
of	O
intravenously	O
and	O
orally	O
administered	O
aldosterone	O
:	O
evidence	O
for	O
extrahepatic	O
formation	O
of	O
acid-hydrolyzable	O
conjugate	O
in	O
man	O
.	O
Binding	O
of	O
sulfobromophthalein	O
(	O
BSP	O
)	O
sodium	O
by	O
plasma	O
albumin	O
.	O
Its	O
role	O
in	O
hepatic	O
BSP	O
extraction	O
.	O
The	O
rationale	O
of	O
extended	SYMP
resection	SYMP
for	O
complicated	SYMP
cancer	SYMP
of	SYMP
the	SYMP
large	SYMP
bowel	SYMP
.	O
Etiology	O
and	O
incidence	O
of	O
renal	SYMP
stones	SYMP
.	O
Diagnosis	O
of	O
stone	SYMP
disease	SYMP
.	O
Medical	SYMP
treatment	SYMP
of	O
stone	SYMP
disease	SYMP
.	O
Surgical	SYMP
treatment	SYMP
of	O
urinary	SYMP
stones	SYMP
.	O
Prevention	O
of	O
stone	SYMP
formation	SYMP
.	O
Urinary	O
calculi	O
.	O
Is	O
the	O
task	O
hopeless	O
?	O
The	O
family	O
medicine	O
program	O
of	O
the	O
University	O
of	O
Miami	O
.	O
Electron	O
microscopic	O
studies	O
of	O
Mycoplasma	O
(	O
PPLO	O
strain	O
880	O
)	O
in	O
artificial	O
medium	O
and	O
in	O
tissue	O
culture	O
.	O
Chemotherapeutic	O
effects	O
on	O
mammalian	SYMP
tumor	SYMP
cells	SYMP
.	O
3	O
.	O
Modification	O
of	O
leukemia	O
L1210	O
growth	O
kinetics	O
with	O
an	O
antimetabolite	O
.	O
Comparison	O
of	O
the	O
sensitivity	O
of	O
normal	O
hematopoietic	O
and	O
transplanted	O
lymphoma	O
colony-forming	O
cells	O
of	O
mice	O
to	O
vinblastine	O
administered	O
in	O
vivo	O
.	O
Evidence	O
for	O
an	O
immunological	O
reaction	O
of	O
the	O
host	O
directed	O
against	O
its	O
own	O
actively	O
growing	O
primary	SYMP
tumor	SYMP
.	O
Hyperbaric	SYMP
oxygen	SYMP
,	SYMP
whole-body	SYMP
X	SYMP
irradiation	SYMP
,	SYMP
and	SYMP
cyclophosphamide	SYMP
combination	SYMP
therapy	SYMP
in	O
mouse	SYMP
leukemia	SYMP
L1210	SYMP
.	O
Clinical	O
staging	O
in	O
cancer	SYMP
of	SYMP
the	SYMP
larynx	SYMP
:	O
a	O
report	O
on	O
788	O
cases	O
using	O
the	O
American	O
Joint	O
Committee	O
's	O
method	O
of	O
stage	O
classification	O
.	O
Comparison	O
of	O
the	O
international	O
and	O
American	O
systems	O
for	O
the	O
staging	O
of	O
breast	SYMP
cancer	SYMP
.	O
Effects	O
of	O
tryptophan	O
mustard	O
on	O
incorporation	O
of	O
amino	O
acids	O
into	O
proteins	O
in	O
tumor-bearing	O
rats	O
.	O
An	O
electron	O
microscope	O
study	O
of	O
plant	SYMP
neoplasia	SYMP
induced	O
by	O
wound	SYMP
tumor	SYMP
virus	SYMP
.	O
Possibilities	O
of	O
surgical	SYMP
correction	SYMP
of	O
malformations	SYMP
of	SYMP
the	SYMP
bones	SYMP
of	SYMP
the	SYMP
foot	SYMP
The	O
postprandial	O
period	O
of	O
the	O
gastrectomized	O
patient	O
.	O
Radiocinematographic	O
and	O
clinical	O
correlation	O
Muscle	O
pathology	O
;	O
contribution	O
of	O
experimentation	O
Origin	O
of	O
milk	O
cholesterol	O
in	O
the	O
rat	O
:	O
dietary	O
versus	O
endogenous	O
sources	O
.	O
Comparative	O
effects	O
of	O
two	O
benzodiazepine	O
compounds	O
on	O
isolated	O
human	O
myometrium	O
.	O
Histochemistry	O
of	O
hydrolytic	O
and	O
oxidative	O
enzymes	O
in	O
the	O
human	O
and	O
experimentally	O
induced	O
adenocarcinoma	SYMP
of	O
the	O
endometrium	O
.	O
Cardiac	O
monitors	O
work	O
--	O
but	O
they	O
should	O
report	O
more	O
than	O
they	O
do	O
.	O
Delivery	O
room	O
pediatrics	O
.	O
The	O
responsibilities	O
of	O
the	O
obstetrician	O
.	O
A	O
pediatrician	O
's	O
checklist	O
for	O
adolescents	O
.	O
Community	O
clinic	O
treatment	O
for	O
back-ward	O
patients	O
.	O
Studies	O
in	O
infantile	SYMP
malnutrition	SYMP
.	O
V	O
.	O
The	O
effect	O
of	O
dietary	O
protein	O
source	O
on	O
serum	O
proteins	O
.	O
Fish	SYMP
protein	SYMP
concentrates	SYMP
in	O
the	O
treatment	O
of	O
kwashiorkor	SYMP
.	O
athyrism	SYMP
in	O
the	O
fetal	O
rat	O
.	O
Evidence	O
for	O
impairment	O
of	O
elastin	O
formation	O
.	O
Familial	SYMP
vitamin	SYMP
D	SYMP
resistant	SYMP
rickets	SYMP
in	O
untreated	O
adult	O
.	O
Bony	O
proliferation	O
of	O
neural	O
arches	O
with	O
cord	O
compression	O
.	O
Amyloidosis	SYMP
of	O
the	O
cornea	O
.	O
Report	O
of	O
a	O
case	O
without	O
conjunctival	O
involvement	O
.	O
Effect	O
of	O
tranquilizing	SYMP
drugs	SYMP
on	O
postnatal	O
behavior	O
.	O
Fathers	O
in	O
the	O
delivery	O
room	O
--	O
an	O
opposition	O
standpoint	O
.	O
Fathers	O
in	O
the	O
delivery	O
--	O
''	O
helpful	O
and	O
supportive	O
''	O
.	O
``	O
Return	O
the	O
joy	O
of	O
home	O
delivery	O
''	O
with	O
fathers	O
in	O
the	O
delivery	O
room	O
.	O
Fathers	O
in	O
the	O
delivery	O
room	O
--	O
long	O
experience	O
molds	O
one	O
viewpoint	O
.	O
Doctors	O
--	O
we	O
need	O
you	O
.	O
Pharmacological	O
blockade	O
of	O
ovulation	O
in	O
the	O
ewe	O
.	O
Some	O
factors	O
affecting	O
the	O
response	O
of	O
the	O
immature	O
mouse	O
to	O
pregnant	O
mare	O
serum	O
gonadotrophin	O
and	O
human	O
chorionic	O
gonadotrophin	O
.	O
The	O
metabolism	O
of	O
cortisol	O
by	O
human	O
extra-hepatic	O
tissues	O
.	O
Aromatization	O
of	O
7-alpha-hydroxydehydroepiandrosterone	O
and	O
of	O
its	O
3-sulphate	O
by	O
ovarian	O
and	O
placental	O
tissue	O
cultures	O
.	O
Metabolic	O
and	O
endocrine	O
effects	O
of	O
lysergic	O
acid	O
diethylamide	O
(	O
LSD-25	O
)	O
on	O
male	O
rats	O
.	O
Mutation	O
frequencies	O
detected	O
following	O
irradiation	SYMP
of	O
virgin	O
and	O
inseminated	O
Drosophila	O
melanogaster	O
females	O
.	O
Relationship	O
of	O
fractons	O
of	O
soybeans	O
and	O
a	O
crystalline	O
soybean	O
trypsin	O
inhibitor	O
to	O
the	O
effects	O
of	O
feeding	O
unheated	O
soybean	O
meal	O
to	O
chicks	O
.	O
Metabolism	O
of	O
polyunsaturated	O
fatty	O
acids	O
and	O
serum	O
cholesterol	O
levels	O
in	O
the	O
rat	O
.	O
Comparison	O
of	O
neutral	O
fat	O
and	O
free	O
fatty	O
acids	O
in	O
high	O
lipid-low	O
carbohydrate	O
diets	O
for	O
the	O
growing	O
chicken	O
.	O
An	O
approach	O
to	O
quantitative	O
analysis	O
of	O
intrauterine	O
pressure	O
data	O
.	O
Intracranial	SYMP
teratomas	SYMP
in	O
fetal	O
life	O
and	O
infancy	O
.	O
Twinning	O
in	O
relation	O
to	O
birth	O
weight	O
,	O
mortality	O
,	O
and	O
congenital	SYMP
anomalies	SYMP
.	O
Breast	O
engorgement	O
and	O
postpartum	SYMP
fever	SYMP
.	O
Evolution	O
of	O
a	O
placenta	O
circumvallata	O
.	O
Sequential	O
estrogen-progestogen	SYMP
therapy	SYMP
in	O
gynecology	O
.	O
Ovarian	SYMP
carcinoma	SYMP
.	O
The	O
problems	O
of	O
staging	O
and	O
grading	O
.	O
Oxytocin	O
induction	O
in	O
pregnant	O
rabbits	O
,	O
with	O
special	O
reference	O
to	O
the	O
stillbirth	O
rate	O
.	O
Significance	O
of	O
a	O
single	O
umbilical	O
artery	O
.	O
Report	O
from	O
the	O
collaborative	O
study	O
of	O
cerebral	O
palsy	O
.	O
Perforated	SYMP
peptic	SYMP
ulcer	SYMP
in	O
pregnancy	O
.	O
Poverty	O
as	O
an	O
isolated	O
factor	O
in	O
relation	O
to	O
perinatal	SYMP
asphyxia	SYMP
.	O
Perforation	SYMP
of	SYMP
the	SYMP
postpartum	SYMP
uterus	SYMP
with	O
an	O
intrauterine	O
contraceptive	O
device	O
.	O
Congenital	SYMP
heart	SYMP
disease	SYMP
,	O
deaf-mutism	SYMP
and	O
associated	SYMP
somatic	SYMP
malformations	SYMP
occurring	O
in	O
several	O
members	O
of	O
one	O
family	O
.	O
Toward	O
a	O
community	O
alcoholism	O
program	O
.	O
Cases	O
8	O
and	O
9	O
.	O
Anesthesia	SYMP
accidents	O
.	O
Gynaecological	O
pain	O
.	O
Profileplasty	SYMP
.	O
Hypertrophic	O
obstructive	O
cardiomyopathy	SYMP
.	O
Oral	SYMP
contraceptives	SYMP
,	O
thrombosis	SYMP
,	O
and	O
cyclical	O
factors	O
affecting	O
veins	O
.	O
On	O
the	O
influence	O
of	O
cytostatic	O
agents	O
and	O
immune	O
bodies	O
on	O
choriocarcinoma	O
cells	O
in	O
tissue	O
culture	O
Fat	O
absorption	O
:	O
a	O
transport	O
problem	O
.	O
Corpora	SYMP
lutea	SYMP
in	O
proven	O
mules	O
.	O
Reconstructive	O
tubal	SYMP
surgery	SYMP
.	O
Studies	O
on	O
the	O
natural	O
posterior	O
pituitary	O
hormones	O
.	O
II	O
On	O
the	O
official	O
inspection	O
of	O
coal-tar	O
dyes	O
in	O
1969	O
.	O
3	O
.	O
Analysis	O
of	O
Cr	O
,	O
Zn	O
,	O
Fe	O
and	O
Pb	O
contaminants	O
in	O
food	O
coal-tar	O
dyes	O
and	O
their	O
aluminium	O
lakes	O
by	O
atomic	O
absorption	O
spectrophotometry	O
Radiosterilization	O
of	O
medical	O
products	O
.	O
I	O
.	O
Effects	O
of	O
radiation	O
on	O
physical	O
and	O
chemical	O
properties	O
of	O
injection	O
needles	O
Screening	O
tests	O
of	O
microorganisms	O
for	O
the	O
microbial	O
transformation	O
of	O
griseophenone	O
A	O
,	O
N-methylcoclaurine	O
and	O
sparteine	O
Gas	O
chromatographic	O
studies	O
on	O
organic	O
mercurials	O
Application	O
of	O
infra-red	O
absorption	O
spectroscopy	O
to	O
examination	O
of	O
drugs	O
and	O
their	O
preparation	O
.	O
XIX	O
.	O
Determination	O
of	O
silicone	O
oil	O
in	O
disposable	O
plastic	O
syringes	O
Observation	O
of	O
air	O
pollution	O
with	O
the	O
aid	O
of	O
continuous	O
analysers	O
.	O
3	O
.	O
Correlation	O
between	O
the	O
concentration	O
of	O
various	O
kinds	O
of	O
pollutants	O
in	O
atmosphere	O
and	O
wind	O
direction	O
and	O
velocity	O
at	O
Kasumigaseki	O
,	O
central	O
district	O
of	O
Tokyo	O
Ultramicro-analysis	O
of	O
cyclohexylamine	O
and	O
low	O
fatty	O
amines	O
by	O
gas	O
chromatography	O
Some	O
knowledges	O
on	O
the	O
potency	O
of	O
heparin	O
fractions	O
obtained	O
by	O
gel	O
filtration	O
On	O
the	O
peripheral	O
effects	O
of	O
endotoxin	O
and	O
leucocyte	O
pyrogen	O
in	O
rabbit	O
A	O
tentative	O
draft	O
of	O
qualitative	O
test	O
of	O
fluoride	O
for	O
adoption	O
to	O
the	O
general	O
tests	O
of	O
eighth	O
revised	O
edition	O
of	O
the	O
Pharmacopoeia	O
of	O
Japan	O
Identification	O
of	O
tranquillizers	SYMP
by	O
thin-layer	O
chromatography	O
Analysis	O
of	O
steroids	O
.	O
II	O
.	O
A	O
note	O
on	O
the	O
assay	O
of	O
corticoid	O
preparations	O
by	O
tetrazolium	O
salt	O
Analysis	O
of	O
steroids	O
.	O
3	O
.	O
Colorimetric	O
assay	O
of	O
thiomesterone	O
Studies	O
on	O
the	O
radioimmunoassay	O
of	O
insulin	SYMP
.	O
I	O
.	O
The	O
production	O
and	O
detection	O
of	O
anti-insulin	O
serum	O
and	O
anti-guinea-pig	O
globulin	O
rabbit	O
serum	O
Synthesis	O
of	O
lysergic	O
acid	O
diethylamide	O
(	O
LSD	O
)	O
Studies	O
on	O
the	O
anti-microbial	O
activity	O
of	O
nonionic	O
and	O
anionic	O
surfactants	O
On	O
the	O
National	O
Institute	O
of	O
Hygienic	O
Sciences	O
Standard	O
``	O
lysozyme	O
standard	O
''	O
On	O
the	O
examination	O
of	O
ginseng	O
and	O
powdered	O
ginseng	O
in	O
1969	O
On	O
the	O
standardization	O
of	O
plastic	SYMP
suture	SYMP
Undergraduate	O
research	O
assistants	O
in	O
the	O
Faculty	O
of	O
Medicine	O
.	O
University	O
College	O
of	O
Rhodesia	O
.	O
Congenital	SYMP
aortic	SYMP
stenosis	SYMP
Sodium	O
in	O
heart	SYMP
failure	SYMP
Potassium	O
in	O
heart	SYMP
failure	SYMP
Hydrogen	O
ion	O
equilibrium	O
in	O
heart	SYMP
failure	SYMP
Various	O
aspects	O
of	O
water-salt	O
metabolism	O
in	O
heart	SYMP
congestive	SYMP
failure	SYMP
Clinical	O
physiopathology	O
of	O
the	O
patency	O
of	O
the	O
interatrial	O
septum	O
Various	O
aspects	O
of	O
diuresis	SYMP
in	O
heart	SYMP
congestive	SYMP
failure	SYMP
Changes	O
in	O
the	O
mechanism	O
of	O
renal	O
acidification	O
in	O
congestive	SYMP
heart	SYMP
failure	SYMP
:	O
effects	O
of	O
diuretic	SYMP
treatment	SYMP
on	O
the	O
acid-base	O
equilibrium	O
Defects	O
of	O
the	O
interventricular	O
septum	O
not	O
associated	O
with	O
other	O
malformations	O
Clinical	O
physiopathology	O
of	O
the	O
patency	O
of	O
Botallo	SYMP
's	SYMP
ductus	SYMP
arteriosus	SYMP
Clinical	O
physiopathology	O
of	O
congenital	SYMP
cyanogenic	SYMP
cardiopathies	SYMP
Electronic	O
computers	O
in	O
medical	O
education	O
of	O
the	O
future	O
.	O
Anesthesiology	O
and	O
computers	O
.	O
Immediate	O
outcome	O
and	O
long-term	O
results	O
of	O
108	O
sphincterotomies	O
of	O
Oddi	O
's	O
sphincter	O
of	O
biliary	O
indication	O
Neuraminic	O
acid-containing	O
oligosaccharides	O
of	O
human	O
urine	O
:	O
isolation	O
and	O
identification	O
of	O
di-N-acetylneuraminyl-3-galactosyl-N-acetylgalactosamine	O
,	O
6-2-Nacetylneuraminyl-lactose	O
,	O
6-2-N-acetylneuraminyl-N-acetyllactosamine	O
and	O
3-2-N-acetylneuraminyl-lactose	O
.	O
Determination	O
of	O
serum	O
oxytocinase	O
(	O
1-cystine-aminopeptidase	O
)	O
activity	O
.	O
Intolerance	O
to	O
milk	O
in	O
ulcerative	SYMP
colitis	SYMP
.	O
A	O
preliminary	O
report	O
.	O
Rhinitis	SYMP
in	O
herds	O
with	O
piglet	SYMP
influenza	SYMP
Research	O
on	O
breeding	O
hygiene	O
in	O
pigs	O
and	O
piglets	O
free	O
from	O
epidemic	SYMP
diseases	SYMP
The	O
stimulatory	O
effect	O
of	O
luteinizing	O
hormone	O
on	O
adenosine	O
3	O
'	O
,	O
5'-monophosphate	O
accumulation	O
in	O
corpus	O
luteum	O
slices	O
.	O
Electrolyte	O
and	O
acid-base	O
balance	O
in	O
fetal	O
and	O
maternal	O
blood	O
.	O
An	O
experimental	O
and	O
a	O
clinical	O
study	O
.	O
Q	SYMP
fever	SYMP
at	O
a	O
combined	O
meat	O
and	O
poultry	O
abattoir	O
.	O
Some	O
functional	O
and	O
morphological	O
alterations	O
occurring	O
during	O
and	O
after	O
the	O
adaptation	O
of	O
BHK	O
21	O
clone	O
13	O
cells	O
to	O
suspension	O
culture	O
.	O
Asbestos	O
as	O
an	O
urban	O
air	O
contaminant	O
.	O
Gas	O
permeability	O
of	O
plastic	O
membranes	O
for	O
artificial	SYMP
lungs	SYMP
.	O
Technoogy	O
,	O
automation	O
and	O
human	O
welfare	O
.	O
A	O
radium	O
accident	O
in	O
a	O
hospital	O
.	O
High	O
energy	O
roentgen	O
ray	O
contamination	O
of	O
the	O
electron	O
beam	O
from	O
a	O
medical	O
betatron	O
.	O
The	O
genetically	O
significant	O
dose	O
from	O
roentgen	O
examinations	O
in	O
Finland	O
in	O
1963	O
.	O
Differential	O
expression	O
of	O
fibroblast	O
growth	O
factor-2	O
and	O
receptor	O
by	O
glial	O
cells	O
in	O
experimental	O
autoimmune	SYMP
encephalomelitis	SYMP
(	SYMP
EAE	SYMP
)	SYMP
Cesarean	O
deliveries	O
at	O
a	O
university	O
hospital	O
:	O
analysis	O
of	O
rates	O
and	O
indications	O
.	O
Increase	O
in	O
ambient	O
temperature	O
may	O
explain	O
decrease	O
in	O
amniotic	O
fluid	O
index	O
.	O
Early	O
treatment	O
of	O
gestational	SYMP
diabetes	SYMP
reduces	O
the	O
rate	O
of	O
fetal	SYMP
macrosomia	SYMP
.	O
Antenatally	O
detectable	O
markers	O
for	O
the	O
diagnosis	O
of	O
autosomally	SYMP
trisomic	SYMP
fetuses	SYMP
in	O
at-risk	O
pregnancies	O
.	O
The	O
rate	O
of	O
severe	O
preeclampsia	SYMP
is	O
increased	O
in	O
triplet	O
as	O
compared	O
to	O
twin	O
gestations	O
.	O
Thermal	O
equipment	O
usage	O
patterns	O
in	O
neonatal	O
intensive	O
care	O
units	O
:	O
interunit	O
variability	O
and	O
intraunit	O
consistency	O
.	O
Massive	O
fetomaternal	SYMP
hemorrhage	SYMP
.	O
Perinatal	O
features	O
of	O
omphalocele-exstrophy-imperforate	SYMP
anus-spinal	SYMP
defects	SYMP
(	SYMP
OEIS	SYMP
complex	SYMP
)	SYMP
associated	O
with	O
large	O
meningomyeloceles	SYMP
and	O
severe	SYMP
limb	SYMP
defects	SYMP
.	O
Subchorial	SYMP
hematoma	SYMP
:	O
a	O
probable	O
cause	O
of	O
reversible	O
nonimmune	O
hydrops	O
fetalis	SYMP
.	O
Pregnancy	O
in	O
chronic	O
progressive	O
external	O
ophthalmoplegia	SYMP
:	O
a	O
case	O
report	O
.	O
Effect	O
of	O
magnesium	O
sulfate	O
on	O
the	O
development	O
of	O
cystic	O
periventricular	O
leukomalacia	SYMP
in	O
preterm	O
infants	O
.	O
Repeated	O
courses	O
of	O
steroids	O
in	O
preterm	O
membrane	O
rupture	O
do	O
not	O
increase	O
the	O
risk	O
of	O
histologic	O
chorioamnionitis	O
.	O
Intrapartum	O
sonography	O
of	O
the	O
lower	O
uterine	O
segment	O
in	O
patients	O
with	O
breech-presenting	O
fetuses	O
.	O
Isolated	O
persistent	O
fetal	O
bradycardia	O
in	O
complete	O
A-V	O
block	O
:	O
a	O
conservative	O
approach	O
is	O
appropriate	O
.	O
A	O
case	O
report	O
and	O
a	O
review	O
of	O
the	O
literature	O
.	O
Spontaneous	O
rectus	SYMP
sheath	SYMP
hematoma	SYMP
during	O
pregnancy	O
mimicking	O
abruptio	SYMP
placenta	SYMP
.	O
Amnioinfusion	SYMP
for	O
prevention	O
of	O
pulmonary	SYMP
hypoplasia	SYMP
in	O
second-trimester	O
rupture	O
of	O
membranes	O
.	O
Trauma	O
and	O
pregnancy	O
.	O
Fetal	O
breathing	O
movements	O
within	O
24	O
hours	O
of	O
delivery	O
in	O
prematurity	O
are	O
related	O
to	O
histologic	O
and	O
clinical	O
evidence	O
of	O
amnionitis	SYMP
.	O
Laerdal	O
infant	O
resuscitators	O
are	O
unreliable	O
as	O
free-flow	O
oxygen	O
delivery	O
devices	O
.	O
Laryngeal	SYMP
obstruction	SYMP
caused	O
by	O
lingual	SYMP
thyroglossal	SYMP
duct	SYMP
cyst	SYMP
presenting	O
at	O
birth	O
.	O
Oligohydramnios	O
and	O
the	O
appropriately	O
grown	O
fetus	O
.	O
Ultrastructure	O
of	O
human	O
colostral	O
cells	O
.	O
Dubowitz	O
assessment	O
of	O
gestational	O
age	O
and	O
agreement	O
with	O
prenatal	O
methods	O
.	O
Low	O
prenatal	O
weight	O
gain	O
among	O
low-income	O
women	O
:	O
what	O
are	O
the	O
risk	O
factors	O
?	O
Depression	SYMP
after	O
childbirth	O
:	O
the	O
views	O
of	O
medical	O
students	O
and	O
women	O
compared	O
.	O
Breastfeeding	O
and	O
the	O
use	O
of	O
pacifiers	O
.	O
Care	O
in	O
normal	O
birth	O
:	O
a	O
practical	O
guide	O
.	O
Technical	O
Working	O
Group	O
,	O
World	O
Health	O
Organization	O
.	O
Cesarean	O
sections	O
:	O
women	O
's	O
choice	O
for	O
giving	O
birth	O
?	O
Epidurals	SYMP
and	O
breastfeeding	O
.	O
Lamaze	O
and	O
Bradley	O
childbirth	O
classes	O
.	O
Concerns	O
about	O
the	O
institutionalization	O
of	O
childbirth	O
education	O
.	O
Index	O
to	O
current	O
literature	O
.	O
A	O
randomized	O
trial	O
of	O
one-to-one	O
nurse	O
support	O
of	O
women	O
in	O
labor	O
.	O
Commentary	O
:	O
are	O
nurses	O
effective	O
providers	O
of	O
labor	O
support	O
?	O
Should	O
they	O
be	O
?	O
Can	O
they	O
be	O
?	O
Women	O
's	O
views	O
of	O
different	O
models	O
of	O
antenatal	O
care	O
in	O
Victoria	O
,	O
Australia	O
.	O
The	O
effect	O
of	O
discharge	O
pack	O
formula	O
and	O
breast	O
pumps	O
on	O
breastfeeding	O
duration	O
and	O
choice	O
of	O
infant	O
feeding	O
method	O
.	O
Commentary	O
:	O
discharge	O
packs	O
:	O
how	O
much	O
do	O
they	O
matter	O
?	O
Quality	O
framework	O
for	O
force	O
plate	O
testing	O
.	O
Bone	O
registration	O
method	O
for	O
robot	SYMP
assisted	SYMP
surgery	SYMP
:	O
pedicle	O
screw	O
insertion	O
.	O
Parameter	O
sensitivity	O
of	O
a	O
mathematical	O
model	O
of	O
the	O
anterior	O
cruciate	O
ligament	O
.	O
Simultaneous	O
measurement	O
of	O
stiffness	O
and	O
energy	O
absorptive	O
properties	O
of	O
articular	O
cartilage	O
and	O
subchondral	O
trabecular	O
bone	O
.	O
Estimation	O
of	O
loads	O
and	O
stresses	O
in	O
abdominal	O
muscles	O
during	O
slow	O
lifts	O
.	O
Contralateral	O
modification	O
of	O
transitory	O
evoked	O
otoacoustic	O
emissions	O
Treatment	O
of	O
cavernous	SYMP
hemangiomas	SYMP
with	O
the	O
neodymium	SYMP
:	SYMP
YAG	SYMP
laser	SYMP
Mucous	SYMP
membrane	SYMP
melanomas	SYMP
of	O
the	O
upper	O
aerodigestive	O
tract	O
.	O
An	O
analysis	O
of	O
34	O
cases	O
Are	O
the	O
products	O
of	O
CD44	O
exons	O
v5	O
and	O
v6	O
markers	O
for	O
metastasis	O
of	O
laryngeal	SYMP
carcinomas	SYMP
?	O
Detection	O
of	O
differentially	O
expressed	O
genes	O
in	O
head-neck	SYMP
carcinomas	SYMP
Tuberculosis	SYMP
of	O
the	O
parotid	O
gland	O
:	O
a	O
rare	O
differential	O
diagnosis	O
of	O
parotid	SYMP
tumor	SYMP
A	O
case	O
of	O
sarcoidosis	SYMP
of	O
the	O
mastoid	O
Genomic	O
medicine	O
.	O
Internet	O
resources	O
for	O
medical	O
genetics	O
.	O
Genetics	O
.	O
A	O
piece	O
of	O
my	O
mind	O
.	O
A	O
'normal	O
'	O
practice	O
.	O
Predisposition	O
genetic	O
testing	O
for	O
late-onset	SYMP
disorders	SYMP
in	O
adults	O
.	O
A	O
position	O
paper	O
of	O
the	O
National	O
Society	O
of	O
Genetic	O
Counselors	O
.	O
Scientists	O
revel	O
in	O
new	O
research	O
tool	O
:	O
an	O
online	O
index	O
of	O
cancer	O
genes	O
.	O
Center	O
for	O
genetic	O
research	O
on	O
scleroderma	SYMP
.	O
As	O
discoveries	O
unfold	O
,	O
a	O
new	O
urgency	O
to	O
bring	O
genetic	O
literacy	O
to	O
physicians	O
.	O
greater	O
than	O
From	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
.	O
Gonorrhea	SYMP
among	O
men	O
who	O
have	O
sex	O
with	O
men	O
--	O
selected	O
sexually	O
transmitted	O
diseases	O
clinics	O
,	O
1993-1996	O
.	O
greater	O
than	O
From	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
.	O
Chlamydia	SYMP
screening	O
practices	O
of	O
primary-care	O
providers	O
--	O
Wake	O
County	O
,	O
North	O
Carolina	O
,	O
1996	O
.	O
Social	O
ties	O
and	O
susceptibility	O
to	O
the	O
common	SYMP
cold	SYMP
.	O
Prevention	O
of	O
bacterial	SYMP
endocarditis	SYMP
:	O
American	O
Heart	O
Association	O
recommendations	O
.	O
Issues	O
regarding	O
antiretroviral	SYMP
treatment	SYMP
for	O
patients	O
with	O
HIV-1	SYMP
infection	SYMP
.	O
Prescribing	O
protease	SYMP
inhibitors	SYMP
for	O
the	O
homeless	O
.	O
Treatment	O
of	O
verruca	SYMP
vulgaris	SYMP
with	O
topical	SYMP
cidofovir	SYMP
.	O
Complete	O
genomic	O
screen	O
in	O
late-onset	O
familial	O
Alzheimer	SYMP
disease	SYMP
.	O
Evidence	O
for	O
a	O
new	O
locus	O
on	O
chromosome	O
12	O
.	O
BRCA1	O
sequence	O
analysis	O
in	O
women	O
at	O
high	O
risk	O
for	O
susceptibility	O
mutations	O
.	O
Risk	O
factor	O
analysis	O
and	O
implications	O
for	O
genetic	O
testing	O
.	O
Characteristics	O
of	O
prostate	SYMP
cancer	SYMP
in	O
families	O
potentially	O
linked	O
to	O
the	O
hereditary	O
prostate	O
cancer	O
1	O
(	O
HPC1	O
)	O
locus	O
.	O
Chromosome	O
19	O
single-locus	O
and	O
multilocus	O
haplotype	O
associations	O
with	O
multiple	SYMP
sclerosis	SYMP
.	O
Evidence	O
of	O
a	O
new	O
susceptibility	O
locus	O
in	O
Caucasian	O
and	O
Chinese	O
patients	O
.	O
Cancer	SYMP
incidence	O
after	O
retinoblastoma	SYMP
.	O
Radiation	O
dose	O
and	O
sarcoma	O
risk	O
.	O
Genetic	O
testing	O
in	O
hereditary	O
colorectal	SYMP
cancer	SYMP
.	O
Molecular	O
neurogenetics	O
:	O
the	O
genome	O
is	O
settling	O
the	O
issue	O
.	O
Family	O
history	O
and	O
genetic	O
risk	O
factors	O
:	O
forward	O
to	O
the	O
future	O
.	O
Preparing	O
health	O
professionals	O
for	O
the	O
genetic	O
revolution	O
.	O
Preterm	O
premature	O
rupture	SYMP
of	SYMP
the	SYMP
membranes	SYMP
associated	O
with	O
recent	O
cocaine	O
use	O
.	O
Attitudes	O
toward	O
health-care	O
,	O
HIV	SYMP
infection	SYMP
,	O
and	O
perinatal	O
transmission	O
interventions	O
in	O
a	O
cohort	O
of	O
inner-city	O
,	O
pregnant	O
women	O
.	O
Association	O
of	O
parvovirus	SYMP
infection	SYMP
with	O
isolated	O
fetal	O
effusions	O
.	O
Early	O
and	O
long-term	O
results	O
of	O
rehabilitation	O
of	O
cochlear	SYMP
implant	SYMP
patients	O
)	O
Principles	O
of	O
signal	O
detection	O
in	O
pharmacovigilance	O
.	O
Homology	O
modeling	O
of	O
adenylosuccinate	O
synthetase	O
from	O
Saccharomyces	O
cerevisiae	O
reveals	O
a	O
possible	O
binding	O
region	O
for	O
single-stranded	O
ARS	O
sequences	O
.	O
Deletion	O
analysis	O
of	O
the	O
p16/CDKN2	O
gene	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	SYMP
using	O
quantitative	O
polymerase	O
chain	O
reaction	O
method	O
.	O
Ribosomal	O
S6	O
kinase	O
p90rsk	O
and	O
mRNA	O
cap-binding	O
protein	O
eIF4E	O
phosphorylations	O
correlate	O
with	O
MAP	O
kinase	O
activation	O
during	O
meiotic	O
reinitiation	O
of	O
mouse	O
oocytes	O
.	O
Hyaluronidase	O
activity	O
of	O
macaque	O
sperm	O
assessed	O
by	O
an	O
in	O
vitro	O
cumulus	O
penetration	O
assay	O
.	O
The	O
comparison	O
of	O
the	O
responsiveness	O
of	O
human	O
isolated	O
internal	O
mammary	O
and	O
gastroepiploic	O
arteries	O
to	O
levcromakalim	O
:	O
an	O
alternative	O
approach	O
to	O
the	O
management	O
of	O
graft	O
spasm	O
.	O
Single-dose	O
pharmacokinetics	O
of	O
felbamate	O
in	O
patients	O
with	O
renal	O
dysfunction	O
.	O
Reporting	O
of	O
adverse	O
drug	O
reactions	O
by	O
hospital	O
doctors	O
and	O
the	O
response	O
to	O
intervention	O
.	O
Glutamate	O
receptors	O
and	O
gene	O
induction	O
:	O
signalling	O
from	O
receptor	O
to	O
nucleus	O
.	O
Role	O
of	O
phosphatidylinositol	O
3-kinase	O
in	O
degranulation	O
induced	O
by	O
IgE-dependent	O
and	O
-independent	O
mechanisms	O
in	O
rat	O
basophilic	O
RBL-2H3	O
(	O
ml	O
)	O
cells	O
.	O
Platelet-derived	O
growth	O
factor	O
activates	O
a	O
mammalian	O
Ste20	O
coupled	O
mitogen-activated	O
protein	O
kinase	O
in	O
airway	O
smooth	O
muscle	O
.	O
Cyclic	O
AMP	O
inhibitors	O
inhibits	O
PDGF-stimulated	O
mitogen-activated	O
protein	O
kinase	O
activity	O
in	O
rat	O
aortic	O
smooth	O
muscle	O
cells	O
via	O
inactivation	O
of	O
c-Raf-1	O
kinase	O
and	O
induction	O
of	O
MAP	O
kinase	O
phosphatase-1	O
.	O
Mitochondrial	O
cytopathies	O
and	O
renal	SYMP
tubular	SYMP
acidosis	SYMP
.	O
Elective	SYMP
surgery	SYMP
for	O
colorectal	SYMP
cancer	SYMP
in	O
the	O
aged	O
:	O
a	O
clinical-economical	O
evaluation	O
.	O
Leukaemia	SYMP
and	O
non-Hodgkin	SYMP
's	SYMP
lymphoma	SYMP
in	O
children	O
and	O
young	O
adults	O
:	O
are	O
prenatal	O
and	O
neonatal	O
factors	O
important	O
determinants	O
of	O
disease	O
?	O
Inverse	O
correlation	O
between	O
loss	O
of	O
heterozygosity	O
of	O
the	O
short	O
arm	O
of	O
chromosome	O
12	O
and	O
p15ink4B/p16ink4	O
gene	O
inactivation	O
in	O
childhood	SYMP
acute	SYMP
lymphoblastic	SYMP
leukaemia	SYMP
.	O
Drug	O
resistance	O
markers	O
:	O
are	O
they	O
bad	O
or	O
good	O
?	O
Elective	SYMP
surgery	SYMP
for	O
gastrointestinal	SYMP
tumours	SYMP
in	O
the	O
elderly	O
.	O
Folate	SYMP
and	O
heart	SYMP
disease	SYMP
:	O
theoretical	O
link	O
needs	O
study	O
.	O
A	O
call	O
for	O
stepped-up	O
melanoma	SYMP
screening	O
.	O
New	O
approaches	O
to	O
stroke	SYMP
require	O
immediate	O
action	O
.	O
The	O
focus	O
is	O
now	O
on	O
standards	O
and	O
privacy	O
in	O
electronic	O
patient	O
records	O
.	O
Osteopathic	O
manifesto	O
.	O
I	O
.	O
Introduction	O
.	O
II	O
.	O
The	O
roots	O
.	O
1981	O
.	O
Treatment	O
uncertainties	O
surround	O
early	O
diagnosis	O
of	O
breast	SYMP
cancer	SYMP
.	O
Depression	SYMP
in	O
the	O
chronically	O
ill	O
needs	O
separate	O
treatment	O
.	O
Medical	O
centers	O
tackle	O
delays	O
,	O
reduce	O
wait	O
times	O
.	O
Epilepsy	O
and	O
attention	O
deficit	O
hyperactivity	O
disorder	O
:	O
is	O
methylphenidate	O
safe	O
and	O
effective	O
?	O
Applying	O
the	O
AIDS	SYMP
paradigm	O
to	O
hepatitis	SYMP
.	O
New	O
asthma	SYMP
guidelines	O
emphasize	O
better	O
diagnosis	O
,	O
stricter	O
control	O
.	O
Osteopathic	O
manifesto	O
.	O
IV	O
.	O
The	O
search	O
.	O
1981	O
.	O
Researchers	O
puzzle	O
over	O
origin	O
of	O
type	O
2	O
diabetes	SYMP
.	O
Ovarian	SYMP
cancer	SYMP
:	O
diagnostic	O
limitations	O
,	O
treatment	O
obstacles	O
.	O
Osteopathic	O
manifesto	O
.	O
V	O
.	O
Legislative	O
and	O
legal	O
vigilance	O
.	O
1981	O
.	O
Osteopathic	O
manifesto	O
.	O
VI	O
.	O
The	O
light	O
of	O
the	O
profession	O
.	O
1981	O
.	O
Electrophysiological	O
evidence	O
on	O
the	O
time	O
course	O
of	O
semantic	O
and	O
phonological	O
processes	O
in	O
speech	O
production	O
.	O
Effects	O
of	O
alanine	O
and	O
glycine	O
substitution	O
for	O
tryptophan	O
on	O
the	O
heterogeneity	O
of	O
gramicidin	O
A	O
analogs	O
in	O
micelles	O
.	O
Torsion-angle	O
molecular	O
dynamics	O
as	O
a	O
new	O
efficient	O
tool	O
for	O
NMR	O
structure	O
calculation	O
.	O
Time-domain	O
quanification	O
of	O
amplitude	O
,	O
chemical	O
shift	O
,	O
apparent	O
relaxation	O
time	O
T2	O
,	O
and	O
phase	O
by	O
wavelet-transform	O
analysis	O
.	O
Application	O
to	O
biomedical	O
magnetic	O
resonance	O
spectroscopy	O
.	O
Investigation	O
of	O
uncertainties	O
in	O
relaxation	O
analysis	O
of	O
2D	O
NOE	O
which	O
arise	O
from	O
spectral	O
noise	O
.	O
An	O
efficient	O
HN	O
(	O
CA	O
)	O
NH	O
pluse	O
scheme	O
for	O
triple-resonance	O
4D	O
correlation	O
of	O
sequential	O
amide	O
protons	O
and	O
nitrogens-15	O
in	O
deuterated	O
proteins	O
.	O
Optimal	O
detection	O
of	O
weak	O
nJ	O
(	O
1H-	O
119Sn	O
)	O
couplings	O
by	O
gradient-enhanced	O
1D	O
and	O
2D	O
heteronuclear	O
multiple-quantum	O
correlation	O
spectroscopy	O
.	O
Application	O
to	O
a	O
novel	O
tin	O
derivative	O
of	O
erythromycin	O
A	O
.	O
Thermoelectric	O
cooling	O
for	O
NMR	O
sample	O
temperature	O
control	O
.	O
H2NCO-E.COSY	O
,	O
a	O
simple	O
method	O
for	O
the	O
sterospecific	O
assignment	O
of	O
side-chain	O
amide	O
protons	O
in	O
proteins	O
.	O
Applying	O
excitation	O
sculpting	O
to	O
construct	O
singly	O
and	O
doubly	O
selective	O
1D	O
NMR	O
experiments	O
.	O
Radiation	O
dosimetry	O
by	O
localized	O
magnetic	O
resonance	O
spectroscopy	O
.	O
The	O
2D	O
NMR	O
experiments	O
H	O
(	O
C	O
)	O
CO2	O
and	O
HCCO2	O
for	O
assignment	O
and	O
pH	O
titration	O
of	O
carboxylate	O
groups	O
in	O
uniformly	O
15N/13C-labeled	O
proteins	O
.	O
Post-acquisition	O
solvent	O
suppression	O
by	O
singular-value	O
decomposition	O
.	O
Osteopathic	O
manifesto	O
.	O
IX	O
.	O
What	O
about	O
our	O
distinctiveness	O
?	O
1981	O
.	O
Preparing	O
for	O
thalidomide	SYMP
's	SYMP
comeback	O
.	O
Heart	SYMP
disease	SYMP
:	O
women	O
's	O
unique	O
risks	O
demand	O
attention	O
.	O
Resolution	O
due	O
in	O
medical	O
software	O
regulation	O
.	O
Osteopathic	O
manifesto	O
.	O
VII	O
.	O
Shadows	O
and	O
images	O
.	O
1981	O
.	O
The	O
practical	O
use	O
of	O
PCR	O
for	O
rapid	O
detection	O
of	O
methicillin	SYMP
resistance	O
among	O
staphylococcal	O
clinical	O
isolates	O
from	O
Turkish	O
hospitals	O
.	O
Randomised	O
double-blind	O
trial	O
of	O
fixed	O
low-dose	O
warfarin	SYMP
with	SYMP
aspirin	SYMP
after	O
myocardial	SYMP
infarction	SYMP
.	O
Coumadin	O
Aspirin	O
Reinfarction	O
Study	O
(	O
CARS	O
)	O
Investigators	O
.	O
Randomised	O
trial	O
of	O
roxithromycin	SYMP
in	O
non-Q-wave	SYMP
coronary	SYMP
syndromes	SYMP
:	O
ROXIS	O
Pilot	O
Study	O
.	O
ROXIS	O
Study	O
Group	O
.	O
Association	O
between	O
5-HT2A	O
gene	O
promoter	O
polymorphism	O
and	O
anorexia	SYMP
nervosa	SYMP
.	O
Randomised	O
study	O
of	O
radical	SYMP
surgery	SYMP
versus	SYMP
radiotherapy	SYMP
for	O
stage	SYMP
Ib-IIa	SYMP
cervical	SYMP
cancer	SYMP
.	O
State	O
regulation	O
in	O
a	O
world	O
of	O
``	O
boundary-less	O
''	O
technology	O
.	O
Screening	O
for	O
Chlamydia	SYMP
trachomatis	SYMP
?	O
Physician-assisted	O
suicide	O
in	O
Oregon	O
.	O
Common	O
nutritional	O
issues	O
in	O
pediatric	O
and	O
adult	O
critical	O
care	O
medicine	O
.	O
A	O
multifactorial	O
analysis	O
of	O
facial	O
nerve	O
results	O
in	O
surgery	O
for	O
cerebellopontine	O
angle	O
tumors	O
.	O
Osteopathic	O
manifesto	O
.	O
VIII	O
.	O
Our	O
distinct	O
image	O
.	O
1981	O
.	O
Quality	O
in	O
general	O
practice	O
.	O
Winning	O
the	O
war	O
on	O
cancer	SYMP
.	O
Clinical	O
problem-solving	O
--	O
where	O
did	O
good	O
old	O
clinical	O
diagnosis	O
go	O
?	O
The	O
named	O
nurse	O
:	O
patient	O
and	O
nurse	O
expectations	O
.	O
Genetic	O
testing	O
opens	O
brave	O
new	O
world	O
.	O
Heterologous	O
vaccines	SYMP
:	O
proponent	O
sparks	O
some	O
interest	O
.	O
Steps	O
still	O
being	O
taken	O
to	O
undo	O
damage	O
of	O
``	O
America	O
's	O
Nuremberg	O
''	O
.	O
Patient-centered	O
ethics	O
reclaiming	O
center	O
stage	O
.	O
Social	O
ties	O
and	O
susceptibility	O
to	O
the	O
common	SYMP
cold	SYMP
.	O
Connecting	O
peptide	O
,	O
correcting	O
peptide	O
?	O
Winning	O
health	O
victories	O
with	O
community	O
commitment	O
.	O
Telemedicine	O
gets	O
a	O
chance	O
to	O
prove	O
itself	O
.	O
Additional	O
opinions	O
on	O
the	O
mortality	O
of	O
animal	O
research	O
.	O
Recurrent	SYMP
strokes	SYMP
in	O
a	O
34-year-old	O
man	O
.	O
A	O
plan	O
for	O
improving	O
outcomes	O
for	O
patients	O
with	O
chronic	SYMP
renal	SYMP
failure	SYMP
.	O
Scientific	O
evidence	O
in	O
family	O
and	O
community	O
medicine	O
Evidence	O
that	O
the	O
expression	O
of	O
progesterone-induced	O
blocking	O
factor	O
by	O
maternal	O
T-lymphocytes	O
is	O
positively	O
correlated	O
with	O
conception	O
.	O
Another	O
use	O
of	O
androgens	SYMP
:	O
treatment	O
of	O
anemia	SYMP
of	SYMP
end-stage	SYMP
renal	SYMP
disease	SYMP
.	O
Isotopic	O
evidence	O
for	O
extraterrestrial	O
non-racemic	O
amino	O
acids	O
in	O
the	O
Murchison	O
meteorite	O
.	O
The	O
American	O
Medical	O
Association	O
Guidelines	O
for	O
Adolescent	O
Preventive	O
Services	O
.	O
Classification	O
of	O
malignant	SYMP
lymphomas	SYMP
:	O
the	O
updated	O
Kiel	O
classification	O
.	O
Rethink	O
on	O
screening	O
for	O
breast	SYMP
cancer	SYMP
.	O
Sports-related	O
ocular	SYMP
injuries	SYMP
.	O
Fruit	O
juice	O
consumption	O
.	O
The	O
case	O
of	O
the	O
missing	O
methylphenidate	SYMP
.	O
Intensive	SYMP
insulin	SYMP
treatment	SYMP
after	O
acute	SYMP
myocardial	SYMP
infarction	SYMP
in	O
diabetes	SYMP
mellitus	SYMP
.	O
Intensive	O
insulin	O
regimens	O
in	O
primary	O
prevention	O
should	O
be	O
assessed	O
.	O
GPs	O
'	O
perceptions	O
of	O
tolerability	O
of	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
and	O
tricyclic	O
antidepressants	SYMP
.	O
Research	O
into	O
long	O
term	O
use	O
is	O
needed	O
.	O
Diagnosing	O
and	O
managing	O
polymyalgia	SYMP
rheumatica	SYMP
and	O
temporal	SYMP
arteritis	SYMP
.	O
Sensitivity	O
of	O
temporal	O
artery	O
biopsy	O
varies	O
with	O
biopsy	O
length	O
and	O
sectioning	O
strategy	O
.	O
Obstructive	O
sleep	SYMP
apnoea	SYMP
.	O
Authors	O
'	O
reply	O
.	O
Impact	O
of	O
postmenopausal	O
hormone	SYMP
therapy	SYMP
on	O
cardiovascular	O
events	O
and	O
cancer	SYMP
.	O
Search	O
for	O
studies	O
was	O
limited	O
.	O
Treating	O
shoulder	O
complaints	O
in	O
general	O
practice	O
.	O
Diagnostic	O
criteria	O
must	O
be	O
used	O
and	O
therapeutic	O
regimens	O
standardised	O
.	O
Authorship	O
.	O
System	O
acknowledging	O
roles	O
of	O
contributors	O
is	O
best	O
.	O
Authorship	O
.	O
New	O
authorship	O
practices	O
are	O
needed	O
in	O
developing	O
countries	O
.	O
Authorship	O
.	O
Researchers	O
'	O
objective	O
is	O
to	O
get	O
the	O
job	O
done	O
.	O
Quality	O
and	O
clinical	O
audit	O
.	O
Transurethral	SYMP
microwave	SYMP
thermotherapy	SYMP
.	O
Management	O
of	O
ileosigmoid	SYMP
knotting	SYMP
.	O
Epitome	O
of	O
myocarditis	SYMP
.	O
Producing	O
consistent	O
estimates	O
of	O
the	O
power	O
spectral	O
density	O
of	O
NN	O
sequences	O
.	O
Environmental	O
tobacco	O
smoke	O
and	O
coronary	SYMP
heart	SYMP
disease	SYMP
.	O
Long-term	O
benefit	O
of	O
one	O
thrombolytic	SYMP
over	O
another	O
.	O
Coupling	O
of	O
hemodynamic	O
measurements	O
with	O
oxygen	O
during	O
exercise	O
does	O
not	O
improve	O
risk	O
stratification	O
in	O
patients	O
with	O
heart	SYMP
failure	SYMP
.	O
Smoking	O
--	O
good	O
or	O
bad	O
for	O
semen	O
?	O
The	O
pruning	O
of	O
Doctor	O
McDonough	O
and	O
the	O
``	O
humanizing	O
''	O
of	O
statistics	O
.	O
Violence	O
.	O
Prevention	O
in	O
the	O
home	O
health	O
setting	O
.	O
Contempo	O
1997	O
:	O
obstetrics	O
and	O
gynecology	O
.	O
Mortality	O
and	O
refusal	O
of	O
ICU	O
admission	O
.	O
Extracorporeal	O
photopheresis	O
in	O
S	O
(	O
c	O
)	O
zary	O
syndrome	O
.	O
Attacks	O
on	O
tobacco	O
industry	O
.	O
Does	O
blinding	O
of	O
readers	O
affect	O
results	O
of	O
meta-analyses	O
?	O
Consumption	O
of	O
alcohol	O
and	O
mortality	O
in	O
Russia	O
.	O
Presenilin	O
polymorphisms	O
in	O
Alzheimer	SYMP
's	SYMP
disease	SYMP
.	O
Autoimmune	SYMP
enteropathy	SYMP
in	O
adults	O
.	O
Cyclosporiasis	SYMP
and	O
raspberries	O
.	O
Protean	O
agonists	O
.	O
Keys	O
to	O
receptor	O
active	O
states	O
?	O
Kinetic	O
models	O
of	O
ion	O
channels	O
.	O
Agonist	O
efficacy	O
and	O
allosteric	O
models	O
of	O
receptor	O
action	O
.	O
Receptor	O
Classification	O
:	O
The	O
Integration	O
of	O
Operational	O
,	O
Structural	O
,	O
and	O
Transductional	O
Information	O
.	O
Conference	O
proceedings	O
.	O
Verona	O
,	O
Italy	O
,	O
September	O
21-22	O
,	O
1995	O
.	O
Policies	O
for	O
posting	O
biomedical	O
journal	O
information	O
on	O
the	O
Internet	O
.	O
International	O
Committee	O
of	O
Medical	O
Journal	O
Editors	O
.	O
Who	O
understands	O
the	O
menopause	O
?	O
Comparison	O
of	O
two	O
methods	O
of	O
screening	O
for	O
genital	O
chlamydial	SYMP
infection	SYMP
in	O
women	O
attending	O
in	O
general	O
practice	O
:	O
cross	O
sectional	O
survey	O
.	O
Antimicrobial	SYMP
therapy	SYMP
in	O
neutropenia	SYMP
M1/4llerian	O
agenesis	O
:	O
an	O
update	O
.	O
The	O
US	O
attack	O
on	O
Cuba	O
's	O
health	O
.	O
Patient	O
consent	O
for	O
publication	O
and	O
the	O
health	O
of	O
the	O
public	O
.	O
Brain	SYMP
serotonin	SYMP
neurotoxicity	SYMP
and	O
primary	SYMP
pulmonary	SYMP
hypertension	SYMP
from	O
fenfluramine	SYMP
and	O
dexfenfluramine	SYMP
.	O
Battling	O
HI	SYMP
on	O
many	O
fronts	O
.	O
Medical	O
Injury	O
Compensation	O
Reform	O
Act	O
:	O
good	O
or	O
bad	O
?	O
Fever	O
of	O
unknown	O
origin	O
.	O
Moxonidine	SYMP
for	O
hypertension	SYMP
.	O
Researchers	O
make	O
slow	O
headway	O
in	O
managing	O
dry	SYMP
mouth	SYMP
.	O
A	O
kinder	O
,	O
gentler	O
approach	O
.	O
Putting	O
patients	O
first	O
?	O
Managing	O
the	O
anxious	O
and	O
phobic	O
dental	O
patient	O
.	O
Do	O
it	O
or	O
lose	O
it	O
.	O
Assessment	O
of	O
fetal	O
nuchal	O
translucency	O
test	O
for	O
Down	SYMP
's	SYMP
syndrome	SYMP
.	O
Amiodarone	SYMP
and	O
thyroid	O
function	O
.	O
Chemotherapy	SYMP
with	SYMP
praziquantel	SYMP
has	O
the	O
potential	O
to	O
reduce	O
the	O
prevalence	O
of	O
Echinococcus	SYMP
multilocularis	SYMP
in	O
wild	O
foxes	O
(	O
Vulpes	O
vulpes	O
)	O
.	O
Death	O
rates	O
from	O
childhood	SYMP
leukaemia	SYMP
near	O
nuclear	O
sites	O
.	O
Other	O
studies	O
showed	O
that	O
radiation	O
levels	O
in	O
Newbury	O
area	O
were	O
low	O
.	O
Haemoptysis	SYMP
:	O
a	O
rare	O
cause	O
.	O
Human	SYMP
papillomavirus	SYMP
types	O
52	O
and	O
58	O
are	O
prevalent	O
in	O
cervical	SYMP
cancer	SYMP
from	O
Chinese	O
women	O
.	O
Breastfeeding	O
after	O
early	O
discharge	O
.	O
Malnutrition	SYMP
and	O
microcephaly	SYMP
in	O
Australian	O
aboriginal	O
children	O
.	O
Probucol	SYMP
and	SYMP
multivitamins	SYMP
in	O
the	O
prevention	O
of	O
restenosis	SYMP
after	O
coronary	O
angioplasty	O
.	O
Generalised	O
caseous	SYMP
lymphadenitis	SYMP
.	O
Public	O
health	O
approach	O
to	O
activated	O
protein	O
C	O
resistance	O
assay	O
.	O
Hormone	SYMP
replacement	SYMP
therapy	SYMP
.	O
Dose-volume	O
histograms	O
can	O
be	O
interpreted	O
in	O
different	O
ways	O
.	O
Addressing	O
needle-stick	O
concerns	O
.	O
Cervical	SYMP
cancer	SYMP
screening	O
.	O
CyberCHEST	O
.	O
An	O
open	O
future	O
.	O
Keeping	O
us	O
on	O
our	O
toes	O
!	O
Thalidomide	O
in	O
oral	O
Crohn	O
's	O
disease	O
refractory	O
to	O
conventional	O
medical	O
treatment	O
.	O
Mortality	O
and	O
length	O
of	O
stay	O
in	O
teaching	O
vs	O
nonteaching	O
hospitals	O
.	O
Early	O
discharge	O
of	O
newborns	O
.	O
Patient	O
consent	O
for	O
publication	O
.	O
Flucticasone	SYMP
propionate	SYMP
is	O
safe	O
in	O
recommended	O
doses	O
Fetal	O
nuchal	O
translucency	O
test	O
for	O
Down	SYMP
's	SYMP
syndrome	SYMP
.	O
Treatment	O
of	O
hypertension	SYMP
in	O
elderly	O
patients	O
.	O
Meta-analyses	O
and	O
large	O
randomized	O
,	O
controlled	O
trials	O
.	O
Low-fat	O
diets	O
.	O
Ultrasonographic	O
evaluation	O
of	O
parathyroid	SYMP
hyperplasia	SYMP
.	O
Misconceptions	O
about	O
mosaicism	SYMP
.	O
Are	O
normal	O
hearing	O
thresholds	O
a	O
sufficient	O
condition	O
for	O
click-evoked	O
otoacoustic	O
emissions	O
?	O
Structure	O
and	O
in	O
vitro	O
substrate	O
specificity	O
of	O
the	O
murine	O
multidrug	O
resistance-associated	O
protein	O
.	O
ATP-dependent	O
transport	O
of	O
lipophilic	O
cytotoxic	O
drugs	O
by	O
membrane	O
vesicles	O
prepared	O
from	O
MRP-overexpressing	O
HL60/ADR	O
cells	O
.	O
Cellular	O
and	O
in	O
vitro	O
transport	O
of	O
glutathione	O
conjugates	O
by	O
MRP	O
.	O
Dominant	O
negative	O
and	O
cooperative	O
effects	O
of	O
mutant	O
forms	O
of	O
prolactin	O
receptor	O
.	O
Effect	O
of	O
calcium	O
and	O
vitamin	O
D	O
supplementation	O
on	O
bone	O
density	O
in	O
men	O
and	O
women	O
65	O
years	O
of	O
age	O
or	O
older	O
.	O
Infection	O
control	O
and	O
contaminated	O
waste	O
disposal	O
practices	O
in	O
Southern	O
Sydney	O
Area	O
Health	O
Service	O
Dental	O
Clinics	O
.	O
Vitamins	O
and	O
minerals	O
:	O
efficacy	O
and	O
safety	O
.	O
Joint	O
Commission	O
on	O
Accreditation	O
of	O
Healthcare	O
Organizations	O
'	O
infection	O
control	O
requirements	O
:	O
fact	O
or	O
fiction	O
?	O
Poppy	O
tea	O
and	O
the	O
baker	O
's	O
first	O
seizure	SYMP
.	O
ABC	O
of	O
mental	O
health	O
.	O
Mental	O
health	O
and	O
the	O
law	O
.	O
Female	O
embryonic	O
lethality	O
in	O
mice	O
nullizygous	O
for	O
both	O
Msh2	O
and	O
p53	O
.	O
Tests	O
of	O
the	O
double-strand	O
break	O
,	O
lethal-potentially	O
lethal	O
and	O
repair-misrepair	O
models	O
for	O
mammalian	O
cell	O
survival	O
using	O
data	O
for	O
survival	O
as	O
a	O
function	O
of	O
delayed-plating	O
interval	O
for	O
log-phase	O
Chinese	O
hamster	O
V79	O
cells	O
.	O
Influence	O
of	O
physician	O
confidentiality	O
assurances	O
on	O
adolescents	O
'	O
willingness	O
to	O
disclose	O
information	O
and	O
seek	O
future	O
health	O
care	O
.	O
A	O
randomized	O
controlled	O
trial	O
.	O
Fever	SYMP
in	O
Africa	O
:	O
do	O
patients	O
know	O
when	O
they	O
are	O
hot	O
?	O
Randomised	O
placebo-controlled	O
trial	O
of	O
granulocyte-colony	SYMP
stimulating	SYMP
factor	SYMP
in	O
diabetic	SYMP
foot	SYMP
infection	SYMP
.	O
Systemic	O
absorption	O
of	O
sunscreen	O
after	O
topical	O
application	O
.	O
A	O
comparison	O
of	O
continuous	SYMP
infusion	SYMP
of	SYMP
alteplase	SYMP
with	SYMP
double-bolus	SYMP
administration	SYMP
for	O
acute	SYMP
myocardial	SYMP
infarction	SYMP
.	O
The	O
Continuous	O
Infusion	O
versus	O
Double-Bolus	O
Administration	O
of	O
Alteplase	O
(	O
COBALT	O
)	O
Investigators	O
.	O
Evaluation	O
and	O
management	O
of	O
traumatic	SYMP
lacerations	SYMP
.	O
Atrial	SYMP
fibrillation	SYMP
begets	O
trouble	O
.	O
Ethics	O
of	O
HIV	O
trials	O
.	O
The	O
ethics	O
industry	O
.	O
Fever	SYMP
in	O
Africa	O
and	O
WHO	O
recommendation	O
.	O
``	SYMP
Whiplash	SYMP
''	SYMP
injury	SYMP
of	O
the	O
cervical	O
spine	O
:	O
value	O
of	O
modern	O
diagnostic	O
imaging	O
Guidelines	O
and	O
cardiac	O
anaesthetists	O
.	O
Antibiotic	SYMP
management	SYMP
of	O
sore	SYMP
throat	SYMP
.	O
Lansoprazole	SYMP
,	O
H.	O
pylori	O
,	O
and	O
atrophic	SYMP
gastritis	SYMP
.	O
Help	O
wanted	O
:	O
ultrasonographers	O
.	O
``	O
Children	O
are	O
not	O
supposed	O
to	O
die	O
.	O
''	O
Combined	O
pediatric	O
and	O
radiation	O
oncology	O
grand	O
rounds	O
addresses	O
severe	O
illness	O
and	O
death	O
.	O
Structure-activity	O
and	O
mechanism	O
studies	O
on	O
silicon	O
phthalocyanines	O
with	O
Plasmodium	O
falciparum	O
in	O
the	O
dark	O
and	O
under	O
red	O
light	O
.	O
The	O
importance	O
of	O
being	O
where	O
?	O
Balancing	O
the	O
perspective	O
on	O
practice	O
coverage	O
.	O
Effects	O
of	O
dobutamine	SYMP
at	O
maximally	O
tolerated	O
dose	O
on	O
myocardial	O
blood	O
flow	O
in	O
humans	O
with	O
ischemic	SYMP
heart	SYMP
disease	SYMP
.	O
Cholesterol-lowering	SYMP
therapy	SYMP
.	O
Ion	O
composition	O
of	O
airway	O
surface	O
liquid	O
of	O
patients	O
with	O
cystic	SYMP
fibrosis	SYMP
as	O
compared	O
with	O
normal	O
and	O
disease-control	O
subjects	O
.	O
Research	O
in	O
Copenhagen	O
hospitals	O
--	O
a	O
bibliometric	O
evaluation	O
More	O
on	O
infertility	SYMP
.	O
Dermatobia	O
--	O
tropical	SYMP
myiasis	SYMP
.	O
Progressive	O
sensorineural	O
hearing	SYMP
loss	SYMP
,	O
subjective	O
tinnitus	SYMP
and	O
vertigo	SYMP
caused	O
by	O
elevated	O
blood	O
lipids	O
.	O
Chronic	O
telogen	SYMP
effluvium	SYMP
:	O
potential	O
complication	O
for	O
clinical	O
trials	O
in	O
female	O
androgenetic	SYMP
alopecia	SYMP
?	O
Measles	SYMP
vaccination	SYMP
and	O
inflammatory	O
bowel	O
disease	O
.	O
Treatment	O
of	O
suicidal	O
patients	O
.	O
The	O
systemic	O
amyloidoses	SYMP
.	O
Cancer	SYMP
therapy	SYMP
and	O
tumor	O
physiology	O
.	O
Mutual	O
relationships	O
based	O
on	O
equality	O
.	O
Specialists	O
and	O
nurses	O
:	O
the	O
pillars	O
of	O
hospital	O
care	O
Disability	O
models	O
in	O
geriatrics	O
:	O
comprehensive	O
rather	O
than	O
competing	O
models	O
should	O
be	O
promoted	O
.	O
Ethical	O
issues	O
in	O
interventional	SYMP
radiology	SYMP
.	O
Taking	O
issue	O
with	O
UK	O
funding	O
priorities	O
.	O
Phototherapeutic	SYMP
keratectomy	SYMP
in	O
recurrent	SYMP
corneal	SYMP
erosions	SYMP
refractory	O
to	O
other	O
forms	O
of	O
treatment	O
.	O
Wegener	SYMP
's	SYMP
granulomatosis	SYMP
from	O
infancy	O
to	O
adolescence	O
.	O
Hormonal	O
responses	O
to	O
restraint	O
in	O
rhesus	O
monkeys	O
.	O
Planned	O
parenthood	O
and	O
artifical	O
selection	O
.	O
Valvular	SYMP
heart	SYMP
disease	SYMP
associated	O
with	O
fenfluramine-phentermine	SYMP
.	O
The	O
role	O
of	O
procedures	O
in	O
family	O
practice	O
:	O
is	O
there	O
a	O
right	O
answer	O
?	O
Arthrodesis	SYMP
of	SYMP
the	SYMP
first	SYMP
metatarsophalangeal	SYMP
joint	SYMP
to	O
salvage	O
failed	SYMP
silicone	SYMP
implant	SYMP
arthroplasty	SYMP
.	O
Methadone	SYMP
maintenance	SYMP
treatment	SYMP
:	O
a	O
Canadian	O
perspective	O
.	O
Survey	O
on	O
rotavirus	SYMP
infections	SYMP
in	O
a	O
German	O
pediatric	O
hospital	O
.	O
Stroke	SYMP
incidence	O
rates	O
among	O
black	O
residents	O
of	O
Harare	O
--	O
a	O
prospective	O
community-based	O
study	O
.	O
Long-term	O
effect	O
of	O
calcium	O
supplementation	O
during	O
pregnancy	O
on	O
the	O
blood	O
pressure	O
of	O
offspring	O
:	O
follow	O
up	O
of	O
a	O
randomised	O
controlled	O
trial	O
.	O
The	O
catalytic	O
role	O
of	O
carbon	O
dioxide	O
in	O
the	O
decomposition	O
of	O
peroxynitrite	O
.	O
Unethical	O
trials	O
of	O
interventions	O
to	O
reduce	O
perinatal	O
transmission	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
in	O
developing	O
countries	O
.	O
Ropinirole	SYMP
for	O
the	O
treatment	O
of	O
early	SYMP
Parkinson	SYMP
's	SYMP
disease	SYMP
.	O
The	O
Ropinirole	O
Study	O
Group	O
.	O
DOTS	O
--	O
are	O
we	O
over-optimistic	O
?	O
Activation	O
at	O
the	O
germinal	O
vesicle	O
stage	O
of	O
starfish	O
oocytes	O
produces	O
parthenogenetic	O
development	O
through	O
the	O
failure	O
of	O
polar	O
body	O
extrusion	O
.	O
Female	O
genital	O
mutilation	O
:	O
a	O
contemporary	O
issue	O
,	O
and	O
a	O
Victorian	O
obsession	O
.	O
Early	O
death	O
amongst	O
anaesthetists	O
.	O
Fluoride	SYMP
treatment	SYMP
increased	O
serum	O
IGF-1	O
,	O
bone	O
turnover	O
,	O
and	O
bone	O
mass	O
,	O
but	O
not	O
bone	O
strength	O
,	O
in	O
rabbits	O
.	O
Retrospective	O
comparison	O
of	O
techniques	O
to	O
prevent	O
secondary	SYMP
cataract	SYMP
formation	SYMP
after	O
posterior	O
chamber	O
intraocular	O
lens	SYMP
implantation	SYMP
in	O
infants	O
and	O
children	O
.	O
Serotonin	O
as	O
a	O
regulator	O
of	O
hypothalamic-pituitary-interrenal	O
activity	O
in	O
teleost	O
fish	O
.	O
Predicting	O
functional	O
appliance	O
treatment	O
outcome	O
in	O
Class	O
II	O
malocclusions	SYMP
--	O
a	O
review	O
.	O
Effect	O
of	O
cereal	O
fibre	O
source	O
and	O
processing	O
on	O
rectal	O
epithelial	O
cell	O
proliferation	O
.	O
Update	O
:	O
influenza	SYMP
activity	O
--	O
worldwide	O
,	O
March-August	O
1997	O
.	O
A	O
drop	O
in	O
pediatric	O
subject	O
examination	O
scores	O
after	O
curriculum	O
changes	O
that	O
emphasize	O
general	O
pediatric	O
topics	O
.	O
Paradigms	O
and	O
the	O
rise	O
(	O
or	O
fall	O
?	O
)	O
of	O
molecular	O
biology	O
.	O
Water	O
fluoridation	O
,	O
tooth	SYMP
decay	SYMP
in	O
5	O
year	O
olds	O
,	O
and	O
social	O
deprivation	O
measured	O
by	O
the	O
Jarman	O
score	O
:	O
analysis	O
of	O
data	O
from	O
British	O
dental	O
surveys	O
.	O
The	O
diabetes	SYMP
audit	O
and	O
research	O
in	O
Tayside	O
Scotland	O
(	O
DARTS	O
)	O
study	O
:	O
electronic	O
record	O
linkage	O
to	O
create	O
a	O
diabetes	O
register	O
.	O
DARTS/MEMO	O
Collaboration	O
.	O
Pharmaceutical	O
industry	O
is	O
invited	O
to	O
respond	O
to	O
amnesty	O
for	O
unreported	O
trials	O
.	O
Should	O
we	O
screen	O
for	O
gestational	SYMP
diabetes	SYMP
?	O
Vesico-uterine	SYMP
fistula	SYMP
--	O
a	O
rare	O
complication	O
of	O
vacuum	SYMP
extraction	SYMP
in	O
a	O
patient	O
with	O
previous	O
caesarean	SYMP
section	SYMP
.	O
Managing	O
endophthalmitis	SYMP
.	O
The	O
plug	O
and	O
patch	O
repair	O
for	O
managing	O
the	O
inguinal	O
hernia	O
of	O
the	O
adult	O
Human	O
herpesvirus	O
8	O
variants	O
in	O
sarcoid	O
tissues	O
.	O
Practice	O
parameters	O
for	O
the	O
assessment	O
and	O
treatment	O
of	O
children	O
and	O
adolescents	O
with	O
schizophrenia	SYMP
.	O
American	O
Academy	O
of	O
Child	O
and	O
Adolescent	O
Psychiatry	O
.	O
Practice	O
parameters	O
for	O
the	O
psychiatric	O
assessment	O
of	O
infants	O
and	O
toddlers	O
(	O
0-36	O
months	O
)	O
.	O
American	O
Academy	O
of	O
Child	O
and	O
Adolescent	O
Psychiatry	O
.	O
Practice	O
parameters	O
for	O
the	O
forensic	O
evaluation	O
of	O
children	O
and	O
adolescents	O
who	O
may	O
have	O
been	O
physically	O
or	O
sexually	O
abused	O
.	O
American	O
Academy	O
of	O
Child	O
and	O
Adolescent	O
Psychiatry	O
.	O
Practice	O
parameters	O
for	O
the	O
psychiatric	O
assessment	O
of	O
children	O
and	O
adolescents	O
.	O
American	O
Academy	O
of	O
Child	O
and	O
Adolescent	O
Psychiatry	O
.	O
Alternative	O
medicine	O
.	O
Leprosy	SYMP
beyond	O
the	O
year	O
2000	O
.	O
Effect	O
of	O
danaparoid	SYMP
sodium	SYMP
on	O
hard	O
exudates	O
in	O
diabetic	SYMP
retinopathy	SYMP
.	O
Lead	O
based	O
paint	O
hazards	O
in	O
early	O
childhood	O
centres	O
in	O
the	O
Wellington	O
region	O
.	O
Gene	O
technology	O
and	O
democracy	O
.	O
Use	O
of	O
statins	SYMP
.	O
Adequacy	O
of	O
SMAC	O
's	O
statement	O
should	O
be	O
judged	O
by	O
clinicians	O
,	O
not	O
health	O
economists	O
.	O
Glasgow	O
has	O
already	O
produced	O
strategy	O
for	O
treatment	O
.	O
Evidence	O
on	O
effectiveness	O
is	O
stronger	O
for	O
statins	SYMP
than	O
for	O
other	O
treatments	O
.	O
Evidence	O
based	O
advertising	O
?	O
Half	O
of	O
drug	O
advertisements	O
in	O
BMJ	O
over	O
six	O
months	O
cited	O
no	O
supporting	O
evidence	O
.	O
Non-steroidal	SYMP
anti-inflammatory	SYMP
therapy	SYMP
for	O
bronchial	SYMP
asthma	SYMP
.	O
Drugs	O
for	O
the	O
Third	O
World	O
.	O
Getting	O
a	O
handle	O
on	O
the	O
molecules	O
that	O
guide	O
axons	O
.	O
The	O
functional	O
neuroanatomy	O
of	O
episodic	O
memory	O
retrieval	O
.	O
Re	O
:	O
``	O
Biologic	O
synergism	O
and	O
parallelism	O
''	O
.	O
Shifting	O
medical	O
education	O
from	O
the	O
icebox	O
to	O
the	O
refrigerator	O
.	O
Reattendance	O
and	O
complications	O
in	O
a	O
randomised	O
trial	O
of	O
prescribing	O
strategies	O
for	O
sore	O
throat	O
:	O
the	O
medicalising	O
effect	O
of	O
prescribing	O
antibiotics	O
.	O
Pure	SYMP
alexia	SYMP
could	O
not	O
be	O
a	O
disconnection	O
syndrome	O
.	O
A	O
randomized	O
,	O
double-blind	O
,	O
dose-response	O
comparison	O
of	O
epidural	SYMP
fentanyl	SYMP
versus	O
sufentanil	SYMP
analgesia	SYMP
after	O
cesarean	SYMP
section	SYMP
.	O
Coronary	O
artery	O
problems	O
during	O
homograft	O
aortic	O
valve	O
replacement	O
:	O
role	O
of	O
transesophageal	O
echocardiography	O
.	O
Spontaneous	O
splenic	SYMP
rupture	SYMP
following	O
administration	O
of	O
granulocyte	SYMP
colony-stimulating	SYMP
factor	SYMP
(	SYMP
G-CSF	SYMP
)	SYMP
:	O
occurrence	O
in	O
an	O
allogeneic	O
donor	O
of	O
peripheral	O
blood	O
stem	O
cells	O
.	O
Evidence-based	O
medicine	O
and	O
general	O
practice	O
.	O
Koch	O
's	O
or	O
Crohn	O
's	O
?	O
Female	O
Stress	O
Urinary	O
Incontinence	O
Clinical	O
Guidelines	O
Panel	O
summary	O
report	O
on	O
surgical	SYMP
management	SYMP
of	O
female	SYMP
stress	SYMP
urinary	SYMP
incontinence	SYMP
.	O
The	O
American	O
Urological	O
Association	O
.	O
Haemodynamic	O
performance	O
of	O
a	O
16-mm	O
Carbomedics	O
aortic	O
prosthesis	O
.	O
Case	O
records	O
of	O
the	O
Massachusetts	O
General	O
Hospital	O
.	O
Weekly	O
clinicopathological	O
exercises	O
.	O
Case	O
30-1997	O
.	O
A	O
preterm	O
newborn	O
female	O
triplet	O
with	O
diffuse	O
cystic	O
changes	O
in	O
the	O
left	O
lung	O
.	O
Cure	O
of	O
Helicobacter	SYMP
pylori	SYMP
infection	SYMP
improves	O
gastric	O
acid	O
secretion	O
in	O
patients	O
with	O
corpus	SYMP
gastritis	SYMP
.	O
Increased	O
incidence	O
of	O
preeclampsia	SYMP
in	O
women	O
conceiving	O
by	O
intrauterine	SYMP
insemination	SYMP
with	SYMP
donor	SYMP
versus	SYMP
partner	SYMP
sperm	SYMP
for	O
treatment	O
of	O
primary	SYMP
infertility	SYMP
.	O
Pediatric	SYMP
cervical	SYMP
spine	SYMP
injury	SYMP
sustained	O
in	O
falls	O
from	O
low	O
heights	O
.	O
Prophylaxis	O
after	O
occupational	O
exposure	O
to	O
HIV	O
.	O
How	O
critical	O
are	O
critical	O
values	O
?	O
Back	O
from	O
the	O
dead	O
:	O
extracorporeal	SYMP
rewarming	SYMP
of	O
severe	SYMP
accidental	SYMP
hypothermia	SYMP
victims	O
in	O
accident	O
and	O
emergency	O
.	O
A	O
classification	O
of	O
nucleotide-diphospho-sugar	O
glycosyltransferases	O
based	O
on	O
amino	O
acid	O
sequence	O
similarities	O
.	O
EU	O
directive	O
on	O
bovine	SYMP
spongiform	SYMP
encephalopathy	SYMP
will	O
not	O
affect	O
drugs	O
.	O
Management	O
of	O
patients	O
with	O
HIV/AIDS	SYMP
.	O
Who	O
should	O
care	O
?	O
Anesthesiology	O
.	O
Second	O
of	O
two	O
parts	O
.	O
Overdrugging	O
and	O
undertreatment	O
in	O
primary	O
health	O
care	O
.	O
Transesophageal	O
echocardiography	O
probe	O
holder	O
.	O
Pregnancy	O
outcomes	O
in	O
women	O
with	O
gestational	SYMP
diabetes	SYMP
compared	O
with	O
the	O
general	O
obstetric	O
population	O
.	O
Confidentiality	O
as	O
a	O
barrier	O
to	O
treatment	O
.	O
Recombinant	O
human	O
DNase	O
(	O
rhDNase	O
)	O
influences	O
phospholipid	O
composition	O
,	O
surface	O
activity	O
,	O
rheology	O
and	O
consecutively	O
clearance	O
indices	O
of	O
cystic	SYMP
fibrosis	SYMP
sputum	O
.	O
Palliative	O
options	O
of	O
last	O
resort	O
:	O
a	O
comparison	O
of	O
voluntarily	O
stopping	O
eating	O
and	O
drinking	O
,	O
terminal	O
sedation	O
,	O
physician-assisted	O
suicide	O
,	O
and	O
voluntary	O
active	O
euthanasia	O
.	O
Automation	O
in	O
cervical	O
cytology	O
:	O
whose	O
cost	O
and	O
whose	O
benefit	O
?	O
Losing	O
weight	O
--	O
an	O
ill-fated	O
New	O
Year	O
's	O
resolution	O
.	O
Lumbar	SYMP
puncture	SYMP
need	O
n't	O
be	O
a	O
headache	O
.	O
Profiting	O
from	O
closure	O
:	O
the	O
private	O
finance	O
initiative	O
and	O
the	O
NHS	O
.	O
Incidence	O
of	O
dog	SYMP
bite	SYMP
injuries	SYMP
treated	O
in	O
emergency	O
departments	O
.	O
Use	O
of	O
rotational	O
movements	O
to	O
remove	O
mandibular	O
molars	O
.	O
Comparison	O
of	O
three	O
methods	O
used	O
for	O
assessment	O
of	O
pain	SYMP
in	O
dogs	O
.	O
Randomised	O
controlled	O
trial	O
of	O
magnetic-resonance	SYMP
pelvimetry	SYMP
in	O
breech	SYMP
presentation	SYMP
at	SYMP
term	SYMP
.	O
Single-breath	O
diffusing	O
capacities	O
for	O
NO	O
,	O
CO	O
and	O
C18O2	O
in	O
rabbits	O
.	O
Improved	O
control	O
will	O
provide	O
better	O
quality	O
.	O
Interview	O
by	O
Tom	O
Heinemann	O
.	O
Case	O
of	O
the	O
month	O
.	O
Autopsy	O
Committee	O
of	O
the	O
College	O
of	O
American	O
Pathologists	O
.	O
Cor	O
pulmonale	O
.	O
Human	O
papillomavirus	O
in	O
the	O
woman	O
with	O
HIV	O
.	O
Reducing	O
risk	O
is	O
best	O
strategy	O
.	O
The	O
realpolitik	O
of	O
a	O
new	O
National	O
Health	O
Service	O
for	O
the	O
UK	O
.	O
What	O
is	O
your	O
diagnosis	O
?	O
Foreign	O
body	O
in	O
the	O
abdomen	O
.	O
Septic	SYMP
arthritis	SYMP
.	O
Brain	SYMP
tumours	SYMP
and	O
mobile	O
phones	O
?	O
Lung	SYMP
cancer	SYMP
,	O
tobacco	O
smoking	O
and	O
environmental	O
factors	O
in	O
Denmark	O
Emergency	O
department	O
use	O
as	O
a	O
component	O
of	O
total	O
ambulatory	O
care	O
:	O
a	O
population	O
perspective	O
.	O
Occupational	SYMP
therapy	SYMP
and	O
outcomes	O
for	O
older	O
adults	O
.	O
Anesthesiology	O
.	O
Low-molecular-weight	O
heparins	O
.	O
Case	O
30-1997	O
:	O
pulmonary	SYMP
interstitial	SYMP
emphysema	SYMP
in	O
infancy	O
.	O
The	O
tobacco	O
settlement	O
.	O
Two	O
actions	O
are	O
possible	O
for	O
doctors	O
wanting	O
to	O
promote	O
human	O
welfare	O
in	O
Africa	O
.	O
Carcinogenesis	O
in	O
transgenic	O
mouse	O
models	O
.	O
Trouble	O
in	O
paradise	O
.	O
Atomic	O
legacy	O
in	O
the	O
Marshall	O
Islands	O
.	O
The	O
road	O
to	O
justice	O
.	O
Solvent	O
solution	O
.	O
Role	O
of	O
free	O
radicals	O
,	O
telomeres	O
,	O
and	O
telomerases	O
in	O
aging	O
and	O
cancerogenesis	O
The	O
effect	O
of	O
ephedrine	O
on	O
the	O
onset	O
time	O
of	O
rocuronium	O
.	O
Antibody	O
class	O
switch	O
recombinase	O
activity	O
is	O
B	O
cell	O
stage	O
specific	O
and	O
functions	O
stochastically	O
in	O
the	O
absence	O
of	O
'targeted	O
accessibility	O
'	O
control	O
.	O
Systematic	O
review	O
of	O
prophylactic	O
vs	O
rescue	O
surfactant	O
.	O
The	O
safety-net	O
role	O
of	O
international	O
medical	O
graduates	O
.	O
The	O
prevalence	O
of	O
chemical	O
substance	O
and	O
alcohol	O
abuse	O
in	O
an	O
obstetric	O
population	O
in	O
Dublin	O
.	O
schizophrenia	SYMP
as	O
failure	O
of	O
hemispheric	O
dominance	O
for	O
language	O
.	O
Late	O
prenatal	O
ultrasound	O
features	O
of	O
hydrometrocolpos	O
secondary	O
to	O
cloacal	SYMP
anomaly	SYMP
:	O
case	O
reports	O
and	O
review	O
of	O
the	O
literature	O
.	O
Familial	O
and	O
primary	O
(	O
AL	O
)	O
cardiac	SYMP
amyloidosis	SYMP
:	O
echocardiographically	O
similar	O
diseases	O
with	O
distinctly	O
different	O
clinical	O
outcomes	O
.	O
Diabetic	O
retinopathy	O
,	O
promoter	O
(	O
4G/5G	O
)	O
polymorphism	O
of	O
PAI-1	O
gene	O
,	O
and	O
PAI-1	O
activity	O
in	O
Pima	O
Indians	O
with	O
type	O
2	O
diabetes	SYMP
.	O
Evaluation	O
of	O
diagnostic	O
peritoneal	O
lavage	O
in	O
stable	O
patients	O
with	O
gunshot	SYMP
wounds	SYMP
to	O
the	O
abdomen	O
.	O
Cerebral	SYMP
abscesses	SYMP
in	O
a	O
patient	O
with	O
AIDS	SYMP
caused	O
by	O
methicillin-resistant	O
Staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
A	O
randomised	O
comparison	O
of	O
the	O
EuroQol	O
and	O
Short	O
Form-36	O
after	O
stroke	SYMP
.	O
United	O
Kingdom	O
collaborators	O
in	O
the	O
International	O
Stroke	O
Trial	O
.	O
Clinical	O
significance	O
of	O
Blastocystis	SYMP
hominis	SYMP
infection	SYMP
:	O
epidemiologic	O
study	O
Karolinska	O
Institute	O
rocked	O
by	O
research	O
misconduct	O
.	O
Hepatic	O
glutamine	O
synthetase	O
deficiency	O
in	O
fatal	O
hyperammonemia	O
after	O
lung	O
transplantation	O
.	O
Where	O
next	O
in	O
the	O
treatment	O
of	O
rectal	SYMP
cancer	SYMP
?	O
GAPS	O
(	O
AMA	O
Guidelines	O
for	O
Adolescent	O
Preventive	O
Services	O
)	O
Protocols	O
for	O
wound	O
management	O
.	O
Chronic	O
leg	SYMP
ulcers	SYMP
:	O
beware	O
the	O
'wolf	O
in	O
sheep	O
's	O
clothing	O
!	O
'	O
.	O
Role	O
of	O
fine	SYMP
needle	SYMP
aspiration	SYMP
cytology	SYMP
in	O
the	O
management	O
of	O
the	O
discrete	SYMP
parotid	SYMP
lump	SYMP
.	O
More	O
than	O
20	O
years	O
second-look	O
surgery	SYMP
in	O
advanced	SYMP
epithelial	SYMP
ovarian	SYMP
cancer	SYMP
:	O
what	O
did	O
we	O
learn	O
?	O
Evaluating	O
prostate	SYMP
needle	SYMP
biopsy	SYMP
:	O
therapeutic	O
and	O
prognostic	O
importance	O
.	O
Sudden	O
cryptococcal	SYMP
deafness	SYMP
.	O
Methicillin-resistant	O
Staphylococcus	O
aureus	O
clinical	O
strain	O
with	O
reduced	O
vancomycin	SYMP
susceptibility	O
.	O
HIV	O
and	O
AIDS	SYMP
awareness	O
:	O
an	O
evaluation	O
of	O
a	O
short	O
training	O
programme	O
for	O
midwives	O
.	O
What	O
investigations	O
and	O
procedures	O
do	O
patients	O
in	O
hospices	O
want	O
?	O
Interview	O
based	O
survey	O
of	O
patients	O
and	O
their	O
nurses	O
.	O
Occupational	O
asthma	SYMP
due	O
to	O
porcine	O
pancreatic	O
amylase	O
.	O
Double-blind	O
study	O
of	O
pulsing	SYMP
magnetic	SYMP
field	SYMP
effects	O
on	O
multiple	SYMP
sclerosis	SYMP
.	O
CDA	O
opposes	O
proposed	O
HBV	O
recommendations	O
.	O
The	O
influence	O
of	O
allergy	SYMP
and	O
smoking	O
on	O
the	O
sulphation	O
of	O
nasal	O
mucins	O
.	O
Clinical	O
problem-solving	O
.	O
A	O
hidden	O
agenda	O
.	O
A	O
comparison	O
of	O
the	O
early	O
outcome	O
of	O
acute	O
myocardial	SYMP
infarction	SYMP
in	O
women	O
and	O
men	O
.	O
The	O
Third	O
International	O
Study	O
of	O
Infarct	O
Survival	O
Collaborative	O
Group	O
.	O
Management	O
of	O
life-threatening	O
acid-base	SYMP
disorders	SYMP
.	O
Second	O
of	O
two	O
parts	O
.	O
Freeze-dried	O
cortical	O
allograft	O
in	O
posterior	O
spinal	O
arthrodesis	O
:	O
use	O
with	O
segmental	O
instrumentation	O
for	O
idiopathic	O
adolescent	O
scoliosis	O
.	O
Removal	O
of	O
a	O
broken	O
solid-core	O
intramedullary	O
femoral	O
nail	O
using	O
both	O
antegrade	O
and	O
retrograde	O
starting	O
points	O
.	O
Do	O
no	O
harm	O
.	O
Thalidomide	SYMP
,	O
laser	O
cavity	O
preparation	O
and	O
oral	O
hydrogen	O
peroxide	O
.	O
Emergency	O
!	O
Meningococcal	SYMP
disease	SYMP
.	O
First	O
the	O
bad	O
news	O
...	O
.	O
Does	O
hyperglycemia	SYMP
really	O
cause	O
coronary	SYMP
heart	SYMP
disease	SYMP
?	O
Diagnosis	O
and	O
therapy	O
of	O
primary	O
stomach	SYMP
lymphoma	SYMP
.	O
Consensus	O
of	O
the	O
Surgical	O
Working	O
Group	O
for	O
Oncology	O
,	O
the	O
Working	O
Group	O
for	O
Medical	O
Oncology	O
and	O
the	O
Working	O
Group	O
for	O
Radiologic	O
Oncology	O
Rate	O
of	O
RhD	O
sensitisation	O
before	O
and	O
after	O
implementation	O
of	O
a	O
community	O
based	O
antenatal	O
prophylaxis	O
programme	O
.	O
Ovine	SYMP
Johne	SYMP
's	SYMP
disease	SYMP
.	O
Effect	O
of	O
HAART	O
on	O
natural	O
history	O
of	O
AIDS-related	SYMP
opportunistic	SYMP
disorders	SYMP
.	O
Psoas	SYMP
abscess	SYMP
.	O
Diagnosed	O
if	O
suspected	O
.	O
Breastfeeding	O
and	O
catch-up	O
growth	O
in	O
infants	O
born	O
small	O
for	O
gestational	O
age	O
.	O
Health	O
practices	O
of	O
critical	O
care	O
nurses	O
:	O
are	O
these	O
nurses	O
good	O
role	O
models	O
for	O
patients	O
?	O
Testing	O
for	O
Helicobacter	SYMP
pylori	SYMP
infection	SYMP
after	O
antibiotic	SYMP
treatment	SYMP
.	O
Bullous	O
eruption	O
in	O
a	O
patient	O
with	O
systemic	SYMP
lupus	SYMP
erythematosus	SYMP
:	O
mite	SYMP
dermatitis	SYMP
caused	O
by	O
Cheyletiella	O
blakei	O
.	O
A	O
case-control	O
study	O
of	O
cytochrome	O
P450	O
1A1	O
,	O
glutathione	O
S-transferase	O
M1	O
,	O
cigarette	O
smoking	O
and	O
lung	O
cancer	O
susceptibility	O
(	O
Massachusetts	O
,	O
United	O
States	O
)	O
Association	O
between	O
thrombolytic	SYMP
treatment	SYMP
and	O
the	O
prognosis	O
of	O
hemodynamically	O
stable	O
patients	O
with	O
major	SYMP
pulmonary	SYMP
embolism	SYMP
:	O
results	O
of	O
a	O
multicenter	O
registry	O
.	O
Metastatic	SYMP
malignant	SYMP
mesothelioma	SYMP
presenting	O
as	O
colonic	O
polyps	O
.	O
Microelectrode-guided	SYMP
posteroventral	SYMP
pallidotomy	SYMP
for	O
treatment	O
of	O
Parkinson	SYMP
's	SYMP
disease	SYMP
:	O
postoperative	O
magnetic	O
resonance	O
imaging	O
analysis	O
.	O
A	O
positive	O
cannabinoids	O
workplace	O
drug	O
test	O
following	O
the	O
ingestion	O
of	O
commercially	O
available	O
hemp	O
seed	O
oil	O
.	O
Congenital	SYMP
diaphragmatic	SYMP
hernia	SYMP
:	O
what	O
happens	O
after	O
discharge	O
?	O
Goldilocks	O
and	O
Mrs	O
.	O
Ilych	O
:	O
a	O
critical	O
look	O
at	O
the	O
``	O
philosophy	O
of	O
hospice	O
''	O
.	O
Sensitivity	O
and	O
specificity	O
of	O
the	O
neonatal	O
brain-stem	O
auditory	O
evoked	O
potential	O
for	O
hearing	O
and	O
language	O
deficits	O
in	O
survivors	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
.	O
The	O
Federated	O
Council	O
of	O
Internal	O
Medicine	O
's	O
resource	O
guide	O
for	O
residency	O
education	O
:	O
an	O
instrument	O
for	O
curricular	O
change	O
.	O
A	O
reluctant	O
doctor	O
shopper	O
.	O
Frequent	O
users	O
of	O
emergency	O
services	O
Localized	O
Darier	SYMP
disease	SYMP
.	O
Implications	O
for	O
genetic	O
studies	O
.	O
Follow	O
up	O
after	O
potential	O
curative	O
surgery	SYMP
of	O
colorectal	SYMP
cancer	SYMP
.	O
Guidelines	O
from	O
the	O
Norwegian	O
Gastrointestinal	O
Cancer	O
Group	O
The	O
prison	O
patient	O
.	O
Fulminant	O
hepatic	SYMP
failure	SYMP
in	O
murine	SYMP
hepatitis	SYMP
virus	SYMP
strain	SYMP
3	SYMP
infection	SYMP
:	O
tissue-specific	O
expression	O
of	O
a	O
novel	O
fgl2	O
prothrombinase	O
.	O
Lung	SYMP
volume	SYMP
reduction	SYMP
surgery	SYMP
for	O
emphysema	SYMP
.	O
The	O
use	O
and	O
effects	O
of	O
postcoital	O
contraception	O
Vancomycin-resistant	O
Staphylococcus	O
aureus	O
:	O
apocalypse	O
now	O
?	O
Reflex	SYMP
sympathetic	SYMP
dystrophy	SYMP
:	O
fact	O
and	O
fiction	O
.	O
Acute	SYMP
hydrocephalus	SYMP
and	O
brain	SYMP
abscess	SYMP
in	O
Listeria	SYMP
monocytogenes	SYMP
meningitis	SYMP
Antisense	O
suppression	O
of	O
4-coumarate	O
:	O
coenzyme	O
A	O
ligase	O
activity	O
in	O
Arabidopsis	O
leads	O
to	O
altered	O
lignin	O
subunit	O
composition	O
.	O
Alopecia	O
as	O
a	O
consequence	O
of	O
tacrolimus	O
therapy	O
in	O
renal	O
transplantation	O
?	O
Implementation	O
of	O
pharmaceutical	O
practice	O
guidelines	O
.	O
In	O
vitro	O
interactions	O
of	O
oxidatively	O
modified	O
LDL	O
with	O
type	O
I	O
,	O
II	O
,	O
III	O
,	O
IV	O
,	O
and	O
V	O
collagen	O
,	O
laminin	O
,	O
fibronectin	O
,	O
and	O
poly-D-lysine	O
.	O
Factors	O
influencing	O
blood	O
flow	O
in	O
the	O
optic	O
nerve	O
head	O
.	O
Mutations	O
of	O
the	O
Drosophila	O
dDP	O
,	O
dE2F	O
,	O
and	O
cyclin	O
E	O
genes	O
reveal	O
distinct	O
roles	O
for	O
the	O
E2F-DP	O
transcription	O
factor	O
and	O
cyclin	O
E	O
during	O
the	O
G1-S	O
transition	O
.	O
SYT-SSX	O
gene	O
fusion	O
as	O
a	O
determinant	O
of	O
morphology	O
and	O
prognosis	O
in	O
synovial	O
sarcoma	O
.	O
A	O
rapid	O
molecular	O
method	O
(	O
polymerase	O
chain	O
reaction	O
with	O
sequence-specific	O
primers	O
)	O
to	O
genotype	O
for	O
ABO	O
blood	O
group	O
and	O
secretor	O
status	O
and	O
its	O
potential	O
for	O
organ	SYMP
transplants	SYMP
.	O
A	O
population-based	O
registry	O
on	O
paraproteinaemia	SYMP
in	O
The	O
Netherlands	O
.	O
Comprehensive	O
Cancer	O
Centre	O
West	O
,	O
Leiden	O
,	O
The	O
Netherlands	O
.	O
Intra-	O
and	O
inter-individual	O
biological	O
variability	O
data	O
bank	O
.	O
Genetic	O
testing	O
for	O
cancer	SYMP
risk	O
:	O
how	O
to	O
reconcile	O
the	O
conflicts	O
.	O
Run-in	O
periods	O
in	O
randomized	O
trials	O
:	O
implications	O
for	O
the	O
application	O
of	O
results	O
in	O
clinical	O
practice	O
.	O
Rapid	O
and	O
ultrarapid	O
opioid	SYMP
detoxification	SYMP
techniques	O
.	O
Fulminant	O
hepatitis	SYMP
associated	O
with	O
hepatitis	SYMP
A	SYMP
virus	SYMP
superinfection	SYMP
in	O
patients	O
with	O
chronic	O
hepatitis	SYMP
C	SYMP
.	O
The	O
Overactive	SYMP
Bladder	SYMP
:	O
From	O
Basic	O
Science	O
to	O
Clinical	O
Management	O
Consensus	O
Conference	O
.	O
Proceedings	O
.	O
London	O
,	O
England	O
,	O
June	O
29	O
,	O
1997	O
.	O
Techniques	O
for	O
erbium	SYMP
:	SYMP
YAG	SYMP
laser	SYMP
skin	SYMP
resurfacing	SYMP
:	O
initial	O
pearls	O
from	O
the	O
first	O
100	O
patients	O
.	O
Predicting	O
changes	O
in	O
the	O
distribution	O
of	O
sweating	SYMP
following	O
thoracoscopic	SYMP
sympathectomy	SYMP
.	O
The	O
AACC	O
Lectureship	O
Award	O
Address	O
.	O
The	O
market	O
for	O
health	O
care	O
:	O
where	O
is	O
the	O
patient	O
?	O
Human	O
fetal	O
pituitary	O
expresses	O
functional	O
growth	O
hormone-releasing	O
peptide	O
receptors	O
.	O
The	O
Bizarro	O
world	O
of	O
osteodistraction	SYMP
.	O
A	O
piece	O
of	O
my	O
mind	O
.	O
Leaders	O
or	O
lemmings	O
?	O
Sales	O
of	O
food	O
aid	O
as	O
sign	O
of	O
distress	O
,	O
not	O
excess	O
.	O
Gastrointestinal	O
absorption	O
of	O
metals	O
.	O
Embryonic	O
stem	O
cells	O
and	O
hematopoietic	O
stem	O
cell	O
biology	O
.	O
Shark	SYMP
cartilage	SYMP
for	O
cancer	SYMP
?	O
The	O
role	O
of	O
the	O
school	O
in	O
the	O
management	O
of	O
attention	SYMP
deficit	SYMP
hyperactivity	SYMP
disorder	SYMP
.	O
Photorepair	O
mutants	O
of	O
Arabidopsis	O
.	O
Toxic	SYMP
shock	SYMP
syndrome	SYMP
without	O
rash	SYMP
in	O
a	O
young	O
child	O
:	O
link	O
with	O
syndrome	O
of	O
hemorrhagic	SYMP
shock	SYMP
and	O
encephalopathy	SYMP
?	O
Mediastinal	O
growing	O
teratoma	SYMP
syndrome	SYMP
.	O
Structure	O
and	O
expression	O
of	O
the	O
chicken	O
calmodulin	O
I	O
gene	O
.	O
Fibromyalgia	SYMP
--	O
out	O
of	O
control	O
?	O
Fibromyalgia	SYMP
:	O
La	O
Maladie	O
est	O
Morte	O
.	O
Vive	O
le	O
Malade	O
!	O
Electron	O
beam	O
computed	O
tomographic	O
coronary	O
calcium	O
as	O
a	O
predictor	O
of	O
coronary	O
events	O
:	O
comparison	O
of	O
two	O
protocols	O
.	O
The	O
ethics	O
of	O
genetic	O
research	O
on	O
sexual	O
orientation	O
.	O
Testicular	SYMP
sperm	SYMP
retrieval	SYMP
by	SYMP
percutaneous	SYMP
fine	SYMP
needle	SYMP
sperm	SYMP
aspiration	SYMP
compared	O
with	O
testicular	SYMP
sperm	SYMP
extraction	SYMP
by	SYMP
open	SYMP
biopsy	SYMP
in	O
men	O
with	O
non-obstructive	SYMP
azoospermia	SYMP
.	O
Cyclin	O
D1	O
overexpression	O
in	O
malignant	SYMP
lymphomas	SYMP
.	O
Patient	O
safety	O
and	O
scented	O
pediatric	O
anesthesia	O
facemasks	O
.	O
Ion	O
channels	O
.	O
SHARPs	O
:	O
mammalian	O
enhancer-of-split-	O
and	O
hairy-related	O
proteins	O
coupled	O
to	O
neuronal	O
stimulation	O
.	O
Complementary	O
and	O
alternative	O
medicine	O
:	O
friend	O
,	O
foe	O
,	O
or	O
OWA	O
?	O
Ondansetron	SYMP
is	O
not	O
a	O
panacea	O
Masking	O
,	O
blinding	O
,	O
and	O
peer	O
review	O
:	O
the	O
blind	O
leading	O
the	O
blinded	O
.	O
Human	O
cervico-facial	O
morphogenesis	O
.	O
Evaluation	O
of	O
acquired	O
data	O
and	O
current	O
outlook	O
.	O
(	O
Part	O
1	O
:	O
facial	O
morphogenesis	O
)	O
The	O
effect	O
of	O
TRK-530	SYMP
on	O
experimental	O
arthritis	SYMP
in	O
mice	O
.	O
Spontaneous	O
exfoliation	O
of	O
teeth	O
following	O
severe	O
elemental	O
mercury	SYMP
poisoning	SYMP
:	O
case	O
report	O
and	O
histological	O
investigation	O
for	O
mechanism	O
.	O
Small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
can	O
express	O
CD34	O
antigen	O
.	O
X	O
inactivation	O
in	O
females	O
with	O
X-linked	SYMP
disease	SYMP
.	O
Report	O
of	O
spores	O
of	O
Henneguya	O
salminicola	O
(	O
Myxozoa	O
)	O
in	O
human	O
stool	O
specimens	O
:	O
possible	O
source	O
of	O
confusion	O
with	O
human	O
spermatozoa	O
.	O
Evaluation	O
of	O
a	O
ventilation	SYMP
strategy	SYMP
to	O
prevent	O
barotrauma	SYMP
in	O
patients	O
at	O
high	O
risk	O
for	O
acute	SYMP
respiratory	SYMP
distress	SYMP
syndrome	SYMP
.	O
Pressure-	O
and	O
Volume-Limited	O
Ventilation	O
Strategy	O
Group	O
.	O
Audit	O
commission	O
tackles	O
anaesthetic	O
services	O
.	O
Abdominal	SYMP
tuberculosis	SYMP
involving	O
hepatic	O
hilar	O
lymph	O
nodes	O
.	O
A	O
cause	O
of	O
portal	SYMP
vein	SYMP
thrombosis	SYMP
and	O
portal	SYMP
hypertension	SYMP
.	O
Treatment	O
of	O
men	O
with	O
paraphilia	SYMP
with	O
a	O
long-acting	O
analogue	SYMP
of	SYMP
gonadotropin-releasing	SYMP
hormone	SYMP
.	O
Analgesic	SYMP
nephropathy	SYMP
.	O
Translocations	O
of	O
11q13	O
in	O
mantle	SYMP
cell	SYMP
lymphoma	SYMP
fail	O
to	O
disrupt	O
the	O
S	O
mu	O
bp-2	O
gene	O
.	O
Variation	O
in	O
proficiency	O
testing	O
performance	O
by	O
testing	O
site	O
.	O
The	SYMP
``	SYMP
H	SYMP
''	SYMP
graft	SYMP
:	O
an	O
alternative	O
approach	O
for	O
performing	O
minimally	O
invasive	O
direct	SYMP
coronary	SYMP
artery	SYMP
bypass	SYMP
.	O
Effect	O
of	O
interferon	SYMP
on	O
hepatitis	SYMP
B	SYMP
.	O
Health	O
insurance	O
for	O
children	O
--	O
a	O
model	O
for	O
incremental	O
health	O
reform	O
?	O
Distinction	O
awards	O
and	O
racial	O
discrimination	O
.	O
Potential	O
biases	O
were	O
not	O
taken	O
into	O
account	O
in	O
study	O
of	O
waiting	O
times	O
.	O
Factors	O
affecting	O
uptake	O
of	O
antenatal	O
HIV	O
testing	O
in	O
London	O
:	O
results	O
of	O
a	O
multicentre	O
study	O
.	O
Coronary	O
arterioluminal	O
communications	O
in	O
routine	O
angiography	O
.	O
Peptide	O
nucleic	O
acid	O
(	O
PNA	O
)	O
from	O
DNA	O
recognition	O
to	O
antisense	O
and	O
DNA	O
structure	O
.	O
Homeopathy	SYMP
for	O
postoperative	SYMP
ileus	SYMP
?	O
A	O
meta-analysis	O
.	O
Treatment	O
of	O
postmenopausal	SYMP
osteoporosis	SYMP
.	O
Fascioloidiasis	SYMP
in	O
game-ranched	O
elk	O
from	O
Montana	O
.	O
Connexin-26	O
mutations	O
in	O
sporadic	O
non-syndromal	SYMP
sensorineural	SYMP
deafness	SYMP
.	O
Lyme	SYMP
disease	SYMP
presenting	O
as	O
Tourette	SYMP
's	SYMP
syndrome	SYMP
.	O
The	O
screening	O
muddle	O
.	O
Treatment	O
of	O
hypertensive	O
patients	O
with	O
diabetes	SYMP
.	O
China	O
's	O
human-organ	O
trade	O
highlighted	O
by	O
US	O
arrest	O
of	O
``	O
salesman	O
''	O
.	O
Dimension	O
in	O
defining	O
tumor	SYMP
response	O
.	O
Administration	O
of	O
dexamethasone	SYMP
induces	O
proteinuria	SYMP
of	O
glomerular	O
origin	O
in	O
mice	O
.	O
Preoperative	O
thromboxane	O
A2/prostaglandin	O
H2	O
receptor	O
activity	O
predicts	O
early	O
graft	SYMP
thrombosis	SYMP
.	O
Hypertension	SYMP
treatment	O
and	O
control	O
in	O
sub-Saharan	O
Africa	O
:	O
the	O
epidemiological	O
basis	O
for	O
policy	O
.	O
Needle-exchange	O
programmes	O
in	O
the	O
USA	O
.	O
A	O
discriminant	O
function	O
for	O
preeclampsia	SYMP
:	O
case-control	O
study	O
of	O
minor	O
hemoglobins	O
,	O
red	O
cell	O
enzymes	O
,	O
and	O
clinical	O
laboratory	O
values	O
.	O
Patterning	O
of	O
immobilized	O
antibody	O
layers	O
via	O
photolithography	O
and	O
oxygen	O
plasma	O
exposure	O
.	O
A	O
cell-based	O
immunobiosensor	O
with	O
engineered	O
molecular	O
recognition	O
--	O
Part	O
II	O
:	O
Enzyme	O
amplification	O
systems	O
.	O
Evanescent	O
wave	O
fibre	O
optic	O
sensor	O
for	O
detection	O
of	O
L.	O
donovani	O
specific	O
antibodies	O
in	O
sera	O
of	O
kala	O
azar	O
patients	O
.	O
Multianalyte	O
biosensors	O
on	O
optical	O
imaging	O
bundles	O
.	O
Specific	O
binding	O
of	O
low	O
molecular	O
weight	O
ligands	O
with	O
direct	O
optical	O
detection	O
.	O
Amperometric	O
lactate	O
oxidase	O
catheter	O
for	O
real-time	O
lactate	O
monitoring	O
based	O
on	O
thin	O
film	O
technology	O
.	O
Dual-fractal	O
analysis	O
for	O
antigen	O
--	O
antibody	O
binding	O
kinetics	O
for	O
biosensor	O
applications	O
.	O
Dipstick	O
only	O
urinalysis	O
screen	O
for	O
the	O
pediatric	O
emergency	O
room	O
.	O
Cytoplasmic	O
transport	O
in	O
Drosophila	O
ovarian	O
follicles	O
:	O
the	O
migration	O
of	O
microinjected	O
fluorescent	O
probes	O
through	O
intercellular	O
bridges	O
depends	O
neither	O
on	O
electrical	O
charge	O
nor	O
on	O
external	O
osmolarity	O
.	O
Further	O
evidence	O
for	O
the	O
importance	O
of	O
an	O
androgen	O
response	O
element	O
in	O
the	O
factor	O
IX	O
promoter	O
.	O
The	O
obstetric	O
experience	O
of	O
carriers	O
of	O
haemophilia	SYMP
.	O
Acquired	O
haemophilia	SYMP
,	O
an	O
unusual	O
cause	O
of	O
severe	O
postpartum	SYMP
haemorrhage	SYMP
.	O
Zoonotic	O
and	O
viral	SYMP
infection	SYMP
in	O
fetal	O
loss	O
after	O
12	O
weeks	O
.	O
High-affinity	O
binding	O
of	O
the	O
neonatal	O
Fc	O
receptor	O
to	O
its	O
IgG	O
ligand	O
requires	O
receptor	O
immobilization	O
.	O
Molecular	O
distances	O
from	O
dipolar	O
coupled	O
spin-labels	O
:	O
the	O
global	O
analysis	O
of	O
multifrequency	O
continuous	O
wave	O
electron	O
paramagnetic	O
resonance	O
data	O
.	O
Computer	O
science	O
and	O
biology	O
--	O
the	O
German	O
Conference	O
on	O
Bioinformatics	O
(	O
GCB'96	O
)	O
.	O
Surface	O
plasmon	O
resonance	O
analysis	O
of	O
topoisomerase	O
I-DNA	O
binding	O
:	O
effect	O
of	O
Mg2+	O
and	O
DNA	O
sequence	O
.	O
The	O
1996	O
list	O
.	O
Proposed	O
new	O
bacterial	O
taxa	O
and	O
proposed	O
changes	O
of	O
bacterial	O
names	O
published	O
during	O
1996	O
and	O
considered	O
to	O
be	O
of	O
interest	O
to	O
medical	O
or	O
veterinary	O
bacteriology	O
.	O
An	O
informational	O
note	O
.	O
The	O
1995	O
list	O
.	O
Proposed	O
new	O
bacterial	O
taxa	O
and	O
proposed	O
changes	O
of	O
bacterial	O
names	O
published	O
during	O
1995	O
and	O
considered	O
to	O
be	O
of	O
interest	O
to	O
medical	O
or	O
veterinary	O
bacteriology	O
.	O
An	O
informational	O
note	O
.	O
Biobehavioral	O
pain	SYMP
research	O
:	O
a	O
multi-institute	O
assessment	O
of	O
cross-cutting	O
issues	O
and	O
research	O
needs	O
.	O
Use	O
of	O
surface	O
plasmon	O
resonance	O
to	O
probe	O
the	O
equilibrium	O
and	O
dynamic	O
aspects	O
of	O
interactions	O
between	O
biological	O
macromolecules	O
.	O
ABC	O
of	O
mental	O
health	O
.	O
Psychosexual	SYMP
problems	SYMP
.	O
Hazards	O
of	O
running	O
a	O
marathon	O
.	O
Troponin-T	O
concentrations	O
should	O
be	O
measured	O
.	O
Second	O
Strang	O
International	O
Cancer	O
Conference	O
:	O
genetics	O
and	O
the	O
environment	O
New	O
York	O
,	O
USA	O
,	O
15-16	O
November	O
1996	O
.	O
Use	O
of	O
a	O
modified	O
version	O
of	O
the	O
Overt	O
Aggression	O
Scale	O
in	O
the	O
measurement	O
and	O
assessment	O
of	O
aggressive	O
behaviours	O
following	O
brain	SYMP
injury	SYMP
.	O
Ectopic	SYMP
pregnancy	SYMP
recurrence	O
:	O
role	O
of	O
gynecologic	O
,	O
obstetric	O
,	O
contraceptive	O
and	O
smoking	O
history	O
AIDS	O
:	O
a	O
world	O
,	O
a	O
desire	O
Urogynaecology	O
proceedings	O
of	O
the	O
joint	O
RCOG/BAUS	O
urogynaecology	O
meeting	O
.	O
19	O
September	O
1996	O
.	O
The	O
naming	O
of	O
a	O
syndrome	O
.	O
The	O
use	O
of	O
implantable	O
venous	O
access	O
devices	O
(	O
IVADs	O
)	O
in	O
children	O
with	O
hemophilia	SYMP
.	O
Nephrotic	SYMP
syndrome	SYMP
associated	O
with	O
hypocomplementemia	SYMP
in	O
a	O
4-year-old	O
boy	O
with	O
hemophilia	SYMP
B	SYMP
.	O
Growth	O
hormone	O
secretion	O
in	O
HIV-positive	O
versus	O
HIV-negative	O
hemophilic	O
males	O
with	O
abnormal	O
growth	O
and	O
pubertal	O
development	O
.	O
The	O
Hemophilia	O
Growth	O
and	O
Development	O
Study	O
.	O
Trends	O
in	O
HIV	O
counseling	O
and	O
testing	O
of	O
clients	O
attending	O
a	O
public	O
sexually	O
transmitted	O
disease	O
clinic	O
in	O
Portland	O
,	O
Oregon	O
,	O
1989-1995	O
.	O
Risk	O
factors	O
for	O
HIV-1	SYMP
infection	SYMP
among	O
pregnant	O
women	O
in	O
French	O
Guiana	O
.	O
Angiogenesis	O
in	O
inflammatory	SYMP
disease	SYMP
.	O
Epidemiology	O
and	O
association	O
with	O
extra-gastrointestinal	SYMP
diseases	SYMP
.	O
Extra-gastrointestinal	SYMP
diseases	SYMP
and	O
Helicobacter	O
pylori	O
.	O
Update	O
on	O
Helicobacter	O
pylori	O
research	O
.	O
Diagnosis	O
.	O
Uptake	O
on	O
Helicobacter	O
pylori	O
research	O
.	O
Pathogenesis	O
and	O
host	O
response	O
.	O
Update	O
on	O
Helicobacter	O
pylori	O
research	O
.	O
Malignancies	O
.	O
Update	O
on	O
Helicobacter	O
pylori	O
research	O
.	O
Dyspepsia	SYMP
.	O
Update	O
on	O
Helicobacter	O
pylori	O
research	O
.	O
Eradication	O
.	O
Sequence	O
analysis	O
of	O
the	O
36-kb	O
region	O
between	O
gntZ	O
and	O
trnY	O
genes	O
of	O
Bacillus	O
subtilis	O
genome	O
.	O
A	O
review	O
of	O
interferon	O
immunogenicity	O
.	O
Based	O
on	O
a	O
roundtable	O
workshop	O
held	O
in	O
London	O
,	O
United	O
Kingdom	O
,	O
9	O
February	O
1996	O
.	O
Histologic	O
diagnosis	O
of	O
chronic	SYMP
hepatitis	SYMP
,	O
grading	O
and	O
staging	O
Inositol	SYMP
treatment	O
of	O
autism	SYMP
.	O
Current	O
progress	O
in	O
early	O
pregnancy	O
investigation	O
.	O
Truncated-gene	O
reporter	O
system	O
for	O
studying	O
the	O
regulation	O
of	O
manganese	O
peroxidase	O
expression	O
.	O
Disparate	O
sequence	O
characteristics	O
of	O
the	O
Erysiphe	O
graminis	O
f.sp	O
.	O
hordei	O
glyceraldehyde-3-phosphate	O
dehydrogenase	O
gene	O
.	O
The	O
Integrative	O
Neurobiology	O
of	O
Affiliation	O
.	O
Proceedings	O
of	O
a	O
conference	O
.	O
Washington	O
,	O
DC	O
,	O
USA	O
.	O
March	O
14-17	O
,	O
1996	O
.	O
Proceedings	O
of	O
the	O
10th	O
International	O
Symposium	O
on	O
the	O
Pharmacology	O
of	O
Thermoregulation	O
.	O
Memphis	O
,	O
Tennessee	O
,	O
USA	O
.	O
August	O
17-22	O
,	O
1996	O
.	O
Neuropeptides	O
in	O
Development	O
and	O
Aging	O
.	O
Proceedings	O
of	O
a	O
conference	O
.	O
Breckenridge	O
,	O
Colorado	O
,	O
USA	O
.	O
February	O
3-6	O
,	O
1996	O
.	O
Receptor	O
Classification	O
:	O
The	O
Integration	O
of	O
Operational	O
,	O
Structural	O
,	O
and	O
Transductional	O
Information	O
.	O
Proceedings	O
of	O
a	O
conference	O
.	O
Verona	O
,	O
Italy	O
,	O
September	O
21-22	O
,	O
1995	O
.	O
Psychobiology	O
of	O
Postraumatic	SYMP
Stress	SYMP
Disorder	SYMP
.	O
Proceedings	O
of	O
a	O
conference	O
.	O
New	O
York	O
,	O
New	O
York	O
,	O
USA	O
.	O
September	O
7-10	O
,	O
1996	O
.	O
Adolescent	O
Gynecology	O
and	O
Endocrinology	O
:	O
Basic	O
and	O
Clinical	O
Aspects	O
.	O
Proceedings	O
of	O
the	O
3rd	O
International	O
Congress	O
.	O
Athens	O
,	O
Greece	O
,	O
December	O
6-9	O
,	O
1995	O
.	O
Proceedings	O
of	O
the	O
3rd	O
International	O
Conference	O
on	O
Neuroprotective	O
Agents	O
:	O
Clinical	O
and	O
Experimental	O
Aspects	O
.	O
Lake	O
Como	O
,	O
Italy	O
,	O
September	O
9-12	O
,	O
1996	O
.	O
Exon/intron	O
structure	O
of	O
the	O
human	O
AF-4	O
gene	O
,	O
a	O
member	O
of	O
the	O
AF-4/LAF-4/FMR-2	O
gene	O
family	O
coding	O
for	O
a	O
nuclear	O
protein	O
with	O
structural	O
alterations	O
in	O
acute	O
leukaemia	SYMP
.	O
Cloning	O
and	O
characterization	O
of	O
a	O
neural	O
cell	O
recognition	O
molecule	O
on	O
axons	O
of	O
the	O
retinotectal	O
system	O
and	O
spinal	O
cord	O
.	O
Identification	O
,	O
localization	O
,	O
and	O
expression	O
of	O
two	O
novel	O
human	O
genes	O
similar	O
to	O
deoxyribonuclease	O
I	O
.	O
Drug	O
resistance	O
during	O
indinavir	SYMP
therapy	SYMP
is	O
caused	O
by	O
mutations	O
in	O
the	O
protease	O
gene	O
and	O
in	O
its	O
Gag	O
substrate	O
cleavage	O
sites	O
.	O
A	O
protein	O
with	O
a	O
novel	O
calcium-binding	O
domain	O
associated	O
with	O
calcareous	O
corpuscles	O
in	O
Echinococcus	SYMP
granulosus	SYMP
.	O
Oncogenic	O
raf-1	O
induces	O
the	O
expression	O
of	O
non-histone	O
chromosomal	O
architectural	O
protein	O
HMGI-C	O
via	O
a	O
p44/p42	O
mitogen-activated	O
protein	O
kinase-dependent	O
pathway	O
in	O
salivary	O
epithelial	O
cells	O
.	O
Pendred	SYMP
syndrome	SYMP
is	O
caused	O
by	O
mutations	O
in	O
a	O
putative	O
sulphate	O
transporter	O
gene	O
(	O
PDS	O
)	O
.	O
Meis2	O
,	O
a	O
novel	O
mouse	O
Pbx-related	O
homeobox	O
gene	O
induced	O
by	O
retinoic	O
acid	O
during	O
differentiation	O
of	O
P19	O
embryonal	O
carcinoma	O
cells	O
.	O
Proceedings	O
of	O
the	O
VIIIth	O
International	O
Conference	O
on	O
the	O
Na/K-ATPase	O
and	O
Related	O
Transport	O
ATPases	O
.	O
Mar	O
del	O
Plata	O
,	O
Argentina	O
,	O
August	O
26-30	O
,	O
1996	O
.	O
Targeted	O
development	O
of	O
microsatellite	O
markers	O
from	O
the	O
defined	O
region	O
of	O
bovine	O
chromosome	O
6q21-31	O
.	O
Genetic	O
population	O
structure	O
in	O
the	O
yellow	O
mongoose	O
,	O
Cynictis	O
penicillata	O
.	O
ETTIN	O
patterns	O
the	O
Arabidopsis	O
floral	O
meristem	O
and	O
reproductive	O
organs	O
.	O
Ancient	O
DNA	O
from	O
amber	O
fossil	O
bees	O
?	O
The	O
histone	O
H1	O
genes	O
of	O
the	O
dipteran	O
insect	O
,	O
Chironomus	O
thummi	O
,	O
fall	O
under	O
two	O
divergent	O
classes	O
and	O
encode	O
proteins	O
with	O
distinct	O
intranuclear	O
distribution	O
and	O
potentially	O
different	O
functions	O
.	O
Characterization	O
of	O
the	O
orf31-petG	O
gene	O
cluster	O
from	O
the	O
plastid	O
genome	O
of	O
Populus	O
deltoides	O
.	O
Xenopus	O
Pax-2	O
displays	O
multiple	O
splice	O
forms	O
during	O
embryogenesis	O
and	O
pronephric	O
kidney	O
development	O
.	O
International	O
Workshop	O
on	O
Bone	O
Research	O
in	O
Space	O
.	O
Tokyo	O
,	O
Japan	O
,	O
November	O
11-13	O
,	O
1996	O
.	O
Proceedings	O
.	O
Joint	O
meeting	O
of	O
the	O
Benelux	O
Society	O
for	O
Microcirculation	O
and	O
the	O
Gesellschaft	O
f1/4r	O
Mikrozirkulation	O
e.V	O
.	O
Mainz	O
,	O
Germany	O
,	O
October	O
23-25	O
,	O
1997	O
.	O
Abstracts	O
.	O
3rd	O
Congress	O
of	O
the	O
French	O
Society	O
of	O
Blood	SYMP
Transfusion	SYMP
.	O
Marseille	O
,	O
France	O
,	O
28-30	O
April	O
1998	O
Central	O
and	O
East	O
European	O
Regional	O
INTERASMA	O
Conference	O
.	O
Budapest	O
,	O
Hungary	O
,	O
August	O
24-27	O
,	O
1997	O
.	O
Summary	O
of	O
symposium	O
,	O
antisense	O
oligonucleotides	O
:	O
strategies	O
and	O
successes	O
.	O
Sarasota	O
,	O
Florida	O
,	O
USA	O
.	O
April	O
21	O
,	O
1995	O
.	O
International	O
forensic	O
science	O
and	O
justice	O
.	O
Proceedings	O
of	O
the	O
6th	O
Congress	O
of	O
the	O
Soci	O
(	O
c	O
)	O
t	O
(	O
c	O
)	O
de	O
Pharmaco-Toxicologie	O
Cellulaire	O
and	O
the	O
Soci	O
(	O
c	O
)	O
t	O
(	O
c	O
)	O
Franaise	O
de	O
Toxicologie	O
G	O
(	O
c	O
)	O
n	O
(	O
c	O
)	O
tique	O
.	O
Paris	O
,	O
France	O
,	O
March	O
6-7	O
,	O
1997	O
.	O
The	O
Italian	O
Association	O
for	O
the	O
Study	O
of	O
Glaucoma	SYMP
.	O
Proceedings	O
of	O
the	O
12th	O
annual	O
general	O
meeting	O
.	O
Rapallo	O
,	O
Italy	O
,	O
14-15	O
March	O
1997	O
.	O
Report	O
of	O
the	O
61st	O
National	O
Scientific	O
Meeting	O
of	O
the	O
American	O
College	O
of	O
Rheumatology	O
,	O
Washington	O
DC	O
,	O
8-12	O
November	O
1997	O
.	O
Topical	O
dictionary	O
USAN	O
Council	O
.	O
List	O
No	O
.	O
404	O
.	O
New	O
names	O
.	O
Nagrestipen	O
.	O
Proposed	O
genetic	O
nomenclature	O
rules	O
for	O
Tetrahymena	O
thermophila	O
,	O
Paramecium	O
primaurelia	O
and	O
Paramecium	O
tetraurelia	O
.	O
The	O
Seventh	O
International	O
Meeting	O
on	O
Ciliate	O
Molecular	O
Biology	O
Genetics	O
Nomenclature	O
.	O
Joint	O
annual	O
session	O
of	O
the	O
North	O
German	O
Society	O
of	O
Radiology	O
and	O
the	O
Radiology	O
Society	O
of	O
Lower	O
Saxony	O
and	O
Sachsen	O
Anhalt	O
.	O
Kiel	O
,	O
20-21	O
February	O
1998	O
.	O
Abstracts	O
Neurone	O
development	O
and	O
death	O
,	O
from	O
a	O
cell	O
biologist	O
's	O
perspective	O
.	O
3rd	O
Neurotrauma/Polytrauma	O
Symposium	O
.	O
Cologne	O
,	O
Germany	O
,	O
March	O
14-15	O
,	O
1998	O
.	O
Abstracts	O
Neuroimmunomodulation	O
:	O
Molecular	O
Aspects	O
,	O
Integrative	O
Systems	O
,	O
and	O
Clinical	O
Advances	O
.	O
Proceedings	O
of	O
the	O
3rd	O
Congress	O
of	O
the	O
International	O
Society	O
of	O
NeuroImmunoModulation	O
(	O
ISNIM	O
)	O
.	O
Bethesda	O
,	O
Maryland	O
,	O
USA	O
.	O
November	O
13-15	O
,	O
1996	O
.	O
8th	O
European	O
Meeting	O
on	O
Dysmorphology	O
.	O
Strasbourg	O
,	O
France	O
,	O
3-6	O
September	O
1997	O
.	O
Abstracts	O
.	O
EU	O
Working	O
Group	O
on	O
Tobacco	O
and	O
Oral	O
Health	O
Consensus	O
Meeting	O
.	O
Copenhagen	O
,	O
23-26	O
October	O
1997	O
.	O
Abstracts	O
.	O
Presentations	O
from	O
the	O
2nd	O
NIH	O
Symposium	O
on	O
Therapeutic	O
Oligonucleotides	O
:	O
Targeting	O
Transcription	O
Factors	O
and	O
Signaling	O
Pathways	O
.	O
Bethesda	O
,	O
Maryland	O
,	O
USA	O
.	O
December	O
5	O
,	O
1997	O
.	O
Infectious	SYMP
diseases	SYMP
:	O
their	O
impact	O
on	O
dentistry	O
.	O
What	O
's	O
new	O
in	O
protein	O
folding	O
?	O
EMBO	O
workshop	O
:	O
protein	O
folding	O
and	O
misfolding	O
inside	O
and	O
outside	O
the	O
cell	O
.	O
Meeting	O
of	O
the	O
European	O
forum	O
of	O
nurses	O
.	O
17th	O
European	O
Workshop	O
on	O
the	O
Cell	O
Biology	O
of	O
Phagocytes	O
.	O
Catania	O
,	O
Italy	O
,	O
May	O
27-31	O
,	O
1998	O
.	O
Abstracts	O
.	O
Onset	O
of	O
the	O
preovulatory	O
luteinizing	O
hormone	O
surge	O
:	O
diurnal	O
timing	O
and	O
critical	O
follicular	O
prerequisites	O
.	O
Municipal	O
animal	O
control	O
ordinances	O
--	O
some	O
legal	O
issues	O
.	O
Psychosexual	O
care	O
in	O
a	O
multi-ethnic	O
society	O
.	O
Serologic	O
evidence	O
for	O
mother-to-child	O
transmission	O
of	O
Kaposi	SYMP
sarcoma-associated	SYMP
herpesvirus	SYMP
infection	SYMP
.	O
Brandon/Hill	O
selected	O
list	O
of	O
nursing	O
books	O
and	O
journals	O
.	O
Retraction	O
.	O
The	O
TSG101	O
tumor	O
susceptibility	O
gene	O
is	O
located	O
in	O
chromosome	O
11	O
band	O
p15	O
and	O
is	O
mutated	O
in	O
human	O
breast	SYMP
cancer	SYMP
.	O
An	O
omission	O
.	O
Indoor	O
pollution	O
and	O
health	O
Dioxins	O
:	O
current	O
knowledge	O
about	O
health	O
effects	O
Influence	O
of	O
environmental	O
factors	O
on	O
fertility	O
:	O
example	O
of	O
the	O
diminution	O
of	O
sperm	O
quality	O
New	O
developments	O
in	O
the	O
treatment	O
of	O
diabetes	SYMP
and	O
hyperlipidemias	SYMP
Role	O
of	O
beta-blockers	SYMP
in	O
the	O
treatment	O
of	O
cardiac	SYMP
insufficiency	SYMP
Which	O
calcium	SYMP
antagonists	SYMP
for	O
hypertension	SYMP
?	O
Correct	O
use	O
of	O
serotonin	SYMP
agonists	SYMP
in	O
migraine	SYMP
:	O
oral	O
or	O
injectable	O
form	O
?	O
Overtraining	O
and	O
recovery	O
.	O
A	O
conceptual	O
model	O
.	O
Saliva	O
composition	O
and	O
exercise	O
.	O
Lipid	O
metabolism	O
during	O
exercise	O
.	O
Golf	SYMP
injuries	SYMP
.	O
An	O
overview	O
.	O
Prevention	O
of	O
ankle	SYMP
injuries	SYMP
.	O
Academic	O
medicine	O
--	O
alternative	O
medicine	O
from	O
the	O
viewpoint	O
of	O
public	O
health	O
public	O
health	O
directors	O
Academic	O
medicine	O
and	O
complementary	O
medicine	O
--	O
campaign	O
for	O
the	O
truth	O
in	O
medical	O
theories	O
The	O
academic	O
medicine	O
--	O
alternative	O
medicine	O
tension	O
field	O
Are	O
academic	O
medicine-alternative	O
medicine	O
incompatible	O
,	O
compatible	O
,	O
complementary	O
?	O
Research	O
in	O
complementary	O
medicine	O
:	O
results	O
and	O
problems	O
Subcutaneous	SYMP
hematomas	SYMP
,	O
reduced	O
Quick	O
value	O
.	O
Factor	SYMP
VII	SYMP
deficiency	SYMP
Mononucleosis	SYMP
infectiosa	SYMP
(	O
Epstein-Barr	SYMP
virus	SYMP
infection	SYMP
Morphology	O
and	O
molecular	O
biology	O
of	O
malignant	O
soft	SYMP
tissue	SYMP
sarcomas	SYMP
Surgical	O
aspects	O
in	O
the	O
multidisciplinary	O
treatment	O
of	O
soft	SYMP
tissue	SYMP
sarcomas	SYMP
Surgical	SYMP
management	SYMP
of	O
soft	SYMP
tissue	SYMP
sarcomas	SYMP
:	O
principles	O
of	O
resection	SYMP
and	O
reconstructive	O
plastic	O
procedures	O
Adjuvant	SYMP
chemotherapy	SYMP
in	O
early	O
soft	SYMP
tissue	SYMP
sarcoma	SYMP
and	O
palliative	SYMP
chemotherapy	SYMP
in	O
advanced	O
soft	SYMP
tissue	SYMP
sarcoma	SYMP
in	O
adults	O
Radiotherapy	SYMP
of	O
soft	SYMP
tissue	SYMP
sarcomas	SYMP
Spinal	SYMP
muscular	SYMP
atrophy	SYMP
:	O
where	O
are	O
we	O
in	O
1998	O
?	O
Diseases	O
transmitted	O
by	O
non-conventional	O
agents	O
(	O
``	O
prions	O
''	O
)	O
:	O
nosology	O
and	O
diagnosis	O
A	O
note	O
on	O
the	O
epidemiology	O
of	O
Creutzfeldt-Jakob	SYMP
syndrome	SYMP
Biology	O
of	O
non-conventional	O
transmissible	O
agents	O
or	O
prions	O
Cerebral	SYMP
hemosiderosis	SYMP
related	O
to	O
hereditary	O
ceruloplasmin	SYMP
deficiency	SYMP
.	O
Clinical	O
familial	O
case	O
study	O
Intramedullary	O
metastases	O
of	O
bronchogenic	SYMP
carcinoma	SYMP
.	O
Two	O
cases	O
Nervous	SYMP
system	SYMP
borreliosis	SYMP
with	O
pseudo-lymphoma	O
cells	O
in	O
cerebrospinal	O
fluid	O
Epidural	O
and	O
intramedullary	O
abscess	O
of	O
acute	O
onset	O
Cranial	SYMP
nerve	SYMP
injuries	SYMP
during	O
multifocal	O
neuropathies	O
with	O
persistent	O
conduction	O
blocks	O
Cytokines	O
and	O
peripheral	O
neuropathies	O
Clinical	O
diagnosis	O
of	O
frontotemporal	SYMP
dementia	SYMP
Study	O
of	O
cortical	SYMP
atrophy	SYMP
with	O
magnetic	O
resonance	O
imaging	O
in	O
corticobasal	SYMP
degeneration	SYMP
Autosomal	O
dominant	O
nocturnal	O
frontal	O
lobe	O
epilepsy	SYMP
Eosinophilic	SYMP
meningitis	SYMP
due	O
to	O
Angiostrongylus	O
cantonensis	O
Case	O
of	O
superficial	SYMP
hemosiderosis	SYMP
of	SYMP
the	SYMP
central	SYMP
nervous	SYMP
system	SYMP
treated	O
with	O
trientine	SYMP
Germinal	SYMP
tumor	SYMP
metastases	SYMP
.	O
Case	O
report	O
Bradycardia	SYMP
:	O
an	O
unrecognized	O
complication	O
of	O
some	O
epileptic	O
crises	O
Facial	SYMP
palsy	O
relevant	O
to	O
HIV	O
seropositivity	O
Pneumosinus	O
dilatans	O
:	O
a	O
little-known	O
diagnostic	O
tool	O
Current	O
status	O
of	O
mitochondrial	SYMP
diseases	SYMP
Vascular	SYMP
Parkinson	SYMP
syndromes	SYMP
:	O
a	O
controversial	O
concept	O
Epilepsy	SYMP
and	O
psychiatric	SYMP
disorders	SYMP
:	O
epidemiological	O
data	O
Auditory	SYMP
perception	SYMP
disorders	SYMP
due	O
to	O
bilateral	SYMP
cortical	SYMP
lesions	SYMP
.	O
An	O
electrophysiology	O
study	O
Zinc	SYMP
gluconate	SYMP
lozenges	SYMP
for	O
treating	O
the	O
common	SYMP
cold	SYMP
.	O
Body	O
weight	O
and	O
mortality	O
among	O
women	O
.	O
Survey	O
and	O
assessment	O
of	O
the	O
actual	O
state	O
of	O
routine	O
measurement	O
of	O
glycohaemoglobin/GHb	O
by	O
commercial	O
methods	O
:	O
warning	O
to	O
the	O
users	O
and	O
the	O
providers	O
.	O
The	O
radiological	O
investigation	O
of	O
suspected	O
lower	O
limb	O
deep	SYMP
vein	SYMP
thrombosis	SYMP
.	O
p53	O
mutations	O
in	O
BRCA1-associated	O
familial	O
breast	SYMP
cancer	SYMP
.	O
Metronidazole	SYMP
(	O
Flagyl	O
)	O
The	O
Preterm	O
Prediction	O
Study	O
:	O
association	O
of	O
cesarean	SYMP
delivery	SYMP
with	O
increases	O
in	O
maternal	O
weight	O
and	O
body	O
mass	O
index	O
.	O
Controversies	O
in	O
hydrating	O
the	O
terminally	O
ill	O
patient	O
.	O
Frequency	O
and	O
significance	O
of	O
antinuclear	O
antibodies	O
in	O
multiple	SYMP
sclerosis	SYMP
.	O
Magnetic	O
resonance	O
imaging	O
of	O
the	O
bone	O
marrow	O
in	O
hematologic	SYMP
malignancies	SYMP
.	O
Generation	O
of	O
diversity	O
in	O
mammalian	O
gut-associated	O
lymphoid	O
tissues	O
:	O
restricted	O
V	O
gene	O
usage	O
does	O
not	O
preclude	O
complex	O
V	O
gene	O
organization	O
.	O
A	O
major	O
non-LTR	O
retrotransposon	O
of	O
Bombyx	O
mori	O
,	O
L1Bm	O
.	O
Algae	O
or	O
protozoa	O
:	O
phylogenetic	O
position	O
of	O
euglenophytes	O
and	O
dinoflagellates	O
as	O
inferred	O
from	O
mitochondrial	O
sequences	O
.	O
Structure	O
and	O
function	O
of	O
the	O
long	O
terminal	O
repeats	O
of	O
feline	O
leukemia	O
viruses	O
derived	O
from	O
naturally	O
occurring	O
acute	SYMP
myeloid	SYMP
leukemias	SYMP
in	O
cats	O
.	O
Use	O
of	O
protein-C	SYMP
concentrate	SYMP
,	SYMP
heparin	SYMP
,	SYMP
and	SYMP
haemodiafiltration	SYMP
in	O
meningococcus-induced	SYMP
purpura	SYMP
fulminans	SYMP
.	O
Satellite	O
DNA	O
repeat	O
sequence	O
variation	O
is	O
low	O
in	O
three	O
species	O
of	O
burying	O
beetles	O
in	O
the	O
genus	O
Nicrophorus	O
(	O
Coleoptera	O
:	O
Silphidae	O
)	O
.	O
The	O
importance	O
of	O
patient	O
registration	O
and	O
processing	O
.	O
Dose-dependent	O
effects	O
of	O
recombinant	O
human	O
interleukin-6	O
on	O
glucose	O
regulation	O
.	O
Genomic	O
sequence	O
of	O
a	O
Lyme	SYMP
disease	SYMP
spirochaete	O
,	O
Borrelia	O
burgdorferi	O
.	O
Interaction	O
between	O
electronic	O
article	O
surveillance	O
systems	O
and	O
implantable	O
defibrillators	O
:	O
insights	O
from	O
a	O
fourth	O
generation	O
ICD	O
.	O
Human	O
bodily	O
health	O
and	O
the	O
common	O
good	O
.	O
Proposals	O
for	O
action	O
by	O
individuals	O
and	O
the	O
Catholic	O
Church	O
.	O
Invited	O
commentary	O
:	O
le	O
mystre	O
de	O
Montr	O
(	O
c	O
)	O
al	O
.	O
Why	O
Oedipus	O
and	O
not	O
Christ	O
?	O
:	O
a	O
psychoanalytic	O
inquiry	O
into	O
innocence	O
,	O
human	O
sacrifice	O
,	O
and	O
the	O
sacred	O
--	O
Part	O
I	O
:	O
Innocence	O
,	O
spirituality	O
,	O
and	O
human	O
sacrifice	O
.	O
Equine	O
dinucleotide	O
repeat	O
loci	O
LEX049-LEX063	O
.	O
Molecular	O
systematics	O
of	O
tanagers	O
(	O
Thraupinae	O
)	O
:	O
evolution	O
and	O
biogeography	O
of	O
a	O
diverse	O
radiation	O
of	O
neotropical	O
birds	O
.	O
Expression	O
of	O
cytokeratin	O
20	O
in	O
urinary	O
cytology	O
of	O
patients	O
with	O
bladder	SYMP
carcinoma	SYMP
.	O
A	O
family	O
of	O
highly	O
repetitive	O
DNAs	O
from	O
``	O
ginbuna	O
''	O
(	O
Carassius	O
auratus	O
langsdorfi	O
)	O
genome	O
common	O
to	O
Carassius	O
auratus	O
populations	O
.	O
Characterization	O
of	O
cDNA	O
clones	O
in	O
size-fractionated	O
cDNA	O
libraries	O
from	O
human	O
brain	O
.	O
Respiratory	O
arrest	O
following	O
peribulbar	O
anesthesia	O
for	O
cataract	O
surgery	O
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O
Mouse	O
LIM-kinase	O
2	O
gene	O
:	O
cDNA	O
cloning	O
,	O
genomic	O
organization	O
,	O
and	O
tissue-specific	O
expression	O
of	O
two	O
alternatively	O
initiated	O
transcripts	O
.	O
A	O
gross	O
and	O
microscopic	O
study	O
of	O
cerebral	SYMP
injuries	SYMP
accompanying	O
maxillofacial	O
high-velocity	O
projectile	SYMP
wounding	SYMP
in	O
dogs	O
.	O
Does	O
this	O
patient	O
have	O
a	O
mole	O
or	O
a	O
melanoma	SYMP
?	O
Methotrexate	SYMP
and	O
trimethoprim	SYMP
:	O
a	O
fatal	O
interaction	O
.	O
Pellagra	SYMP
and	O
the	O
origin	O
of	O
a	O
myth	O
:	O
evidence	O
from	O
European	O
literature	O
and	O
folklore	O
.	O
Absorbable	SYMP
suture	SYMP
technique	SYMP
:	O
solution	O
to	O
the	O
growth	O
problem	O
in	O
pediatric	O
pacing	O
with	O
endocardial	O
leads	O
.	O
Undergraduate	O
orthodontic	O
education	O
:	O
what	O
should	O
we	O
teach	O
rather	O
than	O
what	O
can	O
we	O
teach	O
?	O
Genetic	O
variation	O
in	O
the	O
dimorphic	O
regions	O
of	O
RAP-1	O
genes	O
and	O
rap-1	O
loci	O
of	O
Babesia	SYMP
bigemina	SYMP
.	O
History	O
--	O
a	O
living	O
museum	O
.	O
Interview	O
by	O
Grethe	O
Kjaergaard	O
.	O
Gastric	O
site	O
of	O
epidermoid	SYMP
carcinoma	SYMP
Hypodermic	O
needles	O
in	O
the	O
neuropathic	O
foot	O
of	O
a	O
patient	O
with	O
diabetes	SYMP
.	O
Helicobacter	O
pylori	O
--	O
more	O
light	O
,	O
less	O
heat	O
.	O
A	O
national	O
survey	O
of	O
physician-assisted	O
suicide	O
and	O
euthanasia	O
in	O
the	O
United	O
States	O
.	O
Death	O
is	O
a	O
journey	O
to	O
be	O
undertaken	O
.	O
Replicated	O
declines	O
in	O
assault	O
rates	O
after	O
implementation	O
of	O
the	O
Assaulted	O
Staff	O
Action	O
Program	O
.	O
Positive	O
patch	O
test	O
to	O
cocamidopropyl	O
betaine	O
in	O
a	O
hairdresser	O
.	O
Management	O
of	O
dyslipidemia	SYMP
in	O
adults	O
with	O
diabetes	SYMP
.	O
American	O
Diabetes	O
Association	O
.	O
Acute	SYMP
diverticulitis	SYMP
.	O
Investigation	O
of	O
the	O
yeast	O
mitochondrial	O
unselective	O
channel	O
in	O
intact	O
and	O
permeabilized	O
spheroplasts	O
.	O
Acute	SYMP
sciatica	SYMP
with	O
an	O
infective	O
cause	O
.	O
An	O
ecologic	O
analysis	O
of	O
psychosocial	SYMP
stress	SYMP
and	O
heart	SYMP
disease	SYMP
in	O
British	O
Columbia	O
.	O
Human	O
leukocyte	O
antigen	O
frequencies	O
in	O
a	O
selected	O
group	O
of	O
Lebanese	O
Greek	O
Orthodox	O
.	O
Alcohol	O
and	O
the	O
heart	O
.	O
Spontaneous	SYMP
ovarian	SYMP
hyperstimulation	SYMP
syndrome	SYMP
with	O
pregnancy	O
.	O
Will	O
the	O
real	O
plastic	O
surgeon	O
please	O
stand	O
up	O
?	O
Modulation	O
of	O
ultraviolet	O
light-induced	O
epidermal	SYMP
damage	SYMP
:	O
beneficial	O
effects	O
of	O
tocopherol	SYMP
.	O
A	O
survey	O
of	O
the	O
attitudes	O
of	O
chronic	O
psychiatric	O
patients	O
living	O
in	O
the	O
community	O
toward	O
their	O
medication	O
.	O
Alterations	O
in	O
the	O
developing	O
immune	O
system	O
of	O
the	O
F344	O
rat	O
after	O
perinatal	O
exposure	O
to	O
2	O
,	O
3	O
,	O
7	O
,	O
8-tetrachlorodibenzo-p-dioxin	O
:	O
II	O
.	O
Effects	O
on	O
the	O
pup	O
and	O
the	O
adult	O
.	O
Renal	O
ultrasonography	O
:	O
a	O
procedure	O
for	O
nephrologists	O
.	O
Use	O
of	O
cisapride	SYMP
in	O
treatment	O
of	O
constipation	SYMP
in	O
children	O
.	O
Bilateral	O
sampling	O
of	O
the	O
internal	O
jugular	O
vein	O
to	O
distinguish	O
between	O
mechanisms	O
of	O
adrenocorticotropic	O
hormone-dependent	O
Cushing	SYMP
syndrome	SYMP
.	O
The	O
influence	O
of	O
patients	O
'	O
hopes	O
of	O
receiving	O
a	O
prescription	O
on	O
doctors	O
'	O
perceptions	O
and	O
the	O
decision	O
to	O
prescribe	O
:	O
a	O
questionnaire	O
survey	O
.	O
Coronary	SYMP
endothelial	SYMP
dysfunction	SYMP
in	O
humans	O
is	O
associated	O
with	O
myocardial	SYMP
perfusion	SYMP
defects	SYMP
.	O
Medical	O
devices	O
and	O
the	O
year	O
2000	O
problem	O
.	O
Internists	O
'	O
and	O
surgeons	O
'	O
attitudes	O
toward	O
guns	O
and	O
firearm	O
injury	O
prevention	O
.	O
Firearm	O
injury	O
prevention	O
.	O
American	O
College	O
of	O
Physicians	O
.	O
Management	O
of	O
vaginal	SYMP
vault	SYMP
prolapse	SYMP
.	O
Death	O
rates	O
of	O
characters	O
in	O
soap	O
operas	O
on	O
British	O
television	O
:	O
is	O
a	O
government	O
health	O
warning	O
required	O
?	O
Child	O
sexual	O
abuse	O
:	O
when	O
a	O
doctor	O
's	O
duty	O
to	O
report	O
abuse	O
conflicts	O
with	O
a	O
duty	O
of	O
confidentiality	O
to	O
the	O
victim	O
.	O
Tissue	O
adhesives	O
--	O
revisited	O
.	O
Racial	O
discrimination	O
in	O
the	O
allocation	O
of	O
distinction	O
awards	O
?	O
Analysis	O
of	O
list	O
of	O
award	O
holders	O
by	O
type	O
of	O
award	O
,	O
specialty	O
and	O
region	O
.	O
Multicenter	O
study	O
of	O
surfactant	SYMP
(	SYMP
beractant	SYMP
)	SYMP
use	O
in	O
the	O
treatment	O
of	O
term	O
infants	O
with	O
severe	SYMP
respiratory	SYMP
failure	SYMP
.	O
Survanta	O
in	O
Term	O
Infants	O
Study	O
Group	O
.	O
Consultation	O
section	O
.	O
Cataract	SYMP
surgical	O
problem	O
.	O
Changing	O
the	O
law	O
on	O
decision	O
making	O
for	O
mentally	O
incapacitated	O
adults	O
.	O
The	O
coding	O
audit	O
.	O
Providing	O
primary	O
care	O
in	O
the	O
accident	O
and	O
emergency	O
department	O
.	O
Challenges	O
to	O
Native	O
American	O
health	O
care	O
.	O
Federal	O
programs	O
and	O
Indian	O
country	O
:	O
a	O
time	O
for	O
reinvention	O
.	O
Chicago	O
report	O
profiles	O
.	O
Big	O
city	O
health	O
.	O
College-age	O
drinking	O
problems	O
.	O
Using	O
YPLL	O
in	O
health	O
planning	O
.	O
WHO	O
decides	O
:	O
food	O
irradiation	O
safe	O
at	O
any	O
level	O
.	O
Genetic	O
sampling	O
:	O
big	O
brother	O
or	O
big	O
science	O
?	O
Physician	O
assistants	O
and	O
nurse	O
practitioners	O
in	O
hospital	O
outpatient	O
departments	O
,	O
1993-1994	O
.	O
Laying	O
the	O
foundation	O
for	O
Healthy	O
People	O
2010	O
.	O
The	O
first	O
year	O
of	O
consultation	O
.	O
The	O
veracious	O
etiology	O
of	O
ectopic	SYMP
pregnancy	SYMP
.	O
Is	O
dietary	O
fat	O
a	O
major	O
determinant	O
of	O
body	O
fat	O
?	O
Factors	O
involved	O
in	O
the	O
rate	O
of	O
fall	O
of	O
thyroid	O
stimulating	O
hormone	O
in	O
treated	O
hypothyroidism	SYMP
.	O
Case	O
complexity	O
.	O
Imaging	O
pulmonary	SYMP
embolism	SYMP
.	O
Early	O
inpatient	O
rehabilitation	O
after	O
elective	O
hip	O
and	O
knee	O
arthroplasty	SYMP
.	O
Inpatient	O
rehabilitation	O
after	O
total	O
joint	SYMP
replacement	SYMP
.	O
Delayed	O
healing	O
of	O
rhytidectomy	SYMP
flap	O
resurfaced	O
with	O
CO2	O
laser	O
.	O
The	O
SAPHO	SYMP
syndrome	SYMP
:	O
an	O
evolving	O
concept	O
for	O
unifying	O
several	O
idiopathic	O
disorders	O
of	O
bone	O
and	O
skin	O
.	O
Beverage	O
use	O
and	O
risk	O
for	O
kidney	SYMP
stones	SYMP
in	O
women	O
.	O
Use	O
of	O
a	O
Foley	O
catheter	O
in	O
the	O
removal	O
of	O
a	O
substernal	SYMP
goiter	SYMP
.	O
Early	O
identification	O
of	O
variant	O
Creutzfeldt-Jakob	SYMP
disease	SYMP
.	O
Slater	O
revisited	O
:	O
6	O
year	O
follow	O
up	O
study	O
of	O
patients	O
with	O
medically	O
unexplained	O
motor	SYMP
symptoms	SYMP
.	O
Re	O
:	O
Intermediate	O
term	O
assessment	O
of	O
the	O
reliability	O
,	O
function	O
and	O
patient	O
satisfaction	O
with	O
the	O
AMS700	O
ultrex	O
penile	O
prosthesis	O
.	O
Reduced	O
ratio	O
of	O
male	O
to	O
female	O
births	O
in	O
several	O
industrial	O
countries	O
:	O
a	O
sentinel	O
health	O
indicator	O
?	O
Should	O
we	O
accept	O
mediocrity	O
?	O
Resolution	O
of	O
recalcitrant	SYMP
molluscum	SYMP
contagiosum	SYMP
virus	SYMP
lesions	SYMP
in	O
human	O
immunodeficiency	O
virus-infected	O
patients	O
treated	O
with	O
cidofovir	SYMP
.	O
Colonoscopic	O
removal	O
of	O
chicken	O
bones	O
impacted	O
in	O
the	O
sigmoid	O
in	O
two	O
patients	O
.	O
``	O
Pull	O
''	O
or	O
``	O
push	O
''	O
PEG	O
:	O
the	O
reinsertion	O
of	O
the	O
gastroscope	O
is	O
often	O
unnecessary	O
.	O
Clear	SYMP
cell	SYMP
papulosis	SYMP
:	O
case	O
report	O
and	O
literature	O
review	O
.	O
Malignant	SYMP
melanoma	SYMP
in	O
situ	O
:	O
an	O
oxymoron	O
whose	O
time	O
has	O
come	O
.	O
External	SYMP
beam	SYMP
radiation	SYMP
therapy	SYMP
for	O
choroidal	SYMP
neovascularization	SYMP
.	O
Somatic	O
mesoderm	O
differentiation	O
and	O
the	O
development	O
of	O
a	O
subset	O
of	O
pericardial	O
cells	O
depend	O
on	O
the	O
not	O
enough	O
muscles	O
(	O
nem	O
)	O
locus	O
,	O
which	O
contains	O
the	O
inscuteable	O
gene	O
and	O
the	O
intron	O
located	O
gene	O
,	O
skittles	O
.	O
Hemodynamic	O
effects	O
of	O
acute	O
tetrandrine	O
and	O
terlipressin	O
administration	O
on	O
portal	O
hypertensive	O
rats	O
.	O
Nonneoplastic	SYMP
disorders	SYMP
of	SYMP
the	SYMP
eccrine	SYMP
glands	SYMP
.	O
Cerebrospinal	O
fluid	O
and	O
plasma	O
insulin	O
levels	O
in	O
Alzheimer	SYMP
's	SYMP
disease	SYMP
:	O
relationship	O
to	O
severity	O
of	O
dementia	SYMP
and	O
apolipoprotein	O
E	O
genotype	O
.	O
Isolated	O
internal	SYMP
ophthalmoplegia	SYMP
associated	O
with	O
IgG	O
anti-GQ1b	O
antibody	O
.	O
Bolus	SYMP
thrombolytic	SYMP
infusions	SYMP
during	O
CPR	O
for	O
patients	O
with	O
refractory	SYMP
arrest	SYMP
rhythms	SYMP
:	O
outcome	O
of	O
a	O
case	O
series	O
.	O
Enthesopathy	SYMP
in	O
a	O
case	O
of	O
primary	SYMP
biliary	SYMP
cirrhosis	SYMP
with	O
positive	O
HLA-B27	O
.	O
Remifentanil	SYMP
in	O
the	O
critically	O
ill	O
.	O
Hyponatremia	SYMP
with	O
venlafaxine	SYMP
.	O
Use	O
of	O
a	O
nerve	SYMP
stimulator	SYMP
for	O
phrenic	SYMP
nerve	SYMP
block	SYMP
in	O
treatment	O
of	O
hiccups	SYMP
.	O
Anaesthesia	O
for	O
laparoscopic	SYMP
cholecystectomy	SYMP
in	O
a	O
patient	O
with	O
Eisenmenger	SYMP
's	SYMP
syndrome	SYMP
.	O
Micronutrients	SYMP
and	O
human	O
cancer	SYMP
risks	SYMP
--	O
prospects	O
for	O
prevention	O
.	O
Joint	O
International	O
Symposium	O
of	O
the	O
Danish	O
Cancer	O
Society	O
,	O
European	O
Cancer	O
Prevention	O
Organization	O
and	O
National	O
Food	O
Agency	O
of	O
Denmark	O
.	O
Aarhus	O
,	O
Denmark	O
,	O
21-24	O
May	O
1997	O
.	O
Abstracts	O
.	O
Vitamin	O
K2	O
and	O
serum	O
cholesterol	O
in	O
patients	O
on	O
continuous	O
ambulatory	O
peritoneal	SYMP
dialysis	SYMP
.	O
Income	O
inequality	O
and	O
population	O
health	O
.	O
Naloxone	SYMP
-precipitated	O
acute	SYMP
opioid	SYMP
withdrawal	SYMP
syndrome	SYMP
after	O
epidural	SYMP
morphine	SYMP
.	O
Idiopathic	SYMP
atrial	SYMP
flutter	SYMP
Munchausen	SYMP
's	SYMP
syndrome	SYMP
.	O
Clinical	O
evaluation	O
of	O
adjuvant	SYMP
chemoradiotherapy	SYMP
with	SYMP
CDDP	SYMP
,	SYMP
5-FU	SYMP
,	SYMP
and	SYMP
VP-16	SYMP
for	O
advanced	SYMP
esophageal	SYMP
cancer	SYMP
.	O
New	SYMP
drug	SYMP
treatment	SYMP
for	O
Alzheimer	SYMP
's	SYMP
disease	SYMP
:	O
lessons	O
for	O
healthcare	O
policy	O
.	O
Development	O
of	O
neurosurgery	SYMP
in	O
Greece	O
:	O
past	O
,	O
present	O
,	O
and	O
future	O
.	O
Intravascular-catheter-related	SYMP
infections	SYMP
.	O
The	O
effect	O
of	O
a	O
social	O
support	O
boosting	O
intervention	O
on	O
stress	O
,	O
coping	O
,	O
and	O
social	O
support	O
in	O
caregivers	O
of	O
children	O
with	O
HIV/AIDS	SYMP
.	O
Point-counterpoint	O
.	O
Mass	O
population	O
skin	SYMP
cancer	SYMP
screening	O
is	O
not	O
worthwhile	O
.	O
Persons	O
successful	O
at	O
long-term	O
weight	O
loss	O
and	O
maintenance	O
continue	O
to	O
consume	O
a	O
low-energy	O
,	O
low-fat	O
diet	O
.	O
Ultrasound	O
measurements	O
of	O
the	O
newborn	O
hip	O
.	O
Comparison	O
of	O
two	O
methods	O
in	O
657	O
newborns	O
.	O
Inferences	O
from	O
symphysiotomy	SYMP
experience	O
.	O
1995	O
coronary	SYMP
artery	SYMP
bypass	SYMP
risk	O
model	O
:	O
The	O
Society	O
of	O
Thoracic	O
Surgeons	O
Adult	O
Cardiac	O
National	O
Database	O
.	O
Informed	O
consent	O
:	O
edging	O
forwards	O
(	O
and	O
backwards	O
)	O
Online	O
medical	O
surveys	O
:	O
using	O
the	O
Internet	O
as	O
a	O
research	O
tool	O
.	O
US-guided	O
puncture	O
of	O
the	O
internal	O
jugular	O
vein	O
:	O
complications	O
and	O
anatomic	O
considerations	O
.	O
Mouth	O
care	O
and	O
skin	O
care	O
in	O
palliative	O
medicine	O
.	O
Simple	O
antiseptic	SYMP
mouthwashes	SYMP
are	O
best	O
for	O
infection	SYMP
.	O
The	O
effect	O
of	O
melatonin	O
administration	O
on	O
ethanol-induced	O
lipid	O
peroxidation	O
in	O
rats	O
.	O
A	O
comparison	O
of	O
aspirin	SYMP
plus	SYMP
tirofiban	SYMP
with	O
aspirin	SYMP
plus	SYMP
heparin	SYMP
for	O
unstable	SYMP
angina	SYMP
.	O
Platelet	O
Receptor	O
Inhibition	O
in	O
Ischemic	O
Syndrome	O
Management	O
(	O
PRISM	O
)	O
Study	O
Investigators	O
.	O
Mike	O
Grace	O
talks	O
to	O
Mike	O
Joy	O
.	O
Interview	O
by	O
Mike	O
Grace	O
.	O
Multivalent	O
cations	O
depress	O
ligand	O
affinity	O
of	O
insulin-like	O
growth	O
factor-binding	O
proteins-3	O
and	O
-5	O
on	O
human	O
GM-10	O
fibroblast	O
cell	O
surfaces	O
.	O
Effect	O
of	O
continuous	O
spinal	O
remifentanil	O
infusion	O
on	O
behaviour	O
and	O
spinal	O
glutamate	O
release	O
evoked	O
by	O
subcutaneous	O
formalin	O
in	O
the	O
rat	O
.	O
How	O
long	O
should	O
suction	O
drains	O
stay	O
in	O
after	O
breast	SYMP
surgery	SYMP
with	O
axillary	SYMP
dissection	SYMP
?	O
Physicians	O
disciplined	O
for	O
sex-related	O
offenses	O
.	O
Something	O
from	O
nothing	O
:	O
the	O
evolution	O
and	O
utility	O
of	O
satellite	O
repeats	O
.	O
Sudden	O
death	O
in	O
young	O
athletes	O
:	O
screening	O
for	O
the	O
needle	O
in	O
a	O
haystack	O
.	O
Chemotherapy	SYMP
alone	SYMP
compared	O
with	O
chemotherapy	SYMP
plus	SYMP
radiotherapy	SYMP
for	O
localized	O
intermediate-	O
and	O
high-grade	O
non-Hodgkin	SYMP
's	SYMP
lymphoma	SYMP
.	O
Prevention	O
of	O
a	O
first	O
stroke	SYMP
by	O
transfusions	SYMP
in	O
children	O
with	O
sickle	O
cell	O
anemia	O
and	O
abnormal	O
results	O
on	O
transcranial	O
Doppler	O
ultrasonography	O
.	O
HIV	SYMP
vaccines	SYMP
:	O
prospects	O
and	O
challenges	O
.	O
Occupation	O
:	O
the	O
keystone	O
of	O
a	O
curriculum	O
for	O
a	O
self-defined	O
profession	O
.	O
Touch	O
sensibility	O
in	O
the	O
breast	O
after	O
subcutaneous	SYMP
mastectomy	SYMP
and	O
immediate	O
reconstruction	O
with	O
a	O
prosthesis	O
.	O
Iatrogenic	SYMP
ruptures	SYMP
of	O
the	O
tracheobronchial	O
tree	O
.	O
Endoscopic	SYMP
hemostasis	SYMP
of	O
bleeding	SYMP
duodenal	SYMP
ulcer	SYMP
in	O
a	O
child	O
with	O
Henoch-Schnlein	SYMP
purpura	SYMP
.	O
Classification	O
of	O
primary	O
gastric	SYMP
lymphomas	SYMP
according	O
to	O
histologic	O
features	O
.	O
SCIM	O
--	O
spinal	O
cord	O
independence	O
measure	O
:	O
a	O
new	O
disability	O
scale	O
for	O
patients	O
with	O
spinal	SYMP
cord	SYMP
lesions	SYMP
.	O
Molecular	O
analysis	O
of	O
cellulose	O
biosynthesis	O
in	O
Arabidopsis	O
.	O
Users	O
'	O
guides	O
to	O
the	O
medical	O
literature	O
:	O
XIV	O
.	O
How	O
to	O
decide	O
on	O
the	O
applicability	O
of	O
clinical	O
trial	O
results	O
to	O
your	O
patient	O
.	O
Evidence-Based	O
Medicine	O
Working	O
Group	O
.	O
Hemispheric	O
difference	O
in	O
human	O
skin	O
color	O
.	O
Limitations	O
of	O
diagnostic	O
criteria	O
and	O
assessment	O
instruments	O
for	O
mental	SYMP
disorders	SYMP
.	O
Implications	O
for	O
research	O
and	O
policy	O
.	O
Causing	O
death	O
or	O
allowing	O
to	O
die	O
?	O
Developments	O
in	O
the	O
law	O
.	O
Albumin	O
synthesis	O
rates	O
are	O
not	O
decreased	O
in	O
hypoalbuminemic	SYMP
cachectic	SYMP
cancer	SYMP
patients	O
with	O
an	O
ongoing	O
acute-phase	O
protein	O
response	O
.	O
Brain-gut	O
axis	O
in	O
health	O
and	O
disease	O
.	O
Pins	O
and	O
Rubbers	O
Traction	O
System	O
.	O
A	O
specialist	O
nurse	O
can	O
replace	O
pre-registration	O
house	O
officers	O
in	O
the	O
surgical	O
pre-admission	O
clinic	O
.	O
Voluntary	O
death	O
:	O
a	O
comparison	O
of	O
terminal	O
dehydration	SYMP
and	O
physician-assisted	O
suicide	O
.	O
Ionized	O
magnesium	O
in	O
serum	O
and	O
ultrafiltrate	O
:	O
pH	O
and	O
bicarbonate	O
effect	O
on	O
measurements	O
with	O
the	O
AVL	O
988-4	O
electrolyte	O
analyzer	O
.	O
Anterior	SYMP
glenohumeral	SYMP
dislocations	SYMP
:	O
what	O
to	O
do	O
and	O
how	O
to	O
do	O
it	O
.	O
Relationship	O
between	O
topotecan	SYMP
systemic	O
exposure	O
and	O
tumor	O
response	O
in	O
human	O
neuroblastoma	SYMP
xenografts	SYMP
.	O
Cerebral	SYMP
infarct	SYMP
following	O
central	SYMP
venous	SYMP
cannulation	SYMP
The	O
Gram	O
stain	O
.	O
Heavy	O
caffeine	O
intake	O
in	O
pregnancy	O
and	O
sudden	SYMP
infant	SYMP
death	SYMP
syndrome	SYMP
.	O
New	O
Zealand	O
Cot	O
Death	O
Study	O
Group	O
.	O
When	O
can	O
odds	O
ratios	O
mislead	O
?	O
Treatment	O
of	O
renal	SYMP
failure	SYMP
in	O
idiopathic	SYMP
membranous	SYMP
nephropathy	SYMP
with	O
azathioprine	SYMP
and	SYMP
prednisolone	SYMP
.	O
Enzyme	O
structure	O
with	O
two	O
catalytic	O
sites	O
for	O
double-sieve	O
selection	O
of	O
substrate	O
.	O
Role	O
of	O
the	O
ketogenic	SYMP
diet	SYMP
in	O
children	O
with	O
intractable	SYMP
seizures	SYMP
.	O
Building-associated	O
pulmonary	SYMP
disease	SYMP
from	O
exposure	O
to	O
Stachybotrys	O
chartarum	O
and	O
Aspergillus	O
versicolor	O
.	O
Interleukin-8	O
participates	O
in	O
angiogenesis	O
in	O
non-small	O
cell	O
,	O
but	O
not	O
small	O
cell	O
carcinoma	SYMP
of	O
the	O
lung	O
.	O
Antenatal	SYMP
indomethacin	SYMP
--	O
adverse	O
fetal	O
effects	O
confirmed	O
.	O
Evaluation	O
of	O
the	O
microparticle	O
enzyme	O
immunoassay	O
Abbott	O
IMx	O
Select	O
Chlamydia	O
and	O
the	O
importance	O
of	O
urethral	O
site	O
sampling	O
to	O
detect	O
Chlamydia	SYMP
trachomatis	SYMP
in	O
women	O
.	O
The	O
persistent	O
vegetative	O
state	O
after	O
closed	SYMP
head	SYMP
injury	SYMP
:	O
clinical	O
and	O
magnetic	O
resonance	O
imaging	O
findings	O
in	O
42	O
patients	O
.	O
Wegener	SYMP
's	SYMP
granulomatosis	SYMP
of	O
the	O
head	O
and	O
neck	O
.	O
Chromosomal	O
abnormalities	O
of	O
a	O
new	O
nasopharyngeal	SYMP
carcinoma	SYMP
cell	O
line	O
(	O
NPC-BM1	O
)	O
derived	O
from	O
a	O
bone	SYMP
marrow	SYMP
metastatic	SYMP
lesion	SYMP
.	O
Relation	O
between	O
intellectual	SYMP
dysfunctioning	SYMP
and	O
mortality	O
in	O
community-residing	O
older	O
people	O
.	O
Anxiety	O
and	O
autonomic	O
flexibility	O
:	O
a	O
cardiovascular	O
approach	O
.	O
Cross-reactivity	O
of	O
specific	O
antibodies	O
directed	O
to	O
heat	O
shock	O
proteins	O
from	O
periodontopathogenic	O
bacteria	O
and	O
of	O
human	O
origin	O
(	O
corrected	O
)	O
Immunogenicity	O
of	O
hepatitis	SYMP
B	SYMP
vaccine	SYMP
in	O
term	O
and	O
preterm	O
infants	O
.	O
Secondary	O
prevention	O
for	O
stroke	SYMP
after	O
CAPRIE	SYMP
and	SYMP
ESPS-2	SYMP
.	O
New-onset	O
angina	O
preceding	O
acute	O
myocardial	O
infarction	O
is	O
associated	O
with	O
improved	O
contractile	O
recovery	O
after	O
thrombolysis	O
.	O
Magnetic	O
resonance	O
imaging	O
in	O
focal	SYMP
myositis	SYMP
.	O
Concomitant	SYMP
alveolitis	SYMP
and	O
asthma	SYMP
following	O
exposure	O
to	O
triphenylmethane	O
triisocyanate	O
.	O
Gorlin	SYMP
syndrome	SYMP
:	O
identification	O
of	O
4	O
novel	O
germ-line	O
mutations	O
of	O
the	O
human	O
patched	O
(	O
PTCH	O
)	O
gene	O
.	O
Mutations	O
in	O
brief	O
no	O
.	O
137	O
.	O
Online	O
.	O
Genetic	O
findings	O
in	O
congenital	SYMP
bilateral	SYMP
aplasia	SYMP
of	O
vas	O
deferens	O
patients	O
and	O
identification	O
of	O
six	O
novel	O
mutatations	O
.	O
Mutations	O
in	O
brief	O
no	O
.	O
138	O
.	O
Online	O
.	O
A	O
novel	O
point	O
mutation	O
in	O
a	O
splice	O
acceptor	O
site	O
of	O
intron	O
1	O
of	O
the	O
human	O
low	O
density	O
lipoprotein	O
receptor	O
gene	O
which	O
causes	O
severe	O
hypercholesterolemia	SYMP
:	O
an	O
unexpected	O
absence	O
of	O
exon	O
skipping	O
.	O
Mutations	O
in	O
brief	O
no	O
.	O
139	O
.	O
Online	O
.	O
A	O
de	O
novo	O
missense	O
mutation	O
(	O
R1623Q	O
)	O
of	O
the	O
SCN5A	O
gene	O
in	O
a	O
Japanese	O
girl	O
with	O
sporadic	SYMP
long	SYMP
QT	SYMP
sydrome	SYMP
.	O
Mutations	O
in	O
brief	O
no	O
.	O
140	O
.	O
Online	O
.	O
Missense	O
mutation	O
in	O
exon	O
11	O
(	O
Codon	O
378	O
)	O
of	O
the	O
presenilin-1	O
gene	O
in	O
a	O
French	O
family	O
with	O
early-onset	O
Alzheimer	SYMP
's	SYMP
disease	SYMP
and	O
transmission	O
study	O
by	O
mismatch	O
enhanced	O
allele	O
specific	O
amplification	O
.	O
Mutations	O
in	O
brief	O
no	O
.	O
141	O
.	O
Online	O
.	O
besancon	O
@	O
rockefeller1.univ.lyon1.fr	O
.	O
Mutation	O
sharing	O
,	O
predominant	O
involvement	O
of	O
the	O
MLH1	O
gene	O
and	O
description	O
of	O
four	O
novel	O
mutations	O
in	O
hereditary	SYMP
nonpolyposis	SYMP
colorectal	SYMP
cancer	SYMP
.	O
Mutations	O
in	O
brief	O
no	O
.	O
144	O
.	O
Online	O
.	O
A	O
new	O
informative	O
Alw	O
26	O
I	O
polymorphism	O
in	O
exon	O
10	O
of	O
the	O
human	O
low	O
density	O
lipoprotein	O
receptor	O
gene	O
.	O
Application	O
to	O
prenatal	O
diagnosis	O
.	O
Mutations	O
in	O
brief	O
no	O
.	O
145	O
.	O
Online	O
.	O
Novel	O
acceptor	O
splice	O
site	O
mutation	O
in	O
the	O
invariant	O
AG	O
of	O
intron	O
6	O
of	O
alpha-galactosidase	O
A	O
gene	O
,	O
causing	O
Fabry	SYMP
disease	SYMP
.	O
Mutations	O
in	O
brief	O
no	O
.	O
146	O
.	O
Online	O
.	O
Meta-analysis	O
of	O
trials	O
comparing	O
antidepressants	SYMP
with	O
active	O
placebos	O
.	O
Evidence-based	O
guidelines	O
for	O
universal	O
counselling	O
and	O
offering	O
of	O
HIV	O
testing	O
in	O
pregnancy	O
in	O
Canada	O
.	O
Chelation	SYMP
therapy	SYMP
for	O
peripheral	SYMP
arterial	SYMP
occlusive	SYMP
disease	SYMP
:	O
a	O
systematic	O
review	O
.	O
Sodium	SYMP
channel	SYMP
block	SYMP
with	SYMP
mexiletine	SYMP
is	O
effective	O
in	O
reducing	O
dispersion	O
of	O
repolarization	O
and	O
preventing	O
torsade	SYMP
des	SYMP
pointes	SYMP
in	O
LQT2	O
and	O
LQT3	O
models	O
of	O
the	O
long-QT	O
syndrome	O
.	O
Simultaneous	O
microsurgical	SYMP
vasal	SYMP
reconstruction	SYMP
and	O
varicocele	SYMP
ligation	SYMP
:	O
safety	O
profile	O
and	O
outcomes	O
.	O
A	O
predetermined	O
design	O
for	O
easier	O
aesthetic	SYMP
abdominoplasty	SYMP
.	O
Significance	O
of	O
revision	O
of	O
the	O
occupational	O
illness	O
legislation	O
for	O
evaluating	O
intervertebral	SYMP
disk	SYMP
damage	SYMP
Serum	O
urate	O
during	O
bouts	O
of	O
acute	SYMP
gouty	SYMP
arthritis	SYMP
.	O
Isolated	O
axial	O
lateral	O
pulse	O
as	O
a	O
sign	O
of	O
latero-bulbar	SYMP
ischemia	SYMP
:	O
clinical	O
topographic	O
correlation	O
Microalbuminuria	SYMP
is	O
positively	O
associated	O
with	O
usual	O
dietary	O
saturated	O
fat	O
intake	O
and	O
negatively	O
associated	O
with	O
usual	O
dietary	O
protein	O
intake	O
in	O
people	O
with	O
insulin-dependent	SYMP
diabetes	SYMP
mellitus	SYMP
.	O
Endoscopic	SYMP
ultrasound	SYMP
miniprobe-guided	SYMP
steroid	SYMP
injection	SYMP
for	O
treatment	O
of	O
refractory	SYMP
esophageal	SYMP
strictures	SYMP
.	O
Purification	O
and	O
characterization	O
of	O
an	O
acetyl	O
xylan	O
esterase	O
from	O
Bacillus	O
pumilus	O
.	O
The	O
Stresst'er	O
ergometer	O
as	O
an	O
alternative	O
to	O
treadmill	O
testing	O
in	O
patients	O
with	O
claudication	SYMP
.	O
Renal	SYMP
trauma	SYMP
and	O
the	O
risk	O
of	O
long-term	O
complications	O
in	O
shock	SYMP
wave	SYMP
lithotripsy	SYMP
.	O
Current	O
management	O
of	O
corneal	SYMP
abrasions	SYMP
:	O
evidence	O
based	O
practice	O
?	O
Placebo	O
in	O
drug	O
clinical	O
trials	O
Chromosome	O
22qII	O
deletions	O
.	O
An	O
under-recognised	O
cause	O
of	O
idiopathic	SYMP
learning	SYMP
disability	SYMP
.	O
Serial	O
magnetic	O
resonance	O
imaging	O
findings	O
for	O
a	O
spontaneously	O
resolving	O
spinal	SYMP
subdural	SYMP
hematoma	SYMP
:	O
case	O
report	O
.	O
A	O
simple	O
technique	O
for	O
correction	O
of	O
mucosal	SYMP
irregularities	SYMP
of	SYMP
the	SYMP
lip	SYMP
.	O
Cancer	SYMP
risk	O
in	O
the	O
rubber	O
industry	O
:	O
a	O
review	O
of	O
the	O
recent	O
epidemiological	O
evidence	O
.	O
HIV	O
treatment	O
strategies	O
:	O
planning	O
for	O
the	O
long	O
term	O
.	O
The	O
project	O
of	O
a	O
national	O
control	O
program	O
for	O
tuberculosis	SYMP
in	O
Spain	O
Decrease	O
in	O
antibiotic	O
susceptibility	O
or	O
increase	O
in	O
resistance	O
?	O
Helicobacter	O
pylori	O
and	O
abdominal	O
symptoms	O
:	O
a	O
population-based	O
study	O
among	O
preschool	O
children	O
in	O
southern	O
Germany	O
.	O
Have	O
we	O
treated	O
AIDS	SYMP
too	O
well	O
?	O
Rationing	O
and	O
the	O
future	O
of	O
AIDS	O
exceptionalism	O
.	O
Recommendations	O
on	O
antiretroviral	SYMP
treatment	SYMP
.	O
The	O
AIDS	O
Study	O
Group	O
of	O
the	O
Spanish	O
Society	O
of	O
Infectious	O
Diseases	O
and	O
Clinical	O
Microbiology	O
Requirements	O
for	O
training	O
to	O
ensure	O
competence	O
of	O
endoscopists	O
performing	O
invasive	O
procedures	O
in	O
children	O
.	O
Safe	O
motherhood	O
:	O
can	O
we	O
make	O
a	O
difference	O
?	O
Lumbar	SYMP
spine	SYMP
stenosis	SYMP
:	O
a	O
common	O
cause	O
of	O
back	O
and	O
leg	O
pain	SYMP
.	O
Myoepithelial	SYMP
carcinoma	SYMP
with	O
predominance	O
of	O
plasmacytoid	O
cells	O
arising	O
in	O
a	O
pleomorphic	SYMP
adenoma	SYMP
of	O
the	O
parotid	O
gland	O
.	O
Lonomia	O
obliqua	O
caterpillar	O
spicules	O
trigger	O
human	O
blood	O
coagulation	O
via	O
activation	O
of	O
factor	O
X	O
and	O
prothrombin	O
.	O
Doing	O
everything	O
.	O
Successful	O
replantation	O
of	O
an	O
amputated	O
tongue	O
.	O
Morbidity	O
and	O
healthcare	O
utilisation	O
of	O
children	O
in	O
households	O
with	O
one	O
adult	O
:	O
comparative	O
observational	O
study	O
.	O
A	O
novel	O
frameshift	O
mutation	O
840delA	O
and	O
a	O
novel	O
polymorphism	O
D203A	O
in	O
the	O
steroidogenic	O
acute	O
regulatory	O
protein	O
gene	O
in	O
a	O
Japanese	O
patient	O
with	O
congenital	SYMP
lipoid	SYMP
adrenal	SYMP
hyperplasia	SYMP
.	O
Mutations	O
in	O
brief	O
no	O
.	O
117	O
.	O
Online	O
.	O
Identification	O
of	O
five	O
new	O
mutations	O
and	O
three	O
novel	O
polymorphisms	O
in	O
the	O
muscle	O
chloride	O
channel	O
gene	O
(	O
CLCN1	O
)	O
in	O
20	O
Italian	O
patients	O
with	O
dominant	O
and	O
recessive	O
myotonia	SYMP
congenita	SYMP
.	O
Mutations	O
in	O
brief	O
no	O
.	O
118	O
.	O
Online	O
.	O
Identification	O
of	O
a	O
large	O
insertion	O
and	O
two	O
novel	O
point	O
mutations	O
(	O
3671del8	O
and	O
S1221X	O
)	O
in	O
tuberous	SYMP
sclerosis	SYMP
complex	SYMP
(	SYMP
TSC	SYMP
)	SYMP
patients	O
.	O
Mutations	O
in	O
brief	O
no	O
.	O
119	O
.	O
Online	O
.	O
Mutational	O
analysis	O
of	O
the	O
cystathionine	O
beta-synthase	O
gene	O
:	O
a	O
splicing	O
mutation	O
,	O
two	O
missense	O
mutations	O
and	O
an	O
insertion	O
in	O
patients	O
with	O
homocystinuria	SYMP
.	O
Mutations	O
in	O
brief	O
no	O
.	O
120	O
.	O
Online	O
.	O
Analysis	O
of	O
five	O
mutations	O
in	O
20	O
mucopolysaccharidois	SYMP
type	O
1	O
patients	O
:	O
high	O
prevalence	O
of	O
the	O
W402X	O
mutation	O
.	O
Mutations	O
in	O
brief	O
no	O
.	O
121	O
.	O
Online	O
.	O
A	O
novel	O
missense	O
mutation	O
Ile538Val	O
in	O
the	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
in	O
hypochondroplasia	SYMP
.	O
Mutations	O
in	O
brief	O
no	O
.	O
122	O
.	O
Online	O
.	O
Detection	O
of	O
four	O
novel	O
mutations	O
in	O
the	O
iduronate-2-sulfatase	O
gene	O
.	O
Mutations	O
in	O
brief	O
no	O
.	O
123	O
.	O
Online	O
.	O
Polymorphisms	O
in	O
the	O
coding	O
exons	O
of	O
the	O
human	O
luteinizing	O
hormone	O
receptor	O
gene	O
.	O
Mutations	O
in	O
brief	O
no	O
.	O
124	O
.	O
Online	O
.	O
Independent	O
occurrence	O
of	O
the	O
novel	O
Arg2163	O
to	O
His	O
mutation	O
in	O
the	O
factor	O
VIII	O
gene	O
in	O
three	O
unrelated	O
families	O
with	O
haemophila	SYMP
A	SYMP
with	O
different	O
phenotypes	O
.	O
Mutations	O
in	O
brief	O
no	O
.	O
126	O
.	O
Online	O
.	O
Are	O
Japanese	O
researchers	O
exploiting	O
Thai	O
HIV	O
patients	O
?	O
Underutilization	O
of	O
aspirin	SYMP
in	O
older	O
patients	O
with	O
prior	SYMP
myocardial	SYMP
infarction	SYMP
at	O
the	O
time	O
of	O
admission	O
to	O
a	O
nursing	O
home	O
.	O
Distinguishing	O
silent	SYMP
lacunar	SYMP
infarction	SYMP
from	O
enlarged	SYMP
Virchow-Robin	SYMP
spaces	SYMP
:	O
a	O
magnetic	O
resonance	O
imaging	O
and	O
pathological	O
study	O
.	O
Correlation	O
is	O
not	O
causation	O
.	O
Inhalation	O
of	O
ammonium	O
nitrate	O
fuel	O
oil	O
explosive	O
(	O
ANFO	O
)	O
Management	O
of	O
polycythaemia	SYMP
in	O
adults	O
with	O
cyanotic	SYMP
congenital	SYMP
heart	SYMP
disease	SYMP
.	O
Bolstering	O
Sisyphus	O
.	O
Use	O
of	O
public	O
performance	O
reports	O
:	O
a	O
survey	O
of	O
patients	O
undergoing	O
cardiac	SYMP
surgery	SYMP
.	O
Role	O
of	O
a	O
p53	O
polymorphism	O
in	O
the	O
development	O
of	O
human	SYMP
papillomavirus-associated	SYMP
cancer	SYMP
.	O
The	O
use	O
of	O
nurses	O
in	O
alternative	O
dispute	O
resolution	O
.	O
Re	O
:	O
Friday	O
afternoon	O
pulmonary	SYMP
arteriography	SYMP
(	SYMP
FAPA	SYMP
)	SYMP
:	O
are	O
Fridays	O
good	O
for	O
your	O
health	O
?	O
Hormone	SYMP
replacement	SYMP
therapy	SYMP
and	O
breast	SYMP
cancer	SYMP
.	O
Physician	O
heal	O
thyself	O
:	O
are	O
antibiotics	SYMP
the	O
cure	O
or	O
the	O
disease	O
?	O
Primary	SYMP
biliary	SYMP
cirrhosis	SYMP
.	O
Polymorphism	O
in	O
promoter	O
region	O
of	O
inducible	O
nitric	O
oxide	O
synthase	O
gene	O
and	O
protection	O
against	O
malaria	SYMP
.	O
Ventilatory	O
responses	O
to	O
acute	O
and	O
sustained	O
hypoxia	O
during	O
isoflurane	O
anesthesia	O
.	O
Leprosy	SYMP
type	SYMP
1	SYMP
reaction	O
as	O
the	O
first	O
manifestation	O
of	O
borderline	O
lepromatous	SYMP
leprosy	SYMP
in	O
a	O
young	O
native	O
German	O
.	O
A	O
systematic	O
review	O
of	O
five	O
systemic	SYMP
treatments	SYMP
for	O
severe	SYMP
psoriasis	SYMP
.	O
Trisomy	O
10	O
in	O
leukemia	SYMP
.	O
Receptive	O
properties	O
of	O
primary	O
afferent	O
fibres	O
from	O
rabbit	O
pleura	O
,	O
in	O
vitro	O
.	O
Congenital	SYMP
anomalies	SYMP
of	SYMP
tracheobronchial	SYMP
branching	SYMP
patterns	SYMP
:	O
spiral	O
CT	O
aspects	O
in	O
adults	O
.	O
American	O
Heart	O
Association	O
urges	O
caution	O
on	O
new	O
diet	O
drug	O
.	O
Absence	O
of	O
renal	O
and	O
hepatic	O
toxicity	O
after	O
four	O
hours	O
of	O
1.25	O
minimum	O
alveolar	O
anesthetic	O
concentration	O
sevoflurane	O
anesthesia	O
in	O
volunteers	O
.	O
Linear	SYMP
lichen	SYMP
planopilaris	SYMP
of	O
the	O
face	O
.	O
Electrolyte	O
abnormalities	O
in	O
patients	O
with	O
chronic	SYMP
renal	SYMP
failure	SYMP
receiving	O
parenteral	O
nutrition	O
.	O
Risk	O
factors	O
for	O
hemiretinal	SYMP
vein	SYMP
occlusion	SYMP
:	O
comparison	O
with	O
risk	O
factors	O
for	O
central	SYMP
and	SYMP
branch	SYMP
retinal	SYMP
vein	SYMP
occlusion	SYMP
:	O
the	O
eye	O
disease	O
case-control	O
study	O
.	O
The	O
psychological	O
profiles	O
of	O
patients	O
with	O
whiplash-associated	SYMP
headache	SYMP
.	O
Fatal	O
spontaneous	O
spinal	O
epidural	O
hematoma	O
following	O
thrombolysis	O
for	O
myocardial	O
infarction	O
.	O
Bifid	O
T	O
waves	O
induced	O
by	O
isoprenaline	SYMP
in	O
a	O
patient	O
with	O
Brugada	SYMP
syndrome	SYMP
.	O
Quo	O
vadis	O
``	O
suprema	O
lex	O
''	O
?	O
Death	O
in	O
springtime	O
.	O
Clinical	SYMP
management	SYMP
and	O
treatment	O
outcomes	O
of	O
Merkel	SYMP
cell	SYMP
carcinoma	SYMP
.	O
Relatives	O
in	O
the	O
resuscitation	O
room	O
:	O
their	O
point	O
of	O
view	O
.	O
Large	SYMP
airway	SYMP
disease	SYMP
associated	O
with	O
inflammatory	SYMP
bowel	SYMP
disease	SYMP
.	O
Autonomy	O
in	O
the	O
face	O
of	O
a	O
devastating	O
diagnosis	O
.	O
Advanced	O
practice	O
nursing	O
:	O
is	O
the	O
physician	O
's	O
assistant	O
an	O
accident	O
of	O
history	O
or	O
a	O
failure	O
to	O
act	O
?	O
Acute	SYMP
obstructive	SYMP
hydrocephalus	SYMP
complicating	O
bacterial	SYMP
meningitis	SYMP
in	O
childhood	O
.	O
Subcutaneous	O
autologous	O
ovarian	O
transplantation	O
in	O
Wistar	O
rats	O
maintains	O
hormone	O
secretion	O
.	O
Teaching	O
irritable	SYMP
bowel	SYMP
syndrome	SYMP
patients	O
to	O
care	O
for	O
themselves	O
.	O
Nonanesthetic	O
volatile	O
drugs	O
obey	O
the	O
Meyer-Overton	O
correlation	O
in	O
two	O
molecular	O
protein	O
site	O
models	O
.	O
Inhaled	SYMP
sodium	SYMP
cromoglycate	SYMP
in	O
young	O
children	O
with	O
moderate	O
asthma	SYMP
.	O
Directly	O
observed	O
therapy	O
and	O
treatment	O
completion	O
for	O
tuberculosis	SYMP
in	O
the	O
United	O
States	O
:	O
is	O
universal	O
supervised	O
therapy	O
necessary	O
?	O
Investigation	O
of	O
antibiotic	SYMP
prophylaxis	SYMP
usage	O
for	O
vascular	O
and	O
nonvascular	O
interventional	O
procedures	O
.	O
Effect	O
of	O
protein	O
kinase	O
C	O
inhibitors	O
on	O
cardioprotection	O
by	O
ischemic	O
preconditioning	O
depends	O
on	O
the	O
number	O
of	O
preconditioning	O
episodes	O
.	O
How	O
do	O
you	O
treat	O
refractory	SYMP
pouchitis	SYMP
and	O
when	O
do	O
you	O
decide	O
to	O
remove	O
the	O
pouch	O
?	O
Filter	O
paper	O
blood	O
spot	O
assay	O
of	O
human	O
insulin-like	O
growth	O
factor	O
I	O
(	O
IGF-I	O
)	O
and	O
IGF-binding	O
protein-3	O
and	O
preliminary	O
application	O
in	O
the	O
evaluation	O
of	O
growth	O
hormone	O
status	O
.	O
Effect	O
of	O
iodixanol	SYMP
on	O
renal	O
function	O
immediately	O
after	O
abdominal	SYMP
angiography	SYMP
.	O
Clinical	O
comparison	O
with	O
iomeprol	SYMP
and	O
ioxaglate	SYMP
.	O
A	O
new	O
modified	O
technique	O
for	O
harvest	O
of	O
calcaneal	O
bone	O
grafts	O
in	O
surgery	SYMP
on	O
the	O
foot	O
and	O
ankle	O
.	O
Is	O
prevaccination	O
screening	O
for	O
hepatitis	SYMP
B	SYMP
among	O
sexually	O
active	O
adolescents	O
cost-effective	O
?	O
Epilepsy	SYMP
--	O
a	O
guide	O
to	O
medical	O
treatment	O
.	O
1	O
:	O
Antiepileptic	SYMP
drugs	SYMP
.	O
Adolescent	O
pregnancy	O
and	O
sexual	O
abuse	O
.	O
Normoxic	SYMP
cardiopulmonary	SYMP
bypass	SYMP
reduces	O
oxidative	SYMP
myocardial	SYMP
damage	SYMP
and	SYMP
nitric	SYMP
oxide	SYMP
during	O
cardiac	O
operations	O
in	O
the	O
adult	O
.	O
A	O
multidimensional	O
study	O
of	O
preference	O
judgements	O
for	O
excerpts	O
of	O
music	O
.	O
Extending	O
the	O
benefits	O
of	O
breast	SYMP
cancer	SYMP
screening	O
.	O
Still	O
hard	O
to	O
know	O
how	O
large	O
the	O
benefits	O
will	O
really	O
be	O
.	O
Rhabdomyolysis	SYMP
and	O
carbon	SYMP
monoxide	SYMP
poisoning	SYMP
Effect	O
of	O
dental	SYMP
treatment	SYMP
on	O
the	O
lung	O
function	O
of	O
children	O
with	O
asthma	SYMP
.	O
conclusions	O
:	O
apc	SYMP
is	O
effective	O
for	O
the	O
treatment	O
of	O
endoluminal	SYMP
hemoptysis	SYMP
and	O
airway	SYMP
obstruction	SYMP
induction	SYMP
chemotherapy	SYMP
(	SYMP
cisplatin	SYMP
+	SYMP
vinorelbine	SYMP
)	SYMP
is	O
found	O
to	O
be	O
markedly	O
effective	O
for	O
squamous	SYMP
cell	SYMP
lung	SYMP
carcinoma	SYMP
with	SYMP
sarcoidosis	SYMP
--	O
a	O
case	O
report	O
in	O
conclusion	O
,	O
3d	O
computer-assisted	O
analysis	O
of	O
the	O
internal	O
structure	O
of	O
small	O
pulmonary	O
nodules	O
using	O
contrast-enhanced	O
dh-ct	O
was	O
found	O
to	O
be	O
effective	O
for	O
differentiating	O
between	O
benign	O
and	O
malignant	O
nodules	O
the	O
patient	O
was	O
a	O
62-year-old	O
man	O
with	O
squamous	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
,	O
which	O
was	O
first	O
successfully	O
treated	O
by	O
a	O
combination	SYMP
of	SYMP
radiation	SYMP
therapy	SYMP
and	SYMP
chemotherapy	SYMP
,	O
but	O
showed	O
local	O
recurrence	O
after	O
8	O
months	O
.	O
the	O
combination	SYMP
of	SYMP
txt	SYMP
,	SYMP
gem	SYMP
and	SYMP
cddp	SYMP
may	O
be	O
effective	O
for	O
recurrent	SYMP
non-small-cell	SYMP
lung	SYMP
carcinoma	SYMP
,	O
even	O
in	O
patients	O
that	O
have	O
failed	O
to	O
respond	O
to	O
more	O
than	O
one	O
chemotherapy	O
regimen	O
.	O
the	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
compare	O
the	O
objective	O
response	O
and	O
survival	O
rates	O
of	O
patients	O
with	O
mrcc	SYMP
treated	O
with	O
il-2	SYMP
administered	O
either	O
systemically	O
(	O
syst	O
,	O
subcutaneously	O
)	O
or	O
via	O
inhalation	O
(	O
inh	O
)	O
,	O
using	O
relatively	O
large	O
sample	O
sizes	O
to	O
afford	O
a	O
more	O
meaningful	O
comparison	O
.	O
conclusion	O
:	O
as	O
expected	O
,	O
the	O
type	O
of	O
chemotherapy	SYMP
we	O
used	O
,	O
to	O
treat	O
non-seminomatous	SYMP
germ-cell	SYMP
tumors	SYMP
proved	O
to	O
be	O
highly	O
effective	O
for	O
seminomatous	SYMP
types	SYMP
,	O
as	O
well	O
.	O
carboplatin	SYMP
and	SYMP
ifosfamide	SYMP
performed	O
well	O
and	O
safe	O
,	O
in	O
the	O
treatment	O
of	O
non-bulky	SYMP
metastatic	SYMP
seminoma	SYMP
.	O
these	O
results	O
suggested	O
that	O
the	O
sp1	SYMP
decoy	SYMP
strategy	SYMP
would	O
be	O
effective	O
for	O
regulating	O
tumor	SYMP
growth	SYMP
by	O
simultaneously	O
reducing	O
cancer	O
cell	O
(	O
a	O
)	O
angiogenic	O
growth	O
factor	O
expression	O
,	O
(	O
b	O
)	O
proliferation	O
,	O
and	O
(	O
c	O
)	O
invasiveness	O
.	O
considering	O
that	O
hamsters	O
had	O
a	O
lung	O
metastasis	O
rate	O
of	O
50	O
%	O
before	O
mdp-lys	O
treatment	O
,	O
liposomal	SYMP
mdp-lys	SYMP
given	O
at	O
a	O
dose	O
of	O
20	O
microg	O
twice/week	O
was	O
effective	O
for	O
inhibiting	O
lung	SYMP
metastasis	SYMP
at	O
a	O
far	O
lower	O
dose	O
of	O
mdp-lys	O
than	O
that	O
given	O
as	O
a	O
solution	O
(	O
40	O
microg	O
vs.	O
350	O
microg	O
per	O
week	O
)	O
.	O
we	O
have	O
documented	O
previously	O
that	O
adenovirus-mediated	SYMP
interleukin	SYMP
12	SYMP
(	SYMP
il-12	SYMP
)	SYMP
gene	SYMP
therapy	SYMP
is	O
effective	O
for	O
orthotopic	SYMP
tumor	SYMP
control	O
and	O
suppression	O
of	O
pre-established	SYMP
metastases	SYMP
in	SYMP
a	SYMP
preclinical	SYMP
prostate	SYMP
cancer	SYMP
model	SYMP
(	O
y.	O
nasu	O
et	O
al	O
.	O
,	O
gene	O
ther	O
.	O
we	O
further	O
developed	O
a	O
vaccine	O
model	O
based	O
on	O
s.c.injection	O
of	O
infected	O
,	O
irradiated	O
rm-9	O
cells	O
and	O
found	O
that	O
both	O
admil-12	SYMP
and	SYMP
admil-12/b7	SYMP
are	O
effective	O
at	O
suppressing	O
the	O
development	O
and	O
growth	O
of	O
challenge	SYMP
orthotopic	SYMP
tumors	SYMP
using	O
this	O
protocol	O
.	O
despite	O
the	O
marked	O
toxicity	O
of	O
the	O
initial	O
intensive	SYMP
chemotherapy	SYMP
,	O
the	O
treatments	O
are	O
tolerable	O
and	O
effective	O
in	O
the	O
control	O
of	O
extra-thoracic	SYMP
micrometastases	SYMP
,	O
whereas	O
they	O
are	O
less	O
effective	O
for	O
thoracic	O
primary	O
tumor	O
.	O
radiotherapy	SYMP
is	O
effective	O
for	O
palliation	O
of	O
symptoms	SYMP
associated	SYMP
with	SYMP
sblc	SYMP
.	O
clinically	O
,	O
oral	SYMP
administration	SYMP
of	SYMP
uft	SYMP
has	O
proved	O
to	O
be	O
effective	O
as	O
an	O
adjuvant	SYMP
therapy	SYMP
after	O
surgery	O
for	O
some	O
malignant	SYMP
tumors	SYMP
such	SYMP
as	SYMP
non-small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
.	O
moreover	O
,	O
uft	SYMP
has	O
proved	O
to	O
be	O
effective	O
for	O
inoperable	SYMP
advanced	SYMP
malignancies	SYMP
such	SYMP
as	SYMP
colorectal	SYMP
cancer	SYMP
,	O
especially	O
in	O
combination	O
with	O
leucovorin	SYMP
or	SYMP
cisplatin	SYMP
.	O
a	O
phase	O
ii	O
study	O
of	O
fractionated	O
administration	O
of	O
irinotecan	SYMP
(	SYMP
cpt-11	SYMP
)	SYMP
and	SYMP
cisplatin	SYMP
(	SYMP
cddp	SYMP
)	SYMP
in	O
patients	O
with	O
non-small-cell	SYMP
lung	SYMP
cancer	SYMP
(	SYMP
nsclc	SYMP
)	SYMP
was	O
conducted	O
.	O
in	O
conclusion	O
,	O
fractionated	O
administration	O
of	O
cpt-11	SYMP
and	SYMP
cddp	SYMP
was	O
highly	O
effective	O
for	O
advanced	SYMP
nsclc	SYMP
with	O
manageable	O
toxicities	O
.	O
we	O
report	O
the	O
use	O
of	O
paclitaxel	SYMP
in	O
the	O
successful	O
treatment	O
of	O
a	O
patient	O
with	O
recurrent	SYMP
adenocarcinoma	SYMP
of	SYMP
the	SYMP
cervix	SYMP
.	O
weekly	O
paclitaxel	SYMP
was	O
very	O
well	O
tolerated	O
,	O
yet	O
was	O
effective	O
for	O
recurrent	SYMP
cervical	SYMP
adenocarcinoma	SYMP
.	O
conclusion	O
:	O
our	O
results	O
suggest	O
that	O
pseudoephedrine	SYMP
plus	SYMP
acetaminophen	SYMP
is	O
effective	O
for	O
relief	O
of	O
symptoms	SYMP
attributable	SYMP
to	SYMP
the	SYMP
paranasal	SYMP
sinuses	SYMP
that	O
may	O
develop	O
early	O
in	O
the	O
course	O
of	O
a	O
cold	O
.	O
reviewer	O
's	O
conclusions	O
:	O
a	O
single	O
dose	O
of	O
nasal	SYMP
decongestant	SYMP
in	O
the	O
common	O
cold	O
is	O
moderately	O
effective	O
for	O
the	O
short	O
term	O
relief	O
of	O
congestion	SYMP
in	O
adults	O
,	O
while	O
there	O
is	O
no	O
evidence	O
available	O
to	O
show	O
benefit	O
after	O
repeated	O
use	O
over	O
several	O
days	O
.	O
conclusions	O
:	O
members	O
of	O
an	O
ethnically	O
diverse	O
community	O
believe	O
antibiotics	SYMP
are	O
effective	O
for	O
colds	SYMP
,	O
are	O
very	O
likely	O
to	O
seek	O
care	O
for	O
colds	O
,	O
and	O
often	O
obtain	O
antibiotics	O
without	O
a	O
prescription	O
.	O
the	O
available	O
inactivated	O
vaccine	SYMP
is	O
effective	O
for	O
preventing	O
influenza	SYMP
and	O
the	O
serious	O
disease	O
and	O
death	O
that	O
can	O
accompany	O
it	O
.	O
amantadine	SYMP
,	O
rimantadine	SYMP
,	O
and	O
the	O
newly	O
available	O
drugs	O
zanamivir	SYMP
and	O
oseltamivir	SYMP
are	O
effective	O
for	O
influenza	SYMP
prevention	SYMP
and	SYMP
treatment	SYMP
(	O
the	O
former	O
two	O
for	O
influenza	O
a	O
only	O
)	O
.	O
the	O
availability	O
of	O
four	O
antiviral	SYMP
agents	SYMP
that	O
effectively	O
prevent	O
and	O
treat	O
influenza	SYMP
provides	O
the	O
physician	O
with	O
considerable	O
flexibility	O
for	O
their	O
use	O
in	O
influenza	O
control	O
.	O
thus	O
influenza	SYMP
vaccination	SYMP
is	O
effective	O
for	O
preventing	O
influenza	SYMP
disease	SYMP
in	O
persons	O
aged	O
65	O
years	O
and	O
over	O
,	O
and	O
should	O
be	O
an	O
integral	O
part	O
of	O
the	O
care	O
of	O
this	O
population	O
residing	O
in	O
nursing	O
homes	O
.	O
intravenous	SYMP
injection	SYMP
of	SYMP
pb2-as	SYMP
,	SYMP
as	SYMP
a	SYMP
complex	SYMP
with	SYMP
dmrie-c	SYMP
,	SYMP
a	SYMP
cationic	SYMP
liposome	SYMP
,	O
was	O
most	O
effective	O
for	O
prolonging	O
the	O
mean	O
survival	O
time	O
in	O
days	O
(	O
msds	O
)	O
and	O
increasing	O
the	O
survival	O
rates	O
of	O
mice	O
infected	O
with	O
the	O
influenza	SYMP
a	SYMP
virus	SYMP
.	O
background	O
and	O
objectives	O
:	O
thoracic	SYMP
paravertebral	SYMP
block	SYMP
(	SYMP
tpvb	SYMP
)	SYMP
is	O
a	O
unilateral	O
analgesic	O
technique	O
that	O
has	O
been	O
advocated	O
in	O
both	O
acute	SYMP
and	SYMP
chronic	SYMP
thoracic	SYMP
and	SYMP
abdominal	SYMP
pain	SYMP
.	O
other	SYMP
blocks	SYMP
such	SYMP
as	SYMP
interpleural	SYMP
and	SYMP
epidural	SYMP
can	O
be	O
effectively	O
used	O
in	O
pleuritic	SYMP
pain	SYMP
.	O
this	O
report	O
illustrates	O
that	O
tpvb	SYMP
could	O
also	O
be	O
effective	O
for	O
this	O
kind	O
of	O
pain	SYMP
.	O
conclusions	O
:	O
this	O
case	O
report	O
supports	O
the	O
notion	O
that	O
,	O
in	O
practice	O
,	O
the	SYMP
paravertebral	SYMP
block	SYMP
could	O
be	O
an	O
effective	O
and	O
safe	O
alternative	O
to	O
relief	O
of	O
pleuritic	SYMP
pain	SYMP
.	O
conclusion	O
:	O
mr-guided	SYMP
rfa	SYMP
using	SYMP
single	SYMP
cooled	SYMP
tip	SYMP
electrodes	SYMP
is	O
safe	O
and	O
technically	O
effective	O
for	O
treatment	O
of	O
hepatic	SYMP
neoplasms	SYMP
up	O
to	O
3	O
cm	O
in	O
size	O
,	O
however	O
further	O
improvements	O
are	O
necessary	O
.	O
a	O
68-year-old	O
man	O
underwent	O
curative	SYMP
pancreaticoduodenectomy	SYMP
for	O
bile	SYMP
duct	SYMP
cancer	SYMP
.	O
one	O
course	O
of	O
chronochemotherapy	SYMP
was	O
effective	O
for	O
lymph	SYMP
node	SYMP
and	SYMP
peritoneum	SYMP
metastases	SYMP
.	O
the	O
only	O
specific	O
antidote	O
for	O
dosage-dependent	SYMP
hepatotoxicity	SYMP
is	O
n-acetylcysteine	SYMP
(	SYMP
and	SYMP
some	SYMP
other	SYMP
sulfhydryl	SYMP
donors	SYMP
)	SYMP
,	O
which	O
is	O
highly	O
effective	O
for	O
the	O
prevention	O
of	O
significant	O
hepatotoxicity	O
after	O
acetaminophen	O
overdose	O
.	O
corticosteroids	SYMP
can	O
be	O
considered	O
for	O
cases	O
of	O
drug-induced	SYMP
hepatitis	SYMP
,	O
especially	O
those	O
with	O
evidence	O
of	O
immune	O
hypersensitivity	O
,	O
if	O
no	O
improvement	O
is	O
seen	O
in	O
8	O
to	O
12	O
weeks	O
.	O
our	O
conclusion	O
was	O
that	O
the	O
covered-ems	SYMP
can	O
be	O
effective	O
for	O
the	O
palliation	O
of	O
esophagorespiratory	SYMP
fistulas	SYMP
.	O
the	O
food	O
and	O
drug	O
administration	O
(	O
fda	O
)	O
recently	O
approved	O
the	O
first	O
protein-polysaccharide	SYMP
conjugate	SYMP
vaccine	SYMP
to	O
prevent	O
invasive	SYMP
pneumococcal	SYMP
diseases	SYMP
in	O
infants	O
and	O
toddlers	O
less	O
than	O
2	O
years	O
of	O
age	O
.	O
this	O
conjugated	SYMP
vaccine	SYMP
against	O
pneumococcus	SYMP
uses	O
the	O
same	O
technology	O
as	O
the	O
successful	O
vaccine	SYMP
against	O
haemophilus	SYMP
influenzae	SYMP
type	SYMP
b	SYMP
.	O
the	O
most	O
recent	O
study	O
,	O
involving	O
over	O
37	O
,	O
000	O
young	O
children	O
,	O
also	O
evaluated	O
the	O
vaccine	O
's	O
efficacy	O
,	O
and	O
reported	O
that	O
the	O
vaccine	SYMP
is	O
highly	O
effective	O
in	O
preventing	O
invasive	SYMP
disease	SYMP
and	O
has	O
had	O
an	O
impact	O
on	O
otitis	SYMP
media	SYMP
.	O
conclusions	O
:	O
the	O
heptavalent	SYMP
pneumococcal	SYMP
conjugate	SYMP
vaccine	SYMP
is	O
safe	O
and	O
highly	O
effective	O
in	O
preventing	O
pneumococcal	SYMP
meningitis	SYMP
and	SYMP
bacteremic	SYMP
pneumonia	SYMP
in	O
young	O
children	O
less	O
than	O
2	O
years	O
of	O
age	O
;	O
it	O
is	O
less	O
effective	O
in	O
preventing	O
otitis	O
media	O
.	O
based	O
on	O
the	O
results	O
of	O
three	O
well-designed	O
studies	O
demonstrating	O
the	O
vaccine	O
's	O
safety	O
,	O
immunogenicity	O
,	O
and	O
efficacy	O
,	O
the	O
vaccine	SYMP
is	O
safe	O
and	O
effective	O
for	O
active	O
immunization	O
of	O
children	O
less	O
than	O
2	O
years	O
of	O
age	O
against	O
invasive	SYMP
disease	SYMP
caused	SYMP
by	SYMP
seven	SYMP
streptococcus	SYMP
pneumoniae	SYMP
serotypes	SYMP
included	O
in	O
the	O
vaccine	O
.	O
i	O
concluded	O
that	O
6-month	O
regimen	O
containing	O
pyrazinamide	SYMP
was	O
effective	O
for	O
the	O
patients	O
with	O
isoniazid-rifampicin	SYMP
susceptible	SYMP
tuberculosis	SYMP
patients	O
except	O
the	O
patients	O
complicated	O
with	O
diabetes	SYMP
mellitus	SYMP
.	O
only	O
the	O
combination	SYMP
of	SYMP
a	SYMP
cell	SYMP
wall-active	SYMP
antibiotic	SYMP
to	SYMP
which	SYMP
the	SYMP
enterococcus	SYMP
is	SYMP
susceptible	SYMP
(	SYMP
ie	SYMP
,	SYMP
certain	SYMP
beta-lactams	SYMP
or	SYMP
vancomycin	SYMP
)	SYMP
plus	SYMP
an	SYMP
aminoglycoside	SYMP
(	SYMP
ie	SYMP
,	SYMP
gentamicin	SYMP
or	SYMP
streptomycin	SYMP
)	SYMP
is	O
bactericidal	O
,	O
and	O
is	O
required	O
for	O
cure	O
of	O
endocarditis	SYMP
,	SYMP
meningitis	SYMP
and	SYMP
probably	SYMP
infection	SYMP
in	SYMP
neutropenic	SYMP
patients	SYMP
;	O
bacteriostatic	O
activity	O
is	O
sufficient	O
to	O
treat	O
most	O
other	O
infections	O
.	O
two	SYMP
triazole	SYMP
antifungal	SYMP
agents	SYMP
,	SYMP
fluconazole	SYMP
and	SYMP
itraconazole	SYMP
,	O
were	O
introduced	O
over	O
a	O
decade	O
ago	O
and	O
since	O
then	O
have	O
been	O
used	O
extensively	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
a	O
variety	O
of	O
fungal	SYMP
infections	SYMP
.	O
the	O
use	O
of	O
topical	SYMP
corticosteroids	SYMP
has	O
revolutionised	O
the	O
treatment	O
of	O
inflammatory	SYMP
skin	SYMP
diseases	SYMP
.	O
in	O
particular	O
,	O
tacrolimus	SYMP
and	SYMP
ascomycin	SYMP
derivatives	SYMP
have	O
been	O
shown	O
to	O
be	O
effective	O
for	O
treating	O
atopic	SYMP
dermatitism	SYMP
with	O
a	O
surprising	O
lack	O
of	O
side	O
effects	O
.	O
cyclophosphamide	SYMP
therapy	SYMP
is	O
effective	O
for	O
bronchiolitis	SYMP
obliterans	SYMP
occurring	SYMP
as	SYMP
a	SYMP
late	SYMP
manifestation	SYMP
of	SYMP
lupus	SYMP
erythematosus	SYMP
(	O
letter	O
)	O
in	O
summary	O
,	O
gemifloxacin	SYMP
was	O
found	O
to	O
be	O
well	O
tolerated	O
and	O
effective	O
for	O
the	O
treatment	O
of	O
aecb	SYMP
,	O
suggesting	O
it	O
is	O
well	O
suited	O
for	O
empirical	O
treatment	O
of	O
this	O
common	O
respiratory	O
condition	O
in	O
the	O
current	O
clinical	O
environment	O
.	O
d-penicillamine	SYMP
(	SYMP
2-amino-3-mercapto-3-methylbutanoic	SYMP
acid	SYMP
)	SYMP
,	SYMP
a	SYMP
well-known	SYMP
heavy	SYMP
metal	SYMP
chelator	SYMP
,	O
is	O
the	O
drug	O
of	O
choice	O
in	O
the	O
treatment	O
of	O
wilson	SYMP
's	SYMP
disease	SYMP
and	O
is	O
also	O
effective	O
for	O
the	O
treatment	O
of	O
several	SYMP
disorders	SYMP
including	SYMP
rheumatoid	SYMP
arthritis	SYMP
,	SYMP
primary	SYMP
biliary	SYMP
cirrhosis	SYMP
,	SYMP
scleroderma	SYMP
,	SYMP
fibrotic	SYMP
lung	SYMP
diseases	SYMP
and	SYMP
progressive	SYMP
systemic	SYMP
sclerosis	SYMP
.	O
stages	O
of	O
non-small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
(	SYMP
nsclc	SYMP
)	SYMP
that	O
are	O
potential	O
candidates	O
for	O
surgical	SYMP
resection	SYMP
have	O
been	O
treated	O
in	O
several	O
ways	O
:	O
surgery	SYMP
alone	O
is	O
curative	O
in	O
only	O
two-thirds	O
of	O
cases	O
and	O
post-operative	SYMP
radiotherapy	SYMP
(	SYMP
rt	SYMP
)	SYMP
provides	O
only	O
weak	O
control	O
of	O
advanced-stage	O
disease	O
.	O
among	O
these	O
,	O
the	O
gemcitabine/cisplatin	SYMP
study	O
protocol	O
(	O
gc	O
)	O
,	O
set	O
up	O
in	O
a	O
phase	O
ii	O
study	O
for	O
patients	O
with	O
stage	SYMP
iiia	SYMP
n2	SYMP
nsclc	SYMP
,	O
was	O
very	O
effective	O
(	O
objective	O
response	O
(	O
or	O
)	O
:	O
70.2	O
%	O
;	O
median	O
survival	O
:	O
19	O
months	O
)	O
and	O
should	O
be	O
promising	O
for	O
stages	O
ib	O
and	O
ii	O
.	O
several	O
studies	O
have	O
suggested	O
that	O
non-small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
(	SYMP
nsclc	SYMP
)	SYMP
patients	O
whose	O
tumors	O
have	O
neuroendocrine	O
(	O
ne	O
)	O
features	O
may	O
be	O
more	O
responsive	O
to	O
chemotherapy	SYMP
in	O
addition	O
,	O
increased	O
expression	O
of	O
p53	O
and	O
her2	O
may	O
confer	O
relative	O
chemotherapy	O
resistance	O
and	O
shortened	O
survival	O
.	O
the	O
cancer	O
and	O
leukemia	O
group	O
b	O
performed	O
a	O
series	O
of	O
studies	O
involving	O
sequential	SYMP
chemotherapy	SYMP
followed	SYMP
by	SYMP
radiation	SYMP
for	O
patients	O
with	O
unresectable	SYMP
stage	SYMP
iii	SYMP
nsclc	SYMP
.	O
this	O
london	O
lung	O
cancer	O
group	O
trial	O
of	O
gemcitabine/carboplatin	SYMP
may	O
define	O
an	O
active	O
,	O
safe	O
,	O
and	O
acceptable	O
treatment	O
for	O
patients	O
with	O
extensive-stage	O
and	O
poor-prognosis	O
small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
.	O
gemcitabine	SYMP
and	SYMP
carboplatin	SYMP
for	O
patients	O
with	O
advanced	SYMP
non-small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
an	SYMP
aggressive	SYMP
surgical	SYMP
approach	SYMP
is	O
justified	O
in	O
patients	O
with	O
mplc	SYMP
and	O
offers	O
the	O
greatest	O
chance	O
for	O
long-term	O
survival	O
even	O
in	O
the	O
case	O
of	O
limited	O
resection	O
.	O
methods	O
and	O
materials	O
:	O
eleven	O
patients	O
with	O
small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
(	SYMP
sclc	SYMP
)	SYMP
,	O
who	O
had	O
presented	O
complete	O
response	O
of	O
disease	O
after	O
chemotherapy	SYMP
and	O
radical	SYMP
radiotherapy	SYMP
in	SYMP
the	SYMP
lung	SYMP
,	O
were	O
prescribed	O
to	O
receive	O
a	O
prophylacting	O
cranial	O
irradiation	O
(	O
pci	O
)	O
with	O
a	O
6	O
mev	O
linear	O
accelerator	O
.	O
only	O
22	O
patients	O
(	O
10	O
%	O
)	O
were	O
alive	O
at	O
five	O
years	O
:	O
19	O
patients	O
with	O
nsclc	SYMP
who	O
had	O
got	O
surgical	SYMP
treatment	SYMP
,	O
one	O
patient	O
with	O
nsclc	SYMP
(	SYMP
stage	SYMP
iiib	SYMP
)	SYMP
who	O
had	O
recieved	O
radiotherapy	SYMP
,	O
and	O
two	O
patients	O
with	O
sclc	SYMP
,	SYMP
limited	SYMP
disease	SYMP
,	O
treated	O
with	O
chemo-	SYMP
and	SYMP
radiotherapy	SYMP
.	O
the	O
standard	O
care	O
for	O
patients	O
with	O
non-small-cell	SYMP
lung	SYMP
cancer	SYMP
is	O
chemotherapy	SYMP
of	SYMP
supportive	SYMP
care	SYMP
,	O
with	O
surgery	SYMP
being	O
reserved	O
for	O
palliation	O
of	O
symptoms	O
;	O
however	O
,	O
there	O
is	O
a	O
small	O
group	O
of	O
patients	O
with	O
a	O
finite	O
number	O
of	O
extrathoracic	SYMP
metastases	SYMP
(	SYMP
oligometastases	SYMP
)	SYMP
who	O
may	O
experience	O
improved	O
survival	O
by	O
resection	SYMP
of	SYMP
their	SYMP
metastases	SYMP
and	SYMP
the	SYMP
primary	SYMP
site	SYMP
,	O
with	O
or	O
without	O
systemic	O
treatment	O
.	O
five	O
new	O
agents	O
,	O
paclitaxel	SYMP
,	O
docetaxel	SYMP
,	O
vinorelbine	SYMP
,	O
gemcitabine	SYMP
and	O
irinotecan	SYMP
,	O
have	O
been	O
introduced	O
for	O
the	O
treatment	O
of	O
nsclc	SYMP
and	O
investigated	O
extensively	O
both	O
preclinically	O
and	O
clinically	O
.	O
whether	O
the	O
era	O
of	O
platinum-based	SYMP
chemotherapy	SYMP
in	O
the	O
treatment	O
of	O
nsclc	SYMP
should	O
continue	O
or	O
not	O
must	O
be	O
determined	O
by	O
phase	O
iii	O
trials	O
,	O
evaluating	O
the	O
use	O
of	O
a	O
platinum	O
agent	O
with	O
one	O
of	O
the	O
new	O
agent	O
combinations	O
.	O
these	O
aggressive	SYMP
chemotherapeutic	SYMP
combinations	SYMP
will	O
hopefully	O
improve	O
survival	O
and	O
quality	O
of	O
life	O
for	O
patients	O
with	O
advanced	SYMP
nsclc	SYMP
.	O
results	O
:	O
we	O
have	O
performed	O
60	O
carinal	SYMP
resections	SYMP
for	O
bronchogenic	SYMP
carcinoma	SYMP
:	O
18	O
isolated	SYMP
carinal	SYMP
resections	SYMP
for	O
tumor	SYMP
confined	SYMP
to	SYMP
the	SYMP
carinal	SYMP
or	SYMP
proximal	SYMP
main	SYMP
stem	SYMP
bronchus	SYMP
;	O
35	O
carinal	SYMP
pneumonectomies	SYMP
;	O
5	O
carinal	SYMP
plus	SYMP
lobar	SYMP
resections	SYMP
,	O
and	O
2	O
carinal	SYMP
resections	SYMP
for	O
stump	SYMP
recurrence	SYMP
after	SYMP
prior	SYMP
pneumonectomy	SYMP
.	O
conclusions	O
:	O
this	O
constitutes	O
one	O
of	O
the	O
largest	O
single-institution	O
reports	O
on	O
carinal	SYMP
resection	SYMP
for	O
bronchogenic	SYMP
carcinoma	SYMP
involving	SYMP
the	SYMP
carina	SYMP
.	O
extracorporeal	SYMP
photopheresis	SYMP
has	O
evolved	O
as	O
a	O
possible	O
therapy	O
for	O
patients	O
with	O
acute	SYMP
nd	SYMP
chronic	SYMP
lung	SYMP
allograft	SYMP
rejection	SYMP
.	O
methods	O
:	O
we	O
retrospectively	O
reviewed	O
14	O
patients	O
diagnosed	O
with	O
bos	SYMP
who	O
underwent	O
therapy	SYMP
with	SYMP
extracorporeal	SYMP
photopheresis	SYMP
.	O
in	O
three	O
patients	O
with	O
bos	SYMP
and	SYMP
concurrent	SYMP
acute	SYMP
rejection	SYMP
,	O
therapy	SYMP
with	SYMP
extracorporeal	SYMP
photopheresis	SYMP
led	O
to	O
the	O
resolution	O
of	O
the	O
acute	O
rejection	O
episode	O
.	O
conclusion	O
:	O
extracorporeal	SYMP
photopheresis	SYMP
appears	O
to	O
be	O
a	O
promising	O
therapy	O
for	O
patients	O
with	O
early	SYMP
bos	SYMP
.	O
purpose	O
:	O
many	O
patients	O
with	O
locally	SYMP
advanced	SYMP
non-small-cell	SYMP
lung	SYMP
cancer	SYMP
(	SYMP
la-nsclc	SYMP
)	SYMP
are	O
eligible	O
for	O
combined-modality	SYMP
therapy	SYMP
(	SYMP
cmt	SYMP
;	SYMP
chemotherapy	SYMP
and	SYMP
radiotherapy	SYMP
)	SYMP
.	O
over	O
the	O
past	O
twenty	O
years	O
combination	SYMP
chemotherapy	SYMP
has	O
continued	O
to	O
produce	O
small	O
survival	O
gains	O
for	O
patients	O
with	O
sclc	SYMP
.	O
purpose	O
:	O
the	O
benefit	O
of	O
whole-lung	SYMP
irradiation	SYMP
(	SYMP
wli	SYMP
)	SYMP
for	O
patients	O
who	O
have	O
pulmonary	SYMP
metastases	SYMP
(	SYMP
pm	SYMP
)	SYMP
of	SYMP
ewing	SYMP
sarcoma	SYMP
family	SYMP
tumors	SYMP
(	SYMP
esft	SYMP
)	SYMP
is	O
unclear	O
.	O
extent	O
of	O
pulmonary	O
involvement	O
at	O
diagnosis	O
,	O
response	O
of	O
pm	SYMP
after	O
induction	SYMP
chemotherapy	SYMP
,	O
local	O
treatment	O
of	O
pm	O
thereafter	O
,	O
and	O
clinical	O
outcome	O
were	O
recorded	O
.	O
conclusions	O
:	O
the	O
comparable	O
survival	O
of	O
patients	O
with	O
poor	O
and	O
good	O
response	O
of	O
pm	SYMP
to	O
induction	SYMP
chemotherapy	SYMP
suggests	O
that	O
wli	SYMP
may	O
benefit	O
poor	O
responders	O
.	O
objective	O
:	O
to	O
report	O
the	O
use	O
of	O
heparin	SYMP
and	O
enoxaparin	SYMP
for	O
radiation-induced	SYMP
myelopathy	SYMP
.	O
therefore	O
,	O
patients	O
with	O
radiation-induced	SYMP
spinal	SYMP
cord	SYMP
injury	SYMP
may	O
benefit	O
from	O
anticoagulant	SYMP
therapy	SYMP
.	O
conclusions	O
:	O
heparin	SYMP
and/or	SYMP
enoxaparin	SYMP
may	O
be	O
considered	O
as	O
potential	O
treatments	O
for	O
patients	O
with	O
radiation-induced	SYMP
myelopathy	SYMP
.	O
tracheal	O
stent	O
insertion	O
is	O
a	O
useful	O
method	O
for	O
patients	O
with	O
malignant	O
tracheal	O
stenosis	O
.	O
expandable	SYMP
metal	SYMP
stents	SYMP
were	O
inserted	O
in	O
two	O
patients	O
with	O
severe	SYMP
dyspnea	SYMP
due	SYMP
to	SYMP
tracheal	SYMP
stenosis	SYMP
caused	SYMP
by	SYMP
lung	SYMP
cancer	SYMP
and	SYMP
esophageal	SYMP
cancer	SYMP
.	O
thus	O
,	O
we	O
should	O
recognize	O
this	O
immanent	O
risk	O
and	O
perform	O
peri-	SYMP
and	SYMP
postoperative	SYMP
management	SYMP
for	O
patients	O
with	O
gh-producing	SYMP
tumors	SYMP
.	O
background	O
:	O
at	O
present	O
the	O
addition	SYMP
of	SYMP
thoracic	SYMP
irradiation	SYMP
to	SYMP
combination	SYMP
chemotherapy	SYMP
is	O
a	O
standard	O
treatment	O
for	O
limited	SYMP
staged	SYMP
small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
.	O
we	O
conducted	O
a	O
phase	O
ii	O
study	O
of	O
etoposide	SYMP
(	SYMP
vp-16	SYMP
)	SYMP
-ifosfamide-cisplatin	SYMP
(	SYMP
vip	SYMP
)	SYMP
combination	SYMP
chemotherapy	SYMP
plus	SYMP
early	SYMP
concurrent	SYMP
thoracic	SYMP
irradiation	SYMP
for	O
the	O
patients	O
with	O
previously	O
untreated	SYMP
limited	SYMP
small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
in	O
order	O
to	O
assess	O
if	O
the	O
treatment	O
modality	O
could	O
improve	O
the	O
response	O
rate	O
and	O
the	O
toxicity	O
.	O
methods	O
:	O
forty-four	O
patients	O
with	O
limited	SYMP
small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
were	O
treated	O
with	O
etoposide-ifosfamide-cisplatin	SYMP
and	SYMP
concurrent	SYMP
thoracic	SYMP
irradiation	SYMP
.	O
conclusion	O
:	O
vip	SYMP
combination	SYMP
chemotherapy	SYMP
and	SYMP
early	SYMP
concurrent	SYMP
thoracic	SYMP
irradiation	SYMP
for	O
patients	O
with	O
limited	SYMP
stage	SYMP
small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
revealed	O
excellent	O
antitumor	O
response	O
with	O
tolerable	O
toxicity	O
.	O
in	O
this	O
study	O
we	O
analyzed	O
33	O
cases	O
which	O
underwent	O
complete	SYMP
surgical	SYMP
resection	SYMP
to	O
assess	O
the	O
role	O
of	O
surgery	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
n	SYMP
2	SYMP
nsclc	SYMP
.	O
we	O
thereby	O
recommend	O
that	O
surgery	SYMP
should	O
only	O
be	O
performed	O
for	O
those	O
n	SYMP
2	SYMP
nsclc	SYMP
patients	O
diagnosed	O
as	O
t	O
1	O
or	O
t	O
2	O
with	O
a	O
classification	O
of	O
p1	O
or	O
less	O
.	O
inhaled	SYMP
corticosteroid	SYMP
therapy	SYMP
is	O
recommended	O
for	O
patients	O
with	O
persistent	SYMP
disease	SYMP
,	O
and	O
careful	O
instruction	O
in	O
the	O
use	O
of	O
metered-dose	O
inhalers	O
is	O
particularly	O
important	O
for	O
the	O
elderly	O
.	O
background	O
:	O
the	O
role	O
of	O
surgical	SYMP
staging	SYMP
of	O
patients	O
with	O
non-small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
(	SYMP
nsclc	SYMP
)	SYMP
continues	O
to	O
evolve	O
.	O
this	O
report	O
describes	O
our	O
findings	O
utilizing	O
routine	O
cervical	O
mediastinoscopy	O
in	O
the	O
evaluation	O
of	O
peripheral	O
t1	O
(	O
less	O
than	O
3	O
cm	O
)	O
lung	O
tumors	O
.	O
mediastinoscopy	O
facilitates	O
identification	O
of	O
patients	O
with	O
regionally	SYMP
advanced	SYMP
disease	SYMP
prior	SYMP
to	SYMP
resection	SYMP
,	O
allowing	O
neoadjuvant	SYMP
therapy	SYMP
and	O
avoiding	O
unnecessary	O
resections	O
.	O
purpose	O
:	O
given	O
the	O
cisplatin-related	O
myelotoxicity	O
and	O
nonhematologic	O
toxicities	O
,	O
we	O
were	O
prompted	O
to	O
undertake	O
a	O
study	O
of	O
the	O
noncisplatin	SYMP
combination	SYMP
of	SYMP
paclitaxel	SYMP
plus	SYMP
gemcitabine	SYMP
to	O
evaluate	O
the	O
efficacy	O
,	O
tolerance	O
,	O
and	O
survival	O
of	O
this	O
combination	O
in	O
patients	O
with	O
locally	SYMP
advanced	SYMP
and	SYMP
metastatic	SYMP
non-small-cell	SYMP
lung	SYMP
cancer	SYMP
(	SYMP
nsclc	SYMP
)	SYMP
.	O
we	O
evaluated	O
the	O
role	O
of	O
systemic	SYMP
chemotherapy	SYMP
for	O
patients	O
with	O
malignant	SYMP
pleural	SYMP
effusions	SYMP
from	SYMP
nsclc	SYMP
.	O
methods	O
:	O
we	O
analyzed	O
34	O
patients	O
who	O
were	O
found	O
to	O
have	O
malignant	SYMP
pleural	SYMP
effusions	SYMP
in	O
the	O
course	O
of	O
diagnosis	O
of	O
118	O
patients	O
enrolled	O
in	O
three	O
consecutive	O
clinical	O
trials	O
on	O
advanced	O
nsclc	SYMP
assessing	O
combination	SYMP
chemotherapy	SYMP
of	SYMP
cisplatin	SYMP
,	SYMP
ifosfamide	SYMP
,	SYMP
and	SYMP
irinotecan	SYMP
with	SYMP
recombinant	SYMP
human	SYMP
granulocyte	SYMP
colony-stimulating	SYMP
factor	SYMP
support	SYMP
.	O
conclusions	O
:	O
both	O
the	O
response	O
rate	O
and	O
survival	O
data	O
in	O
this	O
retrospective	O
study	O
suggest	O
a	O
high	O
degree	O
of	O
activity	O
of	O
this	O
combination	SYMP
chemotherapy	SYMP
in	O
patients	O
with	O
malignant	SYMP
pleural	SYMP
effusions	SYMP
from	SYMP
nsclc	SYMP
.	O
in	O
contrast	O
,	O
the	O
introduction	O
and	O
improvement	O
of	O
chemotherapy	SYMP
since	O
the	O
1970s	O
gave	O
rise	O
to	O
an	O
improvement	O
in	O
-	O
only	O
short-term	O
(	O
less	O
than	O
2	O
years	O
)	O
-	O
survival	O
for	O
patients	O
with	O
small-cell	SYMP
lung	SYMP
cancer	SYMP
.	O
between	O
july	O
1992	O
and	O
december	O
1997	O
,	O
1799	O
patients	O
were	O
diagnosed	O
as	O
having	O
lung	SYMP
cancer	SYMP
in	O
our	O
hospital	O
and	O
926	O
patients	O
received	O
chemotherapy	SYMP
and/or	SYMP
thoracic	SYMP
radiotherapy	SYMP
.	O
the	O
administration	O
of	O
mitomycin	SYMP
c	SYMP
in	O
addition	O
to	O
cisplatin-based	SYMP
regimens	SYMP
for	O
patients	O
with	O
lung	SYMP
cancer	SYMP
should	O
be	O
carefully	O
considered	O
.	O
570	O
patients	O
with	O
osteosarcoma	SYMP
of	SYMP
the	SYMP
extremities	SYMP
were	O
treated	O
with	O
five	O
different	O
protocols	O
of	O
neoadjuvant	SYMP
chemotherapy	SYMP
at	O
rizzoli	O
institute	O
between	O
1983	O
and	O
1995	O
.	O
we	O
conclude	O
that	O
for	O
patients	O
with	O
osteosarcoma	SYMP
of	SYMP
the	SYMP
extremities	SYMP
treated	O
with	O
neoadjuvant	SYMP
chemotherapy	SYMP
:	O
(	O
a	O
)	O
the	O
pattern	O
of	O
systemic	O
relapse	O
changes	O
according	O
to	O
the	O
efficacy	O
of	O
the	O
protocol	O
of	O
chemotherapy	O
used	O
.	O
the	O
degree	O
of	O
healing	O
and	O
damage	O
of	O
the	O
bronchial	O
wall	O
after	O
photodynamic	SYMP
therapy	SYMP
,	SYMP
nd-yag	SYMP
laser	SYMP
and	SYMP
electrocautery	SYMP
for	O
intraluminal	SYMP
early-stage	SYMP
cancer	SYMP
have	O
been	O
analysed	O
.	O
to	O
examine	O
whether	O
efficacy	O
of	O
postoperative	O
oral	O
administration	O
of	O
uft	SYMP
,	SYMP
a	SYMP
5-fluorouracil	SYMP
derivative	SYMP
chemotherapeutic	SYMP
agent	SYMP
,	O
may	O
be	O
influenced	O
by	O
incidence	O
of	O
apoptosis	O
(	O
apoptosis	O
index	O
)	O
or	O
apoptosis-related	O
gene	O
status	O
(	O
p53	O
and	O
bcl-2	O
)	O
of	O
the	O
tumour	O
,	O
a	O
total	O
of	O
162	O
patients	O
with	O
pathologic	SYMP
stage	SYMP
i	SYMP
non-small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
were	O
retrospectively	O
reviewed	O
.	O
objectives	O
:	O
the	O
purpose	O
of	O
this	O
study	O
is	O
to	O
review	O
our	O
experience	O
with	O
the	O
spectrum	O
of	O
neuroendocrine	SYMP
neoplasms	SYMP
of	SYMP
the	SYMP
lung	SYMP
with	O
emphasis	O
on	O
the	O
histopathologic	O
classification	O
and	O
surgical	SYMP
therapy	SYMP
of	O
each	O
class	O
of	O
neoplasm	O
.	O
patients	O
:	O
during	O
this	O
period	O
,	O
a	O
total	O
of	O
77	O
patients	O
underwent	O
lung	SYMP
resection	SYMP
for	O
the	O
following	O
neuroendocrine	SYMP
neoplasms	SYMP
:	O
typical	SYMP
carcinoid	SYMP
(	SYMP
tc	SYMP
)	SYMP
,	O
50	O
patients	O
;	O
atypical	SYMP
carcinoid	SYMP
(	SYMP
ac	SYMP
)	SYMP
,	O
5	O
patients	O
;	O
large	SYMP
cell	SYMP
neuroendocrine	SYMP
carcinoma	SYMP
(	SYMP
lcnec	SYMP
)	SYMP
,	O
9	O
patients	O
;	O
mixed	SYMP
large-small	SYMP
cell	SYMP
neuroendocrine	SYMP
carcinoma	SYMP
(	SYMP
lsnec	SYMP
)	SYMP
,	O
4	O
patients	O
;	O
or	O
small	SYMP
cell	SYMP
neuroendocrine	SYMP
carcinoma	SYMP
(	SYMP
scc	SYMP
)	SYMP
,	O
9	O
patients	O
.	O
despite	O
the	O
poor	O
overall	O
prognosis	O
in	O
high-grade	O
neuroendocrine	SYMP
tumors	SYMP
of	SYMP
the	SYMP
lung	SYMP
,	O
surgery	SYMP
remains	O
a	O
viable	O
adjunct	O
in	O
the	O
early	O
stages	O
of	O
this	O
disease	O
.	O
urpose	O
:	O
to	O
assess	O
results	O
with	O
twice-daily	O
high-dose	O
radiotherapy	SYMP
(	SYMP
rt	SYMP
)	SYMP
for	O
non-small-cell	SYMP
lung	SYMP
cancer	SYMP
(	SYMP
nsclc	SYMP
)	SYMP
.	O
is	O
prolonged	O
survival	O
possible	O
for	O
patients	O
with	O
supraclavicular	SYMP
node	SYMP
metastases	SYMP
in	SYMP
nsclc	SYMP
treated	O
with	O
chemoradiotherapy	SYMP
?	O
ijrobp	O
1999	O
;	O
44	O
(	O
4	O
)	O
:	O
847-853	O
.	O
we	O
aimed	O
to	O
investigate	O
whether	O
biological	O
factors	O
related	O
to	O
radiosensitivity	O
and	O
chemosensitivity	O
have	O
prognostic	O
significance	O
in	O
non-small-cell-lung-cancer	SYMP
(	SYMP
nsclc	SYMP
)	SYMP
patients	O
treated	O
with	O
daily	O
low	O
doses	O
of	O
cisplatin	SYMP
and	SYMP
radiotherapy	SYMP
.	O
we	O
treated	O
27	O
nsclcm	SYMP
patients	O
with	O
concomitant	O
daily	O
low-dose	O
cisplatin	SYMP
and	SYMP
radiotherapy	SYMP
between	O
1993	O
and	O
1995	O
.	O
background	O
:	O
we	O
examined	O
the	O
complications	O
and	O
outcomes	O
of	O
placing	O
stents	SYMP
for	O
both	O
esophageal	SYMP
and	SYMP
tracheobronchial	SYMP
stenoses	SYMP
.	O
methods	O
:	O
we	O
placed	O
stents	SYMP
for	O
both	O
esophageal	SYMP
and	SYMP
tracheobronchial	SYMP
stenoses	SYMP
in	O
8	O
patients	O
(	O
7	O
with	O
esophageal	O
cancer	O
and	O
1	O
with	O
lung	O
cancer	O
)	O
.	O
covered	O
or	O
noncovered	O
metallic	SYMP
stents	SYMP
were	O
used	O
for	O
the	O
esophageal	SYMP
stenoses	SYMP
,	O
except	O
in	O
1	O
patient	O
treated	O
with	O
a	O
silicone	O
stent	O
.	O
silicone	SYMP
stents	SYMP
were	O
used	O
for	O
the	O
tracheobronchial	SYMP
stenoses	SYMP
.	O
results	O
:	O
all	O
patients	O
experienced	O
improvement	O
of	O
grades	O
of	O
both	O
dysphagia	SYMP
and	SYMP
respiratory	SYMP
symptoms	SYMP
after	O
stent	SYMP
therapy	SYMP
.	O
conclusions	O
:	O
for	O
patients	O
with	O
both	O
esophageal	SYMP
and	SYMP
tracheobronchial	SYMP
stenoses	SYMP
,	O
a	O
stent	SYMP
should	O
be	O
introduced	O
into	O
the	O
tracheobronchus	O
first	O
.	O
because	O
placement	O
of	O
stents	O
in	O
both	O
the	O
esophagus	O
and	O
tracheobronchus	O
has	O
a	O
high	O
risk	O
of	O
enlargement	O
of	O
the	O
fistula	O
,	O
a	O
covered	SYMP
metallic	SYMP
stent	SYMP
is	O
preferable	O
for	O
esophageal	SYMP
cancer	SYMP
involving	SYMP
the	SYMP
tracheobronchus	SYMP
.	O
a	O
retrospective	O
immunohistochemical	O
study	O
was	O
performed	O
on	O
material	O
from	O
patients	O
who	O
were	O
newly	O
diagnosed	O
with	O
osteogenic	SYMP
sarcoma	SYMP
who	O
were	O
treated	O
according	O
to	O
the	O
t12	SYMP
protocol	SYMP
from	O
the	O
authors	O
'	O
institution	O
between	O
1986	O
to	O
1993	O
.	O
these	O
data	O
suggest	O
that	O
her2/erbb-2	O
should	O
be	O
evaluated	O
prospectively	O
as	O
a	O
prognostic	O
indicator	O
and	O
clinical	O
trials	O
using	O
antibodies	SYMP
that	O
target	O
this	O
receptor	O
should	O
be	O
considered	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
osteogenic	SYMP
sarcoma	SYMP
.	O
objective	O
:	O
to	O
examine	O
the	O
effectiveness	O
of	O
ninjin	SYMP
yoei	SYMP
to	SYMP
(	SYMP
nyt	SYMP
;	SYMP
ren-shen-yang-rong-tang	SYMP
in	SYMP
chinese	SYMP
medicine	SYMP
;	SYMP
kotaro	SYMP
pharmaceutical	SYMP
co.	SYMP
,	SYMP
ltd.	SYMP
,	SYMP
osaka	SYMP
,	SYMP
japan	SYMP
)	SYMP
,	SYMP
one	SYMP
of	SYMP
the	SYMP
traditional	SYMP
herbal	SYMP
medicines	SYMP
,	O
against	O
lung	SYMP
carcinoma	SYMP
.	O
setting	O
:	O
the	O
nursing	O
center	O
himawari	O
design	O
,	O
patient	O
,	O
and	O
preparation	O
:	O
the	O
regular	O
dosage	O
of	O
nyt	SYMP
(	O
15	O
g/d	O
)	O
was	O
prescribed	O
for	O
7	O
weeks	O
to	O
one	O
elderly	O
patient	O
with	O
lung	SYMP
carcinoma	SYMP
.	O
conclusion	O
:	O
nyt	SYMP
has	O
a	O
positive	O
effect	O
on	O
life	O
expectancy	O
for	O
patients	O
with	O
malignancy	SYMP
.	O
background	O
:	O
the	O
costs	O
of	O
videothoracoscopic	SYMP
procedures	SYMP
for	O
patients	O
with	O
lung	SYMP
carcinoma	SYMP
were	O
compared	O
with	O
those	O
of	O
patients	O
who	O
underwent	O
open	SYMP
thoracotomy	SYMP
in	O
japan	O
.	O
methods	O
:	O
the	O
cost	O
of	O
surgical	SYMP
treatment	SYMP
in	O
1997	O
and	O
1998	O
for	O
patients	O
with	O
resectable	SYMP
primary	SYMP
or	SYMP
metastatic	SYMP
lung	SYMP
carcinoma	SYMP
was	O
analyzed	O
from	O
itemized	O
statements	O
of	O
hospital	O
charges	O
.	O
for	O
patients	O
with	O
lung	SYMP
carcinoma	SYMP
who	O
are	O
in	O
relatively	O
poor	O
health	O
,	O
the	O
authors	O
chose	O
videothoracoscopic	SYMP
lobectomy	SYMP
or	SYMP
partial	SYMP
resection	SYMP
of	SYMP
the	SYMP
lung	SYMP
instead	O
of	O
an	O
open	O
thoracotomy	O
.	O
for	O
patients	O
with	O
solitary	SYMP
pulmonary	SYMP
metastasis	SYMP
,	O
the	O
authors	O
routinely	O
performed	O
thoracoscopic	SYMP
partial	SYMP
resection	SYMP
of	SYMP
the	SYMP
lung	SYMP
.	O
background	O
:	O
curative	SYMP
therapy	SYMP
is	O
available	O
for	O
patients	O
with	O
stage	SYMP
0	SYMP
lung	SYMP
carcinoma	SYMP
,	O
with	O
a	O
greater	O
than	O
90	O
%	O
5-year	O
survival	O
rate	O
.	O
promising	O
chemopreventive	SYMP
agents	SYMP
also	O
are	O
under	O
investigation	O
currently	O
to	O
reduce	O
the	O
risk	O
of	O
lung	SYMP
carcinoma	SYMP
in	O
high	O
risk	O
populations	O
.	O
object	O
:	O
the	O
purpose	O
of	O
this	O
retrospective	O
study	O
was	O
to	O
compare	O
the	O
effectiveness	O
of	O
gamma	SYMP
knife	SYMP
radiosurgery	SYMP
(	SYMP
gks	SYMP
)	SYMP
for	O
multiple	SYMP
cerebral	SYMP
metastases	SYMP
with	O
that	O
of	O
whole-brain	SYMP
radiation	SYMP
therapy	SYMP
(	SYMP
wbrt	SYMP
)	SYMP
.	O
in	O
the	O
gks	O
group	O
,	O
large	O
lesions	O
(	O
greater	O
than	O
30	O
mm	O
)	O
were	O
removed	O
surgically	O
and	O
all	O
other	O
small	SYMP
lesions	SYMP
(	O
less	O
than	O
or	O
=	O
30	O
mm	O
)	O
were	O
treated	O
by	O
gks	SYMP
.	O
new	O
distant	SYMP
lesions	SYMP
were	O
treated	O
by	O
repeated	O
gks	SYMP
without	O
prophylactic	O
wbrt	O
.	O
conclusions	O
:	O
gamma	SYMP
knife	SYMP
radiosurgery	SYMP
without	O
prophylactic	O
wbrt	O
could	O
be	O
a	O
primary	O
choice	O
of	O
treatment	O
for	O
patients	O
with	O
as	O
many	O
as	O
10	O
cerebral	SYMP
metastases	SYMP
from	SYMP
nonsmall	SYMP
cell	SYMP
cancer	SYMP
.	O
the	O
notable	O
exception	O
has	O
been	O
docetaxel	SYMP
,	O
which	O
has	O
been	O
extensively	O
studied	O
as	O
a	O
second-line	O
therapy	O
for	O
nsclc	SYMP
.	O
object	O
:	O
the	O
purpose	O
of	O
this	O
retrospective	O
study	O
was	O
to	O
compare	O
the	O
effectiveness	O
of	O
gamma	SYMP
knife	SYMP
radiosurgery	SYMP
(	SYMP
gks	SYMP
)	SYMP
for	O
multiple	SYMP
cerebral	SYMP
metastases	SYMP
with	O
that	O
of	O
whole-brain	SYMP
radiation	SYMP
therapy	SYMP
(	SYMP
wbrt	SYMP
)	SYMP
.	O
patients	O
with	O
a	O
single	SYMP
non-sclc	SYMP
,	SYMP
breast	SYMP
,	SYMP
melanoma	SYMP
,	SYMP
renal	SYMP
cell	SYMP
,	SYMP
and	SYMP
ovarian	SYMP
carcinoma	SYMP
brain	SYMP
metastasis	SYMP
have	O
the	O
best	O
chance	O
for	O
long-term	O
survival	O
if	O
treated	O
with	O
surgical	SYMP
resection	SYMP
and	SYMP
wbrt	SYMP
.	O
objective	O
:	O
careful	O
patient	O
selection	O
is	O
vital	O
when	O
video-assisted	SYMP
thoracoscopic	SYMP
surgical	SYMP
(	SYMP
vats	SYMP
)	SYMP
therapeutic	SYMP
pulmonary	SYMP
metastasectomy	SYMP
of	O
colorectal	SYMP
carcinoma	SYMP
is	O
considered	O
.	O
we	O
reviewed	O
our	O
vats	O
experience	O
for	O
therapeutic	SYMP
metastasectomy	SYMP
of	O
peripheral	SYMP
colorectal	SYMP
pulmonary	SYMP
metastases	SYMP
.	O
methods	O
:	O
over	O
90	O
months	O
,	O
therapeutic	SYMP
vats	SYMP
metastasectomy	SYMP
was	O
accomplished	O
upon	O
80	O
patients	O
with	O
colorectal	SYMP
metastases	SYMP
.	O
conclusions	O
:	O
therapeutic	SYMP
vats	SYMP
resection	SYMP
of	O
colorectal	SYMP
metastases	SYMP
appears	O
efficacious	O
.	O
objectives	O
:	O
to	O
review	O
the	O
spectrum	O
of	O
presentation	O
and	O
the	O
surgical	SYMP
management	SYMP
of	O
non	SYMP
small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
(	SYMP
nsclc	SYMP
)	SYMP
and	O
the	O
role	O
of	O
various	O
diagnostic	O
modalities	O
in	O
predicting	O
the	O
post-operative	O
stage	O
and	O
the	O
correlation	O
of	O
the	O
post-operative	O
stage	O
with	O
the	O
chances	O
of	O
recurrence	O
.	O
patients	O
with	O
limited-stage	SYMP
small-cell	SYMP
carcinoma	SYMP
of	SYMP
the	SYMP
lung	SYMP
are	O
treated	O
with	O
combined-modality	SYMP
therapy	SYMP
with	O
the	O
intent	O
to	O
cure	O
.	O
in	O
the	O
past	O
several	O
years	O
,	O
new	SYMP
chemotherapeutic	SYMP
agents	SYMP
,	SYMP
including	SYMP
the	SYMP
taxanes	SYMP
and	SYMP
the	SYMP
topoisomerase	SYMP
i	SYMP
inhibitors	SYMP
,	O
have	O
demonstrated	O
substantial	O
activity	O
against	O
small-cell	SYMP
carcinoma	SYMP
.	O
we	O
evaluated	O
the	O
role	O
of	O
chemotherapy	SYMP
for	O
patients	O
with	O
brain	SYMP
metastases	SYMP
from	SYMP
nsclc	SYMP
.	O
methods	O
:	O
we	O
analyzed	O
30	O
patients	O
who	O
were	O
discovered	O
to	O
have	O
brain	O
metastases	O
during	O
the	O
diagnosis	O
of	O
121	O
patients	O
enrolled	O
in	O
three	O
consecutive	O
clinical	O
trials	O
on	O
advanced	SYMP
nsclc	SYMP
assessing	O
combination	SYMP
chemotherapy	SYMP
of	SYMP
cisplatin	SYMP
,	SYMP
ifosfamide	SYMP
and	SYMP
irinotecan	SYMP
with	SYMP
rhg-csf	SYMP
support	SYMP
.	O
conclusions	O
:	O
both	O
the	O
response	O
rate	O
and	O
survival	O
data	O
in	O
this	O
retrospective	O
study	O
suggest	O
a	O
high	O
degree	O
of	O
activity	O
of	O
this	O
combination	SYMP
chemotherapy	SYMP
in	O
patients	O
with	O
brain	SYMP
metastases	SYMP
from	SYMP
nsclc	SYMP
.	O
the	O
aim	O
of	O
this	O
study	O
was	O
the	O
evaluation	O
of	O
both	O
the	O
antitumour	O
activity	O
and	O
toxicity	O
of	O
an	O
immunochemotherapeutic	SYMP
regimen	SYMP
consisting	SYMP
of	SYMP
interferon-alpha2b	SYMP
and	SYMP
interleukin-2	SYMP
in	SYMP
combination	SYMP
with	SYMP
fotemustine	SYMP
for	O
patients	O
with	O
metastatic	SYMP
melanoma	SYMP
.	O
to	O
explore	O
the	O
induction	O
of	O
chemotherapy	SYMP
(	SYMP
ct	SYMP
)	SYMP
dna	O
damage	O
and	O
its	O
correlation	O
with	O
tumor	O
response	O
and	O
patient	O
survival	O
,	O
we	O
undertook	O
the	O
present	O
study	O
in	O
20	O
small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
(	SYMP
sclc	SYMP
)	SYMP
patients	O
.	O
in	O
patients	O
with	O
metastatic	SYMP
colorectal	SYMP
cancer	SYMP
,	O
intravenous	SYMP
oxaliplatin	SYMP
has	O
been	O
trialled	O
as	O
a	O
monotherapy	O
and	O
in	O
combination	O
with	O
other	O
agents	O
.	O
neoadjuvant	SYMP
therapy	SYMP
with	SYMP
oxaliplatin/fluorouracil/folinic	SYMP
acid	SYMP
has	O
proven	O
beneficial	O
in	O
enabling	O
surgical	O
removal	O
of	O
previously	O
unresectable	SYMP
liver	SYMP
metastases	SYMP
.	O
in	O
2	O
studies	O
,	O
surgery	SYMP
with	O
curative	O
intent	O
was	O
performed	O
in	O
16	O
and	O
51	O
%	O
of	O
patients	O
with	O
initially	O
unresectable	SYMP
liver	SYMP
metastases	SYMP
following	O
oxaliplatin/fluorouracil/folinic	SYMP
acid	SYMP
therapy	SYMP
;	O
the	O
5-year	O
survival	O
rates	O
were	O
40	O
and	O
50	O
%	O
,	O
respectively	O
.	O
in	O
patients	O
with	O
advanced	SYMP
ovarian	SYMP
cancer	SYMP
,	O
first-line	O
therapy	O
with	O
oxaliplatin/cyclophosphamide	SYMP
achieved	O
an	O
objective	O
response	O
rate	O
which	O
did	O
not	O
differ	O
significantly	O
from	O
that	O
of	O
cisplatin/cyclophosphamide	SYMP
(	O
33	O
vs	O
42	O
%	O
)	O
.	O
in	O
addition	O
,	O
oxaliplatin	SYMP
has	O
shown	O
efficacy	O
in	O
patients	O
with	O
platinum-pretreated	SYMP
ovarian	SYMP
cancer	SYMP
and	O
achieved	O
objective	O
response	O
rates	O
similar	O
to	O
paclitaxel	O
in	O
this	O
setting	O
(	O
16	O
vs	O
17	O
%	O
)	O
.	O
promising	O
results	O
have	O
also	O
been	O
found	O
with	O
oxaliplatin	SYMP
in	O
patients	O
with	O
non-hodgkin	SYMP
's	SYMP
lymphoma	SYMP
,	SYMP
breast	SYMP
cancer	SYMP
,	SYMP
mesothelioma	SYMP
and	SYMP
non-small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
.	O
conclusion	O
:	O
oxaliplatin	SYMP
in	SYMP
combination	SYMP
with	SYMP
fluorouracil/folinic	SYMP
acid	SYMP
is	O
an	O
effective	O
treatment	O
option	O
for	O
patients	O
with	O
metastatic	SYMP
colorectal	SYMP
cancer	SYMP
,	O
both	O
as	O
a	O
first-line	O
therapy	O
and	O
in	O
patients	O
refractory	O
to	O
previous	O
chemotherapy	O
.	O
additional	O
clinical	O
investigation	O
of	O
oxaliplatin	SYMP
in	O
patients	O
with	O
other	O
cancers	SYMP
is	O
warranted	O
given	O
the	O
promising	O
results	O
achieved	O
in	O
early	O
trials	O
,	O
most	O
notably	O
in	O
patients	O
with	O
platinum-pretreated	O
ovarian	O
cancer	O
.	O
combined	SYMP
modality	SYMP
treatment	SYMP
has	O
'come	O
out	O
of	O
age	O
'	O
and	O
increasingly	O
represents	O
standard	O
of	O
care	O
for	O
a	O
rapidly	O
growing	O
number	O
of	O
patients	O
in	O
locally	O
advanced	O
stages	O
of	O
nsclc	SYMP
.	O
the	O
current	O
study	O
was	O
designed	O
to	O
assess	O
the	O
prognostic	O
value	O
of	O
immunomorphologic	O
changes	O
in	O
locoregional	O
lymph	O
nodes	O
and	O
lymphocytic	O
infiltration	O
of	O
primary	O
tumor	O
(	O
li	O
)	O
in	O
patients	O
who	O
undergo	O
resection	SYMP
for	O
bronchogenic	SYMP
carcinoma	SYMP
.	O
conclusions	O
:	O
lymph	O
node	O
immunoreactivity	O
and	O
li	O
significantly	O
influence	O
long	O
term	O
survival	O
after	O
curative	SYMP
surgery	SYMP
for	O
patients	O
with	O
carcinoma	SYMP
of	SYMP
the	SYMP
lung	SYMP
and	O
may	O
be	O
useful	O
in	O
stratifying	O
patients	O
for	O
prospective	O
trials	O
of	O
adjuvant	O
treatment	O
,	O
including	O
immunotherapy	O
.	O
the	O
drug	O
is	O
currently	O
in	O
phase	O
iii	O
clinical	O
trials	O
for	O
patients	O
with	O
non-small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
in	O
combination	O
with	O
paclitaxel	SYMP
and	SYMP
carboplatin	SYMP
,	O
as	O
well	O
as	O
in	O
advanced	SYMP
hormone	SYMP
refractory	SYMP
prostate	SYMP
cancer	SYMP
in	O
combination	O
with	O
mitoxantrone	SYMP
.	O
standard	O
treatment	O
of	O
sclc	SYMP
consists	O
of	O
platinum-based	SYMP
combination	SYMP
chemotherapy	SYMP
,	O
with	O
thoracic	O
irradiation	O
added	O
for	O
patients	O
with	O
limited-stage	O
disease	O
.	O
several	O
newer	O
chemotherapeutic	SYMP
drugs	SYMP
have	O
recently	O
been	O
shown	O
to	O
have	O
significant	O
activity	O
in	O
patients	O
with	O
untreated	SYMP
or	SYMP
relapsed	SYMP
sclc	SYMP
.	O
we	O
recently	O
performed	O
completion	SYMP
pneumonectomy	SYMP
of	SYMP
the	SYMP
left	SYMP
lung	SYMP
in	O
a	O
70-year-old	O
man	O
with	O
hemophilia	O
a	O
,	O
for	O
squamous	SYMP
cell	SYMP
carcinoma	SYMP
in	O
the	O
residual	O
left	O
lung	O
.	O
objective	O
:	O
several	O
reports	O
emphasize	O
the	O
importance	O
of	O
en-bloc	SYMP
resection	SYMP
as	O
the	O
optimal	O
surgical	O
treatment	O
of	O
lung	SYMP
cancer	SYMP
with	O
chest	O
wall	O
invasion	O
.	O
methods	O
:	O
between	O
1981	O
and	O
1998	O
,	O
100	O
patients	O
(	O
90	O
male	O
;	O
ten	O
female	O
)	O
,	O
with	O
a	O
median	O
age	O
of	O
60	O
years	O
(	O
36-84	O
)	O
,	O
underwent	O
radical	SYMP
en-bloc	SYMP
resection	SYMP
of	O
non-small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
(	SYMP
nsclc	SYMP
)	SYMP
with	O
chest	O
wall	O
involvement	O
.	O
over	O
the	O
past	O
17	O
years	O
(	O
1981	O
to	O
1997	O
)	O
,	O
29	O
patients	O
underwent	O
complete	SYMP
pulmonary	SYMP
resection	SYMP
for	O
primary	SYMP
lung	SYMP
cancer	SYMP
accompanied	O
by	O
satellite	O
nodules	O
in	O
the	O
same	O
lobe	O
as	O
the	O
primary	O
.	O
of	O
1	O
,	O
042	O
patients	O
with	O
primary	SYMP
lung	SYMP
cancer	SYMP
who	O
underwent	O
resection	SYMP
from	O
1982	O
to	O
1995	O
,	O
549	O
patients	O
with	O
adenocarcinoma	O
(	O
ad	O
)	O
and	O
363	O
with	O
squamous	O
cell	O
carcinoma	O
(	O
sq	O
)	O
were	O
included	O
in	O
this	O
study	O
.	O
for	O
small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
(	SYMP
sclc	SYMP
)	SYMP
,	O
which	O
accounts	O
for	O
approximately	O
20	O
%	O
of	O
cases	O
of	O
lung	O
cancer	O
,	O
the	O
primary	O
treatment	O
is	O
chemotherapy	SYMP
and	O
in	O
the	O
majority	O
of	O
cases	O
the	O
primary	O
aim	O
is	O
to	O
control	O
the	O
disease	O
which	O
generally	O
would	O
have	O
spread	O
beyond	O
the	O
lungs	O
at	O
the	O
time	O
of	O
presentation	O
.	O
a	O
growing	O
body	O
of	O
evidence	O
suggests	O
that	O
postoperative	SYMP
irradiation	SYMP
for	O
non-small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
may	O
cause	O
life-threatening	O
toxicity	O
and	O
,	O
when	O
the	O
risk	O
of	O
local-regional	O
recurrence	O
is	O
low	O
,	O
the	O
toxicity	O
of	O
irradiation	O
may	O
outweight	O
the	O
benefit	O
.	O
as	O
a	O
best-case	O
scenario	O
,	O
postoperative	SYMP
irradiation	SYMP
may	O
improve	O
the	O
chance	O
for	O
long-term	O
survival	O
in	O
patients	O
with	O
n2	SYMP
tumors	SYMP
.	O
for	O
patients	O
with	O
stage	SYMP
i	SYMP
or	SYMP
ii	SYMP
non-small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
(	SYMP
nsclc	SYMP
)	SYMP
,	O
surgical	SYMP
resection	SYMP
is	O
considered	O
the	O
standard	O
of	O
care	O
.	O
efforts	O
at	O
improving	O
survival	O
for	O
early-stage	SYMP
nsclc	SYMP
patients	O
have	O
focused	O
on	O
the	O
use	O
of	O
chemotherapy	SYMP
administered	O
postoperatively	O
(	O
adjuvant	O
)	O
or	O
preoperatively	O
(	O
neoadjuvant	O
or	O
induction	O
)	O
to	O
eradicate	O
micrometastatic	SYMP
disease	SYMP
.	O
chemotherapy	SYMP
administered	O
before	O
surgery	O
or	O
definitive	O
irradiation	O
has	O
improved	O
survival	O
rates	O
in	O
patients	O
with	O
stage	SYMP
iii	SYMP
nsclc	SYMP
.	O
patients	O
:	O
patients	O
with	O
a	O
single	O
(	O
n	O
=	O
2	O
,	O
764	O
)	O
and	O
synchronous	O
nsclc	SYMP
(	O
n	O
=	O
85	O
)	O
who	O
underwent	O
pulmonary	SYMP
resection	SYMP
.	O
background	O
:	O
prophylactic	SYMP
cranial	SYMP
irradiation	SYMP
halves	O
the	O
rate	O
of	O
brain	O
metastases	O
in	O
patients	O
with	O
small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
.	O
objectives	O
:	O
this	O
study	O
aims	O
to	O
test	O
whether	O
prophylactic	SYMP
cranial	SYMP
irradiation	SYMP
prolongs	O
survival	O
of	O
patients	O
with	O
small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
in	O
complete	O
remission	O
.	O
reviewer	O
's	O
conclusions	O
:	O
prophylactic	SYMP
cranial	SYMP
irradiation	SYMP
significantly	O
improves	O
survival	O
and	O
disease-free	O
survival	O
for	O
patients	O
with	O
small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
in	O
complete	O
remission	O
.	O
methods	O
:	O
non-small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
cells	O
were	O
treated	O
with	O
gemcitabine	SYMP
,	O
harvested	O
,	O
and	O
nuclear	O
extracts	O
analyzed	O
for	O
nf-kappab	O
dna	O
binding	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O
novel	O
treatment	O
strategies	O
for	O
patients	O
with	O
advanced	SYMP
nsclc	SYMP
may	O
involve	O
chemotherapy	SYMP
combined	O
with	O
inhibition	O
of	O
nf-kappab-dependent	O
cell-survival	O
pathways	O
.	O
combination	SYMP
chemotherapy	SYMP
is	O
the	O
cornerstone	O
of	O
treatment	O
that	O
confers	O
a	O
meaningful	O
survival	O
benefit	O
for	O
patients	O
with	O
small-cell	SYMP
lung	SYMP
cancer	SYMP
.	O
in	O
single-agent	O
phase	O
ii	O
studies	O
,	O
irinotecan	SYMP
yielded	O
response	O
rates	O
between	O
16	O
%	O
and	O
47	O
%	O
in	O
patients	O
with	O
previously	O
treated	O
small-cell	SYMP
lung	SYMP
cancer	SYMP
.	O
a	O
phase	O
ii	O
study	O
of	O
irinotecan	SYMP
in	SYMP
combination	SYMP
with	SYMP
cisplatin	SYMP
(	SYMP
platinol	SYMP
)	SYMP
resulted	O
in	O
a	O
response	O
rate	O
of	O
86	O
%	O
and	O
a	O
median	O
survival	O
of	O
13.0	O
months	O
in	O
patients	O
with	O
extensive-disease	SYMP
small-cell	SYMP
lung	SYMP
cancer	SYMP
.	O
based	O
on	O
these	O
results	O
,	O
the	O
irinotecan	SYMP
and	SYMP
cisplatin	SYMP
combination	SYMP
is	O
a	O
new	O
standard	O
regimen	O
in	O
the	O
treatment	O
of	O
extensive-disease	SYMP
small-cell	SYMP
lung	SYMP
cancer	SYMP
.	O
background	O
:	O
both	O
gemcitabine	SYMP
and	SYMP
etoposide	SYMP
are	O
active	O
in	O
the	O
treatment	O
of	O
small-cell	SYMP
lung	SYMP
cancer	SYMP
(	SYMP
sclc	SYMP
)	SYMP
,	O
and	O
are	O
characterised	O
by	O
mild	O
toxicity	O
profiles	O
.	O
patients	O
and	O
methods	O
:	O
forty-two	O
chemo-naive	O
extensive	O
disease	O
sclc	SYMP
patients	O
were	O
enrolled	O
to	O
receive	O
gemcitabine	SYMP
1000	O
mg/m2	O
,	O
days	O
1	O
,	O
8	O
and	O
15	O
,	O
and	O
etoposide	SYMP
80	O
mg/m2	O
,	O
days	O
8	O
,	O
9	O
and	O
10	O
of	O
a	O
28-day	O
cycle	O
.	O
background	O
:	O
to	O
find	O
the	O
maximum	O
tolerated	O
dose	O
for	O
ifosfamide	SYMP
in	SYMP
combination	SYMP
with	SYMP
paclitaxel	SYMP
and	SYMP
carboplatin	SYMP
in	O
small-cell	SYMP
lung	SYMP
cancer	SYMP
patients	O
(	O
sclc	O
)	O
,	O
who	O
are	O
resistant	O
to	O
cyclophosphamide	O
,	O
doxorubicin	O
and	O
etoposide	O
(	O
cde	O
)	O
.	O
conclusions	O
:	O
the	O
maximum	O
tolerated	O
dose	O
of	O
this	O
combination	O
for	O
patients	O
with	O
resistant	SYMP
sclc	SYMP
is	O
ifosfamide	SYMP
2000	O
mg/m2	O
in	O
combination	O
with	O
paclitaxel	SYMP
175	O
mg/m2	O
and	O
carboplatin	SYMP
auc	O
6	O
mg/ml	O
min	O
administered	O
on	O
the	O
first	O
day	O
of	O
a	O
21-day	O
cycle	O
.	O
many	O
endobronchial	SYMP
treatment	SYMP
modalities	SYMP
are	O
available	O
to	O
supplement	O
traditional	O
therapies	O
for	O
advanced	SYMP
lung	SYMP
cancer	SYMP
.	O
methods	O
:	O
the	O
author	O
reviews	O
the	O
use	O
of	O
several	O
endobronchial	SYMP
treatment	SYMP
modalities	SYMP
that	SYMP
can	SYMP
augment	SYMP
standard	SYMP
antitumor	SYMP
therapies	SYMP
for	O
advanced	O
lung	SYMP
cancer	SYMP
,	O
including	O
rigid	O
and	O
flexible	O
bronchoscopy	O
,	O
laser	O
therapy	O
,	O
endobronchial	O
prosthesis	O
,	O
and	O
photodynamic	O
therapy	O
.	O
conclusions	O
:	O
endobronchial	SYMP
interventions	SYMP
are	O
important	O
adjuncts	O
in	O
the	O
multimodality	O
management	O
of	O
lung	SYMP
cancer	SYMP
and	O
should	O
become	O
standard	O
considerations	O
in	O
the	O
management	O
of	O
patients	O
with	O
advanced	O
lung	O
cancer	O
.	O
standard	O
operations	O
for	O
lung	SYMP
cancer	SYMP
patients	O
are	O
generally	O
accepted	O
as	O
performing	O
lobectomy	SYMP
or	SYMP
pneumonectomy	SYMP
on	O
the	O
tumor	O
baring	O
lung	O
and	O
ipsilateral	O
hilar	O
and	O
mediastinal	O
lymphadenectomy	O
including	O
subcarinal	O
lymph	O
nodes	O
.	O
small	SYMP
cell	SYMP
lung	SYMP
cancer	SYMP
is	O
a	O
frequently	O
relapsing	O
tumor	O
despite	O
a	O
high	O
rate	O
of	O
response	O
after	O
first-line	O
chemotherapy	SYMP
.	O
for	O
symptomatic	SYMP
metastases	SYMP
in	SYMP
bone	SYMP
or	SYMP
brain	SYMP
,	O
radiotherapy	SYMP
usually	O
gives	O
temporary	O
palliation	O
.	O
for	O
intrathoracic	SYMP
relapse	SYMP
and	SYMP
severe	SYMP
obstruction	SYMP
of	SYMP
main	SYMP
bronchus	SYMP
and/or	SYMP
superior	SYMP
caval	SYMP
vein	SYMP
,	O
radiotherapy	SYMP
is	O
a	O
possibility	O
if	O
not	O
given	O
as	O
part	O
of	O
first-line	O
treatment	O
.	O
tumor	SYMP
vaccines	SYMP
against	O
gangliosides	O
that	O
are	O
expressed	O
on	O
almost	O
all	O
human	O
sclc	SYMP
cells	O
have	O
been	O
recently	O
developed	O
.	O
an	O
anti-idiotypic	SYMP
monoclonal	SYMP
antibody	SYMP
against	O
the	O
gd3	O
ganglioside	O
,	O
bec-2	O
,	O
is	O
being	O
evaluated	O
after	O
chemotherapy	O
in	O
sclc	SYMP
patients	O
in	O
a	O
european	O
study	O
.	O
the	O
matrix	SYMP
metalloproteinase	SYMP
inhibitors	SYMP
marimastat	SYMP
and	SYMP
bms-275291	SYMP
are	O
under	O
evaluation	O
in	O
sclc	SYMP
.	O
we	O
attempted	O
a	O
new	O
regimen	O
of	O
intermittent	O
administration	O
of	O
5-fu	SYMP
and	SYMP
low-dose	SYMP
isovorin	SYMP
(	SYMP
f.i	SYMP
)	SYMP
to	O
four	O
patients	O
with	O
advanced	O
and	O
recurrent	O
colon	SYMP
cancer	SYMP
.	O
purpose/objectives	O
:	O
to	O
describe	O
the	O
relationship	O
between	O
fatigue	O
and	O
nutritional	O
status	O
in	O
patients	O
receiving	O
radiation	SYMP
therapy	SYMP
for	O
lung	SYMP
cancer	SYMP
.	O
sample	O
:	O
45	O
adults	O
with	O
primary	O
cancer	SYMP
of	SYMP
the	SYMP
lung	SYMP
receiving	O
less	O
than	O
outpatient	O
primary	O
or	O
adjuvant	O
radiation	SYMP
therapy	SYMP
.	O
we	O
present	O
the	O
case	O
of	O
a	O
patient	O
with	O
metastatic	SYMP
transitional	SYMP
cell	SYMP
carcinoma	SYMP
of	SYMP
the	SYMP
bladder	SYMP
and	SYMP
renal	SYMP
failure	SYMP
who	O
underwent	O
successful	O
systemic	SYMP
chemotherapy	SYMP
with	SYMP
paclitaxel	SYMP
and	SYMP
carboplatin	SYMP
.	O
background	O
:	O
the	O
objective	O
of	O
this	O
phase	O
ii	O
study	O
was	O
to	O
evaluate	O
the	O
concept	O
of	O
sequential	SYMP
chemotherapy	SYMP
in	O
the	O
treatment	O
of	O
patients	O
with	O
advanced	SYMP
nonsmall	SYMP
cell	SYMP
lung	SYMP
carcinoma	SYMP
(	SYMP
nsclc	SYMP
)	SYMP
by	O
the	O
administration	O
of	O
carboplatin	SYMP
plus	SYMP
gemcitabine	SYMP
followed	SYMP
by	SYMP
of	SYMP
paclitaxel	SYMP
.	O
conclusions	O
:	O
this	O
study	O
is	O
the	O
first	O
to	O
evaluate	O
planned	SYMP
sequential	SYMP
chemotherapy	SYMP
in	O
patients	O
with	O
nsclc	SYMP
.	O
patients	O
who	O
benefit	O
from	O
a	O
surgical	SYMP
resection	SYMP
for	O
non-small-cell	SYMP
lung	SYMP
cancer	SYMP
with	O
aneuploid	O
dna	O
content	O
prove	O
to	O
have	O
a	O
higher	O
risk	O
of	O
death	O
.	O
purpose	O
:	O
this	O
randomized	O
trial	O
was	O
designed	O
to	O
determine	O
whether	O
paclitaxel	SYMP
plus	SYMP
carboplatin	SYMP
(	SYMP
pc	SYMP
)	SYMP
offered	O
a	O
survival	O
advantage	O
over	O
vinorelbine	SYMP
plus	SYMP
cisplatin	SYMP
(	SYMP
vc	SYMP
)	SYMP
for	O
patients	O
with	O
advanced	SYMP
non	SYMP
--	SYMP
small-cell	SYMP
lung	SYMP
cancer	SYMP
.	O
conclusion	O
:	O
pc	SYMP
is	O
equally	O
efficacious	O
as	O
vc	SYMP
for	O
the	O
treatment	O
of	O
advanced	SYMP
non	SYMP
--	SYMP
small-cell	SYMP
lung	SYMP
cancer	SYMP
.	O
purpose	O
:	O
a	O
prospective	O
randomized	O
trial	O
in	O
small-cell	O
lung	O
cancer	O
(	O
sclc	O
)	O
was	O
performed	O
to	O
determine	O
if	O
intensification	O
of	O
the	O
platinum	O
dose	O
by	O
giving	O
cisplatin	SYMP
and	SYMP
carboplatin	SYMP
in	O
combination	O
to	O
patients	O
with	O
sclc	SYMP
yields	O
higher	O
response	O
rates	O
and	O
survival	O
,	O
than	O
carboplatin	SYMP
alone	SYMP
in	SYMP
a	SYMP
combination	SYMP
chemotherapy	SYMP
regimen	SYMP
.	O
conclusions	O
:	O
the	O
intensification	SYMP
of	SYMP
platinum	SYMP
dose	SYMP
(	SYMP
cisplatin	SYMP
plus	SYMP
carboplatin	SYMP
)	SYMP
in	SYMP
combination	SYMP
chemotherapy	SYMP
significantly	O
increased	O
the	O
complete	O
response	O
rate	O
,	O
overall	O
survival	O
and	O
number	O
of	O
two-year	O
survivors	O
among	O
sclc	SYMP
patients	O
with	O
limited	O
disease	O
compared	O
to	O
combination	SYMP
therapy	SYMP
with	SYMP
carboplatin	SYMP
alone	SYMP
,	O
suggesting	O
that	O
a	O
more	O
aggressive	O
treatment	O
to	O
this	O
category	O
of	O
patients	O
is	O
worthwhile	O
,	O
while	O
no	O
difference	O
in	O
treatment	O
outcome	O
was	O
observed	O
for	O
patients	O
with	O
extensive	O
disease	O
.	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
relationships	O
among	O
technetium-99m	O
tetrofosmin	O
(	O
tc-tf	O
)	O
accumulation	O
in	O
untreated	O
small	O
cell	O
lung	O
cancer	O
(	O
sclc	O
)	O
,	O
the	O
expression	O
of	O
p-glycoprotein	O
(	O
pgp	O
)	O
and	O
multidrug	O
resistance	O
related	O
protein-1	O
(	O
mrp1	O
)	O
,	O
and	O
the	O
response	O
to	O
chemotherapy	SYMP
in	O
patients	O
with	O
untreated	SYMP
sclc	SYMP
.	O
tc-tf	O
chest	O
scintigraphy	O
correlated	O
well	O
with	O
pgp	O
or	O
mrp1	O
expression	O
and	O
accurately	O
predicted	O
the	O
response	O
to	O
chemotherapy	SYMP
in	O
patients	O
with	O
sclc	SYMP
.	O
exploratory	SYMP
interventions	SYMP
,	SYMP
partial	SYMP
tumor	SYMP
resections	SYMP
and	SYMP
lung	SYMP
resections	SYMP
for	O
metastasis	SYMP
were	O
more	O
frequently	O
performed	O
in	O
young	O
patients	O
than	O
in	O
older	O
patients	O
.	O
in	O
the	O
present	O
report	O
,	O
we	O
reviewed	O
articles	O
on	O
pulmonary	SYMP
angiography	SYMP
for	O
patients	O
with	O
pulmonary	SYMP
hypertension	SYMP
.	O
prophylactic	SYMP
cranial	SYMP
irradiation	SYMP
(	SYMP
pci	SYMP
)	SYMP
has	O
been	O
demonstrated	O
to	O
significantly	O
reduce	O
the	O
incidence	O
of	O
brain	O
relapse	O
from	O
limited	SYMP
disease	SYMP
small-cell	SYMP
lung	SYMP
cancer	SYMP
(	SYMP
ld	SYMP
sclc	SYMP
)	SYMP
,	O
but	O
concerns	O
about	O
neurologic	O
toxicity	O
remain	O
.	O
thus	O
,	O
twice-daily	O
pci	SYMP
should	O
be	O
considered	O
for	O
patients	O
with	O
ld	SYMP
sclc	SYMP
who	O
achieve	O
a	O
complete	O
response	O
to	O
chemoirradiation	O
.	O
animal	O
studies	O
suggest	O
that	O
the	O
kidney	O
is	O
involved	O
in	O
the	O
elimination	O
of	O
recombinant	SYMP
human	SYMP
granulocyte	SYMP
colony-stimulating	SYMP
factor	SYMP
(	SYMP
rhg-csf	SYMP
)	SYMP
,	O
which	O
is	O
used	O
for	O
patients	O
with	O
neutropenia	SYMP
during	O
cancer	SYMP
chemotherapy	SYMP
.	O
amifostine	SYMP
(	SYMP
wr-2721	SYMP
)	SYMP
is	O
a	O
cytoprotective	O
agent	O
that	O
protects	O
a	O
broad	O
range	O
of	O
normal	O
tissues	O
from	O
the	O
toxic	SYMP
effects	SYMP
of	SYMP
chemotherapy	SYMP
and	SYMP
radiotherapy	SYMP
without	O
attenuating	O
tumour	O
response	O
.	O
in	O
a	O
pivotal	O
phase	O
iii	O
trial	O
,	O
242	O
patients	O
with	O
advanced	SYMP
ovarian	SYMP
cancer	SYMP
were	O
randomised	O
to	O
receive	O
treatment	O
with	O
cisplatin	SYMP
100	O
mg/m2	O
and	O
cyclophosphamide	SYMP
1000	O
mg/m2	O
every	O
3	O
weeks	O
with	O
or	O
without	O
pretreatment	O
with	O
intravenous	O
amifostine	O
910	O
mg/m2	O
.	O
over	O
6	O
cycles	O
of	O
therapy	O
,	O
amifostine	SYMP
significantly	O
reduced	O
haematological	SYMP
,	SYMP
renal	SYMP
and	SYMP
neurological	SYMP
toxicities	SYMP
:	O
treatment	O
delays	O
,	O
treatment	O
discontinuation	O
and	O
days	O
in	O
hospital	O
related	O
to	O
these	O
adverse	O
events	O
were	O
also	O
significantly	O
reduced	O
in	O
patients	O
receiving	O
amifostine	O
versus	O
patients	O
receiving	O
chemotherapy	O
alone	O
.	O
in	O
another	O
randomised	O
phase	O
iii	O
trial	O
in	O
303	O
patients	O
with	O
head	SYMP
and	SYMP
neck	SYMP
cancer	SYMP
undergoing	O
irradiation	SYMP
therapy	SYMP
(	O
total	O
dose	O
50	O
to	O
70gy	O
)	O
,	O
pretreatment	O
with	O
intravenous	O
amifostine	SYMP
200	O
mg/m2	O
significantly	O
reduced	O
the	O
incidence	O
of	O
acute	O
and	O
late	O
grade	O
greater	O
than	O
or	O
=2	O
xerostomia	SYMP
.	O
amifostine	SYMP
(	O
340	O
mg/m2	O
)	O
also	O
provided	O
significant	O
protection	O
against	O
pneumonitis	SYMP
and	SYMP
oesophagitis	SYMP
in	O
patients	O
with	O
lung	SYMP
cancer	SYMP
receiving	O
thoracic	SYMP
irradiation	SYMP
in	O
a	O
preliminary	O
report	O
from	O
a	O
phase	O
iii	O
trial	O
(	O
n	O
=	O
144	O
)	O
.	O
amifostine	SYMP
has	O
also	O
been	O
shown	O
to	O
stimulate	O
haematopoietic	O
stem	O
cells	O
and	O
has	O
been	O
investigated	O
as	O
a	O
therapy	O
for	O
patients	O
with	O
myelodysplastic	SYMP
syndrome	SYMP
in	O
number	O
of	O
small	O
preliminary	O
studies	O
.	O
conclusion	O
:	O
the	O
results	O
of	O
phase	O
iii	O
trials	O
have	O
confirmed	O
the	O
safety	O
and	O
efficacy	O
of	O
amifostine	SYMP
as	O
a	O
cytoprotectant	O
to	O
ameliorate	O
cisplatin-induced	SYMP
cumulative	SYMP
renal	SYMP
toxicity	SYMP
,	O
for	O
which	O
it	O
is	O
the	O
only	O
agent	O
proven	O
to	O
be	O
effective	O
,	O
and	O
neutropenia	SYMP
in	O
patients	O
with	O
advanced	O
ovarian	O
cancer	O
,	O
and	O
to	O
reduce	O
xerostomia	SYMP
in	O
patients	O
with	O
head	SYMP
and	SYMP
neck	SYMP
cancer	SYMP
receiving	O
irradiation	SYMP
therapy	SYMP
.	O
depending	O
on	O
the	O
outcome	O
of	O
numerous	O
ongoing	O
clinical	O
trials	O
,	O
amifostine	SYMP
may	O
eventually	O
find	O
broader	O
clinical	O
applications	O
,	O
both	O
as	O
a	O
cytoprotectant	O
and	O
as	O
a	O
potential	O
therapy	O
in	O
myelodysplastic	SYMP
syndrome	SYMP
.	O
to	O
perform	O
a	O
curative	O
operation	O
for	O
the	O
lung	SYMP
cancer	SYMP
without	O
myocardial	O
infarction	O
,	O
minimally	SYMP
invasive	SYMP
direct	SYMP
coronary	SYMP
artery	SYMP
bypass	SYMP
and	SYMP
left	SYMP
lower	SYMP
lobectomy	SYMP
with	SYMP
video-endoscopic	SYMP
assistance	SYMP
were	O
performed	O
simultaneously	O
.	O
A	O
review	O
of	O
the	O
fetal-maternal	O
carboxyhemoglobin	O
relationships	O
and	O
the	O
differences	O
in	O
fetal	O
oxyhemoglobin	O
physiology	O
are	O
used	O
to	O
explain	O
the	O
recommendation	O
that	O
pregnant	O
women	O
with	O
carbon	SYMP
monoxide	SYMP
poisoning	SYMP
should	O
receive	O
100	O
%	O
oxygen	SYMP
therapy	SYMP
for	O
up	O
to	O
five	O
times	O
longer	O
than	O
is	O
otherwise	O
necessary	O
.	O
The	O
authors	O
describe	O
the	O
case	O
of	O
a	O
child	O
with	O
status	SYMP
epilepticus	SYMP
in	O
whom	O
phenytoin	SYMP
was	O
administered	O
via	O
the	O
intraosseous	O
route	O
,	O
and	O
seizure	O
resolution	O
and	O
therapeutic	O
serum	O
levels	O
were	O
achieved	O
.	O
A	O
patient	O
suffering	O
baclofen	SYMP
overdose	SYMP
successfully	O
treated	O
with	O
atropine	SYMP
is	O
reported	O
.	O
Atropine	SYMP
appears	O
to	O
be	O
useful	O
in	O
treating	O
cases	O
of	O
baclofen	SYMP
overdose	SYMP
complicated	O
by	O
bradycardia	O
and	O
hypotension	O
.	O
Therapeutic	O
effect	O
of	O
a	O
left	SYMP
ventricular	SYMP
assist	SYMP
device	SYMP
on	O
acute	SYMP
myocardial	SYMP
infarction	SYMP
evaluated	O
by	O
magnetic	O
resonance	O
imaging	O
.	O
Continuous	SYMP
arteriovenous	SYMP
hemofiltration	SYMP
for	O
the	O
treatment	O
of	O
anasarca	SYMP
and	SYMP
acute	SYMP
renal	SYMP
failure	SYMP
in	O
severely	O
burned	O
patients	O
.	O
Continuous	SYMP
renal	SYMP
replacement	SYMP
therapy	SYMP
in	O
patients	O
with	O
acute	SYMP
renal	SYMP
dysfunction	SYMP
undergoing	O
intraaortic	O
balloon	O
pump	O
and/or	O
left	O
ventricular	O
device	O
support	O
.	O
Continuous	SYMP
arterio-venous	SYMP
hemofiltration	SYMP
in	O
a	O
wearable	O
device	O
to	O
treat	O
end-stage	SYMP
renal	SYMP
disease	SYMP
.	O
The	O
effectiveness	O
of	O
neostigmine	SYMP
0.07	SYMP
mg	SYMP
kg-1	SYMP
and	SYMP
edrophonium	SYMP
0.8	O
mg	O
kg-1	O
as	O
antagonists	O
of	O
profound	SYMP
neuromuscular	SYMP
blockade	SYMP
induced	O
by	O
vecuronium	O
0.1	O
mg	O
kg-1	O
or	O
atracurium	O
0.5	O
mg	O
kg-1	O
was	O
studied	O
in	O
59	O
healthy	O
patients	O
.	O
Antagonism	O
of	O
atracurium-induced	O
neuromuscular	SYMP
blockade	SYMP
by	O
neostigmine	SYMP
or	SYMP
edrophonium	SYMP
has	O
been	O
studied	O
using	O
the	O
tetanic	O
(	O
50	O
Hz	O
)	O
and	O
train-of-four	O
(	O
2	O
Hz	O
)	O
or	O
single	O
twitch	O
responses	O
of	O
the	O
adductor	O
pollicis	O
muscle	O
in	O
22	O
anaesthetized	O
patients	O
.	O
Active	SYMP
forms	SYMP
of	SYMP
vitamin	SYMP
D3	SYMP
,	SYMP
1	SYMP
alpha-hydroxyvitamin	SYMP
D3	SYMP
and	SYMP
1	SYMP
alpha	SYMP
,	SYMP
25-dihydroxyvitamin	SYMP
D3	SYMP
,	O
were	O
administered	O
in	O
an	O
open-design	O
study	O
to	O
40	O
patients	O
with	O
psoriasis	SYMP
vulgaris	SYMP
in	O
three	O
ways	O
:	O
to	O
17	O
patients	O
1	O
alpha-hydroxyvitamin	O
D3	O
was	O
given	O
orally	O
at	O
a	O
dose	O
of	O
1.0	O
micrograms/day	O
for	O
6	O
months	O
,	O
to	O
four	O
patients	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
was	O
given	O
orally	O
at	O
a	O
dose	O
of	O
0.5	O
microgram/day	O
for	O
6	O
months	O
,	O
and	O
19	O
patients	O
were	O
given	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
applied	O
topically	O
at	O
concentration	O
of	O
0.5	O
microgram/g	O
of	O
base	O
for	O
8	O
weeks	O
.	O
These	O
data	O
suggest	O
that	O
psoriasis	SYMP
may	O
respond	O
to	O
active	SYMP
metabolites	SYMP
of	SYMP
vitamin	SYMP
D3	SYMP
and	O
that	O
abnormalities	O
in	O
vitamin	O
D	O
metabolism	O
or	O
in	O
responsiveness	O
of	O
the	O
skin	O
cells	O
to	O
active	O
metabolites	O
of	O
vitamin	O
D	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
this	O
skin	O
disease	O
.	O
Successful	O
treatment	O
of	O
psoriasis	SYMP
with	O
topical	O
application	O
of	O
active	SYMP
vitamin	SYMP
D3	SYMP
analogue	SYMP
,	SYMP
1	SYMP
alpha	SYMP
,	SYMP
24-dihydroxycholecalciferol	SYMP
.	O
We	O
suggest	O
that	O
1	SYMP
alpha	SYMP
,	SYMP
24	SYMP
(	SYMP
OH	SYMP
)	SYMP
2D3	SYMP
merits	O
further	O
investigation	O
as	O
a	O
potentially	O
useful	O
topical	O
therapy	O
for	O
psoriasis	SYMP
.	O
When	O
indomethacin	SYMP
was	O
applied	O
immediately	O
after	O
irradiation	O
,	O
UVR	O
(	O
ultraviolet	O
radiation	O
)	O
dose-dependent	O
suppression	O
of	O
erythema	SYMP
was	O
demonstrated	O
for	O
both	O
wavelengths	O
until	O
36	O
h	O
after	O
irradiation	O
when	O
both	O
indomethacin	O
and	O
control	O
gel	O
base-treated	O
sites	O
were	O
equally	O
erythematous	O
.	O
Suppression	O
of	O
erythema	SYMP
also	O
occurred	O
when	O
application	O
of	O
indomethacin	SYMP
was	O
delayed	O
until	O
24	O
h	O
after	O
irradiation	O
,	O
showing	O
that	O
for	O
both	O
wavelengths	O
prostaglandin	O
synthesis	O
remains	O
increased	O
throughout	O
this	O
period	O
.	O
There	O
was	O
one	O
retinal	O
dialysis	O
,	O
and	O
one	O
lens	SYMP
dislocation	SYMP
requiring	O
extraction	SYMP
.	O
Rates	O
of	O
superoxide	O
(	O
SA	O
)	O
generation	O
by	O
blood	O
monocytes	O
stimulated	O
ex	O
vivo	O
were	O
studied	O
before	O
and	O
during	O
corticosteroid	SYMP
treatment	O
of	O
rheumatoid	SYMP
arthritis	SYMP
(	SYMP
RA	SYMP
)	SYMP
patients	O
,	O
in	O
control	O
patients	O
and	O
in	O
healthy	O
controls	O
.	O
Significant	O
inhibition	O
of	O
monocyte	O
SA	O
output	O
stimulated	O
with	O
IgG-treated	O
zymosan	O
(	O
ITZ	O
)	O
and	O
fluoride	O
ion	O
(	O
F	O
)	O
,	O
but	O
not	O
serum-treated	O
zymosan	O
(	O
STZ	O
)	O
was	O
demonstrated	O
following	O
steroid	SYMP
therapy	SYMP
in	O
RA	SYMP
.	O
Methotrexate	SYMP
(	SYMP
MTX	SYMP
)	SYMP
appears	O
to	O
be	O
useful	O
in	O
patients	O
with	O
rheumatoid	SYMP
arthritis	SYMP
(	SYMP
RA	SYMP
)	SYMP
refractory	O
to	O
other	O
drugs	O
but	O
its	O
long-term	O
toxicity	O
and	O
efficacy	O
are	O
uncertain	O
.	O
MTX	SYMP
in	O
a	O
low-dose	O
regimen	O
is	O
useful	O
in	O
refractory	SYMP
RA	SYMP
and	O
superior	O
to	O
low-dose	O
purine	O
analogues	O
.	O
Twelve	O
patients	O
with	O
intractable	SYMP
rheumatoid	SYMP
arthritis	SYMP
were	O
treated	O
with	O
antilymphocyte	SYMP
globulin	SYMP
(	SYMP
ALG	SYMP
)	SYMP
,	SYMP
prednisolone	SYMP
and	SYMP
a	SYMP
cytotoxic	SYMP
agent	SYMP
,	SYMP
usually	SYMP
azathioprine	SYMP
,	O
and	O
were	O
followed	O
for	O
1	O
year	O
.	O
Rigid	SYMP
ureteroscopy	SYMP
for	O
the	O
treatment	O
of	O
ureteric	SYMP
calculi	SYMP
:	O
experience	O
in	O
120	O
cases	O
.	O
Over	O
a	O
1-year	O
period	O
,	O
rigid	SYMP
ureteroscopy	SYMP
has	O
been	O
used	O
to	O
retrieve	O
ureteric	SYMP
calculi	SYMP
in	O
120	O
patients	O
.	O
Eleven	O
patients	O
with	O
vesicoureteric	SYMP
reflux	SYMP
secondary	O
to	O
neuropathic	O
bladder	O
were	O
treated	O
by	O
endoscopic	SYMP
injection	SYMP
of	SYMP
pyrolised	SYMP
polytetrafluoroethylene	SYMP
(	SYMP
Polytef	SYMP
)	SYMP
paste	SYMP
.	O
Two	O
hundred	O
and	O
seventy-seven	O
patients	O
with	O
advanced	SYMP
prostatic	SYMP
cancer	SYMP
were	O
treated	O
by	O
either	O
orchiectomy	SYMP
or	SYMP
oestrogen	SYMP
.	O
Use	O
of	O
scarred	O
flaps	O
and	O
secondary	O
flaps	O
for	O
reconstructive	SYMP
surgery	SYMP
of	O
extensive	SYMP
burns	SYMP
.	O
A	O
patient	O
with	O
a	O
vesico-enteric	SYMP
fistula	SYMP
was	O
successfully	O
treated	O
with	O
resection	SYMP
of	SYMP
the	SYMP
small	SYMP
intestine	SYMP
and	SYMP
dome	SYMP
of	SYMP
the	SYMP
bladder	SYMP
and	SYMP
drainage	SYMP
of	SYMP
the	SYMP
intervening	SYMP
abscess	SYMP
.	O
Supramaximal	SYMP
horizontal	SYMP
rectus	SYMP
surgery	SYMP
in	O
the	O
management	O
of	O
third	SYMP
and	SYMP
sixth	SYMP
nerve	SYMP
palsy	SYMP
.	O
Supramaximal	SYMP
medial	SYMP
and	SYMP
lateral	SYMP
rectus	SYMP
surgery	SYMP
was	O
performed	O
to	O
correct	O
horizontal	SYMP
deviations	SYMP
in	SYMP
seven	SYMP
cases	SYMP
of	SYMP
sixth	SYMP
nerve	SYMP
palsy	SYMP
and	SYMP
three	SYMP
cases	SYMP
of	SYMP
third	SYMP
nerve	SYMP
palsy	SYMP
,	O
with	O
satisfactory	O
results	O
in	O
most	O
cases	O
.	O
Steroid	SYMP
therapy	SYMP
was	O
also	O
used	O
in	O
two	O
patients	O
with	O
NSAID-induced	SYMP
proteinuria	SYMP
.	O
Recombinant	SYMP
leukocyte	SYMP
A	SYMP
interferon	SYMP
(	SYMP
rIFN-alpha	SYMP
A	SYMP
)	SYMP
in	O
the	O
treatment	O
of	O
disseminated	SYMP
malignant	SYMP
melanoma	SYMP
.	O
Ninety-six	O
patients	O
with	O
disseminated	SYMP
malignant	SYMP
melanoma	SYMP
received	O
thrice	O
weekly	O
intramuscular	O
injections	O
of	O
leukocyte	SYMP
A	SYMP
recombinant	SYMP
interferon	SYMP
(	SYMP
rIFN-alpha	SYMP
A	SYMP
,	SYMP
Roferon-A	SYMP
,	SYMP
Hoffmann	SYMP
La	SYMP
Roche	SYMP
)	SYMP
at	O
doses	O
of	O
12	O
X	O
10	O
(	O
6	O
)	O
U/m2	O
or	O
50	O
X	O
10	O
(	O
6	O
)	O
U/m2	O
with	O
or	O
without	O
cimetidine	O
as	O
an	O
immunorestorative	O
agent	O
.	O
As	O
noted	O
previously	O
,	O
using	O
chemotherapy	O
,	O
a	O
small	O
proportion	O
of	O
patients	O
with	O
advanced	SYMP
malignant	SYMP
melanoma	SYMP
,	O
despite	O
prior	O
therapy	O
,	O
may	O
achieve	O
prolonged	O
objective	O
regression	O
with	O
rIFN-alpha	SYMP
A	SYMP
.	O
Clinical	O
course	O
of	O
breast	O
cancer	O
patients	O
with	O
osseous	SYMP
metastasis	SYMP
treated	O
with	O
combination	SYMP
chemotherapy	SYMP
.	O
Between	O
July	O
1973	O
and	O
December	O
1979	O
,	O
1171	O
patients	O
with	O
metastatic	SYMP
breast	SYMP
cancer	SYMP
were	O
treated	O
with	O
doxorubicin-containing	SYMP
chemotherapy	SYMP
.	O
Two	O
patients	O
with	O
metastatic	SYMP
dysgerminoma	SYMP
of	SYMP
the	SYMP
ovary	SYMP
were	O
treated	O
with	O
a	SYMP
combination	SYMP
of	SYMP
etoposide	SYMP
,	SYMP
bleomycin	SYMP
,	SYMP
and	SYMP
cisplatin	SYMP
at	O
The	O
University	O
of	O
Texas	O
M.D	O
.	O
Chemotherapy	SYMP
may	O
be	O
an	O
alternative	O
to	O
radiotherapy	O
for	O
the	O
treatment	O
of	O
metastatic	SYMP
dysgerminoma	SYMP
and	O
should	O
also	O
be	O
considered	O
for	O
selected	O
patients	O
with	O
Stage	O
I	O
disease	O
.	O
Long-term	O
survival	O
and	O
morbidity	O
in	O
patients	O
with	O
metastatic	SYMP
malignant	SYMP
germ	SYMP
cell	SYMP
tumors	SYMP
treated	O
with	O
cisplatin-based	SYMP
combination	SYMP
chemotherapy	SYMP
.	O
Treatment	O
of	O
advanced	SYMP
stage	SYMP
mycosis	SYMP
fungoides	SYMP
with	O
bleomycin	SYMP
,	SYMP
doxorubicin	SYMP
,	SYMP
and	SYMP
methotrexate	SYMP
with	SYMP
topical	SYMP
nitrogen	SYMP
mustard	SYMP
(	SYMP
BAM-M	SYMP
)	SYMP
.	O
Ten	O
patients	O
with	O
advanced	SYMP
stage	SYMP
(	SYMP
TNM	SYMP
IIB-IVB	SYMP
)	SYMP
mycosis	SYMP
fungoides	SYMP
were	O
treated	O
with	O
a	O
combination	SYMP
chemotherapy	SYMP
program	SYMP
consisting	SYMP
of	SYMP
bleomycin	SYMP
and	SYMP
methotrexate	SYMP
weekly	SYMP
,	SYMP
doxorubicin	SYMP
every	SYMP
3	SYMP
weeks	SYMP
,	SYMP
and	SYMP
topical	SYMP
nitrogen	SYMP
mustard	SYMP
daily	SYMP
(	SYMP
BAM-M	SYMP
)	SYMP
.	O
Three	O
patients	O
in	O
whom	O
splenomegaly	SYMP
was	O
detected	O
during	O
their	O
staging	O
evaluation	O
underwent	O
splenectomy	SYMP
.	O
This	O
study	O
indicates	O
that	O
BAM-M	SYMP
is	O
effective	O
therapy	O
for	O
advanced	SYMP
stage	SYMP
mycosis	SYMP
fungoides	SYMP
and	O
suggests	O
that	O
the	O
therapeutic	O
role	O
of	O
splenectomy	O
should	O
be	O
evaluated	O
further	O
.	O
Only	O
patients	O
whose	O
primary	SYMP
head	SYMP
and	SYMP
neck	SYMP
tumor	SYMP
shows	O
a	O
response	O
to	O
systemic	O
therapy	O
undergo	O
Ommaya	SYMP
placement	SYMP
.	O
Additional	O
chemotherapy	SYMP
may	O
thus	O
have	O
eradicated	O
these	O
micrometastases	SYMP
in	O
the	O
older	O
children	O
,	O
since	O
the	O
age	O
influence	O
on	O
Stage	O
II	O
disease	O
disappeared	O
when	O
multimodal	O
treatment	O
was	O
given	O
in	O
this	O
study	O
.	O
Traditional	O
therapy	O
for	O
malignant	SYMP
pleural	SYMP
effusions	SYMP
includes	O
thoracentesis	SYMP
or	SYMP
tube	SYMP
drainage	SYMP
with	O
instillation	O
of	O
irritants	O
to	O
achieve	O
pleurodesis	O
.	O
We	O
feel	O
that	O
pleuroperitoneal	SYMP
shunting	SYMP
is	O
a	O
valid	O
new	O
method	O
for	O
treatment	O
of	O
malignant	SYMP
pleural	SYMP
effusions	SYMP
which	O
can	O
effectively	O
palliate	O
respiratory	O
symptoms	O
with	O
low	O
morbidity	O
.	O
When	O
right	SYMP
ventricular	SYMP
failure	SYMP
prohibits	O
separation	O
from	O
cardiopulmonary	O
bypass	O
,	O
standard	SYMP
methods	SYMP
of	SYMP
increasing	SYMP
pulmonary	SYMP
blood	SYMP
flow	SYMP
should	O
be	O
employed	O
,	O
including	O
correction	O
of	O
hypoxia	O
and	O
acidosis	O
,	O
volume	O
loading	O
,	O
and	O
inotropic	O
support	O
of	O
the	O
right	O
ventricle	O
.	O
For	O
refractory	SYMP
right	SYMP
ventricular	SYMP
failure	SYMP
following	O
the	O
surgical	O
repair	O
of	O
congenital	O
cardiac	O
defects	O
in	O
which	O
the	O
placement	O
of	O
right	O
atrial	O
and	O
pulmonary	O
artery	O
cannulae	O
is	O
not	O
technically	O
feasible	O
,	O
use	SYMP
of	SYMP
high-frequency	SYMP
high-volume	SYMP
ventilation	SYMP
appears	O
to	O
be	O
quite	O
promising	O
.	O
Current	O
results	O
suggest	O
that	O
RHBP	SYMP
remains	O
the	O
gold	O
standard	O
for	O
severe	SYMP
RV	SYMP
failure	SYMP
,	O
but	O
further	O
clinical	O
experience	O
with	O
PABC	O
may	O
more	O
clearly	O
define	O
its	O
role	O
in	O
the	O
management	O
of	O
RV	O
failure	O
.	O
Guiding	O
surgical	SYMP
therapy	SYMP
of	O
ventricular	SYMP
tachycardia	SYMP
by	O
preoperative	O
endocardial	O
catheter	O
mapping	O
necessitates	O
improvement	O
of	O
the	O
accuracy	O
of	O
localization	O
of	O
the	O
arrhythmogenic	O
site	O
.	O
However	O
,	O
the	O
results	O
of	O
this	O
study	O
indicate	O
that	O
procainamide	SYMP
may	O
be	O
effective	O
in	O
suppressing	O
the	O
induction	O
of	O
sustained	O
ventricular	SYMP
tachycardia	SYMP
at	O
a	O
relatively	O
low	O
plasma	O
concentration	O
,	O
but	O
not	O
at	O
a	O
higher	O
plasma	O
concentration	O
.	O
Coronary	SYMP
angioplasty	SYMP
for	O
early	SYMP
postinfarction	SYMP
unstable	SYMP
angina	SYMP
.	O
Coronary	SYMP
angioplasty	SYMP
was	O
performed	O
in	O
53	O
patients	O
in	O
whom	O
unstable	SYMP
angina	SYMP
had	O
reoccurred	O
after	O
48	O
hr	O
and	O
within	O
30	O
days	O
after	O
sustained	O
myocardial	O
infarction	O
.	O
At	O
6	O
months	O
follow-up	O
26	O
%	O
(	O
14/53	O
)	O
of	O
all	O
the	O
patients	O
who	O
underwent	O
angioplasty	SYMP
had	O
recurrence	O
of	O
angina	SYMP
,	O
which	O
was	O
successfully	O
treated	O
with	O
repeat	SYMP
angioplasty	SYMP
,	SYMP
bypass	SYMP
surgery	SYMP
,	SYMP
or	SYMP
medical	SYMP
therapy	SYMP
.	O
Coronary	SYMP
dissection	SYMP
and	SYMP
total	SYMP
coronary	SYMP
occlusion	SYMP
leading	O
to	O
emergency	SYMP
coronary	SYMP
surgery	SYMP
are	O
the	O
most	O
frequent	O
complications	O
of	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
(	O
PTCA	O
)	O
and	O
their	O
occurrence	O
usually	O
is	O
unpredictable	O
.	O
Effect	O
of	O
zanamivir	SYMP
on	O
duration	O
and	O
resolution	O
of	O
influenza	SYMP
symptoms	O
.	O
A	O
comparison	O
of	O
a	O
five-day	O
regimen	O
of	O
cefdinir	SYMP
with	O
a	O
seven-day	O
regimen	O
of	O
loracarbef	SYMP
for	O
the	O
treatment	O
of	O
acute	O
exacerbations	O
of	O
chronic	SYMP
bronchitis	SYMP
.	O
Initial	O
empiric	O
therapy	O
for	O
community-acquired	O
bacterial	SYMP
meningitis	SYMP
should	O
be	O
based	O
on	O
the	O
possibility	O
that	O
penicillin-resistant	O
pneumococci	O
may	O
be	O
the	O
etiologic	O
organisms	O
and	O
,	O
hence	O
,	O
should	O
include	O
a	O
combination	O
of	O
third-generation	O
cephalosporin	SYMP
(	SYMP
cefotaxime	SYMP
or	SYMP
ceftriaxone	SYMP
)	SYMP
and	SYMP
vancomycin	SYMP
.	O
Ampicillin	SYMP
should	O
be	O
included	O
if	O
the	O
patient	O
has	O
predisposing	O
factors	O
that	O
are	O
associated	O
with	O
a	O
risk	O
for	O
infection	SYMP
with	SYMP
Listeria	SYMP
monocytogenes	SYMP
.	O
Results	O
of	O
clinical	O
trials	O
and	O
meta-analysis	O
suggest	O
that	O
dexamethasone	SYMP
therapy	SYMP
improves	O
the	O
outcome	O
for	O
patients	O
with	O
bacterial	SYMP
meningitis	SYMP
.	O
Placebo-controlled	O
trials	O
have	O
shown	O
that	O
vitamin	SYMP
C	SYMP
supplementation	O
decreases	O
the	O
duration	O
and	O
severity	O
of	O
common	SYMP
cold	SYMP
infections	SYMP
.	O
Since	O
few	O
trials	O
have	O
examined	O
the	O
effects	O
of	O
therapeutic	O
supplementation	O
and	O
their	O
results	O
have	O
been	O
variable	O
,	O
further	O
therapeutic	O
trials	O
are	O
required	O
to	O
examine	O
the	O
role	O
of	O
vitamin	SYMP
C	SYMP
in	O
the	O
treatment	O
of	O
colds	SYMP
.	O
Progressive	SYMP
multifocal	SYMP
leukoencephalopathy	SYMP
following	O
oral	SYMP
fludarabine	SYMP
treatment	O
of	O
chronic	SYMP
lymphocytic	SYMP
leukemia	SYMP
.	O
PURPOSE	O
:	O
To	O
review	O
reported	O
inflammatory	SYMP
reactions	SYMP
occurring	O
after	O
initiation	O
of	O
highly	O
active	O
antiretroviral	SYMP
therapy	SYMP
(	SYMP
HAART	SYMP
)	SYMP
in	O
persons	O
infected	O
with	O
HIV-1	SYMP
and	O
to	O
explore	O
the	O
mechanisms	O
leading	O
to	O
these	O
reactions	O
.	O
Levofloxacin	SYMP
versus	SYMP
intravenous	SYMP
ceftriaxone	SYMP
and	SYMP
amoxicillin/clavulanate	SYMP
in	O
the	O
treatment	O
of	O
community-acquired	O
pneumonia	SYMP
that	O
require	O
hospitalization	O
Overall	O
1	O
year	O
survival	O
(	O
operative	O
deaths	O
excluded	O
)	O
was	O
68	O
%	O
after	O
tumor	SYMP
resection	SYMP
compared	O
to	O
31	O
%	O
after	O
palliative	O
surgery	O
(	O
P	O
less	O
than	O
0.001	O
)	O
.	O
The	O
results	O
of	O
this	O
study	O
show	O
that	O
resection	SYMP
of	O
extrahepatic	SYMP
bile	SYMP
duct	SYMP
carcinomas	SYMP
,	O
particularly	O
in	O
an	O
upper-third	O
localization	O
,	O
is	O
often	O
associated	O
with	O
worthwhile	O
long-term	O
survival	O
.	O
Background	O
:	O
N-acetylcysteine	SYMP
(	SYMP
NAC	SYMP
)	SYMP
and	SYMP
ambroxol	SYMP
(	SYMP
AMB	SYMP
)	SYMP
have	O
recently	O
been	O
proposed	O
as	O
possible	O
therapeutic	O
agents	O
in	O
the	O
treatment	O
of	O
pulmonary	SYMP
disorders	SYMP
.	O
Postoperative	O
alkaline	SYMP
reflux	SYMP
after	O
total	SYMP
gastrectomy	SYMP
for	O
stomach	SYMP
cancer	SYMP
Antimicrobial	SYMP
therapy	SYMP
for	O
respiratory	SYMP
disease	SYMP
.	O
Corticosteroids	SYMP
for	O
the	O
treatment	O
of	O
croup	SYMP
.	O
BACKGROUND	O
:	O
In	O
the	O
present	O
study	O
we	O
investigated	O
the	O
efficacy	O
and	O
tolerability	O
of	O
i.m	SYMP
.	SYMP
octreotide	SYMP
acetate	SYMP
(	SYMP
octreotide	SYMP
LAR	SYMP
)	SYMP
in	O
patients	O
with	O
metastatic	SYMP
neuroendocrine	SYMP
tumors	SYMP
(	SYMP
NETs	SYMP
)	SYMP
previously	O
treated	O
and	O
failed	O
on	O
i.m	SYMP
.	SYMP
lanreotide	SYMP
.	O
The	O
PR	O
was	O
observed	O
in	O
one	O
patient	O
with	O
non-functioning	SYMP
endocrine	SYMP
pancreatic	SYMP
tumor	SYMP
with	SYMP
progressive	SYMP
liver	SYMP
and	SYMP
lymph	SYMP
node	SYMP
metastases	SYMP
after	O
16	O
months	O
of	O
i.m	SYMP
.	SYMP
lanreotide	SYMP
therapy	SYMP
.	O
CONCLUSIONS	O
:	O
Octreotide	SYMP
LAR	SYMP
20	O
mg	O
shows	O
significant	O
efficacy	O
in	O
terms	O
of	O
objective	O
response	O
rate	O
(	O
PR	O
+	O
SD	O
)	O
,	O
biochemical	O
and	O
symptomatic	O
control	O
in	O
patients	O
with	O
metastatic	SYMP
NETs	SYMP
of	O
the	O
GEP	O
system	O
pretreated	O
and	O
progressing	O
on	O
slow	O
release	O
lanreotide	O
.	O
Inchinko-to	SYMP
(	SYMP
TJ-135	SYMP
)	SYMP
is	O
a	O
herbal	O
medicine	O
consisting	O
of	O
three	O
kinds	O
of	O
crude	O
drugs	O
,	O
and	O
in	O
Japan	O
it	O
is	O
administered	O
mainly	O
to	O
patients	O
with	O
cholestasis	SYMP
.	O
The	O
present	O
study	O
evaluated	O
the	O
effects	O
of	O
TJ-135	SYMP
on	O
concanavalin	SYMP
A	SYMP
(	SYMP
con	SYMP
A	SYMP
)	SYMP
-induced	SYMP
hepatitis	SYMP
in	O
mice	O
in	O
vivo	O
and	O
con	O
A-induced	O
cytokine	O
production	O
in	O
vitro	O
.	O
These	O
results	O
suggest	O
that	O
con	SYMP
A-induced	SYMP
hepatitis	SYMP
was	O
ameliorated	O
by	O
pretreatment	O
with	O
TJ-135	SYMP
.	O
Therefore	O
administration	O
of	O
TJ-135	SYMP
may	O
be	O
useful	O
in	O
patients	O
with	O
severe	O
acute	O
hepatitis	SYMP
accompanying	SYMP
cholestasis	SYMP
or	O
in	O
those	O
with	O
autoimmune	SYMP
hepatitis	SYMP
.	O
Zinc	SYMP
lozenges	SYMP
--	O
a	O
cure	O
for	O
common	SYMP
colds	SYMP
?	O
T-helper	SYMP
type	SYMP
2	SYMP
cell-directed	SYMP
therapy	SYMP
for	O
asthma	SYMP
.	O
Effects	O
of	O
the	O
Japanese	SYMP
herbal	SYMP
medicine	SYMP
'Inchinko-to	SYMP
'	SYMP
(	SYMP
TJ-135	SYMP
)	SYMP
on	O
concanavalin	SYMP
A-induced	SYMP
hepatitis	SYMP
in	O
mice	O
.	O
Presumed	O
cavernomas	O
have	O
been	O
documented	O
following	O
radiation	SYMP
for	O
malignancy	SYMP
(	O
5-6	O
)	O
,	O
and	O
sterotactic	O
cerebral	O
biopsy	O
(	O
7	O
)	O
.	O
Surgical	SYMP
management	SYMP
of	O
syringomyelia	SYMP
associated	SYMP
with	SYMP
spinal	SYMP
adhesive	SYMP
arachnoiditis	SYMP
.	O
Discontinuation	O
of	O
secondary	O
prophylaxis	O
for	O
cryptococcal	SYMP
meningitis	SYMP
in	O
HIV-infected	O
patients	O
responding	O
to	O
highly	O
active	O
antiretroviral	SYMP
therapy	SYMP
Hepatectomy	SYMP
for	O
cholangiocarcinoma	SYMP
complicated	O
with	O
right	O
umbilical	O
portion	O
:	O
anomalous	O
configuration	O
of	O
the	O
intrahepatic	O
biliary	O
tree	O
.	O
Traditionally	O
,	O
the	O
therapy	O
of	O
symptomatic	SYMP
bronchiectasis	SYMP
is	O
based	O
on	O
antibiotics	SYMP
,	SYMP
antibronchoobstructive	SYMP
medication	SYMP
,	SYMP
and	SYMP
chest	SYMP
physical	SYMP
therapy	SYMP
.	O
Bilateral	SYMP
lung	SYMP
transplantation	SYMP
should	O
be	O
considered	O
in	O
younger	O
patients	O
with	O
severe	O
,	O
generalized	O
bronchiectasis	SYMP
and	SYMP
respiratory	SYMP
failure	SYMP
.	O
Prospective	O
,	O
randomized	O
,	O
largescale	O
trials	O
supporting	O
any	O
of	O
the	O
different	O
treatment	O
strategies	O
are	O
not	O
available	O
,	O
but	O
antibiotics	SYMP
and	SYMP
surgery	SYMP
probably	O
have	O
improved	O
the	O
long-term	O
outcome	O
of	O
many	O
patients	O
with	O
bronchiectasis	SYMP
.	O
OBJECTIVES	O
:	O
Interest	O
in	O
zinc	SYMP
as	O
a	O
treatment	O
for	O
the	O
common	SYMP
cold	SYMP
has	O
grown	O
following	O
the	O
recent	O
publication	O
of	O
several	O
controlled	O
trials	O
.	O
The	O
objective	O
of	O
this	O
review	O
was	O
to	O
assess	O
the	O
effects	O
of	O
zinc	SYMP
lozenges	SYMP
for	O
cold	SYMP
symptoms	SYMP
.	O
Results	O
from	O
two	O
trials	O
(	O
04	O
-	O
Mossad	O
;	O
08	O
-	O
Smith	O
)	O
suggested	O
zinc	SYMP
lozenges	SYMP
reduced	O
the	O
severity	O
and	O
duration	O
of	O
cold	SYMP
symptoms	SYMP
.	O
Given	O
the	O
potential	O
for	O
treatment	O
to	O
produce	O
side	O
effects	O
,	O
the	O
use	O
of	O
zinc	SYMP
lozenges	SYMP
to	O
treat	O
cold	SYMP
symptoms	SYMP
deserves	O
further	O
study	O
.	O
Randomized	O
trial	O
of	O
interferon-alpha	SYMP
plus	SYMP
ursodeoxycholic	SYMP
acid	SYMP
versus	O
interferon	SYMP
plus	SYMP
placebo	SYMP
in	O
patients	O
with	O
chronic	SYMP
hepatitis	SYMP
C	SYMP
resistant	SYMP
to	SYMP
interferon	SYMP
We	O
describe	O
a	O
rare	O
case	O
of	O
spontaneous	SYMP
rupture	SYMP
of	SYMP
a	SYMP
hepatic	SYMP
metastasis	SYMP
from	SYMP
renal	SYMP
cell	SYMP
carcinoma	SYMP
that	O
was	O
treated	O
successfully	O
by	O
hepatic	SYMP
arterial	SYMP
embolization	SYMP
.	O
A	O
65-year-old	O
woman	O
,	O
who	O
had	O
been	O
undergoing	O
immunotherapy	SYMP
for	O
inoperably	SYMP
disseminated	SYMP
renal	SYMP
carcinoma	SYMP
and	SYMP
lung	SYMP
metastases	SYMP
,	O
presented	O
with	O
severe	O
abdominal	O
pain	O
in	O
a	O
state	O
of	O
hypovolemic	O
shock	O
.	O
Although	O
hepatic	O
rupture	O
due	O
to	O
metastatic	O
cancer	O
is	O
extremely	O
rare	O
,	O
transcatheter	SYMP
arterial	SYMP
embolization	SYMP
(	SYMP
TAE	SYMP
)	SYMP
is	O
an	O
appropriate	O
and	O
useful	O
treatment	O
for	O
massive	SYMP
hemorrhage	SYMP
caused	SYMP
by	SYMP
spontaneous	SYMP
rupture	SYMP
of	SYMP
liver	SYMP
metastasis	SYMP
.	O
Patients	O
with	O
classical	O
symptoms	O
such	O
as	O
heartburn	SYMP
and	SYMP
regurgitation	SYMP
may	O
be	O
treated	O
pharmaceutically	SYMP
combined	SYMP
with	SYMP
life	SYMP
style	SYMP
counselling	SYMP
.	O
Surgical	SYMP
treatment	SYMP
is	O
a	O
good	O
alternative	O
for	O
patients	O
with	O
persistent	SYMP
severe	SYMP
regurgitation	SYMP
during	O
medical	O
therapy	O
and	O
for	O
young	O
patients	O
who	O
prefer	O
surgery	O
to	O
lifelong	O
medication	O
.	O
The	O
surgical	SYMP
treatment	SYMP
of	O
lung	SYMP
lacerations	SYMP
and	SYMP
major	SYMP
bronchial	SYMP
disruptions	SYMP
caused	O
by	O
blunt	O
thoracic	O
trauma	O
.	O
BACKGROUND	O
:	O
An	O
increasing	O
number	O
of	O
reports	O
indicate	O
symptomatic	O
relief	O
of	O
biliary	O
colic	O
symptoms	O
after	O
cholecystectomy	SYMP
for	O
biliary	SYMP
dyskinesia	SYMP
.	O
Despite	O
this	O
,	O
cholecystectomy	SYMP
as	O
a	O
treatment	O
for	O
biliary	SYMP
dyskinesia	SYMP
remains	O
controversial	O
.	O
Our	O
aim	O
was	O
to	O
determine	O
efficacy	O
of	O
cholecystectomy	SYMP
in	O
alleviating	O
biliary	SYMP
dyskinesia	SYMP
symptoms	SYMP
and	O
the	O
correlation	O
with	O
histologic	O
findings	O
.	O
CONCLUSIONS	O
:	O
Biliary	SYMP
dyskinesia	SYMP
patients	O
who	O
underwent	O
cholecystectomy	SYMP
had	O
significantly	O
greater	O
symptom	O
improvement	O
compared	O
with	O
nonsurgical	O
patients	O
.	O
Cholecystectomy	SYMP
should	O
be	O
a	O
first-line	O
therapy	O
for	O
biliary	SYMP
dyskinesia	SYMP
patients	O
.	O
Transbronchial	O
biopsy	O
revealed	O
inflammatory	SYMP
nonspecific	SYMP
alveolar	SYMP
lesions	SYMP
suggestive	SYMP
of	SYMP
bronchiolitis	SYMP
obliterans	SYMP
organizing	SYMP
pneumonia	SYMP
,	O
which	O
responded	O
well	O
clinically	O
and	O
radiologically	O
to	O
oral	SYMP
corticosteroids	SYMP
.	O
Novel	O
treatment	O
strategies	O
for	O
patients	O
with	O
advanced	SYMP
NSCLC	SYMP
may	O
involve	O
chemotherapy	SYMP
combined	O
with	O
inhibition	O
of	O
NF-kappaB-dependent	O
cell-survival	O
pathways	O
.	O
Effectiveness	O
of	O
pseudoephedrine	SYMP
plus	SYMP
acetaminophen	SYMP
for	O
treatment	O
of	O
symptoms	O
attributed	O
to	O
the	O
paranasal	O
sinuses	O
associated	O
with	O
the	O
common	SYMP
cold	SYMP
OBJECTIVE	O
:	O
This	O
retrospective	O
study	O
was	O
designed	O
to	O
confirm	O
that	O
aggressive	SYMP
pulmonary	SYMP
resection	SYMP
can	O
provide	O
effective	O
long-term	O
palliation	O
of	O
disease	O
for	O
patients	O
with	O
pulmonary	SYMP
aspergilloma	SYMP
.	O
METHODS	O
AND	O
RESULTS	O
:	O
From	O
1959	O
to	O
1998	O
,	O
84	O
patients	O
underwent	O
a	O
total	O
of	O
90	O
operations	SYMP
for	O
treatment	O
of	O
pulmonary	SYMP
aspergilloma	SYMP
in	O
the	O
Marie-Lannelongue	O
Hospital	O
.	O
The	O
lesion	SYMP
was	O
resected	O
by	O
video-assisted	SYMP
thoracoscopic	SYMP
surgery	SYMP
because	O
it	O
was	O
suspected	O
of	O
being	O
a	O
lung	O
abscess	O
that	O
had	O
caused	O
repeated	O
episodes	O
of	O
inflammation	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
expression	O
and	O
therapeutic	O
potential	O
of	O
TRAIL	SYMP
in	O
cholangiocarcinoma	SYMP
,	O
one	O
of	O
the	O
most	O
devastating	O
human	O
hepatic	O
malignancies	O
.	O
Finally	O
,	O
in	O
vivo	O
administration	O
of	O
recombinant	O
TRAIL	SYMP
substantially	O
inhibited	O
subcutaneous	O
tumor	O
growth	O
of	O
human	O
cholangiocarcinoma	SYMP
cells	O
.	O
Induction	O
of	O
apoptosis	O
in	O
tumor	O
cells	O
is	O
possible	O
with	O
a	O
biologically	O
active	O
TRAIL	SYMP
,	O
and	O
suggests	O
that	O
this	O
cytokine	O
is	O
a	O
promising	O
antitumor	O
agent	O
against	O
human	SYMP
cholangiocarcinoma	SYMP
.	O
Interferon	SYMP
plays	O
a	O
critical	O
role	O
in	O
the	O
host	O
's	O
natural	O
defense	O
against	O
viral	SYMP
infections	SYMP
and	O
in	O
their	O
treatment	O
.	O
This	O
study	O
investigated	O
whether	O
intensive	O
chemotherapy	SYMP
might	O
have	O
a	O
positive	O
effect	O
on	O
asthma	SYMP
in	O
these	O
special	O
cases	O
and	O
whether	O
asthma	O
generally	O
relapses	O
after	O
completion	O
of	O
chemotherapy	O
.	O
The	O
authors	O
monitored	O
clinical	O
outcome	O
and	O
lung	O
function	O
of	O
43	O
children	O
with	O
acute	SYMP
lymphoblastic	SYMP
leukemia	SYMP
and	SYMP
non-Hodgkin	SYMP
lymphoma	SYMP
who	O
received	O
chemotherapy	SYMP
at	O
the	O
University	O
Children	O
's	O
Hospital	O
of	O
Greifswald	O
between	O
1993	O
and	O
1998	O
.	O
She	O
was	O
diagnosed	O
as	O
miliary	SYMP
tuberculosis	SYMP
and	O
treated	O
with	O
antituberculous	SYMP
drugs	SYMP
.	O
The	O
hemorrhage	SYMP
was	O
successfully	O
stopped	O
by	O
microcoil	SYMP
embolization	SYMP
.	O
Immunomodulatory	O
effects	O
of	O
acupuncture	SYMP
in	O
the	O
treatment	O
of	O
allergic	SYMP
asthma	SYMP
:	O
a	O
randomized	O
controlled	O
study	O
.	O
An	O
open-label	O
study	O
of	O
lamivudine	SYMP
for	O
chronic	SYMP
hepatitis	SYMP
B	SYMP
in	O
six	O
patients	O
with	O
chronic	O
renal	O
failure	O
before	O
and	O
after	O
kidney	O
transplantation	O
.	O
CONCLUSION	O
:	O
The	O
WDTA	O
is	O
an	O
intrinsically	O
motivating	O
educational	O
program	O
that	O
has	O
the	O
ability	O
to	O
effect	O
determinants	O
of	O
asthma	SYMP
self-management	SYMP
behavior	O
in	O
9-	O
to	O
13-year-old	O
children	O
with	O
asthma	O
.	O
Usefulness	O
of	O
percutaneous	SYMP
transhepatic	SYMP
biliary	SYMP
drainage	SYMP
in	O
patients	O
with	O
surgical	SYMP
jaundice	SYMP
--	O
a	O
prospective	O
randomised	O
study	O
.	O
Neutralization	O
of	O
hepatitis	SYMP
A	SYMP
virus	SYMP
(	SYMP
HAV	SYMP
)	SYMP
by	O
an	O
immunoadhesin	SYMP
containing	SYMP
the	SYMP
cysteine-rich	SYMP
region	SYMP
of	SYMP
HAV	SYMP
cellular	SYMP
receptor-1	SYMP
To	O
ascertain	O
the	O
results	O
of	O
standard	SYMP
ABVD	SYMP
chemotherapy	SYMP
(	SYMP
doxorubicin	SYMP
,	SYMP
bleomycin	SYMP
,	SYMP
vinblastine	SYMP
,	SYMP
dacarbazine	SYMP
)	SYMP
in	O
HIV-infected	O
patients	O
with	O
newly	SYMP
diagnosed	SYMP
Hodgkin	SYMP
's	SYMP
disease	SYMP
(	SYMP
HD	SYMP
)	SYMP
,	O
a	O
nonrandomized	O
,	O
prospective	O
,	O
multiinstitutional	O
clinical	O
trial	O
was	O
conducted	O
by	O
the	O
AIDS	O
Clinical	O
Trials	O
Group	O
(	O
ACTG	O
)	O
,	O
in	O
HIV-infected	O
patients	O
with	O
Hodgkin	O
's	O
disease	O
.	O
The	O
effectiveness	O
of	O
glucocorticoids	SYMP
in	O
treating	O
croup	SYMP
:	O
meta-analysis	O
(	O
see	O
comments	O
)	O
PURPOSE	O
:	O
Inhaled	O
corticosteroids	SYMP
have	O
beneficial	O
effects	O
on	O
pulmonary	O
function	O
and	O
inflammation	O
in	O
patients	O
with	O
asthma	SYMP
,	O
but	O
they	O
also	O
cause	O
systemic	O
adverse	O
effects	O
,	O
such	O
as	O
adrenal	O
suppression	O
.	O
Second	O
,	O
children	O
in	O
the	O
first	O
year	O
of	O
life	O
are	O
at	O
highest	O
risk	O
of	O
progression	O
and	O
should	O
be	O
treated	O
with	O
trimethoprim-sulfamethoxazole	SYMP
to	O
prevent	O
Pneumocystis	SYMP
carinii	SYMP
pneumonia	SYMP
,	O
and	O
targeted	O
for	O
receiving	O
antiretrovirals	O
.	O
Effectiveness	O
of	O
casein	SYMP
hydrolysate	SYMP
feedings	O
in	O
infants	O
with	O
colic	SYMP
(	O
see	O
comments	O
)	O
We	O
conclude	O
that	O
antimicrobial/	SYMP
antituberculous	SYMP
agents	SYMP
have	O
only	O
a	O
minor	O
short-term	O
effect	O
in	O
long-lasting	O
CGM	SYMP
of	O
undetermined	O
cause	O
.	O
The	O
patient	O
had	O
previously	O
been	O
immunized	O
with	O
two	O
doses	O
of	O
Hib	SYMP
conjugate	O
vaccine	SYMP
(	O
PRP-T	O
)	O
.	O
Thus	O
,	O
s-ECP	O
appears	O
to	O
be	O
a	O
useful	O
marker	O
for	O
determining	O
when	O
a	O
step-down	O
in	O
iBDP	SYMP
therapy	SYMP
is	O
indicated	O
,	O
and	O
thus	O
may	O
contribute	O
to	O
successful	O
long-term	O
management	O
of	O
chronic	SYMP
asthma	SYMP
.	O
Twinrix	SYMP
(	O
SmithKline	O
Beecham	O
Biologicals	O
)	O
is	O
a	O
combined	O
hepatitis	SYMP
A	SYMP
and	SYMP
B	SYMP
vaccine	SYMP
licensed	O
with	O
a	O
three-dose	O
schedule	O
.	O
A	O
two-dose	O
combined	O
hepatitis	SYMP
A	SYMP
and	SYMP
B	SYMP
vaccine	SYMP
would	O
facilitate	O
immunisation	O
programs	O
.	O
Therefore	O
,	O
it	O
can	O
be	O
concluded	O
that	O
with	O
two	O
injections	O
of	O
the	O
high-dose	O
hepatitis	SYMP
A	SYMP
and	SYMP
B	SYMP
vaccine	SYMP
,	O
6	O
months	O
apart	O
,	O
a	O
similar	O
immune	O
response	O
can	O
be	O
obtained	O
as	O
induced	O
with	O
three	O
doses	O
of	O
Twinrix	SYMP
at	O
months	O
0	O
,	O
1	O
and	O
6	O
.	O
AIM	O
:	O
To	O
assess	O
the	O
impact	O
on	O
community-based	O
pediatricians	O
of	O
the	O
conclusions	O
of	O
the	O
10th	O
Conference	O
de	O
Consensus	O
en	O
Therapeutique	O
Anti-Infectieuse	O
(	O
CCTAI	O
)	O
on	O
the	O
antibiotic	SYMP
treatment	SYMP
in	O
acute	SYMP
nasopharyngitis	SYMP
(	SYMP
ANP	SYMP
)	SYMP
.	O
CONCLUSIONS	O
:	O
These	O
data	O
,	O
the	O
first	O
evidence	O
that	O
chronic	O
stress	O
can	O
inhibit	O
the	O
stability	O
of	O
the	O
IgG	O
antibody	O
response	O
to	O
a	O
bacterial	SYMP
vaccine	SYMP
for	O
pneumonia	SYMP
,	O
provide	O
additional	O
evidence	O
of	O
health	O
risks	O
associated	O
with	O
dementia	O
caregiving	O
.	O
We	O
assessed	O
the	O
prevalence	O
of	O
head	O
louse	O
infestation	O
and	O
the	O
effectiveness	O
of	O
1	SYMP
%	SYMP
permethrin	SYMP
against	O
head	SYMP
lice	SYMP
in	O
Kosovar	O
refugees	O
.	O
Refugees	O
with	O
crawling	SYMP
lice	SYMP
were	O
treated	O
with	O
a	O
pediculicide	SYMP
containing	SYMP
1	SYMP
%	SYMP
permethrin	SYMP
.	O
We	O
conclude	O
that	O
1	SYMP
%	SYMP
permethrin	SYMP
treatment	SYMP
was	O
effective	O
in	O
louse	SYMP
control	O
in	O
this	O
refugee	O
population	O
.	O
Antibiotics	SYMP
for	O
Salmonella	SYMP
meningitis	SYMP
in	O
children	O
.	O
Four	O
patients	O
developed	O
mild	O
pancreatitis	SYMP
,	O
one	O
had	O
moderate	O
pancreatitis	SYMP
and	O
one	O
had	O
leak	O
of	O
contrast	O
,	O
which	O
was	O
treated	O
by	O
administration	SYMP
of	SYMP
clear	SYMP
fluids	SYMP
orally	O
for	O
one	O
day	O
.	O
We	O
treated	O
two	O
children	O
with	O
influenza-associated	SYMP
acute	SYMP
encephalopathy	SYMP
by	O
a	O
combination	SYMP
of	SYMP
mild	SYMP
hypothermia	SYMP
and	SYMP
steroid	SYMP
pulse	SYMP
therapy	SYMP
.	O
Successful	O
treatment	O
of	O
anaerobic	SYMP
pleuropulmonary	SYMP
infections	SYMP
requires	O
a	O
combination	SYMP
of	SYMP
antibiotic	SYMP
therapy	SYMP
and	SYMP
surgical	SYMP
interventions	SYMP
.	O
Treatment	O
of	O
spontaneous	SYMP
carotid-cavernous	SYMP
fistula	SYMP
in	SYMP
Ehlers-Danlos	SYMP
syndrome	SYMP
by	O
transvenous	SYMP
occlusion	SYMP
with	SYMP
Guglielmi	SYMP
detachable	SYMP
coils	SYMP
.	O
PURPOSE	O
:	O
Macrolide	SYMP
antibiotics	SYMP
are	O
frequently	O
prescribed	O
to	O
patients	O
with	O
symptoms	SYMP
of	SYMP
a	SYMP
common	SYMP
cold	SYMP
.	O
Because	O
the	O
symptoms	O
of	O
rhinovirus	O
colds	O
are	O
attributed	O
to	O
the	O
inflammatory	O
response	O
to	O
infection	O
,	O
we	O
studied	O
the	O
effects	O
of	O
treatment	O
with	O
clarithromycin	SYMP
on	O
the	O
symptomatic	O
and	O
inflammatory	O
response	O
to	O
nasal	O
inoculation	O
with	O
rhinovirus	SYMP
.	O
Therapeutic	SYMP
pneumothorax	SYMP
(	SYMP
TP	SYMP
)	SYMP
proved	O
its	O
efficacy	O
in	O
pre-antibiotic	O
era	O
,	O
so	O
one	O
can	O
assume	O
that	O
it	O
can	O
be	O
applied	O
with	O
the	O
same	O
success	O
in	O
multidrug	SYMP
resistant	SYMP
TB	SYMP
.	O
In	O
conclusion	O
,	O
in	O
some	O
cases	O
of	O
MDR	SYMP
TB	SYMP
,	O
the	O
TP	SYMP
(	O
if	O
there	O
are	O
no	O
pleural	O
adherences	O
)	O
may	O
lead	O
to	O
good	O
results	O
.	O
Acupuncture	SYMP
treatment	O
of	O
common	SYMP
cold	SYMP
CONCLUSIONS	O
:	O
These	O
data	O
,	O
the	O
first	O
evidence	O
that	O
chronic	O
stress	O
can	O
inhibit	O
the	O
stability	O
of	O
the	O
IgG	O
antibody	O
response	O
to	O
a	O
bacterial	SYMP
vaccine	SYMP
for	O
pneumonia	SYMP
,	O
provide	O
additional	O
evidence	O
of	O
health	O
risks	O
associated	O
with	O
dementia	O
caregiving	O
.	O
When	O
bleeding	SYMP
is	O
stopped	O
via	O
surgical	SYMP
or	SYMP
radiological	SYMP
methods	SYMP
,	O
the	O
clinical	O
course	O
of	O
hemobilia-associated	O
pancreatitis	O
appears	O
to	O
be	O
benign	O
.	O
A	O
case	O
of	O
biliary	SYMP
stenosis	SYMP
in	O
polycystic	O
liver	O
improved	O
by	O
injection	SYMP
of	SYMP
minocycline	SYMP
hydrochloride	SYMP
to	O
a	O
hepatic	O
cyst	O
The	O
ruptured	SYMP
horn	SYMP
was	O
excised	O
by	O
laparotomy	SYMP
.	O
Therapy	O
designed	O
to	O
control	O
the	O
efferent	SYMP
phase	SYMP
of	SYMP
established	SYMP
asthma	SYMP
by	O
augmenting	SYMP
down-regulatory	SYMP
Th1	SYMP
counterbalancing	SYMP
mechanisms	SYMP
should	O
be	O
effective	O
.	O
All	O
children	O
with	O
croup	SYMP
symptoms	O
who	O
demonstrate	O
increased	O
work	O
of	O
breathing	O
in	O
the	O
clinics	O
or	O
emergency	O
departments	O
should	O
be	O
treated	O
with	O
glucocorticoids	SYMP
.	O
Increasing	O
resistance	O
among	O
the	O
common	SYMP
respiratory	SYMP
pathogens	SYMP
has	O
encouraged	O
assessment	O
of	O
alternative	O
agents	O
,	O
for	O
example	O
,	O
levofloxacin	SYMP
.	O
Unlike	O
earlier	O
quinolones	O
,	O
levofloxacin	SYMP
has	O
excellent	O
activity	O
against	O
Streptococcus	SYMP
pneumoniae	SYMP
,	O
including	O
strains	O
resistant	O
to	O
penicillin	O
.	O
Clinical	O
trials	O
show	O
levofloxacin	SYMP
to	O
be	O
as	O
effective	O
as	O
cephalosporins	O
in	O
acute	O
exacerbation	O
of	O
chronic	SYMP
bronchitis	SYMP
and	O
as	O
effective	O
as	O
co-amoxiclav	O
,	O
cephalosporins	O
or	O
amoxycillin	O
in	O
community-acquired	SYMP
pneumonia	SYMP
.	O
Additionally	O
,	O
epidemiologic	O
evidence	O
of	O
a	O
marked	O
decline	O
in	O
new	O
KS	SYMP
since	O
the	O
widespread	O
use	O
of	O
highly	SYMP
active	SYMP
antiretroviral	SYMP
therapy	SYMP
(	SYMP
HAART	SYMP
)	SYMP
advocates	O
its	O
use	O
.	O
A	O
field	O
study	O
was	O
carried	O
out	O
to	O
evaluate	O
the	O
effect	O
of	O
vaccination	SYMP
against	O
swine	SYMP
enzootic	SYMP
pneumonia	SYMP
in	O
different	O
production	O
systems	O
(	O
closed	O
or	O
one-site	O
,	O
and	O
open	O
,	O
two-	O
or	O
three-site	O
,	O
systems	O
)	O
.	O
Humoral	O
immune	O
response	O
after	O
vaccination	SYMP
against	O
influenza	SYMP
in	O
patients	O
with	O
breast	O
cancer	O
.	O
Gingyo-san	SYMP
and	O
its	O
components	O
were	O
administered	O
orally	O
to	O
mice	O
1	O
day	O
before	O
,	O
then	O
1	O
and	O
4	O
days	O
after	O
the	O
inhalation	O
of	O
a	O
mouse-adopted	SYMP
strain	SYMP
of	SYMP
influenza	SYMP
A2	SYMP
(	SYMP
H2N2	SYMP
)	SYMP
virus	SYMP
.	O
From	O
these	O
results	O
Gingyo-san	SYMP
was	O
shown	O
to	O
be	O
an	O
antiviral	O
agent	O
in	O
mice	O
infected	O
with	O
a	O
lethal	O
amount	O
of	O
a	O
mouse-adopted	SYMP
strain	SYMP
of	SYMP
influenza	SYMP
A2	SYMP
virus	SYMP
.	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
analyze	O
the	O
association	O
of	O
recurrent	O
abdominal	O
pain	O
and	O
H.	O
pylori	O
infection	O
in	O
children	O
and	O
to	O
evaluate	O
the	O
efficacy	O
of	O
antimicrobial	SYMP
treatment	SYMP
in	O
patients	O
with	O
evidence	O
of	O
infection	SYMP
.	O
Patients	O
with	O
evidence	O
of	O
infection	SYMP
with	SYMP
H.	SYMP
pylori	SYMP
were	O
treated	O
with	O
a	O
combination	SYMP
of	SYMP
omeprazole	SYMP
,	SYMP
amoxicillin	SYMP
,	SYMP
and	SYMP
clarithromycin	SYMP
.	O
Treatment	O
with	O
omeprazole	SYMP
,	SYMP
amoxicillin	SYMP
,	SYMP
and	SYMP
clarithromycin	SYMP
resulted	O
in	O
eradication	O
of	O
the	O
infection	SYMP
in	O
all	O
and	O
in	O
resolution	O
of	O
the	O
clinical	O
symptoms	O
in	O
15	O
(	O
80	O
%	O
)	O
of	O
19	O
patients	O
who	O
had	O
a	O
follow-up	O
examination	O
.	O
A	O
combined	SYMP
therapy	SYMP
results	O
in	O
eradication	O
of	O
the	O
bacterium	SYMP
and	O
in	O
improvement	O
of	O
the	O
clinical	O
symptoms	O
in	O
a	O
significant	O
majority	O
of	O
the	O
patients	O
.	O
In	O
certain	O
clinical	O
settings	O
,	O
interventional	SYMP
radiologic	SYMP
procedures	SYMP
have	O
become	O
an	O
important	O
alternative	O
to	O
surgery	O
in	O
the	O
treatment	O
of	O
gallstones	SYMP
and	O
their	O
complications	O
;	O
techniques	O
include	O
percutaneous	SYMP
cholecystostomy	SYMP
and	SYMP
gallstone	SYMP
removal	SYMP
.	O
BACKGROUND	O
:	O
The	O
administration	O
of	O
salbutamol	SYMP
is	O
permitted	O
only	O
by	O
inhalation	O
by	O
the	O
International	O
Olympic	O
Committee	O
(	O
IOC	O
)	O
for	O
the	O
management	O
of	O
asthma	SYMP
and	SYMP
exercise-induced	SYMP
asthma	SYMP
in	O
athletes	O
.	O
Urine	O
was	O
also	O
obtained	O
from	O
subjects	O
who	O
had	O
received	O
the	O
maximum	O
dosage	O
of	O
inhaled	O
salbutamol	SYMP
advisable	O
for	O
competing	O
athletes	O
to	O
provide	O
protection	O
from	O
exercise-induced	O
asthma	O
and	O
treatment	O
of	O
asthma	SYMP
(	O
1600	O
microg	O
in	O
24	O
h	O
,	O
800	O
microg	O
being	O
in	O
the	O
last	O
4	O
h	O
)	O
.	O
Antimicrobials	SYMP
were	O
prescribed	O
to	O
175	O
(	O
83.73	O
per	O
cent	O
)	O
patients	O
with	O
common	SYMP
cold	SYMP
and	O
78	O
(	O
82.11	O
per	O
cent	O
)	O
patients	O
with	O
diarrhea	SYMP
.	O
OBJECTIVE	O
:	O
to	O
evaluate	O
the	O
possible	O
existence	O
of	O
the	O
so-called	O
less	O
than	O
Roux-en-Y	O
syndrome	O
greater	O
than	O
in	O
a	O
group	O
of	O
21	O
patients	O
who	O
underwent	O
surgery	SYMP
to	O
correct	O
postoperative	SYMP
alkaline	SYMP
reflux	SYMP
gastritis	SYMP
.	O
All	O
had	O
undergone	O
Billroth	SYMP
II	SYMP
subtotal	SYMP
gastrectomy	SYMP
(	O
20	O
for	O
ulcer	SYMP
and	O
1	O
for	O
gastric	SYMP
cancer	SYMP
)	O
.	O
CONCLUSIONS	O
:	O
we	O
found	O
no	O
evidence	O
of	O
disturbances	O
in	O
gastric	O
remnant	O
emptying	O
after	O
Roux-en-Y	SYMP
gastrojejunostomy	SYMP
to	O
treat	O
postoperative	SYMP
alkaline	SYMP
gastric	SYMP
reflux	SYMP
.	O
BACKGROUND	O
:	O
Drainage	O
methods	O
for	O
the	O
gastric	O
conduit	O
after	O
esophagectomy	SYMP
for	O
carcinoma	SYMP
have	O
been	O
controversial	O
.	O
CONCLUSIONS	O
:	O
This	O
study	O
indicates	O
that	O
the	O
use	O
of	O
a	O
computerized	O
physician	O
reminder	O
and	O
a	O
mailed	O
patient	O
reminder	O
had	O
a	O
positive	O
impact	O
on	O
influenza	SYMP
immunizations	SYMP
for	O
older	O
adults	O
in	O
a	O
large	O
family	O
practice	O
office	O
.	O
Contemporary	O
asthma	O
management	O
guidelines	O
list	O
inhaled	SYMP
corticosteroids	SYMP
as	O
the	O
preferred	O
controller	O
medication	O
for	O
patients	O
with	O
persistent	SYMP
asthma	SYMP
.	O
Fluticasone	SYMP
propionate	SYMP
is	O
one	O
of	O
several	O
inhaled	O
corticosteroids	O
used	O
for	O
the	O
treatment	O
of	O
asthma	SYMP
.	O
A	O
series	O
of	O
comparative	O
analyses	O
show	O
that	O
inhaled	SYMP
fluticasone	SYMP
propionate	SYMP
is	O
more	O
cost	O
effective	O
than	O
oral	O
zafirlukast	O
and	O
triamcinolone	O
acetonide	O
and	O
slightly	O
more	O
cost	O
effective	O
than	O
flunisolide	O
in	O
adult	O
patients	O
with	O
asthma	SYMP
.	O
Quality-of-life	O
assessments	O
in	O
patients	O
with	O
mild	O
to	O
moderate	O
disease	O
show	O
that	O
inhaled	SYMP
fluticasone	SYMP
propionate	SYMP
achieved	O
improvements	O
which	O
were	O
deemed	O
to	O
be	O
clinically	O
meaningful	O
in	O
patients	O
with	O
mild	O
to	O
moderate	O
asthma	SYMP
;	O
these	O
changes	O
were	O
significantly	O
greater	O
than	O
those	O
achieved	O
with	O
oral	O
zafirlukast	O
,	O
inhaled	O
triamcinolone	O
acetonide	O
or	O
placebo	O
.	O
CONCLUSIONS	O
:	O
In	O
addition	O
to	O
the	O
considerable	O
body	O
of	O
clinical	O
evidence	O
supporting	O
the	O
use	O
of	O
inhaled	SYMP
fluticasone	SYMP
propionate	SYMP
in	O
patients	O
with	O
asthma	SYMP
,	O
accumulating	O
short	O
term	O
cost-effectiveness	O
data	O
also	O
suggest	O
that	O
this	O
agent	O
can	O
be	O
administered	O
for	O
a	O
similar	O
or	O
lower	O
cost	O
per	O
outcome	O
than	O
other	O
inhaled	O
corticosteroids	O
or	O
oral	O
zafirlukast	O
.	O
Importantly	O
,	O
the	O
clinical	O
benefits	O
offered	O
by	O
fluticasone	SYMP
propionate	SYMP
in	O
patients	O
with	O
persistent	SYMP
asthma	SYMP
are	O
accompanied	O
by	O
clinically	O
significant	O
improvements	O
in	O
quality	O
of	O
life	O
.	O
OBJECTIVE	O
:	O
To	O
describe	O
the	O
effect	O
of	O
influenza	SYMP
vaccination	SYMP
on	O
long-term	O
change	O
in	O
CD4	O
count	O
and	O
HIV	O
RNA	O
level	O
,	O
and	O
on	O
progression	O
to	O
AIDS	O
or	O
death	O
.	O
Combination	SYMP
therapy	SYMP
with	SYMP
interferon-alpha	SYMP
(	SYMP
IFN	SYMP
alpha	SYMP
)	SYMP
plus	SYMP
Ribavirin	SYMP
has	O
been	O
shown	O
to	O
improve	O
the	O
response	O
rate	O
in	O
patients	O
with	O
chronic	SYMP
hepatitis	SYMP
C	SYMP
as	O
compared	O
to	O
IFN	O
alpha	O
alone	O
.	O
To	O
prove	O
,	O
whether	O
Ribavirin	SYMP
has	O
any	O
additional	O
effect	O
on	O
the	O
decline	O
of	O
hepatitis	SYMP
C	SYMP
viremia	SYMP
during	O
the	O
first	O
weeks	O
of	O
treatment	O
patients	O
with	O
and	O
without	O
combination	O
therapy	O
were	O
compared	O
.	O
In	O
patients	O
with	O
combination	SYMP
therapy	SYMP
,	O
a	O
further	O
reduction	O
of	O
viremia	SYMP
level	O
could	O
be	O
observed	O
,	O
whereas	O
viremia	O
levels	O
in	O
patients	O
with	O
IFN	O
alpha	O
alone	O
slightly	O
increased	O
.	O
Ribavirin	SYMP
in	SYMP
combination	SYMP
with	SYMP
IFN	SYMP
alpha	SYMP
exerts	O
an	O
additional	O
anti-viral/immunmodulatory	O
effect	O
which	O
manifests	O
itself	O
in	O
phase	O
2	O
of	O
hepatitis	SYMP
C	SYMP
viremia	SYMP
decline	O
.	O
Surgical	SYMP
clearance	SYMP
of	O
CBD	SYMP
stones	SYMP
was	O
achieved	O
in	O
58	O
patients	O
(	O
93.5	O
%	O
;	O
group	O
Ia	O
)	O
.	O
Use	O
of	O
ES	SYMP
to	O
treat	O
CBD	SYMP
stones	SYMP
on	O
a	O
routine	O
basis	O
was	O
therefore	O
not	O
found	O
to	O
be	O
any	O
better	O
than	O
one-time	O
surgical	O
exploration	O
.	O
Effect	O
of	O
cholecystectomy	SYMP
on	O
gastroesophageal	SYMP
and	SYMP
duodenogastric	SYMP
reflux	SYMP
It	O
is	O
suggested	O
that	O
damaged	SYMP
mucosal	SYMP
tissues	SYMP
with	O
AHF	SYMP
can	O
be	O
effectively	O
compensated	O
by	O
enhanced	O
regeneration	O
response	O
due	O
to	O
an	O
adequately	O
high	O
dose	O
intensity	O
,	O
suggesting	O
a	O
possible	O
tolerability	O
advantage	O
for	O
AHF	O
.	O
Minimally	O
invasive	O
treatment	O
of	O
abscesses	SYMP
by	O
CT-controlled	SYMP
drainage	SYMP
with	SYMP
a	SYMP
basket	SYMP
catheter	SYMP
system	SYMP
PL	SYMP
granule	SYMP
is	O
one	O
of	O
the	O
most	O
common	O
forms	O
of	O
composite	O
medicine	O
for	O
colds	SYMP
in	O
Japan	O
,	O
including	O
acetaminophen	O
.	O
A	O
72-year	O
old	O
man	O
who	O
had	O
been	O
prescribed	O
amiodarone	SYMP
for	O
more	O
than	O
one	O
year	O
before	O
for	O
arrhythmogenic	SYMP
right	SYMP
ventricular	SYMP
dystrophy	SYMP
,	O
repeatedly	O
took	O
PL	O
granules	O
at	O
one-week	O
intervals	O
because	O
of	O
sneezing	O
and	O
fever	O
.	O
He	O
needed	O
mechanical	SYMP
ventilation	SYMP
for	O
severe	SYMP
hypoxemia	SYMP
,	O
but	O
recovered	O
with	O
glucocorticoid	SYMP
pulse	SYMP
therapy	SYMP
.	O
In	O
a	O
follow-up	O
study	O
operative	O
risk	O
,	O
postoperative	O
functional	O
disorders	O
and	O
incidence	O
of	O
anastomotic	O
(	O
recurrent	O
)	O
ulcer	O
after	O
partial	SYMP
gastrectomy	SYMP
with	SYMP
Roux-en-Y	SYMP
gastrojejunostomy	SYMP
for	O
gastroduodenal	SYMP
ulcer	SYMP
were	O
evaluated	O
in	O
52	O
patients	O
.	O
With	O
regard	O
to	O
the	O
high	O
rate	O
of	O
recurrent	SYMP
ulcer	SYMP
Roux-en-Y	SYMP
reconstruction	SYMP
after	O
partial	SYMP
gastrectomy	SYMP
for	O
primary	SYMP
ulcer	SYMP
surgery	SYMP
should	O
be	O
avoided	O
and	O
reconstruction	O
procedures	O
preferred	O
,	O
which	O
guarantee	O
duodenogastric	O
reflux	O
.	O
OBJECTIVE	O
:	O
The	O
aim	O
of	O
these	O
studies	O
was	O
to	O
compare	O
the	O
pharmacokinetics	O
of	O
inhaled	SYMP
fluticasone	SYMP
propionate	SYMP
(	SYMP
FP	SYMP
)	SYMP
after	O
repeated	O
administration	O
via	O
the	O
Diskus	O
or	O
Diskhaler	O
dry	O
powder	O
inhalers	O
(	O
DPIs	O
)	O
to	O
patients	O
with	O
mild-to-moderate	SYMP
asthma	SYMP
.	O
CONCLUSION	O
:	O
In	O
patients	O
with	O
asthma	SYMP
receiving	O
repeated	SYMP
inhaled	SYMP
doses	SYMP
of	SYMP
FP	SYMP
,	O
the	O
systemic	O
exposure	O
(	O
AUC	O
)	O
after	O
inhalation	O
from	O
the	O
Diskus	O
was	O
similar	O
to	O
that	O
from	O
the	O
Diskhaler	O
,	O
with	O
no	O
difference	O
between	O
the	O
DPIs	O
in	O
the	O
effects	O
on	O
cortisol	O
suppression	O
.	O
DATA	O
SYNTHESIS	O
:	O
Recently	O
,	O
an	O
expert	O
panel	O
of	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
recommended	O
use	O
of	O
only	O
three	O
of	O
16	O
systemic	SYMP
antibiotics	SYMP
approved	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
for	O
treatment	O
of	O
AOM	SYMP
:	O
amoxicillin	SYMP
,	SYMP
cefuroxime	SYMP
axetil	SYMP
,	SYMP
and	SYMP
ceftriaxone	SYMP
.	O
A	O
three-step	O
treatment	O
algorithm	O
for	O
refractory	SYMP
AOM	SYMP
that	O
employs	O
amoxicillin	SYMP
,	SYMP
trimethoprim/sulfamethoxazole	SYMP
(	SYMP
TMP/SMX	SYMP
)	SYMP
,	SYMP
or	SYMP
high-dose	SYMP
amoxicillin/clavulanate	SYMP
(	SYMP
depending	SYMP
on	SYMP
the	SYMP
prior	SYMP
dose	SYMP
of	SYMP
and	SYMP
adherence	SYMP
to	SYMP
amoxicillin	SYMP
therapy	SYMP
)	SYMP
,	SYMP
and	SYMP
ceftriaxone	SYMP
or	SYMP
tympanocentesis	SYMP
at	O
steps	O
1	O
,	O
2	O
,	O
and	O
3	O
,	O
respectively	O
,	O
appears	O
rational	O
and	O
cost-effective	O
.	O
CONCLUSIONS	O
:	O
Amoxicillin	SYMP
remains	O
the	O
antibiotic	O
of	O
choice	O
for	O
initial	O
empiric	O
treatment	O
of	O
AOM	SYMP
,	O
although	O
the	O
traditional	O
dosage	O
should	O
be	O
increased	O
in	O
patients	O
at	O
risk	O
for	O
drug-resistant	O
S.	O
pneumoniae	O
.	O
We	O
support	O
the	O
use	O
of	O
conjugate	SYMP
pneumococcal	SYMP
vaccine	SYMP
per	O
guidelines	O
for	O
prevention	O
of	O
Raom	SYMP
from	O
the	O
Advisory	O
Committee	O
on	O
Immunization	O
Practice	O
of	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
,	O
with	O
consideration	O
given	O
to	O
influenza	SYMP
vaccine	SYMP
for	O
cases	O
of	O
rAOM	O
that	O
historically	O
worsen	O
during	O
the	O
flu	O
season	O
.	O
This	O
model	O
can	O
be	O
used	O
to	O
test	O
the	O
safety	O
and	O
efficacy	O
of	O
liver-assist	SYMP
devices	SYMP
aimed	O
at	O
temporizing	O
the	O
detoxification	O
functions	O
of	O
the	O
failing	SYMP
liver	SYMP
.	O
Recent	O
major	O
epidemiologic	O
trends	O
in	O
bacterial	O
meningitis	O
include	O
a	O
dramatic	O
decline	O
in	O
the	O
incidence	O
of	O
Haemophilus	SYMP
influenzae	SYMP
meningitis	SYMP
since	O
the	O
introduction	O
of	O
the	O
protein-conjugated	SYMP
H.	SYMP
influenzae	SYMP
vaccines	SYMP
,	O
and	O
a	O
worldwide	O
increase	O
in	O
infections	O
with	O
antibiotic-resistant	O
strains	O
of	O
bacterial	O
pathogens	O
.	O
dverse	O
outcomes	O
and	O
opioid	SYMP
analgesic	SYMP
administration	SYMP
in	O
acute	SYMP
abdominal	SYMP
pain	SYMP
We	O
examined	O
the	O
remnant	O
stomach	O
for	O
H.	O
pylori	O
infection	O
after	O
gastrectomy	SYMP
for	O
gastric	SYMP
cancer	SYMP
or	SYMP
peptic	SYMP
ulcer	SYMP
between	O
October	O
1992	O
and	O
July	O
1997	O
.	O
The	O
recent	O
introduction	O
of	O
ribavirin	SYMP
,	O
given	O
in	O
combination	O
,	O
has	O
led	O
to	O
a	O
re-appraisal	O
of	O
the	O
management	O
of	O
chronic	SYMP
hepatitis	SYMP
C	SYMP
.	O
The	O
current	O
report	O
considers	O
the	O
additional	O
benefit	O
of	O
combination	SYMP
therapy	SYMP
(	SYMP
interferon	SYMP
alfa	SYMP
and	SYMP
ribavirin	SYMP
)	SYMP
compared	O
with	O
monotherapy	O
(	O
interferon	O
alfa	O
alone	O
)	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
chronic	SYMP
hepatitis	SYMP
C	SYMP
.	O
OBJECTIVE	O
:	O
To	O
review	O
the	O
clinical	O
effectiveness	O
and	O
cost-effectiveness	O
of	O
combination	SYMP
therapy	SYMP
with	SYMP
interferon	SYMP
alfa	SYMP
and	SYMP
ribavirin	SYMP
in	O
patients	O
with	O
chronic	SYMP
hepatitis	SYMP
C	SYMP
.	O
Sida	SYMP
cordifolia	SYMP
L.	SYMP
(	SYMP
Malvaceae	SYMP
)	SYMP
is	O
used	O
in	O
folk	O
medicine	O
for	O
the	O
treatment	O
of	O
inflammation	SYMP
of	SYMP
the	SYMP
oral	SYMP
mucosa	SYMP
,	SYMP
blenorrhea	SYMP
,	SYMP
asthmatic	SYMP
bronchitis	SYMP
and	SYMP
nasal	SYMP
congestion	SYMP
.	O
Double-blind	O
placebo-controlled	O
trial	O
of	O
Mycobacterium	SYMP
vaccae	SYMP
immunotherapy	SYMP
for	O
tuberculosis	SYMP
in	O
KwaZulu	O
,	O
South	O
Africa	O
,	O
1991-97	O
.	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
efficacy	O
of	O
oral	SYMP
tacrolimus	SYMP
as	O
an	O
induction	O
agent	O
in	O
steroid-refractory	SYMP
severe	SYMP
colitis	SYMP
.Study	O
design	O
:	O
Open-label	O
,	O
multicenter	O
trial	O
of	O
oral	O
tacrolimus	O
in	O
patients	O
with	O
severe	O
colitis	O
.	O
CONCLUSION	O
:	O
Although	O
tacrolimus	SYMP
is	O
effective	O
induction	O
therapy	O
for	O
severe	SYMP
ulcerative	SYMP
or	SYMP
Crohn	SYMP
's	SYMP
colitis	SYMP
,	O
fewer	O
than	O
50	O
%	O
of	O
patients	O
treated	O
will	O
successfully	O
achieve	O
a	O
long-term	O
remission	O
.	O
Cytomegalovirus	SYMP
(	SYMP
CMV	SYMP
)	SYMP
infection	SYMP
was	O
one	O
of	O
the	O
most	O
common	O
opportunistic	O
infections	O
in	O
AIDS	O
patients	O
,	O
leading	O
to	O
blindness	O
or	O
life-threatening	O
disease	O
in	O
about	O
40	O
%	O
of	O
patients	O
in	O
the	O
later	O
stages	O
of	O
AIDS	O
before	O
highly	SYMP
active	SYMP
antiretroviral	SYMP
therapy	SYMP
(	SYMP
HAART	SYMP
)	SYMP
.	O
New	SYMP
vaccines	SYMP
are	O
under	O
study	O
to	O
further	O
control	O
bacterial	SYMP
meningitis	SYMP
.	O
The	O
study	O
involved	O
117	O
infants	O
(	O
mean	O
age	O
2.6	O
months	O
)	O
,	O
who	O
needed	O
hospital	SYMP
treatment	SYMP
because	O
of	O
RSV	SYMP
bronchiolitis	SYMP
.	O
According	O
to	O
the	O
present	O
study	O
it	O
seems	O
that	O
inhaled	SYMP
corticosteroid	SYMP
treatment	SYMP
during	O
and	O
after	O
the	O
acute	O
phase	O
of	O
infant	SYMP
RSV	SYMP
bronchiolitis	SYMP
may	O
have	O
a	O
beneficial	O
effect	O
on	O
subsequent	O
bronchial	O
wheezing	O
tendency	O
.	O
OBJECTIVE	O
:	O
This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
safety	O
and	O
estimate	O
the	O
efficacy	O
of	O
oral	SYMP
budesonide	SYMP
in	O
patients	O
with	O
primary	SYMP
sclerosing	SYMP
cholangitis	SYMP
(	SYMP
PSC	SYMP
)	SYMP
.	O
Combined	SYMP
interferon	SYMP
and	SYMP
lamivudine	SYMP
therapy	SYMP
:	O
is	O
this	O
the	O
treatment	O
of	O
choice	O
for	O
patients	O
with	O
chronic	SYMP
hepatitis	SYMP
B	SYMP
virus	SYMP
infection	SYMP
?	O
She	O
had	O
been	O
taking	O
amitriptyline	SYMP
75	O
mg	O
at	O
night	O
for	O
depression	SYMP
for	O
four	O
months	O
before	O
her	O
admission	O
.	O
Side	O
effects	O
from	O
influenza	SYMP
vaccination	SYMP
:	O
differences	O
between	O
returned	O
and	O
random	O
surveys	O
OBJECTIVE	O
:	O
To	O
study	O
the	O
relationship	O
between	O
interleukin-2	O
(	O
IL-2	O
)	O
,	O
soluble	O
interleukin-2	O
receptor	O
(	O
sIL-2R	O
)	O
and	O
the	O
non-and-hypo-responsiveness	O
to	O
hepatitis	SYMP
B	SYMP
vaccine	SYMP
.	O
We	O
assessed	O
the	O
effects	O
of	O
early	SYMP
replacement	SYMP
therapy	SYMP
with	SYMP
protein-C	SYMP
concentrate	SYMP
together	SYMP
with	SYMP
continuous	SYMP
veno-venous	SYMP
haemodiafiltration	SYMP
and	O
conventional	O
treatment	O
in	O
meningococcaemia	SYMP
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
topical	SYMP
DL-alpha-tocopherol	SYMP
(	SYMP
vitamin	SYMP
E	SYMP
)	SYMP
could	O
reduce	O
ultraviolet-induced	SYMP
damage	SYMP
to	SYMP
the	SYMP
epidermis	SYMP
.	O
We	O
observed	O
the	O
effects	O
of	O
cisapride	SYMP
in	O
the	O
management	O
of	O
idiopathic	SYMP
constipation	SYMP
in	O
children	O
.	O
METHODS	O
:	O
Thirty-seven	O
children	O
with	O
a	O
history	O
of	O
constipation	SYMP
(	O
i.e	O
.	O
,	O
pain	O
and	O
difficulty	O
or	O
delay	O
in	O
defecation	O
for	O
greater	O
than	O
3	O
months	O
)	O
were	O
recruited	O
and	O
randomly	O
assigned	O
to	O
8	O
weeks	O
of	O
treatment	O
with	O
either	O
cisapride	SYMP
,	O
0.2	O
mg/kg	O
three	O
times	O
daily	O
,	O
or	O
matching	O
placebo	O
after	O
a	O
2-week	O
run-in	O
period	O
in	O
a	O
double-blind	O
,	O
parallel-group	O
study	O
design	O
.	O
Patient	O
1	O
demonstrated	O
dramatic	O
clearing	O
of	O
his	O
MCV	SYMP
lesions	SYMP
when	O
intravenous	SYMP
cidofovir	SYMP
therapy	SYMP
was	O
started	O
for	O
his	O
treatment-resistant	SYMP
bilateral	SYMP
CMV	SYMP
retinitis	SYMP
and	O
because	O
of	O
cidofovir	SYMP
's	SYMP
possible	O
activity	O
against	O
MCV	SYMP
.	O
In	O
case	O
2	O
,	O
cidofovir	SYMP
was	O
compounded	O
as	O
a	O
3	O
%	O
cream	O
in	O
a	O
combination	O
vehicle	O
(	O
Dermovan	O
)	O
for	O
extensive	O
facial	O
involvement	O
,	O
and	O
complete	O
resolution	O
of	O
MCV	SYMP
was	O
seen	O
after	O
1	O
month	O
of	O
therapy	O
.	O
In	O
case	O
3	O
,	O
intravenous	SYMP
cidofovir	SYMP
therapy	SYMP
was	O
started	O
both	O
for	O
CMV	SYMP
retinitis	SYMP
and	O
in	O
an	O
attempt	O
to	O
clear	O
90	O
%	O
facial	O
MCV	SYMP
involvement	O
;	O
after	O
1	O
month	O
of	O
treatment	O
,	O
all	O
clinical	O
evidence	O
of	O
MCV	SYMP
had	O
resolved	O
.	O
CONCLUSIONS	O
:	O
Cidofovir	SYMP
,	O
a	O
nucleotide	O
analog	O
of	O
deoxycytidine	O
monophosphate	O
,	O
appears	O
to	O
have	O
contributed	O
to	O
clearing	O
of	O
advanced	SYMP
MCV	SYMP
lesions	SYMP
in	O
these	O
3	O
patients	O
,	O
thus	O
providing	O
suggestive	O
evidence	O
of	O
clinical	O
activity	O
against	O
MCV	SYMP
.	O
Controlled	O
trials	O
of	O
cidofovir	SYMP
therapy	SYMP
for	O
MCV	SYMP
in	O
persons	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
are	O
warranted	O
.	O
OBJECTIVE	O
:	O
This	O
study	O
aimed	O
to	O
determine	O
the	O
effect	O
of	O
external	SYMP
beam	SYMP
radiation	SYMP
therapy	SYMP
on	O
choroidal	SYMP
neovascularization	SYMP
(	SYMP
CNV	SYMP
)	SYMP
secondary	O
to	O
age-related	SYMP
macular	SYMP
degeneration	SYMP
(	SYMP
AMD	SYMP
)	SYMP
.	O
Thrombolytic	SYMP
therapy	SYMP
has	O
been	O
accepted	O
in	O
the	O
treatment	O
of	O
acute	SYMP
myocardial	SYMP
infarction	SYMP
.	O
A	O
bolus	O
infusion	O
of	O
tissue	SYMP
plasminogen	SYMP
activator	SYMP
was	O
administered	O
during	O
CPR	SYMP
in	O
refractory	SYMP
ventricular	SYMP
fibrillation	SYMP
(	O
two	O
cases	O
)	O
and	O
pulseless	SYMP
ventricular	SYMP
tachycardia	SYMP
(	O
one	O
case	O
)	O
.	O
We	O
conclude	O
that	O
bolus	SYMP
thrombolytic	SYMP
infusions	SYMP
during	O
CPR	SYMP
may	O
facilitate	O
spontaneous	O
return	O
of	O
circulation	O
in	O
select	O
patients	O
with	O
confirmed	SYMP
acute	SYMP
myocardial	SYMP
infarction	SYMP
,	O
witnessed	O
cardiac	SYMP
arrest	SYMP
in	O
the	O
ED	O
,	O
and	O
refractory	SYMP
ventricular	SYMP
fibrillation	SYMP
or	O
tachycardia	SYMP
.	O
CASE	O
SUMMARY	O
:	O
A	O
92-year	O
old	O
white	O
woman	O
who	O
was	O
receiving	O
venlafaxine	SYMP
for	O
management	O
of	O
depression	SYMP
was	O
found	O
to	O
have	O
hyponatremia	O
.	O
Touch	O
sensibility	O
was	O
assessed	O
with	O
von	O
Frey	O
's	O
monofilaments	O
in	O
the	O
breasts	O
of	O
10	O
healthy	O
women	O
(	O
controls	O
)	O
and	O
of	O
80	O
women	O
with	O
breast	SYMP
cancer	SYMP
who	O
at	O
least	O
1	O
year	O
previously	O
had	O
undergone	O
subcutaneous	SYMP
mastectomy	SYMP
and	O
immediate	O
reconstruction	O
with	O
a	O
prosthesis	O
.	O
Although	O
improved	O
glycemic	SYMP
control	SYMP
,	O
maintenance	O
of	O
normal	O
blood	O
pressure	O
,	O
and	O
use	O
of	O
angiotensin-converting	SYMP
enzyme	SYMP
inhibitors	SYMP
are	O
important	O
strategies	O
to	O
avoid	O
developing	O
microalbuminuria	SYMP
,	O
dietary	O
macronutrient	O
intake	O
may	O
also	O
play	O
a	O
role	O
.	O
Local	O
injection	O
of	O
corticosteroids	SYMP
into	O
refractory	O
esophageal	O
strictures	O
to	O
decrease	O
the	O
restenosis	SYMP
rate	O
has	O
been	O
reported	O
.	O
We	O
systematically	O
reviewed	O
the	O
evidence	O
concerning	O
the	O
ability	O
of	O
five	O
systemic	SYMP
treatments	SYMP
to	O
induce	O
remission	O
in	O
patients	O
with	O
severe	SYMP
psoriasis	SYMP
:	O
ultraviolet	SYMP
B	SYMP
(	SYMP
UVB	SYMP
)	SYMP
,	O
photochemotherapy	SYMP
(	SYMP
PUVA	SYMP
)	SYMP
,	O
methotrexate	SYMP
(	SYMP
MTX	SYMP
)	SYMP
,	O
retinoids	SYMP
(	SYMP
RET	SYMP
)	SYMP
and	O
cyclosporin	SYMP
A	SYMP
(	SYMP
CYA	SYMP
)	SYMP
.	O
Consequently	O
,	O
parenteral	SYMP
nutrition	SYMP
(	SYMP
PN	SYMP
)	SYMP
solutions	SYMP
used	O
to	O
treat	O
malnourished	O
patients	O
with	O
chronic	SYMP
renal	SYMP
failure	SYMP
usually	O
are	O
prepared	O
with	O
little	O
supplementation	O
of	O
these	O
cations	O
.	O
CONCLUSIONS	O
:	O
Malnourished	O
patients	O
with	O
chronic	SYMP
renal	SYMP
failure	SYMP
receiving	O
PN	SYMP
are	O
at	O
risk	O
of	O
developing	O
electrolyte	SYMP
abnormalities	SYMP
,	O
particularly	O
hypophosphatemia	SYMP
.	O
PURPOSE	O
:	O
We	O
report	O
a	O
multicenter	O
experience	O
using	O
tubularized	SYMP
incised	SYMP
plate	SYMP
urethroplastym	SYMP
for	O
proximal	SYMP
hypospadias	SYMP
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
From	O
August	O
1993	O
to	O
December	O
1996	O
tubularized	SYMP
incised	SYMP
plate	SYMP
urethroplasty	SYMP
was	O
performed	O
in	O
27	O
boys	O
6	O
months	O
to	O
3	O
years	O
old	O
with	O
mid	SYMP
shaft	SYMP
and	SYMP
penoscrotal	SYMP
hypospadias	SYMP
.	O
RESULTS	O
:	O
Tubularized	SYMP
incised	SYMP
plate	SYMP
surgery	SYMP
created	O
a	O
functional	O
neourethra	O
even	O
in	O
penoscrotal	SYMP
hypospadias	SYMP
.	O
CONCLUSIONS	O
:	O
Tubularized	SYMP
incised	SYMP
plate	SYMP
urethroplasty	SYMP
is	O
a	O
versatile	O
operation	O
that	O
corrects	O
proximal	SYMP
hypospadias	SYMP
defects	SYMP
with	O
few	O
complications	O
and	O
superior	O
cosmetic	O
results	O
.	O
Aortocoronary	SYMP
bypass	SYMP
grafting	SYMP
is	O
an	O
accepted	O
procedure	O
for	O
ischemic	SYMP
heart	SYMP
disease	SYMP
.	O
Immunotherapy	SYMP
of	O
mice	O
with	O
preexisting	O
cancers	SYMP
with	O
heat	SYMP
shock	SYMP
protein	SYMP
preparations	SYMP
derived	SYMP
from	SYMP
autologous	SYMP
cancer	SYMP
resulted	O
in	O
retarded	O
progression	O
of	O
the	O
primary	O
cancer	SYMP
,	O
a	O
reduced	O
metastatic	O
load	O
,	O
and	O
prolongation	O
of	O
life-span	O
.	O
Intrapleural	SYMP
injection	SYMP
of	SYMP
irradiated	SYMP
LLC-IL2	SYMP
cured	O
pre-existing	SYMP
lung	SYMP
LLC	SYMP
tumors	SYMP
and	O
extended	O
the	O
survival	O
of	O
the	O
mice	O
but	O
did	O
not	O
affect	O
survival	O
of	O
mice	O
with	O
pre-existing	O
peritoneal	SYMP
tumors	SYMP
nor	O
did	O
it	O
affect	O
the	O
growth	O
of	O
s.c.	SYMP
tumors	SYMP
.	O
Intraperitoneal	SYMP
injection	SYMP
of	SYMP
irradiated	SYMP
LLC-IL2	SYMP
cured	O
pre-existing	SYMP
LLC	SYMP
peritoneal	SYMP
tumors	SYMP
and	O
extended	O
the	O
survival	O
of	O
the	O
mice	O
but	O
did	O
not	O
affect	O
survival	O
of	O
mice	O
bearing	O
lung	SYMP
tumors	SYMP
nor	O
did	O
it	O
affect	O
the	O
growth	O
of	O
s.c.	SYMP
tumors	SYMP
.	O
Subcutaneous	SYMP
injection	SYMP
of	SYMP
irradiated	SYMP
LLC-IL2	SYMP
did	O
not	O
affect	O
the	O
growth	O
of	O
preexisting	O
s.c.	SYMP
tumors	SYMP
and	O
also	O
did	O
not	O
improve	O
survival	O
of	O
mice	O
bearing	O
the	O
lung	SYMP
or	SYMP
peritoneal	SYMP
tumors	SYMP
.	O
We	O
describe	O
such	O
an	O
event	O
in	O
a	O
man	O
who	O
underwent	O
allogeneic	SYMP
BMT	SYMP
for	O
APL	SYMP
in	O
second	O
relapse	O
and	O
4	O
years	O
later	O
presented	O
with	O
testicular	O
relapse	O
.	O
Olanzapine	SYMP
is	O
an	O
atypical	O
antipsychotic	O
effective	O
in	O
the	O
treatment	O
of	O
schizophrenic	SYMP
patients	SYMP
.	O
After	O
a	O
2-	O
to	O
9-day	O
placebo	O
lead-in	O
,	O
79	O
inpatients	O
with	O
schizophrenia	SYMP
according	O
to	O
DSM-III-R	O
criteria	O
were	O
placed	O
on	O
an	O
olanzapine	SYMP
dosage	O
of	O
10	O
mg/day	O
or	O
1	O
mg/day	O
for	O
up	O
to	O
6	O
weeks	O
.	O
Fludarabine	SYMP
and	O
ara-C	SYMP
successfully	O
eradicated	O
bone	SYMP
marrow	SYMP
disease	SYMP
in	O
16	O
of	O
27	O
patients	O
(	O
59	O
%	O
)	O
,	O
23	O
patients	O
of	O
which	O
had	O
been	O
treated	O
previously	O
with	O
high-dose	O
ara-C	SYMP
.	O
These	O
results	O
verified	O
the	O
synergistic	O
effect	O
fludarabine	SYMP
exhibited	O
in	O
augmenting	O
ara-CTP	SYMP
concentrations	O
in	O
patients	O
'	O
leukemic	O
blasts	O
,	O
thus	O
improving	O
the	O
clinical	O
response	O
in	O
relapsed	SYMP
pediatric	SYMP
leukemias	SYMP
.	O
BACKGROUND	O
:	O
The	O
growing	O
use	O
of	O
heparin	SYMP
in	O
acute	SYMP
thrombotic	SYMP
disorders	SYMP
,	O
coupled	O
with	O
the	O
availability	O
of	O
many	O
new	O
antithrombotic	SYMP
agents	SYMP
,	O
emphasizes	O
the	O
need	O
for	O
adequate	O
characterization	O
of	O
the	O
platelet	O
effects	O
of	O
the	O
various	O
anticoagulants	SYMP
.	O
METHODS	O
AND	O
RESULTS	O
:	O
Platelet	O
P-selectin	O
(	O
CD62	O
)	O
and	O
activated	O
GP	O
IIb/IIIa	O
(	O
PAC-1	O
)	O
expression	O
on	O
platelet	O
membrane	O
was	O
quantified	O
in	O
whole	O
blood	O
as	O
well	O
as	O
platelet	O
aggregation	O
in	O
platelet-rich	O
plasma	O
in	O
43	O
patients	O
with	O
unstable	SYMP
angina	SYMP
before	O
and	O
during	O
treatment	O
with	O
UFH	SYMP
or	O
enoxaparin	SYMP
.	O
PURPOSE	O
:	O
We	O
review	O
our	O
initial	O
experience	O
with	O
direct	SYMP
percutaneous	SYMP
transluminal	SYMP
angioplasty	SYMP
(	SYMP
PTA	SYMP
)	SYMP
as	O
a	O
reperfusion	SYMP
treatment	SYMP
for	O
acute	SYMP
occlusion	SYMP
of	SYMP
the	SYMP
middle	SYMP
cerebral	SYMP
artery	SYMP
.	O
CONCLUSION	O
:	O
Direct	O
PTA	O
may	O
be	O
performed	O
safely	O
as	O
an	O
alternative	O
to	O
thrombolytic	O
therapy	O
in	O
patients	O
with	O
acute	O
occlusion	O
of	O
the	O
middle	O
cerebral	O
artery	O
when	O
early	O
CT	O
findings	O
and/or	O
lenticulostriate	O
artery	O
involvement	O
are	O
present	O
or	O
when	O
superselective	O
local	O
angiography	O
shows	O
the	O
presence	O
of	O
a	O
large	O
embolus	O
or	O
high-grade	O
stenosis	O
.	O
Women	O
randomised	O
to	O
screen-and-treat	O
received	O
appropriate	O
antibiotics	SYMP
only	O
if	O
screening	O
proved	O
positive	O
for	O
one	O
or	O
more	O
infection	SYMP
.	O
A	O
71-year-old	O
woman	O
with	O
autoimmune	O
hemolytic	O
anemia	O
underwent	O
an	O
emergency	O
endocardial	SYMP
patch	SYMP
repair	SYMP
for	O
ventricular	SYMP
septal	SYMP
perforation	SYMP
after	O
acute	O
myocardial	O
infarction	O
.	O
Use	O
of	O
washed	SYMP
red	SYMP
blood	SYMP
cells	SYMP
was	O
effective	O
in	O
averting	O
hemolytic	SYMP
crisis	SYMP
throughout	O
perioperative	O
period	O
.	O
Therefore	O
,	O
prudent	O
management	O
and	O
use	O
of	O
washed	SYMP
red	SYMP
blood	SYMP
cells	SYMP
transfusion	SYMP
would	O
prevent	O
hemolytic	SYMP
aggravation	SYMP
even	O
in	O
open	O
heart	O
surgery	O
.	O
We	O
report	O
a	O
case	O
of	O
a	O
29-year-old	O
male	O
chronic	O
HBV	O
carrier	O
who	O
developed	O
fulminant	SYMP
reactivated	SYMP
HBV	SYMP
infection	SYMP
following	O
intensive	O
chemotherapy	SYMP
for	O
stage	SYMP
IVB	SYMP
large	SYMP
cell	SYMP
B-cell	SYMP
non-Hodgkin	SYMP
's	SYMP
lymphoma	SYMP
associated	O
with	O
extensive	O
central	O
nervous	O
system	O
and	O
bone	O
marrow	O
involvement	O
.	O
We	O
advise	O
that	O
lamivudine	SYMP
should	O
be	O
considered	O
during	O
intensive	O
chemotherapy	SYMP
treatment	SYMP
of	O
chronic	O
carriers	O
of	O
HBV	SYMP
.	O
OBJECTIVES	O
:	O
The	O
purpose	O
of	O
this	O
analysis	O
was	O
to	O
determine	O
the	O
influence	O
of	O
an	O
additional	O
treatment	O
delay	O
inherent	O
in	O
transfer	O
to	O
an	O
angioplasty	O
center	O
for	O
primary	SYMP
angioplasty	SYMP
of	O
patients	O
with	O
acute	SYMP
myocardial	SYMP
infarction	SYMP
who	O
are	O
first	O
admitted	O
to	O
hospitals	O
without	O
angioplasty	O
facilities	O
.	O
BACKGROUND	O
:	O
Several	O
randomized	O
trials	O
have	O
demonstrated	O
the	O
benefits	O
of	O
primary	SYMP
angioplasty	SYMP
in	O
acute	SYMP
myocardial	SYMP
infarction	SYMP
.	O
We	O
report	O
the	O
first	O
case	O
(	O
to	O
our	O
knowledge	O
)	O
of	O
an	O
endoscopic	SYMP
removal	SYMP
of	O
a	O
forehead	SYMP
soft	SYMP
tissue	SYMP
mass	SYMP
.	O
As	O
the	O
overview	O
shows	O
,	O
both	O
groups	O
of	O
substances	O
are	O
useful	O
for	O
individualized	O
treatment	O
of	O
benign	SYMP
prostatic	SYMP
hyperplasia	SYMP
(	SYMP
BPH	SYMP
)	SYMP
,	O
provided	O
that	O
conservative	O
pharmacological	SYMP
treatment	SYMP
of	O
BPH	SYMP
is	O
basically	O
accepted	O
and	O
that	O
the	O
patients	O
'	O
quality	O
of	O
life	O
is	O
also	O
considered	O
.	O
The	O
results	O
of	O
several	O
clinical	O
investigations	O
showed	O
the	O
efficacy	O
and	O
safety	O
of	O
artichoke	SYMP
extracts	SYMP
(	SYMP
Cynara	SYMP
scolymus	SYMP
L.	SYMP
)	SYMP
in	O
the	O
treatment	O
of	O
hepato-biliary	SYMP
dysfunction	SYMP
and	SYMP
digestive	SYMP
complaints	SYMP
,	O
such	O
as	O
sensation	O
of	O
fullness	O
,	O
loss	SYMP
of	SYMP
appetite	SYMP
,	O
nausea	SYMP
and	O
abdominal	SYMP
pain	SYMP
.	O
Besides	O
the	O
well-known	O
nonsteroidal	SYMP
antiinflammatory	SYMP
drugs	SYMP
(	SYMP
NSAID	SYMP
)	SYMP
for	O
the	O
treatment	O
of	O
rheumatic	SYMP
pain	SYMP
herbal	SYMP
medicine	SYMP
can	O
also	O
be	O
applied	O
successfully	O
.	O
Extracts	O
of	O
the	O
secondary	O
tubers	O
of	O
Devil	SYMP
's	SYMP
Claw	SYMP
(	SYMP
Harpagophytum	SYMP
procumbens	SYMP
)	SYMP
are	O
recommended	O
for	O
the	O
supportive	O
treatment	O
of	O
degenerative	SYMP
painful	SYMP
rheumatism	SYMP
.	O
High-dose	SYMP
intravenous	SYMP
immunoglobulin	SYMP
(	SYMP
hdIVIg	SYMP
)	SYMP
is	O
increasingly	O
used	O
to	O
treat	O
a	O
range	O
of	O
inflammatory	SYMP
and	SYMP
autoimmune	SYMP
diseases	SYMP
.	O
The	O
current	O
dermatological	O
uses	O
of	O
hdIVIg	SYMP
include	O
the	O
treatment	O
of	O
dermatomyositis	SYMP
and	O
the	O
autoimmune	SYMP
bullous	SYMP
disorders	SYMP
,	O
epidermolysis	SYMP
bullosa	SYMP
acquisita	SYMP
,	O
pemphigoid	SYMP
,	O
and	O
pemphigus	SYMP
.	O
Unfortunately	O
,	O
current	O
dermatological	O
uses	O
of	O
hdIVIg	O
have	O
been	O
limited	O
to	O
either	O
uncontrolled	O
trials	O
or	O
anecdotal	O
case	O
reports	O
,	O
except	O
for	O
a	O
single	O
controlled	O
trial	O
of	O
hdIVIg	SYMP
as	O
adjunctive	O
therapy	O
in	O
patients	O
with	O
dermatomyositis	SYMP
,	O
which	O
documented	O
a	O
significant	O
benefit	O
.	O
We	O
describe	O
a	O
technique	O
that	O
enables	O
the	O
autologous	SYMP
repair	SYMP
of	O
large	SYMP
midline	SYMP
incisional	SYMP
hernias	SYMP
by	O
restoring	O
the	O
functional	O
musculoaponeurotic	O
support	O
of	O
the	O
abdominal	O
wall	O
.	O
OBJECTIVE	O
AND	O
IMPORTANCE	O
:	O
The	O
use	O
of	O
chronic	SYMP
intrathecal	SYMP
morphine	SYMP
for	O
the	O
treatment	O
of	O
intractable	SYMP
,	SYMP
nonmalignant	SYMP
pain	SYMP
is	O
becoming	O
more	O
prevalent	O
.	O
METHODS	O
:	O
During	O
a	O
19-month	O
period	O
,	O
seven	O
children	O
with	O
empyema	SYMP
underwent	O
thoracoscopy	SYMP
.	O
We	O
describe	O
a	O
patient	O
with	O
left	SYMP
cardiac	SYMP
herniation	SYMP
presenting	O
after	O
intrapericardial	SYMP
pulmonectomy	SYMP
for	O
primary	SYMP
lung	SYMP
cancer	SYMP
.	O
The	O
growing	O
use	O
of	O
automated	SYMP
night-time	SYMP
dialysis	SYMP
(	SYMP
APD	SYMP
)	SYMP
in	O
peritoneal	SYMP
dialysis	SYMP
over	O
the	O
last	O
few	O
years	O
shows	O
that	O
this	O
method	O
represents	O
a	O
valid	O
alternative	O
to	O
continuous	SYMP
ambulatory	SYMP
peritoneal	SYMP
dialysis	SYMP
(	SYMP
CAPD	SYMP
)	SYMP
.	O
La	O
Serna	O
et	O
al	O
.	O
(	O
Lancet	O
1987	O
;	O
26	O
:	O
1517	O
)	O
were	O
the	O
first	O
to	O
treat	O
adults	O
with	O
recurrent	SYMP
pericarditis	SYMP
with	O
colchicine	SYMP
,	O
and	O
were	O
followed	O
by	O
other	O
authors	O
.	O
While	O
these	O
findings	O
are	O
observed	O
for	O
all	O
classes	O
of	O
oral	O
drugs	O
,	O
the	O
issue	O
is	O
especially	O
critical	O
for	O
cancer	SYMP
chemotherapy	SYMP
,	O
in	O
which	O
a	O
narrow	O
therapeutic	O
index	O
is	O
frequently	O
observed	O
.	O
Treatment	O
for	O
low-grade	SYMP
NHL	SYMP
during	O
the	O
past	O
30	O
yr	O
has	O
consisted	O
of	O
high-dose	SYMP
radiation	SYMP
and	O
cytotoxic	SYMP
agents	SYMP
,	O
administered	O
alone	O
or	O
in	O
combination	O
,	O
and	O
high-dose	SYMP
therapy	SYMP
with	SYMP
stem	SYMP
cell	SYMP
transplant	SYMP
.	O
However	O
,	O
recent	O
clinical	O
use	O
of	O
monoclonal	SYMP
antibodies	SYMP
(	SYMP
mAbs	SYMP
)	SYMP
in	O
patients	O
with	O
low-grade	SYMP
or	SYMP
transformed	SYMP
low-grade	SYMP
NHL	SYMP
has	O
resulted	O
in	O
less	O
toxicity	O
than	O
conventional	O
treatments	O
,	O
as	O
well	O
as	O
response	O
rates	O
that	O
are	O
comparable	O
or	O
superior	O
to	O
those	O
achieved	O
with	O
chemotherapy	SYMP
.	O
Therefore	O
,	O
interest	O
is	O
growing	O
in	O
mAbs	SYMP
as	O
therapeutic	O
alternatives	O
for	O
patients	O
with	O
low-grade	SYMP
NHL	SYMP
and	O
those	O
with	O
transformed	O
histology	O
.	O
CONCLUSION	O
:	O
The	O
treatment	O
paradigm	O
for	O
NHL	SYMP
is	O
expected	O
to	O
change	O
over	O
the	O
next	O
few	O
years	O
to	O
include	O
radiolabeled	SYMP
mAbs	SYMP
,	O
administered	O
alone	O
or	O
in	O
combination	O
with	O
cytotoxic	SYMP
agents	SYMP
.	O
RESULTS	O
:	O
Clinical	O
trials	O
of	O
UFT	SYMP
published	O
in	O
the	O
Western	O
world	O
have	O
included	O
581	O
patients	O
with	O
colorectal	SYMP
cancer	SYMP
.	O
The	O
activity	O
of	O
oral	SYMP
UFT	SYMP
in	O
large-bowel	SYMP
cancer	SYMP
when	O
administered	O
with	O
oral	SYMP
LV	SYMP
(	O
approximately	O
50	O
mg/dose	O
)	O
has	O
resulted	O
in	O
objective	O
response	O
rates	O
of	O
approximately	O
40	O
%	O
.	O
CONCLUSION	O
:	O
UFT	SYMP
is	O
a	O
fluoropyrimidine	SYMP
active	O
in	O
colorectal	SYMP
cancer	SYMP
.	O
BACKGROUND	O
:	O
Adrenalectomy	SYMP
is	O
the	O
current	O
treatment	O
for	O
phaeochromocytoma	SYMP
.	O
CONCLUSION	O
:	O
Adrenal-sparing	SYMP
surgery	SYMP
is	O
safe	O
and	O
effective	O
,	O
and	O
may	O
become	O
the	O
treatment	O
of	O
choice	O
in	O
patients	O
with	O
hereditary	SYMP
phaeochromocytoma	SYMP
.	O
PURPOSE	O
:	O
The	O
purposes	O
of	O
this	O
descriptive	O
,	O
longitudinal	O
study	O
were	O
to	O
evaluate	O
the	O
MacDibbs	O
Mouth	O
Assessment	O
instrument	O
for	O
the	O
assessment	O
of	O
mucositis	O
in	O
the	O
radiation	SYMP
therapy	SYMP
patient	O
being	O
treated	O
for	O
head	SYMP
and	SYMP
neck	SYMP
cancer	SYMP
and	O
to	O
describe	O
the	O
course	O
of	O
radiation-induced	SYMP
mucositis	SYMP
in	O
these	O
patients	O
.	O
As	O
concomitant	SYMP
thrombocytosis	SYMP
persisted	O
despite	O
treatment	O
with	O
hydroxyurea	SYMP
,	O
the	O
new	O
megakaryocyte	SYMP
inhibitor	SYMP
anagrelide	SYMP
(	SYMP
Agrelin	SYMP
)	SYMP
was	O
administered	O
and	O
led	O
to	O
normalization	O
of	O
the	O
platelet	O
count	O
within	O
11	O
days	O
.	O
Background	O
:	O
Troglitazone	SYMP
is	O
a	O
new	O
drug	O
for	O
the	O
treatment	O
of	O
type	SYMP
2	SYMP
diabetes	SYMP
.	O
For	O
a	O
subset	O
of	O
patients	O
with	O
Kaposi	SYMP
's	SYMP
sarcoma	SYMP
who	O
were	O
treated	O
with	O
recombinant	SYMP
interferon	SYMP
alfa-2a	SYMP
,	O
the	O
disease	O
is	O
in	O
complete	O
remission	O
,	O
without	O
opportunistic	SYMP
infection	SYMP
,	O
and	O
they	O
appear	O
to	O
be	O
culture-negative	O
for	O
the	O
etiologic	O
retrovirus	O
that	O
causes	O
their	O
immune	SYMP
deficiency	SYMP
.	O
Interferon	SYMP
alfa-2a	SYMP
appears	O
to	O
have	O
antineoplastic	O
efficacy	O
,	O
(	O
and	O
may	O
have	O
antiretroviral	O
efficacy	O
as	O
well	O
)	O
in	O
this	O
epidemic	O
neoplasm	SYMP
.	O
In	O
three	O
consecutive	O
Phase	O
II	O
trials	O
of	O
recombinant	SYMP
interferon	SYMP
alfa-2a	SYMP
(	O
rIFN	O
alfa-2a	O
;	O
Roferon-A	O
Hoffmann-La	O
Roche	O
,	O
Nutley	O
,	O
NJ	O
)	O
involving	O
96	O
patients	O
with	O
advanced	SYMP
malignant	SYMP
melanoma	SYMP
,	O
an	O
overall	O
response	O
rate	O
of	O
22	O
%	O
was	O
observed	O
.	O
As	O
single	O
agent	O
therapy	O
in	O
malignant	SYMP
melanoma	SYMP
,	O
interferon	SYMP
alfa-2a	SYMP
was	O
only	O
marginally	O
useful	O
in	O
most	O
patients	O
.	O
Studies	O
with	O
various	O
interferon	SYMP
alpha	SYMP
preparations	SYMP
,	O
including	O
interferons	SYMP
induced	O
in	O
human	O
leukocytes	O
,	O
interferon	SYMP
alfa-N1	SYMP
,	O
interferon	SYMP
alfa-2a	SYMP
,	O
and	O
interferon	SYMP
alfa-2b	SYMP
,	O
have	O
all	O
provided	O
evidence	O
for	O
modest	O
but	O
reproducible	O
antitumor	O
activity	O
in	O
advanced	SYMP
renal	SYMP
cell	SYMP
carcinoma	SYMP
.	O
Preliminary	O
evidence	O
suggests	O
that	O
interferons	SYMP
beta	SYMP
and	SYMP
gamma	SYMP
may	O
also	O
induce	O
regression	O
of	O
metastatic	SYMP
renal	SYMP
cell	SYMP
carcinoma	SYMP
.	O
The	O
rationale	O
for	O
antileukemic	SYMP
therapy	SYMP
in	O
hairy	SYMP
cell	SYMP
leukemia	SYMP
is	O
to	O
reduce	O
the	O
significant	O
risk	O
of	O
infection	O
and	O
other	O
potential	O
serious	O
complications	O
.	O
Splenectomy	SYMP
presumably	O
alleviates	O
the	O
pancytopenic	O
effect	O
of	O
hypersplenism	SYMP
by	O
removing	O
the	O
preferred	O
site	O
of	O
leukemic	O
cell	O
proliferation	O
.	O
Recombinant	O
and	O
natural	O
forms	O
of	O
interferon	SYMP
alpha	SYMP
have	O
been	O
shown	O
to	O
bring	O
about	O
tumor	O
regressions	O
in	O
patients	O
with	O
low-grade	SYMP
non-Hodgkin	SYMP
's	SYMP
lymphoma	SYMP
.	O
Current	O
studies	O
using	O
interferon	SYMP
in	O
patients	O
with	O
low-grade	SYMP
non-Hodgkin	SYMP
's	SYMP
lymphomas	SYMP
are	O
evaluating	O
lower	O
,	O
and	O
perhaps	O
better	O
tolerated	O
doses	O
of	O
interferon	SYMP
.	O
This	O
approach	O
is	O
being	O
extended	O
to	O
the	O
clinic	O
,	O
and	O
trials	O
are	O
now	O
underway	O
evaluating	O
combinations	O
of	O
interferon	SYMP
and	O
various	O
cytotoxic	SYMP
drugs	SYMP
known	O
from	O
previous	O
studies	O
to	O
be	O
active	O
in	O
patients	O
with	O
low-grade	SYMP
non-Hodgkin	SYMP
's	SYMP
lymphomas	SYMP
.	O
While	O
the	O
demonstrated	O
antiviral	O
,	O
antiproliferative	O
,	O
and	O
immunomodulatory	O
properties	O
of	O
interferons	SYMP
have	O
led	O
to	O
a	O
number	O
of	O
theories	O
regarding	O
their	O
potential	O
use	O
in	O
treating	O
individuals	O
with	O
chronic	SYMP
myelogenous	SYMP
leukemia	SYMP
(	SYMP
CML	SYMP
)	SYMP
,	O
their	O
limited	O
availability	O
has	O
prevented	O
thorough	O
clinical	O
investigation	O
.	O
The	O
data	O
resulting	O
from	O
these	O
clinical	O
trials	O
indicate	O
that	O
interferon	SYMP
alfa-2a	SYMP
is	O
effective	O
in	O
inducing	O
hematologic	O
remissions	O
in	O
the	O
majority	O
of	O
minimally	O
treated	O
,	O
benign-phase	SYMP
CML	SYMP
,	O
Ph1-positive	O
patients	O
.	O
More	O
than	O
1600	O
patients	O
with	O
neoplastic	SYMP
disorders	SYMP
have	O
received	O
recombinant	SYMP
human	SYMP
interferon	SYMP
alfa-2a	SYMP
(	SYMP
Roferon-A	SYMP
,	SYMP
Hoffmann-La	SYMP
Roche	SYMP
,	SYMP
Nutley	SYMP
,	SYMP
NJ	SYMP
)	SYMP
as	O
part	O
of	O
ongoing	O
or	O
completed	O
clinical	O
trials	O
.	O
PURPOSE	O
:	O
A	O
phase	O
I/II	O
trial	O
of	O
docetaxel	SYMP
,	O
cisplatin	SYMP
,	O
fluorouracil	SYMP
(	SYMP
5-FU	SYMP
)	SYMP
,	O
and	O
leucovorin	SYMP
(	SYMP
TPFL5	SYMP
)	SYMP
induction	SYMP
chemotherapy	SYMP
for	O
patients	O
with	O
locally	SYMP
advanced	SYMP
squamous	SYMP
cell	SYMP
carcinoma	SYMP
of	SYMP
the	SYMP
head	SYMP
and	SYMP
neck	SYMP
(	SYMP
SCCHN	SYMP
)	SYMP
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
Twenty-three	O
previously	O
untreated	O
patients	O
with	O
stage	SYMP
III	SYMP
or	SYMP
IV	SYMP
SCCHN	SYMP
and	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
functional	O
status	O
less	O
than	O
or	O
equal	O
to	O
2	O
were	O
treated	O
with	O
TPFL5	SYMP
.	O
Intrathecal	SYMP
sufentanil	SYMP
provides	O
approximately	O
2	O
h	O
of	O
excellent	O
labor	SYMP
analgesia	O
with	O
minimal	O
motor	O
blockade	O
.	O
OBJECTIVE	O
:	O
We	O
report	O
the	O
results	O
of	O
a	O
double-blind	O
,	O
double-dummy	O
,	O
active-control	O
study	O
designed	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
lamotrigine	SYMP
(	SYMP
LTG	SYMP
)	SYMP
administered	O
as	O
monotherapy	O
to	O
adult	O
outpatients	O
with	O
partial	SYMP
seizures	SYMP
.	O
BACKGROUND	O
:	O
The	O
effectiveness	O
of	O
LTG	SYMP
as	O
add-on	O
therapy	O
for	O
partial	SYMP
seizures	SYMP
in	O
adults	O
has	O
previously	O
been	O
established	O
.	O
CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
LTG	SYMP
is	O
effective	O
and	O
well	O
tolerated	O
when	O
administered	O
as	O
monotherapy	O
in	O
adult	O
patients	O
with	O
partial	SYMP
seizures	SYMP
.	O
BACKGROUND	O
:	O
Omega3	O
fatty	O
acids	O
may	O
inhibit	O
neuronal	O
signal	O
transduction	O
pathways	O
in	O
a	O
manner	O
similar	O
to	O
that	O
of	O
lithium	SYMP
carbonate	SYMP
and	O
valproate	SYMP
,	O
2	O
effective	O
treatments	O
for	O
bipolar	SYMP
disorder	SYMP
.	O
The	O
present	O
study	O
was	O
performed	O
to	O
examine	O
whether	O
omega3	SYMP
fatty	SYMP
acids	SYMP
also	O
exhibit	O
mood-stabilizing	O
properties	O
in	O
bipolar	SYMP
disorder	SYMP
.	O
CONCLUSION	O
:	O
Omega3	SYMP
fatty	SYMP
acids	SYMP
were	O
well	O
tolerated	O
and	O
improved	O
the	O
short-term	O
course	O
of	O
illness	O
in	O
this	O
preliminary	O
study	O
of	O
patients	O
with	O
bipolar	SYMP
disorder	SYMP
.	O
Several	O
large-scale	O
trials	O
have	O
firmly	O
established	O
the	O
effectiveness	O
of	O
thrombolytic	SYMP
therapy	SYMP
,	O
beta	SYMP
blockers	SYMP
,	O
and	O
aspirin	SYMP
in	O
the	O
treatment	O
of	O
AMI	SYMP
.	O
While	O
diastolic	SYMP
left	SYMP
ventricular	SYMP
(	SYMP
LV	SYMP
)	SYMP
dysfunction	SYMP
is	O
frequent	O
and	O
associated	O
with	O
cardiovascular	SYMP
complications	SYMP
in	O
end-stage	SYMP
renal	SYMP
disease	SYMP
treated	O
with	O
dialysis	SYMP
,	O
controversial	O
information	O
exists	O
on	O
diastolic	O
LV	O
function	O
after	O
renal	O
transplantation	O
.	O
METHODS	O
:	O
Fluvastatin	SYMP
40	O
mg	O
daily	O
was	O
administered	O
to	O
25	O
patients	O
with	O
hypercholesterolaemia	SYMP
for	O
up	O
to	O
24	O
weeks	O
.	O
The	O
inhibitory	O
effect	O
of	O
n-3	SYMP
polyunsaturated	SYMP
fatty	SYMP
acids	SYMP
on	O
human	SYMP
colorectal	SYMP
cancer	SYMP
has	O
been	O
speculated	O
on	O
from	O
epidemiological	O
data	O
and	O
animal	O
studies	O
.	O
We	O
conducted	O
a	O
long-term	O
trial	O
of	O
docosahexanoic	SYMP
acid	SYMP
(	SYMP
DHA	SYMP
)	SYMP
-concentrated	SYMP
fish	SYMP
oil	SYMP
capsules	SYMP
for	O
patients	O
in	O
a	O
high-risk	O
group	O
for	O
colorectal	SYMP
cancer	SYMP
.	O
Three	O
patients	O
with	O
FAP	SYMP
and	O
two	O
patients	O
with	O
multiple	O
(	O
more	O
than	O
30	O
)	O
colorectal	SYMP
polyps	SYMP
were	O
administered	O
DHA-concentrated	SYMP
fish	SYMP
oil	SYMP
capsules_Hlk427554600	SYMP
(	SYMP
2.2	SYMP
g	SYMP
of	SYMP
DHA	SYMP
and	SYMP
0.6	SYMP
g	SYMP
of	SYMP
eicosapentanoic	SYMP
acid	SYMP
(	SYMP
EPA	SYMP
)	SYMP
per	SYMP
day	SYMP
)	SYMP
for	O
one	O
or	O
two	O
years	O
.	O
This	O
article	O
reviews	O
current	O
trends	O
in	O
management	O
of	O
esophageal	SYMP
achalasia	SYMP
,	O
highlighting	O
short-term	O
outcome	O
and	O
cost	O
comparisons	O
of	O
three	O
treatments	O
:	O
botulinum	SYMP
toxin	SYMP
injection	SYMP
,	O
pneumatic	SYMP
dilation	SYMP
,	O
and	O
laparoscopic	SYMP
myotomy	SYMP
.	O
The	O
clinical	O
application	O
of	O
therapeutic	SYMP
hysteroscopy	SYMP
,	O
mainly	O
in	O
the	O
field	O
of	O
the	O
treatment	O
of	O
abnormal	SYMP
uterine	SYMP
bleeding	SYMP
,	O
started	O
in	O
the	O
1980s	O
.	O
In	O
this	O
article	O
,	O
evidence	O
of	O
effectiveness	O
and	O
cost-effectiveness	O
of	O
the	O
following	O
procedures	O
is	O
reviewed	O
:	O
(	O
1	O
)	O
laser	SYMP
treatment	SYMP
of	O
bladder	SYMP
tumors	SYMP
;	O
(	O
2	O
)	O
extracorporeal	O
shock-wave	O
lithotripsy	O
and	O
percutaneous	O
nephrolithotomy	O
;	O
(	O
3	O
)	O
laparoscopic	SYMP
treatment	SYMP
of	O
endometriosis	SYMP
;	O
(	O
4	O
)	O
laparoscopic	SYMP
removal	SYMP
of	O
ovarian	SYMP
cysts	SYMP
;	O
(	O
5	O
)	O
laparoscopic	O
cholecystectomy	O
;	O
(	O
6	O
)	O
laparoscopic	O
appendectomy	O
;	O
(	O
7	O
)	O
catheter	SYMP
treatment	SYMP
of	O
coronary	SYMP
artery	SYMP
disease	SYMP
;	O
(	O
8	O
)	O
palliation	O
of	O
colon	O
cancer	O
by	O
endoscopic	O
intervention	O
;	O
(	O
9	O
)	O
treatment	O
of	O
upper	SYMP
gastrointestinal	SYMP
(	SYMP
UGI	SYMP
)	SYMP
bleeding	SYMP
by	O
endoscopic	SYMP
intervention	SYMP
;	O
and	O
(	O
10	O
)	O
arthroscopic	O
knee	O
surgery	O
.	O
Gene	SYMP
therapy	SYMP
of	O
malignant	SYMP
brain	SYMP
tumors	SYMP
Treatment	O
of	O
irritable	SYMP
bowel	SYMP
syndrome	SYMP
with	O
Chinese	SYMP
herbal	SYMP
medicine	SYMP
:	O
a	O
randomized	O
controlled	O
trial	O
.	O
Randomised	O
trial	O
of	O
interferon	SYMP
alpha2b	SYMP
plus	SYMP
ribavirin	SYMP
for	O
48	O
weeks	O
or	O
for	O
24	O
weeks	O
versus	O
interferon	SYMP
alpha2b	SYMP
plus	SYMP
placebo	SYMP
for	O
48	O
weeks	O
for	O
treatment	O
of	O
chronic	SYMP
infection	SYMP
with	SYMP
hepatitis	SYMP
C	SYMP
virus	SYMP
.	O
Low-molecular-weight	SYMP
heparin	SYMP
for	O
immediate	O
management	O
of	O
thromboembolic	SYMP
disease	SYMP
in	O
pregnancy	O
.	O
Tubularized	SYMP
incised	SYMP
plate	SYMP
hypospadias	SYMP
repair	SYMP
for	O
proximal	SYMP
hypospadias	SYMP
.	O
Comparison	O
of	O
radical	SYMP
prostatectomy	SYMP
and	O
iodine	SYMP
125	SYMP
interstitial	SYMP
radiotherapy	SYMP
for	O
the	O
treatment	O
of	O
clinically	SYMP
localized	SYMP
prostate	SYMP
cancer	SYMP
:	O
a	O
7-year	O
biochemical	O
(	O
PSA	O
)	O
progression	O
analysis	O
.	O
The	O
effectiveness	O
of	O
acupuncture	SYMP
in	O
treating	O
acute	SYMP
dental	SYMP
pain	SYMP
:	O
a	O
systematic	O
review	O
.	O
Correction	O
of	O
cardiac	SYMP
defects	SYMP
through	O
a	O
right	SYMP
thoracotomy	SYMP
in	O
children	O
.	O
New	O
technique	O
for	O
mesh	SYMP
repair	SYMP
of	O
paracolostomy	SYMP
hernias	SYMP
.	O
Immunotherapy	SYMP
of	O
tumors	SYMP
with	O
autologous	SYMP
tumor-derived	SYMP
heat	SYMP
shock	SYMP
protein	SYMP
preparations	SYMP
.	O
Comprehensive	SYMP
modified	SYMP
diet	SYMP
simplifies	O
nutrition	SYMP
management	SYMP
of	O
adults	O
with	O
short-bowel	SYMP
syndrome	SYMP
.	O
Extended	O
use	O
of	O
glatiramer	SYMP
acetate	SYMP
(	SYMP
Copaxone	SYMP
)	SYMP
is	O
well	O
tolerated	O
and	O
maintains	O
its	O
clinical	O
effect	O
on	O
multiple	SYMP
sclerosis	SYMP
relapse	O
rate	O
and	O
degree	O
of	O
disability	O
.	O
European	O
register	O
of	O
patients	O
with	O
sickle	SYMP
cell	SYMP
disease	SYMP
treated	O
with	O
hydroxyurea	SYMP
is	O
being	O
set	O
up	O
.	O
Understanding	O
the	O
culture	O
of	O
prescribing	O
:	O
qualitative	O
study	O
of	O
general	O
practitioners	O
'	O
and	O
patients	O
'	O
perceptions	O
of	O
antibiotics	SYMP
for	O
sore	SYMP
throats	SYMP
.	O
Steroid	SYMP
delivery	SYMP
in	O
croup	SYMP
.	O
Haematoma	SYMP
block	SYMP
versus	O
intravenous	SYMP
regional	SYMP
anaesthesia	SYMP
in	O
Colles	SYMP
'	SYMP
fractures	SYMP
.	O
Direct	SYMP
percutaneous	SYMP
transluminal	SYMP
angioplasty	SYMP
for	O
acute	SYMP
middle	SYMP
cerebral	SYMP
artery	SYMP
occlusion	SYMP
.	O
Magnesium	SYMP
sulphate	SYMP
for	O
the	O
control	O
of	O
spasms	SYMP
in	SYMP
severe	SYMP
tetanus	SYMP
.	O
Protective	O
effect	O
of	O
pralidoxime	SYMP
on	O
muscle	SYMP
fiber	SYMP
necrosis	SYMP
induced	O
by	O
organophosphate	O
compounds	O
.	O
Assessment	O
of	O
atrioventricular	SYMP
junction	SYMP
ablation	SYMP
and	SYMP
VVIR	SYMP
pacemaker	SYMP
versus	O
pharmacological	SYMP
treatment	SYMP
in	O
patients	O
with	O
heart	SYMP
failure	SYMP
and	SYMP
chronic	SYMP
atrial	SYMP
fibrillation	SYMP
:	O
a	O
randomized	O
,	O
controlled	O
study	O
.	O
Statins	SYMP
for	O
prevention	O
of	O
stroke	SYMP
.	O
Repair	O
of	O
ventral	SYMP
hernias	SYMP
with	O
expanded	SYMP
polytetrafluoroethylene	SYMP
patch	SYMP
.	O
Spinal	SYMP
manipulation	SYMP
in	O
the	O
treatment	O
of	O
episodic	SYMP
tension-type	SYMP
headache	SYMP
:	O
a	O
randomized	O
controlled	O
trial	O
.	O
Successful	O
treatment	O
with	O
lamivudine	SYMP
for	O
fulminant	SYMP
reactivated	SYMP
hepatitis	SYMP
B	SYMP
infectioN	SYMP
following	O
intensive	SYMP
therapy	SYMP
for	O
high-grade	SYMP
non-Hodgkin	SYMP
's	SYMP
lymphoma	SYMP
.	O
Influence	O
of	O
treatment	O
delay	O
on	O
infarct	O
size	O
and	O
clinical	O
outcome	O
in	O
patients	O
with	O
acute	SYMP
myocardial	SYMP
infarction	SYMP
treated	O
with	O
primary	SYMP
angioplasty	SYMP
.	O
Should	O
patients	O
with	O
advanced	SYMP
sarcomas	SYMP
be	O
treated	O
with	O
chemotherapy	SYMP
?	O
.	O
Plasma	SYMP
exchange	SYMP
and	SYMP
tacrolimus-mycophenolate	SYMP
rescue	SYMP
for	O
acute	SYMP
humoral	SYMP
rejection	SYMP
in	O
kidney	O
transplantation	O
.	O
Hyperbaric	SYMP
oxygen	SYMP
therapy	SYMP
for	O
children	O
with	O
cerebral	SYMP
palsy	SYMP
.	O
Endoscopic	SYMP
excision	SYMP
of	O
a	SYMP
forehead	SYMP
mass	SYMP
.	O
Effect	O
of	O
photodynamic	SYMP
therapy	SYMP
in	SYMP
combination	SYMP
with	SYMP
mitomycin	SYMP
C	SYMP
on	O
a	O
mitomycin-resistant	SYMP
bladder	SYMP
cancer	SYMP
cell	O
line	O
.	O
Is	O
conservative	SYMP
surgery	SYMP
for	O
tubal	SYMP
pregnancy	SYMP
preferable	O
to	O
salpingectomy	SYMP
?	O
An	O
economic	O
analysis	O
.	O
Laparoscopic	SYMP
cornuostomy	SYMP
in	O
the	O
treatment	O
of	O
interstitial	SYMP
pregnancy	SYMP
with	O
subsequent	O
hysterosalpingography	O
.	O
Experimental	O
evaluation	O
of	O
the	O
use	O
of	O
recombinant	SYMP
prourokinase	SYMP
and	O
its	O
immobilized	O
forms	O
in	O
the	O
treatment	O
of	O
postoperative	SYMP
fibrinoid	SYMP
syndrome	SYMP
in	O
ophthalmology	O
In	O
vitro	O
and	O
in	O
vivo	O
comparison	O
between	O
the	O
effects	O
of	O
treatment	O
with	O
adenosine	SYMP
triphosphate	SYMP
and	O
treatment	O
with	O
buthionine	SYMP
sulfoximine	SYMP
on	O
chemosensitization	O
and	O
tumour	O
growth	O
of	O
B16	SYMP
melanoma	SYMP
.	O
Effects	O
of	O
transpupillary	SYMP
thermotherapy	SYMP
on	O
immunological	O
parameters	O
and	O
apoptosis	O
in	O
a	O
case	O
of	O
primary	SYMP
uveal	SYMP
melanoma	SYMP
.	O
Is	O
there	O
a	O
rational	O
therapy	O
for	O
symptomatic	O
treatment	O
of	O
benign	SYMP
prostatic	SYMP
hyperplasia	SYMP
with	O
phytogenic	SYMP
drugs	SYMP
?	O
Illustrated	O
with	O
the	O
example	O
of	O
the	O
prostate	O
agent	O
from	O
Serenoa	O
repens	O
(	O
Sabal	O
fructus	O
)	O
Pharmacological	O
and	O
clinical	O
effectiveness	O
of	O
a	O
fixed	SYMP
phytogenic	SYMP
combination	SYMP
trembling	SYMP
poplar	SYMP
(	SYMP
Populus	SYMP
tremula	SYMP
)	SYMP
,	SYMP
true	SYMP
goldenrod	SYMP
(	SYMP
Solidago	SYMP
virgaurea	SYMP
)	SYMP
and	SYMP
ash	SYMP
(	SYMP
Fraxinus	SYMP
excelsior	SYMP
)	SYMP
in	O
mild	SYMP
to	SYMP
moderate	SYMP
rheumatic	SYMP
complaints	SYMP
Therapy	O
of	O
degenerative	SYMP
diseases	SYMP
of	SYMP
the	SYMP
musculoskeletal	SYMP
system	SYMP
with	O
South	SYMP
African	SYMP
devil	SYMP
's	SYMP
claw	SYMP
(	SYMP
Harpagophytum	SYMP
procumbens	SYMP
DC	SYMP
)	SYMP
Treatment	O
strategy	O
for	O
mucin-producing	SYMP
intrahepatic	SYMP
cholangiocarcinoma	SYMP
:	O
value	O
of	O
percutaneous	SYMP
transhepatic	SYMP
biliary	SYMP
drainage	SYMP
and	O
cholangioscopy	SYMP
.	O
Strategy	O
for	O
surgical	SYMP
management	SYMP
of	O
ileocolonic	SYMP
anastomotic	SYMP
recurrence	SYMP
in	SYMP
Crohn	SYMP
's	SYMP
disease	SYMP
.	O
Nerve-sparing	SYMP
surgery	SYMP
for	O
advanced	SYMP
rectal	SYMP
cancer	SYMP
patients	O
:	O
special	O
reference	O
to	O
Dukes	O
C	O
patients	O
.	O
Prognostic	O
factors	O
in	O
patients	O
with	O
locally	O
advanced	O
rectal	SYMP
adenocarcinoma	SYMP
treated	O
with	O
preoperative	SYMP
radiotherapy	SYMP
and	O
surgery	SYMP
.	O
Current	O
surgical	SYMP
therapy	SYMP
for	O
bronchiectasis	SYMP
.	O
Thoracic	SYMP
surgery	SYMP
for	O
hydatid	SYMP
disease	SYMP
.	O
Surgical	SYMP
treatment	SYMP
of	O
postpneumonic	SYMP
empyema	SYMP
.	O
Thoracoscopic	SYMP
surgery	SYMP
for	O
pulmonary	SYMP
tuberculosis	SYMP
.	O
Thoracoscopic	SYMP
surgery	SYMP
for	O
spontaneous	SYMP
pneumothorax	SYMP
.	O
Surgery	SYMP
for	O
chronic	SYMP
thromboembolic	SYMP
pulmonary	SYMP
hypertension	SYMP
.	O
Transabdominal	SYMP
extensive	SYMP
esophagogastric	SYMP
devascularization	SYMP
with	SYMP
gastroesophageal	SYMP
stapling	SYMP
for	O
management	O
of	O
noncirrhotic	SYMP
portal	SYMP
hypertension	SYMP
:	O
long-term	O
results	O
.	O
Surgical	SYMP
treatment	SYMP
for	O
lung	SYMP
hydatid	SYMP
disease	SYMP
.	O
Sliding	SYMP
door	SYMP
technique	SYMP
for	O
the	O
repair	O
of	O
midline	SYMP
incisional	SYMP
hernias	SYMP
.	O
One-lung	SYMP
ventilation	SYMP
in	O
patients	O
with	O
difficult	SYMP
airways	SYMP
.	O
Thoracoscopy	SYMP
for	O
empyema	SYMP
in	O
children	O
.	O
Sex	O
differences	O
in	O
the	O
use	O
of	O
asthma	SYMP
drugs	SYMP
:	O
cross	O
sectional	O
study	O
.	O
Conventional	SYMP
treatments	SYMP
for	O
non-Hodgkin	SYMP
's	SYMP
lymphoma	SYMP
:	O
the	O
need	O
for	O
new	O
therapies	O
.	O
Adrenal-sparing	SYMP
surgery	SYMP
for	O
phaeochromocytoma	SYMP
.	O
Antiplatelet	SYMP
therapy	SYMP
in	O
acute	SYMP
cerebral	SYMP
ischemia	SYMP
.	O
Laugier-Hunziker	SYMP
syndrome	SYMP
:	O
case	O
report	O
and	O
treatment	O
with	O
the	O
Q-switched	SYMP
Nd-Yag	SYMP
laser	SYMP
.	O
Thoracoscopic	SYMP
operation	SYMP
for	O
secondary	SYMP
pneumothorax	SYMP
under	O
local	O
and	O
epidural	O
anesthesia	O
in	O
high-risk	O
patients	O
.	O
Troglitazone-induced	SYMP
hepatic	SYMP
failure	SYMP
leading	O
to	O
liver	SYMP
transplantation	SYMP
.	O
A	O
modified	O
technique	O
of	O
tubeless	O
anaesthesia	O
for	O
microlaryngoscopy	SYMP
and	SYMP
bronchoscopy	SYMP
in	O
young	O
children	O
with	O
stridor	SYMP
.	O
A	O
randomized	O
trial	O
of	O
Lactobacillus	SYMP
acidophilus	SYMP
BG2FO4	SYMP
to	O
treat	O
lactose	SYMP
intolerance	SYMP
.	O
Treatment	O
of	O
idiopathic	SYMP
thrombopenic	SYMP
purpura	SYMP
in	O
adolescents	O
by	O
intravenous	SYMP
immunoglobulin	SYMP
Azithromycin	SYMP
therapy	SYMP
for	O
scrub	SYMP
typhus	SYMP
during	O
pregnancy	O
.	O
Excimer	SYMP
laser	SYMP
assisted	SYMP
in	SYMP
situ	SYMP
keratomileusis	SYMP
for	O
hyperopia	SYMP
.	O
Three	O
consecutive	O
phase	O
II	O
studies	O
of	O
recombinant	SYMP
interferon	SYMP
alfa-2a	SYMP
in	O
advanced	SYMP
malignant	SYMP
melanoma	SYMP
.	O
Interferon	SYMP
treatment	SYMP
of	O
renal	SYMP
cell	SYMP
carcinoma	SYMP
.	O
Current	O
and	O
future	O
uses	O
of	O
recombinant	SYMP
interferon	SYMP
alpha	SYMP
in	O
the	O
treatment	O
of	O
low-grade	SYMP
non-Hodgkin	SYMP
's	SYMP
lymphoma	SYMP
.	O
Antimicrobial	SYMP
treatment	SYMP
options	O
in	O
the	O
management	O
of	O
odontogenic	SYMP
infections	SYMP
.	O
Recombinant	SYMP
glycoprotein	SYMP
vaccine	SYMP
for	O
the	O
prevention	O
of	O
genital	SYMP
HSV-2	SYMP
infection	SYMP
:	O
two	O
randomized	O
controlled	O
trials	O
.	O
Induction	SYMP
chemotherapy	SYMP
with	SYMP
docetaxel	SYMP
,	SYMP
cisplatin	SYMP
,	SYMP
fluorouracil	SYMP
,	SYMP
and	SYMP
leucovorin	SYMP
for	O
squamous	SYMP
cell	SYMP
carcinoma	SYMP
of	O
the	O
head	O
and	O
neck	O
:	O
a	O
phase	O
I/II	O
trial	O
.	O
Low-dose	SYMP
steroids	SYMP
reduce	O
flu-like	SYMP
symptoms	SYMP
at	O
the	O
initiation	O
of	O
IFNbeta-1b	O
in	O
relapsing-remitting	O
MS	O
.	O
Study	O
of	O
three	O
different	O
doses	O
of	O
epidural	SYMP
neostigmine	SYMP
coadministered	SYMP
with	SYMP
lidocaine	SYMP
for	O
postoperative	SYMP
analgesia	SYMP
.	O
An	O
active-control	O
trial	O
of	O
lamotrigine	SYMP
monotherapy	SYMP
for	O
partial	SYMP
seizures	SYMP
.	O
Safety	O
of	O
intrathecal	SYMP
sodium	SYMP
nitroprusside	SYMP
for	O
the	O
treatment	O
and	O
prevention	O
of	O
refractory	SYMP
cerebral	SYMP
vasospasm	SYMP
and	SYMP
ischemia	SYMP
in	O
humans	O
.	O
The	O
effect	O
of	O
heliox	SYMP
in	O
acute	SYMP
severe	SYMP
asthma	SYMP
:	O
a	O
randomized	O
controlled	O
trial	O
.	O
Long-term	O
survival	O
of	O
patients	O
with	O
unresectable	SYMP
colorectal	SYMP
cancer	SYMP
liver	SYMP
metastases	SYMP
following	O
infusional	SYMP
chemotherapy	SYMP
with	SYMP
5-fluorouracil	SYMP
,	SYMP
leucovorin	SYMP
,	SYMP
oxaliplatin	SYMP
and	SYMP
surgery	SYMP
.	O
Fatal	SYMP
acute	SYMP
haemolysis	SYMP
in	O
an	O
AIDS	SYMP
patient	O
treated	O
with	O
lindinavir	SYMP
.	O
A	O
simplified	O
laparoscopic	SYMP
technique	SYMP
for	SYMP
mesh	SYMP
placement	SYMP
in	O
ventral	SYMP
hernia	SYMP
repair	O
.	O
Pharmacological	SYMP
management	SYMP
of	O
acute	SYMP
myocardial	SYMP
infarction	SYMP
.	O
Mesenteric	SYMP
venous	SYMP
thrombosis	SYMP
:	O
successful	O
treatment	O
by	O
intraarterial	SYMP
lytic	SYMP
therapy	SYMP
.	O
Gene	SYMP
therapy	SYMP
for	O
myocardial	SYMP
angiogenesis	SYMP
.	O
Dipyridamole	SYMP
plus	SYMP
aspirin	SYMP
in	O
cerebrovascular	SYMP
disease	SYMP
.	O
What	O
is	O
the	O
real	O
role	O
of	O
CD40	O
in	O
cancer	SYMP
immunotherapy	SYMP
?	O
The	O
effects	O
of	O
oral	SYMP
liarozole	SYMP
on	O
epidermal	O
proliferation	O
and	O
differentiation	O
in	O
severe	SYMP
plaque	SYMP
psoriasis	SYMP
are	O
comparable	O
with	O
those	O
of	O
acitretin	SYMP
.	O
Safety	O
and	O
potential	O
effectiveness	O
of	O
daunorubicin-containing	SYMP
liposomes	SYMP
in	O
patients	O
with	O
advanced	SYMP
recurrent	SYMP
malignant	SYMP
CNS	SYMP
tumors	SYMP
.	O
An	O
experimental	O
application	O
of	O
gene	SYMP
therapy	SYMP
for	O
human	SYMP
retinoblastoma	SYMP
.	O
Acid	SYMP
suppression	SYMP
therapy	SYMP
in	O
Barrett	SYMP
's	SYMP
esophagus	SYMP
:	O
the	O
importance	O
of	O
pH	O
monitoring	O
.	O
Surgical	SYMP
approaches	SYMP
to	O
pediatric	SYMP
defecatory	SYMP
disorders	SYMP
.	O
Lutein	SYMP
improves	O
visual	O
function	O
in	O
some	O
patients	O
with	O
retinal	SYMP
degeneration	SYMP
:	O
a	O
pilot	O
study	O
via	O
the	O
Internet	O
.	O
Drug	O
information	O
questions	O
and	O
answers	O
:	O
new	O
for	O
psoriasis	SYMP
:	O
colchicine	SYMP
.	O
IPPB	SYMP
in	O
severe	SYMP
pulmonary	SYMP
emphysema	SYMP
:	O
limited	O
applications	O
.	O
Long-term	O
mortality	O
in	O
patients	O
after	O
a	O
British	O
trial	O
of	O
anticoagulants	SYMP
in	O
acute	SYMP
myocardial	SYMP
infarction	SYMP
.	O
Our	O
results	O
in	O
the	O
surgical	SYMP
treatment	SYMP
of	O
habitual	SYMP
shoulder	SYMP
dislocation	SYMP
with	O
special	O
reference	O
to	O
occupational	O
disability	O
Alkaline	O
phosphatase	O
in	O
neutrophil	O
leukocytes	O
of	O
patients	O
with	O
infectious	SYMP
mononucleosis	SYMP
and	O
the	O
effect	O
of	O
corticosteroid	SYMP
therapy	SYMP
.	O
Surgical	SYMP
treatment	SYMP
of	O
uterine	SYMP
cervix	SYMP
insufficiency	SYMP
during	O
the	O
2d	O
trimester	O
of	O
pregnancy	O
Physiologic	SYMP
treatment	SYMP
of	O
depressive	SYMP
reactions	SYMP
:	O
a	O
pilot	O
study	O
.	O
The	O
use	O
of	O
quinidine	SYMP
sulphate	SYMP
for	O
the	O
treatment	O
of	O
atrial	SYMP
fibrillation	SYMP
in	O
twelve	O
horses	O
.	O
Synergism	O
in	O
the	O
chemotherapy	SYMP
of	O
Eimeria	SYMP
infections	SYMP
of	O
chicks	O
.	O
Treatment	O
of	O
hydrocele	SYMP
and	SYMP
cysts	SYMP
of	SYMP
the	SYMP
epididymis	SYMP
with	O
sclerosing	SYMP
injections	SYMP
of	SYMP
quinine	SYMP
and	SYMP
urea	SYMP
chlorhydrolactate	SYMP
in	O
a	O
30	O
per	O
cent	O
solution	O
The	O
single-place	SYMP
caisson	SYMP
in	O
the	O
treatment	O
of	O
decompression	SYMP
accidents	SYMP
Blood	O
volume	O
measurements	O
in	O
burn	SYMP
therapy	SYMP
.	O
Phenylbutazone	SYMP
and	O
acute	SYMP
leukemia	SYMP
.	O
The	O
place	O
of	O
surgery	SYMP
in	O
hypertrophic	SYMP
obstructive	SYMP
cardiomyopathy	SYMP
(	SYMP
idiopathic	SYMP
hypertrophic	SYMP
subaortic	SYMP
stenosis	SYMP
)	SYMP
.	O
The	O
treatment	O
of	O
autoimmune	SYMP
hemolytic	SYMP
anemia	SYMP
with	O
heparin	SYMP
.	O
Effects	O
of	O
clomiphene	SYMP
citrate	SYMP
on	O
endometrial	SYMP
hyperplasia	SYMP
in	O
the	O
premenopausal	O
female	O
.	O
Prolonged	O
use	O
of	O
methyldopa	SYMP
in	O
severe	SYMP
hypertension	SYMP
in	O
pregnancy	O
.	O
The	O
effects	O
of	O
social	O
class	O
and	O
friends	O
'	O
expectations	O
on	O
oral	O
polio	SYMP
vaccination	SYMP
participation	O
.	O
Glutathione	O
S-transferase	O
activity	O
in	O
epithelial	SYMP
ovarian	SYMP
cancer	SYMP
:	O
association	O
with	O
response	O
to	O
chemotherapy	SYMP
and	O
disease	O
outcome	O
.	O
Interferon-alpha-2b	SYMP
in	O
the	O
management	O
of	O
patients	O
with	O
relapsed	O
and/or	O
refractory	O
Hodgkin	SYMP
's	SYMP
disease	SYMP
.	O
Frontal	SYMP
dysfunction	SYMP
blocks	O
the	O
therapeutic	O
effect	O
of	O
THA	SYMP
on	O
attention	O
in	O
Alzheimer	SYMP
's	SYMP
disease	SYMP
.	O
Effects	O
of	O
clomipramine	SYMP
on	O
plasma	O
amino	O
acids	O
and	O
serotonergic	O
parameters	O
in	O
panic	SYMP
disorder	SYMP
and	SYMP
depression	SYMP
.	O
Thalidomide	SYMP
for	O
aphthous	SYMP
ulcers	SYMP
in	O
HIV	SYMP
infection	SYMP
.	O
Aspirin	SYMP
therapy	SYMP
in	O
diabetes	SYMP
mellitus	SYMP
.	O
Combined	SYMP
pancreas-/kidney	SYMP
transplantation	SYMP
as	O
a	O
standard	O
procedure	O
in	O
therapy	O
of	O
kidney	SYMP
failure	SYMP
in	SYMP
type	SYMP
I	SYMP
diabetic	SYMP
patients	SYMP
Corticosteroid	SYMP
injections	SYMP
for	O
sciatica	SYMP
.	O
Flutamide	SYMP
plus	SYMP
castration	SYMP
in	O
patients	O
with	O
previously	O
untreated	O
prostate	SYMP
cancer	SYMP
.	O
The	O
immediate	O
effectiveness	O
of	O
electrical	SYMP
nerve	SYMP
stimulation	SYMP
and	O
electrical	SYMP
muscle	SYMP
stimulation	SYMP
on	O
myofascial	SYMP
trigger	SYMP
points	SYMP
.	O
In	O
vitro	O
radiation-induced	O
apoptosis	O
and	O
tumour	O
response	O
to	O
radiotherapy	SYMP
:	O
a	O
prospective	O
study	O
in	O
patients	O
with	O
non-Hodgkin	SYMP
lymphomas	SYMP
treated	O
by	O
low-dose	SYMP
irradiation	SYMP
.	O
Drug	SYMP
therapy	SYMP
for	O
coronary	SYMP
heart	SYMP
disease	SYMP
:	O
the	O
Sheffield	O
table	O
.	O
Percutaneous	SYMP
drainage	SYMP
of	O
hydatid	SYMP
cysts	SYMP
.	O
Surgery	SYMP
for	O
ectopia	SYMP
lentis	SYMP
.	O
Antiplatelet	SYMP
therapy	SYMP
to	O
prevent	O
stroke	SYMP
:	O
risk	O
of	O
brain	SYMP
hemorrhage	SYMP
and	O
efficacy	O
in	O
atrial	SYMP
fibrillation	SYMP
.	O
High-dose	SYMP
chemotherapy	SYMP
with	SYMP
autologous	SYMP
hematopoietic	SYMP
stem-cell	SYMP
support	SYMP
for	O
breast	SYMP
cancer	SYMP
in	O
North	O
America	O
.	O
Is	O
concomitant	SYMP
radiotherapy	SYMP
and	SYMP
chemotherapy	SYMP
superior	O
to	O
optimal	O
radiotherapy	SYMP
alone	O
in	O
anal	SYMP
cancer	SYMP
?	O
Standard	SYMP
versus	SYMP
high-dose	SYMP
therapy	SYMP
in	O
10+	O
breast	SYMP
cancer	SYMP
.	O
Anal	O
continence	O
after	O
surgery	SYMP
for	O
rectal	SYMP
prolapse	SYMP
.	O
Aspirin	SYMP
therapy	SYMP
for	O
cardiovascular	SYMP
disease	SYMP
.	O
Dosing	O
of	O
amoxicillin/clavulanate	SYMP
for	O
treatment	O
of	O
lower	SYMP
respiratory	SYMP
tract	SYMP
infection	SYMP
.	O
Pharmacoeconomic	O
analysis	O
of	O
ampicillin-sulbactam	SYMP
versus	O
cefoxitin	SYMP
in	O
the	O
treatment	O
of	O
intraabdominal	SYMP
infections	SYMP
.	O
New	SYMP
therapies	SYMP
for	O
severe	SYMP
meningococcal	SYMP
disease	SYMP
.	O
Another	O
potential	O
use	O
of	O
troglitazone	SYMP
in	O
noninsulin-dependent	SYMP
diabetes	SYMP
mellitus	SYMP
.	O
Jaw	SYMP
clenching	SYMP
following	O
Gamma	SYMP
Knife	SYMP
treatment	SYMP
for	O
trigeminal	SYMP
neuralgia	SYMP
.	O
The	O
protective	O
effect	O
of	O
condoms	SYMP
and	O
nonoxynol-9	SYMP
against	O
HIV	SYMP
infection	SYMP
.	O
Evaluation	O
of	O
adjuvant	SYMP
psychological	SYMP
therapy	SYMP
in	O
patients	O
with	O
testicular	SYMP
cancer	SYMP
:	O
randomised	O
controlled	O
trial	O
.	O
The	O
effect	O
of	O
an	O
endothelin-receptor	SYMP
antagonist	SYMP
,	SYMP
bosentan	SYMP
,	O
on	O
blood	O
pressure	O
in	O
patients	O
with	O
essential	SYMP
hypertension	SYMP
.	O
Guidelines	O
for	O
the	O
use	O
of	O
antiretroviral	SYMP
agents	SYMP
in	O
HIV	SYMP
-infected	O
adults	O
and	O
adolescents	O
.	O
Long-term	O
therapy	O
with	O
long-acting	SYMP
octreotide	SYMP
(	SYMP
Sandostatin-LAR	SYMP
)	SYMP
for	O
the	O
management	O
of	O
acromegaly	SYMP
.	O
Are	O
ABVD	SYMP
and	O
MOPP/ABV	SYMP
truly	O
equivalent	O
for	O
treating	O
Hodgkin	SYMP
's	SYMP
disease	SYMP
at	O
advanced	O
stages	O
?	O
Paclitaxel	SYMP
for	O
the	O
treatment	O
of	O
lymphoma	SYMP
.	O
Montelukast	SYMP
,	SYMP
a	SYMP
leukotriene-receptor	SYMP
antagonist	SYMP
,	SYMP
for	O
the	O
treatment	O
of	O
mild	SYMP
asthma	SYMP
and	SYMP
exercise-induced	SYMP
bronchoconstriction	SYMP
.	O
Atypical	O
antipsychotic	SYMP
agents	SYMP
in	O
the	O
treatment	O
of	O
Schizophrenia	SYMP
and	SYMP
other	SYMP
psychiatric	SYMP
disorders	SYMP
.	O
Percutaneous	SYMP
transluminal	SYMP
angioplasty	SYMP
in	O
the	O
treatment	O
of	O
renovascular	SYMP
hypertension	SYMP
:	O
sequential	O
prospective	O
study	O
.	O
Esophageal	SYMP
intubation	SYMP
for	O
palliative	O
treatment	O
in	O
advanced	SYMP
carcinoma	SYMP
of	SYMP
the	SYMP
esophagus	SYMP
and	SYMP
cardia	SYMP
Pathological	O
staging	O
and	O
biochemical	O
recurrence	O
after	O
neoadjuvant	SYMP
androgen	SYMP
deprivation	SYMP
therapy	SYMP
in	O
combination	O
with	O
radical	SYMP
prostatectomy	SYMP
in	O
clinically	O
localized	O
prostate	SYMP
cancer	SYMP
.	O
How	O
often	O
does	O
surgery	SYMP
for	O
peptic	SYMP
ulceration	SYMP
eradicate	O
Helicobacter	O
pylori	O
?	O
Systematic	O
review	O
of	O
36	O
studies	O
.	O
A	O
comparison	O
of	O
noninvasive	SYMP
positive-pressure	SYMP
ventilation	SYMP
and	O
conventional	SYMP
mechanical	SYMP
ventilation	SYMP
in	O
patients	O
with	O
acute	SYMP
respiratory	SYMP
failure	SYMP
.	O
Long-term	O
safety	O
and	O
effectiveness	O
of	O
iron-chelation	SYMP
therapy	SYMP
with	SYMP
deferiprone	SYMP
for	O
thalassemia	SYMP
major	SYMP
.	O
Positron	O
emission	O
tomography	O
in	O
assessing	O
response	O
to	O
neoadjuvant	SYMP
chemotherapy	SYMP
for	O
non-small-cell	SYMP
lung	SYMP
cancer	SYMP
.	O
Reconstruction	O
of	O
thoracic	O
wall	O
defects	O
after	O
tumor	SYMP
resection	SYMP
using	O
a	O
polytetrafluoroethylene	O
soft	O
tissue	O
(	O
Gore-Tex	O
)	O
patch	O
.	O
A	O
comparison	O
of	O
rectal	SYMP
diazepam	SYMP
gel	SYMP
and	O
placebo	O
for	O
acute	SYMP
repetitive	SYMP
seizures	SYMP
.	O
Effect	O
of	O
long-term	O
salmeterol	SYMP
treatment	SYMP
on	O
exercise-induced	SYMP
asthma	SYMP
.	O
Randomized	O
trial	O
of	O
intensive	SYMP
cyclophosphamide	SYMP
,	SYMP
epirubicin	SYMP
,	SYMP
and	SYMP
fluorouracil	SYMP
chemotherapy	SYMP
compared	O
with	O
cyclophosphamide	SYMP
,	SYMP
methotrexate	SYMP
,	SYMP
and	SYMP
fluorouracil	SYMP
in	O
premenopausal	O
women	O
with	O
node-positive	SYMP
breast	SYMP
cancer	SYMP
.	O
Acute	O
effect	O
of	O
lorazepam	SYMP
on	O
respiratory	O
muscles	O
in	O
patients	O
with	O
chronic	SYMP
obstructive	SYMP
pulmonary	SYMP
disease	SYMP
Low-molecular-weight	SYMP
heparins	SYMP
in	O
the	O
treatment	O
of	O
venous	SYMP
thromboembolism	SYMP
.	O
5-year	O
outcome	O
of	O
surgical	SYMP
resection	SYMP
and	O
watchful	O
waiting	O
for	O
men	O
with	O
moderately	O
symptomatic	O
benign	SYMP
prostatic	SYMP
hyperplasia	SYMP
:	O
a	O
Department	O
of	O
Veterans	O
Affairs	O
cooperative	O
study	O
.	O
For	O
how	O
long	O
should	O
antipsychotic	SYMP
medication	SYMP
be	O
continued	O
after	O
the	O
first	O
psychotic	SYMP
episode	SYMP
in	SYMP
schizophrenics	SYMP
?	O
IDA-FLAG	SYMP
(	SYMP
idarubicin	SYMP
,	SYMP
fludarabine	SYMP
,	SYMP
cytarabine	SYMP
,	SYMP
G-CSF	SYMP
)	SYMP
,	O
an	O
effective	O
remission-induction	SYMP
therapy	SYMP
for	O
poor-prognosis	SYMP
AML	SYMP
of	SYMP
childhood	SYMP
prior	O
to	O
allogeneic	O
or	O
autologous	O
bone	O
marrow	O
transplantation	O
:	O
experiences	O
of	O
a	O
phase	O
II	O
trial	O
.	O
Effects	O
of	O
anal	SYMP
invasive	SYMP
treatment	SYMP
and	O
incontinence	SYMP
on	O
mental	O
health	O
and	O
psychosocial	O
functioning	O
of	O
adolescents	O
with	O
Hirshsprung	SYMP
's	SYMP
disease	SYMP
and	O
low	O
anorectal	SYMP
anomalies	SYMP
.	O
Single	O
or	O
double	O
lung	SYMP
transplantation	SYMP
for	O
pulmonary	SYMP
hypertension	SYMP
.	O
Interferon	SYMP
beta	SYMP
treatment	SYMP
for	O
multiple	SYMP
sclerosis	SYMP
.	O
Ten-year	O
disease	O
free	O
survival	O
after	O
transperineal	SYMP
sonography-guided	SYMP
iodine-125	SYMP
brachytherapy	SYMP
with	O
or	O
without	O
45-Gray	SYMP
external	SYMP
beam	SYMP
irradiation	SYMP
in	O
the	O
treatment	O
of	O
patients	O
with	O
clinically	O
localized	O
,	O
low	O
to	O
high	O
Gleason	SYMP
grade	SYMP
prostate	SYMP
carcinoma	SYMP
.	O
Partial	O
or	O
near	O
total	O
pancreatectomy	SYMP
for	O
persistent	SYMP
neonatal	SYMP
hyperinsulinaemic	SYMP
hypoglycaemia	SYMP
:	O
the	O
pathologist	O
's	O
role	O
.	O
Radical	SYMP
prostatectomy	SYMP
for	O
prostate	SYMP
cancer	SYMP
:	O
the	O
perineal	O
approach	O
increases	O
the	O
risk	O
of	O
surgically	O
induced	O
positive	O
margins	O
and	O
capsular	O
incisions	O
.	O
Open	SYMP
capsulorrhaphy	SYMP
with	SYMP
suture	SYMP
anchors	SYMP
for	O
recurrent	SYMP
anterior	SYMP
dislocation	SYMP
of	SYMP
the	SYMP
shoulder	SYMP
.	O
Intravenous	SYMP
immunoglobulin	SYMP
treatment	SYMP
in	O
multiple	SYMP
sclerosis	SYMP
.	O
Randomised	O
trial	O
of	O
irinotecan	SYMP
versus	O
fluorouracil	SYMP
by	O
continuous	O
infusion	O
after	O
fluorouracil	O
failure	O
in	O
patients	O
with	O
metastatic	SYMP
colorectal	SYMP
cancer	SYMP
.	O
The	O
effectiveness	O
of	O
intraocular	SYMP
pressure	SYMP
reduction	SYMP
in	O
the	O
treatment	O
of	O
normal-tension	SYMP
glaucoma	SYMP
.	O
Perceived	O
contraindications	O
to	O
thrombolytic	SYMP
treatment	SYMP
in	O
acute	SYMP
myocardial	SYMP
infarction	SYMP
.	O
Lignocaine	SYMP
or	O
bupivacaine	SYMP
for	O
digital	SYMP
ring	SYMP
block	SYMP
.	O
Steroids	SYMP
in	O
lateral	SYMP
epicondylitis	SYMP
.	O
Steroids	SYMP
in	O
De	SYMP
Quervain	SYMP
's	SYMP
tenosynovitis	SYMP
.	O
Antibiotics	SYMP
after	O
dog	SYMP
bite	SYMP
.	O
Immobilisation	SYMP
after	O
first	O
anterior	O
shoulder	SYMP
dislocation	SYMP
.	O
Stereotactic	SYMP
radiosurgery	SYMP
for	O
acoustic	SYMP
neuroma	SYMP
:	O
a	O
Canadian	O
perspective	O
.	O
Anticytokine	SYMP
therapy	SYMP
--	O
a	O
new	O
era	O
in	O
the	O
treatment	O
of	O
rheumatoid	SYMP
arthritis	SYMP
?	O
Control	O
of	O
the	O
malignant	SYMP
hyperpyrexic	SYMP
syndrome	SYMP
in	O
MHS	O
swine	O
by	O
dantrolene	SYMP
sodium	SYMP
.	O
Hematopoietic	SYMP
stem-cell	SYMP
transplantation	SYMP
for	O
the	O
treatment	O
of	O
severe	SYMP
combined	SYMP
immunodeficiency	SYMP
.	O
Low-dose	SYMP
clozapine	SYMP
for	O
the	O
treatment	O
of	O
drug-induced	SYMP
psychosis	SYMP
in	SYMP
Parkinson	SYMP
's	SYMP
disease	SYMP
.	O
Comparing	O
the	O
efficacy	O
and	O
safety	O
of	O
fluoxetine	SYMP
and	O
venlafaxine	SYMP
in	O
outpatient	SYMP
depression	SYMP
.	O
Cost-effectiveness	O
of	O
interferon	SYMP
treatment	SYMP
for	O
hepatitis	SYMP
C	SYMP
.	O
Hyperbaric	SYMP
oxygen	SYMP
therapy	SYMP
for	O
children	O
with	O
cerebral	SYMP
palsy	SYMP
.	O
Peripheral	SYMP
retinal	SYMP
cryotherapy	SYMP
for	O
postvitrectomy	SYMP
diabetic	SYMP
vitreous	SYMP
hemorrhage	SYMP
in	O
phakic	O
patients	O
.	O
Hyperbaric	SYMP
or	SYMP
normobaric	SYMP
oxygen	SYMP
for	O
acute	SYMP
carbon	SYMP
monoxide	SYMP
poisoning	SYMP
:	O
a	O
randomised	O
controlled	O
clinical	O
trial	O
.	O
Multicentre	O
clinical	O
evaluation	O
of	O
vigabatrin	SYMP
(	SYMP
Sabril	SYMP
)	SYMP
in	O
mild	SYMP
to	SYMP
moderate	SYMP
partial	SYMP
epilepsies	SYMP
.	O
Matrix	SYMP
metalloproteinase	SYMP
inhibitors	SYMP
in	O
the	O
treatment	O
of	O
cancer	SYMP
.	O
High	O
dose	O
cyclophosphamide	SYMP
with	O
carboplatin	SYMP
:	O
a	O
tolerable	O
regimen	O
suitable	O
for	O
dose	O
intensification	O
in	O
children	O
with	O
solid	SYMP
tumors	SYMP
.	O
Microsurgical	SYMP
treatment	SYMP
of	O
supratentorial	SYMP
cavernous	SYMP
malformations	SYMP
.	O
Microsurgical	SYMP
treatment	SYMP
of	O
infratentorial	SYMP
malformations	SYMP
.	O
Stereotactic	SYMP
radiosurgery	SYMP
for	O
management	O
of	O
deep	SYMP
brain	SYMP
cavernous	SYMP
malformations	SYMP
.	O
Interferon-antibodies	SYMP
and	O
the	O
breakthrough	O
phenomenon	O
during	O
ribavirin/interferon-alpha	SYMP
combination	SYMP
therapy	SYMP
and	O
interferon-alpha	SYMP
monotherapy	SYMP
of	O
patients	O
with	O
chronic	SYMP
hepatitis	SYMP
C	SYMP
.	O
Treatment	O
of	O
Barrett	SYMP
esophagus	SYMP
with	O
argon	SYMP
plasma	SYMP
coagulation	SYMP
with	SYMP
acid	SYMP
suppression	SYMP
--	O
a	O
prospective	O
study	O
Meta-analysis	O
of	O
typhoid	SYMP
vaccine	SYMP
efficacy	O
trials	O
showed	O
that	O
whole	O
cell	O
vaccines	O
are	O
more	O
effective	O
than	O
either	O
the	O
oral	O
,	O
attenuated	O
vaccine	O
or	O
the	O
Vi	O
polysaccharide	O
vaccine	O
.	O
Experimental	O
vaccination	SYMP
against	O
Mycoplasma	SYMP
agalactiae	SYMP
using	O
different	O
inactivated	O
vaccines	O
.	O
A	O
randomized	O
,	O
controlled	O
study	O
in	O
adults	O
of	O
the	O
immunogenicity	O
of	O
a	O
novel	O
hepatitis	SYMP
B	SYMP
vaccine	SYMP
containing	O
MF59	O
adjuvant	O
.	O
Immunogenicity	O
of	O
three	O
Haemophilus	SYMP
influenzae	SYMP
type	SYMP
b	SYMP
protein	O
conjugate	O
vaccines	SYMP
in	O
HIV	O
seropositive	O
adults	O
and	O
analysis	O
of	O
predictors	O
of	O
vaccine	O
response	O
.	O
Vaccination	SYMP
against	O
Schistosoma	SYMP
mansoni	SYMP
infection	SYMP
using	O
74	O
kDa	O
Schistosoma	O
protein	O
antigen	O
.	O
Phase	O
1	O
safety	O
and	O
immune	O
response	O
studies	O
of	O
a	O
DNA	SYMP
vaccine	SYMP
encoding	O
hepatitis	SYMP
B	SYMP
surface	O
antigen	O
delivered	O
by	O
a	O
gene	O
delivery	O
device	O
.	O
Protection	O
of	O
swine	O
from	O
foot-and-mouth	SYMP
disease	SYMP
with	O
one	O
dose	O
of	O
an	O
all-D	SYMP
retro	SYMP
peptide	SYMP
.	O
Intranasal	SYMP
immunization	SYMP
with	O
Chlamydia	SYMP
trachomatis	SYMP
,	SYMP
serovar	SYMP
E	SYMP
,	O
protects	O
from	O
a	O
subsequent	O
vaginal	O
challenge	O
with	O
the	O
homologous	O
serovar	O
.	O
Mutants	O
of	O
cholera	O
toxin	O
as	O
an	O
effective	O
and	O
safe	O
adjuvant	O
for	O
nasal	SYMP
influenza	SYMP
vaccine	SYMP
.	O
Field	O
evaluation	O
of	O
the	O
clinical	O
effectiveness	O
of	O
vaccines	SYMP
against	O
pertussis	SYMP
,	SYMP
measles	SYMP
,	SYMP
rubella	SYMP
and	SYMP
mumps	SYMP
:	O
comments	O
.	O
Transmural	SYMP
drainage	SYMP
of	O
pancreatic	SYMP
fluid	SYMP
collections	SYMP
without	O
electrocautery	O
using	O
the	O
Seldinger	O
technique	O
.	O
Echocardiography-guided	SYMP
ethanol	SYMP
septal	SYMP
reduction	SYMP
for	O
hypertrophic	SYMP
obstructive	SYMP
cardiomyopathy	SYMP
.	O
Alterations	O
of	O
monocyte	O
function	O
in	O
patients	O
with	O
growth	SYMP
hormone	SYMP
(	SYMP
GH	SYMP
)	SYMP
deficiency	SYMP
:	O
effect	O
of	O
substitutive	O
GH	SYMP
therapy	SYMP
.	O
Comparison	O
of	O
the	O
effects	O
of	O
salmeterol	SYMP
and	O
ipratropium	SYMP
bromide	SYMP
on	O
exercise	O
performance	O
and	O
breathlessness	O
in	O
patients	O
with	O
stable	SYMP
chronic	SYMP
obstructive	SYMP
pulmonary	SYMP
disease	SYMP
.	O
Safety	O
trial	O
with	O
the	O
5HT1B/1D	SYMP
agonist	SYMP
avitriptan	SYMP
(	O
BMS-180048	O
)	O
in	O
patients	O
with	O
migraine	SYMP
who	O
have	O
experienced	O
pressure	SYMP
,	SYMP
tightness	SYMP
,	SYMP
and/or	SYMP
pain	SYMP
in	O
the	O
chest	O
,	O
neck	O
,	O
and/or	O
throat	O
following	O
sumatriptan	SYMP
.	O
Double	O
blind	O
,	O
cluster	O
randomised	O
trial	O
of	O
low	O
dose	O
supplementation	O
with	O
vitamin	SYMP
A	SYMP
or	O
beta	SYMP
carotene	SYMP
on	O
mortality	SYMP
related	SYMP
to	SYMP
pregnancy	SYMP
in	O
Nepal	O
.	O
Medical	SYMP
treatments	SYMP
for	O
balding	SYMP
in	O
men	O
.	O
Carbon	SYMP
monoxide	SYMP
poisoning	SYMP
treated	O
with	O
hyperbaric	SYMP
oxygen	SYMP
:	O
metabolic	O
acidosis	O
as	O
a	O
predictor	O
of	O
treatment	O
requirements	O
.	O
Medication	SYMP
received	O
by	O
patients	O
with	O
depression	SYMP
following	O
the	O
acute	O
episode	O
:	O
adequacy	O
and	O
relation	O
to	O
outcome	O
.	O
Reduced	SYMP
bone	SYMP
density	SYMP
at	O
completion	O
of	O
chemotherapy	SYMP
for	O
a	O
malignancy	SYMP
.	O
Surgical-site	SYMP
complications	SYMP
associated	O
with	O
a	O
morphine	SYMP
nerve	SYMP
paste	SYMP
used	O
for	O
postoperative	SYMP
pain	SYMP
control	SYMP
after	SYMP
laminectomy	SYMP
.	O
Splenectomy	SYMP
during	O
pregnancy	O
:	O
an	O
option	O
in	O
the	O
treatment	O
of	O
autoimmune	SYMP
thrombocytopenic	SYMP
purpura	SYMP
.	O
Melatonin	SYMP
treatment	SYMP
of	O
sleep-wake	SYMP
cycle	SYMP
disorders	SYMP
in	O
children	O
and	O
adolescents	O
.	O
Randomized	O
phase	O
II	O
study	O
of	O
the	O
neurokinin	SYMP
1	SYMP
receptor	SYMP
antagonist	SYMP
CJ-11	SYMP
,	SYMP
974	SYMP
in	O
the	O
control	O
of	O
cisplatin-induced	SYMP
emesis	SYMP
.	O
Cataract	SYMP
surgery	SYMP
and	O
its	O
effect	O
on	O
intraocular	O
pressure	O
.	O
The	O
outcome	O
of	O
arthroscopic	SYMP
treatment	SYMP
of	O
temporomandibular	SYMP
joint	SYMP
arthropathy	SYMP
.	O
Neostigmine	SYMP
for	O
acute	SYMP
colonic	SYMP
pseudo-obstruction	SYMP
.	O
New	O
vaccine	SYMP
targets	O
childhood	SYMP
pneumonia	SYMP
.	O
A	O
comparison	O
of	O
botulinum	SYMP
toxin	SYMP
and	O
nitroglycerin	SYMP
ointment	SYMP
for	O
chronic	SYMP
anal	SYMP
fissure	SYMP
.	O
The	O
effect	O
of	O
bisoprolol	SYMP
on	O
perioperative	SYMP
mortality	SYMP
and	O
myocardial	SYMP
infarction	SYMP
in	O
high-risk	O
patients	O
undergoing	O
vascular	SYMP
surgery	SYMP
.	O
Surgical	SYMP
management	SYMP
of	O
severe	SYMP
secondary	SYMP
peritonitis	SYMP
.	O
Early	SYMP
surgical	SYMP
treatment	SYMP
for	O
supratentorial	SYMP
intracerebral	SYMP
hemorrhage	SYMP
:	O
a	O
randomized	O
feasibility	O
study	O
.	O
Evaluation	O
of	O
clomipramine	SYMP
as	O
an	O
adjunct	O
to	O
behavioural	SYMP
therapy	SYMP
in	O
the	O
treatment	O
of	O
separation-related	SYMP
problems	SYMP
in	O
dogs	O
.	O
NICE	O
to	O
rule	O
on	O
influenza	SYMP
flu	SYMP
drug	O
zanamivir	SYMP
.	O
Longitudinal	SYMP
melanonychia	SYMP
associated	O
with	O
hydroxyurea	SYMP
therapy	SYMP
in	O
a	O
patient	O
with	O
essential	SYMP
thrombocytosis	SYMP
.	O
Biologic	O
markers	O
as	O
predictors	O
of	O
clinical	O
outcome	O
from	O
systemic	SYMP
therapy	SYMP
for	O
primary	O
operable	O
breast	SYMP
cancer	SYMP
.	O
Treatment	O
of	O
hypertension	SYMP
with	O
ascorbic	SYMP
acid	SYMP
.	O
Postoperative	SYMP
peritonitis	SYMP
originating	O
from	O
the	O
duodenum	O
:	O
operative	O
management	O
by	O
intubation	SYMP
and	SYMP
continuous	SYMP
intraluminal	SYMP
irrigation	SYMP
.	O
Efficacy	O
of	O
open-bite	SYMP
treatment	O
with	O
the	O
Thera-spoon	SYMP
.	O
Pompholyx	SYMP
(	SYMP
vesicular	SYMP
eczema	SYMP
)	SYMP
after	O
i.v	SYMP
.	SYMP
immunoglobulin	SYMP
therapy	SYMP
for	O
neurologic	SYMP
disease	SYMP
.	O
Mitomycin	SYMP
,	SYMP
ifosfamide	SYMP
,	SYMP
and	SYMP
cisplatin	SYMP
in	O
unresectable	SYMP
non-small-cell	SYMP
lung	SYMP
cancer	SYMP
:	O
effects	O
on	O
survival	O
and	O
quality	O
of	O
life	O
.	O
Hepatic	O
arterial	O
infusion	O
of	O
chemotherapy	SYMP
after	O
resection	SYMP
of	O
hepatic	SYMP
metastases	SYMP
from	O
colorectal	SYMP
cancer	SYMP
.	O
Waiting	O
for	O
the	O
definitive	O
trial	O
of	O
hepatic	SYMP
arterial	SYMP
chemotherapy	SYMP
for	O
colorectal	SYMP
cancer	SYMP
.	O
Phase	O
III	O
randomized	O
study	O
of	O
cisplatin	SYMP
versus	O
paclitaxel	SYMP
versus	O
cisplatin	SYMP
and	SYMP
paclitaxel	SYMP
in	O
patients	O
with	O
suboptimal	O
stage	O
III	O
or	O
IV	O
ovarian	SYMP
cancer	SYMP
:	O
a	O
gynecologic	O
oncology	O
group	O
study	O
.	O
Evidence	O
for	O
double	O
resistance	O
to	O
permethrin	SYMP
and	SYMP
malathion	SYMP
in	O
head	SYMP
lice	SYMP
.	O
Urgent	O
colonoscopy	SYMP
for	O
the	O
diagnosis	O
and	O
treatment	O
of	O
severe	SYMP
diverticular	SYMP
hemorrhage	SYMP
.	O
Treatment	O
of	O
Parkinson	SYMP
's	SYMP
disease	SYMP
should	O
begin	O
with	O
a	O
dopamine	SYMP
agonist	SYMP
.	O
Ulceration	SYMP
in	O
an	O
ileocolic	SYMP
anastomosis	SYMP
treated	O
with	O
ranitidin	SYMP
.	O
Low-molecular-weight	SYMP
heparin	SYMP
vs	O
heparin	SYMP
in	O
the	O
treatment	O
of	O
patients	O
with	O
pulmonary	SYMP
embolism	SYMP
.	O
Radiotherapy	SYMP
in	O
breast-conserving	SYMP
treatment	SYMP
for	O
ductal	SYMP
carcinoma	SYMP
in	O
situ	O
:	O
first	O
results	O
of	O
the	O
EORTC	O
randomised	O
phase	O
III	O
trial	O
10853	O
.	O
Methadone	SYMP
maintenance	SYMP
vs	O
180-day	O
psychosocially	O
enriched	O
detoxification	SYMP
for	O
treatment	O
of	O
opioid	SYMP
dependence	SYMP
:	O
a	O
randomized	O
controlled	O
trial	O
.	O
Cryogen	O
spray	O
cooling	O
during	O
Nd	SYMP
:	SYMP
YAG	SYMP
laser	SYMP
treatment	SYMP
of	O
hemangiomas	SYMP
.	O
Effects	O
of	O
tolcapone	SYMP
,	SYMP
a	SYMP
catechol-O-methyltransferase	SYMP
inhibitor	SYMP
,	O
on	O
motor	O
symptoms	O
and	O
pharmacokinetics	O
of	O
levodopa	SYMP
in	O
patients	O
with	O
Parkinson	SYMP
's	SYMP
disease	SYMP
.	O
Gene	SYMP
therapy	SYMP
for	O
cancer	SYMP
.	O
Therapeutic	O
effects	O
of	O
LDL	SYMP
apheresis	SYMP
in	O
the	O
prevention	O
of	O
atherosclerosis	SYMP
.	O
Dry	SYMP
powdered	SYMP
formoterol	SYMP
,	O
twice	O
a	O
day	O
versus	O
aerosolized	SYMP
salbutamol	SYMP
,	O
four	O
times	O
a	O
day	O
,	O
in	O
patients	O
with	O
stable	SYMP
asthma	SYMP
Cell-based	SYMP
vaccination	SYMP
against	O
melanoma	SYMP
--	O
background	O
,	O
preliminary	O
results	O
,	O
and	O
perspective	O
.	O
Celecoxib	SYMP
for	O
arthritis	SYMP
.	O
Poliomyelitis	SYMP
prevention	O
:	O
revised	O
recommendations	O
for	O
use	O
of	O
inactivated	O
and	O
live	O
oral	O
poliovirus	SYMP
vaccines	SYMP
.	O
Mesh	O
plug	O
repair	O
and	O
groin	SYMP
hernia	SYMP
surgery	SYMP
.	O
Brimonidine	SYMP
tartrate	SYMP
0.2	O
%	O
twice	O
daily	O
vs	O
timolol	SYMP
0.5	O
%	O
twice	O
daily	O
:	O
1-year	O
results	O
in	O
glaucoma	SYMP
patients	O
.	O
Ticarcillin/clavulanate	SYMP
versus	O
imipenem/cilistatin	SYMP
for	O
the	O
treatment	O
of	O
infections	SYMP
associated	SYMP
with	SYMP
gangrenous	SYMP
and	SYMP
perforated	SYMP
appendicitis	SYMP
.	O
Is	O
zero	O
dose	O
oral	O
polio	SYMP
vaccine	SYMP
effective	O
in	O
preterm	O
babies	O
?	O
An	O
economic	O
analysis	O
of	O
different	O
strategies	O
of	O
immunization	SYMP
against	O
hepatitis	SYMP
A	SYMP
virus	SYMP
in	O
developed	O
countries	O
.	O
Issues	O
and	O
challenges	O
with	O
antithrombotic	SYMP
therapy	SYMP
in	O
diabetic	O
patients	O
with	O
acute	SYMP
coronary	SYMP
syndromes	SYMP
.	O
Global	O
risk	O
assessment	O
for	O
lipid	SYMP
therapy	SYMP
to	O
prevent	O
coronary	SYMP
heart	SYMP
disease	SYMP
.	O
The	O
role	O
of	O
fibric	SYMP
acid	SYMP
derivatives	SYMP
in	O
the	O
secondary	O
prevention	O
of	O
coronary	SYMP
heart	SYMP
disease	SYMP
.	O
Epoetin	SYMP
:	O
a	O
pharmacoeconomic	O
review	O
of	O
its	O
use	O
in	O
chronic	SYMP
renal	SYMP
failure	SYMP
and	O
its	O
effects	O
on	O
quality	O
of	O
life	O
.	O
Rationale	O
for	O
the	O
use	O
of	O
antiplatelet	SYMP
drugs	SYMP
in	O
patients	O
with	O
peripheral	SYMP
vascular	SYMP
disease	SYMP
.	O
The	O
fluoroquinolones	SYMP
for	O
urinary	SYMP
tract	SYMP
infections	SYMP
:	O
a	O
review	O
.	O
Reduction	O
of	O
vasoreactivity	SYMP
and	O
thrombogenicity	SYMP
with	O
laser-thermal	SYMP
angioplasty	SYMP
:	O
comparison	O
with	O
balloon	SYMP
angioplasty	SYMP
.	O
Effects	O
of	O
ultrasound	SYMP
energy	SYMP
on	O
total	SYMP
peripheral	SYMP
artery	SYMP
occlusions	SYMP
:	O
initial	O
angiographic	O
and	O
angioscopic	O
results	O
.	O
High-dose	SYMP
chemotherapy	SYMP
with	SYMP
autologous	SYMP
stem-cell	SYMP
support	SYMP
for	O
epithelial	SYMP
ovarian	SYMP
cancer	SYMP
.	O
Pelvic	SYMP
floor	SYMP
stimulation	SYMP
in	O
the	O
treatment	O
of	O
adult	SYMP
urinary	SYMP
incontinence	SYMP
.	O
Chronic	SYMP
vagus	SYMP
nerve	SYMP
stimulation	SYMP
for	O
treatment	O
of	O
seizures	SYMP
.	O
``	SYMP
Tandem	SYMP
''	SYMP
high-dose	SYMP
chemoradiotherapy	SYMP
with	SYMP
autologous	SYMP
stem-cell	SYMP
support	SYMP
in	O
the	O
treatment	O
of	O
newly	O
diagnosed	O
or	O
responsive	O
multiple	SYMP
myeloma	SYMP
.	O
Special	O
report	O
:	O
comparative	O
efficacy	O
of	O
different	O
types	O
of	O
pneumatic	SYMP
compression	SYMP
pumps	SYMP
for	O
the	O
treatment	O
of	O
lymphedema	SYMP
.	O
Special	O
report	O
:	O
pressure-reducing	SYMP
support	SYMP
surfaces	SYMP
in	O
the	O
prevention	O
and	O
treatment	O
of	O
pressure	SYMP
ulcers	SYMP
:	O
group	O
1	O
technologies	O
.	O
Intravenous	SYMP
immune	SYMP
globulin	SYMP
for	O
recurrent	SYMP
spontaneous	SYMP
abortion	SYMP
.	O
External	SYMP
counterpulsation	SYMP
for	O
treatment	O
of	O
chronic	SYMP
stable	SYMP
angina	SYMP
pectoris	SYMP
.	O
Intra-articular	SYMP
hyaluronan	SYMP
injections	SYMP
for	O
treatment	O
of	O
osteoarthritis	SYMP
of	O
the	O
knee	O
.	O
Pneumococcal	SYMP
vaccine	SYMP
:	O
a	O
second	O
look	O
.	O
